PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Pascual, JI; Lorente, N; Song, Z; Conrad, H; Rust, HP				Pascual, JI; Lorente, N; Song, Z; Conrad, H; Rust, HP			Selectivity in vibrationally mediated single-molecule chemistry	NATURE			English	Article							DESORPTION; EXCITATION; SPECTROSCOPY; AMMONIA	The selective excitation of molecular vibrations provides a means to directly influence the speed and outcome of chemical reactions. Such mode-selective chemistry(1) has traditionally used laser pulses to prepare reactants in specific vibrational states(2) to enhance reactivity(3,4) or modify the distribution of product species(5,6). Inelastic tunnelling electrons may also excite molecular vibrations(7,8) and have been used to that effect on adsorbed molecules, to cleave individual chemical bonds(9) and induce molecular motion(10-13) or dissociation(14-17). Here we demonstrate that inelastic tunnelling electrons can be tuned to induce selectively either the translation or desorption of individual ammonia molecules on a Cu(100) surface. We are able to select a particular reaction pathway by adjusting the electronic tunnelling current and energy during the reaction induction such that we activate either the stretching vibration of ammonia or the inversion of its pyramidal structure. Our results illustrate the ability of the scanning tunnelling microscope to probe single-molecule events in the limit of very low yield and very low power irradiation, which should allow the investigation of reaction pathways not readily amenable to study by more conventional approaches.	Max Planck Gesell, Fritz Haber Inst, D-14194 Berlin, Germany; CSIC, Inst Ciencia Mat Barcelona, E-08193 Barcelona, Spain; Univ Toulouse 3, Lab Collis Agregats React, UMR 5589, F-31062 Toulouse, France; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA	Max Planck Society; Fritz Haber Institute of the Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia de Materiales de Barcelona (ICMAB); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; United States Department of Energy (DOE); Brookhaven National Laboratory	Pascual, JI (corresponding author), Max Planck Gesell, Fritz Haber Inst, Faradayweg 4-6, D-14194 Berlin, Germany.	pascual@icmab.es	Lorente, Nicolas/M-6125-2013; Pascual, Jose Ignacio/N-3102-2016; Lorente, Nicolas/ABD-4438-2021; Pascual, Jose I/F-3489-2011	Pascual, Jose Ignacio/0000-0002-7152-4747; Lorente, Nicolas/0000-0003-0952-8031; 				AVOURIS P, 1995, ACCOUNTS CHEM RES, V28, P95, DOI 10.1021/ar00051a002; Bartels L, 1999, CHEM PHYS LETT, V313, P544, DOI 10.1016/S0009-2614(99)01108-2; BRONIKOWSKI MJ, 1991, J CHEM PHYS, V95, P8647, DOI 10.1063/1.461243; Dai H. L., 1995, LASER SPECTROSCOPY P; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; HANSMA PK, 1982, TUNNELLING SPECTROSC; HERTEL T, 1995, J CHEM PHYS, V102, P3414, DOI 10.1063/1.469215; Higgins J, 2001, J CHEM PHYS, V114, P5277, DOI 10.1063/1.1349895; Hla SW, 2000, PHYS REV LETT, V85, P2777, DOI 10.1103/PhysRevLett.85.2777; Ho W, 1998, ACCOUNTS CHEM RES, V31, P567, DOI 10.1021/ar9501784; HUSSLA I, 1985, PHYS REV B, V32, P3489, DOI 10.1103/PhysRevB.32.3489; Jortner J., 1991, MODE SELECTIVE CHEM; Kim Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.126104; Komeda T, 2002, SCIENCE, V295, P2055, DOI 10.1126/science.1069016; Lorente N, 2000, PHYS REV LETT, V85, P2997, DOI 10.1103/PhysRevLett.85.2997; Lorente N, 2000, FARADAY DISCUSS, V117, P277, DOI 10.1039/b002826f; POTTER ED, 1992, NATURE, V355, P66, DOI 10.1038/355066a0; PRYBYLA JA, 1990, PHYS REV LETT, V64, P1537, DOI 10.1103/PhysRevLett.64.1537; Rust HP, 1997, REV SCI INSTRUM, V68, P129, DOI 10.1063/1.1147846; SALAM GP, 1994, PHYS REV B, V49, P10655, DOI 10.1103/PhysRevB.49.10655; SINHA A, 1991, J CHEM PHYS, V94, P4928, DOI 10.1063/1.460578; Stipe BC, 1998, PHYS REV LETT, V81, P1263, DOI 10.1103/PhysRevLett.81.1263; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; Stipe BC, 1997, PHYS REV LETT, V78, P4410, DOI 10.1103/PhysRevLett.78.4410	24	276	277	2	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2003	423	6939					525	528		10.1038/nature01649	http://dx.doi.org/10.1038/nature01649			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774118				2022-12-28	WOS:000183162900039
J	Eastham, JA; Riedel, E; Scardino, PT; Shike, M; Fleisher, M; Schatzkin, A; Lanza, E; Latkany, L; Begg, CB				Eastham, JA; Riedel, E; Scardino, PT; Shike, M; Fleisher, M; Schatzkin, A; Lanza, E; Latkany, L; Begg, CB		Poly Prevention Trial Study Grp	Variation of serum prostate-specific antigen levels - An evaluation of year-to-year fluctuations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; HIGH-FIBER DIET; RADICAL PROSTATECTOMY; BIOLOGICAL VARIATION; CANCER MORTALITY; LOW-FAT; MEN; TRIAL; AGE; BIOPSY	Context Serum prostate-specific antigen (PSA) testing is frequently used in early detection programs for prostate cancer. While PSA testing has resulted in an increase in prostate cancer detection, its routine use has been questioned because of a lack of specificity. Objective To determine whether year-to-year fluctuations in PSA levels are due to natural variation and render a single PSA test result unreliable. Design, Setting, and Participants Retrospective analysis of an unscreened population of 972 men (median age, 62 years) participating in the Polyp Prevention Trial (1991-1998). Five consecutive blood samples were obtained during a 4-year period and were assessed for total and free PSA levels. Main Outcome Measure Abnormal PSA test result based on a PSA level higher than 4 ng/mL; a PSA level higher than 2.5 ng/mL; a PSA level above the age-specific cutoff; a PSA level in the range of 4 to 10 ng/mL and a free-to-total ratio of less than 0.25 ng/mL; or a PSA velocity higher than 0.75 ng/mL per year. Results Prostate biopsy would have been recommended in 207 participants (21%) with a PSA level higher than 4 ng/mL; in 358 (37%) with a level higher than 2.5 ng/mL; in 172 (18%) with a level above the age-specific cutoff; in 190 (20%) with a level between 4 and 10 ng/mL and a free-to-total ratio of less than 0.25 ng/mL; and in 145 (15%) with a velocity higher than 0.75 ng/mL per year. Among men with an abnormal PSA finding, a high proportion had a normal PSA finding at 1 or more subsequent visits during 4-year follow-up: 68 (44%) of 154 participants with a PSA level higher than 4 ng/mL; 116 (40%) of 291 had a level higher than 2.5 ng/mL; 64 (55%) of 117 had an elevated level above the age-specific cutoff; and 76 (53%) of 143 had a level between 4 and 10 ng/mL and a free-to-total ratio of less than 0.25 ng/mL. Conclusion An isolated elevation in PSA level should be confirmed several weeks later before proceeding with further testing, including prostate biopsy.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Eastham, JA (corresponding author), 353 E 68th St,Suite 527, New York, NY 10021 USA.	easthamj@mskcc.org		Russo, Lianne/0000-0002-6966-250X	NCI NIH HHS [N01-SC-05318] Funding Source: Medline; DIVISION OF CLINICAL SCIENCES - NCI [N01SC005318] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01CN000151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartsch G, 2001, UROLOGY, V58, P417, DOI 10.1016/S0090-4295(01)01264-X; CARTER HB, 1992, CANCER RES, V52, P3323; Carter HB, 1999, UROLOGY, V53, P126, DOI 10.1016/S0090-4295(98)00466-X; Catalona WJ, 2000, UROLOGY, V55, P791, DOI 10.1016/S0090-4295(99)00602-0; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; Catalona WJ, 1998, JAMA-J AM MED ASSOC, V279, P1542, DOI 10.1001/jama.279.19.1542; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; Chapple A, 2002, BRIT MED J, V325, P737, DOI 10.1136/bmj.325.7367.737; COPLEN DE, 1991, J UROLOGY, V146, P75, DOI 10.1016/S0022-5347(17)37717-0; Crawford ED, 1999, PROSTATE, V38, P296; EPSTEIN JI, 1994, J UROLOGY, V152, P1721, DOI 10.1016/S0022-5347(17)32370-4; Epstein JI, 2001, J UROLOGY, V166, P1688, DOI 10.1016/S0022-5347(05)65654-6; FEIGHTNER JW, 1994, CANADIAN GUIDE CLIN, P812; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Hakama M, 2001, J UROLOGY, V166, P2189, DOI 10.1016/S0022-5347(05)65532-2; HAMMER P, 1996, J UROLOGY, V151, P99; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; JACOBSEN SJ, 1995, UROLOGY, V45, P447, DOI 10.1016/S0090-4295(99)80014-4; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Lanza E, 1996, CANCER EPIDEM BIOMAR, V5, P385; Lu-Yao G, 2002, BMJ-BRIT MED J, V325, P740, DOI 10.1136/bmj.325.7367.740; Nixon RG, 1997, J UROLOGY, V157, P2183, DOI 10.1016/S0022-5347(01)64711-6; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; OHORI M, 1994, J UROLOGY, V152, P1714, DOI 10.1016/S0022-5347(17)32369-8; Ornstein DK, 1997, J UROLOGY, V157, P2179, DOI 10.1016/S0022-5347(01)64708-6; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Schatzkin A, 1996, CANCER EPIDEM BIOMAR, V5, P375; Shike M, 2002, J CLIN ONCOL, V20, P3592, DOI 10.1200/JCO.2002.02.040; STAMEY TA, 1989, J UROLOGY, V141, P1070; Steele CB, 2000, AM J PUBLIC HEALTH, V90, P1595, DOI 10.2105/AJPH.90.10.1595; STENMAN UH, 1991, CANCER RES, V51, P222; Tchetgen MBN, 1997, UROL CLIN N AM, V24, P283, DOI 10.1016/S0094-0143(05)70374-8; *US PREV SERV TASK, REC RAT SCREEN PROST; *US PREV SERV TASK, REC PROST CANC SCREE	34	168	175	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2695	2700		10.1001/jama.289.20.2695	http://dx.doi.org/10.1001/jama.289.20.2695			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682DG	12771116	Bronze			2022-12-28	WOS:000183075600028
J	Young, JB; Abraham, WT; Smith, AL; Leon, AR; Lieberman, R; Wilkoff, B; Canby, RC; Schroeder, JS; Liem, LB; Hall, S; Wheelan, K				Young, JB; Abraham, WT; Smith, AL; Leon, AR; Lieberman, R; Wilkoff, B; Canby, RC; Schroeder, JS; Liem, LB; Hall, S; Wheelan, K		MIRACLE ICD Trial Investigators	Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure - The MIRACLE ICD Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BUNDLE-BRANCH BLOCK; DILATED CARDIOMYOPATHY; INSYNC; CONDUCTION; EFFICACY; THERAPY; DEVICES	Context Cardiac resynchronization therapy (CRT) through biventricular pacing is an effective treatment for heart failure (HF) with a wide QRS; however, the outcomes of patients requiring CRT and implantable cardioverter defibrillator (ICD) therapy are unknown. Objective To examine the efficacy and safety of combined CRT and ICD therapy in patients with New York Heart Association (NYHA) class III or IV congestive HF despite appropriate medical management. Design, Setting, and Participants Randomized, double-blind, parallel-controlled trial conducted from October 1, 1999, to August 31, 2001, of 369 patients with left ventricular ejection fraction of 35% or less, QRS duration of 130 ms, at high risk of life-threatening ventricular arrhythmias, and in NYHA class III (n=328) or IV (n=41) despite optimized medical treatment. Interventions Of 369 randomized patients who received devices with combined CRT and ICD capabilities, 182 were controls (ICD activated, CRT off) and 187 were in the CRT group (ICD activated, CRT on). Main Outcome Measures The primary double-blind study end points were changes between baseline and 6 months in quality of life, functional class, and distance covered during a 6-minute walk. Additional outcome measures included changes in exercise capacity, plasma neurohormones, left ventricular function, and overall HF status. Survival, incidence of ventricular arrhythmias, and rates of hospitalization were also compared. Results At 6 months, patients assigned to CRT had a greater improvement in median (95% confidence interval) quality of life score (-17.5 [-21 to -14] vs -11.0 [-16 to -7], P=.02) and functional class (-1 [-1 to -1] vs 0 [-1 to 0], P=.007) than controls but were no different in the change in distance walked in 6 minutes (55 m [44-79] vs 53 m [43-75], P=36). Peak oxygen consumption increased by 1.1 mL/kg per minute (0.7-1.6) in the CRT group vs 0.1 mL/kg per minute (-0.1 to 0.8) in controls (P=.04), although treadmill exercise duration increased by 56 seconds (30-79) in the CRT group and decreased by 11 seconds (-55 to 12) in controls (P<.001). No significant differences were observed in changes in left ventricular size or function, overall HF status, survival, and rates of hospitalization. No proarrhythmia was observed and arrhythmia termination capabilities were not impaired. Conclusions Cardiac resynchronization improved quality of life, functional status, and,exercise capacity in patients with moderate to severe HF, a wide QRS interval, and life-threatening arrhythmias. These improvements occurred in the context of underlying appropriate medical management without proarrhythmia or compromised ICD function.	Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Kentucky, Lexington, KY USA; Emory Univ, Sch Med, Atlanta, GA USA; Harper Grace Hosp, Detroit, MI USA; Texas Cardiac Arrhythmia, Austin, TX USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Baylor Univ, Med Ctr, Dallas, TX USA	Cleveland Clinic Foundation; University of Kentucky; Emory University; Stanford University; Baylor University; Baylor University Medical Center	Young, JB (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave,Desk F25, Cleveland, OH 44195 USA.			Wilkoff, Bruce/0000-0001-8905-9233				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Abraham WT, 2000, J CARD FAIL, V6, P369, DOI 10.1054/jcaf.2000.20841; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; Gras D, 1998, PACE, V21, P2249, DOI 10.1111/j.1540-8159.1998.tb01162.x; Gregoratos G, 1998, CIRCULATION, V97, P1325, DOI 10.1161/01.CIR.97.13.1325; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Hahn, 1991, STAT INTERVALS GUIDE, P82; Higgins SL, 2000, J AM COLL CARDIOL, V36, P824, DOI 10.1016/S0735-1097(00)00795-6; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1051, DOI 10.1056/NEJM198210213071704; KOCOVIC DZ, 2002, PACING CLIN ELECTROP, V25, P600; Leclercq C, 1998, J AM COLL CARDIOL, V32, P1825, DOI 10.1016/S0735-1097(98)00492-6; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Littmann L, 2000, J ELECTROCARDIOL, V33, P115, DOI 10.1054/jelc.2000.20330; Lozano I, 2000, PACE, V23, P1711; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; NAIR VN, 1984, TECHNOMETRICS, V26, P265, DOI 10.2307/1267553; Nelson GS, 2000, CIRCULATION, V102, P3053; Packer M, 2001, J CARD FAIL, V7, P176, DOI 10.1054/jcaf.2001.25652; Rector TS, 1987, HEART FAIL, V3, P198; Saxon LA, 1998, J CARDIOVASC ELECTR, V9, P13, DOI 10.1111/j.1540-8167.1998.tb00862.x; Stellbrink C, 1999, AM J CARDIOL, V83, p143D; The Criteria Committee of the New York Heart Association, 1994, NOM CRIT DIAGN DIS H; Walker S, 2000, AM J CARDIOL, V86, P231, DOI 10.1016/S0002-9149(00)00865-1; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115; Xiao HB, 1996, INT J CARDIOL, V53, P163, DOI 10.1016/0167-5273(95)02502-2; XIAO HB, 1992, BRIT HEART J, V68, P403; Zagrodzky JD, 2001, AM J CARDIOL, V87, P1208, DOI 10.1016/S0002-9149(01)01498-9; Zardini M, 2000, EUR HEART J SUPPL, V2, pJ16	31	1137	1228	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2685	2694		10.1001/jama.289.20.2685	http://dx.doi.org/10.1001/jama.289.20.2685			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682DG	12771115				2022-12-28	WOS:000183075600027
J	Sudou, H; Iguchi, S; Murata, Y; Taniguchi, Y				Sudou, H; Iguchi, S; Murata, Y; Taniguchi, Y			Orbital motion in the radio galaxy 3C 66B: Evidence for a supermassive black hole binary	SCIENCE			English	Article							ACTIVE GALACTIC NUCLEI; ULTRALUMINOUS INFRARED GALAXIES; OJ-287; MODELS; JETS	Supermassive black hole binaries may exist in the centers of active galactic nuclei such as quasars and radio galaxies, and mergers between galaxies may result in the formation of supermassive binaries during the course of galactic evolution. Using the very-long-baseline interferometer, we imaged the radio galaxy 3C 66B at radio frequencies and found that the unresolved radio core of 3C 66B shows well-defined elliptical motions with a period of 1.05 +/- 0.03 years, which provides a direct detection of a supermassive black hole binary.	Tohoku Univ, Grad Sch Sci, Astron Inst, Sendai, Miyagi 9808578, Japan; Natl Astron Observ, Tokyo 1818588, Japan; Inst Space & Astronaut Sci, Kanagawa 2298510, Japan	Tohoku University; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS)	Sudou, H (corresponding author), Gifu Univ, Fac Engn, Gifu 5011193, Japan.			Iguchi, Satoru/0000-0002-7191-2301				Abraham Z, 2000, ASTRON ASTROPHYS, V355, P915; BEGELMAN MC, 1980, NATURE, V287, P307, DOI 10.1038/287307a0; FUKUSHIGE T, 1992, ASTROPHYS J, V396, pL61, DOI 10.1086/186517; GASKELL M, 2002, JETS STARS GALACTIC, P165; Ghez AM, 2000, NATURE, V407, P349, DOI 10.1038/35030032; KONIGL A, 1981, ASTROPHYS J, V243, P700, DOI 10.1086/158638; KORMENDY J, 1995, ANNU REV ASTRON ASTR, V33, P581, DOI 10.1146/annurev.aa.33.090195.003053; Lehto HJ, 1996, ASTROPHYS J, V460, P207, DOI 10.1086/176962; Lobanov AP, 1998, ASTRON ASTROPHYS, V330, P79; MATTHEWS TA, 1964, ASTROPHYS J, V140, P35, DOI 10.1086/147890; Merritt D, 2002, SCIENCE, V297, P1310, DOI 10.1126/science.1074688; MILLER HR, 1978, ASTROPHYS J, V220, P19, DOI 10.1086/155878; MIYOSHI M, 1995, NATURE, V373, P127, DOI 10.1038/373127a0; REES MJ, 1984, ANNU REV ASTRON ASTR, V22, P471, DOI 10.1146/annurev.aa.22.090184.002351; REFSDAL S, 1964, MON NOT R ASTRON SOC, V128, P295, DOI 10.1093/mnras/128.4.295; ROOS N, 1993, ASTROPHYS J, V409, P130, DOI 10.1086/172647; SANDERS DB, 1988, ASTROPHYS J, V325, P74, DOI 10.1086/165983; Taniguchi Y, 1999, ASTROPHYS J, V514, pL9, DOI 10.1086/311931; THOMPSON R, 1986, INTERFEROMETRY SYNTH, P554; THORNE KS, 1976, ASTROPHYS J, V204, pL1, DOI 10.1086/182042; Valtaoja E, 2000, ASTROPHYS J, V531, P744, DOI 10.1086/308494; Yu QJ, 2002, MON NOT R ASTRON SOC, V331, P935, DOI 10.1046/j.1365-8711.2002.05242.x	23	102	102	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1263	1265		10.1126/science.1082817	http://dx.doi.org/10.1126/science.1082817			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764190	Green Submitted			2022-12-28	WOS:000183042400040
J	Hwang, HY; Olson, SK; Esko, JD; Horvitz, HR				Hwang, HY; Olson, SK; Esko, JD; Horvitz, HR			Caenorhabditis elegans early embryogenesis and vulval morphogenesis require chondroitin biosynthesis	NATURE			English	Article							UDP-GLUCURONIC ACID; HEPARAN-SULFATE; EPITHELIAL INVAGINATION; MOLECULAR-CLONING; GENE; PROTEOGLYCAN; EXPRESSION; SQV-7; GLYCOSAMINOGLYCANS; GALACTOSE	Defects in glycosaminoglycan biosynthesis disrupt animal development and can cause human disease(1-4). So far much of the focus on glycosaminoglycans has been on heparan sulphate. Mutations in eight squashed vulva (sqv) genes in Caenorhabditis elegans cause defects in cytokinesis during embryogenesis and in vulval morphogenesis during postembryonic development(5,6). Seven of the eight sqv genes have been shown to control the biosynthesis of the glycosaminoglycans chondroitin and heparan sulphate(6-11). Here we present the molecular identification and characterization of the eighth gene, sqv-5. This gene encodes a bifunctional glycosyltransferase that is probably localized to the Golgi apparatus and is responsible for the biosynthesis of chondroitin but not heparan sulphate. Our findings show that chondroitin is crucial for both cytokinesis and morphogenesis during C. elegans development.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, Room 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.			Hwang, Ho-Yon/0000-0003-0204-8932				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Austin C. R., 1965, FERTILIZATION; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255; ELLIS RE, 1995, GENETICS, V139, P561; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; ESKO JD, 1993, CURRENT PROTOCOLS MO; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hwang HY, 2003, J BIOL CHEM, V278, P11735, DOI 10.1074/jbc.C200518200; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14224, DOI 10.1073/pnas.172522499; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; LANE MC, 1993, DEVELOPMENT, V117, P1049; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Wei G, 2000, J BIOL CHEM, V275, P27733; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	30	154	158	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					439	443		10.1038/nature01634	http://dx.doi.org/10.1038/nature01634			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761549				2022-12-28	WOS:000183012000042
J	Pergams, ORW; Barnes, WM; Nyberg, D				Pergams, ORW; Barnes, WM; Nyberg, D			Rapid change in mouse mitochondrial DNA	NATURE			English	Article							PCR; AMPLIFICATION; FIDELITY		Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Washington University (WUSTL)	Pergams, ORW (corresponding author), Nature Conservancy, Chicago Zool Soc, Dept Conservat Biol, Brookfield, IL 60513 USA.							BARNES WM, 1994, TRENDS BIOCHEM SCI, V19, P342, DOI 10.1016/0968-0004(94)90075-2; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; BARNES WM, 1995, Patent No. 5436149; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; GOODYEAR PD, 1994, BIOTECHNIQUES, V16, P232; Pergams ORW, 2001, J MAMMAL, V82, P984, DOI 10.1644/1545-1542(2001)082<0984:MCOMCT>2.0.CO;2; PERGAMS ORW, UNPUB P R SOC LOND B; Steinberg EK, 1999, MOL ECOL, V8, P1075; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018	10	33	35	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					397	397		10.1038/423397a	http://dx.doi.org/10.1038/423397a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761536	Bronze			2022-12-28	WOS:000183012000027
J	Spiegel, BMR; Targownik, L; Dulai, GS; Gralnek, IM				Spiegel, BMR; Targownik, L; Dulai, GS; Gralnek, IM			The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HELICOBACTER-PYLORI INFECTION; RANDOMIZED CONTROLLED-TRIAL; PEPTIC-ULCER DISEASE; RHEUMATOID-ARTHRITIS; MYOCARDIAL-INFARCTION; UNITED-STATES; DOUBLE-BLIND; GASTROINTESTINAL ENDOSCOPY; NONULCER DYSPEPSIA	Background: Rofecoxib and celecoxib (coxibs) effectively treat chronic arthritis pain and reduce ulcer complications by 50% compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). However, their absolute risk reduction is small and the cost-effectiveness of treatment is uncertain. Objective: To determine whether the degree of risk reduction in gastrointestinal complications by coxibs offsets their increased cost compared with a generic nonselective NSAID. Design: Cost-utility analysis. Data Sources: Systematic review of MEDLINE and published abstracts. Target Population: Patients with osteoarthritis or rheumatoid arthritis who are not taking aspirin and who require long-term NSAID therapy for moderate to severe arthritis pain. Perspective: Third-party payer. Interventions: Naproxen, 500 mg twice daily, and coxib, once daily. Patients intolerant of naproxen were switched to a coxib. Outcome Measures: Incremental cost per quality-adjusted life-year (QALY) gained. Results of Base-Case Analysis: Using a coxib instead of a nonselective NSAID in average-risk patients cost an incremental $275 809 per year to gain 1 additional QALY. Results of Sensitivity Analysis: The incremental cost per QALY gained decreased to $55 803 when the analysis was limited to the subset of patients with a history of bleeding ulcers. The coxib strategy became dominant when the cost of coxibs was reduced by 90% of the current average wholesale price. In probabilistic sensitivity analysis, if a third-party payer was willing to pay $150 000 per QALY gained, then 4.3% of average-risk patients would fall within the budget. Conclusions: The risk reduction seen with coxibs does not offset their increased costs compared with nonselective NSAIDs in the management of average-risk patients with chronic arthritis. However, coxibs may provide an acceptable incremental cost-effectiveness ratio in the subgroup of patients with a history of bleeding ulcers.	Univ Calif Los Angeles, CURE Digest Dis Res Ctr,David Geffen Sch Med, Ctr Study Digest Healthcare Qual & Outcomes, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Gralnek, IM (corresponding author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr,David Geffen Sch Med, Ctr Study Digest Healthcare Qual & Outcomes, Vet Adm Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 115,Room 215B, Los Angeles, CA 90073 USA.	igralnek@mednet.ucla.edu	Targownik, Laura/ABD-2427-2021	Targownik, Laura/0000-0002-4366-9076	NCRR NIH HHS [K23 RR-16188] Funding Source: Medline; NIDDK NIH HHS [DK-07180] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR016188] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Al MJ, 1996, PHARMACOECONOMICS, V10, P141, DOI 10.2165/00019053-199610020-00006; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; *ARTHR PAIN SOC, 2002, GUID MAN PAIN OST RH; Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; Berg AO, 2002, ANN INTERN MED, V136, P157, DOI 10.7326/0003-4819-136-2-200201150-00015; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; Cantor SB, 2002, J PAIN SYMPTOM MANAG, V24, pS28, DOI 10.1016/S0885-3924(02)00412-8; Centers for Disease Control and Prevention, NAT VIT STAT REP; Chan FKL, 2002, NEW ENGL J MED, V347, P2104, DOI 10.1056/NEJMoa021907; Chan FKL, 2001, NEW ENGL J MED, V344, P967, DOI 10.1056/NEJM200103293441304; *CTR MED MED SERV, 2002, MED PROV AN REV MEDP; Danesh J, 2000, ARCH INTERN MED, V160, P1192, DOI 10.1001/archinte.160.8.1192; Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781; DEBOER WA, 1995, SCAND J GASTROENTERO, V30, P401, DOI 10.3109/00365529509093298; Deeks JJ, 2002, BRIT MED J, V325, P619, DOI 10.1136/bmj.325.7365.619; Dekkers CPM, 1999, ALIMENT PHARM THERAP, V13, P179; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Ebell MH, 1997, J FAM PRACTICE, V44, P545; ECKMAN MH, 1993, NEW ENGL J MED, V329, P696, DOI 10.1056/NEJM199309023291005; Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6; Fendrick AM, 2002, ARTHRIT RHEUM-ARTHR, V47, P36, DOI 10.1002/art1.10159; Geba GP, 2002, JAMA-J AM MED ASSOC, V287, P64, DOI 10.1001/jama.287.1.64; Geusens PP, 2002, SCAND J RHEUMATOL, V31, P230, DOI 10.1080/030097402320318431; Gold MR, 1996, COST EFFECTIVENESS H; Goldstein JL, 2002, GASTROENTEROLOGY, V122, pA469; Goldstein JL, 2001, GASTROENTEROLOGY, V120, pA105, DOI 10.1016/S0016-5085(08)80516-1; Goldstein JL, 2001, AM J GASTROENTEROL, V96, P1019; Groeneveld PW, 2001, AM J GASTROENTEROL, V96, P338; Hamel MB, 2000, AM J MED, V109, P614, DOI 10.1016/S0002-9343(00)00591-X; Hamel MB, 1997, ANN INTERN MED, V127, P195, DOI 10.7326/0003-4819-127-3-199708010-00003; Hawkey CJ, 2000, GASTROENTEROLOGY, V119, P521, DOI 10.1053/gast.2000.9561; HIRSCHHORN LR, 1994, J INFECT DIS, V169, P127, DOI 10.1093/infdis/169.1.127; Huang JQ, 2002, LANCET, V359, P14, DOI 10.1016/S0140-6736(02)07273-2; Jaakkimainen RL, 1999, BMJ-BRIT MED J, V319, P1040, DOI 10.1136/bmj.319.7216.1040; Juni P, 2002, ARCH INTERN MED, V162, P2639, DOI 10.1001/archinte.162.22.2639-a; KNILLJONES R, 1990, POSTGRAD MED J, V66, P639, DOI 10.1136/pgmj.66.778.639; Kuntz KM, 1999, ANN INTERN MED, V130, P709, DOI 10.7326/0003-4819-130-9-199905040-00002; Lai KC, 2001, GASTROENTEROLOGY, V120, pA104, DOI 10.1016/S0016-5085(08)80512-4; Laine L, 1999, GASTROENTEROLOGY, V117, P776, DOI 10.1016/S0016-5085(99)70334-3; Laine L, 2002, GASTROENTEROLOGY, V122, pA53; Laine L, 2001, ANN INTERN MED, V134, P361, DOI 10.7326/0003-4819-134-5-200103060-00008; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; Langman MJ, 1999, JAMA-J AM MED ASSOC, V282, P1929, DOI 10.1001/jama.282.20.1929; LARKAI EN, 1987, AM J GASTROENTEROL, V82, P1153; Lau JYW, 1999, NEW ENGL J MED, V340, P751, DOI 10.1056/NEJM199903113401002; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Lawrence WF, 1996, J CLIN EPIDEMIOL, V49, P1239, DOI 10.1016/S0895-4356(96)00220-X; Lieu TA, 1997, J AM COLL CARDIOL, V30, P1741, DOI 10.1016/S0735-1097(97)00391-4; Maetzel A, 1998, ARTHRITIS RHEUM, V41, P16, DOI 10.1002/1529-0131(199801)41:1<16::AID-ART3>3.3.CO;2-W; MALFERTHEINER P, 1993, SCAND J GASTROENTERO, V28, P34, DOI 10.3109/00365529309098341; Mamdani M, 2002, BRIT MED J, V325, P624, DOI 10.1136/bmj.325.7365.624; March LM, 1997, BAILLIERE CLIN RHEUM, V11, P817, DOI 10.1016/S0950-3579(97)80011-8; Marra CA, 2000, J RHEUMATOL, V27, P2731; MATON PN, 1991, NEW ENGL J MED, V324, P965; McKenna F, 2001, SCAND J RHEUMATOL, V30, P11; Moayyedi P, 2000, GASTROENTEROLOGY, V118, pA471, DOI 10.1016/S0016-5085(00)84002-0; Moore RD, 1997, J ACQ IMMUN DEF SYND, V16, P15, DOI 10.1097/00042560-199709010-00003; MUENNIG P, 2002, DESIGNING CONDUCTING; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Nyman JA, 2002, ARCH INTERN MED, V162, P177, DOI 10.1001/archinte.162.2.177; OFMAN JJ, IN PRESS ARTHRITIS C; Pellissier JM, 2001, CLIN THER, V23, P1061, DOI 10.1016/S0149-2918(01)80092-8; PETITTI DB, 2000, METAANALYSIS DECISIO; QUINE MA, 1995, BRIT J SURG, V82, P530, DOI 10.1002/bjs.1800820430; REIERTSEN O, 1987, ENDOSCOPY, V19, P1, DOI 10.1055/s-2007-1013011; Revicki DA, 1998, J AFFECT DISORDERS, V48, P25, DOI 10.1016/S0165-0327(97)00117-1; Saag K, 2000, ARCH FAM MED, V9, P1124, DOI 10.1001/archfami.9.10.1124; Sanders GD, 2001, ANN INTERN MED, V135, P870, DOI 10.7326/0003-4819-135-10-200111200-00007; SCHNITZER T, 2002, ARTHRITIS RHEUM, V46, pA326; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; Sonnenberg A, 1997, AM J GASTROENTEROL, V92, P614; SPENCER CM, 1994, DRUGS, V48, P404, DOI 10.2165/00003495-199448030-00007; Spigel BMR, 2002, GASTROENTEROLOGY, V122, P1270, DOI 10.1053/gast.2002.33019; Straus WL, 2002, AM J GASTROENTEROL, V97, P1951; TEARE JP, 1995, EUR J GASTROEN HEPAT, V7, P275; THIJS JC, 1993, SCAND J GASTROENTERO, V28, P934, DOI 10.3109/00365529309098287; *THOM MED EC, 2002, 2002 RED BOOK; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; *US FDA, 2001, OPDRA POSTM SAF REV; *US FDA, 2001, 21042 US FDA ADV COM; *US FDA, 2001, CARD SAF REV; VALENZUELA JE, 1991, DIGEST DIS SCI, V36, P761, DOI 10.1007/BF01311234; Watson DJ, 2000, ARCH INTERN MED, V160, P2998, DOI 10.1001/archinte.160.19.2998; Weideman RA, 2002, AM J MANAG CARE, V8, P869; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	89	90	90	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					795	806		10.7326/0003-4819-138-10-200305200-00007	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755551				2022-12-28	WOS:000182920700003
J	Krishnan, P; Mungherera, M; Jones, SB				Krishnan, P; Mungherera, M; Jones, SB			Tobacco and the Commonwealth: a call to action	LANCET			English	Editorial Material							POLICY		British Med Assoc, Tobacco Control Resource Ctr, Edinburgh ED2 1DA, Midlothian, Scotland; Uganda Med Assoc, Kampala, Uganda; Commonwealth Med Assoc, Kuala Lumpur, Malaysia		Jones, SB (corresponding author), British Med Assoc, Tobacco Control Resource Ctr, Edinburgh ED2 1DA, Midlothian, Scotland.			Jones, Sinead/0000-0002-1364-4150				[Anonymous], 1999, CURB EP GOV EC TOB C; Assunta M, 2002, TOB CONTROL, V11, P277, DOI 10.1136/tc.11.3.277; *BAT, Q REP 31 MARCH 2003; CORROA MA, 2000, TOBACCO CONTROL COUN; Ernster V, 2000, B WORLD HEALTH ORGAN, V78, P891; Framework Convention on Tobacco Control, FRAM CONV TOB CONTR; Mackay J., 2002, TOBACCO ATLAS, P51; *ROYAL COLL PHYS, 2000, NIC ADD BRIT REP TOB, P5; Saloojee Y, 2000, B WORLD HEALTH ORGAN, V78, P911; SAMET JM, 2001, WOMEN TOBACCO EPIDEM, pR6; van Walbeek C, 2002, SAMJ S AFR MED J, V92, P468; Warren CW, 2000, B WORLD HEALTH ORGAN, V78, P868	12	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 17	2003	361	9370					1669	1670		10.1016/S0140-6736(03)13381-8	http://dx.doi.org/10.1016/S0140-6736(03)13381-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767730				2022-12-28	WOS:000182919700005
J	Relman, AS				Relman, AS			Defending professional independence - ACCME's proposed new guidelines for commercial support of CME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INDUSTRY		Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Relman, AS (corresponding author), Harvard Univ, Sch Med, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	arelman@rics.bwh.harvard.edu						*ACCR COUNC CONT M, 2003, NEW ACCME STAND COMM; HENSLEY S, 2003, WALL STREET J   0114, pD5; Holmer AF, 2001, JAMA-J AM MED ASSOC, V285, P2012, DOI 10.1001/jama.285.15.2012; Petersen Melody, 2001, NY TIMES        0424, pA1; PINES WL, 2001, PHARM EXECUTIVE  JUL, P18; Relman AS, 2002, NEW REPUBLIC, V227, P27; Relman AS, 2001, JAMA-J AM MED ASSOC, V285, P2009, DOI 10.1001/jama.285.15.2009; *WASH LEG FDN, 2003, ACCMES PROP STAND CO; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	9	37	37	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2418	2420		10.1001/jama.289.18.2418	http://dx.doi.org/10.1001/jama.289.18.2418			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677WF	12746367				2022-12-28	WOS:000182831200033
J	Huang, E; Cheng, SH; Dressman, H; Pittman, J; Tsou, MH; Horng, CF; Bild, A; Iversen, ES; Liao, M; Chen, CM; West, M; Nevins, JR; Huang, AT				Huang, E; Cheng, SH; Dressman, H; Pittman, J; Tsou, MH; Horng, CF; Bild, A; Iversen, ES; Liao, M; Chen, CM; West, M; Nevins, JR; Huang, AT			Gene expression predictors of breast cancer outcomes	LANCET			English	Article							LYMPH-NODE METASTASIS; PROGNOSTIC FACTORS; CLASSIFICATION; DISCOVERY	Background Correlation of risk factors with genomic data promises to provide specific treatment for individual patients, and needs interpretation of complex, multivariate patterns in gene expression data, as well as assessment of their ability to improve clinical predictions. We aimed to predict nodal metastatic states and relapse for breast cancer patients.. Methods We analysed DNA microarray data from samples of primary breast tumours, using non-linear statistical analyses to assess multiple patterns of interactions of groups of genes that have predictive value for the individual patient, with respect to lymph node metastasis and cancer recurrence. Findings We identified aggregate patterns of gene expression (metagenes) that associate with lymph node status and recurrence, and that are capable of predicting outcomes in individual patients with about 90% accuracy. The metagenes defined distinct groups of genes, suggesting different biological processes underlying these two characteristics of breast cancer. Initial external validation came from similarly accurate predictions of nodal status of a small sample in a distinct population. Interpretation Multiple aggregate measures of profiles of gene expression define valuable predictive associations with lymph node metastasis and disease recurrence for individual patients. Gene expression data have the potential to aid accurate, individualised, prognosis. Importantly, these data are assessed in terms of precise numerical predictions, with ranges of probabilities of outcome. Precise and statistically valid assessments of risks specific for patients, will ultimately be of most value to clinicians faced with treatment decisions.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27708 USA; Duke Univ, Dept Med, Durham, NC 27708 USA; Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27708 USA; Duke Univ, Inst Stat & Decis Sci, Durham, NC 27708 USA; Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan; Howard Hughes Med Inst, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27708 USA.		Huang, Erich/B-1894-2008	Huang, Erich/0000-0001-5547-9408; Clarke, Jennifer/0000-0002-2723-7249				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Cheng SH, 2000, BREAST CANCER RES TR, V63, P213, DOI 10.1023/A:1006468514396; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Jatoi I, 1999, J CLIN ONCOL, V17, P2334, DOI 10.1200/JCO.1999.17.8.2334; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; MCGUIRE WL, 1987, BREAST CANCER RES TR, V10, P5, DOI 10.1007/BF01806129; MITTRA I, 1991, EUR J CANCER, V27, P1574, DOI 10.1016/0277-5379(91)90418-D; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Singletary SE, 2002, J CLIN ONCOL, V20, P3628, DOI 10.1200/JCO.2002.02.026; Spang Rainer, 2002, In Silico Biology, V2, P369; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; 2001, LANCET, V352, P930	17	494	534	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1590	1596		10.1016/S0140-6736(03)13308-9	http://dx.doi.org/10.1016/S0140-6736(03)13308-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747878				2022-12-28	WOS:000182746300008
J	Moran, M; Ford, N				Moran, M; Ford, N			The G8 and access to medicines: no more broken promises	LANCET			English	Editorial Material									Med Sans Frontieres, London EC1N 8QX, England	Doctors Without Borders	Ford, N (corresponding author), Med Sans Frontieres, London EC1N 8QX, England.	Nathan.FORD@london.msf.org						Cooper Helene, 2001, WALL STREET J   0302; PECOUL B, 1999, JAMA-J AM MED ASSOC, V4, P361; Piot P, 2002, LANCET, V360, P86, DOI 10.1016/S0140-6736(02)09342-X; t Hoen Ellen F. M., 2002, CHICAGO J INT LAW, V3, P27; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; *UN GEN ASS, 2001, SPEC SESS AIDS; *US DEP STAT INT F, 2001, COMM G 8 SUMM GEN 22; 2003, CAMPAIGN ACCESS ESSE; 2003, NY TIMES        0106	9	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	2003	361	9369					1578	1579		10.1016/S0140-6736(03)13324-7	http://dx.doi.org/10.1016/S0140-6736(03)13324-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747874				2022-12-28	WOS:000182746300004
J	Vasconcelos, PFC				Vasconcelos, PFC			Diagnosis of viral disease	LANCET			English	Editorial Material									Minist Hlth, FUNASA, Inst Evandro Chagas, Dept Arbovirus, BR-66090000 Belem, Para, Brazil	Instituto Evandro Chagas	Vasconcelos, PFC (corresponding author), Minist Hlth, FUNASA, Inst Evandro Chagas, Dept Arbovirus, BR-66090000 Belem, Para, Brazil.		Vasconcelos, Pedro/AAH-3142-2019						0	1	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1589	1589		10.1016/S0140-6736(03)13307-7	http://dx.doi.org/10.1016/S0140-6736(03)13307-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747877				2022-12-28	WOS:000182746300007
J	Ashworth, AC; Thompson, FC				Ashworth, AC; Thompson, FC			A fly in the biogeographic ointment	NATURE			English	Article							TRANSANTARCTIC MOUNTAINS; SIRIUS GROUP; ANTARCTICA		N Dakota State Univ, Dept Geosci, Fargo, ND 58105 USA; Smithsonian Inst, USDA, Systemat Entomol Lab, Washington, DC 20560 USA	North Dakota State University Fargo; Smithsonian Institution; Smithsonian National Museum of Natural History; United States Department of Agriculture (USDA)	Ashworth, AC (corresponding author), N Dakota State Univ, Dept Geosci, Fargo, ND 58105 USA.							Ashworth AC, 2003, PALAEOGEOGR PALAEOCL, V191, P191, DOI 10.1016/S0031-0182(02)00712-5; Ashworth AC, 2003, J MOLLUS STUD, V69, P89, DOI 10.1093/mollus/69.1.89; Askin RA., 2000, TERRA ANTARTICA, V7, P493; CONEY P, 1996, EUR J ENTOMOL, V93, P1; de Souza DA, 2002, ANN SOC ENTOMOL FR, V38, P177; DeConto RM, 2003, NATURE, V421, P245, DOI 10.1038/nature01290; Hill RS, 1996, REV PALAEOBOT PALYNO, V94, P11, DOI 10.1016/S0034-6667(96)00003-6; Marchant DR, 2002, GEOL SOC AM BULL, V114, P718, DOI 10.1130/0016-7606(2002)114<0718:FOPGAS>2.0.CO;2; Webb PN, 1996, MAR MICROPALEONTOL, V27, P273, DOI 10.1016/0377-8398(95)00066-6; WYGODZINSKY P, 1966, PAC INSECTS MONOGR, V9, P1; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	11	22	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					135	136		10.1038/423135a	http://dx.doi.org/10.1038/423135a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736672				2022-12-28	WOS:000182699600033
J	Looger, LL; Dwyer, MA; Smith, JJ; Hellinga, HW				Looger, LL; Dwyer, MA; Smith, JJ; Hellinga, HW			Computational design of receptor and sensor proteins with novel functions	NATURE			English	Article							BINDING; CHALLENGES; DOMAIN	The formation of complexes between proteins and ligands is fundamental to biological processes at the molecular level. Manipulation of molecular recognition between ligands and proteins is therefore important for basic biological studies(1) and has many biotechnological applications, including the construction of enzymes(2-4), biosensors(5,6), genetic circuits(7), signal transduction pathways(8) and chiral separations(9). The systematic manipulation of binding sites remains a major challenge. Computational design offers enormous generality for engineering protein structure and function(10). Here we present a structure-based computational method that can drastically redesign protein ligand-binding specificities. This method was used to construct soluble receptors that bind trinitrotoluene, L-lactate or serotonin with high selectivity and affinity. These engineered receptors can function as biosensors for their new ligands; we also incorporated them into synthetic bacterial signal transduction pathways, regulating gene expression in response to extracellular trinitrotoluene or L-lactate. The use of various ligands and proteins shows that a high degree of control over biomolecular recognition has been established computationally. The biological and biosensing activities of the designed receptors illustrate potential applications of computational design.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hellinga, HW (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	hwh@biochem.duke.edu						Arnold FH, 2001, NATURE, V409, P253, DOI 10.1038/35051731; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; Benson DE, 2002, BIOCHEMISTRY-US, V41, P3262, DOI 10.1021/bi011359i; Bishop A, 2000, ANNU REV BIOPH BIOM, V29, P577, DOI 10.1146/annurev.biophys.29.1.577; Bolon DN, 2001, P NATL ACAD SCI USA, V98, P14274, DOI 10.1073/pnas.251555398; Burlage R. S., 1999, U.S. Patent, Patent No. [5,972,638., 5972638, US5972638A]; BURTIS CA, 1999, TIME TXB CLIN CHEM; Cumming CJ, 2001, IEEE T GEOSCI REMOTE, V39, P1119, DOI 10.1109/36.927423; Dahiyat BI, 1996, PROTEIN SCI, V5, P895, DOI 10.1002/pro.5560050511; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Daunert S, 2000, CHEM REV, V100, P2705, DOI 10.1021/cr990115p; De Lorimier RM, 2002, PROTEIN SCI, V11, P2655, DOI 10.1110/ps.021860; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Harris JL, 1998, CURR OPIN CHEM BIOL, V2, P127, DOI 10.1016/S1367-5931(98)80044-6; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; Hellinga HW, 1998, TRENDS BIOTECHNOL, V16, P183, DOI 10.1016/S0167-7799(98)01174-3; Koh JT, 2002, CHEM BIOL, V9, P17, DOI 10.1016/S1074-5521(02)00087-X; Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997; Looger LL, 2001, J MOL BIOL, V307, P429, DOI 10.1006/jmbi.2000.4424; Maier NM, 2001, J CHROMATOGR A, V906, P3, DOI 10.1016/S0021-9673(00)00532-X; Mead KS, 2002, TRENDS BIOTECHNOL, V20, P276, DOI 10.1016/S0167-7799(02)01979-0; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; Reina J, 2002, NAT STRUCT BIOL, V9, P621, DOI 10.1038/nsb815; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; Yinon J, 2002, TRAC-TREND ANAL CHEM, V21, P292, DOI 10.1016/S0165-9936(02)00408-9	30	506	546	4	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					185	190		10.1038/nature01556	http://dx.doi.org/10.1038/nature01556			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736688				2022-12-28	WOS:000182699600050
J	Silove, D				Silove, D			Overcoming obstacles in confronting torture	LANCET			English	Editorial Material							REFUGEES; IMPACT		Liverpool Hosp, Psychiat Res & Teaching Unit, Liverpool, NSW 2170, Australia	Liverpool Hospital	Silove, D (corresponding author), Liverpool Hosp, Psychiat Res & Teaching Unit, Level 4,Hlth Serv Bldg, Liverpool, NSW 2170, Australia.							*AMN INT, 2002, AMN INT REP 2002; BASOGLU M, 1994, AM J PSYCHIAT, V151, P76; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; Shrestha NM, 1998, JAMA-J AM MED ASSOC, V280, P443, DOI 10.1001/jama.280.5.443; SILOVE D, 1991, AUST NZ J PSYCHIAT, V25, P481, DOI 10.3109/00048679109064441; Silove D, 2002, COMPR PSYCHIAT, V43, P49, DOI 10.1053/comp.2002.29843; Summerfield D, 2003, BRIT MED J, V326, P773, DOI 10.1136/bmj.326.7393.773	7	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1555	1555		10.1016/S0140-6736(03)13160-1	http://dx.doi.org/10.1016/S0140-6736(03)13160-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674WB	12737881				2022-12-28	WOS:000182658900028
J	Trotter, CL; McVernon, J; Andrews, NJ; Burrage, M; Ramsay, ME				Trotter, CL; McVernon, J; Andrews, NJ; Burrage, M; Ramsay, ME			Antibody to Haemophilus influenzae type b after routine and catch-up vaccination	LANCET			English	Article								Since 1999, the number of cases of Haemophilus Influenzae type b (Hib) disease in the UK has risen. We investigated the role of population immunity in this change by testing more than 2600 serum samples from children aged 1-15 years. After the introduction of the routine Hib conjugate vaccination programme for infants, median antibody titres rose significantly in 1-year-olds. Individuals who received their first dose of vaccine at age 1-4 years in the original catch-up campaign initially had much higher concentrations of antibody than those who had been immunised in infancy. A second catch-up campaign in children aged 6 months to 4 years should be highly effective in boosting immunity and reducing disease in the short term.	Hlth Protect Agcy, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England; Hlth Protect Agcy, Ctr Appl Microbiol & Res, Immunoassay Lab, Salisbury, Wilts, England	Health Protection Agency; Health Protection Agency	Trotter, CL (corresponding author), Hlth Protect Agcy, Ctr Communicable Dis Surveillance, Immunisat Div, 61 Colindale Ave, London NW9 5EQ, England.	caroline.trotter@hpa.org.uk	Trotter, Caroline L/H-5077-2013; Ramsay, Mary Elizabeth/S-8281-2016	McVernon, Jodie/0000-0001-9774-1961; Ramsay, Mary Elizabeth/0000-0002-7156-7640; Trotter, Caroline/0000-0003-4000-2708				Heath PT, 2000, JAMA-J AM MED ASSOC, V284, P2334, DOI 10.1001/jama.284.18.2334; KAYHTY H, 1983, J INFECT DIS, V147, P1100; PHIPPS DC, 1990, J IMMUNOL METHODS, V135, P121, DOI 10.1016/0022-1759(90)90264-V; Trotter C L, 2003, Commun Dis Public Health, V6, P55; van Alphen L, 1997, J PEDIATR-US, V131, P869, DOI 10.1016/S0022-3476(97)70035-0	5	54	55	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2003	361	9368					1523	1524		10.1016/S0140-6736(03)13172-8	http://dx.doi.org/10.1016/S0140-6736(03)13172-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737867				2022-12-28	WOS:000182658900015
J	Anand, K; Ziebuhr, J; Wadhwani, P; Mesters, JR; Hilgenfeld, R				Anand, K; Ziebuhr, J; Wadhwani, P; Mesters, JR; Hilgenfeld, R			Coronavirus main proteinase (3CL(pro)) structure: Basis for design of anti-SARS drugs	SCIENCE			English	Article							VIRUS-ENCODED PROTEINASES; 229E 3C-LIKE PROTEINASE; PROTEASES	A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (M-pro, also called 3CL(pro)), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) M-pro and for an inhibitor complex of porcine coronavirus [ transmissible gastroenteritis virus ( TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) M-pro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV M-pro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3C(pro) inhibitors may be modified to make them useful for treating SARS.	Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany; Univ Wurzburg, Inst Virol & Immunol, D-97078 Wurzburg, Germany; Univ Jena, Inst Mol Biol, D-07745 Jena, Germany	University of Lubeck; University of Wurzburg; Friedrich Schiller University of Jena	Hilgenfeld, R (corresponding author), Univ Lubeck, Inst Biochem, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	hilgenfeld@biochem.uni-luebeck.de	Hilgenfeld, Rolf/C-9675-2011; Ziebuhr, John/G-7669-2015	Wadhwani, Parvesh/0000-0002-7290-5154; Mesters, Jeroen/0000-0001-8532-6699; Ziebuhr, John/0000-0002-5741-8825				Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595; Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581; HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; MARRA M, 2003, SCIENCE, V30, P1399, DOI DOI 10.1126/SC2ENCE.1085953; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Ryan MD, 1997, J GEN VIROL, V78, P699, DOI 10.1099/0022-1317-78-4-699; Siddell S.G., 1995, CORONAVIRIDAE, P389; Siddell SG., 1995, CORONAVIRIDAE INTRO, DOI [10.1007/978-1-4899-1531-3, DOI 10.1007/978-1-4899-1531-3]; Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001; Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853; ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995	18	1133	1228	32	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1763	1767		10.1126/science.1085658	http://dx.doi.org/10.1126/science.1085658			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12746549				2022-12-28	WOS:000183459700056
J	Kanemaki, M; Sanchez-Diaz, A; Gambus, A; Labib, K				Kanemaki, M; Sanchez-Diaz, A; Gambus, A; Labib, K			Functional proteomic identification of DNA replication proteins by induced proteolysis in vivo	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST PROTEOME; FIRING ORIGINS; BUDDING YEAST; S-PHASE; PURIFICATION; COMPLEXES; CDC7	Evolutionarily diverse eukaryotic cells share many conserved proteins of unknown function. Some are essential for cell viability(1,2), emphasising their importance for fundamental processes of cell biology but complicating their analysis. We have developed an approach to the large-scale characterization of such proteins, based on conditional and rapid degradation of the target protein in vivo, so that the immediate consequences of bulk protein depletion can be examined(3). Budding yeast strains have been constructed in which essential proteins of unknown function have been fused to a 'heat-inducible-degron' cassette that targets the protein for proteolysis at 37 degreesC (ref. 4). By screening the collection for defects in cell-cycle progression, here we identify three DNA replication factors that interact with each other and that have uncharacterized homologues in human cells. We have used the degron strains to show that these proteins are required for the establishment and normal progression of DNA replication forks. The degron collection could also be used to identify other, essential, proteins with roles in many other processes of eukaryotic cell biology.	Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK, Manchester M20 4BX, Lancs, England	Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Labib, K (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK, Wilmslow Rd, Manchester M20 4BX, Lancs, England.		Gambus, Aga/AAK-4687-2021; Sanchez-Diaz, Alberto/L-2320-2014; Kanemaki, Masato/Q-3246-2019	Gambus, Aga/0000-0002-4648-0332; Sanchez-Diaz, Alberto/0000-0002-3308-4824; Kanemaki, Masato/0000-0002-7657-1649				Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Levy F, 1999, EUR J BIOCHEM, V259, P244, DOI 10.1046/j.1432-1327.1999.00024.x; Lindner K, 2002, MOL BIOL CELL, V13, P435, DOI 10.1091/mbc.01-11-0537; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Yabuki N, 2002, GENES CELLS, V7, P781, DOI 10.1046/j.1365-2443.2002.00559.x	29	200	208	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					720	724		10.1038/nature01692	http://dx.doi.org/10.1038/nature01692			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12768207				2022-12-28	WOS:000183443400035
J	Green, CS; Bavelier, D				Green, CS; Bavelier, D			Action video game modifies visual selective attention	NATURE			English	Article							USEFUL FIELD; SEARCH; TASK; ORIENTATION; CAPACITY; BLINK; DISCRIMINATION; IDENTIFICATION; ENUMERATION; VIEW	As video-game playing has become a ubiquitous activity in today's society, it is worth considering its potential consequences on perceptual and motor skills. It is well known that exposing an organism to an altered visual environment often results in modification of the visual system of the organism. The field of perceptual learning provides many examples of training-induced increases in performance. But perceptual learning, when it occurs, tends to be specific to the trained task; that is, generalization to new tasks is rarely found(1-10). Here we show, by contrast, that action-video-game playing is capable of altering a range of visual skills. Four experiments establish changes in different aspects of visual attention in habitual video-game players as compared with non-video-game players. In a fifth experiment, non-players trained on an action video game show marked improvement from their pre-training abilities, thereby establishing the role of playing in this effect.	Univ Rochester, Ctr Visual Sci, Dept Brain & Cognit Sci, Rochester, NY 14627 USA	University of Rochester	Bavelier, D (corresponding author), Univ Rochester, Ctr Visual Sci, Dept Brain & Cognit Sci, Rochester, NY 14627 USA.	daphne@cvs.rochester.edu		Bavelier, Daphne/0000-0002-5904-1240				Ahissar M, 1998, VISION RES, V38, P3095, DOI 10.1016/S0042-6989(97)00449-5; Ahissar M, 2000, VISION RES, V40, P1349, DOI 10.1016/S0042-6989(00)00002-X; Arnell KM, 1999, J EXP PSYCHOL HUMAN, V25, P630, DOI 10.1037/0096-1523.25.3.630; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; BALL K, 1982, SCIENCE, V218, P697, DOI 10.1126/science.7134968; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; BROADBENT DE, 1987, PERCEPT PSYCHOPHYS, V42, P105, DOI 10.3758/BF03210498; CHUN MM, 1995, J EXP PSYCHOL HUMAN, V21, P109; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; FAHLE M, 1993, VISION RES, V33, P397, DOI 10.1016/0042-6989(93)90094-D; FIORENTINI A, 1980, NATURE, V287, P43, DOI 10.1038/287043a0; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KAUFMAN EL, 1949, AM J PSYCHOL, V62, P498, DOI 10.2307/1418556; Lavie N, 1997, PSYCHOL SCI, V8, P395, DOI 10.1111/j.1467-9280.1997.tb00432.x; Myers RS, 2000, PERCEPT MOTOR SKILL, V91, P279, DOI 10.2466/PMS.91.5.279-290; POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770; Potter MC, 1998, J EXP PSYCHOL LEARN, V24, P979, DOI 10.1037/0278-7393.24.4.979; Proksch J, 2002, J COGNITIVE NEUROSCI, V14, P687, DOI 10.1162/08989290260138591; RAMACHANDRAN VS, 1973, PERCEPTION, V2, P371, DOI 10.1068/p020371; RAYMOND JE, 1992, J EXP PSYCHOL HUMAN, V18, P849, DOI 10.1037/0096-1523.18.3.849; SAGI D, 1994, CURR OPIN NEUROBIOL, V4, P195, DOI 10.1016/0959-4388(94)90072-8; Sireteanu R, 2000, VISION RES, V40, P2925, DOI 10.1016/S0042-6989(00)00145-0; TRICK LM, 1993, J EXP PSYCHOL HUMAN, V19, P331, DOI 10.1037/0096-1523.19.2.331; TRICK LM, 1994, PSYCHOL REV, V101, P80, DOI 10.1037/0033-295X.101.1.80; Tuholski SW, 2001, MEM COGNITION, V29, P484, DOI 10.3758/BF03196399	25	1395	1430	49	642	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2003	423	6939					534	537		10.1038/nature01647	http://dx.doi.org/10.1038/nature01647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	683RH	12774121	Bronze			2022-12-28	WOS:000183162900042
J	Kang, HJ; Dai, PC; Lynn, JW; Matsuura, M; Thompson, JR; Zhang, SC; Argyriou, DN; Onose, Y; Tokura, Y				Kang, HJ; Dai, PC; Lynn, JW; Matsuura, M; Thompson, JR; Zhang, SC; Argyriou, DN; Onose, Y; Tokura, Y			Antiferromagnetic order as the competing ground state in electron-doped Nd1.85Ce0.15CuO4	NATURE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTOR; T-C SUPERCONDUCTIVITY; MAGNETIC-FIELD; SINGLE-CRYSTALS; VORTEX CORES; ND2-XCEXCUO4; ENHANCEMENT; DEPENDENCE; SYMMETRY; SPINS	Superconductivity in the high-transition-temperature (high-T-c) copper oxides competes with other possible ground states(1),(2). The physical explanation for superconductivity can be constrained by determining the nature of the closest competing ground state, and establishing if that state is universal among the high-T-c materials. Antiferromagnetism has been theoretically predicted(3,4) to be the competing ground state. A competing ground state is revealed when superconductivity is destroyed by the application of a magnetic field, and antiferromagnetism has been observed in hole-doped materials under the influence of modest fields(5-12). None of the previous experiments have revealed the quantum phase transition from the superconducting state to the antiferromagnetic state, because they failed to reach the upper critical field B-c2. Here we report the results of transport and neutron-scattering experiments on electron-doped Nd1.85Ce0.15CuO4 (refs 13, 14), where B-c2 can be reached(15). The applied field reveals a static, commensurate, anomalously conducting long-range ordered antiferromagnetic state, in which the induced moment scales approximately linearly with the field strength until it saturates at B-c2. This and previous experiments on the hole-doped materials therefore establishes antiferromagnetic order as a competing ground state in the high-T-c copper oxide materials, irrespective of electron or hole doping.	Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA; Oak Ridge Natl Lab, Condensed Matter Sci Div, Oak Ridge, TN 37831 USA; Natl Inst Stand & Technol, NIST Ctr Neutron Res, Gaithersburg, MD 20899 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Hahn Meitner Inst Berlin GmbH, D-14109 Berlin, Germany; Japan Sci & Technol, ERATO, Spin Superstruct Project, Tsukuba, Ibaraki 3058562, Japan; Correlated Electron Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Univ Tokyo, Dept Appl Phys, Tokyo 138656, Japan	University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; National Institute of Standards & Technology (NIST) - USA; Stanford University; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB); Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Dai, PC (corresponding author), Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA.		Onose, Yoshinori/F-1977-2010; Lynn, Jeffrey/R-4030-2019; Zhang, Shou-Cheng/B-2794-2010; Tokura, Yoshinori/C-7352-2009; Lynn, Jeffrey/AAI-2588-2021; Matsuura, Masato/C-2827-2013; Argyriou, Dimitrios/AAC-7860-2020; Dai, Pengcheng/C-9171-2012	Onose, Yoshinori/0000-0002-8398-2956; Lynn, Jeffrey/0000-0003-3626-4932; Tokura, Yoshinori/0000-0002-2732-4983; Matsuura, Masato/0000-0003-4470-0271; Dai, Pengcheng/0000-0002-6088-3170				Arovas DP, 1997, PHYS REV LETT, V79, P2871, DOI 10.1103/PhysRevLett.79.2871; Fournier P, 1998, PHYS REV LETT, V81, P4720, DOI 10.1103/PhysRevLett.81.4720; HIDAKA Y, 1989, NATURE, V338, P635, DOI 10.1038/338635a0; KAKUYANAGI K, 2002, CONDMAT0206362; Katano S, 2000, PHYS REV B, V62, P14677, DOI 10.1103/PhysRevB.62.R14677; Khaykovich B, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.014528; Kurahashi K, 2002, J PHYS SOC JPN, V71, P910, DOI 10.1143/JPSJ.71.910; Lake B, 2001, SCIENCE, V291, P1759, DOI 10.1126/science.1056986; Lake B, 2002, NATURE, V415, P299, DOI 10.1038/415299a; Levi BG, 2002, PHYS TODAY, V55, P14, DOI 10.1063/1.1522154; Lynn J, 2001, HDB PHYSICS CHEM RAR, V31, P315; Miller RI, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.137002; Mitrovic VF, 2001, NATURE, V413, P501, DOI 10.1038/35097039; MITROVIC VF, 2002, CONDMAT0202368; Onose Y, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.217001; Sachdev S, 2002, SCIENCE, V295, P452, DOI 10.1126/science.1068718; SKANTHAKUMAR S, 1993, PHYS REV B, V47, P6173, DOI 10.1103/PhysRevB.47.6173; SKANTHAKUMAR S, 1993, J APPL PHYS, V73, P6326, DOI 10.1063/1.352635; Takahashi T, 2000, ORG LETT, V2, P1197, DOI 10.1021/ol005533r; TOKURA Y, 1989, NATURE, V337, P345, DOI 10.1038/337345a0; Uefuji T, 2002, PHYSICA C, V378, P273, DOI 10.1016/S0921-4534(02)01426-0; Uefuji T, 2001, PHYSICA C, V357, P208, DOI 10.1016/S0921-4534(01)00208-8; Yamada K, 1999, J PHYS CHEM SOLIDS, V60, P1025, DOI 10.1016/S0022-3697(99)00042-6; Zhang SC, 1997, SCIENCE, V275, P1089, DOI 10.1126/science.275.5303.1089	25	105	105	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					522	525		10.1038/nature01641	http://dx.doi.org/10.1038/nature01641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774117	Bronze			2022-12-28	WOS:000183162900038
J	Li, DW; Zhao, R; Lilyestrom, W; Gai, DH; Zhang, RG; DeCaprio, JA; Fanning, E; Jochimiak, A; Szakonyi, G; Chen, XJS				Li, DW; Zhao, R; Lilyestrom, W; Gai, DH; Zhang, RG; DeCaprio, JA; Fanning, E; Jochimiak, A; Szakonyi, G; Chen, XJS			Structure of the replicative helicase of the oncoprotein SV40 large tumour antigen	NATURE			English	Article							LARGE T-ANTIGEN; TEMPERATURE-SENSITIVE MUTANTS; ORIGIN DNA-BINDING; CRYSTAL-STRUCTURE; DOUBLE HEXAMERS; VIRAL ORIGIN; RAS ONCOGENE; IN-VITRO; SIMIAN-VIRUS-40; INITIATION	The oncoprotein large tumour antigen (LTag) is encoded by the DNA tumour virus simian virus 40. LTag transforms cells and induces tumours in animals by altering the functions of tumour suppressors (including pRB and p53) and other key cellular proteins. LTag is also a molecular machine that distorts/melts the replication origin of the viral genome and unwinds duplex DNA. LTag therefore seems to be a functional homologue of the eukaryotic minichromosome maintenance (MCM) complex. Here we present the X-ray structure of a hexameric LTag with DNA helicase activity. The structure identifies the p53-binding surface and reveals the structural basis of hexamerization. The hexamer contains a long, positively charged channel with an unusually large central chamber that binds both single-stranded and double-stranded DNA. The hexamer organizes into two tiers that can potentially rotate relative to each other through connecting alpha-helices to expand/constrict the channel, producing an 'iris' effect that could be used for distorting or melting the origin and unwinding DNA at the replication fork.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Argonne Natl Lab, Adv Photon Source, SBC, Argonne, IL 60439 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Vanderbilt Univ, VU Stn B 1634, Nashville, TN 37235 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; United States Department of Energy (DOE); Argonne National Laboratory; Harvard University; Dana-Farber Cancer Institute; Vanderbilt University	Chen, XJS (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Genet, Denver, CO 80262 USA.	xiaojiang.chen@uchsc.edu	Li, Dawei/I-8751-2016	Li, Dawei/0000-0003-4133-1263				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beachy TM, 2002, J VIROL, V76, P3145, DOI 10.1128/JVI.76.7.3145-3157.2002; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; CAVENDER JF, 1995, J VIROL, V69, P923, DOI 10.1128/JVI.69.2.923-934.1995; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FARBER JM, 1987, J VIROL, V61, P436, DOI 10.1128/JVI.61.2.436-445.1987; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Joo WS, 1998, MOL CELL BIOL, V18, P2677, DOI 10.1128/MCB.18.5.2677; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LOEBER G, 1989, J VIROL, V63, P94, DOI 10.1128/JVI.63.1.94-100.1989; LOEBER G, 1989, J VIROL, V63, P4426, DOI 10.1128/JVI.63.10.4426-4430.1989; Luo XL, 1996, NAT STRUCT BIOL, V3, P1034, DOI 10.1038/nsb1296-1034; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuwald AF, 1999, GENOME RES, V9, P27; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; RAY S, 1992, J VIROL, V66, P6509, DOI 10.1128/JVI.66.11.6509-6516.1992; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Smelkova NV, 1998, J VIROL, V72, P8676, DOI 10.1128/JVI.72.11.8676-8681.1998; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; Wu CX, 1998, J VIROL, V72, P10256, DOI 10.1128/JVI.72.12.10256-10259.1998; Wu CX, 2001, J VIROL, V75, P2839, DOI 10.1128/JVI.75.6.2839-2847.2001; WUNKIM K, 1990, J VIROL, V64, P2014, DOI 10.1128/JVI.64.5.2014-2020.1990	50	240	247	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2003	423	6939					512	518		10.1038/nature01691	http://dx.doi.org/10.1038/nature01691			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774115				2022-12-28	WOS:000183162900036
J	Howitt, A				Howitt, A			A 42 year old man with acute chest pain: case outcome - Commentary: Questions for general practice	BRITISH MEDICAL JOURNAL			English	Editorial Material									Warders Med Ctr, Tonbridge TN9 1LA, Kent, England		Howitt, A (corresponding author), Warders Med Ctr, East St, Tonbridge TN9 1LA, Kent, England.							Hart, 1988, NEW KIND DOCTOR; Klompas M, 2002, JAMA-J AM MED ASSOC, V287, P2262, DOI 10.1001/jama.287.17.2262; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Ruston A, 1998, BRIT MED J, V316, P1060; Wilmink ABM, 1998, BRIT J SURG, V85, P155; 2003, BMJ; 2003, CLIN EVIDENCE	7	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1134	1135		10.1136/bmj.326.7399.1134-a	http://dx.doi.org/10.1136/bmj.326.7399.1134-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763990	Green Published			2022-12-28	WOS:000183245000028
J	Friedlander, RM; Gonzalez, RG; Harris, NL; Medlock, MD; Pfannl, R; Beigel, JH; Afridi, NA				Friedlander, RM; Gonzalez, RG; Harris, NL; Medlock, MD; Pfannl, R; Beigel, JH; Afridi, NA			A 58-year-old woman with left-sided weakness and a right frontal brain mass - Brain abscess due to infection with Streptococcus milleri and Haemophilus aphrophilus.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DIFFERENTIAL-DIAGNOSIS; TUMORS		Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; Massachusetts Gen Hosp, Div Neuroradiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Neuropathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Friedlander, RM (corresponding author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.		Beigel, John/AAQ-4289-2021; Beigel, John H/GNP-2628-2022; Friedlander, Robert M/A-2845-2016	Beigel, John/0000-0002-4879-4941; Friedlander, Robert M/0000-0003-4423-9219				Calfee DP, 2000, SEMIN NEUROL, V20, P353, DOI 10.1055/s-2000-9397; de Louvois J, 2000, BRIT J NEUROSURG, V14, P525; Desprechins B, 1999, AM J NEURORADIOL, V20, P1252; ELLISON D, 1998, NEUROPATHOLOGY REFER; GRAY F, 2002, GREENFIELDS NEUROPAT, V2, P167; HAIMES AB, 1989, AM J ROENTGENOL, V152, P1073, DOI 10.2214/ajr.152.5.1073; HIRSCHBERG H, 1987, J NEUROSURG, V67, P358, DOI 10.3171/jns.1987.67.3.0358; Kim YJ, 1998, AM J ROENTGENOL, V171, P1487, DOI 10.2214/ajr.171.6.9843275; Krabbe K, 1997, NEURORADIOLOGY, V39, P483, DOI 10.1007/s002340050450; Mathisen GE, 1997, CLIN INFECT DIS, V25, P763, DOI 10.1086/515541; MOLINA JM, 1991, SCAND J INFECT DIS, V23, P659, DOI 10.3109/00365549109024289; Roos KL, 2001, HARRISONS PRINCIPLES, V2, P2462; Schuman N J, 1994, Quintessence Int, V25, P411; SEYDOUX C, 1992, CLIN INFECT DIS, V15, P394, DOI 10.1093/clind/15.3.394; SZE G, 1988, RADIOL CLIN N AM, V26, P839; TUNKEL AR, 2000, MANDELL DOUGLAS BENN, V1, P1016; YOUMANS JR, 1996, NEUROLOGICAL SURG CO, V5, P3205	17	21	23	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2125	2132		10.1056/NEJMcpc030011	http://dx.doi.org/10.1056/NEJMcpc030011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761369				2022-12-28	WOS:000183008300010
J	Ware, JH				Ware, JH			The National Emphysema Treatment Trial - How strong is the evidence?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Fishman A, 2001, NEW ENGL J MED, V345, P1075	1	31	31	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2055	2056		10.1056/NEJMp030068	http://dx.doi.org/10.1056/NEJMp030068			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12759478				2022-12-28	WOS:000183008300001
J	Grech, ED				Grech, ED			Percutaneous coronary intervention. I: History and development	BRITISH MEDICAL JOURNAL			English	Review							CARDIOLOGY		Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Grech, ED (corresponding author), Hlth Sci Ctr, Winnipeg, MB, Canada.							COSTA MA, 2002, PRACTICAL INTERVENTI, P279; Gruentzig A., 1978, LANCET, V1, P263; MEYER BJ, 2002, PRACTICAL INTERVENTI, P35; Smith SC, 2001, J AM COLL CARDIOL, V37, P2215, DOI 10.1016/S0735-1097(01)01344-4; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802	5	48	81	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2003	326	7398					1080	1082		10.1136/bmj.326.7398.1080	http://dx.doi.org/10.1136/bmj.326.7398.1080			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681ZD	12750213	Green Published			2022-12-28	WOS:000183064700022
J	Hsu, AL; Murphy, CT; Kenyon, C				Hsu, AL; Murphy, CT; Kenyon, C			Regulation of aging and age-related disease by DAF-16 and heat-shock factor	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; EXTENDED LIFE; LONGEVITY; LONG; IDENTIFICATION; RESISTANCE; STRESS; MUTANT	The Caenorhabditis elegans transcription factor HSF-1, which regulates the heat-shock response, also influences aging. Reducing hsf-1 activity accelerates tissue aging and shortens life-span, and we show that hsf-1 overexpression extends life-span. We find that HSF-1, like the transcription factor DAF-16, is required for daf-2-insulin/IGF-1 receptor mutations to extend life-span. Our findings suggest this is because HSF-1 and DAF-16 together activate expression of specific genes, including genes encoding small heat-shock proteins, which in turn promote longevity. The small heat-shock proteins also delay the onset of polyglutamine-expansion protein aggregation, suggesting that these proteins couple the normal aging process to this type of age-related disease.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Hsu, Ao-Lin Allen/AAX-1856-2020	Hsu, Ao-Lin/0000-0002-2864-3134; Kenyon, Cynthia/0000-0003-3446-2636				Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Garigan D, 2002, GENETICS, V161, P1101; Gems D, 2001, CURR OPIN GENET DEV, V11, P287, DOI 10.1016/S0959-437X(00)00192-1; Gems D, 1998, GENETICS, V150, P129; GLESE KC, 2002, J BIOL CHEM, V277, P46310; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kurapati R, 2000, J GERONTOL A-BIOL, V55, pB552, DOI 10.1093/gerona/55.11.B552; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; MORIMOTO R, COMMUNICATION; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; MURPHY CT, IN PRESS NATURE; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; Tatar M, 1997, NATURE, V390, P30, DOI 10.1038/36237; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; Verbeke P, 2001, CELL BIOL INT, V25, P845, DOI 10.1006/cbir.2001.0789; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Yokoyama K, 2002, FEBS LETT, V516, P53, DOI 10.1016/S0014-5793(02)02470-5; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210	29	1076	1135	6	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1142	1145		10.1126/science.1083701	http://dx.doi.org/10.1126/science.1083701			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678VC	12750521				2022-12-28	WOS:000182886500045
J	McKee, M; Coker, R				McKee, M; Coker, R			The dangerous rise of American exceptionalism	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.		McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683				*AM CIV LIB UN, 2003, ACLU CRIT CAPPS 2 NE; FARMER P, 1999, GLOBAL IMPACT DRUG R; GOODE E, 2003, NY TIMES        0418; Kaiser J, 2003, SCIENCE, V300, P403, DOI 10.1126/science.300.5618.403; Lipset Seymour Martin, 1997, AM EXCEPTIONALISM DO; *NAT PRIOR PROJ, COST WAR IR; PHILIPS S, 2003, TIMES HIGHER ED 0425; Schwartz StephenI., 1998, ATOMIC AUDIT COSTS C; WALLACE R, 1990, B NEW YORK ACAD MED, V66, P391; 2002, LANCET, V360, P1525	10	6	6	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1579	1580		10.1016/S0140-6736(03)13325-9	http://dx.doi.org/10.1016/S0140-6736(03)13325-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747875				2022-12-28	WOS:000182746300005
J	Brivanlou, AH; Gage, FH; Jaenisch, R; Jessell, T; Melton, D; Rossant, J				Brivanlou, AH; Gage, FH; Jaenisch, R; Jessell, T; Melton, D; Rossant, J			Setting standards for human embryonic stem cells	SCIENCE			English	Editorial Material							HUMAN BLASTOCYSTS; MOUSE EMBRYOS; IN-VITRO; DIFFERENTIATION; LINES; ESTABLISHMENT; CULTURE; GROWTH		Rockefeller Univ, New York, NY 10021 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Whitehead Inst, Cambridge, MA 02142 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Harvard Univ, Cambridge, MA 02138 USA; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	Rockefeller University; Salk Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Columbia University; Howard Hughes Medical Institute; Harvard University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Brivanlou, AH (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Eiges R, 2001, CURR BIOL, V11, P514, DOI 10.1016/S0960-9822(01)00144-0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MCKAY R, 2002, WORKSH SPONS NEW YOR; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Richards M, 2002, NAT BIOTECHNOL, V20, P933, DOI 10.1038/nbt726; Rossant J, 2001, STEM CELLS, V19, P477, DOI 10.1634/stemcells.19-6-477; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129	20	247	272	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					913	+		10.1126/science.1082940	http://dx.doi.org/10.1126/science.1082940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738841				2022-12-28	WOS:000182719800033
J	Marmottant, P; Hilgenfeldt, S				Marmottant, P; Hilgenfeldt, S			Controlled vesicle deformation and lysis by single oscillating bubbles	NATURE			English	Article							SONOLUMINESCENCE; CAVITATION; ULTRASOUND; SONOPORATION; BOUNDARY; DYNAMICS; FLOW	The ability of collapsing (cavitating) bubbles to focus and concentrate energy, forces and stresses is at the root of phenomena such as cavitation damage, sonochemistry or sonoluminescence(1,2). In a biomedical context, ultrasound-driven microbubbles have been used to enhance contrast in ultrasonic images(3). The observation of bubble-enhanced sonoporation(4-6)-acoustically induced rupture of membranes-has also opened up intriguing possibilities for the therapeutic application of sonoporation as an alternative to cell-wall permeation techniques such as electroporation(7) and particle guns(8). However, these pioneering experiments have not been able to pinpoint the mechanism by which the violently collapsing bubble opens pores or larger holes in membranes. Here we present an experiment in which gentle (linear) bubble oscillations are sufficient to achieve rupture of lipid membranes. In this regime, the bubble dynamics and the ensuing sonoporation can be accurately controlled. The use of microbubbles as focusing agents makes acoustics on the micrometre scale (microacoustics) a viable tool, with possible applications in cell manipulation and cell-wall permeation as well as in microfluidic devices.	Univ Twente, Fac Appl Phys, NL-7500 AE Enschede, Netherlands	University of Twente	Marmottant, P (corresponding author), Univ Twente, Fac Appl Phys, POB 217, NL-7500 AE Enschede, Netherlands.		Hilgenfeldt, Sascha/B-7356-2009; Marmottant, Philippe/D-6808-2012; Hilgenfeldt, Sascha/A-4593-2014	Hilgenfeldt, Sascha/0000-0002-6799-2118				BLAKE JR, 1974, J ENG MATH, V8, P23, DOI 10.1007/BF02353701; Boal D. H., 2002, MECH CELL; Brujan EA, 2001, J FLUID MECH, V433, P251, DOI 10.1017/S0022112000003347; Chang D.C., 1992, GUIDE ELECTROPORATIO; CHANG DC, 1993, ADV ECHO IMAGING USI; DAVIDSON BJ, 1971, J SOUND VIB, V15, P217, DOI 10.1016/0022-460X(71)90536-0; DIMITROV DS, 1987, PROG COLLOID POLYM S, V73, P48; ELDER SA, 1959, J ACOUST SOC AM, V31, P54, DOI 10.1121/1.1907611; Greenleaf WJ, 1998, ULTRASOUND MED BIOL, V24, P587, DOI 10.1016/S0301-5629(98)00003-9; Hilgenfeldt S, 2000, J ACOUST SOC AM, V107, P3530, DOI 10.1121/1.429438; Hilgenfeldt S, 1999, NATURE, V398, P402, DOI 10.1038/18842; Leighton T.G., 1994, ACOUSTIC BUBBLE, DOI DOI 10.1121/1.410082; LIGHTHILL J, 1978, J SOUND VIB, V61, P391, DOI 10.1016/0022-460X(78)90388-7; Longuet-Higgins MS, 1998, P ROY SOC A-MATH PHY, V454, P725, DOI 10.1098/rspa.1998.0183; MILLER DL, 1988, J ACOUST SOC AM, V84, P1378, DOI 10.1121/1.396636; MILLER DL, 1979, SCIENCE, V205, P505, DOI 10.1126/science.451616; Miller DL, 2000, ULTRASOUND MED BIOL, V26, P661, DOI 10.1016/S0301-5629(99)00170-2; PLESSET MS, 1977, ANNU REV FLUID MECH, V9, P145, DOI 10.1146/annurev.fl.09.010177.001045; Popinet S, 1999, INT J NUMER METH FL, V30, P775, DOI 10.1002/(SICI)1097-0363(19990730)30:6<775::AID-FLD864>3.0.CO;2-#; Pozrikidis C., 1992, BOUNDARY INTEGRAL SI; Prosperetti A, 1997, J ACOUST SOC AM, V101, P2003, DOI 10.1121/1.418133; Rawicz W, 2000, BIOPHYS J, V79, P328, DOI 10.1016/S0006-3495(00)76295-3; RILEY N, 1966, Q J MECH APPL MATH, V19, P461, DOI 10.1093/qjmam/19.4.461; ROONEY JA, 1970, SCIENCE, V169, P869, DOI 10.1126/science.169.3948.869; Seifert U, 1999, EUR PHYS J B, V8, P405, DOI 10.1007/s100510050706; SEKI M, 1991, PLANT MOL BIOL, V17, P259, DOI 10.1007/BF00039501; SUSLICK KS, 1990, SCIENCE, V247, P1439, DOI 10.1126/science.247.4949.1439; Tachibana K, 1999, LANCET, V353, P1409, DOI 10.1016/S0140-6736(99)01244-1; Wang ZQ, 1999, PHYS REV E, V59, P1777, DOI 10.1103/PhysRevE.59.1777; Ward M, 2000, ULTRASOUND MED BIOL, V26, P1169, DOI 10.1016/S0301-5629(00)00260-X	30	627	646	10	280	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					153	156		10.1038/nature01613	http://dx.doi.org/10.1038/nature01613			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736680	Bronze			2022-12-28	WOS:000182699600041
J	Palmer, LI				Palmer, LI			The legal and political future of physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OREGON		Univ Louisville, Louisville, KY 40292 USA	University of Louisville	Palmer, LI (corresponding author), Univ Louisville, Louisville, KY 40292 USA.							ASHCROFT J, 2001, COMMUNCIATION   1106; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Steinbrook R, 2002, NEW ENGL J MED, V346, P460, DOI 10.1056/NEJM200202073460624; 2001, FED REG         1109, V66, P56607	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2283	2283		10.1001/jama.289.17.2283	http://dx.doi.org/10.1001/jama.289.17.2283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675ET	12734144	Green Published, Bronze			2022-12-28	WOS:000182680700035
J	Salerno, SM; Alguire, PC; Waxman, HS				Salerno, SM; Alguire, PC; Waxman, HS			Competency in interpretation of 12-lead electrocardiograms: A summary and appraisal of published evidence	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR HYPERTROPHY; ARTIFICIAL NEURAL-NETWORKS; ACUTE CARDIAC ISCHEMIA; ST-SEGMENT ELEVATION; ECG INTERPRETATION; EMERGENCY-DEPARTMENT; CLINICAL COMPETENCE; MISSED DIAGNOSES; DECISION-MAKING	Background: There have been many proposals for objective standards designed to optimize training, testing, and maintaining competency in interpretation of electrocardiograms (ECGs). However, most of these recommendations are consensus based and are not derived from clinical trials that include patient outcomes. Purpose: To critically review the available data on training, accuracy, and outcomes of computer and physician interpretation of 12-lead resting ECGs. Data Sources: English-language articles were retrieved by searching MEDLINE (1966 to 2002), EMBASE (1974 to 2002), and the Cochrane Controlled Trials Register (1975-2002). The references in articles selected for analysis were also reviewed for relevance. Study Selection: All articles on training, accuracy, and outcomes of ECG interpretations were analyzed. Data Extraction: Study design and results were summarized in evidence tables. Information on physician interpretation compared to a "gold standard," typically a consensus panel of expert electrocardiographers, was extracted, The clinical context of and outcomes related to the ECG interpretation were obtained whenever possible. Data Synthesis: Physicians of all specialties and levels of training, as well as computer software for interpreting ECGs, frequently made errors in interpreting ECGs when compared to expert electrocardiographers. There was also substantial disagreement on interpretations among cardiologists. Adverse patient outcomes occurred infrequently when ECGs were incorrectly interpreted. Conclusions: There is no evidence-based minimum number of ECG interpretations that is ideal for attaining or maintaining competency in ECG interpretation skills. Further research is needed to clarify the optimal way to build and maintain ECG interpretation skills based on patient outcomes.	Amer Coll Physicians, Customer Serv, Philadelphia, PA 19106 USA; Tripler Army Med Ctr, Honolulu, HI 96859 USA	American College of Physicians; United States Department of Defense; United States Army	Salerno, SM (corresponding author), Amer Coll Physicians, Customer Serv, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							*AM BOARD INT MED, 2001, POL PROC CERT; *AM MED ASS, 2002, GRAD MED ED DIR 2002, P86; Brady WJ, 2001, ACAD EMERG MED, V8, P349, DOI 10.1111/j.1553-2712.2001.tb02113.x; Brady WJ, 2000, ACAD EMERG MED, V7, P1256, DOI 10.1111/j.1553-2712.2000.tb00471.x; Brailer DJ, 1997, MED DECIS MAKING, V17, P80, DOI 10.1177/0272989X9701700109; de Bruyne MC, 1998, J ELECTROCARDIOL, V31, P189; deBruyne MC, 1997, J CLIN EPIDEMIOL, V50, P947, DOI 10.1016/S0895-4356(97)00100-5; DUNN PM, 1990, ARCH INTERN MED, V150, P1917, DOI 10.1001/archinte.150.9.1917; FARB A, 1990, J AM COLL CARDIOL, V15, P618, DOI 10.1016/0735-1097(90)90636-4; FINCHER RME, 1988, SOUTH MED J, V81, P1291, DOI 10.1097/00007611-198810000-00020; FISCH C, 1995, CIRCULATION, V91, P2683, DOI 10.1161/01.CIR.91.10.2683; FOSTER DB, 1994, AM J EMERG MED, V12, P25, DOI 10.1016/0735-6757(94)90192-9; Gillespie ND, 1996, J ACCID EMERG MED, V13, P395; GJORUP T, 1992, J INTERN MED, V231, P407, DOI 10.1111/j.1365-2796.1992.tb00952.x; Goodacre S, 2001, POSTGRAD MED J, V77, P455, DOI 10.1136/pmj.77.909.455; GRUM CM, 1993, ACAD MED, V68, pS61, DOI 10.1097/00001888-199310000-00047; Hatala R, 1999, J GEN INTERN MED, V14, P126, DOI 10.1046/j.1525-1497.1999.00298.x; Hatala RA, 1996, ACAD MED, V71, pS68, DOI 10.1097/00001888-199610000-00047; Heden B, 1996, AM J CARDIOL, V78, P600, DOI 10.1016/S0002-9149(96)00377-3; Heden B, 1996, J AM COLL CARDIOL, V28, P1012, DOI 10.1016/S0735-1097(96)00269-0; Herbert ME, 1996, ANN EMERG MED, V27, P35, DOI 10.1016/S0196-0644(96)70293-7; Hicks CM, 2000, J GEN INTERN MED, V15, P716, DOI 10.1046/j.1525-1497.2000.91104.x; HILLSON SD, 1995, MED DECIS MAKING, V15, P107, DOI 10.1177/0272989X9501500202; HO MT, J AM COLL CARDIOL, V15, pA192; Holmvang L, 1998, AM J CARDIOL, V82, P54, DOI 10.1016/S0002-9149(98)00226-4; JAYES RL, 1992, J GEN INTERN MED, V7, P387, DOI 10.1007/BF02599153; Kadish AH, 2001, J AM COLL CARDIOL, V38, P2091, DOI 10.1016/S0735-1097(01)01680-1; Kastrati A, 1998, J AM COLL CARDIOL, V32, P970, DOI 10.1016/S0735-1097(98)00334-9; KINGSTON ME, 1979, J MED EDUC, V54, P107; KUHN M, 1992, ANN EMERG MED, V21, P10, DOI 10.1016/S0196-0644(05)82229-2; LARSEN GC, 1994, J GEN INTERN MED, V9, P666, DOI 10.1007/BF02599006; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; Mason JW, 1997, J AM COLL CARDIOL, V29, P466; Massel D, 2000, AM HEART J, V140, P221, DOI 10.1067/mhj.2000.108240; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; MONTGOMERY H, 1994, BRIT MED J, V309, P1551, DOI 10.1136/bmj.309.6968.1551; MORRISON WG, 1990, ARCH EMERG MED, V7, P108; PINKERTON RE, 1981, JAMA-J AM MED ASSOC, V246, P148, DOI 10.1001/jama.246.2.148; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; Prasad N, 1996, BRIT MED J, V312, P639; Sekiguchi K, 1999, J MED, V30, P75; SHIRATAKA M, 1992, J ELECTROCARDIOL, V25, P185, DOI 10.1016/0022-0736(92)90003-I; SNOEY ER, 1994, J ACCID EMERG MED, V11, P149; Spodick DH, 1997, AM J CARDIOL, V80, P102, DOI 10.1016/S0002-9149(97)00296-8; Srikanthan VS, 1997, HEART, V78, P198, DOI 10.1136/hrt.78.2.198; Storey RF, 1997, J ROY COLL PHYS LOND, V31, P536; THOMSON A, 1989, MED J AUSTRALIA, V151, P428, DOI 10.5694/j.1326-5377.1989.tb101249.x; Todd KH, 1996, ANN EMERG MED, V27, P16, DOI 10.1016/S0196-0644(96)70290-1; WESTDORP EJ, 1992, ANN EMERG MED, V21, P541, DOI 10.1016/S0196-0644(05)82521-1; WESTON MJ, 1976, AUST NZ J MED, V6, P429, DOI 10.1111/j.1445-5994.1976.tb03029.x; WHITE T, 1995, POSTGRAD MED J, V71, P132, DOI 10.1136/pgmj.71.833.132; Widman LE, 1996, AM J CARDIOL, V78, P927, DOI 10.1016/S0002-9149(96)00469-9; WIGTON RS, 1989, ANN INTERN MED, V111, P932, DOI 10.7326/0003-4819-111-11-932; WILLEMS JL, 1990, METHOD INFORM MED, V29, P308; WOOLLEY D, 1992, J FAM PRACTICE, V34, P428	55	160	161	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					751	760		10.7326/0003-4819-138-9-200305060-00013	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00013			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729431				2022-12-28	WOS:000182661400009
J	Bingham, SA; Day, NE; Luben, R; Ferrari, P; Slimani, N; Norat, T; Clavel-Chapelon, F; Kesse, E; Nieters, A; Boeing, H; Tjonneland, A; Overvad, K; Martinez, C; Dorronsoro, M; Gonzalez, CA; Key, TJ; Trichopoulou, A; Naska, A; Vineis, P; Tumino, R; Krogh, V; Bueno-de-Mesquita, HB; Peeters, PHM; Berglund, G; Hallmans, G; Lund, E; Skeie, G; Kaaks, R; Riboli, E				Bingham, SA; Day, NE; Luben, R; Ferrari, P; Slimani, N; Norat, T; Clavel-Chapelon, F; Kesse, E; Nieters, A; Boeing, H; Tjonneland, A; Overvad, K; Martinez, C; Dorronsoro, M; Gonzalez, CA; Key, TJ; Trichopoulou, A; Naska, A; Vineis, P; Tumino, R; Krogh, V; Bueno-de-Mesquita, HB; Peeters, PHM; Berglund, G; Hallmans, G; Lund, E; Skeie, G; Kaaks, R; Riboli, E			Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study	LANCET			English	Article							RISK; RECURRENCE; CALIBRATION; VEGETABLES; ADENOMA; COHORT; FRUIT	Background Dietary fibre is thought to protect against colorectal cancer but this view has been challenged by recent prospective and intervention studies that showed no protective effect. Methods We prospectively examined the association between dietary fibre intake and incidence of colorectal cancer in 519 978 individuals aged 25-70 years taking part in the EPIC study, recruited from ten European countries. Participants completed a dietary questionnaire in 1992-98 and were followed up for cancer incidence. Relative risk estimates were obtained from fibre intake, categorised by sex-specific, cohort-wide quintiles, and from linear models relating the hazard ratio to fibre intake expressed as a continuous variable. Findings Follow-up consisted of 1939 011 person-years, and data for 1065 reported cases of colorectal cancer were included in the analysis. Dietary fibre in foods was inversely related to incidence of large bowel cancer (adjusted relative risk 0.75 [95% CI 0.59-0.95] for the highest versus lowest quintile of intake), the protective effect being greatest for the left side of the colon, and least for the rectum. After calibration with more detailed dietary data, the adjusted relative risk for the highest versus lowest quintile of fibre from food intake was 0.58 (0.41-0.85). No food source of fibre was significantly more protective than others, and non-food supplement sources of fibre were not investigated. Interpretation In populations with low average intake of dietary fibre, an approximate doubling of total fibre intake from foods could reduce the risk of colorectal cancer by 40%.	Int Agcy Res Canc, WHO, Unit Nutr & Canc, F-69372 Lyon 08, France; Univ Cambridge, Strangeways Res Lab, Cambridge CB2 1TN, England; MRC, Dunn Human Nutr Unit, Cambridge, England; Inst Gustave Roussy, INSERM, U521, F-94805 Villejuif, France; German Canc Res Ctr, D-6900 Heidelberg, Germany; German Inst Human Nutr, Potsdam, Germany; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; Aalborg Hosp, Dept Clin Epidemiol, Aalborg, Denmark; Univ Aarhus, Dept Epidemiol & Social Med, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; Andalusian Sch Publ Hlth, Granada, Spain; Dept Publ Hlth Guipuzkoa, San Sebastian, Spain; Catalan Inst Oncol, Barcelona, Spain; Radcliffe Infirm, Canc Res UK, Oxford OX2 6HE, England; Univ Athens, Sch Med, GR-10679 Athens, Greece; Univ Turin, Turin, Italy; CPO Piemonte, Turin, Italy; Ragusa Canc Registry, Ragusa, Sicily, Italy; Natl Canc Inst, Dept Epidemiol, I-20133 Milan, Italy; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; Lund Univ, Malmo Diet & Canc Study, Malmo, Sweden; Umea Univ, Dept Nutr Res, S-90187 Umea, Sweden; Univ Tromso, Inst Community Med, N-9001 Tromso, Norway	World Health Organization; International Agency for Research on Cancer (IARC); University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Helmholtz Association; German Cancer Research Center (DKFZ); Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Danish Cancer Society; Aalborg University; Aalborg University Hospital; Aarhus University; Aarhus University; Escuela Andaluza de Salud Publica; Catalan Institute of Oncology; Cancer Research UK; Radcliffe Infirmary; Athens Medical School; National & Kapodistrian University of Athens; University of Turin; Centro di Riferimento per Epidemiologia e la Prevenzione Oncologica in Piemonte; Fondazione IRCCS Istituto Nazionale Tumori Milan; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center; Lund University; Umea University; UiT The Arctic University of Tromso	Riboli, E (corresponding author), Int Agcy Res Canc, WHO, Unit Nutr & Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ntr@iarc.fr	Clavel-Chapelon, Francoise/G-6733-2014; Luben, Robert N/H-5519-2015; Kesse-Guyot, Emmanuelle/F-2692-2017; Kesse-Guyot, Emmanuelle/K-4689-2012; Kesse-Guyot, Emmanuelle/ABH-7347-2020; Krogh, Vittorio/K-2628-2016; Krogh, Vittorio/AAA-9171-2019; TRICHOPOULOU, ANTONIA/ABF-8727-2021	Luben, Robert N/0000-0002-5088-6343; Kesse-Guyot, Emmanuelle/0000-0002-9715-3534; Krogh, Vittorio/0000-0003-0122-8624; Krogh, Vittorio/0000-0003-0122-8624; TRICHOPOULOU, ANTONIA/0000-0002-7204-6396; Skeie, Guri/0000-0003-2476-4251; Tjonneland, Anne/0000-0003-4385-2097; tumino, rosario/0000-0003-2666-414X; Lund, Eiliv/0000-0002-8071-8711; Riboli, Elio/0000-0001-6795-6080; Overvad, Kim/0000-0001-6429-7921				Agudo A, 2002, PUBLIC HEALTH NUTR, V5, P1179, DOI 10.1079/PHN2002398; Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; BINGHAM SA, 1990, P NUTR SOC, V49, P153, DOI 10.1079/PNS19900021; BOFFA LC, 1992, CANCER RES, V52, P5906; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; BRESLOW NE, 1987, IARC SCI PUBL, V82; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; *COMA WORK GROUP D, 1998, 48 UK DEP HLTH COMA; Day NE, 2001, INT J EPIDEMIOL, V30, P309, DOI 10.1093/ije/30.2.309; Deharveng G, 1999, EUR J CLIN NUTR, V53, P60, DOI 10.1038/sj.ejcn.1600677; *DEP HLTH, 1991, 41 UK DEP HLTH; Domon-Dell C, 2002, GUT, V50, P525, DOI 10.1136/gut.50.4.525; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Holland B., 1991, MCCANCE WIDDOWSONS C, V5th; KAAKS R, 1995, AM J EPIDEMIOL, V142, P548, DOI 10.1093/oxfordjournals.aje.a117673; Key TJ, 1998, PUBLIC HEALTH NUTR, V1, P33, DOI 10.1079/PHN19980006; Kipnis V, 2001, AM J EPIDEMIOL, V153, P394, DOI 10.1093/aje/153.4.394; MCNEIL NI, 1981, DIS COLON RECTUM, V24, P596, DOI 10.1007/BF02605753; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394; Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6; Rosner B, 2001, AM J EPIDEMIOL, V154, P827, DOI 10.1093/aje/154.9.827; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Slimani N, 2002, PUBLIC HEALTH NUTR, V5, P1125, DOI 10.1079/PHN2002395; Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525; Wirfalt E, 2002, PUBLIC HEALTH NUTR, V5, P1197, DOI 10.1079/PHN2002399; World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR), 1997, FOOD NUTR PREV CANC	28	752	805	3	140	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2003	361	9368					1496	1501		10.1016/S0140-6736(03)13174-1	http://dx.doi.org/10.1016/S0140-6736(03)13174-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737858				2022-12-28	WOS:000182658900007
J	Peters, U; Sinha, R; Chatterjee, N; Subar, AF; Ziegler, RG; Kulldorff, M; Bresalier, R; Weissfeld, JL; Flood, A; Schatzkin, A; Hayes, RB				Peters, U; Sinha, R; Chatterjee, N; Subar, AF; Ziegler, RG; Kulldorff, M; Bresalier, R; Weissfeld, JL; Flood, A; Schatzkin, A; Hayes, RB		Prostate Lung Colorectal Ovarian C	Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme	LANCET			English	Article							RANDOMIZED TRIAL; RISK-FACTORS; LOW-FAT; RECURRENCE; POLYPS; MACRONUTRIENTS; PROSTATE; HISTORY; CALCIUM; COLON	Background Although dietary fibre has been reported to have no association with colorectal adenoma and cancer, in some studies this topic remains controversial. Methods We used a 137-item food frequency questionnaire to assess the relation of fibre intake and frequency of colorectal adenoma. The study was done within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a randomised controlled trial designed to investigate methods for early detection of cancer. In our analysis, we compared fibre intake of 33 971 participants who were sigmoidoscopy-negative for polyps, with 3591 cases with at least one histologically verified adenoma in the distal large bowel (ie, descending colon, sigmoid colon, or rectum). Odds ratios were estimated by logistic regression analysis. Findings High intakes of dietary fibre were associated with a lower risk of colorectal adenoma, after adjustment for potential dietary and non-dietary risk factors. Participants in the highest quintile of dietary fibre intake had a 27% (95% Cl 14-38, P-trend=0.002) lower risk of adenoma than those in the lowest quintile. The inverse association was strongest for fibre from grains and cereals and from fruits. Risks were similar for advanced and non-advanced adenoma. Risk of rectal adenoma was not significantly associated with fibre intake. Interpretation Dietary fibre, particularly from grains, cereals, and fruits, was associated with decreased risk of distal colon adenoma.	NCI, Div Canc Epidemiol & Genet, Nutr Epidemiol Branch, NIH,DHHS, Bethesda, MD 20892 USA; NCI, Div Canc Control & Populat Sci, NIH, DHHS, Bethesda, MD 20892 USA; Univ Connecticut, Sch Med, Farmington, CT USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Pittsburgh, Pittsburgh, PA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Connecticut; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Peters, U (corresponding author), NCI, Div Canc Epidemiol & Genet, Nutr Epidemiol Branch, NIH,DHHS, 6129 Execut Blvd,EPS 3024, Bethesda, MD 20892 USA.	petersu@mail.nih.gov	Kulldorff, Martin/H-4282-2011	Bresalier, Robert/0000-0002-9740-281X; Hayes, Richard/0000-0002-0918-661X; Kulldorff, Martin/0000-0002-5284-2993				Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; *AM COLL GASTR, 2000, GASTROENTEROLOGY, V118, P1233; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Breuer-Katschinski B, 2001, DIGEST DIS SCI, V46, P86, DOI 10.1023/A:1005519920643; BURK DL, 1997, VA JL TECH, V1, P3; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Giovannucci E, 2002, J NUTR, V132, p2350S, DOI 10.1093/jn/132.8.2350S; Gohagan JK, 2000, CONTROL CLIN TRIALS, V21, p251S, DOI 10.1016/S0197-2456(00)00097-0; Haile RW, 1997, INT J CANCER, V73, P497, DOI 10.1002/(SICI)1097-0215(19971114)73:4<497::AID-IJC7>3.0.CO;2-V; Hayes RB, 2000, CONTROL CLIN TRIALS, V21, p349S, DOI 10.1016/S0197-2456(00)00101-X; HOFF G, 1986, SCAND J GASTROENTERO, V21, P199, DOI 10.3109/00365528609034647; Kim YI, 2000, GASTROENTEROLOGY, V118, P1235, DOI 10.1016/S0016-5085(00)70377-5; KUNE GA, 1991, NUTR CANCER, V16, P25, DOI 10.1080/01635589109514137; LITTLE J, 1993, BRIT J CANCER, V67, P177, DOI 10.1038/bjc.1993.31; Lubin F, 1997, CANCER EPIDEM BIOMAR, V6, P79; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; MACOUARTMOULIN G, 1987, INT J CANCER, V40, P179, DOI 10.1002/ijc.2910400209; Martinez ME, 1996, EPIDEMIOLOGY, V7, P264, DOI 10.1097/00001648-199605000-00008; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; NEUGUT AI, 1993, ANN INTERN MED, V118, P91, DOI 10.7326/0003-4819-118-2-199301150-00002; Platz EA, 1997, CANCER EPIDEM BIOMAR, V6, P661; SANDLER RS, 1993, JNCI-J NATL CANCER I, V85, P884, DOI 10.1093/jnci/85.11.884; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Subar AF, 2000, AM J EPIDEMIOL, V152, P279, DOI 10.1093/aje/152.3.279; Terry MB, 2002, CANCER EPIDEM BIOMAR, V11, P622; Terry MB, 2002, CANCER EPIDEM BIOMAR, V11, P660; TIPPETT KS, 1998, CONTINUING SURVEY FO; *USDA AGR RES SERV, DAT TABL FOOD NUTR I; WACHOLDER S, 1995, EPIDEMIOLOGY, V6, P157, DOI 10.1097/00001648-199503000-00012; Wolever TMS, 1997, ADV EXP MED BIOL, V427, P35	31	232	254	0	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2003	361	9368					1491	1495		10.1016/S0140-6736(03)13173-X	http://dx.doi.org/10.1016/S0140-6736(03)13173-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737857				2022-12-28	WOS:000182658900006
J	Cassman, M				Cassman, M			Counting on the neuron	SCIENCE			English	Editorial Material									Univ Calif San Francisco, Calif Inst Quantitat Biomed Res, San Francisco, CA 94131 USA	University of California System; University of California San Francisco	Cassman, M (corresponding author), Univ Calif San Francisco, Calif Inst Quantitat Biomed Res, San Francisco, CA 94131 USA.	mcassman@research.ucsf.edu						[Anonymous], 2002, NATURE, V420, P703; *NY AC SCI, 2002, COMP MOD MAMM CELL N; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; NATL RESOURCE CELL A	4	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					756	757		10.1126/science.1082371	http://dx.doi.org/10.1126/science.1082371			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730591				2022-12-28	WOS:000182579800037
J	Spitz, F; Gonzalez, F; Duboule, D				Spitz, F; Gonzalez, F; Duboule, D			A global control region defines a chromosomal regulatory landscape containing the HoxD cluster	CELL			English	Article							GENE-EXPRESSION; TRANSGENIC ANALYSIS; SONIC-HEDGEHOG; LIMB BUD; COMPLEX; MOUSE; SEQUENCE; ULNALESS; DNA; GENOME	During limb development, coordinated expression of several Hoxd genes is required in presumptive digits. We searched for the underlying control sequences upstream from the cluster and found Lunapark (Lnp), a gene which shares limb and CNS expression specificities with both Hoxd genes and Evx2, another gene located nearby. We used a targeted enhancer-trap approach to identify a DNA segment capable of directing reporter gene expression in both digits and CNS, following Lnp, Evx2, and Hoxd-specific patterns. This DNA region showed an unusual interspecies conservation, including with its pufferfish counterpart. It contains a cluster of global enhancers capable of controlling transcription of several genes unrelated in structure or function, thus defining large regulatory domains. These domains were interrupted in the Ulna-less mutation, a balanced inversion that modified the topography of the locus. We discuss the heuristic value of these results in term of locus specific versus gene-specific regulation.	Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland; Univ Geneva, NCCR Frontiers Genet, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.			Gonzalez Grassi, Federico/0000-0002-7147-2246; duboule, denis/0000-0001-9961-2960; Spitz, Francois/0000-0002-1960-829X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Becker M, 1998, COMPUT PHYS, V12, P125; Beckers J, 1998, DEV DYNAM, V213, P1; Biery MC, 2000, NUCLEIC ACIDS RES, V28, P1067, DOI 10.1093/nar/28.5.1067; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; Carvajal JJ, 2001, DEVELOPMENT, V128, P1857; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DAVISSON MT, 1990, J HERED, V81, P151; Dermitzakis ET, 2002, NATURE, V420, P578, DOI 10.1038/nature01251; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; Goodman FR, 2002, AM J HUM GENET, V70, P547, DOI 10.1086/338921; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; Herault Y, 1997, DEVELOPMENT, V124, P3493; Herault Y, 1999, DEV BIOL, V208, P157, DOI 10.1006/dbio.1998.9179; Herault Y, 1996, EMBO J, V15, P6727, DOI 10.1002/j.1460-2075.1996.tb01062.x; JIN JR, 1995, DNA CELL BIOL, V14, P267, DOI 10.1089/dna.1995.14.267; Kleinjan DA, 2001, HUM MOL GENET, V10, P2049, DOI 10.1093/hmg/10.19.2049; Kmita M, 2000, NAT GENET, V26, P451, DOI 10.1038/82593; Kmita M, 2002, DEVELOPMENT, V129, P5521, DOI 10.1242/dev.00151; Kondo T, 1999, CELL, V97, P407, DOI 10.1016/S0092-8674(00)80749-7; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Monge I, 2003, DEV BIOL, V256, P212, DOI 10.1016/S0012-1606(02)00136-7; Morgan BA, 1996, P NATL ACAD SCI USA, V93, P2801, DOI 10.1073/pnas.93.7.2801; Muyrers JPP, 1999, NUCLEIC ACIDS RES, V27, P1555, DOI 10.1093/nar/27.6.1555; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Oliver Brian, 2002, J Biol, V1, P4; Orford M, 2000, Nucleic Acids Res, V28, pE84, DOI 10.1093/nar/28.18.e84; Peichel CL, 1997, DEVELOPMENT, V124, P3481; Peichel CL, 1996, GENETICS, V144, P1757; Pfeifer D, 1999, AM J HUM GENET, V65, P111, DOI 10.1086/302455; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJL, 1997, CURR OPIN GENET DEV, V7, P481; Roy PJ, 2002, NATURE, V418, P975, DOI 10.1038/nature01012; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Spitz F, 2001, GENE DEV, V15, P2209, DOI 10.1101/gad.205701; Sumiyama K, 2002, P NATL ACAD SCI USA, V99, P780, DOI 10.1073/pnas.012584999; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; Zakany J, 1999, NATURE, V401, P761, DOI 10.1038/44511; Zakany J, 1997, P NATL ACAD SCI USA, V94, P13695, DOI 10.1073/pnas.94.25.13695; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262	55	358	373	0	19	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 2	2003	113	3					405	417		10.1016/S0092-8674(03)00310-6	http://dx.doi.org/10.1016/S0092-8674(03)00310-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732147	Bronze			2022-12-28	WOS:000182640800014
J	Bonatti, E; Ligi, M; Brunelli, D; Cipriani, A; Fabretti, P; Ferrante, V; Gasperini, L; Ottolini, L				Bonatti, E; Ligi, M; Brunelli, D; Cipriani, A; Fabretti, P; Ferrante, V; Gasperini, L; Ottolini, L			Mantle thermal pulses below the Mid-Atlantic Ridge and temporal variations in the formation of oceanic lithosphere	NATURE			English	Article							BENEATH MIDOCEAN RIDGES; VEMA FRACTURE-ZONE; CRUSTAL THICKNESS; SPREADING CENTERS; TRANSVERSE RIDGE; MAGMA MIGRATION; NORTH-ATLANTIC; PASSIVE FLOW; GRAVITY; PERIDOTITES	A 20-Myr record of creation of oceanic lithosphere at a segment of the central Mid-Atlantic-Ridge is exposed along an uplifted sliver of lithosphere. The degree of melting of the mantle that is upwelling below the ridge, estimated from the chemistry of the exposed mantle rocks, as well as crustal thickness inferred from gravity measurements, show oscillations of similar to3-4 Myr superimposed on a longer-term steady increase with time. The time lag between oscillations of mantle melting and crustal thickness indicates that the solid mantle is upwelling at an average rate of similar to25 mm yr(-1), but this appears to vary through time. Slow-spreading lithosphere seems to form through dynamic pulses of mantle upwelling and melting, leading not only to along-axis segmentation but also to across-axis structural variability. Also, the central Mid-Atlantic Ridge appears to have become steadily hotter over the past 20 Myr, possibly owing to north-south mantle flow.	CNR, Ist Sci Marine, I-40129 Bologna, Italy; Univ Roma La Sapienza, Dipartimento Sci Terra, I-00187 Rome, Italy; Columbia Univ, Lamont Doherty Earth Observ, Dept Earth & Environm Sci, Palisades, NY 10964 USA; CNR, Ist Geosci & Georisorse, Sez Pavia, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze Marine (ISMAR-CNR); Sapienza University Rome; Columbia University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Geoscienze e Georisorse (IGG-CNR)	Bonatti, E (corresponding author), CNR, Ist Sci Marine, Via Gobetti 101, I-40129 Bologna, Italy.		Ligi, Marco/G-4853-2012; Gasperini, Luca/B-8796-2017; Brunelli, Daniele/B-7893-2012; Cipriani, Anna/A-2797-2012; Brunelli, Daniele/AGI-3668-2022	Ligi, Marco/0000-0002-5098-5907; Brunelli, Daniele/0000-0003-4839-1939; Cipriani, Anna/0000-0001-8457-0147; Brunelli, Daniele/0000-0003-4839-1939; Gasperini, Luca/0000-0002-0276-0607; ferrante, valentina/0000-0003-3147-1529; Bonatti, Enrico/0000-0001-6162-9572				AUZENDE JM, 1989, NATURE, V337, P726, DOI 10.1038/337726a0; BLACKMAN DK, 1992, GEOPH MONOG SERIES, V71, P311; Bonatti E, 2001, GEOLOGY, V29, P979, DOI 10.1130/0091-7613(2001)029<0979:SSCOCF>2.0.CO;2; Braun MG, 2000, EARTH PLANET SC LETT, V176, P339, DOI 10.1016/S0012-821X(00)00015-7; BRUNELLI D, 2001, THESIS U BOLOGNA; BUCK WR, 1989, GEOPHYS RES LETT, V16, P641, DOI 10.1029/GL016i007p00641; CANDE SC, 1988, J GEOPHYS RES-SOLID, V93, P13479, DOI 10.1029/JB093iB11p13479; Choblet G, 2001, EARTH PLANET SC LETT, V184, P589, DOI 10.1016/S0012-821X(00)00330-7; DETRICK RS, 1995, J GEOPHYS RES-SOL EA, V100, P3767, DOI 10.1029/94JB02649; DICK HJB, 1984, EARTH PLANET SC LETT, V69, P88, DOI 10.1016/0012-821X(84)90076-1; FORSYTH DW, 1993, J GEOPHYS RES-SOL EA, V98, P16073, DOI 10.1029/93JB01722; GASPERINI L, 1999, J C ABS, V4, P757; Hellebrand E, 2001, NATURE, V410, P677, DOI 10.1038/35070546; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Hooft EEE, 2000, J GEOPHYS RES-SOL EA, V105, P8205, DOI 10.1029/1999JB900442; HUANG M, 1999, MAR GEOD, V22, P183; JAQUES AL, 1980, CONTRIB MINERAL PETR, V73, P287, DOI 10.1007/BF00381447; JOHNSON KTM, 1990, J GEOPHYS RES-SOLID, V95, P2661, DOI 10.1029/JB095iB03p02661; Kastens K, 1998, MAR GEOPHYS RES, V20, P533, DOI 10.1023/A:1004745127999; KUO BY, 1988, MAR GEOPHYS RES, V10, P205, DOI 10.1007/BF00310065; LANGMUIR CH, 1992, GEOPH MONOG SERIES, V71, P183; Lasaga A. C., 1983, KINETICS EQUILIBRIUM, V3, P81; Li J, 1997, J GEODESY, V71, P209, DOI 10.1007/s001900050088; LIN J, 1990, NATURE, V344, P627, DOI 10.1038/344627a0; LOUDEN KE, 1986, J GEOL SOC LONDON, V143, P795, DOI 10.1144/gsjgs.143.5.0795; LUNDSTROM CC, 1995, SCIENCE, V270, P1958, DOI 10.1126/science.270.5244.1958; MACDONALD KC, 1988, NATURE, V335, P217, DOI 10.1038/335217a0; Magde LS, 2000, EARTH PLANET SC LETT, V175, P55, DOI 10.1016/S0012-821X(99)00281-2; Magde LS, 1997, EARTH PLANET SC LETT, V148, P59, DOI 10.1016/S0012-821X(97)00039-3; MICHAEL PJ, 1985, EARTH PLANET SC LETT, V73, P91, DOI 10.1016/0012-821X(85)90037-8; MORGAN JP, 1988, J GEOPHYS RES-SOLID, V93, P2955, DOI 10.1029/JB093iB04p02955; MYSEN BO, 1977, AM MINERAL, V62, P843; NEUMANN GA, 1993, J GEOPHYS RES-SOL EA, V98, P17891, DOI 10.1029/93JB01550; PARISO JE, 1995, J GEOPHYS RES-SOL EA, V100, P17781, DOI 10.1029/95JB01146; PHIPPSMORGAN J, 1995, EARTH PLANET SC LETT, V129, P73; POTTS CG, 1986, GEOPHYS J INT, V86, P491, DOI 10.1111/j.1365-246X.1986.tb03840.x; PRINCE RA, 1988, J GEOPHYS RES-SOLID, V93, P8051, DOI 10.1029/JB093iB07p08051; REID I, 1981, MAR GEOPHYS RES, V5, P165; Sandwell DT, 1997, J GEOPHYS RES-SOL EA, V102, P10039, DOI 10.1029/96JB03223; SCOTT DR, 1989, J GEOPHYS RES-SOLID, V94, P2973, DOI 10.1029/JB094iB03p02973; SCOTT DR, 1984, GEOPHYS RES LETT, V11, P1161, DOI 10.1029/GL011i011p01161; Seyler M, 1997, EARTH PLANET SC LETT, V146, P273, DOI 10.1016/S0012-821X(96)00220-8; Shen Y, 2002, EARTH PLANET SC LETT, V197, P261, DOI 10.1016/S0012-821X(02)00494-6; SOTIN C, 1989, GEOPHYS RES LETT, V16, P835, DOI 10.1029/GL016i008p00835; SPARKS DW, 1993, J GEOPHYS RES-SOL EA, V98, P21977, DOI 10.1029/93JB02397; SPIEGELMAN M, 1993, EARTH PLANET SC LETT, V118, P1, DOI 10.1016/0012-821X(93)90155-3; SPIEGELMAN M, 1992, EARTH PLANET SC LETT, V109, P611, DOI 10.1016/0012-821X(92)90119-G; Taylor WR, 1998, NEUES JB MINER ABH, V172, P381; Tucholke BE, 1997, J GEOPHYS RES-SOL EA, V102, P10203, DOI 10.1029/96JB03896; YANG XP, 1994, GEOPHYS RES LETT, V21, P309, DOI 10.1029/93GL03261	50	90	94	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					499	505		10.1038/nature01594	http://dx.doi.org/10.1038/nature01594			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774114	Green Published			2022-12-28	WOS:000183162900034
J	Thiru, K; Hassey, A; Sullivan, F				Thiru, K; Hassey, A; Sullivan, F			Systematic review of scope and quality of electronic patient record data in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ISCHEMIC-HEART-DISEASE; GENERAL-PRACTICE DATA; COMPUTERIZED MEDICAL RECORDS; DATA-RETRIEVAL; ACCURACY; MORBIDITY; VALIDATION; RISK; COMPLETENESS; POPULATION		Fisher Med Ctr, Res Unit, Skipton BD23 1EU, N Yorkshire, England; Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland	University of Dundee	Thiru, K (corresponding author), Fisher Med Ctr, Res Unit, Skipton BD23 1EU, N Yorkshire, England.	krish.thiru@st-marys.nhs.uk	Sullivan, Frank m/A-7767-2009; Greiver, Michelle/N-8764-2015; Sullivan, Frank/L-8286-2019	Greiver, Michelle/0000-0001-8957-0285; Sullivan, Frank/0000-0002-6623-4964				BASDEN A, 1980, INT J BIOMED COMPUT, V11, P511, DOI 10.1016/0020-7101(80)90017-3; BOYDELL L, 1995, J EPIDEMIOL COMMUN H, V49, P22, DOI 10.1136/jech.49.Suppl_1.22; BROWN PJ, 2001, MEDINFO, V10, P1116; Cass AR, 1999, INT J PSYCHIAT MED, V29, P293, DOI 10.2190/CPYJ-2HBF-RGCN-64V2; *DEP GEN PRACT, 1995, GPASS DAT VAL REP; Derby L, 2000, J ALLERGY CLIN IMMUN, V105, P912, DOI 10.1067/mai.2000.106044; Derby LE, 1998, EPIDEMIOLOGY, V9, P205, DOI 10.1097/00001648-199803000-00018; EAMES M, 1996, GEN PRACTICE RES DAT; Eland IA, 2000, BRIT J CLIN PHARMACO, V49, P473, DOI 10.1046/j.1365-2125.2000.00196.x; Frischer M, 2000, J PUBLIC HEALTH MED, V22, P362, DOI 10.1093/pubmed/22.3.362; Gill D, 1999, J PSYCHOSOM RES, V46, P349, DOI 10.1016/S0022-3999(98)00102-0; Gray J, 2000, BMJ-BRIT MED J, V321, P548, DOI 10.1136/bmj.321.7260.548; Grimsmo A, 2001, SCAND J PRIM HEALTH, V19, P76; Hansell A, 1999, THORAX, V54, P413, DOI 10.1136/thx.54.5.413; Hassey A, 2001, BRIT MED J, V322, P1401, DOI 10.1136/bmj.322.7299.1401; Hiddema-van de Wal A, 2001, FAM PRACT, V18, P288; Hippisley-Cox J, 2001, BMJ-BRIT MED J, V322, P832, DOI 10.1136/bmj.322.7290.832; Hogan WR, 1997, J AM MED INFORM ASSN, V4, P342, DOI 10.1136/jamia.1997.0040342; HOLLOWELL J, 1997, POPUL TRENDS, V37, P36; *HOUS LORDS, SEL COMM SCI TECHN 4; Hung J, 1998, J AM MED INFORM ASSN, P688; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; JOHNSON N, 1991, BRIT MED J, V302, P763, DOI 10.1136/bmj.302.6779.763; Kaye JA, 2000, BRIT J CANCER, V83, P1556, DOI 10.1054/bjoc.2000.1493; Lawrenson R, 2000, BRIT J CLIN PHARMACO, V49, P591, DOI 10.1046/j.1365-2125.2000.00199.x; MARTIN R, 1995, WORK EMPLOY SOC, V9, P165; McColl A, 2000, QUAL HEALTH CARE, V9, P90, DOI 10.1136/qhc.9.2.90; Meal AG, 2000, FAM PRACT, V17, P394, DOI 10.1093/fampra/17.5.394; Meara J, 1999, AGE AGEING, V28, P99, DOI 10.1093/ageing/28.2.99; MOSS F, 1994, QUAL HEALTH CARE, P46; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; Neal RD, 1996, FAM PRACT, V13, P455, DOI 10.1093/fampra/13.5.455; Njalsson T, 1992, Scand J Prim Health Care, V10, P243, DOI 10.3109/02813439209014069; NJALSSON T, 1995, EUR J GEN PRACT, V1, P59; *OXF MAAG, 2000, CAS STUD REV OXF SCH; Pearson N, 1996, BMJ-BRIT MED J, V312, P1517, DOI 10.1136/bmj.312.7045.1517; Petursson P, 1996, SCAND J PRIM HEALTH, V14, P196, DOI 10.3109/02813439608997085; *PRIMIS, 2000, NOTT PRIM CAR HLTH D; PRINGLE M, 1995, BRIT J GEN PRACT, V45, P537; Rodriguez LAG, 1999, BRIT J CLIN PHARMACO, V48, P847; Scobie S, 1995, J PUBLIC HEALTH MED, V17, P475; SIMPSON DS, 2001, USE INFORMATION TECH; Suarez AP, 2000, PHARMACOEPIDEM DR S, V9, P405, DOI 10.1002/1099-1557(200009/10)9:5<405::AID-PDS521>3.0.CO;2-7; TEASDALE S, 1998, INFORM HEALTHCARE AU, V7, P38; Thiru K, 1999, HLTH INFORM J, V5, P224, DOI DOI 10.1177/146045829900500410; Turnbull S, 1996, BRIT J PSYCHIAT, V169, P705, DOI 10.1192/bjp.169.6.705; Van Staa TP, 2000, PHARMACOEPIDEM DR S, V9, P359, DOI 10.1002/1099-1557(200009/10)9:5<359::AID-PDS507>3.0.CO;2-E; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106; VANWEEL C, 1995, J EPIDEMIOL COMMUN H, V49, P29, DOI 10.1136/jech.49.Suppl_1.29; VERNON M, 1998, J INFORM PRIM CARE; Vlug AE, 1999, METHOD INFORM MED, V38, P339; Whitelaw FG, 1996, BRIT J GEN PRACT, V46, P181; Whitelaw FG, 1996, BRIT J GEN PRACT, V46, P707; WILLIAMS J, 2001, THESIS U SURREY GUIL	55	206	207	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	2003	326	7398					1070	1072A		10.1136/bmj.326.7398.1070	http://dx.doi.org/10.1136/bmj.326.7398.1070			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681ZD	12750210	Green Published, Bronze			2022-12-28	WOS:000183064700018
J	Astakhov, SA; Burbanks, AD; Wiggins, S; Farrelly, D				Astakhov, SA; Burbanks, AD; Wiggins, S; Farrelly, D			Chaos-assisted capture of irregular moons	NATURE			English	Article							TEMPORARY GRAVITATIONAL CAPTURE; SATELLITE CAPTURE; TIME ANALYSIS; GAS DRAG; ORBITS; OBJECTS; ATOM	It has been thought(1-3) that the capture of irregular moons - with non-circular orbits - by giant planets occurs by a process in which they are first temporarily trapped by gravity inside the planet's Hill sphere ( the region where planetary gravity dominates over solar tides(4)). The capture of the moons is then made permanent by dissipative energy loss ( for example, gas drag(3)) or planetary growth(2). But the observed distributions of orbital inclinations, which now include numerous newly discovered moons(5-8), cannot be explained using current models. Here we show that irregular satellites are captured in a thin spatial region where orbits are chaotic(9), and that the resulting orbit is either prograde or retrograde depending on the initial energy. Dissipation then switches these long-lived chaotic orbits(10) into nearby regular (non-chaotic) zones from which escape is impossible. The chaotic layer therefore dictates the final inclinations of the captured moons. We confirm this with three-dimensional Monte Carlo simulations that include nebular drag(3,4,11), and find good agreement with the observed inclination distributions of irregular moons at Jupiter(7) and Saturn(8). In particular, Saturn has more prograde irregular moons than Jupiter, which we can explain as a result of the chaotic prograde progenitors being more efficiently swept away from Jupiter by its galilean moons.	Univ Bristol, Sch Math, Bristol BS8 1TW, Avon, England; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	University of Bristol; Utah System of Higher Education; Utah State University	Wiggins, S (corresponding author), Univ Bristol, Sch Math, Univ Walk, Bristol BS8 1TW, Avon, England.		Burbanks, Andrew D/A-3316-2012	Burbanks, Andrew D/0000-0003-0685-6670; Wiggins, Stephen/0000-0002-0780-0911				Aarseth SJ, 1999, PUBL ASTRON SOC PAC, V111, P1333, DOI 10.1086/316455; Brunello AF, 1997, PHYS REV A, V55, P3730, DOI 10.1103/PhysRevA.55.3730; Carruba V, 2002, ICARUS, V158, P434, DOI 10.1006/icar.2002.6896; COLOMBO G, 1971, ICARUS, V15, P186, DOI 10.1016/0019-1035(71)90073-X; CONTOPOULOS G, 1965, ASTROPHYS J, V142, P802, DOI 10.1086/148348; Gladman B, 2001, NATURE, V412, P163, DOI 10.1038/35084032; HENON M, 1970, ASTRON ASTROPHYS, V9, P24; HEPPENHEIMER TA, 1977, ICARUS, V30, P385, DOI 10.1016/0019-1035(77)90173-7; HUANG TY, 1983, ASTRON J, V88, P1537, DOI 10.1086/113444; KARY DM, 1993, ICARUS, V106, P288, DOI 10.1006/icar.1993.1172; KOZAI Y, 1962, ASTRON J, V67, P591, DOI 10.1086/108790; Lee E, 1997, PHYS REV A, V55, P2203, DOI 10.1103/PhysRevA.55.2203; LICHTENBERG AJ, 1992, REGULAR CHAOTIC DYNA, P174; Marzari F, 1998, ICARUS, V131, P41, DOI 10.1006/icar.1997.5841; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; Namouni F, 1999, ICARUS, V137, P293, DOI 10.1006/icar.1998.6032; Nesvorny D, 2002, CELEST MECH DYN ASTR, V82, P323, DOI 10.1023/A:1015219113959; Neto EV, 2001, ASTRON J, V122, P440, DOI 10.1086/321101; Peale SJ, 1999, ANNU REV ASTRON ASTR, V37, P533, DOI 10.1146/annurev.astro.37.1.533; PERRY AD, 1994, PHYSICA D, V71, P102, DOI 10.1016/0167-2789(94)90184-8; POLLACK JB, 1979, ICARUS, V37, P587, DOI 10.1016/0019-1035(79)90016-2; PRESS WH, 1999, NUMERICAL RECIPES C, P724; SAHA P, 1993, ICARUS, V106, P549, DOI 10.1006/icar.1993.1192; SHEPHARD SS, 2003, 8087 IAU; SHEPHARD SS, 2001, 7555 IAU; SHEPHARD SS, 2002, 7900 IAU; Stern SA, 2000, ASTRON J, V119, P945, DOI 10.1086/301207; Winter OC, 2001, ASTRON ASTROPHYS, V377, P1119, DOI 10.1051/0004-6361:20011165	30	85	85	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					264	267		10.1038/nature01622	http://dx.doi.org/10.1038/nature01622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748635				2022-12-28	WOS:000182853100036
J	Mariani, FV; Martin, GR				Mariani, FV; Martin, GR			Deciphering skeletal patterning: clues from the limb	NATURE			English	Review							APICAL ECTODERMAL RIDGE; HOLT-ORAM-SYNDROME; VERTEBRATE LIMB; CHICK LIMB; SONIC HEDGEHOG; JOINT FORMATION; HOX GENES; DIGIT DEVELOPMENT; LONG-RANGE; CELL-DEATH	Even young children distinguish a Tyrannosaurus rex from a Brontosaurus by observing differences in bone size, shape, number and arrangement, that is, skeletal pattern. But despite our extensive knowledge about cartilage and bone formation per se, it is still largely a mystery how skeletal pattern is established. Much of what we do know has been learned from studying limb development in chicken and mouse embryos. Based on the data from such studies, models for how limb skeletal pattern is established have been proposed and continue to be hotly debated.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mariani, FV (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.	gmartin@itsa.ucsf.edu		Mariani, Francesca/0000-0003-1619-8763				Agarwal P, 2003, DEVELOPMENT, V130, P623, DOI 10.1242/dev.00191; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; Chiang C, 2001, DEV BIOL, V236, P421, DOI 10.1006/dbio.2001.0346; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Cohn MJ, 2002, BIOESSAYS, V24, P460, DOI 10.1002/bies.10088; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; Davenport TG, 2003, DEVELOPMENT, V130, P2263, DOI 10.1242/dev.00431; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Drossopoulou G, 2000, DEVELOPMENT, V127, P1337; Dudley AT, 2002, NATURE, V418, P539, DOI 10.1038/nature00945; DVORAK L, 1991, ANAT REC, V231, P251, DOI 10.1002/ar.1092310213; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; Francis-West PH, 1999, DEVELOPMENT, V126, P1305; Goff DJ, 1997, DEVELOPMENT, V124, P627; Gruneberg, 1963, PATHOLOGY DEVELPMENT; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HORNBRUCH A, 1970, NATURE, V226, P764, DOI 10.1038/226764a0; JANNERS MY, 1970, DEV BIOL, V23, P136, DOI 10.1016/S0012-1606(70)80011-2; JOHNSON RL, 1994, BIOCHEM SOC T, V22, P569, DOI 10.1042/bst0220569; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kardon G, 2002, DEV CELL, V3, P533, DOI 10.1016/S1534-5807(02)00291-5; KIENY M, 1977, ROUX ARCH DEV BIOL, V183, P177, DOI 10.1007/BF00867319; KIENY M, 1977, VERTEBRATE LIMB SOMI, P87; KING JA, 1994, DEV BIOL, V166, P112, DOI 10.1006/dbio.1994.1300; Kingsley D M, 2001, Novartis Found Symp, V232, P213; Kmita M, 2002, NATURE, V420, P145, DOI 10.1038/nature01189; Kraus P, 2001, MECH DEVELOP, V100, P45, DOI 10.1016/S0925-4773(00)00492-5; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lewandoski M, 2000, NAT GENET, V26, P460, DOI 10.1038/82609; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Li QY, 1997, NAT GENET, V15, P21; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; MAINI PK, 1991, INT REV CYTOL, V129, P91; Martin G, 2001, BIOESSAYS, V23, P865, DOI 10.1002/bies.1126; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; Moon AM, 2000, DEVELOPMENT, V127, P989; Nelson CE, 1996, DEVELOPMENT, V122, P1449; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; Niswander L, 2003, NAT REV GENET, V4, P133, DOI 10.1038/nrg1001; OSTER GF, 1988, EVOLUTION, V42, P862, DOI 10.1111/j.1558-5646.1988.tb02508.x; Pearse RV, 1998, J EXP ZOOL, V282, P677, DOI 10.1002/(SICI)1097-010X(19981215)282:6<677::AID-JEZ4>3.0.CO;2-F; ROWE DA, 1982, DEV BIOL, V93, P83, DOI 10.1016/0012-1606(82)90241-X; Saunders JJ, 1968, EPITHELIAL MESENCHYM, P289; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; Slack JMW, 1983, EGG EMBRYO DETERMINA; Storm EE, 1999, DEV BIOL, V209, P11, DOI 10.1006/dbio.1999.9241; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Sun X, 2000, NAT GENET, V25, P83, DOI 10.1038/75644; Tickle C, 2002, NAT CELL BIOL, V4, pE216, DOI 10.1038/ncb0902-e216; Tickle C, 2001, CURR OPIN GENET DEV, V11, P476, DOI 10.1016/S0959-437X(00)00220-3; Vargesson N, 1997, DEVELOPMENT, V124, P1909; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620; WILTING J, 1995, DEV DYNAM, V202, P165, DOI 10.1002/aja.1002020208; Wolpert L, 1971, Curr Top Dev Biol, V6, P183; Wolpert L, 2002, CURR BIOL, V12, pR628, DOI 10.1016/S0960-9822(02)01137-5; WOLPERT L, 1979, J EMBRYOL EXP MORPH, V50, P175; WOLPERT L, 1974, CELL PATTERNING, P95; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262	73	179	188	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					319	325		10.1038/nature01655	http://dx.doi.org/10.1038/nature01655			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748649				2022-12-28	WOS:000182853100051
J	Murthy, VM; van Westrenen, W; Fei, YW				Murthy, VM; van Westrenen, W; Fei, YW			Experimental evidence that potassium is a substantial radioactive heat source in planetary cores	NATURE			English	Article							EARTHS CORE; THERMAL EVOLUTION; TERRESTRIAL PLANETS; SILICATE LIQUIDS; OXYGEN FUGACITY; METALLIC LIQUID; MARS; HISTORY; SULFUR; MELT	The hypothesis that K-40 may be a significant radioactive heat source in the Earth's core was proposed on theoretical grounds(1,2) over three decades ago, but experiments(3-8) have provided only ambiguous and contradictory evidence for the solubility of potassium in iron-rich alloys. The existence of such radioactive heat in the core would have important implications for our understanding of the thermal evolution of the Earth and global processes such as the generation of the geomagnetic field, the core-mantle boundary heat flux and the time of formation of the inner core(9-12). Here we provide experimental evidence to show that the ambiguous results obtained from earlier experiments are probably due to previously unrecognized experimental and analytical difficulties. The high-pressure, high-temperature data presented here show conclusively that potassium enters iron sulphide melts in a strongly temperature-dependent fashion and that K-40 can serve as a substantial heat source in the cores of the Earth and Mars.	Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Swiss Fed Inst Technol, Inst Mineral & Petrog, CH-8092 Zurich, Switzerland	University of Minnesota System; University of Minnesota Twin Cities; Carnegie Institution for Science; Carnegie Institution for Science; Swiss Federal Institutes of Technology Domain; ETH Zurich	Murthy, VM (corresponding author), Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA.		Fei, Yingwei/F-3709-2011; van Westrenen, Wim/D-6495-2012	Fei, Yingwei/0000-0001-9955-5353; van Westrenen, Wim/0000-0001-5828-8885				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; Bertka CM, 1998, SCIENCE, V281, P1838, DOI 10.1126/science.281.5384.1838; Buffett BA, 1996, J GEOPHYS RES-SOL EA, V101, P7989, DOI 10.1029/95JB03539; BUFFETT BA, 2002, GEOPHYS RES LETT, V29, DOI DOI 10.1029/2001GL014649; Chabot NL, 1999, EARTH PLANET SC LETT, V172, P323, DOI 10.1016/S0012-821X(99)00208-3; Fei YW, 2000, AM MINERAL, V85, P1830; Gessmann CK, 2002, EARTH PLANET SC LETT, V200, P63, DOI 10.1016/S0012-821X(02)00593-9; Gessmann CK, 2000, EARTH PLANET SC LETT, V184, P95, DOI 10.1016/S0012-821X(00)00323-X; Goettel K. A., 1972, Physics of the Earth and Planetary Interiors, V6, P161, DOI 10.1016/0031-9201(72)90049-0; GUBBINS D, 1979, GEOPHYS J ROY ASTR S, V59, P57, DOI 10.1111/j.1365-246X.1979.tb02553.x; HALL HT, 1971, EARTH PLANET SC LETT, V11, P239, DOI 10.1016/0012-821X(71)90170-1; Hillgren V.J., 2000, ORIGIN EARTH MOON PP, P245, DOI DOI 10.2307/J.CTV1V7ZDRP.20; Holzheid A, 2002, AM MINERAL, V87, P227; Jana D, 1997, EARTH PLANET SC LETT, V150, P463, DOI 10.1016/S0012-821X(97)00079-4; Labrosse S, 2001, EARTH PLANET SC LETT, V190, P111, DOI 10.1016/S0012-821X(01)00387-9; LEWIS JS, 1971, EARTH PLANET SC LETT, V11, P130, DOI 10.1016/0012-821X(71)90154-3; Li J, 2001, GEOCHIM COSMOCHIM AC, V65, P1821, DOI 10.1016/S0016-7037(00)00613-X; Lodders K, 1997, ICARUS, V126, P373, DOI 10.1006/icar.1996.5653; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; MCKENZIE D, 1981, J GEOPHYS RES, V86, P1667, DOI 10.1029/JB086iB12p11667; MURRELL MT, 1986, J GEOPHYS RES-SOLID, V91, P8126, DOI 10.1029/JB091iB08p08126; Nimmo F, 2000, J GEOPHYS RES-PLANET, V105, P11969, DOI 10.1029/1999JE001216; Ohtani E, 1997, PHYS EARTH PLANET IN, V100, P97, DOI 10.1016/S0031-9201(96)03234-7; OVERSBY VM, 1972, EARTH PLANET SC LETT, V14, P345, DOI 10.1016/0012-821X(72)90134-3; Righter K, 1997, PHYS EARTH PLANET IN, V100, P115, DOI 10.1016/S0031-9201(96)03235-9; Righter K, 1997, EARTH PLANET SC LETT, V146, P541, DOI 10.1016/S0012-821X(96)00243-9; Stevenson DJ, 2001, NATURE, V412, P214, DOI 10.1038/35084155; STEVENSON DJ, 1983, ICARUS, V54, P466, DOI 10.1016/0019-1035(83)90241-5; WALTER MJ, 1995, SCIENCE, V270, P1186, DOI 10.1126/science.270.5239.1186	29	135	141	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					163	165		10.1038/nature01560	http://dx.doi.org/10.1038/nature01560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736683				2022-12-28	WOS:000182699600044
J	Stark, JM; Hart, SC				Stark, JM; Hart, SC			UV-B radiation and soil microbial communities	NATURE			English	Article							BIOMASS-C; NPK FERTILIZER; RESPONSES; CARBON		Utah State Univ, Dept Biol, Logan, UT 84322 USA; Utah State Univ, Ctr Ecol, Logan, UT 84322 USA; No Arizona Univ, Sch Forestry, Flagstaff, AZ 86011 USA; No Arizona Univ, Merriam Powell Ctr Environm Res, Flagstaff, AZ 86011 USA	Utah System of Higher Education; Utah State University; Utah System of Higher Education; Utah State University; Northern Arizona University; Northern Arizona University	Stark, JM (corresponding author), Utah State Univ, Dept Biol, Logan, UT 84322 USA.	jstark@biology.usu.edu	Stark, John/B-4368-2012	Campbell, Colin/0000-0002-5163-7656				[Anonymous], 1996, SOIL MICROBIOLOGY BI; Bauhus J, 1999, GOING UNDERGROUND-ECOLOGICAL STUDIES IN FOREST SOILS, P77; Haubensak KA, 2002, SOIL BIOL BIOCHEM, V34, P1549, DOI 10.1016/S0038-0717(02)00124-4; Johnson D, 2002, NATURE, V416, P82, DOI 10.1038/416082a; Jonasson S, 1996, OECOLOGIA, V106, P507, DOI 10.1007/BF00329709; Michelsen A, 1999, NEW PHYTOL, V143, P523, DOI 10.1046/j.1469-8137.1999.00479.x; MUELLER T, 1992, SOIL BIOL BIOCHEM, V24, P179, DOI 10.1016/0038-0717(92)90275-3; WARDLE DA, 1992, BIOL REV, V67, P321, DOI 10.1111/j.1469-185X.1992.tb00728.x	8	11	13	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					137	138		10.1038/423137a	http://dx.doi.org/10.1038/423137a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736675				2022-12-28	WOS:000182699600036
J	Ferguson, LR; Harris, PJ				Ferguson, LR; Harris, PJ			The dietary fibre debate: more food for thought	LANCET			English	Editorial Material							COLORECTAL-CANCER; RISK; RECURRENCE		Univ Auckland, Discipline Nutr, Auckland 1, New Zealand; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand	University of Auckland; University of Auckland	Ferguson, LR (corresponding author), Univ Auckland, Discipline Nutr, Auckland 1, New Zealand.	l.ferguson@auckland.ac.nz	Ferguson, Lynnette Robin/F-5989-2011; Harris, Philip J/P-9317-2016	Harris, Philip J/0000-0003-1807-8079				Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; *AM COLL GASTR, 2000, GASTROENTEROLOGY, V118, P1233; Bacic A., 1988, BIOCHEM PLANT, V14, P297, DOI [DOI 10.1016/B978-0-08-092615-5.50014-X, 10.1016/B978-0-08-092615-5.50014-X]; ENGLYST HN, 1988, J ASSOC OFF ANA CHEM, V71, P808; Ferguson LR, 1999, EUR J CANCER PREV, V8, P17, DOI 10.1097/00008469-199902000-00003; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Harris PJ, 1999, MUTAT RES-GEN TOX EN, V443, P95, DOI 10.1016/S1383-5742(99)00013-7; Kroon PA, 1997, J AGR FOOD CHEM, V45, P661, DOI 10.1021/jf9604403; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; PROSKY L, 1988, J ASSOC OFF ANA CHEM, V71, P1017; SANTANARIOS G, 2000, MUTAT RES, V429, P269; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525	13	62	68	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2003	361	9368					1487	1488		10.1016/S0140-6736(03)13219-9	http://dx.doi.org/10.1016/S0140-6736(03)13219-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737854				2022-12-28	WOS:000182658900003
J	Savvidou, MD; Hingorani, AD; Tsikas, D; Frolich, JC; Vallance, P; Nicolaides, KH				Savvidou, MD; Hingorani, AD; Tsikas, D; Frolich, JC; Vallance, P; Nicolaides, KH			Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia	LANCET			English	Article							NITRIC-OXIDE SYNTHASE; HYPERTENSIVE DISORDERS; MEDIATED VASODILATION; ENOS-GENE; RISK; INHIBITOR; LOCUS	Background Maternal endothelial dysfunction is a feature of established pre-eclampsia but whether this is a cause or consequence of the disorder is not clear. We tested the hypothesis that endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine (ADMA), the endogenous inhibitor of endothelial nitric oxide synthase, precede and contribute to the development of pre-eclampsia. Methods We assessed uterine artery doppler waveforms in 86 women, at 23-25 weeks' gestation. We tested endothelial function in all women using flow-mediated dilation of the brachial artery at 23-25 weeks' gestation. Plasma concentrations of ADMA were also measured. Findings 43 women had normal uterine artery doppler waveforms and subsequently had a normal outcome. The second group of 43 had evidence of impaired placental perfusion and of these, 19 (44%) had normal outcome, 14 (33%) developed intrauterine growth restriction of the fetus (IUGR), and pre-eclampsia arose in ten (23%). Women who developed pre-eclampsia had significantly lower flow-mediated dilation than did women who had normal outcome (3-58% [SD 2.76] vs 8.59% [2.76]; p<0.0001). Irrespective of pregnancy outcome, women with evidence of impaired placental perfusion had significantly higher levels of ADMA than did women with normal doppler waveforms (2.4 mu mol/L [IQR 1.97-3.14] vs 0.81 mu mol/L [0.49-1.08]; p<0.0001). There was a strong inverse correlation between ADMA and flow-mediated dilation but only in the group of women who eventually developed pre-eclampsia (r= -0.8, p=0.005). Interpretation Maternal endothelial function is impaired in women who eventually develop pre-eclampsia and it occurs before the development of the clinical syndrome. Furthermore, women with high resistance placental circulation at risk of pre-eclampsia, IUGR, or both have raised concentrations of ADMA, which is a potential contributory factor for pre-eclampsia, and is associated with endothelial dysfunction in some women.	Kings Coll Hosp London, Harris Birthright Res Ctr Fetal Med, London SE5 8RS, England; UCL, Dept Med, British Heart Fdn Labs, Ctr Clin Pharmacol, London WC1E 6BT, England; Hannover Med Sch, Inst Clin Pharmacol, D-3000 Hannover, Germany	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; University College London; Hannover Medical School	Nicolaides, KH (corresponding author), Kings Coll Hosp London, Harris Birthright Res Ctr Fetal Med, Denmark Hill, London SE5 8RS, England.	Kypros@technocom.com		Nicolaides, Kypros/0000-0003-1266-0711; Hingorani, Aroon/0000-0001-8365-0081; SAVVIDOU, MAKRINA/0000-0002-0125-2299				Albaiges G, 2000, OBSTET GYNECOL, V96, P559, DOI 10.1016/S0029-7844(00)00946-7; Arngrimsson R, 1997, AM J HUM GENET, V61, P354, DOI 10.1086/514843; Bosio PM, 1999, OBSTET GYNECOL, V94, P978, DOI 10.1016/S0029-7844(99)00430-5; CALVER A, 1993, J HUM HYPERTENS, V7, P193; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Cockell AP, 1997, HYPERTENSION, V30, P247, DOI 10.1161/01.HYP.30.2.247; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; Dorup I, 1999, AM J PHYSIOL-HEART C, V276, pH821; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; Holden DP, 1998, AM J OBSTET GYNECOL, V178, P551, DOI 10.1016/S0002-9378(98)70437-5; Kielstein JT, 2002, J AM SOC NEPHROL, V13, P170, DOI 10.1681/ASN.V131170; Lade JA, 1999, HYPERTENS PREGNANCY, V18, P81, DOI 10.3109/10641959909009613; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; MACALLISTER RJ, 1994, KIDNEY INT, V45, P737, DOI 10.1038/ki.1994.98; Meis PJ, 1998, AM J OBSTET GYNECOL, V178, P562, DOI 10.1016/S0002-9378(98)70439-9; MEREDITH JT, 1996, AM J PHYSIOL, V270, pH1435; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Redman CWG, 1999, AM J OBSTET GYNECOL, V180, P499, DOI 10.1016/S0002-9378(99)70239-5; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; ROBSON SC, 1989, AM J PHYSIOL, V256, pH1060, DOI 10.1152/ajpheart.1989.256.4.H1060; Savvidou MD, 2001, HYPERTENSION, V38, P1289, DOI 10.1161/hy1201.097305; Savvidou MD, 2000, ULTRASOUND OBST GYN, V15, P502, DOI 10.1046/j.1469-0705.2000.00131.x; Sibai BM, 2000, AM J OBSTET GYNECOL, V182, P938, DOI 10.1016/S0002-9378(00)70350-4; Sibai BM, 2000, AM J OBSTET GYNECOL, V182, P364, DOI 10.1016/S0002-9378(00)70225-0; Sikkema JM, 2001, PLACENTA, V22, P304, DOI 10.1053/plac.2001.0629; Tsikas D, 1998, J CHROMATOGR B, V705, P174; Valkonen VP, 2001, LANCET, V358, P2127, DOI 10.1016/S0140-6736(01)07184-7; VALLANCE P, 1992, LANCET, V339, P572; Williams DJ, 1997, AM J PHYSIOL-HEART C, V272, pH748, DOI 10.1152/ajpheart.1997.272.2.H748	30	383	414	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2003	361	9368					1511	1517		10.1016/S0140-6736(03)13177-7	http://dx.doi.org/10.1016/S0140-6736(03)13177-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737861				2022-12-28	WOS:000182658900010
J	Berkley, AJ; Xu, H; Ramos, RC; Gubrud, MA; Strauch, FW; Johnson, PR; Anderson, JR; Dragt, AJ; Lobb, CJ; Wellstood, FC				Berkley, AJ; Xu, H; Ramos, RC; Gubrud, MA; Strauch, FW; Johnson, PR; Anderson, JR; Dragt, AJ; Lobb, CJ; Wellstood, FC			Entangled macroscopic quantum states in two superconducting qubits	SCIENCE			English	Article							BIASED JOSEPHSON JUNCTION; ZERO-VOLTAGE STATE; SUPERPOSITION; OSCILLATIONS	We present spectroscopic evidence for the creation of entangled macroscopic quantum states in two current-biased Josephson-junction qubits coupled by a capacitor. The individual junction bias currents are used to control the interaction between the qubits by tuning the energy level spacings of the junctions in and out of resonance with each other. Microwave spectroscopy in the 4 to 6 gigahertz range at 20 millikelvin reveals energy levels that agree well with theoretical results for entangled states. The single qubits are spatially separate, and the entangled states extend over the 0.7-millimeter distance between the two qubits.	Univ Maryland, Ctr Superconduct Res, Dept Phys, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Berkley, AJ (corresponding author), Univ Maryland, Ctr Superconduct Res, Dept Phys, College Pk, MD 20742 USA.			Berkley, Andrew/0000-0002-4235-8452				BERKLEY AJ, IN PRESS IEEE T APPL; Blais A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.127901; DEVORET MH, 1985, PHYS REV LETT, V55, P1908, DOI 10.1103/PhysRevLett.55.1908; Friedman JR, 2000, NATURE, V406, P43, DOI 10.1038/35017505; HUGHES R, 2002, QUANTUM INFORMATION; Johnson PR, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.020509; JOSEPHSON BD, 1962, PHYS LETT, V1, P251, DOI 10.1016/0031-9163(62)91369-0; Landau LD, 1976, MECHANICS; Leggett A J, 1980, PROG THEOR PHYS SUPP, V69, P80; MARTINIS JM, 1985, PHYS REV LETT, V55, P1543, DOI 10.1103/PhysRevLett.55.1543; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; NIELSEN MA, 2001, QUANTUM COMPUTATION; Pashkin YA, 2003, NATURE, V421, P823, DOI 10.1038/nature01365; Ramos RC, 2001, IEEE T APPL SUPERCON, V11, P998, DOI 10.1109/77.919517; RAMOS RC, IN PRESS IEEE T APPL; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; VOSS RF, 1981, PHYS REV LETT, V47, P265, DOI 10.1103/PhysRevLett.47.265; Wallraff A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.037003; Yu Y, 2002, SCIENCE, V296, P889, DOI 10.1126/science.1069452	22	379	390	3	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1548	1550		10.1126/science.1084528	http://dx.doi.org/10.1126/science.1084528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12750479				2022-12-28	WOS:000183333100047
J	Gray, NS; MacCulloch, MJ; Smith, J; Morris, M; Snowden, RJ				Gray, NS; MacCulloch, MJ; Smith, J; Morris, M; Snowden, RJ			Violence viewed by psychopathic murderers	NATURE			English	Article									Cardiff Univ, Sch Psychol, Cardiff CF10 3YG, S Glam, Wales; Clanrhyd Hosp, Caswell Clin, S Wales Forens Psychiat Serv, Yancyville CF36 4LN, Mid Glamorgan, Wales; HM Prisons, Aylesbury HP18 OTL, Bucks, England	Cardiff University	Gray, NS (corresponding author), Cardiff Univ, Sch Psychol, Cardiff CF10 3YG, S Glam, Wales.			Gray, Nicola Susan/0000-0003-3849-8118				BELLEZZA FS, 1986, BEHAV RES METH INSTR, V18, P299, DOI 10.3758/BF03204403; CLECKLEY M, 1941, MASK SANITY; Cooke DJ, 1999, J ABNORM PSYCHOL, V108, P58, DOI 10.1037/0021-843X.108.1.58; Gray NS, 2003, J FORENSIC PSYCHI PS, V14, P27, DOI 10.1080/1478994031000074289; Greenwald AG, 1998, J PERS SOC PSYCHOL, V74, P1464, DOI 10.1037/0022-3514.74.6.1464; Hare R., 1999, CONSCIENCE; Hare R. D., 2003, HARE PSYCHOPATHY CHE, V2nd; Nelson HE., 1982, NATL ADULT READING T; RICE ME, 1992, LAW HUMAN BEHAV, V16, P399, DOI 10.1007/BF02352266	9	84	84	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					497	498		10.1038/423497a	http://dx.doi.org/10.1038/423497a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	683RH	12774112	Bronze			2022-12-28	WOS:000183162900032
J	Kalnay, E; Cai, M				Kalnay, E; Cai, M			Impact of urbanization and land-use change on climate	NATURE			English	Article							TEMPERATURE TRENDS; HEAT-ISLAND	The most important anthropogenic influences on climate are the emission of greenhouse gases(1) and changes in land use, such as urbanization and agriculture(2). But it has been difficult to separate these two influences because both tend to increase the daily mean surface temperature(3,4). The impact of urbanization has been estimated by comparing observations in cities with those in surrounding rural areas, but the results differ significantly depending on whether population data(5) or satellite measurements of night light(6-8) are used to classify urban and rural areas(7,8). Here we use the difference between trends in observed surface temperatures in the continental United States and the corresponding trends in a reconstruction of surface temperatures determined from a reanalysis of global weather over the past 50 years, which is insensitive to surface observations, to estimate the impact of land-use changes on surface warming. Our results suggest that half of the observed decrease in diurnal temperature range is due to urban and other land-use changes. Moreover, our estimate of 0.27degreesC mean surface warming per century due to land-use changes is at least twice as high as previous estimates based on urbanization alone(7,8).	Univ Maryland, College Pk, MD 20770 USA	University System of Maryland; University of Maryland College Park	Kalnay, E (corresponding author), Univ Maryland, College Pk, MD 20770 USA.	ekalnay@atmos.umd.edu	Kalnay, Eugenia/F-4393-2010	Kalnay, Eugenia/0000-0002-9984-9906				Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364; Gallezot P, 1996, APPL CATAL B-ENVIRON, V9, pL11; Gallo KP, 1999, J CLIMATE, V12, P1344, DOI 10.1175/1520-0442(1999)012<1344:TTOTUS>2.0.CO;2; Gallo KP, 1999, J APPL METEOROL, V38, P806, DOI 10.1175/1520-0450(1993)032<0899:TUONAD>2.0.CO;2; Hansen J, 2001, J GEOPHYS RES-ATMOS, V106, P23947, DOI 10.1029/2001JD000354; IPCC, 2001, ADV CLIM CHANG RES; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Kistler R, 2001, B AM METEOROL SOC, V82, P247, DOI 10.1175/1520-0477(2001)082<0247:TNNYRM>2.3.CO;2; NRC, 2000, REV US NAV EXP STAND, P1; Owen TW, 1998, INT J REMOTE SENS, V19, P3451, DOI 10.1080/014311698214127; Pielke RA, 2002, PHILOS T ROY SOC A, V360, P1705, DOI 10.1098/rsta.2002.1027; Runnalls KE, 2000, PHYS GEOGR, V21, P283, DOI 10.1080/02723646.2000.10642711; Travis DJ, 2002, NATURE, V418, P601, DOI 10.1038/418601a	13	1499	1705	67	1345	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2003	423	6939					528	531		10.1038/nature01675	http://dx.doi.org/10.1038/nature01675			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774119	Bronze			2022-12-28	WOS:000183162900040
J	Rapp, SR; Espeland, MA; Shumaker, SA; Henderson, VW; Brunner, RL; Manson, JE; Gass, MLS; Stefanick, ML; Lane, DS; Hays, J; Johnson, KC; Coker, LH; Dailey, M; Bowen, D				Rapp, SR; Espeland, MA; Shumaker, SA; Henderson, VW; Brunner, RL; Manson, JE; Gass, MLS; Stefanick, ML; Lane, DS; Hays, J; Johnson, KC; Coker, LH; Dailey, M; Bowen, D		WHIMS Investigators	Effect of estrogen plus progestin on global cognitive function in postmenopausal women - The Women's Health Initiative Memory Study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE-REPLACEMENT THERAPY; MENTAL-STATE-EXAMINATION; CEREBRAL BLOOD-FLOW; OLDER WOMEN; ELDERLY WOMEN; DEMENTIA; PREVALENCE; IMPAIRMENT; COMMUNITY; 3MS	Context Observational studies have suggested that postmenopausal hormone treatment may improve cognitive function, but data from randomized clinical trials have been sparse and inconclusive. The Women's Health Initiative Memory Study (WHIMS) is an ancillary study of the Women's Health Initiative (WHI) hormone therapy trials. On July 8, 2002, the estrogen plus progestin therapy in the WHI trial was discontinued because of certain increased health risks for women. Objective To determine whether estrogen plus progestin therapy protects global cognitive function in older postmenopausal women. Design, Setting, and Participants A randomized, double-blind, placebo-controlled clinical trial, WHIMS is an ancillary study of geographically diverse, community-dwelling women aged 65 years or older from 39 of 40 clinical centers within the WHI estrogen plus progestin trial that started in June 1995. Of 4894 eligible postmenopausal women aged 65 years or older and free of probable dementia at baseline, 4532 (92.6%) were enrolled in the estrogen plus progestin component of WHIMS. A total of 4381 participants (96.7%) provided at least 1 valid cognitive function score between June 1995 and July 8, 2002. Interventions Participants received either 1 daily tablet containing 0.625 mg of conjugated equine estrogen with 2.5 mg of medroxyprogesterone acetate (n=2145) or matching placebo (n=2236). Main Outcome Measure Global cognitive function measured annually with the Modified Mini-Mental State Examination. Results The Modified Mini-Mental State Examination mean total scores in both groups increased slightly over time (mean follow-up of 4.2 years). Women in the estrogen plus progestin group had smaller average increases in total scores compared with women receiving placebo (P=.03), but these differences were not clinically important. Removing women by censoring them after adjudicated dementia, mild cognitive impairment, or stroke, and nonadherence to study protocol, did not alter the findings. Prior hormone therapy use and duration of prior use did not affect the interpretation of the results, nor did timing of prior hormone therapy initiation with respect to the final menstrual period. More women in the estrogen plus progestin group had a substantial and clinically important decline (greater than or equal to2 SDs) in Modified Mini-Mental State Examination total score (6.7%) compared with the placebo group (4.8%) (P=.008). Conclusions Among postmenopausal women aged 65 years or older, estrogen plus progestin did not improve cognitive function when compared with placebo. While most women receiving estrogen plus progestin did not experience clinically relevant adverse effects on cognition compared with placebo, a small increased risk of clinically meaningful cognitive decline occurred in the estrogen plus progestin group.	Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Univ Nevada, Dept Family & Community Med, Reno, NV 89557 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA USA; Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH USA; Stanford Univ, Stanford Ctr Res Dis Prevent, Stanford, CA 94305 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Arkansas System; University of Arkansas Medical Sciences; Nevada System of Higher Education (NSHE); University of Nevada Reno; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University System of Ohio; University of Cincinnati; Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Baylor College of Medicine; University of Tennessee System; University of Tennessee Health Science Center; Fred Hutchinson Cancer Center	Rapp, SR (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.		Henderson, V/AAW-4744-2021	Hays-Grudo, Jennifer/0000-0002-8107-1243; Bowen, Deborah/0000-0002-5177-8520				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; BARKER A, 1995, BRIT J PSYCHIAT, V167, P642, DOI 10.1192/bjp.167.5.642; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Bethea CL, 2002, FRONT NEUROENDOCRIN, V23, P41, DOI 10.1006/frne.2001.0225; Binder EF, 2001, MATURITAS, V38, P137, DOI 10.1016/S0378-5122(00)00214-0; Bland RC, 2001, CAN J PSYCHIAT, V46, P506, DOI 10.1177/070674370104600604; Bravo G, 1997, NEUROEPIDEMIOLOGY, V16, P141; Brinton RD, 2000, NEUROBIOL AGING, V21, P475, DOI 10.1016/S0197-4580(00)00109-3; Carlson MC, 2001, NEUROLOGY, V57, P2210, DOI 10.1212/WNL.57.12.2210; CORIA F, 1993, J NEUROL NEUROSUR PS, V56, P973, DOI 10.1136/jnnp.56.9.973; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; Foy MR, 2000, CURR DIR PSYCHOL SCI, V9, P148, DOI 10.1111/1467-8721.00081; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; HAYS J, 2003, N ENGL J MED; Henderson VW, 2003, NEUROLOGY, V60, P1369, DOI 10.1212/01.WNL.0000059413.75888.BE; HENDERSON VW, 2000, HORMONE THERAPY BRAI; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; Hogervorst E, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003122; HOLST J, 1989, MATURITAS, V11, P13, DOI 10.1016/0378-5122(89)90116-3; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; Larrabee G J, 1994, Int Psychogeriatr, V6, P95, DOI 10.1017/S1041610294001663; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Maki PM, 2001, AM J PSYCHIAT, V158, P227, DOI 10.1176/appi.ajp.158.2.227; Maki PM, 2000, NEUROBIOL AGING, V21, P373, DOI 10.1016/S0197-4580(00)00123-8; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; McCaffrey RJ, 1995, NEUROPSYCHOL REV, V5, P203, DOI 10.1007/BF02214762; McDowell I, 1997, J CLIN EPIDEMIOL, V50, P377, DOI 10.1016/S0895-4356(97)00060-7; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Murray DM, 1998, STAT MED, V17, P1581, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1581::AID-SIM864>3.0.CO;2-N; NADLER JD, 1995, J GERIATR PSYCH NEUR, V8, P177, DOI 10.1177/089198879500800307; Osterlund MK, 2000, J NEUROCHEM, V75, P1390, DOI 10.1046/j.1471-4159.2000.0751390.x; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Polo-Kantola P, 1998, OBSTET GYNECOL, V91, P459, DOI 10.1016/S0029-7844(97)00700-X; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 1997, NEUROLOGY, V49, P1491, DOI 10.1212/WNL.49.6.1491; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; Rosendaal FR, 2002, ARTERIOSCL THROM VAS, V22, P201, DOI 10.1161/hq0202.102318; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SCHAIE KW, 1994, AM PSYCHOL, V49, P304, DOI 10.1037/0003-066X.49.4.304; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TENG EL, 1990, PSYCHOGERIATRICS BIO, P189; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; TORANALLERAND CD, 1991, PSYCHONEUROENDOCRINO, V16, P7, DOI 10.1016/0306-4530(91)90068-5; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Yaffe K, 2001, NEW ENGL J MED, V344, P1207, DOI 10.1056/NEJM200104193441604	58	685	709	1	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2663	2672		10.1001/jama.289.20.2663	http://dx.doi.org/10.1001/jama.289.20.2663			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	682DG	12771113				2022-12-28	WOS:000183075600025
J	Verdon, F; Burnand, B; Stubi, CLF; Bonard, C; Graff, M; Michaud, A; Bischoff, T; de Vevey, M; Studer, JP; Herzig, L; Chapuis, C; Tissot, J; Pecoud, A; Favrat, B				Verdon, F; Burnand, B; Stubi, CLF; Bonard, C; Graff, M; Michaud, A; Bischoff, T; de Vevey, M; Studer, JP; Herzig, L; Chapuis, C; Tissot, J; Pecoud, A; Favrat, B			Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial	BRITISH MEDICAL JOURNAL			English	Article							FAMILY-PRACTICE; GENERAL HEALTH; PRIMARY-CARE; DEFICIENCY; PREVALENCE; COMPLAINT; SAMPLE; MEN	Objective To determine the subjective response to iron therapy in non-anaemic women with unexplained fatigue. Design Double blind randomised placebo controlled trial. Setting Academic primary care centre and eight general practices in western Switzerland. Participants 144 women aged 18 to 55, assigned to either oral ferrous sulphate (80 mg/day of elemental iron daily; n=75) or placebo (n=69) for four weeks. Main outcome measures Level of fatigue, measured by a 10 point visual analogue scale. Results 136 (94%) women completed the study. Most had a low serum ferritin concentration; less than or equal to 20 mug/l in 69 (51%) women. Mean age, haemoglobin concentration, serum ferritin concentration, level of fatigue, depression, and anxiety were similar in both groups at baseline. Both groups were also similar for compliance and dropout rates. The level of fatigue after one month decreased by - 1.82/6.37 points (29%) in the iron group compared with -0.85/6.46 points (13%) in the placebo group (difference 0.95 points, 95% confidence interval 0.32 to 1.62; P=0.004). Subgroups analysis showed that only women with ferritin concentrations less than or equal to 50 mug/l improved with oral supplementation. Conclusion Non-anaemic women with unexplained fatigue may benefit from iron supplementation. The effect may be restricted to women with low or borderline serum ferritin concentrations.	Univ Lausanne, Med Outpatient Clin, CH-1011 Lausanne, Switzerland; Univ Lausanne, Gen Practice Unit, CH-1011 Lausanne, Switzerland; Univ Lausanne, Inst Social & Prevent Med, Hlth Care Evaluat Unit, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; University of Lausanne	Favrat, B (corresponding author), Univ Lausanne, Med Outpatient Clin, Rue Bugnon 44, CH-1011 Lausanne, Switzerland.		Tissot, Jean-Daniel/L-6310-2016; Favrat, Bernard/B-2640-2009	Tissot, Jean-Daniel/0000-0003-2493-8469; Verdon, Francois/0000-0002-7178-2201; Favrat, Bernard/0000-0001-6920-099X				AVERBUCH M, 1990, Journal of Clinical Research and Pharmacoepidemiology, V4, P199; BALLIN A, 1992, AM J DIS CHILD, V146, P803, DOI 10.1001/archpedi.1992.02160190035015; BATES DW, 1993, ARCH INTERN MED, V153, P2759, DOI 10.1001/archinte.153.24.2759; Bensing JM, 1999, MED CARE, V37, P1078, DOI 10.1097/00005650-199910000-00011; BEUTLER E, 1960, ANN INTERN MED, V52, P378, DOI 10.7326/0003-4819-52-2-378; Bruner AB, 1996, LANCET, V348, P992, DOI 10.1016/S0140-6736(96)02341-0; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; DALLMAN PR, 1989, J INTERN MED, V226, P367, DOI 10.1111/j.1365-2796.1989.tb01410.x; Galan P, 1998, EUR J CLIN NUTR, V52, P383, DOI 10.1038/sj.ejcn.1600561; GUYATT GH, 1992, J GEN INTERN MED, V7, P145, DOI 10.1007/BF02598003; HALLBERG L, 1993, BRIT J HAEMATOL, V85, P787, DOI 10.1111/j.1365-2141.1993.tb03225.x; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; MORRISON JD, 1980, J FAM PRACTICE, V10, P795; OHIRA Y, 1979, BRIT J HAEMATOL, V41, P365, DOI 10.1111/j.1365-2141.1979.tb05869.x; Patterson AJ, 2000, QUAL LIFE RES, V9, P491, DOI 10.1023/A:1008978114650; Patterson AJ, 2001, J AM COLL NUTR, V20, P337, DOI 10.1080/07315724.2001.10719054; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; PICHOT P, 1984, ANN MED-PSYCHOL, V142, P862; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; Rushton DH, 2001, BMJ-BRIT MED J, V322, P1355, DOI 10.1136/bmj.322.7298.1355; SCRIMSHAW NS, 1984, J NUTR SCI VITAMINOL, V30, P47, DOI 10.3177/jnsv.30.47; Stewart D, 1998, J WOMENS HEALTH, V7, P69, DOI 10.1089/jwh.1998.7.69; SUGARMAN JR, 1984, J FAM PRACTICE, V19, P643	24	210	217	2	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1124	1126A		10.1136/bmj.326.7399.1124	http://dx.doi.org/10.1136/bmj.326.7399.1124			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	685DF	12763985	Green Published, Bronze			2022-12-28	WOS:000183245000022
J	Liu, JG; Ouyang, ZY; Pimm, SL; Raven, PH; Wang, XK; Miao, H; Han, NY				Liu, JG; Ouyang, ZY; Pimm, SL; Raven, PH; Wang, XK; Miao, H; Han, NY			Protecting China's biodiversity	SCIENCE			English	Editorial Material							GIANT		Michigan State Univ, Dept Fisheries & Wildlife, E Lansing, MI 48824 USA; Chinese Acad Sci, Ecoenvironm Sci Res Ctr, Key Lab Syst Ecol, Beijing, Peoples R China; Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC USA; Missouri Bot Garden, St Louis, MO 63166 USA; Chinas Natl Comm Man & Biosphere, Beijing, Peoples R China	Michigan State University; Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Duke University; Missouri Botanical Gardens	Liu, JG (corresponding author), Michigan State Univ, Dept Fisheries & Wildlife, E Lansing, MI 48824 USA.	jliu@panda.msu.edu	Liu, Jianguo/G-5211-2015; pimm, stuart/ABF-1082-2020	Liu, Jianguo/0000-0001-6344-0087; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039789] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD39789] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		An L, 2001, ECOL MODEL, V140, P31, DOI 10.1016/S0304-3800(01)00267-8; [Anonymous], 2002, PEOPLES REPUBLIC CHI; AXELROD DI, 1998, FLORISTIC CHARACTERI, P43; China's National Committee on Man and Biosphere, 2000, STUD SUST MAN POL CH; *COMP GROUP, 1998, CHIN BIOD COUNT STUD; Dale VH, 2002, CAM STU LAN, P265, DOI 10.1017/CBO9780511613654.015; Ferraro PJ, 2002, SCIENCE, V298, P1718, DOI 10.1126/science.1078104; HAN N, 2000, STUDY SUSTAINABLE MA, P1; LI W, 2000, STUD SUST MAN POL CH, P92; Liu JG, 2001, SCIENCE, V293, P603; Liu JG, 1999, POPUL ENVIRON, V21, P45, DOI 10.1023/A:1022101026466; Liu JG, 1999, CONSERV BIOL, V13, P1360, DOI 10.1046/j.1523-1739.1999.98418.x; Miao H, 2000, STUDY SUSTAINABLE MA, P57; RAVEN PH, 1994, P INT WORKSH SCI FRO, P137; WANG X, 2000, STUDY SUSTAINABLE MA, P81; *WORLD BANK, 2001, WORLD DEV IND 2001; XU H, 2000, STUDY SUSTAINABLE MA, P72; 1994, ACTION PLAN BIODIVER	18	198	235	10	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1240	1241		10.1126/science.1078868	http://dx.doi.org/10.1126/science.1078868			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764180				2022-12-28	WOS:000183042400029
J	Moro, R; Xu, XS; Yin, SY; de Heer, WA				Moro, R; Xu, XS; Yin, SY; de Heer, WA			Ferroelectricity in free niobium clusters	SCIENCE			English	Article							POLARIZABILITIES	Electric deflections of gas-phase, cryogenically cooled, neutral niobium clusters [Nb-N; number of atoms (N) = 2 to 150, temperature (T) = 20 to 300 kelvin], measured in molecular beams, show that cold clusters may attain an anomalous component with very large electric dipole moments. In contrast, room- temperature measurements show normal metallic polarizabilities. Characteristic energies k(B)T(G)(N) [Boltzmann constant k(B) times a transition temperature T-G(N)] are identified, below which the ferroelectric-like state develops. Generally, T-G decreases [110 > T-G(N) > 10 K] as N increases, with pronounced even-odd alternations for N > 38. This new state of metallic matter may be related to bulk superconductivity.	Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Moro, R (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.		Xu, Xiaoshan/B-1255-2009; Xu, Xiaoshan/J-9870-2019; Yin, Shuangye/C-3707-2009	Xu, Xiaoshan/0000-0002-4363-392X; Xu, Xiaoshan/0000-0002-4363-392X; Yin, Shuangye/0000-0002-2779-2584; Moro, Ramiro/0000-0002-9591-3747				ANDERSON PW, 1984, BASIC NOTIONS CONSED; Benichou E, 1999, PHYS REV A, V59, pR1, DOI 10.1103/PhysRevA.59.R1; Berces A, 1998, J CHEM PHYS, V108, P5476, DOI 10.1063/1.475936; Blundell SA, 2000, PHYS REV LETT, V84, P4826, DOI 10.1103/PhysRevLett.84.4826; DEHEER WA, 1991, REV SCI INSTRUM, V62, P670, DOI 10.1063/1.1142066; DEHEER WA, 1993, REV MOD PHYS, V65, P611, DOI 10.1103/RevModPhys.65.611; DEHEER WA, 1988, P 13 INT SCH BERL, P45; DEHEER WA, 1985, THESIS U CALIFORNIA; Dugourd P, 2001, CHEM PHYS LETT, V336, P511, DOI 10.1016/S0009-2614(01)00145-2; Herzberg G., 1966, MOL SPECTRA MOL STRU; KNICKELBEIN MB, 1990, J CHEM PHYS, V93, P1476, DOI 10.1063/1.459159; Knickelbein MB, 2001, J CHEM PHYS, V115, P5957, DOI 10.1063/1.1398578; KNIGHT WD, 1985, PHYS REV B, V31, P2539, DOI 10.1103/PhysRevB.31.2539; Kresin VV., 1997, ELECT DIPOLE POLARIZ; Kumar V, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.125403; MATTHIAS B, 1967, FERROELECTRICITY, P176; RESTA R, 1994, REV MOD PHYS, V66, P899, DOI 10.1103/RevModPhys.66.899; Ring P., 1980, NUCL MANY BODY PROBL, DOI 10.1007/978-3-642-61852-9; Schafer R, 1996, PHYS REV LETT, V76, P471, DOI 10.1103/PhysRevLett.76.471; Scoles G., 1988, ATOMIC MOL BEAM METH; Solov'yov IA, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.053203; STERN H, 1966, PHYS REV, V147, P94, DOI 10.1103/PhysRev.147.94; Townes C.H., 2013, MICROWAVE SPECTROSCO; WHETTEN RL, 1986, J CHEM PHYS, V85, P1697, DOI 10.1063/1.451214; ZIMAN JM, 1972, PRINCIPLES SOLIDS	25	116	117	2	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1265	1269		10.1126/science.1083247	http://dx.doi.org/10.1126/science.1083247			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764191	Green Submitted			2022-12-28	WOS:000183042400041
J	Jumaa, H; Bossaller, L; Portugal, K; Storch, B; Lotz, M; Flemming, A; Schrappe, M; Postila, V; Riikonen, P; Pelkonen, J; Niemeyer, CM; Reth, M				Jumaa, H; Bossaller, L; Portugal, K; Storch, B; Lotz, M; Flemming, A; Schrappe, M; Postila, V; Riikonen, P; Pelkonen, J; Niemeyer, CM; Reth, M			Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia	NATURE			English	Article							DROSOPHILA-TRITHORAX; ANTIGEN RECEPTOR; ACUTE LEUKEMIAS; LINKER PROTEIN; EXPRESSION; CHILDHOOD; TRANSLOCATIONS; ACTIVATION; GENE; MICE	Acute lymphoblastic leukaemia (ALL) is the commonest form of childhood malignancy, and most cases arise from B-cell clones arrested at the pre-B-cell stage of differentiation(1,2). The molecular events that arrest pre-B-cell differentiation in the leukaemic pre-B cells have not been well characterized. Here we show that the differentiation regulator SLP-65 (an adaptor protein also called BLNK or BASH(3-6)) inhibits pre-B-cell leukaemia in mice. Reconstitution of SLP-65 expression in a SLP-65(-/-) pre-B-cell line led to enhanced differentiation in vitro and prevented the development of pre-B-cell leukaemia in immune-deficient mice. Tyrosine 96 of SLP-65 was required for this activity. The murine SLP-65(-/-) pre-B-cell leukaemia resembles human childhood pre-B ALL. Indeed, 16 of the 34 childhood pre-B ALL samples that were tested showed a complete loss or drastic reduction of SLP-65 expression. This loss is probably due to the incorporation of alternative exons into SLP-65 transcripts, leading to premature stop codons. Thus, the somatic loss of SLP-65 and the accompanying block in pre-B-cell differentiation might be one of the primary causes of childhood pre-B ALL.	Univ Freiburg, D-79108 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Med Sch Hanover, Childrens Hosp, D-30625 Hannover, Germany; Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland; Freiburg Univ Hosp, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg; Max Planck Society; University of Eastern Finland; Kuopio University Hospital; Kuopio University Hospital; University of Freiburg	Reth, M (corresponding author), Univ Freiburg, D-79108 Freiburg, Germany.		Schrappe, Martin/A-8109-2010; Schrappe, Martin/ABA-6144-2020	Bossaller, Lukas/0000-0003-0789-4062				Advani AS, 2002, LEUKEMIA RES, V26, P713, DOI 10.1016/S0145-2126(01)00197-7; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; BEISHUIZEN A, 1991, LEUKEMIA, V5, P657; Chiu CW, 2002, EMBO J, V21, P6461, DOI 10.1093/emboj/cdf658; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; EDERY I, 1983, J BIOL CHEM, V258, P1398; Flemming A, 2003, NAT IMMUNOL, V4, P38, DOI 10.1038/ni862; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Goodman PA, 2001, ONCOGENE, V20, P3969, DOI 10.1038/sj.onc.1204515; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; Jennings CD, 1997, BLOOD, V90, P2863, DOI 10.1182/blood.V90.8.2863; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Ma SK, 1999, HEMATOL ONCOL, V17, P91, DOI 10.1002/(SICI)1099-1069(199909)17:3<91::AID-HON643>3.0.CO;2-Y; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Nishii K, 2000, INT J HEMATOL, V71, P372; NORDQVIST K, 1994, MOL CELL BIOL, V14, P437, DOI 10.1128/MCB.14.1.437; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Schrappe M, 2000, LEUKEMIA, V14, P2205, DOI 10.1038/sj.leu.2401973; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; UMIEL T, 1993, LEUKEMIA, V7, P435; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	28	109	111	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					452	456		10.1038/nature01608	http://dx.doi.org/10.1038/nature01608			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761551				2022-12-28	WOS:000183012000045
J	Chow, AWC; Lane, RE; Cowie, MR				Chow, AWC; Lane, RE; Cowie, MR			New pacing technologies for heart failure	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SURVIVAL; RESYNCHRONIZATION; DEFIBRILLATOR; MORBIDITY; MORTALITY; CHAMBER; DELAY		Royal Berkshire & Battle Hosp, Dept Cardiol, Reading RG30 1AJ, Berks, England; St Marys Hosp, Dept Cardiol, London W2 1NY, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London; Imperial College London	Chow, AWC (corresponding author), Royal Berkshire & Battle Hosp, Dept Cardiol, Reading RG30 1AJ, Berks, England.	anthony.chow@rbbh-tr.nhs.uk	Cowie, Martin R/AAQ-2818-2020	Cowie, Martin R/0000-0001-7457-2552				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; Berry C, 2001, EUR J HEART FAIL, V3, P283, DOI 10.1016/S1388-9842(01)00123-4; Bristow MR, 2000, J CARD FAIL, V6, P276, DOI 10.1054/jcaf.2000.9501; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; Cleland JGF, 2001, EUR J HEART FAIL, V3, P481, DOI 10.1016/S1388-9842(01)00176-3; COHN JN, 1993, CIRCULATION, V87, P1; Cowie MR, 2000, HEART, V83, P505, DOI 10.1136/heart.83.5.505; Cowie MR, 1997, EUR HEART J, V18, P208; Cowie MR, 2002, EUR HEART J, V23, P877, DOI 10.1053/euhj.2001.2973; Daubert JC, 1998, PACE, V21, P239, DOI 10.1111/j.1540-8159.1998.tb01096.x; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; KJEKSHUS J, 1992, AM J CARDIOL, V69, P103, DOI 10.1016/0002-9149(92)90683-P; LINDE C, 1995, AM J CARDIOL, V75, P919, DOI 10.1016/S0002-9149(99)80687-0; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; *NAT I CLIN EXC, 2000, TECHN APPR GUID, V11; Nelson GS, 2000, CIRCULATION, V102, P3053; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Reuter S, 2002, AM J CARDIOL, V89, P346, DOI 10.1016/S0002-9149(01)02240-8; Yu CM, 2003, HEART, V89, P54, DOI 10.1136/heart.89.1.54	24	9	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	2003	326	7398					1073	1077		10.1136/bmj.326.7398.1073	http://dx.doi.org/10.1136/bmj.326.7398.1073			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681ZD	12750211	Green Published			2022-12-28	WOS:000183064700019
J	Johnson, BA; Ait-Daoud, N; Bowden, CL; DiClemente, CC; Roache, JD; Lawson, K; Javors, MA; Ma, JZ				Johnson, BA; Ait-Daoud, N; Bowden, CL; DiClemente, CC; Roache, JD; Lawson, K; Javors, MA; Ma, JZ			Oral topiramate for treatment of alcohol dependence: a randomised controlled trial	LANCET			English	Article							COMPULSIVE-DRINKING-SCALE; DOPAMINE RELEASE; GLUTAMATE; VALIDATION; ADDICTION; VALIDITY; SEVERITY	Background Topiramate, a sulphamate fructopyranose derivative, might antagonise alcohol's rewarding effects associated with abuse liability by inhibiting mesocorticolimbic dopamine release via the contemporaneous facilitation of gamma-amino-butyric acid activity and inhibition of glutamate function. We aimed to see whether topiramate was more effective than placebo as a treatment for alcohol dependence. Methods We did a double-blind randomised controlled 12-week clinical trial comparing oral topiramate and placebo for treatment of 150 individuals with alcohol dependence. Of these 150 individuals, 75 were assigned to receive topiramate (escalating dose of 25-300 mg per day) and 75 had placebo as an adjunct to weekly standardised medication compliance management. Primary efficacy variables were: self-reported drinking (drinks per day, drinks per drinking day, percentage of heavy drinking days, percentage of days abstinent) and plasma gamma-glutamyl transferase, an objective index of alcohol consumption. The secondary efficacy variable was self-reported craving. Findings At study end, participants on topiramate, compared with those on placebo, had 2.88 (95% Cl -4.50 to -1.27) fewer drinks per day (p=0.0006), 3.10 (-4.88 to -1.31) fewer drinks per drinking day (p=0.0009), 27.6% fewer heavy drinking days (p=0.0003), 26.2% more days abstinent (p=0.0003), and a log plasma gamma-glutamyl transferase ratio of 0.07 (-0.11 to -0.02) less (p=0.0046). Topiramate-induced differences in craving were also significantly greater than those of placebo, of similar magnitude to the self-reported drinking changes, and highly correlated with them. Interpretation Topiramate (up to 300 mg per day) is more efficacious than placebo as an adjunct to standardised medication compliance management in treatment of alcohol dependence.	Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA; Univ Maryland, Dept Psychol, College Pk, MD 20742 USA	University of Texas System; University of Texas Health San Antonio; University System of Maryland; University of Maryland College Park	Johnson, BA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, 7703 Floyd Curl Dr,Mail Stop 7792, San Antonio, TX 78229 USA.	bjohnson@uthscsa.edu	DiClemente, Carlo C/F-6208-2011	Roache, John/0000-0002-7010-8119	NIAAA NIH HHS [AA 10522-08, K23 AA 00329-01] Funding Source: Medline; PHS HHS [12964-01] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K23AA000329, R01AA010522] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Bohn MJ, 1996, ALCOHOL CLIN EXP RES, V20, P817, DOI 10.1111/j.1530-0277.1996.tb05257.x; BREESE CR, 1995, BRAIN RES, V674, P82, DOI 10.1016/0006-8993(94)01384-T; Conigrave KM, 2002, ALCOHOL CLIN EXP RES, V26, P332, DOI 10.1097/00000374-200203000-00005; Dodd PR, 2000, NEUROCHEM INT, V37, P509, DOI 10.1016/S0197-0186(00)00061-9; EDWARDS G, 1977, J STUD ALCOHOL, V38, P1004, DOI 10.15288/jsa.1977.38.1004; FAWCETT J, 1987, PSYCHOPHARMACOL BULL, V23, P309; Garnett WR, 2000, EPILEPSIA, V41, pS61; Graybill F.A., 1976, THEORY APPL LINEAR M; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; Johnson BA, 2000, PSYCHOPHARMACOLOGY, V149, P327, DOI 10.1007/s002130000371; Johnson BA, 2000, JAMA-J AM MED ASSOC, V284, P963, DOI 10.1001/jama.284.8.963; Kohl RR, 1998, PSYCHOPHARMACOLOGY, V139, P79, DOI 10.1007/s002130050692; LEVINE J, 1986, PSYCHOPHARMACOL BULL, V22, P343; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; Meinert CL., 1986, CLIN TRIALS DESIGN C; MILLER WR, 1984, MANUAL COMPREHENSIVE; Moak DH, 1998, AM J ADDICTION, V7, P14; MOGHADDAM B, 1994, SYNAPSE, V18, P337, DOI 10.1002/syn.890180409; SENN S, 1994, STAT MED, V13, P1715, DOI 10.1002/sim.4780131703; Skradski S, 2000, EPILEPSIA, V41, pS45; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41, DOI 10.1007/978-1-4612-0357-5_3; SPITZER R. L., 1994, STRUCTURED CLIN INTE; STOUT RL, 1994, J STUD ALCOHOL, P70, DOI 10.15288/jsas.1994.s12.70; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; Weiss F, 2002, J NEUROSCI, V22, P3332; White HS, 2000, EPILEPSIA, V41, pS17, DOI 10.1111/j.1528-1157.2000.tb06042.x	28	526	554	0	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1677	1685		10.1016/S0140-6736(03)13370-3	http://dx.doi.org/10.1016/S0140-6736(03)13370-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	679KB	12767733				2022-12-28	WOS:000182919700008
J	Shozu, M; Sebastian, S; Takayama, K; Hsu, WT; Schultz, RA; Neely, K; Bryant, M; Bulun, SE				Shozu, M; Sebastian, S; Takayama, K; Hsu, WT; Schultz, RA; Neely, K; Bryant, M; Bulun, SE			Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; PEUTZ-JEGHERS SYNDROME; CYTOCHROME-P450 CYP19 GENE; HENNY-FEATHERING TRAIT; ADIPOSE-TISSUE; PLASMA ANDROSTENEDIONE; ALTERNATIVE PROMOTERS; REVERSE TRANSCRIPTION; BREAST-CANCER; EXPRESSION	BACKGROUND: Gynecomastia of prepubertal onset may result from increased estrogen owing to excessive aromatase activity in extraglandular tissues. A gene in chromosome 15q21.2 encodes aromatase, the key enzyme for estrogen biosynthesis. Several physiologic tissue-specific promoters regulate the expression of aromatase, giving rise to messenger RNA (mRNA) species with an identical coding region but tissue-specific 5'-untranslated regions in placenta, gonads, brain, fat, and skin. METHODS: We studied skin, fat, and blood samples from a 36-year-old man, his 7-year-old son, and an unrelated 17-year-old boy with severe gynecomastia of prepubertal onset and hypogonadotropic hypogonadism caused by elevated estrogen levels. RESULTS: Aromatase activity and mRNA levels in fat and skin and whole-body aromatization of androstenedione were severely elevated. Treatment with an aromatase inhibitor decreased serum estrogen levels and normalized gonadotropin and testosterone levels. The 5'-untranslated regions of aromatase mRNA contained the same sequence (FLJ) in the father and son and another sequence (TMOD3) in the unrelated boy; neither sequence was found in control subjects. These 5'-untranslated regions normally make up the first exons of two ubiquitously expressed genes clustered in chromosome 15q21.2-3 in the following order (from telomere to centromere): FLJ, TMOD3, and aromatase. The aromatase gene is normally transcribed in the direction opposite to that of TMOD3 and FLJ. Two distinct heterozygous inversions reversed the direction of the TMOD3 or FLJ promoter in the patients. CONCLUSIONS: Heterozygous inversions in chromosome 15q21.2-3, which caused the coding region of the aromatase gene to lie adjacent to constitutively active cryptic promoters that normally transcribe other genes, resulted in severe estrogen excess owing to the overexpression of aromatase in many tissues.	Univ Illinois, Dept Obstet & Gynecol, Chicago, IL 60612 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60612 USA; Kanazawa Univ, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan; Tohoku Univ, Dept Obstet & Gynecol, Sendai, Miyagi 980, Japan; Rush Med Sch, Dept Pediat, Chicago, IL USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA; Childrens Hosp, Dept Pediat, Los Angeles, CA 90027 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Kanazawa University; Tohoku University; Rush University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University; Children's Hospital Los Angeles	Bulun, SE (corresponding author), Northwestern Univ, Sch Med, Dept Obstet & Gynecol, 333 E Super,Suite 490, Chicago, IL 60611 USA.	s-bulun@northwestern.edu			NCI NIH HHS [CA67167] Funding Source: Medline; NICHD NIH HHS [HD38691] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD038691] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038691] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA067167, R29CA067167] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; Agarwal VR, 1997, J CLIN ENDOCR METAB, V82, P70, DOI 10.1210/jc.82.1.70; BERKOVITZ GD, 1985, J CLIN INVEST, V75, P1763, DOI 10.1172/JCI111888; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; BULUN SE, 1993, J CLIN ENDOCR METAB, V76, P1458, DOI 10.1210/jc.76.6.1458; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1616, DOI 10.1210/jc.77.6.1616; BULUN SE, 1994, BREAST CANCER RES TR, V30, P19, DOI 10.1007/BF00682738; BULUN SE, 1994, J CLIN ENDOCR METAB, V78, P428, DOI 10.1210/jc.78.2.428; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; DUBOIS RS, 1982, J PEDIATR-US, V101, P568, DOI 10.1016/S0022-3476(82)80705-1; GEORGE FW, 1980, J CLIN INVEST, V66, P57, DOI 10.1172/JCI109835; HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476, DOI 10.1210/jcem-38-3-476; HEMSELL DL, 1977, J CLIN INVEST, V60, P455, DOI 10.1172/JCI108796; ITO Y, 1993, P NATL ACAD SCI USA, V90, P11673, DOI 10.1073/pnas.90.24.11673; LEIBERMAN E, 1992, HORM RES, V37, P96, DOI 10.1159/000182290; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MATSUMINE H, 1991, J BIOL CHEM, V266, P19900; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; Morley M, 2001, NUCLEIC ACIDS RES, V29, P144, DOI 10.1093/nar/29.1.144; Nagase T, 2000, DNA RES, V7, P347, DOI 10.1093/dnares/7.6.347; Sebastian S, 2001, J CLIN ENDOCR METAB, V86, P4600, DOI 10.1210/jc.86.10.4600; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; Stratakis CA, 1998, J CLIN ENDOCR METAB, V83, P1348, DOI 10.1210/jc.83.4.1348; Takayama K, 1998, FERTIL STERIL, V69, P709, DOI 10.1016/S0015-0282(98)00022-3; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; WILSON DM, 1986, CANCER, V57, P2238, DOI 10.1002/1097-0142(19860601)57:11<2238::AID-CNCR2820571128>3.0.CO;2-C; WILSON JD, 1975, J BIOL CHEM, V250, P3498; YOUNG S, 1995, AM J SURG PATHOL, V19, P50, DOI 10.1097/00000478-199501000-00007; Zeitoun K, 1999, MOL ENDOCRINOL, V13, P239, DOI 10.1210/me.13.2.239	29	96	103	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1855	1865		10.1056/NEJMoa021559	http://dx.doi.org/10.1056/NEJMoa021559			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12736278	Bronze			2022-12-28	WOS:000182684100004
J	Kirk, EC; Cartmill, M; Kay, RF; Lemelin, P				Kirk, EC; Cartmill, M; Kay, RF; Lemelin, P			Comment on "Grasping primate origins"	SCIENCE			English	Editorial Material							PLESIADAPIFORMES; CARPOLESTIDAE; MAMMALIA		Duke Univ, Med Ctr, Dept Biol Anthropol & Anat, Durham, NC 27710 USA; Univ Alberta, Fac Med & Dent, Div Anat, Edmonton, AB T6G 2H7, Canada	Duke University; University of Alberta	Kirk, EC (corresponding author), Duke Univ, Med Ctr, Dept Biol Anthropol & Anat, Box 3170, Durham, NC 27710 USA.	eck@duke.edu						BIKNEVICIUS AR, 1986, AM J PHYS ANTHROPOL, V71, P157, DOI 10.1002/ajpa.1330710204; Bloch JI, 2002, SCIENCE, V298, P1606, DOI 10.1126/science.1078249; Bloch JI, 2001, J VERTEBR PALEONTOL, V21, P119, DOI 10.1671/0272-4634(2001)021[0119:SAOPCM]2.0.CO;2; Bloch Jonathan I., 1998, Contributions from the Museum of Paleontology University of Michigan, V30, P131; Cartmill M., 1972, FUNCTIONAL EVOLUTION, P97, DOI DOI 10.4324/9781315132129; Cartmill Matt, 1992, Evolutionary Anthropology, V1, P105, DOI 10.1002/evan.1360010308; Fox Richard C., 1993, Journal of Vertebrate Paleontology, V13, P516; GINGERICH PD, 1987, CONTRIB MUS PALEONTO, V27, P265; KAY RF, 1992, AM J PHYS ANTHROPOL, V89, P477, DOI 10.1002/ajpa.1330890409; Lemelin P, 1999, J ZOOL, V247, P165, DOI 10.1017/S0952836999002046; Medway Lord, 1964, Malayan Nature Journal, V18, P104; ROSE K D, 1975, Bulletin of the Museum of Comparative Zoology, V147, P1; ROSE KD, 1991, P NATL ACAD SCI USA, V88, P98, DOI 10.1073/pnas.88.1.98; Sargis EJ, 2002, SCIENCE, V298, P1564, DOI 10.1126/science.1079034; Silcox MT, 2001, J VERTEBR PALEONTOL, V21, P132, DOI 10.1671/0272-4634(2001)021[0132:NSOERM]2.0.CO;2; Szalay F. S., 1994, EVOLUTIONARY HIST MA; WIBLE JR, 1987, J HUM EVOL, V16, P1, DOI 10.1016/0047-2484(87)90058-3	17	38	38	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	673KH	12730582				2022-12-28	WOS:000182579800026
J	Hirsch, MS; Harris, NL; Davis, BT; Werner, B; Basgoz, N; Calderon, HA				Hirsch, MS; Harris, NL; Davis, BT; Werner, B; Basgoz, N; Calderon, HA			Case 17-2003: A 38-year-old woman with fever, headache, and confusion - West Nile virus meningoencephalitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ENCEPHALITIS; ASSAY		Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; State Lab Inst, Jamaica Plain, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Hirsch, MS (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.							[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P877; [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P973; ARROYO J, 2002, 42 INT C ANT AG CHEM; Beaty BJ, 1989, DIAGNOSTIC PROCEDURE, P797; *CTR BIOL EV RES, 2002, GUID IND REC ASS DON; Deresiewicz RL, 1997, NEW ENGL J MED, V336, P1867, DOI 10.1056/NEJM199706263362604; Fradin MS, 2002, NEW ENGL J MED, V347, P13, DOI 10.1056/NEJMoa011699; Huang CN, 2002, EMERG INFECT DIS, V8, P1367, DOI 10.3201/eid0812.020532; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Johnson AJ, 2000, J CLIN MICROBIOL, V38, P1827, DOI 10.1128/JCM.38.5.1827-1831.2000; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066, DOI 10.1128/JCM.38.11.4066-4071.2000; Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Petersen LR, 2002, ANN INTERN MED, V137, P173, DOI 10.7326/0003-4819-137-3-200208060-00009; Petersen LR, 2002, NEW ENGL J MED, V347, P1225, DOI 10.1056/NEJMo020128; ROEHRIG JT, 2000, CLIN VIROLOGY MANUAL, P356; 2002, MMWR MORB MORTAL WKL, V51, P825; 1995, MMWR MORB MORTAL WKL, V44, P641; 2001, MMWR MORB MORTAL WKL, V50, P761; 2002, MMWR MORB MORTAL WKL, V51, P951	20	2	3	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2239	2247		10.1056/NEJMcpc030015	http://dx.doi.org/10.1056/NEJMcpc030015			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773652				2022-12-28	WOS:000183134700011
J	Herkner, H				Herkner, H			A 42 year old man with acute chest pain: case outcome - Commentary: Challenge for emergency physicians	BRITISH MEDICAL JOURNAL			English	Editorial Material							THORACIC AORTIC DISSECTION		Vienna Gen Hosp, Dept Emergency Med, A-1090 Vienna, Austria		Herkner, H (corresponding author), Vienna Gen Hosp, Dept Emergency Med, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.			Herkner, Harald/0000-0003-1329-6149				Bayegan K, 2001, EUR J CARDIO-THORAC, V20, P1194, DOI 10.1016/S1010-7940(01)01017-X; Hagan PG, 2000, JAMA-J AM MED ASSOC, V283, P897, DOI 10.1001/jama.283.7.897; HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; Klompas M, 2002, JAMA-J AM MED ASSOC, V287, P2262, DOI 10.1001/jama.287.17.2262; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1134	1134		10.1136/bmj.326.7399.1134	http://dx.doi.org/10.1136/bmj.326.7399.1134			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763991	Green Published			2022-12-28	WOS:000183245000027
J	Yu, D; Wang, CJ; Guyot-Sionnest, P				Yu, D; Wang, CJ; Guyot-Sionnest, P			n-type conducting CdSe nanocrystal solids	SCIENCE			English	Article							ELECTRON-TRANSPORT; FILMS	A bottleneck limiting the widespread application of semiconductor nanocrystal solids is their poor conductivity. We report that the conductivity of thin films of n-type CdSe nanocrystals increases by many orders of magnitude as the occupation of the first two electronic shells, 1S(e) and 1P(e), increases, either by potassium or electrochemical doping. Around half-filling of the 1S(e) shell, a peak in the conductivity is observed, indicating shell-to-shell transport. Introducing conjugated ligands between nanocrystals increases the conductivities of these states to similar to10(-2) siemens per centimeter.	Univ Chicago, James Franck Inst, Chicago, IL 60637 USA	University of Chicago	Guyot-Sionnest, P (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.	pgs@uchicago.edu	Wang, Congjun/A-9608-2010; Yu, Dong/C-7141-2011	Yu, Dong/0000-0002-8386-065X				Beverly KC, 2002, J PHYS CHEM B, V106, P2131, DOI 10.1021/jp012261g; CHIANG CK, 1978, J AM CHEM SOC, V100, P1013, DOI 10.1021/ja00471a081; Collier CP, 1997, SCIENCE, V277, P1978, DOI 10.1126/science.277.5334.1978; COLVIN VL, 1994, NATURE, V370, P354, DOI 10.1038/370354a0; Doty RC, 2001, J PHYS CHEM B, V105, P8291, DOI 10.1021/jp011227z; Drndic M, 2002, J APPL PHYS, V92, P7498, DOI 10.1063/1.1523148; Enright B, 1996, J PHYS CHEM-US, V100, P1027, DOI 10.1021/jp951142w; Ginger DS, 2000, J APPL PHYS, V87, P1361, DOI 10.1063/1.372021; Greenham NC, 1996, PHYS REV B, V54, P17628, DOI 10.1103/PhysRevB.54.17628; Guyot-Sionnest P, 1998, APPL PHYS LETT, V72, P686, DOI 10.1063/1.120846; Guyot-Sionnest P, 2003, J PHYS CHEM B, V107, P7355, DOI 10.1021/jp0275084; HADDON RC, 1991, NATURE, V350, P320, DOI 10.1038/350320a0; Leatherdale CA, 2000, PHYS REV B, V62, P2669, DOI 10.1103/PhysRevB.62.2669; Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545; Noack V, 2002, J PHYS CHEM B, V106, P8514, DOI 10.1021/jp0200270; Norris DJ, 1996, PHYS REV B, V53, P16338, DOI 10.1103/PhysRevB.53.16338; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Parthasarathy R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.186807; Roest AL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.036801; Shim M, 2000, NATURE, V407, P981, DOI 10.1038/35039577; STEIGERWALD ML, 1990, ACCOUNTS CHEM RES, V23, P183, DOI 10.1021/ar00174a003; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Wang CJ, 2002, APPL PHYS LETT, V80, P4, DOI 10.1063/1.1430852; Wang CJ, 2001, SCIENCE, V291, P2390, DOI 10.1126/science.291.5512.2390	24	490	515	1	163	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1277	1280		10.1126/science.1084424	http://dx.doi.org/10.1126/science.1084424			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764194				2022-12-28	WOS:000183042400045
J	Butler, D				Butler, D			Spiralling costs dog comet mission	NATURE			English	News Item																		2003, NATURE, V421, P301	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					372	372		10.1038/423372B	http://dx.doi.org/10.1038/423372B			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761511	Bronze			2022-12-28	WOS:000183012000008
J	Phiel, CJ; Wilson, CA; Lee, VMY; Klein, PS				Phiel, CJ; Wilson, CA; Lee, VMY; Klein, PS			GSK-3 alpha regulates production of Alzheimer's disease amyloid-beta peptides	NATURE			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; SECRETASE CLEAVAGE; HUMAN NEURONS; PRESENILIN; CELLS; LITHIUM; NOTCH; PHOSPHORYLATION	Alzheimer's disease is associated with increased production and aggregation of amyloid-beta (Abeta) peptides(1). Abeta peptides are derived from the amyloid precursor protein (APP) by sequential proteolysis, catalysed by the aspartyl protease BACE(2), followed by presenilin-dependent gamma-secretase cleavage(3). Presenilin interacts with nicastrin(4,5), APH-1 and PEN-2 (ref. 6), all of which are required for gamma-secretase function. Presenilins also interact with alpha-catenin, beta-catenin(7,8) and glycogen synthase kinase-3beta (GSK-3beta)(9-11), but a functional role for these proteins in gamma-secretase activity has not been established. Here we show that therapeutic concentrations of lithium, a GSK-3 inhibitor(12), block the production of Abeta peptides by interfering with APP cleavage at the gamma-secretase step, but do not inhibit Notch processing. Importantly, lithium also blocks the accumulation of Abeta peptides in the brains of mice that overproduce APP. The target of lithium in this setting is GSK-3alpha, which is required for maximal processing of APP. Since GSK-3 also phosphorylates tau protein, the principal component of neurofibrillary tangles, inhibition of GSK-3alpha offers a new approach to reduce the formation of both amyloid plaques and neurofibrillary tangles, two pathological hallmarks of Alzheimer's disease.	Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Klein, PS (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, 415 Curie Blvd, Philadelphia, PA 19104 USA.							Alvarez G, 2002, BIPOLAR DISORD, V4, P153, DOI 10.1034/j.1399-5618.2002.01150.x; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Kang DE, 1999, J NEUROSCI, V19, P4229; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Siman R, 2000, J NEUROSCI, V20, P8717; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Sun X, 2002, NEUROSCI LETT, V321, P61, DOI 10.1016/S0304-3940(01)02583-6; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	30	989	1058	1	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					435	439		10.1038/nature01640	http://dx.doi.org/10.1038/nature01640			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761548				2022-12-28	WOS:000183012000041
J	McAlister, FA; Straus, SE; Sackett, DL; Altman, DG				McAlister, FA; Straus, SE; Sackett, DL; Altman, DG			Analysis and reporting of factorial trials - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIALS; ACUTE MYOCARDIAL-INFARCTION; BROAD-SPECTRUM ANTIBIOTICS; BETA-CAROTENE SUPPLEMENTS; CARDIOVASCULAR EVENTS; CONSORT STATEMENT; ALPHA-TOCOPHEROL; UNSTABLE ANGINA; DOUBLE-BLIND; QUALITY	Context Although factorial trials have become common, standards for the analysis and reporting of such trials have not been established and, despite concerns about the possibility of unrecognized interactions between therapies in factorial trials, the magnitude of this potential problem is unknown. Objective To examine the rationale, methods, and analysis of randomized factorial trials. Data Sources and Study Selection We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register using the terms factorial, interaction, 2 x 2, 2 by 2, and incremental to identify factorial randomized trials published from January 2000 to July 2002. To identify trials missed by the electronic search, we performed a hand search of English-language trials in a defined topic area (using the term myocardial ischemia [exp]) listed in MEDLINE (1966-2002), EMBASE (1980-2002), and the Cochrane Controlled Trials Register, as well as all trials in any topic area published in December 2000, excluding trials reporting only continuous surrogate end points. The final set of 33 eligible publications described 29 unique trials. Data Extraction Two investigators independently identified factorial trials, generated a list of items affecting validity of results, and abstracted these items from each trial. Data Synthesis The sensitivity of electronic searching for identifying factorial trials was 76%. Our 3-pronged search strategy identified 44 factorial trials with clinically important binary outcomes: 36 (82%) were done for reasons of efficiency (testing 2 interventions in the same patient population), and 8 (18%) were done to assess the incremental benefits of combining the 2 treatments. All but 1 of the trials reported treatment effects by comparing all patients who received treatment A (ie, those receiving either A alone or both A and B) vs all those not receiving treatment A (ie, those receiving either B alone or neither A nor B). Twenty-nine of the 44 trials (66%) reported the data from each of the treatment groups separately; 26 trials (59%) reported testing for interactions between the treatments. Only 2 of 31 (6%) comparisons demonstrated a statistically significant interaction between the 2 treatments. Conclusions Accurate interpretation of factorial trials depends on the transparent reporting of data for each treatment cell. Despite concerns about unrecognized interactions, our findings suggest that investigators are appropriately restricting their use of the factorial design to those situations in which 2 (or more) treatments do not have the potential for substantive interaction.	Univ Alberta, Div Gen Internal Med, Edmonton, AB, Canada; Univ Toronto, Div Gen Internal Med & Geriatr, Toronto, ON, Canada; Trout Res & Educ Ctr, Irish Lake, ON, Canada; Ctr Stat Med, Oxford, England	University of Alberta; University of Toronto; University of Oxford	McAlister, FA (corresponding author), Univ Alberta Hosp, 2E3-24 WMC,8440 112 St, Edmonton, AB T6G 2R7, Canada.	Finlay.McAlister@ualberta.ca	McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341				Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 1987, Eur Heart J, V8, P634; [Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; Baigent C, 1998, BMJ-BRIT MED J, V316, P1337, DOI 10.1136/bmj.316.7141.1337; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Bovill EG, 1997, AM J CARDIOL, V79, P391, DOI 10.1016/S0002-9149(96)00773-4; BRITTAIN E, 1989, STAT MED, V8, P161, DOI 10.1002/sim.4780080204; BURR ML, 1989, LANCET, V2, P757; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Cairns JA, 1996, CIRCULATION, V94, P1553, DOI 10.1161/01.CIR.94.7.1553; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; Campeau L, 1997, NEW ENGL J MED, V336, P153; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; COLLINS R, 1995, LANCET, V345, P669; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881; Devereaux PJ, 2002, CONTROL CLIN TRIALS, V23, P380, DOI 10.1016/S0197-2456(02)00214-3; DEVITA C, 1994, LANCET, V343, P1115; Doft BH, 2001, ARCH OPHTHALMOL-CHIC, V119, P650, DOI 10.1001/archopht.119.5.650; Fawzi WW, 2000, J ACQ IMMUN DEF SYND, V23, P246; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Grant A, 2001, BRIT J OBSTET GYNAEC, V108, P34, DOI 10.1111/j.1471-0528.2001.00016.x; Halliday HL, 2001, PEDIATRICS, V107, P232, DOI 10.1542/peds.107.2.232; Heinala P, 2001, J CLIN PSYCHOPHARM, V21, P287, DOI 10.1097/00004714-200106000-00006; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HUNT D, 1992, LANCET, V339, P753; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Karlstrom PO, 2000, ACTA OBSTET GYN SCAN, V79, P37, DOI 10.1034/j.1600-0412.2000.079001037.x; Kenyon SL, 2001, LANCET, V357, P989, DOI 10.1016/S0140-6736(00)04234-3; Kenyon SL, 2001, LANCET, V357, P979, DOI 10.1016/S0140-6736(00)04233-1; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Lincoff AM, 1997, AM J CARDIOL, V79, P286, DOI 10.1016/S0002-9149(96)00749-7; LUBSEN J, 1994, EUR HEART J, V15, P585, DOI 10.1093/oxfordjournals.eurheartj.a060552; Meade TW, 1998, LANCET, V351, P233; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; OConnor CM, 1996, AM J CARDIOL, V77, P791, DOI 10.1016/S0002-9149(97)89171-0; PIANTADOSI S, 2000, CLIN TRIALS METHODOL, P392; Rapola JM, 1998, HEART, V79, P454, DOI 10.1136/hrt.79.5.454; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Sazawal S, 2001, PEDIATRICS, V108, P1280, DOI 10.1542/peds.108.6.1280; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Teo KK, 2000, CIRCULATION, V102, P1748; Tjan-Heijnen VCG, 2001, ANN ONCOL, V12, P1359, DOI 10.1023/A:1012545507920; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Topol E, 1998, CIRCULATION, V97, P2386; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VANDEWERF F, 1990, LANCET, V336, P71; Wallentin L, 1999, LANCET, V354, P708; Wit FWNM, 2001, AIDS, V15, P2423, DOI 10.1097/00002030-200112070-00010; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Yusuf S, 2000, NEW ENGL J MED, V342, P145	61	192	192	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2545	2553		10.1001/jama.289.19.2545	http://dx.doi.org/10.1001/jama.289.19.2545			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680KL	12759326				2022-12-28	WOS:000182976500023
J	Read, J; Winceslaus, SJ				Read, J; Winceslaus, SJ			New strategies for increasing the detection of HIV: analysis of routine data	BRITISH MEDICAL JOURNAL			English	Article									Preston Hall Hosp, Maidstone ME17 7NJ, Kent, England; Guys King Coll, London SE5 9RJ, England; St Thomass Sch Med, London SE5 9RJ, England	University of London; King's College London; University of London; King's College London	Winceslaus, SJ (corresponding author), Preston Hall Hosp, Maidstone ME17 7NJ, Kent, England.			Winceslaus, SJ/0000-0002-9757-1007				Department of Health, 2001, NAT STRAT SEX HLTH H; *PUBL HLTH LAB SER, 2000, TRENDS SEX TRANSM IN; *PUBL HLTH LAB SER, 2001, PHLS EP HIV AIDS	3	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2003	326	7398					1066	1067		10.1136/bmj.326.7398.1066	http://dx.doi.org/10.1136/bmj.326.7398.1066			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681ZD	12750208	Green Published, Bronze			2022-12-28	WOS:000183064700016
J	Anderson, TL; Charlson, RJ; Schwartz, SE; Knutti, R; Boucher, O; Rodhe, H; Heintzenberg, J				Anderson, TL; Charlson, RJ; Schwartz, SE; Knutti, R; Boucher, O; Rodhe, H; Heintzenberg, J			Climate forcing by aerosols - a hazy picture	SCIENCE			English	Editorial Material							SENSITIVITY		Univ Washington, Joint Inst Study Atmosphere & Oceans, Seattle, WA 98195 USA; Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA; Brookhaven Natl Lab, Div Atmospher Sci, Upton, NY 11973 USA; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Univ Sci & Technol Lille, CNRS, Opt Atmospher Lab, F-59655 Villeneuve Dascq, France; Stockholm Univ, Dept Meteorol, SE-10691 Stockholm, Sweden; Inst Tropospher Res, D-04318 Leipzig, Germany	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Bern; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Stockholm University; Leibniz Institut fur Tropospharenforschung (TROPOS)	Anderson, TL (corresponding author), Univ Washington, Joint Inst Study Atmosphere & Oceans, Seattle, WA 98195 USA.		Schwartz, Stephen E/C-2729-2008; Boucher, Olivier/J-5810-2012; Boucher, Olivier/K-7483-2012; Knutti, Reto/B-8763-2008	Schwartz, Stephen E/0000-0001-6288-310X; Boucher, Olivier/0000-0003-2328-5769; Boucher, Olivier/0000-0003-2328-5769; Knutti, Reto/0000-0001-8303-6700				Andronova NG, 2001, J GEOPHYS RES-ATMOS, V106, P22605, DOI 10.1029/2000JD000259; Boucher O, 2001, CLIM DYNAM, V18, P297, DOI 10.1007/s003820100185; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Cubasch U., 2001, PROJECTIONS FUTURE C, P525; Forest CE, 2002, SCIENCE, V295, P113, DOI 10.1126/science.1064419; Gregory JM, 2002, J CLIMATE, V15, P3117, DOI [10.1175/1520-0442(2002)015<3117:AOBEOT>2.0.CO;2, 10.1175/1520-0442(2002)015&lt;3117:AOBEOT&gt;2.0.CO;2]; Hansen JE, 1998, P NATL ACAD SCI USA, V95, P12753, DOI 10.1073/pnas.95.22.12753; Hansen JE, 2001, P NATL ACAD SCI USA, V98, P14778, DOI 10.1073/pnas.261553698; Harvey LDD, 2002, J CLIMATE, V15, P2837, DOI 10.1175/1520-0442(2002)015<2837:SCCSAA>2.0.CO;2; Kiehl JT, 2000, J GEOPHYS RES-ATMOS, V105, P1441, DOI 10.1029/1999JD900495; Knutti R, 2002, NATURE, V416, P719, DOI 10.1038/416719a; Meehl GA, 2003, J CLIMATE, V16, P426, DOI [10.1175/1520-0442(2003)016<0426:SAGGFA>2.0.CO;2, 10.1175/1520-0442(2003)016&lt;0426:SAGGFA&gt;2.0.CO;2]; Menon S, 2002, J ATMOS SCI, V59, P692, DOI 10.1175/1520-0469(2002)059<0692:GSOTAI>2.0.CO;2; Mitchell JFB, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P695; Ramaswamy V., 2001, CLIMATE CHANGE 2001, P349; Rodhe H, 2000, CLIMATIC CHANGE, V44, P419, DOI 10.1023/A:1005536902789; Schwartz SE, 1996, SCIENCE, V272, P1121, DOI 10.1126/science.272.5265.1121; TETT SFB, 2002, J GEOPHYS RES, V107; Wigley TML, 2001, SCIENCE, V293, P451, DOI 10.1126/science.1061604	19	252	280	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1103	1104		10.1126/science.1084777	http://dx.doi.org/10.1126/science.1084777			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750507				2022-12-28	WOS:000182886500030
J	Chen, HK; Fernandez-Funez, P; Acevedo, SF; Lam, YC; Kaytor, MD; Fernandez, MH; Aitken, A; Skoulakis, EMC; Orr, HT; Botas, J; Zoghbi, HY				Chen, HK; Fernandez-Funez, P; Acevedo, SF; Lam, YC; Kaytor, MD; Fernandez, MH; Aitken, A; Skoulakis, EMC; Orr, HT; Botas, J; Zoghbi, HY			Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1	CELL			English	Article							SELECTIVE NEURODEGENERATION; SIGNALING PATHWAY; ALPHA-SYNUCLEIN; PROTEIN; GROWTH; DROSOPHILA; DISEASE; 14-3-3-PROTEINS; SCA1; CELL	Spinocerebellar ataxia type 1 (SCA1) is one of several neurological disorders caused by a CAG repeat expansion. In SCA1, this expansion produces an abnormally long polyglutamine tract in the protein ataxin-1. Mutant polyglutamine proteins accumulate in neurons, inducing neurodegeneration, but the mechanism underlying this accumulation has been unclear. We have discovered that the 14-3-3 protein, a multifunctional regulatory molecule, mediates the neurotoxicity of ataxin-1 by binding to and stabilizing ataxin-1, thereby slowing its normal degradation. The association of ataxin-1 with 14-3-3 is regulated by Akt phosphorylation, and in a Drosophila model of SCA1, both 14-3-3 and Akt modulate neurodegeneration. Our finding that phosphatidylinositol 3-kinase/Akt signaling and 14-3-3 cooperate to modulate the neurotoxicity of ataxin-1 provides insight into SCA1 pathogenesis and identifies potential targets for therapeutic intervention.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Texas A&M Univ, Genet Program, College Stn, TX 77843 USA; CSRC A Fleming, Inst Mol Biol & Genet, Vari 16672, Greece; Univ Edinburgh, Div Biomed & Clin Lab Sci, Edinburgh EH8 9XD, Midlothian, Scotland	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Minnesota System; University of Minnesota Twin Cities; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Edinburgh	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.			Orr, Harry/0000-0001-6118-741X; Chen, Hung-Kai/0000-0002-2169-4924; Zoghbi, Huda/0000-0002-0700-3349; Acevedo, Summer/0000-0002-3206-6819	NICHD NIH HHS [HD24064] Funding Source: Medline; NINDS NIH HHS [NS27699, NS42179, NS22920] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042179, R01NS022920, R37NS027699, R56NS042179, R37NS022920, R01NS027699] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baxter HC, 2002, NEUROSCIENCE, V109, P5, DOI 10.1016/S0306-4522(01)00492-4; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cho KS, 2001, P NATL ACAD SCI USA, V98, P6144, DOI 10.1073/pnas.101596998; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kawamoto Y, 2002, J NEUROPATH EXP NEUR, V61, P245, DOI 10.1093/jnen/61.3.245; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	33	322	339	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 16	2003	113	4					457	468		10.1016/S0092-8674(03)00349-0	http://dx.doi.org/10.1016/S0092-8674(03)00349-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757707	Bronze			2022-12-28	WOS:000182981500008
J	Williams, BRG; Sen, GC				Williams, BRG; Sen, GC			A viral on/off switch for interferon	SCIENCE			English	Editorial Material							NF-KAPPA-B; REGULATORY FACTOR-3; ACTIVATION; IRF3; COMPONENTS; KINASE		Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668	14	14	15	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2003	300	5622					1100	1101		10.1126/science.1085277	http://dx.doi.org/10.1126/science.1085277			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750505				2022-12-28	WOS:000182886500028
J	Snyder, EL; Rinder, HM				Snyder, EL; Rinder, HM			Platelet storage - Time to come in from the cold?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Sch Med, Dept Lab Med, Blood Bank Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Lab Med, Hematol Sect, New Haven, CT 06510 USA	Yale University; Yale University	Snyder, EL (corresponding author), Yale Univ, Sch Med, Dept Lab Med, Blood Bank Sect, New Haven, CT 06510 USA.							BECKER GA, 1973, TRANSFUSION, V13, P61, DOI 10.1111/j.1537-2995.1973.tb05442.x; Gousset K, 2002, J CELL PHYSIOL, V190, P117, DOI 10.1002/jcp.10039; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; Kermode JC, 1999, BLOOD, V94, P199, DOI 10.1182/blood.V94.1.199.413k14_199_207; Tablin F, 2000, J LAB CLIN MED, V135, P339, DOI 10.1067/mlc.2000.105619	5	19	19	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					2032	2033		10.1056/NEJMcibr035099	http://dx.doi.org/10.1056/NEJMcibr035099			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12748320				2022-12-28	WOS:000182823400014
J	Sutherland, WJ				Sutherland, WJ			Parallel extinction risk and global distribution of languages and species	NATURE			English	Article							CONSEQUENCES	There are global threats to biodiversity with current extinction rates well above background levels(1). Although less well publicized, numerous human languages have also become extinct, and others are threatened with extinction(2,3). However, estimates of the number of threatened languages vary considerably owing to the wide range of criteria used. For example, languages have been classified as threatened if the number of speakers is less than 100, 500, 1,000, 10,000, 20,000 or 100,000 (ref. 3). Here I show, by applying internationally agreed criteria for classifying species extinction risk(4), that languages are more threatened than birds or mammals. Rare languages are more likely to show evidence of decline than commoner ones. Areas with high language diversity also have high bird and mammal diversity and all three show similar relationships to area, latitude, area of forest and, for languages and birds, maximum altitude. The time of human settlement has little effect on current language diversity. Although similar factors explain the diversity of languages and biodiversity, the factors explaining extinction risk for birds and mammals ( high altitude, high human densities and insularity) do not explain the numbers of endangered languages.	Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Sutherland, WJ (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England.	w.sutherland@uea.ac.uk	Sutherland, William/B-1291-2013	Sutherland, William/0000-0002-6498-0437				[Anonymous], 1999, TIMES COMPREHENSIVE; Balmford A, 2001, SCIENCE, V291, P2616, DOI 10.1126/science.291.5513.2616; Birdlife International, 2000, THREAT BIRDS WORLD; Brooks TM, 2000, THREATENED BIRDS WOR, P701; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Cavalli-Sforza LL, 1986, AFRICAN PYGMIES; Chapin FS, 2000, NATURE, V405, P234, DOI 10.1038/35012241; Crystal D., 2000, LANGUAGE DEATH; *FAO, 2000, STAT WORLDS FOR 2001; Grimes B.F., 2000, ETHNOLOGUE LANGUAGES, V14th ed.; GROOMBRIDGE B, 2000, GLOBAL BIODIVERSITY; *IUCN SSC, 1994, RED LIST CAT CRIT; KRAUSS M, 1992, LANGUAGE, V68, P4, DOI 10.1353/lan.1992.0075; LANDE R, 1993, AM NAT, V142, P911, DOI 10.1086/285580; MACE R, 1995, P ROY SOC B-BIOL SCI, V261, P117, DOI 10.1098/rspb.1995.0125; Mitchell TD, 2002, AREA, V34, P109, DOI 10.1111/1475-4762.00062; MORRE JL, 2002, P R SOC LOND B, V269, P1645; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Nettle D, 1999, P NATL ACAD SCI USA, V96, P3325, DOI 10.1073/pnas.96.6.3325; Nettle D, 1998, J ANTHROPOL ARCHAEOL, V17, P354, DOI 10.1006/jaar.1998.0328; NETTLE DANIEL, 1999, LINGUISTIC DIVERSITY; Saccheri I, 1998, NATURE, V392, P491, DOI 10.1038/33136; Stephens PA, 1999, TRENDS ECOL EVOL, V14, P401, DOI 10.1016/S0169-5347(99)01684-5	23	190	194	2	67	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					276	279		10.1038/nature01607	http://dx.doi.org/10.1038/nature01607			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748639				2022-12-28	WOS:000182853100040
J	Bates, G				Bates, G			Huntingtin aggregation and toxicity in Huntington's disease	LANCET			English	Review							NEURONAL INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE AGGREGATION; PATHOGENESIS; MECHANISM; PEPTIDES; CHANNELS; BRAIN	Context Huntington's disease is a late onset neurodegenerative disorder for which the mutation is a CAG/polyglutamine (polyQ) repeat expansion in the gene encoding the huntingtin protein. The disease is one of nine inherited neurodegenerative disorders that, are Caused by this type of mutation, and which include dentatorubral pallidoluysian atrophy, spinal and bulbar muscular atrophy, and the spinoperebellar ataxias 1, 2, 3, 6, 7, and 17. The mutant proteins are unrelated except for. the polyQ tract, and aggregated polyQ is a major component of the proteinaceous deposits that are found in patients' brains] for all of these diseases. Starting point Since the discovery of polyQ aggregates, the proposed role of the aggregation process has ranged from being central to disease pathogenesis, to a benign epiphenomenon, or even to being neuroprotective., Attempts to correlate the presence of aggregates with he onset of phenotype have been complicated by the difficulties in detecting and quantifying small aggregated forms of polyQ, and because all possible structural conformers of the repeat are present in the system under analysis. A paper by W Yang and colleagues (Hum Mol Genet 2002; 11: 2905-17) circumvents these limitations' and demonstrates that preformed polyQ aggregates are highly toxic when directed to the cell nucleus. Consistent with aggregate toxicity, pharmacological intervention aimed at inhibiting, aggregate formation has recently shown beneficial effects in a mouse. model of Huntington's disease (I Sanchez and colleagues, Nature 2003; 421:: 373-79). Where next The demonstration that polyQ aggregates are toxic is important because it further validates polyQ aggregation as a therapeutic target. To exploit this finding fully, greater understanding of the formation and structure of polyQ aggregates is needed. However, even without this knowledge, establishing high-throughput screens to identify aggregation inhibitors has been straightforward, and early in-vivo experiments that target aggregation have been promising. As the molecular events that contribute to the early stages, of the pathogenesis of Huntington's disease are uncovered, such events will be developed as therapeutic targets. The inhibition of huntingtin aggregation should be a major focus in this effort and the practicalities of this approach, are likely to unfold over the next 5-10 years.	Univ London Kings Coll, Guys Hosp, GKT Sch Med, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Bates, G (corresponding author), Univ London Kings Coll, Guys Hosp, GKT Sch Med, London SE1 9RT, England.		Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305				Cepeda C, 2003, J NEUROSCI, V23, P961; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen SM, 2001, PROTEIN SCI, V10, P887, DOI 10.1110/ps.42301; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Heiser V, 2002, P NATL ACAD SCI USA, V99, P16400, DOI 10.1073/pnas.182426599; Hirakura Y, 2000, J NEUROSCI RES, V60, P490, DOI 10.1002/(SICI)1097-4547(20000515)60:4<490::AID-JNR7>3.0.CO;2-9; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Monoi H, 2000, BIOPHYS J, V78, P2892, DOI 10.1016/S0006-3495(00)76830-5; Myers RH, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P301; Norremolle A, 2003, J NEUROSCI RES, V71, P132, DOI 10.1002/jnr.10468; OSMAND AP, 2002, SOC NEUR ABSTR, V293, P6; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	24	378	395	2	52	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1642	1644		10.1016/S0140-6736(03)13304-1	http://dx.doi.org/10.1016/S0140-6736(03)13304-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747895				2022-12-28	WOS:000182746300025
J	Zschocke, J; Schaefer, JR				Zschocke, J; Schaefer, JR			Homozygous familial hypercholesterolaemia in identical twins	LANCET			English	Editorial Material									Univ Heidelberg, Dept Paediat, D-69120 Heidelberg, Germany; Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany; Univ Marburg, Dept Internal Med, D-35033 Marburg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Philipps University Marburg	Zschocke, J (corresponding author), Univ Heidelberg, Dept Paediat, D-69120 Heidelberg, Germany.		Zschocke, Johannes/C-5885-2013	Zschocke, Johannes/0000-0002-0046-8274					0	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1641	1641		10.1016/S0140-6736(03)13303-X	http://dx.doi.org/10.1016/S0140-6736(03)13303-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747894				2022-12-28	WOS:000182746300024
J	Yu, EW; McDermott, G; Zgurskaya, HI; Nikaido, H; Koshland, DE				Yu, EW; McDermott, G; Zgurskaya, HI; Nikaido, H; Koshland, DE			Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump	SCIENCE			English	Article							LARGE PERIPLASMIC LOOPS; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; RESISTANCE; TRANSPORTER; RECOGNITION; MECHANISMS	Multidrug efflux pumps cause serious problems in cancer chemotherapy and treatment of bacterial infections. Yet high-resolution structures of ligand-transporter complexes have previously been unavailable. We obtained x-ray crystallographic structures of the trimeric AcrB pump from Escherichia coli with four structurally diverse ligands. The structures show that three molecules of ligands bind simultaneously to the extremely large central cavity of 5000 cubic angstroms, primarily by hydrophobic, aromatic stacking and van der Waals interactions. Each ligand uses a slightly different subset of AcrB residues for binding. The bound ligand molecules often interact with each other, stabilizing the binding.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley Ctr Struct Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Koshland, DE (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NIAID NIH HHS [AI 09644] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009644, R01AI009644] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT A, 1956, J CHEM SOC, P1294, DOI 10.1039/jr9560001294; Avila-Sakar AJ, 2001, J STRUCT BIOL, V136, P81, DOI 10.1006/jsbi.2001.4418; DeLano W.L, PYMOL MOL GRAPHICS S; Elkins CA, 2002, J BACTERIOL, V184, P6490, DOI 10.1128/JB.184.23.6490-6499.2002; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Lewinson O, 2001, BIOCHEMISTRY-US, V40, P12612, DOI 10.1021/bi011040y; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; Mao WM, 2002, MOL MICROBIOL, V46, P889, DOI 10.1046/j.1365-2958.2002.03223.x; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; NIKAIDO H, 1993, ANTIMICROB AGENTS CH, V37, P1393, DOI 10.1128/AAC.37.7.1393; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Tikhonova EB, 2002, J BACTERIOL, V184, P6499, DOI 10.1128/JB.184.23.6499-6507.2002; Yu EW, 2001, P NATL ACAD SCI USA, V98, P9517, DOI 10.1073/pnas.161239298; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000; Zgurskaya HI, 1999, J MOL BIOL, V285, P409, DOI 10.1006/jmbi.1998.2313; Zgurskaya HI, 2000, MOL MICROBIOL, V37, P219, DOI 10.1046/j.1365-2958.2000.01926.x; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	21	322	339	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					976	980		10.1126/science.1083137	http://dx.doi.org/10.1126/science.1083137			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738864				2022-12-28	WOS:000182719800056
J	Ray, WA; Daugherty, JR; Meador, KG				Ray, WA; Daugherty, JR; Meador, KG			Effect of a mental health "carve-out'' program on the continuity of antipsychotic therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MANAGED CARE; SCHIZOPHRENIA; MEDICAID; SERVICES; PHARMACOEPIDEMIOLOGY; CONTRACTS; DATABASES; OUTCOMES; POLICY; AGENTS	BACKGROUND: On July 1, 1996, as a cost-containment strategy, Tennessee's expanded Medicaid program, TennCare, rapidly shifted the provision of mental health services to a fully capitated, specialty ``carve-out'' program, TennCare Partners. We studied the effect of this transition on the continuity of antipsychotic therapy among patients with severe mental illness who had previously adhered to treatment. METHODS: Study patients were 21 to 64 years of age, were enrolled throughout the study period, and had adhered to antipsychotic therapy during a 6-month base-line period that preceded the 12 months of study follow-up. The study population included 4507 patients whose follow-up began on the day the change was implemented (the post-transition cohort) and 3644 patients whose follow-up began one year earlier (the pretransition cohort). We compared the two cohorts in terms of the loss of continuity of antipsychotic therapy (missed treatment for more than 60 days during follow-up) and the mean number of days of antipsychotic therapy during follow-up. RESULTS: As compared with the pretransition cohort, the post-transition cohort had increased odds of loss of continuity (a multivariate odds ratio of 1.18 [95 percent confidence interval, 1.07 to 1.30], P=0.001) and a shorter mean duration of antipsychotic therapy (a mean reduction of 4.2 days [95 percent confidence interval, 1.7 to 6.7], P=0.001) during follow-up. This difference was most pronounced among high-risk patients (those requiring the administration of extended-release [depot] injections of antipsychotic medications or who had been hospitalized for psychosis) at base line, for whom continuity was most important (odds ratio for loss of continuity, 1.79 [95 percent confidence interval, 1.45 to 2.22]; P<0.001; mean reduction in the number of days of antipsychotic therapy, 14.4 days [95 percent confidence interval, 9.4 to 19.4]; P<0.001). These patients had decreased use of antipsychotic drugs immediately after the transition; the lower level persisted throughout the 12 months of follow-up. CONCLUSIONS: These findings underscore the need to ensure that shifts to widely used carve-out programs, which are designed primarily to contain costs, do not adversely affect clinical outcomes.	Nashville Vet Affairs Med Ctr, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN USA; Nashville Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; Durham Vet Affairs Med Ctr, Durham, NC USA	Geriatric Research Education & Clinical Center; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Ray, WA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Prevent Med, Med Ctr N,A-1124, Nashville, TN 37232 USA.	cindy.naron@mcmail.vanderbilt.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060075] Funding Source: NIH RePORTER; AHRQ HHS [HS1-0384] Funding Source: Medline; NIMH NIH HHS [MH60075] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AM MED ASS, 1995, DRUG EV ANN 1995; Bloom Joan R., 1998, J Ment Health Policy Econ, V1, P3, DOI 10.1002/(SICI)1099-176X(199803)1:1<3::AID-MHP4>3.0.CO;2-Q; BRUNELLO N, 1995, NEUROPSYCHOPHARMACOL, V13, P177, DOI 10.1038/sj.npp.1380287; Catalano R, 2000, AM J PUBLIC HEALTH, V90, P1861, DOI 10.2105/AJPH.90.12.1861; Chang CF, 1998, JAMA-J AM MED ASSOC, V279, P864, DOI 10.1001/jama.279.11.864; Csernansky JG, 2002, NEW ENGL J MED, V346, P16, DOI 10.1056/NEJMoa002028; Csernansky JG, 2002, NEW ENGL J MED, V346, P1424; DAVIS JM, 1984, TREATMENT CARE SCHIZ; Dickey B, 1996, ARCH GEN PSYCHIAT, V53, P945; Donohue JM, 2000, HARVARD REV PSYCHIAT, V8, P231, DOI 10.1093/hrp/8.5.231; ESSOCK SM, 1995, HEALTH AFFAIR, V14, P34, DOI 10.1377/hlthaff.14.3.34; FRANK RG, 1995, HEALTH AFFAIR, V14, P50, DOI 10.1377/hlthaff.14.3.50; Garnick DW, 2001, PSYCHIAT SERV, V52, P1502, DOI 10.1176/appi.ps.52.11.1502; Hodgkin D, 2000, J BEHAV HEALTH SER R, V27, P178, DOI 10.1007/BF02287312; HUTTUNEN M, 1995, J CLIN PSYCHOPHARM, V15, pS4, DOI 10.1097/00004714-199502001-00002; Iglehart JK, 1996, NEW ENGL J MED, V334, P131, DOI 10.1056/NEJM199601113340221; JOHNSON DAW, 1988, SCHIZOPHRENIA MAJOR, P158; JOHNSON RE, 1991, J AM GERIATR SOC, V39, P1079, DOI 10.1111/j.1532-5415.1991.tb02872.x; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; Kane JM, 1998, SCHIZOPHRENIA BULL, V24, P20, DOI 10.1093/oxfordjournals.schbul.a033310; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1; Lehman AF, 1999, HEALTH AFFAIR, V18, P52, DOI 10.1377/hlthaff.18.5.52; LEISTER KA, 1981, MED CARE, V19, P658, DOI 10.1097/00005650-198106000-00008; Manning WG, 1999, J BEHAV HEALTH SER R, V26, P442, DOI 10.1007/BF02287304; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; Owens DGC, 1996, DRUGS, V51, P895; Ray WA, 1997, ANN INTERN MED, V127, P712, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00055; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; Stoner T, 1997, HEALTH CARE FINANC R, V18, P73; STROM BL, 1990, EPIDEMIOL REV, V12, P87, DOI 10.1093/oxfordjournals.epirev.a036064; WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563	32	42	42	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1885	1894		10.1056/NEJMsa020584	http://dx.doi.org/10.1056/NEJMsa020584			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675FY	12736282				2022-12-28	WOS:000182684100008
J	DeWitt, DE; Dugdale, DC				DeWitt, DE; Dugdale, DC			Using new insulin strategies in the outpatient treatment of diabetes - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GLYCEMIC CONTROL; NPH INSULIN; GLUCOSE CONTROL; VA CSDM; THERAPY; TYPE-1; GLARGINE; TRIAL; COMBINATION; MELLITUS	Understanding when to use insulin and how to apply the principles of physiologic insulin replacement using existing and new insulins is a key step to improving diabetes care. Insulin analogues and premixed insulins increase physicians' and patients' ability to lower hemoglobin A(1c) levels with fewer episodes of hypoglycemia. Earlier use of insulin and more aggressive dose escalation are important steps in achieving treatment goals. This article discusses using bedtime insulin with oral agents, basal-prandial insulin strategies, and the new insulin analogues.	Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA	University of Washington; University of Washington Seattle	DeWitt, DE (corresponding author), Univ Melbourne, Rural Clin Sch, POB 6500, Shepparton, Vic 3632, Australia.		DeWitt, Dawn E/ABX-0983-2022	DeWitt, Dawn E/0000-0002-9352-3104				ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; Abraira C, 1998, DIABETES CARE, V21, P574, DOI 10.2337/diacare.21.4.574; Annuzzi G, 2001, NUTR METAB CARDIOVAS, V11, P168; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; Holmboe ES, 2002, JAMA-J AM MED ASSOC, V287, P373, DOI 10.1001/jama.287.3.373; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Malone JK, 2000, CLIN THER, V22, P222, DOI 10.1016/S0149-2918(00)88480-5; Malone JK, 2000, DIABETES METAB, V26, P481; MUHLHAUSER I, 1995, J INTERN MED, V237, P591; Ratner RE, 2000, DIABETES CARE, V23, P639, DOI 10.2337/diacare.23.5.639; Roach P, 2001, INT J CLIN PRACT, V55, P177; Rosenstock J, 2001, DIABETES CARE, V24, P631, DOI 10.2337/diacare.24.4.631; Saaddine JB, 2002, ANN INTERN MED, V136, P565, DOI 10.7326/0003-4819-136-8-200204160-00005; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shichiri M, 2000, DIABETES CARE, V23, pB21; TRENCE DL, IN PRESS MANAGEMENT; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Witthaus E, 2001, DIABETIC MED, V18, P619, DOI 10.1046/j.1464-5491.2001.00529.x; Wright A, 2002, DIABETES CARE, V25, P330, DOI 10.2337/diacare.25.2.330; Yki-Jarvinen H, 1999, ANN INTERN MED, V130, P389, DOI 10.7326/0003-4819-130-5-199903020-00002; Yki-Jarvinen H, 2000, DIABETES CARE, V23, P1130, DOI 10.2337/diacare.23.8.1130; [No title captured]	22	33	34	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2265	2269		10.1001/jama.289.17.2265	http://dx.doi.org/10.1001/jama.289.17.2265			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675ET	12734138	Bronze			2022-12-28	WOS:000182680700029
J	Misewich, JA; Martel, R; Avouris, P; Tsang, JC; Heinze, S; Tersoff, J				Misewich, JA; Martel, R; Avouris, P; Tsang, JC; Heinze, S; Tersoff, J			Electrically induced optical emission from a carbon nanotube FET	SCIENCE			English	Article							SINGLE; CIRCUITS; SPECTRA; GROWTH	Polarized infrared optical emission was observed from a carbon nanotube ambipolar field-effect transistor (FET). An effective forward-biased p-n junction, without chemical dopants, was created in the nanotube by appropriately biasing the nanotube device. Electrical measurements show that the observed optical emission originates from radiative recombination of electrons and holes that are simultaneously injected into the undoped nanotube. These observations are consistent with a nanotube FET model in which thin Schottky barriers form at the source and drain contacts. This arrangement is a novel optical recombination radiation source in which the electrons and holes are injected into a nearly field-free region. Such a source may form the basis for ultrasmall integrated photonic devices.	IBM Corp, Div Res, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	Misewich, JA (corresponding author), Brookhaven Natl Lab, Dept Mat Sci, Upton, NY 11973 USA.		Martel, Richard/G-7589-2011	Martel, Richard/0000-0002-9021-4656; Heinze, Stefan/0000-0001-5852-0082; Avouris, Phaedon/0000-0001-9902-8000				Appenzeller J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.126801; Bachilo SM, 2002, SCIENCE, V298, P2361, DOI 10.1126/science.1078727; Bachtold A, 2001, SCIENCE, V294, P1317, DOI 10.1126/science.1065824; Derycke V, 2001, NANO LETT, V1, P453, DOI 10.1021/nl015606f; Dodabalapur A, 1996, APPL PHYS LETT, V68, P1108, DOI 10.1063/1.115728; Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047; Freitag M, 2001, APPL PHYS LETT, V79, P3326, DOI 10.1063/1.1419055; Fuhrer MS, 2000, SCIENCE, V288, P494, DOI 10.1126/science.288.5465.494; Gudiksen MS, 2002, NATURE, V415, P617, DOI 10.1038/415617a; Hagen A, 2003, NANO LETT, V3, P383, DOI 10.1021/nl020237o; Heinze S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.106801; Liu XL, 2001, APPL PHYS LETT, V79, P3329, DOI 10.1063/1.1417516; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; Martel R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.256805; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Rao AM, 1997, SCIENCE, V275, P187, DOI 10.1126/science.275.5297.187; Saito R, 2001, TOP APPL PHYS, V80, P213; Soh HT, 1999, APPL PHYS LETT, V75, P627, DOI 10.1063/1.124462; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Wang JF, 2001, SCIENCE, V293, P1455, DOI 10.1126/science.1062340	21	788	844	2	230	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					783	786		10.1126/science.1081294	http://dx.doi.org/10.1126/science.1081294			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730598				2022-12-28	WOS:000182579800046
J	Joseph, A; Abraham, S; Muliyil, JP; George, K; Prasad, J; Minz, S; Abraham, VJ; Jacob, KS				Joseph, A; Abraham, S; Muliyil, JP; George, K; Prasad, J; Minz, S; Abraham, VJ; Jacob, KS			Evaluation of suicide rates in rural India using verbal autopsies, 1994-9	BRITISH MEDICAL JOURNAL			English	Article									Christian Med Coll & Hosp, Dept Community Med, Vellore 632002, Tamil Nadu, India; Christian Med Coll & Hosp, Dept Psychiat, Vellore, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore; Christian Medical College & Hospital (CMCH) Vellore	Joseph, A (corresponding author), Christian Med Coll & Hosp, Dept Community Med, Vellore 632002, Tamil Nadu, India.							Gururaj G., 2001, NATL I MENTAL HLTH N, V43; Joseph A, 1991, INT J HLTH SCI, V2, P93; WHO, 2001, WORLD HLTH REPORT 20	3	102	102	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1121	1122		10.1136/bmj.326.7399.1121	http://dx.doi.org/10.1136/bmj.326.7399.1121			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763983	Bronze, Green Published			2022-12-28	WOS:000183245000019
J	Cao, D; Parker, R				Cao, D; Parker, R			Computational modeling and experimental analysis of nonsense-mediated decay in yeast	CELL			English	Article							MESSENGER-RNA SURVEILLANCE; SACCHAROMYCES-CEREVISIAE; TRANSLATION INITIATION; TURNOVER; DEADENYLATION; MECHANISMS; MUTATIONS; STABILITY; ELEMENTS; PROTEIN	A conserved mRNA surveillance system, referred to as nonsense-mediated decay (NMD), exists in eukaryotic cells to degrade mRNAs containing nonsense codons. This process is important in checking that mRNAs; have been properly synthesized and functions, at least in part, to increase the fidelity of gene expression by degrading aberrant mRNAs; that, if translated, would produce truncated proteins. Using computational modeling and experimental analysis, we define the alterations in mRNA turnover triggered by NMD in yeast. We demonstrate that the nonsense-containing transcripts are efficiently recognized, targeted for deadenylation-independent decapping, and show NMD triggered accelerated deadenylation regardless of the position of the nonsense codon. We also show that 5' nonsense codons trigger faster rates of decapping than 3' nonsense codons, thereby providing a mechanistic basis for the polar effect of NMD. Finally, we construct a computational model that accurately describes the process of NMD and serves as an explanatory and predictive tool.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Howard Hughes Med Inst, Tucson, AZ 85721 USA	University of Arizona; Howard Hughes Medical Institute; University of Arizona	Parker, R (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045443, R01GM045443] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045443-13, GM45443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; Brogna S, 1999, RNA, V5, P562, DOI 10.1017/S1355838299981359; Cao D, 2001, RNA, V7, P1192, DOI 10.1017/S1355838201010330; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; Dahlseid JN, 1998, GENETICS, V150, P1019; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Gonzalez CI, 2001, GENE, V274, P15, DOI 10.1016/S0378-1119(01)00552-2; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; Hilleren P, 2001, RNA, V7, P753, DOI 10.1017/S1355838201010147; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MAQUAT LE, 1995, RNA, V1, P453; Mendell JT, 2000, MOL CELL BIOL, V20, P8944, DOI 10.1128/MCB.20.23.8944-8957.2000; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Muhlrad D, 1999, MOL BIOL CELL, V10, P3971, DOI 10.1091/mbc.10.11.3971; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; Ruiz-Echevarria MJ, 2001, J BIOL CHEM, V276, P30995, DOI 10.1074/jbc.M010833200; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Tharun S, 1999, GENETICS, V151, P1273; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; vanHoof A, 1996, PLANT J, V10, P415, DOI 10.1046/j.1365-313x.1996.10030415.x; Wang J, 2002, EMBO REP, V3, P274, DOI 10.1093/embo-reports/kvf036; Wilusz CJ, 2001, GENE DEV, V15, P2781	32	113	115	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 16	2003	113	4					533	545		10.1016/S0092-8674(03)00353-2	http://dx.doi.org/10.1016/S0092-8674(03)00353-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757713	Bronze			2022-12-28	WOS:000182981500014
J	Hampsey, M; Reinberg, D				Hampsey, M; Reinberg, D			Tails of intrigue: Phosphorylation of RNA polymerase II mediates histone methylation	CELL			English	Review							ELONGATION-FACTORS; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; IN-VIVO; COMPLEX; TRANSCRIPTION	Histone lysine methylation plays a key role in the organization of chromatin structure and the regulation of gene expression. Recent studies demonstrated that the yeast Set1 and Set2 histone methyltransferases are recruited to mRNA coding regions by the PAF transcription elongation complex in a manner dependent upon the phosphorylation state of the carboxy-terminal domain of RNA polymerase II. These studies define an unexpected link between transcription elongation and histone methylation.	Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Reinberg, D (corresponding author), Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Reinberg, Danny/0000-0003-4288-2016				Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; Jenuwein H, 2002, SCIENCE, V297, P2215, DOI 10.1126/science.1077903; Khan AU, 2002, TRENDS GENET, V18, P387, DOI 10.1016/S0168-9525(02)02746-4; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; KROGAN NJ, 2003, IN PRESS MOL CELL BI, V23; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; VAQUERO A, 2003, SCI STKE; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503	21	251	258	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	2003	113	4					429	432		10.1016/S0092-8674(03)00360-X	http://dx.doi.org/10.1016/S0092-8674(03)00360-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757703	Bronze			2022-12-28	WOS:000182981500004
J	Iakova, P; Awad, SS; Timchenko, NA				Iakova, P; Awad, SS; Timchenko, NA			Aging reduces proliferative capacities of liver by switching pathways of C/EBP alpha growth arrest	CELL			English	Article							TERMINAL ADIPOCYTE DIFFERENTIATION; ENHANCER BINDING-PROTEIN; RETINOBLASTOMA PROTEIN; NEWBORN MICE; C-MYC; REGENERATION; TARGET; GRANULOPOIESIS; ADIPOGENESIS; EXPRESSION	The liver is capable of completely regenerating itself in response to injury and after partial hepatectomy. In liver of old animals, the proliferative response is dramatically reduced, the mechanism for which is unknown. The liver specific protein, C/EBPalpha, normally arrests proliferation of hepatocytes through inhibiting cyclin dependent kinases (cdks). We present evidence that aging switches the liver-specific pathway of C/EBPalpha growth arrest to repression of E2F transcription. We identified an age-specific C/EBPalpha-Rb-E2F4 complex that binds to E2F-dependent promoters and represses these genes. The C/EBPalpha-Rb-E2F4 complex occupies the c-myc promoter and blocks induction of c-myc in livers of old animals after partial hepatectomy. Our results show that the age-dependent switch from cdk inhibition to repression of E2F transcription causes a loss of proliferative response in the liver because of an inability to induce E2F target genes after partial hepatectomy providing a possible mechanism for the age-dependent loss of liver regenerative capacity.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Timchenko, NA (corresponding author), Baylor Coll Med, Huffington Ctr Aging, 1 Baylor Plaza, Houston, TX 77030 USA.				NIA NIH HHS [AG20752-01, AG00765] Funding Source: Medline; NIGMS NIH HHS [GM55188] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG020752] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arora V, 2000, J PHARMACOL EXP THER, V292, P921; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BUCHER NLR, 1964, CANCER RES, V24, P509; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FRY M, 1984, J CELL PHYSIOL, V118, P225, DOI 10.1002/jcp.1041180302; JANSENDURR P, 1994, CELL CYCLE MAT METHO, P243; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; STROBER BE, 1996, MOL CELL BIOL, V16, P1567; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1998, NUCLEIC ACIDS RES, V26, P3293, DOI 10.1093/nar/26.13.3293; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	26	189	194	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 16	2003	113	4					495	506		10.1016/S0092-8674(03)00318-0	http://dx.doi.org/10.1016/S0092-8674(03)00318-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757710	Bronze			2022-12-28	WOS:000182981500011
J	Paul, WE; Germain, RN				Paul, WE; Germain, RN			Charles A. Janeway Jr (1943-2003) - Obituary	NATURE			English	Biographical-Item									NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Paul, WE (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.		Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000403, Z01AI000926] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		JANEWAY CA, PUBLICATION LIST	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					237	237		10.1038/423237a	http://dx.doi.org/10.1038/423237a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748629				2022-12-28	WOS:000182853100030
J	Illing, J; van Zwanenberg, T; Cunningham, WF; Taylor, G; O'Halloran, C; Prescott, R				Illing, J; van Zwanenberg, T; Cunningham, WF; Taylor, G; O'Halloran, C; Prescott, R			Preregistration house officers in general practice: review of evidence	BRITISH MEDICAL JOURNAL			English	Article							VIEWS; EXPERIENCES; ROTATIONS	Objectives To examine the strengths and weaknesses of the national and local schemes for preregistration house officers to spend four months in general practice, to identify any added value from such placements, and to examine the impact on career choices. Design Review of A studies that reported on placements of preregistration house officers in general practice. Setting 19 accounts of preregistration house officers' experience in general practice, ranging from single case reports to a national evaluation study, in a variety of locations in Scotland and England. Participants Views of 180 preregistration house officers, 45 general practitioner trainers, and 105 consultant trainers. Main outcome measures Main findings or themes weighted according to number of studies reporting them and weighted for sample size. Results The studies were unanimous about the educational benefits of the placements. The additional learning included communication skills, social and psychological factors in illness, patient centred consultations, broadening of knowledge base, and dealing with uncertainty about diagnosis and referral. Conclusions Despite the reported benefits and recommendations of the scheme, it is not expanding. General practitioner trainers reported additional supervision that was unremunerated. The reforms of the senior house officer grade may resolve this problem by offering the placements to senior house officers, who require less supervision.	Univ Newcastle Upon Tyne, Postgrad Inst Med & Dent, Newcastle Upon Tyne NE4 2AB, Tyne & Wear, England; Corbridge Hlth Ctr, Corbridge NE45 5JW, Northd, England; Univ Leeds, Dept NHS Postgrad Med & Dent Educ Yorkshire, Leeds LS2 9JT, W Yorkshire, England; Southampton Gen Hosp, New Generat Project, Southampton SO16 6YD, Hants, England; Bishop Auckland Gen Hosp, S Durham Hlth Care NHS Trust, Bishop Auckland DL14 6AD, Durham, England	Newcastle University - UK; University of Leeds; University of Southampton	Illing, J (corresponding author), Univ Newcastle Upon Tyne, Postgrad Inst Med & Dent, Newcastle Upon Tyne NE4 2AB, Tyne & Wear, England.			Illing, Jan/0000-0001-6218-9775; O'Halloran, Catherine/0000-0002-2780-2260				BLACKAMORE M, 2002, BRIT MED J, V324, P111; Cohen M, 1998, HOSP MED, V59, P502; DONALDSON L, 2002, CHIEF MED OFFICER UN; Edwards C, 1997, MED EDUC, V31, P237, DOI 10.1111/j.1365-2923.1997.tb02919.x; FREEMAN GK, 1982, BRIT MED J, V284, P1379, DOI 10.1136/bmj.284.6326.1379; Fuglsang H, 1996, Ugeskr Laeger, V158, P5768; *GEN MED COUNC, 1998, NEW DOCT SUPPL GEN C; Grant J, 2000, PREREGISTRATION HOUS; Greenwood KH, 2001, MED EDUC, V35, P305, DOI 10.1046/j.1365-2923.2001.0901b.x; HARRIS CM, 1985, BRIT MED J, V290, P1811, DOI 10.1136/bmj.290.6484.1811; HEWITT N, 2002, ED GEN PRACT, V12, P185; Holden J, 1997, NEW ZEAL MED J, V110, P377; Illing J, 1999, MED EDUC, V33, P894, DOI 10.1046/j.1365-2923.1999.00411.x; ILLINGWORTH C, 1994, BRIT MED J, V308, P1109, DOI 10.1136/bmj.308.6936.1109; MCGUINNESS BW, 1982, PRACTITIONER, V226, P1216; MOORE I, 2000, ED GEN PRACT, V11, P329; OSWALD N, 1989, MED EDUC, V23, P322, DOI 10.1111/j.1365-2923.1989.tb01556.x; OSWALD N, 1998, BRIT MED J, V317, P2; PAGE J, 2001, EVALUATION EXPERIENC; Parsons S, 1998, QUALITATIVE EVALUATI; ROWANROBINSON M, 2000, ED GEN PRACT, V11, P259; Taylor DN, 1997, WILD ENVIRON MED, V8, P51, DOI 10.1580/1080-6032(1997)008[0051:LTBB]2.3.CO;2; Thistlethwaite JE, 2002, MED EDUC, V36, P49, DOI 10.1046/j.1365-2923.2002.01102.x; Williams C, 2000, MED EDUC, V34, P716, DOI 10.1046/j.1365-2923.2000.00688.x; Williams C, 2001, FAM PRACT, V18, P619, DOI 10.1093/fampra/18.6.619; Williams C, 2001, MED EDUC, V35, P774, DOI 10.1046/j.1365-2923.2001.00979.x; Williams C, 2001, MED EDUC, V35, P572, DOI 10.1046/j.1365-2923.2001.00922.x; WILTON J, 1995, BRIT MED J, V310, P369, DOI 10.1136/bmj.310.6976.369	28	21	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1019	1022		10.1136/bmj.326.7397.1019	http://dx.doi.org/10.1136/bmj.326.7397.1019			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KG	12742926	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000182920500020
J	Oremland, RS; Stolz, JF				Oremland, RS; Stolz, JF			The ecology of arsenic	SCIENCE			English	Review							BACTERIAL DISSIMILATORY REDUCTION; MONO LAKE; ORGANOARSENIC COMPOUNDS; SP-NOV; MOBILIZATION; OXIDATION; WATER; BIOSYNTHESIS; RESPIRATION; METABOLISM	Arsenic is a metalloid whose name conjures up images of murder. Nonetheless, certain prokaryotes use arsenic oxyanions for energy generation, either by oxidizing arsenite or by respiring arsenate. These microbes are phylogenetically diverse and occur in a wide range of habitats. Arsenic cycling may take place in the absence of oxygen and can contribute to organic matter oxidation. In aquifers, these microbial reactions may mobilize arsenic from the solid to the aqueous phase, resulting in contaminated drinking water. Here we review what is known about arsenic-metabolizing bacteria and their potential impact on speciation and mobilization of arsenic in nature.	US Geol Survey, Menlo Pk, CA 94025 USA; Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA	United States Department of the Interior; United States Geological Survey; Duquesne University	Oremland, RS (corresponding author), US Geol Survey, Mailstop 480,345 Middlefield Rd, Menlo Pk, CA 94025 USA.	roremlan@usgs.gov						AFKAR E, UNPUB; AHMANN D, 1994, NATURE, V371, P750, DOI 10.1038/371750a0; Ahmann D, 1997, ENVIRON SCI TECHNOL, V31, P2923, DOI 10.1021/es970124k; ANDREAE MO, 1979, ENVIRON SCI TECHNOL, V13, P738, DOI 10.1021/es60154a001; Aposhian HV, 2000, CHEM RES TOXICOL, V13, P693, DOI 10.1021/tx000114o; Battaglia-Brunet F, 2002, J APPL MICROBIOL, V93, P656, DOI 10.1046/j.1365-2672.2002.01726.x; Blum JS, 1998, ARCH MICROBIOL, V171, P19, DOI 10.1007/s002030050673; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Chowdhury TR, 1999, NATURE, V401, P545, DOI 10.1038/44056; Christen K, 2001, ENVIRON SCI TECHNOL, V35, p184A, DOI 10.1021/es012337m; Craig P., 1989, CHEM METAL CARBON BO, V5, P437; CULLEN WR, 1989, CHEM REV, V89, P713, DOI 10.1021/cr00094a002; Cummings DE, 1999, ENVIRON SCI TECHNOL, V33, P723, DOI 10.1021/es980541c; CZARNECKI GL, 1982, POULTRY SCI, V61, P516, DOI 10.3382/ps.0610516; Dowdle PR, 1996, APPL ENVIRON MICROB, V62, P1664, DOI 10.1128/AEM.62.5.1664-1669.1996; Ehrlich HL, 2002, BOOK SOIL P, P313; Ellis PJ, 2001, STRUCTURE, V9, P125, DOI 10.1016/S0969-2126(01)00566-4; Francesconi KA, 2002, BOOK SOIL P, P51; Gihring TM, 2001, FEMS MICROBIOL LETT, V204, P335, DOI 10.1016/S0378-1097(01)00421-9; Hall LL, 1997, TOXICOL APPL PHARM, V147, P101, DOI 10.1006/taap.1997.8269; Harrington JM, 1998, ENVIRON SCI TECHNOL, V32, P2425, DOI 10.1021/es971129k; Harvey CF, 2002, SCIENCE, V298, P1602, DOI 10.1126/science.1076978; Herbel MJ, 2002, FEMS MICROBIOL ECOL, V41, P59, DOI 10.1111/j.1574-6941.2002.tb00966.x; Hoeft SE, 2002, GEOMICROBIOL J, V19, P23, DOI 10.1080/014904502317246147; Honschopp S, 1996, MICROBIOL RES, V151, P37, DOI 10.1016/S0944-5013(96)80053-X; Huber R, 2000, SYST APPL MICROBIOL, V23, P305, DOI 10.1016/S0723-2020(00)80058-2; Humayoun SB, 2003, APPL ENVIRON MICROB, V69, P1030, DOI 10.1128/AEM.69.2.1030-1042.2003; Inskeep WP, 2002, BOOK SOIL P, P183; Jackson CR, 2001, ENVIRON MICROBIOL, V3, P532, DOI 10.1046/j.1462-2920.2001.00221.x; Jones CA, 2000, SOIL SCI SOC AM J, V64, P600, DOI 10.2136/sssaj2000.642600x; Kaltreider RC, 2001, ENVIRON HEALTH PERSP, V109, P245, DOI 10.1289/ehp.01109245; KARGEL JS, 1993, ICARUS, V105, P1, DOI 10.1006/icar.1993.1108; Kneebone PE, 2002, ENVIRON SCI TECHNOL, V36, P381, DOI 10.1021/es010922h; Kohler M, 2001, CHEMOSPHERE, V42, P425, DOI 10.1016/S0045-6535(00)00060-6; Krafft T, 1998, EUR J BIOCHEM, V255, P647, DOI 10.1046/j.1432-1327.1998.2550647.x; Kuai L, 2001, APPL ENVIRON MICROB, V67, P3168, DOI 10.1128/AEM.67.7.3168-3173.2001; Langner HW, 2000, ENVIRON SCI TECHNOL, V34, P3131, DOI 10.1021/es991414z; LAVERMAN AM, 1995, APPL ENVIRON MICROB, V61, P3556, DOI 10.1128/AEM.61.10.3556-3561.1995; LIU AMF, UNPUB; Macur RE, 2001, ENVIRON SCI TECHNOL, V35, P3676, DOI 10.1021/es0105461; Macy JM, 2000, ARCH MICROBIOL, V173, P49, DOI 10.1007/s002030050007; McArthur JM, 2001, WATER RESOUR RES, V37, P109, DOI 10.1029/2000WR900270; MCBRIDE BC, 1971, BIOCHEMISTRY-US, V10, P4312, DOI 10.1021/bi00799a024; MORRISON J, 1969, J AGR FOOD CHEM, V39, P146; Mukhopadhyay R, 2002, FEMS MICROBIOL REV, V26, P311, DOI 10.1016/S0168-6445(02)00112-2; Nagorski SA, 1999, WATER RESOUR RES, V35, P3441, DOI 10.1029/1999WR900204; National Research Council, 1999, ARS DRINK WAT; Newman DK, 1997, ARCH MICROBIOL, V168, P380, DOI 10.1007/s002030050512; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; Niggemyer A, 2001, APPL ENVIRON MICROB, V67, P5568, DOI 10.1128/AEM.67.12.5568-5580.2001; Nordstrom DK, 2002, SCIENCE, V296, P2143, DOI 10.1126/science.1072375; Nordstrom DK, 2000, MINOR ELEMENTS 2000: PROCESSING AND ENVIRONMENTAL ASPECTS OF AS, SB, SE, TE, AND BI, P21; Nriagu JO, 2002, BOOK SOIL P, P1; OREMLAND RS, 1994, APPL ENVIRON MICROB, V60, P3011, DOI 10.1128/AEM.60.8.3011-3019.1994; Oremland RS, 2002, BOOK SOIL P, P273; Oremland RS, 2002, APPL ENVIRON MICROB, V68, P4795, DOI 10.1128/AEM.68.10.4795-4802.2002; Oremland RS, 2000, GEOCHIM COSMOCHIM AC, V64, P3073, DOI 10.1016/S0016-7037(00)00422-1; Pott WA, 2001, REV ENVIRON CONTAM T, V169, P165; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Salmassi TM, 2002, GEOMICROBIOL J, V19, P53, DOI 10.1080/014904502317246165; SALTIKOV CW, IN PRESS APPL ENV MI; Santini JM, 2002, GEOMICROBIOL J, V19, P67, DOI 10.1080/014904502317246174; Santini JM, 2000, APPL ENVIRON MICROB, V66, P92, DOI 10.1128/AEM.66.1.92-97.2000; Senn DB, 2002, SCIENCE, V296, P2373, DOI 10.1126/science.1072402; Smedley PL, 2001, ARSENIC EXPOSURE AND HEALTH EFFECTS IV, P9; Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5; Stolz JF, 2002, CHEMBIOCHEM, V3, P198, DOI 10.1002/1439-7633(20020301)3:2/3<198::AID-CBIC198>3.0.CO;2-C; Stolz JF, 1999, INT J SYST BACTERIOL, V49, P1177, DOI 10.1099/00207713-49-3-1177; Welch AH, 2000, GROUND WATER, V38, P589, DOI 10.1111/j.1745-6584.2000.tb00251.x; Wilkie JA, 1998, ENVIRON SCI TECHNOL, V32, P657, DOI 10.1021/es970637r; Zobrist J, 2000, ENVIRON SCI TECHNOL, V34, P4747, DOI 10.1021/es001068h	71	1104	1188	28	648	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					939	944		10.1126/science.1081903	http://dx.doi.org/10.1126/science.1081903			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738852				2022-12-28	WOS:000182719800044
J	Richmond, TJ; Davey, CA				Richmond, TJ; Davey, CA			The structure of DNA in the nucleosome core	NATURE			English	Article							B-DNA; HELIX GEOMETRY; SEQUENCE; CHROMATIN; PARTICLE; TRANSCRIPTION; RESOLUTION; CURVATURE; STABILITY; COMPLEXES	The 1.9-Angstrom-resolution crystal structure of the nucleosome core particle containing 147 DNA base pairs reveals the conformation of nucleosomal DNA with unprecedented accuracy. The DNA structure is remarkably different from that in oligonucleotides and nonhistone protein-DNA complexes. The DNA base-pair-step geometry has, overall, twice the curvature necessary to accommodate the DNA superhelical path in the nucleosome. DNA segments bent into the minor groove are either kinked or alternately shifted. The unusual DNA conformational parameters induced by the binding of histone protein have implications for sequence-dependent protein recognition and nucleosome positioning and mobility. Comparison of the 147-base-pair structure with two 146-base-pair structures reveals alterations in DNA twist that are evidently common in bulk chromatin, and which are of probable importance for chromatin fibre formation and chromatin remodelling.	ETH Honggerberg, Inst Mol Biol & Biophys, ETH Zurich, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Richmond, TJ (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, ETH Zurich, CH-8093 Zurich, Switzerland.	richmond@mol.biol.ethz.ch	Davey, Curt A/A-2182-2011					Anselmi C, 1999, J MOL BIOL, V286, P1293, DOI 10.1006/jmbi.1998.2575; ARNOTT S, 1969, ACTA CRYSTALL B-STRU, VB 25, P2192, DOI 10.1107/S0567740869005450; CALLADINE CR, 1986, J MOL BIOL, V192, P907, DOI 10.1016/0022-2836(86)90036-7; CRICK FHC, 1975, NATURE, V255, P530, DOI 10.1038/255530a0; Davey CA, 2002, P NATL ACAD SCI USA, V99, P11169, DOI 10.1073/pnas.172271399; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dickerson RE, 1997, BIOPOLYMERS, V44, P361, DOI 10.1002/(SICI)1097-0282(1997)44:4<361::AID-BIP4>3.0.CO;2-X; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; El Hassan MA, 1998, J MOL BIOL, V282, P331, DOI 10.1006/jmbi.1998.1994; ELGIN SC, 2000, CHROMATIN STRUCTURE; ElHassan MA, 1997, PHILOS T R SOC A, V355, P43, DOI 10.1098/rsta.1997.0002; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; KLUG A, 1981, NUCLEIC ACIDS RES, V9, P4267, DOI 10.1093/nar/9.17.4267; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Olson WK, 1996, CURR OPIN STRUC BIOL, V6, P242, DOI 10.1016/S0959-440X(96)80082-0; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; Packer MJ, 1998, J MOL BIOL, V280, P407, DOI 10.1006/jmbi.1998.1865; Packer MJ, 2001, J AM CHEM SOC, V123, P7399, DOI 10.1021/ja003385u; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Richmond TJ, 2000, CHROMATIN STRUCTURE, P1; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; van Holde K.E., 1988, CHROMATIN; Widom J, 2001, Q REV BIOPHYS, V34, P269, DOI 10.1017/S0033583501003699; Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; YANAGI K, 1991, J MOL BIOL, V217, P201, DOI 10.1016/0022-2836(91)90620-L; YOUNG MA, 1995, BIOPHYS J, V68, P2454, DOI 10.1016/S0006-3495(95)80427-3; ZIVANOVIC Y, 1988, J MOL BIOL, V200, P267, DOI 10.1016/0022-2836(88)90239-2	40	913	941	4	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					145	150		10.1038/nature01595	http://dx.doi.org/10.1038/nature01595			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736678				2022-12-28	WOS:000182699600039
J	Spurny, P; Oberst, J; Heinlein, D				Spurny, P; Oberst, J; Heinlein, D			Photographic observations of Neuschwanstein, a second meteorite from the orbit of the Pribram chondrite	NATURE			English	Article							ASTEROID STREAMS; METEOROIDS; FIREBALLS; NETWORK	Photographic observations of meteoroids passing through the atmosphere provide information about the population of interplanetary bodies in the Earth's vicinity in the size range from 0.1 m to several metres. It is extremely rare that any of these meteoroids survives atmospheric entry to be recovered as a meteorite on the ground. Pribram was the first meteorite (an ordinary chondrite) with a photographically determined orbit; it fell on 7 April 1959 (ref. 1). Here we report the fourth meteorite fall to be captured by camera networks. We determined the atmospheric trajectory and pre-atmospheric orbit of the object from the photographic records. One 1.75-kg meteorite-named Neuschwanstein and classified as an enstatite chondrite(2)-was recovered within the predicted impact area. The bolide's heliocentric orbit is exceptional as it is almost identical to the orbit of Pribram, suggesting that we have discovered a 'stream' of meteoritic objects in an Earth-crossing orbit. The chemical classifications and cosmic-ray exposure ages of the two meteorites are quite different, however, which implies a heterogeneous stream.	Acad Sci Czech Republ, Inst Astron, Ondrejov Observ, CS-25165 Ondrejov, Czech Republic; DLR, Inst Space Sensor Technol & Planetary Explorat, D-12489 Berlin, Germany; DLR Fireball Network, D-86156 Augsburg, Germany	Czech Academy of Sciences; Astronomical Institute of the Czech Academy of Sciences; Helmholtz Association; German Aerospace Centre (DLR)	Spurny, P (corresponding author), Acad Sci Czech Republ, Inst Astron, Ondrejov Observ, CS-25165 Ondrejov, Czech Republic.		Spurny, Pavel/G-9044-2014; Spurný, Pavel/X-9268-2019	Spurný, Pavel/0000-0001-5944-3090				Bischoff A., 2003, LUNAR PLANET SCI C, V34, P1212; BOROVICKA J, 1995, ASTRON ASTROPHYS SUP, V112, P173; BOROVICKA J, 2001, METEORIT PLANET SC S, V36, pA25; BROWN P, 1994, NATURE, V367, P624, DOI 10.1038/367624a0; CEPLECHA Z, 1987, B ASTRON I CZECH, V38, P222; CEPLECHA Z, 1977, B ASTRON I CZECH, V28, P328; CEPLECHA Z, 1993, ASTRON ASTROPHYS, V279, P615; Ceplecha Z., 1961, BAICZ, V12, P21; DODD RT, 1993, J GEOPHYS RES-PLANET, V98, P15105, DOI 10.1029/93JE01331; DRUMMOND JD, 1981, ICARUS, V45, P545, DOI 10.1016/0019-1035(81)90020-8; DRUMMOND JD, 1991, ICARUS, V89, P14, DOI 10.1016/0019-1035(91)90084-7; Drummond JD, 2000, ICARUS, V146, P453, DOI 10.1006/icar.2000.6401; HALLIDAY I, 1987, ICARUS, V69, P550, DOI 10.1016/0019-1035(87)90023-6; HALLIDAY I, 1978, J ROY ASTRON SOC CAN, V72, P15; HALLIDAY I, 1990, METEORITICS, V25, P93, DOI 10.1111/j.1945-5100.1990.tb00981.x; HALLIDAY I, 1983, HIGHLIGHTS ASTRONOMY, V6, P399; JENNISKENS P, 1992, ASTRON ASTROPHYS, V255, P373; McCrosky R. E., 1965, SAO SPECIAL REPORT, V173, P1; MCCROSKY RE, 1971, J GEOPHYS RES, V76, P4090, DOI 10.1029/JB076i017p04090; Oberst J, 1998, METEORIT PLANET SCI, V33, P49, DOI 10.1111/j.1945-5100.1998.tb01606.x; OSTRO SJ, 2000, DPS M, V32; Stauffer H., 1962, B ASTRON I CZECH, V13, P106; TREIMAN AH, 1993, METEORITICS, V28, P246, DOI 10.1111/j.1945-5100.1993.tb00765.x	23	101	102	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					151	153		10.1038/nature01592	http://dx.doi.org/10.1038/nature01592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736679				2022-12-28	WOS:000182699600040
J	Tishler, PV; Larkin, EK; Schluchter, MD; Redline, S				Tishler, PV; Larkin, EK; Schluchter, MD; Redline, S			Incidence of sleep-disordered breathing in an urban adult population - The relative importance of risk factors in the development of sleep-disordered breathing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE AIRWAY PRESSURE; CARDIOVASCULAR-DISEASE; FAMILIAL AGGREGATION; AFRICAN-AMERICANS; APNEA-HYPOPNEA; MEN; PREVALENCE; COMMUNITY; GENETICS; VALIDITY	Context Sleep-disordered breathing (SDB) is both prevalent and associated with serious chronic illness. The incidence of SDB and the effect of risk factors on this incidence are unknown. Objective To determine the 5-year incidence of SDB overall and as influenced by risk factors. Design, Setting, and Participants Of the 1149 participants in the Cleveland Family Study, those aged 18 years or older, from either case or control families, who had 2 in-home sleep studies 5 years apart. The first had to have been performed before June 30, 1997, and had to have normal results (apnea hypopnea index [AHI] <5). Data included questionnaire information on medical and family history, SDB symptoms; measurement of height, weight, blood pressure, waist and hip circumference, and serum cholesterol concentration; and overnight sleep monitoring. Main Outcome Measure Apnea hypopnea index, defined as number of apneas and hypopneas per hour of sleep. Sleep-disordered breathing was defined by an AHI of at least 10 (mild to moderate) or of at least 15 (moderate). Results Forty-seven (16%) of 286 eligible participants, (95% confidence interval [CI], 13%-21%) had a second-study AHI of at least 10 and 29 (10%) participants (95% CI, 7%-14%) had a second-study AHI result of at least 15. For the AHI results of at least 15, we estimate that about 2.5% may represent test variability. By ordinal logistic regression analysis, AHI was significantly associated with age (odds ratio [OR] per 10-year increase, 1.79; 95% CI, 1.41-2.27), body mass index (BMI; OR per 1-unit increase, 1.14; 95% CI, 1.10-1.19), sex (OR for men Vs women, 4.12; 95% CI, 2.29-7.43), waist-hip ratio (OR per 0.1 unit increase, 1.61; 95% CI, 1.04-2.28), and serum cholesterol concentration (OR per 10-mg/dL [0.25-mmol/L] increase, 1.11; 95% Cl, 1.03-1.19). Interactions were noted between age and both sex (P=.003) and BMI (P=.05). The OR for increased AHI per 10-year age increase was 2.41 in women (95% CI, 1.78-3.26) and 1.15 in men (95% CI, 0.78-1.68), with the male vs female OR decreasing from 5.04 (95% CI, 2.19-11.6) at age 30 years to 0.54 (95% CI, 0.15-1.99) at age 60 years. The OR for increased AHI per 1-unit increase in BMI decreased from 1.21 (95% CI, 1.11-1.31) at age 20 years to 1.05 (95% CI, 0.96-1.15) at age 60 years. Conclusions The 5-year incidence is about 7.5% for moderately severe SDB and 16% (or less) for mild to moderately severe SDB. Incidence of SDB is influenced independently by age, sex, BMI, waist-hip ratio, and serum cholesterol concentration. Predominance in men diminishes with increasing age, and by age 50 years, incidence rates among men and women are similar. The effect of BMI also decreases with age and may be negligible at age 60 years.	Vet Affairs Boston Healthcare Syst, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Tishler, PV (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	peter.tishler@channing.harvard.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046380, T32HL007567] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00080-39] Funding Source: Medline; NHLBI NIH HHS [T32-HL07567, HL46380] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alchanatis M, 2001, RESPIRATION, V68, P566, DOI 10.1159/000050574; Asplund R, 1999, DRUG AGING, V14, P91, DOI 10.2165/00002512-199914020-00002; Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079; Bixler EO, 2001, AM J RESP CRIT CARE, V163, P608, DOI 10.1164/ajrccm.163.3.9911064; BRESNITZ EA, 1994, EPIDEMIOL REV, V16, P210, DOI 10.1093/oxfordjournals.epirev.a036151; Buxbaum SG, 2002, GENET EPIDEMIOL, V22, P243, DOI 10.1002/gepi.0170; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Ficker JH, 1998, EUR RESPIR J, V11, P14, DOI 10.1183/09031936.98.11010014; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FLIER JS, 1998, WILLIAMS TXB ENDOCRI, P1061; GISLASON T, 1988, J CLIN EPIDEMIOL, V41, P571, DOI 10.1016/0895-4356(88)90061-3; GORDON T, 1973, DHEW PUBLICATION NIH; Henriksson KM, 2001, EUR J EPIDEMIOL, V17, P521, DOI 10.1023/A:1014508422504; Ip MSM, 2001, CHEST, V119, P62, DOI 10.1378/chest.119.1.62; Javaheri S, 2000, CIRCULATION, V101, P392, DOI 10.1161/01.CIR.101.4.392; Kadotani H, 2001, JAMA-J AM MED ASSOC, V285, P2888, DOI 10.1001/jama.285.22.2888; KUMP K, 1994, AM J RESP CRIT CARE, V150, P735, DOI 10.1164/ajrccm.150.3.8087345; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; Leung RST, 2001, AM J RESP CRIT CARE, V164, P2147, DOI 10.1164/ajrccm.164.12.2107045; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mooe T, 2001, AM J RESP CRIT CARE, V164, P1910, DOI 10.1164/ajrccm.164.10.2101072; Newman AB, 2001, AM J EPIDEMIOL, V154, P50, DOI 10.1093/aje/154.1.50; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Quan SF, 2002, SLEEP, V25, P843; REDLINE S, 1995, AM J RESP CRIT CARE, V151, P682; Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310; REDLINE S, 1992, AM REV RESPIR DIS, V145, P440, DOI 10.1164/ajrccm/145.2_Pt_1.440; REDLINE S, 1991, CHEST, V100, P1281, DOI 10.1378/chest.100.5.1281; Redline S, 2002, LUNG BIOL HEALTH DIS, V166, P235; Redline S, 2001, SLEEP, V24, pA294; REDLINE S, 1994, AM J RESP CRIT CARE, V149, P722, DOI 10.1164/ajrccm.149.3.8118642; REDLINE S, 1991, SLEEP RESPIRATION AG, P189; Saarelainen S, 1998, CLIN GENET, V53, P147; SAHAR E, 2003, IN PRESS AM J RESP C; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; Stokes ME, 2000, CATEGORICAL DATA ANA; Williamson JM, 1999, COMPUT METH PROG BIO, V58, P25, DOI 10.1016/S0169-2607(98)00063-7; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	40	308	321	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2230	2237		10.1001/jama.289.17.2230	http://dx.doi.org/10.1001/jama.289.17.2230			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675ET	12734134	Bronze			2022-12-28	WOS:000182680700025
J	Schimmel, P; Tamura, K				Schimmel, P; Tamura, K			tRNA structure goes from L to lambda	CELL			English	Editorial Material							PHENYLALANINE TRANSFER-RNA	In this issue of Cell, Ishitani et al. (2003) report, in a crystal, a new L-like structure of tRNA designated as X-form, where disruption of universal tertiary interactions is compensated by interactions with an enzyme that makes a base modification at the corner of the L.	Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, BCC379,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							DIGIULIO M, 1992, J THEOR BIOL, V159, P199; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Motorin Y., 2001, ENCY LIFE SCI, P1; Noller H.F., 1993, RNA WORLD, P137; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Rodin S, 1996, P NATL ACAD SCI USA, V93, P4537, DOI 10.1073/pnas.93.10.4537; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146	10	5	5	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					276	278		10.1016/S0092-8674(03)00313-1	http://dx.doi.org/10.1016/S0092-8674(03)00313-1			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732135	Bronze			2022-12-28	WOS:000182640800002
J	Herr, AB; Ballister, ER; Bjorkman, PJ				Herr, AB; Ballister, ER; Bjorkman, PJ			Insights into IgA-mediated immune responses from the crystal structures of human Fc alpha RI and its complex with IgA1-Fc	NATURE			English	Article							INHIBITORY RECEPTOR; LIGAND-BINDING; IMMUNOGLOBULIN; DOMAIN; FRAGMENT; ACTIVATION; REVEALS; CD89; IDENTIFICATION; REFINEMENT	Immunoglobulin-alpha (IgA)-bound antigens induce immune effector responses by activating the IgA-specific receptor FcalphaRI (CD89) on immune cells. Here we present crystal structures of human FcalphaRI alone and in a complex with the Fcalpha region of IgA1 (Fcalpha). FcalphaRI has two immunoglobulin-like domains that are oriented at approximately right angles to each other. Fcalpha resembles the Fcs of immunoglobulins IgG and IgE, but has differently located interchain disulphide bonds and external rather than interdomain N-linked carbohydrates. Unlike 1:1 FcgammaRIII:IgG and FcepsilonRI:IgE complexes, two FcalphaRI molecules bind each Fcalpha dimer, one at each Calpha2-Calpha3 junction. The FcalphaRI-binding site on IgA1 overlaps the reported polymeric immunoglobulin receptor (pIgR)-binding site, which might explain why secretory IgA cannot initiate phagocytosis or bind to FcalphaRI-expressing cells in the absence of an integrin co-receptor.	CALTECH, Div Biol 114 96, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; La Salle High Sch, Pasadena, CA 91107 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Bjorkman, PJ (corresponding author), CALTECH, Div Biol 114 96, Pasadena, CA 91125 USA.	bjorkman@caltech.edu	Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Ballister, Edward/0000-0002-4478-2513				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bracke M, 2001, BLOOD, V97, P3478, DOI 10.1182/blood.V97.11.3478; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P141, DOI 10.1016/S0167-5699(98)01413-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; Chapman TL, 2000, IMMUNITY, V13, P727, DOI 10.1016/S1074-7613(00)00071-6; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Garman SC, 2001, J MOL BIOL, V311, P1049, DOI 10.1006/jmbi.2001.4929; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Hexham JM, 1999, J EXP MED, V189, P747, DOI 10.1084/jem.189.4.747; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; Iikura M, 1998, J IMMUNOL, V161, P1510; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MONTEIRO RC, 1990, J EXP MED, V171, P597, DOI 10.1084/jem.171.3.597; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Morton HC, 1999, J EXP MED, V189, P1715; Motegi Y, 1998, J IMMUNOL, V161, P4340; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Norderhaug IN, 1999, CRIT REV IMMUNOL, V19, P481; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; PUTNAM FW, 1979, J BIOL CHEM, V254, P2865; Saphire EO, 2002, J MOL BIOL, V319, P9, DOI 10.1016/S0022-2836(02)00244-9; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van Egmond M, 2000, NAT MED, V6, P680, DOI 10.1038/76261; van Spriel AB, 2001, BLOOD, V97, P2478, DOI 10.1182/blood.V97.8.2478; Vidarsson G, 2001, J IMMUNOL, V166, P6250, DOI 10.4049/jimmunol.166.10.6250; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; White KD, 2002, J EXP MED, V196, P551, DOI 10.1084/jem.20020581; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6; YANG CY, 1979, H-S Z PHYSIOL CHEM, V360, P1919	50	210	227	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2003	423	6940					614	620		10.1038/nature01685	http://dx.doi.org/10.1038/nature01685			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12768205	Bronze			2022-12-28	WOS:000183301200033
J	McDonald, D; Wu, L; Bohks, SM; KewalRamani, VN; Unutmaz, D; Hope, TJ				McDonald, D; Wu, L; Bohks, SM; KewalRamani, VN; Unutmaz, D; Hope, TJ			Recruitment of HIV and its receptors to dendritic cell-T cell junctions	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DC-SIGN; IMMUNOLOGICAL SYNAPSE; ANTIGEN	Monocyte-derived dendritic cells (MDDCs) can efficiently bind and transfer HIV infectivity without themselves becoming infected. Using live-cell microscopy, we found that HIV was recruited to sites of cell contact in MDDCs. Analysis of conjugates between MDDCs and T cells revealed that, in the absence of antigen-specific signaling, the HIV receptors CD4, CCR5, and CXCR4 on the T cell were recruited to the interface while the MDDCs concentrated HIV to the same region. We propose that contact between dendritic cells and T cells facilitates transmission of HIV by locally concentrating virus, receptor, and coreceptor during the formation of an infectious synapse.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37232 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University	Hope, TJ (corresponding author), Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA.	thope@uic.edu	KewalRamani, Vineet/V-5084-2019; Wu, Li/E-4330-2011; Wu, Li/ABB-2813-2020	Wu, Li/0000-0002-5468-2487; Wu, Li/0000-0002-5468-2487	NIAID NIH HHS [R01-AI52051, R01-AI49131, R01-AI47770, R01 AI052051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052051, R01AI049131, R01AI047770] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Frank I, 2002, J VIROL, V76, P2936, DOI 10.1128/JVI.76.6.2936-2951.2002; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; LOZACH PY, J BIOL CHEM     0227; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; MCDONALD D, UNPUB; Revy P, 2001, NAT IMMUNOL, V2, P925, DOI 10.1038/ni713; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sanders RW, 2002, J VIROL, V76, P7812, DOI 10.1128/JVI.76.15.7812-7821.2002; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841	19	559	578	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1295	1297		10.1126/science.1084238	http://dx.doi.org/10.1126/science.1084238			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12730499				2022-12-28	WOS:000183042400050
J	Foster, GD; Wyatt, HR; Hill, JO; McGuckin, BG; Brill, C; Mohammed, BS; Szapary, PO; Rader, DJ; Edman, JS; Klein, S				Foster, GD; Wyatt, HR; Hill, JO; McGuckin, BG; Brill, C; Mohammed, BS; Szapary, PO; Rader, DJ; Edman, JS; Klein, S			A randomized trial of a low-carbohydrate diet for obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; WEIGHT-LOSS; PLASMA-LIPOPROTEINS; INSULIN SENSITIVITY; RISK FACTOR; NUTRITION; PREVALENCE; REDUCTION; DISEASE; ADULTS	BACKGROUND: Despite the popularity of the low-carbohydrate, high-protein, high-fat (Atkins) diet, no randomized, controlled trials have evaluated its efficacy. METHODS: We conducted a one-year, multicenter, controlled trial involving 63 obese men and women who were randomly assigned to either a low-carbohydrate, high-protein, high-fat diet or a low-calorie, high-carbohydrate, low-fat (conventional) diet. Professional contact was minimal to replicate the approach used by most dieters. RESULTS: Subjects on the low-carbohydrate diet had lost more weight than subjects on the conventional diet at 3 months (mean [+/-SD], -6.8+/-5.0 vs. -2.7+/-3.7 percent of body weight; P=0.001) and 6 months (-7.0+/-6.5 vs. -3.2+/-5.6 percent of body weight, P=0.02), but the difference at 12 months was not significant (-4.4+/-6.7 vs. -2.5+/-6.3 percent of body weight, P=0.26). After three months, no significant differences were found between the groups in total or low-density lipoprotein cholesterol concentrations. The increase in high-density lipoprotein cholesterol concentrations and the decrease in triglyceride concentrations were greater among subjects on the low-carbohydrate diet than among those on the conventional diet throughout most of the study. Both diets significantly decreased diastolic blood pressure and the insulin response to an oral glucose load. CONCLUSIONS: The low-carbohydrate diet produced a greater weight loss (absolute difference, approximately 4 percent) than did the conventional diet for the first six months, but the differences were not significant at one year. The low-carbohydrate diet was associated with a greater improvement in some risk factors for coronary heart disease. Adherence was poor and attrition was high in both groups. Longer and larger studies are required to determine the long-term safety and efficacy of low-carbohydrate, high-protein, high-fat diets.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Washington Univ, Sch Med, St Louis, MO USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	University of Pennsylvania; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Washington University (WUSTL); Jefferson University	Foster, GD (corresponding author), Univ Penn, Sch Med, 3535 Market St,Suite 3027, Philadelphia, PA 19104 USA.	fosterg@mail.med.upenn.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK002703, R01DK037948, P30DK048520, R37DK042549, R01DK042549, P30DK056341] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT1103, AT00058] Funding Source: Medline; NCRR NIH HHS [RR00036, RR00051, RR00040] Funding Source: Medline; NIDDK NIH HHS [DK 56341, DK 37948, DK48520, DK42549, DK02703] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; [Anonymous], 1997, J AM DIET ASSOC, V97, P71; Atkins RC, 1998, ATKINS NEW DIET REVO; Blackburn GL, 2001, CLEV CLIN J MED, V68, P761, DOI 10.3949/ccjm.68.9.761; Boden WE, 2000, AM J CARDIOL, V86, p19L; Brownell K. D., 2000, LEARN PROGRAM WEIGHT; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; *DEP AGR, 1992, 252 DEP AGR; Department of Health and Human Services, 2001, SURG GEN CALL ACT PR; EADES MR, 1999, PROTEIN POWER; Ferrannini E, 1997, J CLIN INVEST, V100, P1166, DOI 10.1172/JCI119628; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Forrester JS, 2001, CURR OPIN CARDIOL, V16, P261, DOI 10.1097/00001573-200107000-00007; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARG A, 1992, DIABETES, V41, P1278, DOI 10.2337/diabetes.41.10.1278; Golay A, 1996, INT J OBESITY, V20, P1067; Golay A, 1996, AM J CLIN NUTR, V63, P174, DOI 10.1093/ajcn/63.2.174; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; LAROSA JC, 1980, J AM DIET ASSOC, V77, P264; LEWIS SB, 1977, AM J CLIN NUTR, V30, P160, DOI 10.1093/ajcn/30.2.160; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Ornish D, 1999, JAMA-J AM MED ASSOC, V281, P1380; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Potteiger JA, 2002, INT J OBESITY, V26, P87, DOI 10.1038/sj.ijo.0801839; RABAST U, 1978, NUTR METAB, V22, P269; Schaefer EJ, 2002, AM J CLIN NUTR, V75, P191, DOI 10.1093/ajcn/75.2.191; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; *SPSS, 2000, SPSS 11 0 WIND; STEWARD HL, 1995, SUGAR BUSTERS; Szapary Philippe O., 2001, Current Opinion in Pharmacology, V1, P113, DOI 10.1016/S1471-4892(01)00028-5; Thomas PR, 1995, WEIGHING OPTIONS CRI; Wadden TA, 2000, MED CLIN N AM, V84, P441, DOI 10.1016/j.psc.2004.09.008; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; YANG MU, 1976, J CLIN INVEST, V58, P722, DOI 10.1172/JCI108519; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586; 2002, CONSUMER REPORTS JUN, P26; 1998, OBES RES, V6, P464	41	1126	1155	2	178	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2082	2090		10.1056/NEJMoa022207	http://dx.doi.org/10.1056/NEJMoa022207			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761365	Bronze			2022-12-28	WOS:000183008300005
J	Cheung, WL; Ajiro, K; Samejima, K; Kloc, M; Cheung, P; Mizzen, CA; Beeser, A; Etkin, LD; Chernoff, J; Earnshaw, WC; Allis, CD				Cheung, WL; Ajiro, K; Samejima, K; Kloc, M; Cheung, P; Mizzen, CA; Beeser, A; Etkin, LD; Chernoff, J; Earnshaw, WC; Allis, CD			Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase	CELL			English	Article							PROGRAMMED CELL-DEATH; STE20-LIKE PROTEIN-KINASE; HP1 CHROMO DOMAIN; DNA FRAGMENTATION; SACCHAROMYCES-CEREVISIAE; N-TERMINUS; LYSINE 9; H3; CONDENSATION; ACTIVATION	DNA in eukaryotic cells is associated with histone proteins; hence, hallmark properties of apoptosis, such as chromatin condensation, may be regulated by post-translational histone modifications. Here we report that phosphorylation of histone H2B at serine 14 (S14) correlates with cells undergoing programmed cell death in vertebrates. We identify a 34 kDa apoptosis-induced H2B kinase as caspase-cleaved Mst1 (mammalian sterile twenty) kinase. Mst1 can phosphorylate H2B at S14 in vitro and in vivo, and the onset of H2B S14 phosphorylation is dependent upon cleavage of Mst1 by caspase-3. These data reveal a histone modification that is uniquely associated with apoptotic chromatin in species ranging from frogs to humans and provide insights into a previously unrecognized physiological substrate for Mst1 kinase. Our data provide evidence for a potential apoptotic "histone code.".	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Virginia; University of Virginia; University of Edinburgh; University of Texas System; UTMD Anderson Cancer Center; Fox Chase Cancer Center	Allis, CD (corresponding author), Rockefeller Univ, Lab Chromatin Biol, 1230 York Ave, New York, NY 10021 USA.	alliscd@mail.rockefeller.edu	Kloc, Malgorzata/AAF-6982-2020; Earnshaw, William/AAY-7438-2020; Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836; Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054168, R01GM040922] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40922, GM54168] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; de la Barre AE, 2001, EMBO J, V20, P6383, DOI 10.1093/emboj/20.22.6383; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Haunstetter A, 2000, CARDIOVASC RES, V45, P795, DOI 10.1016/S0008-6363(99)00264-3; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jason LJM, 2001, J BIOL CHEM, V276, P14597, DOI 10.1074/jbc.M011153200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1974, J CELL SCI, V14, P571; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Loetscher H, 2001, DRUG DISCOV TODAY, V6, P671, DOI 10.1016/S1359-6446(01)01826-8; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Martin LJ, 2001, INT J MOL MED, V7, P455; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Th'ng JPH, 2001, BIOCHEM CELL BIOL, V79, P305, DOI 10.1139/bcb-79-3-305; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; USUKU G, 1965, DEV BIOL, V11, P352, DOI 10.1016/0012-1606(65)90044-8; VANHOLDE KE, 1988, CHROMATIN, P111; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97; Yun DJ, 1998, MOL CELL, V1, P807, DOI 10.1016/S1097-2765(00)80080-5	55	368	412	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	2003	113	4					507	517		10.1016/S0092-8674(03)00355-6	http://dx.doi.org/10.1016/S0092-8674(03)00355-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757711	Bronze			2022-12-28	WOS:000182981500012
J	Hynes, RO				Hynes, RO			Changing partners	SCIENCE			English	Editorial Material							INSIDE-OUT ACTIVATION; CYTOPLASMIC DOMAINS; INTEGRIN; TRANSMEMBRANE		MIT, Canc Res Ctr, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Hynes, RO (corresponding author), MIT, Canc Res Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	12	27	28	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					755	756		10.1126/science.1084854	http://dx.doi.org/10.1126/science.1084854			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730590				2022-12-28	WOS:000182579800036
J	Neubert, T				Neubert, T			On sprites and their exotic kin	SCIENCE			English	Editorial Material							ELECTRICAL-DISCHARGE; AIRCRAFT CAMPAIGN		Danish Space Res Inst, DK-2100 Copenhagen, Denmark	Technical University of Denmark	Neubert, T (corresponding author), Danish Space Res Inst, Juliane Maries Vej 30, DK-2100 Copenhagen, Denmark.	neubert@dsri.dk		Neubert, Torsten/0000-0001-7851-7788				Armstrong RA, 2000, GEOPHYS RES LETT, V27, P653, DOI 10.1029/1999GL003672; Barrington-Leigh CP, 1999, GEOPHYS RES LETT, V26, P683, DOI 10.1029/1999GL900059; CARLSLAW KS, 2002, SCIENCE, V298, P1732; Cummer SA, 1998, GEOPHYS RES LETT, V25, P1281, DOI 10.1029/98GL50937; FISHMAN GJ, 1994, SCIENCE, V264, P1313, DOI 10.1126/science.264.5163.1313; FRANZ RC, 1990, SCIENCE, V249, P48, DOI 10.1126/science.249.4964.48; Gerken EA, 2000, GEOPHYS RES LETT, V27, P2637, DOI 10.1029/2000GL000035; Inan US, 1997, GEOPHYS RES LETT, V24, P583, DOI 10.1029/97GL00404; Morrill J, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014018; Neubert T, 2001, GEOPHYS RES LETT, V28, P3585, DOI 10.1029/2001GL013427; Pasko VP, 1997, J GEOPHYS RES-SPACE, V102, P4529, DOI 10.1029/96JA03528; Pasko VP, 2002, NATURE, V416, P152, DOI 10.1038/416152a; RousselDupre R, 1996, J GEOPHYS RES-SPACE, V101, P2297, DOI 10.1029/95JA03278; SENTMAN DD, 1995, GEOPHYS RES LETT, V22, P1205, DOI 10.1029/95GL00583; Stenbaek-Nielsel HC, 2000, GEOPHYS RES LETT, V27, P3829, DOI 10.1029/2000GL003827; WESCOTT EM, 1995, GEOPHYS RES LETT, V22, P1209, DOI 10.1029/95GL00582	16	61	61	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					747	+		10.1126/science.1083006	http://dx.doi.org/10.1126/science.1083006			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730585				2022-12-28	WOS:000182579800031
J	Dalton, R				Dalton, R			Threat of closure hangs heavy over primate centre	NATURE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					471	471		10.1038/423471b	http://dx.doi.org/10.1038/423471b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774087	Bronze			2022-12-28	WOS:000183162900012
J	Gonzales, R				Gonzales, R			A 65-year-old woman with acute cough illness and an important engagement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RESISTANT STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY-TRACT INFECTIONS; ACUTE UNCOMPLICATED CYSTITIS; ACUTE BRONCHITIS; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC USE; DOUBLE-BLIND; DECREASED SUSCEPTIBILITY; PNEUMOCOCCAL PNEUMONIA; INCREASING PREVALENCE		Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94118 USA	University of California System; University of California San Francisco	Gonzales, R (corresponding author), Univ Calif San Francisco, Dept Med, Div Gen Internal Med, 3333 Calif St,Box 1211,Suite 430, San Francisco, CA 94118 USA.	ralphg@medicine.ucsf.edu						Adams P F, 1995, Vital Health Stat 10, P1; Akram J, 1998, INFECT CONT HOSP EP, V19, P106; Armstrong GL, 1999, ARCH INTERN MED, V159, P2531, DOI 10.1001/archinte.159.21.2531; BECKER L, 1999, ANTIBIOTICS ACUTE BR; Bent S, 1999, AM J MED, V107, P62, DOI 10.1016/S0002-9343(99)00167-9; Birnbaum HG, 2002, CHEST, V122, P603, DOI 10.1378/chest.122.2.603; Bradley JS, 1995, PEDIATR INFECT DIS J, V14, P1037, DOI 10.1097/00006454-199512000-00002; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; CHESNEY PJ, 1995, PEDIATR INFECT DIS J, V14, P1013; DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8; Diekema DJ, 2000, EMERG INFECT DIS, V6, P552, DOI 10.3201/eid0605.000519; Doern GV, 1999, EMERG INFECT DIS, V5, P757, DOI 10.3201/eid0506.990603; Doone JL, 1997, CLIN PEDIATR, V36, P187, DOI 10.1177/000992289703600401; Douglas RM, 2000, COCHRANE DB SYST REV; Eccles R, 1996, PULM PHARMACOL THER, V9, P293, DOI 10.1006/pulp.1996.0038; EMERMAN CL, 1991, ANN EMERG MED, V20, P1215, DOI 10.1016/S0196-0644(05)81474-X; EVANS AS, 1967, MED CLIN N AM, V51, P803, DOI 10.1016/S0025-7125(16)33048-6; Evans AT, 2002, LANCET, V359, P1648, DOI 10.1016/S0140-6736(02)08597-5; Fahey T, 1998, BRIT MED J, V316, P906, DOI 10.1136/bmj.316.7135.906; Feikin DR, 2000, AM J PUBLIC HEALTH, V90, P223, DOI 10.2105/AJPH.90.2.223; Frank S, 1992, Fam Med, V24, P518; FRIEDLAND IR, 1992, LANCET, V339, P405, DOI 10.1016/0140-6736(92)90087-J; Gerberding JL, 2000, AM J MED, V108, P91, DOI 10.1016/S0002-9343(99)00439-8; Gilroy CM, 2003, ARCH INTERN MED, V163, P699, DOI 10.1001/archinte.163.6.699; Gonzales R, 2001, ANN INTERN MED, V134, P521, DOI 10.7326/0003-4819-134-6-200103200-00021; Gonzales R, 2001, Eff Clin Pract, V4, P105; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Gonzales R, 2000, AM J MED, V108, P83, DOI 10.1016/S0002-9343(99)00314-9; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Gupta K, 1999, INT J ANTIMICROB AG, V11, P305, DOI 10.1016/S0924-8579(99)00035-7; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; Hamm RM, 1996, J FAM PRACTICE, V43, P56; Hemila H, 1999, INT J TUBERC LUNG D, V3, P756; HENDLEY JO, 1988, EPIDEMIOL REV, V10, P242, DOI 10.1093/oxfordjournals.epirev.a036024; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HUESTON WJ, 1991, J FAM PRACTICE, V33, P476; HUESTON WJ, 1994, J FAM PRACTICE, V39, P437; HUTCHINSON JM, 1997, 37 INT C ANT AG CHEM; JEFFERSON TO, 1999, NEURAMINIDASE INHIBI; JOHNSON D, 1991, J ASTHMA, V28, P85, DOI 10.3109/02770909109082732; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Lederberg J, 1996, JAMA-J AM MED ASSOC, V276, P417, DOI 10.1001/jama.276.5.417; Levin BR, 1997, CLIN INFECT DIS, V24, pS9, DOI 10.1093/clinids/24.Supplement_1.S9; LEVY SB, 1976, NEW ENGL J MED, V295, P583, DOI 10.1056/NEJM197609092951103; LEVY SB, 1993, JAMA-J AM MED ASSOC, V269, P1840, DOI 10.1001/jama.269.14.1840; Lipsitch M, 2002, EMERG INFECT DIS, V8, P347, DOI 10.3201/eid0804.010312; Littenberg B, 1996, J FAM PRACTICE, V42, P49; LONKS JR, 1995, NEW ENGL J MED, V332, P893, DOI 10.1056/NEJM199503303321317; Mainous AG, 1997, J FAM PRACTICE, V45, P75; Mainous AG, 1997, LANCET, V350, P1077, DOI 10.1016/S0140-6736(05)70457-8; Mangione-Smith R, 1999, PEDIATRICS, V103, P711, DOI 10.1542/peds.103.4.711; Marco CA, 1997, ACAD EMERG MED, V4, P159, DOI 10.1111/j.1553-2712.1997.tb03728.x; Marshall I., 2000, COCHRANE DB SYST REV; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MELBYE H, 1991, FAM PRACT, V8, P216, DOI 10.1093/fampra/8.3.216; MELBYE H, 1994, EUR RESPIR J, V7, P1239, DOI 10.1183/09031936.94.07071239; Melchart D., 2000, COCHRANE DB SYST REV; Metlay JP, 2000, CLIN INFECT DIS, V30, P520, DOI 10.1086/313716; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; Metlay JP, 1997, JAMA-J AM MED ASSOC, V278, P1440, DOI 10.1001/jama.278.17.1440; Metlay JP, 2002, J GEN INTERN MED, V17, P87, DOI 10.1046/j.1525-1497.2002.10711.x; Meza R A, 1994, Aust Fam Physician, V23, P1550; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; Monto AS, 2002, AM J MED, V112, p4S; MORENO F, 1995, J INFECT DIS, V172, P427, DOI 10.1093/infdis/172.2.427; MUSHER DM, 1995, PRINCIPLES PRACTICE, P1811; *NAT CTR INF DIS C, FLU US; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; Nuorti JP, 1998, NEW ENGL J MED, V338, P1861, DOI 10.1056/NEJM199806253382601; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; Oeffinger KC, 1997, J FAM PRACTICE, V45, P402; Pallares R, 1998, MICROB DRUG RESIST, V4, P339, DOI 10.1089/mdr.1998.4.339; Peters EM, 1997, INT J SPORTS MED, V18, pS69, DOI 10.1055/s-2007-972702; Poole Michael D., 1995, Pediatric Infectious Disease Journal, V14, pS23, DOI 10.1097/00006454-199504001-00005; Prasad AS, 2000, ANN INTERN MED, V133, P245, DOI 10.7326/0003-4819-133-4-200008150-00006; RADETSKY MS, 1981, LANCET, V2, P771; Reid R, 1995, PEDIATR INFECT DIS J, V14, P1104, DOI 10.1097/00006454-199512000-00016; ROBERTSON AJ, 1952, LANCET, V262, P12; Rubin Michael A., 2002, Curr Infect Dis Rep, V4, P491, DOI 10.1007/s11908-002-0034-y; Schrag SJ, 2001, JAMA-J AM MED ASSOC, V286, P49, DOI 10.1001/jama.286.1.49; Scott JG, 2001, J FAM PRACTICE, V50, P853; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Teuber M, 2001, CURR OPIN MICROBIOL, V4, P493, DOI 10.1016/S1369-5274(00)00241-1; TUKIAINEN H, 1986, EUR J RESPIR DIS, V69, P95; Turner RB, 2000, CLIN INFECT DIS, V31, P1202, DOI 10.1086/317437; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; WILLIAMSON HA, 1987, J FAM PRACTICE, V25, P251; Wilson AA, 1999, J GEN INTERN MED, V14, P658, DOI 10.1046/j.1525-1497.1999.08118.x; Wright SW, 1999, J GEN INTERN MED, V14, P606, DOI 10.1046/j.1525-1497.1999.10128.x; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044	96	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2701	2708		10.1001/jama.289.20.2701	http://dx.doi.org/10.1001/jama.289.20.2701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682DG	12771117				2022-12-28	WOS:000183075600029
J	Gray, J; Orr, D; Majeed, A				Gray, J; Orr, D; Majeed, A			Use of Read codes in diabetes management in a south London primary care group: implications for establishing disease registers	BRITISH MEDICAL JOURNAL			English	Article							MELLITUS; PEOPLE	Objective To establish current practice in the use of Read codes for diabetes. Design Cross sectional study. Setting 17 practices in the Battersea primary care group in southwest London. Data sources Computerised medical records. Main outcome measures Number of codes in use in all practices; variation in the use of codes between practices; and prevalence of Read code use in diabetic patients. Results At least 9 separate Read code groupings and 25 individual diabetes codes were in use in the 17 general practices. Only one Read code (C 10, diabetes mellitus) and its subcodes was being used in all 17 practices, but its use varied from 14% to 98% of patients with diabetes. The use of other key Read codes for monitoring the care of patients with diabetes also varied widely between practices; for example, < 20% of practices used the code for the location of care. Less than half of patients (45%) with diabetes had their type of diabetes coded, and even fewer (21%) had measures such as the examination of the retina coded. Conclusions The use of Read codes for diabetes needs to be standardised and coding levels improved if valid diabetic registers are to be constructed and the quality of care is to be monitored effectively. Until all patients with diabetes have the C 10 Read code recorded, clinicians will have to use a wide range of Read codes and prescribing data to ensure that diabetes registers are complete.	Bolingbroke Hosp, Battersea Res Grp, London SW11 6HN, England; UCL, Sch Publ Policy, Primary Care Res Unit, London WC1H 9QU, England	University of London; University College London	Gray, J (corresponding author), Bolingbroke Hosp, Battersea Res Grp, London SW11 6HN, England.			Majeed, Azeem/0000-0002-2357-9858				Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1; [Anonymous], 2002, HLTH STAT Q; BARDSLEY M, 2000, MAPPING HLTH PRIMARY; Benson T, 2002, BRIT MED J, V325, P1090, DOI 10.1136/bmj.325.7372.1090; BURNETT SD, 1992, BRIT MED J, V305, P627, DOI 10.1136/bmj.305.6854.627; Buxton C, 1996, DIABETIC MED, V13, pS122; CONNOLLY V, 1995, DIABETIC MED, V12, pS31; Currie CJ, 1997, DIABETIC MED, V14, P686, DOI 10.1002/(SICI)1096-9136(199708)14:8<686::AID-DIA434>3.0.CO;2-D; *DEP HLTH, 2002, DEL IT NHS; *DEP HLTH, 2000, CM4818; Department of Health, 2002, NAT SERV FRAM DIAB S; Gatling W, 1998, DIABETIC MED, V15, P1015, DOI 10.1002/(SICI)1096-9136(1998120)15:12<1015::AID-DIA719>3.0.CO;2-K; HOWITT AJ, 1993, BRIT MED J, V307, P1046, DOI 10.1136/bmj.307.6911.1046; Khunti K, 2001, BRIT J GEN PRACT, V51, P356; Khunti K, 2000, J ROY SOC MED, V93, P183, DOI 10.1177/014107680009300407; Laing SP, 1999, DIABETIC MED, V16, P459, DOI 10.1046/j.1464-5491.1999.00075.x; MACKINNON M, 1995, DIABETIC MED S, V12, pS10; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; Okkes IM, 2000, FAM PRACT, V17, P101, DOI 10.1093/fampra/17.2.101; WHITFORD DL, 1995, DIABETIC MED, V12, P691, DOI 10.1111/j.1464-5491.1995.tb00571.x	20	53	53	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1130	1132A		10.1136/bmj.326.7399.1130	http://dx.doi.org/10.1136/bmj.326.7399.1130			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763987	Green Published, Bronze			2022-12-28	WOS:000183245000024
J	Bilde-Sorensen, JB; Schiotz, J				Bilde-Sorensen, JB; Schiotz, J			Nanocrystals get twins	SCIENCE			English	Editorial Material							METALS; SIMULATION		Riso Natl Lab, Mat Res Dept, DK-4000 Roskilde, Denmark; Tech Univ Denmark, Dept Phys, DK-2800 Lyngby, Denmark	Technical University of Denmark; Technical University of Denmark	Bilde-Sorensen, JB (corresponding author), Riso Natl Lab, Mat Res Dept, DK-4000 Roskilde, Denmark.		Schiøtz, Jakob/A-5692-2011	Schiøtz, Jakob/0000-0002-0670-8013				Chen MW, 2003, SCIENCE, V300, P1275, DOI 10.1126/science.1083727; Derlet PM, 2002, SCRIPTA MATER, V47, P719, DOI 10.1016/S1359-6462(02)00182-3; NIEH TG, 1991, SCRIPTA METALL MATER, V25, P955, DOI 10.1016/0956-716X(91)90256-Z; Randle V, 1999, ACTA MATER, V47, P4187, DOI 10.1016/S1359-6454(99)00277-3; Schiotz J, 1998, NATURE, V391, P561, DOI 10.1038/35328; Tadmor EB, 1999, J MATER RES, V14, P2233, DOI 10.1557/JMR.1999.0300; Van Swygenhoven H, 1999, PHYS REV B, V60, P22, DOI 10.1103/PhysRevB.60.22; Yamakov V, 2002, ACTA MATER, V50, P5005, DOI 10.1016/S1359-6454(02)00318-X; Yamakov V, 2002, NAT MATER, V1, P45, DOI 10.1038/nmat700; Yip S, 1998, NATURE, V391, P532, DOI 10.1038/35254	10	15	16	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1244	1245		10.1126/science.1085577	http://dx.doi.org/10.1126/science.1085577			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764183				2022-12-28	WOS:000183042400032
J	McKone, EF; Emerson, SS; Edwards, KL; Aitken, ML				McKone, EF; Emerson, SS; Edwards, KL; Aitken, ML			Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study	LANCET			English	Article							DISEASE SEVERITY; MESSENGER-RNA; MUTATION; CFTR; GENE; IDENTIFICATION; DELTA-F508	Background Over 1000 mutations of the cystic fibrosis transmembrane conductance regulator gene (CFTR) that cause cystic fibrosis have been identified. We examined the effect of CFTR genotype on mortality and disease phenotype. Methods Using the US Cystic Fibrosis Foundation National Registry, we did a retrospective cohort study to compare standardised mortality rates for the 11 most common genotypes heterozygous for DeltaF508 with those homozygous for DeltaF508. Of the 28455 patients enrolled in the registry at the time of our analysis, :17 853 (63%) were genotyped. We also compared the clinical phenotype, including lung function, age at diagnosis, and nutritional measures, of 22 DeltaF508 heterozygous genotypes. Mortality rates and clinical phenotype were also compared between genotypes classified into six classes on the basis of their functional effect on CFTR production. Findings Between 1991 and 1999, genetic and clinical data were available for 17 853 patients with cystic fibrosis, which was 63% of the total cohort. There were :1547 deaths during the 9 years of follow-up. In the analysis of the 11 most common genotypes, DeltaF508/R117H, DeltaF508/DeltaI507, DeltaF508/3849+10 kbC-->T, and DeltaF508/2789+5G-->A had a significantly lower mortality rate (4.7, 8.0, 11.9, and 4.4, respectively) than the genotype homozygous for DeltaF508 (21.8, p=0.0060). DeltaF508/R117H, DeltaF508/DeltaI507, DeltaF508/ 3849+10 kbC-->T, DeltaF508/2789+5G-->A, and DeltaF508/A455E have a milder clinical phenotype. Outcomes for all functional classes were compared with that of class II (containing DeltaF508 homozygotes) and classes IV and V had a significantly lower mortality rate and milder clinical phenotype. Interpretation Patients with cystic fibrosis have distinct genetic subgroups that are associated with mild clinical manifestations and low mortality. These differences in phenotype are also related to the functional classification of CFTR genotype.	Univ Washington, Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98195 USA; Univ Washington, Adult Cyst Fibrosis Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	McKone, EF (corresponding author), Univ Washington, Med Ctr, Div Pulm & Crit Care Med, BB1253 Hlth Sci Bldg,Box 356522, Seattle, WA 98195 USA.				NCI NIH HHS [R01 CA149051] Funding Source: Medline; NHLBI NIH HHS [K23 HL/70849-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA149051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL070849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accurso FJ, 2003, AM J RESP CRIT CARE, V167, P289, DOI 10.1164/rccm.2210006; [Anonymous], CYSTIC FIBROSIS MUTA; Cystic Fibrosis Foundation Patient Registry, 2000, 1999 ANN DAT REP; Drumm ML, 2001, RESPIR RES, V2, P125, DOI 10.1186/rr47; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; GAN KH, 1995, NEW ENGL J MED, V333, P95, DOI 10.1056/NEJM199507133330204; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; Highsmith WE, 1997, HUM MUTAT, V9, P332, DOI 10.1002/(SICI)1098-1004(1997)9:4<332::AID-HUMU5>3.0.CO;2-7; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; Hull J, 1998, THORAX, V53, P1018, DOI 10.1136/thx.53.12.1018; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; Kerem B, 1996, EUR J HUM GENET, V4, P65; Kerem E, 1996, PEDIATR PULM, V22, P387, DOI 10.1002/(SICI)1099-0496(199612)22:6<387::AID-PPUL7>3.3.CO;2-Y; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Koch C, 2001, PEDIATR PULM, V31, P1, DOI 10.1002/1099-0496(200101)31:1<1::AID-PPUL1000>3.0.CO;2-T; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; Liou TG, 2001, AM J EPIDEMIOL, V153, P345, DOI 10.1093/aje/153.4.345; Massie RJH, 2001, EUR RESPIR J, V17, P1195, DOI 10.1183/09031936.01.00057001; Mickle JE, 2000, MED CLIN N AM, V84, P597, DOI 10.1016/S0025-7125(05)70243-1; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; Schechter MS, 2001, AM J RESP CRIT CARE, V163, P1331, DOI 10.1164/ajrccm.163.6.9912100; STERN RC, 1995, LANCET, V346, P274, DOI 10.1016/S0140-6736(95)92165-6; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; Tzetis M, 2001, HUM GENET, V109, P592, DOI 10.1007/s00439-001-0631-0; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Welsh MJ, 2001, METABOLIC MOL BASES, P5121	30	288	294	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 17	2003	361	9370					1671	1676		10.1016/S0140-6736(03)13368-5	http://dx.doi.org/10.1016/S0140-6736(03)13368-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767731				2022-12-28	WOS:000182919700006
J	White, NJ				White, NJ			Melioidosis	LANCET			English	Review							TUMOR-NECROSIS-FACTOR; CEFTAZIDIME PLUS COTRIMOXAZOLE; COMMUNITY-ACQUIRED SEPTICEMIA; TROPICAL NORTHERN AUSTRALIA; BETA-LACTAM ANTIBIOTICS; BURKHOLDERIA-PSEUDOMALLEI; PSEUDOMONAS-PSEUDOMALLEI; NEUROLOGICAL MELIOIDOSIS; MAINTENANCE TREATMENT; RAPID IDENTIFICATION	Melioidosis, which is infection with the gram-negative bacterium Burkholderia pseudomallei, is an important cause of sepsis in east Asia and northern Australia. In northeastern Thailand, melioidosis accounts for 20% of all community-acquired septicaemias, and causes death in 40% of treated patients. B pseudomallei is an environmental saprophyte found In wet soils. It mostly infects adults with an underlying predisposing condition, mainly diabetes mellitus. Melioidosis is characterised by formation of abscesses, especially in the lungs, liver, spleen, skeletal muscle, and prostate. In a third of paediatric cases in southeast Asia, the disease presents as parotid abscess. In northern Australia, 4% of patients present with brain stem encephalitis. Ceftazidime is the treatment of choice for severe melioldosis, but response to high dose parenteral treatment is slow (median time to abatement of fever 9 days). Maintenance antibiotic treatment is with a four-drug regimen of chloramphenicol, doxycycline, and trimethoprimsulfamethoxazole, or with amoxicillin-clavulanate in children and pregnant women. However, even with 20 weeks' antibiotic treatment, 10% of patients relapse. With improvements in health care and diagnostic microbiology in endemic areas of Asia, and increased travel, melioldosis will probably be recognised increasingly during the next decade.	Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England	Mahidol University; University of Oxford	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.	fnnjw@diamond.mahidol.ac.th	Bisen, Prakash S/H-3392-2019; White, Nick/AAC-6527-2019	Bisen, Prakash S/0000-0002-2818-7829; White, Nick/0000-0002-1897-1978				Abbink FC, 2001, NEW ENGL J MED, V344, P1171, DOI 10.1056/NEJM200104123441516; ANGUS BJ, 2000, BR J CLIN PHARM, V49, P184; Anuntagool N, 2000, J MED MICROBIOL, V49, P1075, DOI 10.1099/0022-1317-49-12-1075; ASHDOWN LR, 1989, J INFECT DIS, V160, P253, DOI 10.1093/infdis/160.2.253; ASHDOWN LR, 1979, PATHOLOGY, V11, P293, DOI 10.3109/00313027909061954; ASHDOWN LR, 1992, MED J AUSTRALIA, V157, P427, DOI 10.5694/j.1326-5377.1992.tb137276.x; Brett PJ, 1998, INT J SYST BACTERIOL, V48, P317, DOI 10.1099/00207713-48-1-317; BROWN AE, 1991, J INFECT DIS, V163, P1145, DOI 10.1093/infdis/163.5.1145; Chaowagul W, 1999, CLIN INFECT DIS, V29, P375, DOI 10.1086/520218; CHAOWAGUL W, 1993, J INFECT DIS, V168, P1181, DOI 10.1093/infdis/168.5.1181; CHAOWAGUL W, 1989, J INFECT DIS, V159, P890, DOI 10.1093/infdis/159.5.890; Chaowagul W, 1997, T ROY SOC TROP MED H, V91, P599, DOI 10.1016/S0035-9203(97)90044-4; Chaowagul W, 1999, CLIN INFECT DIS, V28, P1328, DOI 10.1086/517787; Charuchaimontri C, 1999, CLIN INFECT DIS, V29, P813, DOI 10.1086/520441; Chetchotisakd P, 2001, CLIN INFECT DIS, V33, P29, DOI 10.1086/320878; CURRIE B, 1994, EPIDEMIOL INFECT, V113, P307, DOI 10.1017/S0950268800051736; Currie BJ, 2000, T ROY SOC TROP MED H, V94, P301, DOI 10.1016/S0035-9203(00)90333-X; Currie BJ, 2000, ACTA TROP, V74, P145, DOI 10.1016/S0001-706X(99)00064-9; Currie BJ, 2000, CLIN INFECT DIS, V31, P981, DOI 10.1086/318116; Dance D.A, 1996, WELLCOME TRUST ILLUS, P72; Dance D. A. B., 1990, Reviews in Medical Microbiology, V1, P143; DANCE DAB, 1989, J CLIN PATHOL, V42, P645, DOI 10.1136/jcp.42.6.645; DANCE DAB, 1991, CLIN MICROBIOL REV, V4, P52, DOI 10.1128/CMR.4.1.52-60.1991; DANCE DAB, 1989, J ANTIMICROB CHEMOTH, V24, P311, DOI 10.1093/jac/24.3.311; Dance DAB, 2000, ACTA TROP, V74, P115, DOI 10.1016/S0001-706X(99)00059-5; DANCE DAB, 1989, J INFECT DIS, V159, P654, DOI 10.1093/infdis/159.4.654; DANCE DAB, 1989, J ANTIMICROB CHEMOTH, V24, P295, DOI 10.1093/jac/24.3.295; Dharakul T, 1998, HUM IMMUNOL, V59, P580, DOI 10.1016/S0198-8859(98)00052-4; DHIENSIRI T, 1988, RADIOLOGY, V166, P711, DOI 10.1148/radiology.166.3.3340766; Edmond KM, 2001, J PAEDIATR CHILD H, V37, P337, DOI 10.1046/j.1440-1754.2001.00660.x; Egan AM, 1996, INFECT IMMUN, V64, P4952, DOI 10.1128/IAI.64.12.4952-4959.1996; FRIEDLAND JS, 1992, INFECT IMMUN, V60, P2402, DOI 10.1128/IAI.60.6.2402-2408.1992; GODFREY AJ, 1991, ANTIMICROB AGENTS CH, V35, P1635, DOI 10.1128/AAC.35.8.1635; GREEN RN, 1968, AM J MED, V44, P599, DOI 10.1016/0002-9343(68)90060-0; Halder D., 1993, Singapore Medical Journal, V34, P85; Haussler S, 1998, INFECT IMMUN, V66, P1588; Haussler S, 1999, MED MICROBIOL IMMUN, V188, P91, DOI 10.1007/s004300050110; Heng Bee Hoon, 1998, Annals Academy of Medicine Singapore, V27, P478; Holland DJ, 2002, CLIN INFECT DIS, V35, pE138, DOI 10.1086/344447; Hsueh PR, 2001, EMERG INFECT DIS, V7, P428; Inglis TJJ, 1999, EPIDEMIOL INFECT, V123, P437, DOI 10.1017/S0950268899002964; Jenney AWJ, 2001, INT J ANTIMICROB AG, V17, P109, DOI 10.1016/S0924-8579(00)00334-4; John TJ, 1996, INDIAN J MED RES, V103, P62; Jones SM, 2002, J MED MICROBIOL, V51, P1055, DOI 10.1099/0022-1317-51-12-1055; KANAPHUN P, 1993, J INFECT DIS, V167, P230, DOI 10.1093/infdis/167.1.230; Kespichayawattana W, 2000, INFECT IMMUN, V68, P5377, DOI 10.1128/IAI.68.9.5377-5384.2000; Krishnaswami CS, 1917, INDIAN MED GAZ, V52, P296; Lauw FN, 2000, INFECT IMMUN, V68, P3888, DOI 10.1128/IAI.68.7.3888-3893.2000; Lauw FN, 2000, J INFECT DIS, V182, P206, DOI 10.1086/315642; LEELARASAMEE A, 1989, REV INFECT DIS, V11, P413; LUMBIGANON P, 1988, PEDIATR INFECT DIS J, V7, P634, DOI 10.1097/00006454-198809000-00007; MCCORMICK JB, 1975, ANN INTERN MED, V83, P512, DOI 10.7326/0003-4819-83-4-512; Moore RA, 1999, ANTIMICROB AGENTS CH, V43, P465, DOI 10.1128/AAC.43.3.465; Nuntayanuwat S, 1999, HUM IMMUNOL, V60, P979, DOI 10.1016/S0198-8859(99)00073-7; Phetsouvanh R, 2001, CLIN INFECT DIS, V32, P653, DOI 10.1086/318713; Piliouras P, 2002, INT J ANTIMICROB AG, V19, P427, DOI 10.1016/S0924-8579(02)00016-X; Puthucheary S. D., 2002, HUMAN MELIOIDOSIS; PUTHUCHEARY SD, 1992, T ROY SOC TROP MED H, V86, P683, DOI 10.1016/0035-9203(92)90191-E; Rainbow L, 2002, J MED MICROBIOL, V51, P374, DOI 10.1099/0022-1317-51-5-374; RAJCHANUVONG A, 1995, T ROY SOC TROP MED H, V89, P546, DOI 10.1016/0035-9203(95)90104-3; Ramsay SC, 2001, NUCL MED COMMUN, V22, P1193, DOI 10.1097/00006231-200111000-00005; Reckseidler SL, 2001, INFECT IMMUN, V69, P34, DOI 10.1128/IAI.69.1.34-44.2001; RODE JW, 1981, MED J AUSTRALIA, V1, P181, DOI 10.5694/j.1326-5377.1981.tb135443.x; RUBIN HL, 1963, MIL MED, V128, P538, DOI 10.1093/milmed/128.6.538; SANFORD JP, 1971, AM REV RESPIR DIS, V104, P452, DOI 10.1164/arrd.1971.104.3.452; Santanirand P, 1999, INFECT IMMUN, V67, P3593, DOI 10.1128/IAI.67.7.3593-3600.1999; Schulin T, 2001, J CLIN MICROBIOL, V39, P1676, DOI 10.1128/JCM.39.4.1676-1677.2001; SEXTON MM, 1994, CAN J MICROBIOL, V40, P903, DOI 10.1139/m94-145; Simpson AJH, 1999, J CLIN PATHOL, V52, P616, DOI 10.1136/jcp.52.8.616; Simpson AJH, 1999, CLIN INFECT DIS, V29, P381, DOI 10.1086/520219; Simpson AJH, 1999, ANTIMICROB AGENTS CH, V43, P2332, DOI 10.1128/AAC.43.9.2332; Simpson AJH, 2000, J INFECT DIS, V181, P621, DOI 10.1086/315271; SIRIPANTHONG S, 1991, REV INFECT DIS, V13, P335; SMITH MD, 1993, J CLIN PATHOL, V46, P374, DOI 10.1136/jcp.46.4.374; SMITH MD, 1994, J ANTIMICROB CHEMOTH, V33, P145, DOI 10.1093/jac/33.1.145; Smith MD, 1997, INFECT IMMUN, V65, P4319, DOI 10.1128/IAI.65.10.4319-4321.1997; SOOKPRANEE M, 1992, ANTIMICROB AGENTS CH, V36, P158, DOI 10.1128/AAC.36.1.158; Stanton AT, 1932, MELIOIDOSIS STUDIES, V21; Steinmetz I, 1999, J CLIN MICROBIOL, V37, P225, DOI 10.1128/JCM.37.1.225-228.1999; STEINMETZ I, 1995, INFECT IMMUN, V63, P3959, DOI 10.1128/IAI.63.10.3959-3965.1995; Stevens MP, 2002, MOL MICROBIOL, V46, P649, DOI 10.1046/j.1365-2958.2002.03190.x; SUPUTTAMONGKOL Y, 1992, J INFECT DIS, V165, P561, DOI 10.1093/infdis/165.3.561; SUPUTTAMONGKOL Y, 1994, INT J EPIDEMIOL, V23, P1082, DOI 10.1093/ije/23.5.1082; Suputtamongkol Y, 1999, CLIN INFECT DIS, V29, P408, DOI 10.1086/520223; SUPUTTAMONGKOL Y, 1994, CLIN INFECT DIS, V19, P846, DOI 10.1093/clinids/19.5.846; SUPUTTAMONGKOL Y, 1991, T ROY SOC TROP MED H, V85, P672, DOI 10.1016/0035-9203(91)90391-B; THIN RNT, 1970, Q J MED, V39, P115; Tiangpitayakorn C, 1997, AM J TROP MED HYG, V57, P96, DOI 10.4269/ajtmh.1997.57.96; VATCHARAPREECHASAKUL T, 1992, CLIN INFECT DIS, V14, P412, DOI 10.1093/clinids/14.2.412; Visca P, 2001, CLIN INFECT DIS, V32, pE15, DOI 10.1086/317528; Walsh AL, 1995, CLIN INFECT DIS, V21, P1498, DOI 10.1093/clinids/21.6.1498; Walsh AL, 1996, BRIT J BIOMED SCI, V53, P249; WALSH AL, 1995, T ROY SOC TROP MED H, V89, P124, DOI 10.1016/0035-9203(95)90685-1; WALSH AL, 1994, J CLIN PATHOL, V47, P377, DOI 10.1136/jcp.47.4.377; WHITE NJ, 1989, LANCET, V2, P697, DOI 10.1016/S0140-6736(89)90768-X; Whitmore A, 1912, Ind Med Gaz, V47, P262; Whitmore A, 1913, J HYG-CAMBRIDGE, V13, P1, DOI 10.1017/S0022172400005234; Wibulpolprasert B, 1999, J CLIN ULTRASOUND, V27, P29, DOI 10.1002/(SICI)1097-0096(199901)27:1<29::AID-JCU5>3.0.CO;2-C; WONG KT, 1995, HISTOPATHOLOGY, V26, P51, DOI 10.1111/j.1365-2559.1995.tb00620.x; Woods DE, 1999, MICROBES INFECT, V1, P157, DOI 10.1016/S1286-4579(99)80007-0; WOODS ML, 1992, CLIN INFECT DIS, V15, P163, DOI 10.1093/clinids/15.1.163; WUTHIEKANUN V, 1995, T ROY SOC TROP MED H, V89, P491, DOI 10.1016/0035-9203(95)90080-2; Wuthiekanun V, 2001, J CLIN MICROBIOL, V39, P3801, DOI 10.1128/JCM.39.10.3801-3802.2001; WUTHIEKANUN V, 1995, T ROY SOC TROP MED H, V89, P41, DOI 10.1016/0035-9203(95)90651-7; Wuthiekanun V, 1996, J MED MICROBIOL, V45, P408, DOI 10.1099/00222615-45-6-408; YABUUCHI E, 1992, MICROBIOL IMMUNOL, V36, P1251, DOI 10.1111/j.1348-0421.1992.tb02129.x; Yang S, 2000, ACTA TROP, V77, P157, DOI 10.1016/S0001-706X(00)00139-X; 1995, EPIDEMIOL NEWS B SIN, V21, P69	108	658	696	1	57	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1715	1722		10.1016/S0140-6736(03)13374-0	http://dx.doi.org/10.1016/S0140-6736(03)13374-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767750				2022-12-28	WOS:000182919700024
J	Rosi, NL; Eckert, J; Eddaoudi, M; Vodak, DT; Kim, J; O'Keeffe, M; Yaghi, OM				Rosi, NL; Eckert, J; Eddaoudi, M; Vodak, DT; Kim, J; O'Keeffe, M; Yaghi, OM			Hydrogen storage in microporous metal-organic frameworks	SCIENCE			English	Article							INELASTIC NEUTRON-SCATTERING; ZEOLITE NA-A; MOLECULAR-HYDROGEN; CARBON NANOTUBES; DESIGN; ADSORPTION; ROTATION	Metal-organic framework-5 (MOF-5) of composition Zn4O(BDC)(3) (BDC = 1,4-benzenedicarboxylate) with a cubic three-dimensional extended porous structure adsorbed hydrogen up to 4.5 weight percent (17.2 hydrogen molecules per formula unit) at 78 kelvin and 1.0 weight percent at room temperature and pressure of 20 bar. Inelastic neutron scattering spectroscopy of the rotational transitions of the adsorbed hydrogen molecules indicates the presence of two well-defined binding sites (termed I and II), which we associate with hydrogen binding to zinc and the BDC linker, respectively. Preliminary studies on topologically similar isoreticular metal-organic framework-6 and -8 (IRMOF-6 and -8) having cyclobutylbenzene and naphthalene linkers, respectively, gave approximately double and quadruple (2.0 weight percent) the uptake found for MOF-5 at room temperature and 10 bar.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA; Los Alamos Natl Lab, Los Alamos Neutron Sci Ctr, Los Alamos, NM 87545 USA; Univ S Florida, Dept Chem, Tampa, FL 33620 USA; Arizona State Univ, Dept Chem, Tempe, AZ 85287 USA	University of Michigan System; University of Michigan; University of California System; University of California Santa Barbara; United States Department of Energy (DOE); Los Alamos National Laboratory; State University System of Florida; University of South Florida; Arizona State University; Arizona State University-Tempe	Yaghi, OM (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.		Scuderi, Nicolò/J-2711-2018; Yaghi, Omar M/C-6749-2013; Eddaoudi, Mohamed/D-2298-2009	Scuderi, Nicolò/0000-0002-2458-0498; Eddaoudi, Mohamed/0000-0003-1916-9837; Yaghi, Omar/0000-0002-5611-3325				Anderson CR, 1999, J CHEM PHYS, V111, P7599, DOI 10.1063/1.480104; Berry GD, 1998, ENERG FUEL, V12, P49, DOI 10.1021/ef9700947; BRAID IJ, 1987, ZEOLITES, V7, P214, DOI 10.1016/0144-2449(87)90053-4; Brown CM, 2000, CHEM PHYS LETT, V329, P311, DOI 10.1016/S0009-2614(00)01003-4; Dagani R, 2002, CHEM ENG NEWS, V80, P25, DOI 10.1021/cen-v080n002.p025; Eckert J, 1996, J PHYS CHEM-US, V100, P10646, DOI 10.1021/jp952982d; ECKERT J, 1993, J PHYS CHEM-US, V97, P2378, DOI 10.1021/j100112a044; Eddaoudi M, 2000, J AM CHEM SOC, V122, P1391, DOI 10.1021/ja9933386; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; Eddaoudi M, 2001, ACCOUNTS CHEM RES, V34, P319, DOI 10.1021/ar000034b; Forster PM, 2003, J AM CHEM SOC, V125, P1309, DOI 10.1021/ja028341v; Froudakis GE, 2002, J PHYS-CONDENS MAT, V14, pR453, DOI 10.1088/0953-8984/14/17/201; GREGG SJ, 1982, ADSORPTION SURFACE; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; MacKinnon JA, 2001, J CHEM PHYS, V114, P10137, DOI 10.1063/1.1352733; Mojet BL, 2001, J AM CHEM SOC, V123, P8147, DOI 10.1021/ja016078c; NICOL JM, 1988, J PHYS CHEM-US, V92, P7117, DOI 10.1021/j100336a017; Pradhan BK, 2002, J MATER RES, V17, P2209, DOI 10.1557/JMR.2002.0326; Ren Y, 2001, APPL PHYS LETT, V79, P3684, DOI 10.1063/1.1421639; Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634; SILVERA IF, 1980, REV MOD PHYS, V52, P393, DOI 10.1103/RevModPhys.52.393	21	4234	4370	112	3621	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1127	1129		10.1126/science.1083440	http://dx.doi.org/10.1126/science.1083440			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750515				2022-12-28	WOS:000182886500039
J	Gregg, EW; Cauley, JA; Stone, K; Thompson, TJ; Bauer, DC; Cummings, SR; Ensrud, KE				Gregg, EW; Cauley, JA; Stone, K; Thompson, TJ; Bauer, DC; Cummings, SR; Ensrud, KE		Study Osteoporotic Fractures Res G	Relationship of changes in physical activity and mortality among older women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; ESTROGEN REPLACEMENT THERAPY; ALL-CAUSE MORTALITY; CARDIORESPIRATORY FITNESS; MYOCARDIAL-INFARCTION; ACTIVITY LEVEL; RISK; LONGEVITY; EXERCISE; LIFE	Context Physical activity has been related to reduced mortality, but it is not clear whether changes in physical activity affect mortality among older women. Objective To examine the relationship of changes in physical activity and mortality among older women. Design, Setting, and Participants Prospective cohort study conducted at 4 US research centers (Baltimore, Md; Portland, Ore; Minneapolis, Minn; and Monongahela Valley, Pa) among 9518 community-dwelling white women aged 65 years or older who were assessed at baseline (1986-1988), 7553 of whom were reassessed at a follow-up visit (1992-1994; median,5.7 years later). Main Outcome Measures Walking and other physical activities at baseline and follow-up; vital status, with cause of death confirmed by death certificates/discharge summaries, tracked for up to 12.5 years after baseline (up to 6.7 years after the follow-up visit). Results Compared with continually sedentary women, those who increased physical activity levels between baseline and follow-up had lower mortality from all causes (hazard rate ratio [HRR], 0.52; 95% confidence interval [CI], 0.40-0.69), cardiovascular disease (HRR, 0.64; 95% CI, 0.42-0.97), and cancer (HRR, 0.49; 95% CI, 0.29-0.84), independent of age, smoking, body mass index, comorbid conditions, and baseline physical activity level. Associations between changes in physical activity and reduced mortality were similar in women With and without chronic diseases but tended to be weaker among women aged at least 75 years and among those with poor health status. Women who were physically active at both visits also had lower all-cause mortality (HRR, 0.68; 95% CI, 0.56-0.82) and cardiovascular mortality (HRR, 0.62; 95% CI, 0.44-0.88) than sedentary women. Conclusion Increasing and maintaining physical activity levels could lengthen life for older women but appears to provide less benefit for women aged at least 75 years and those with,poor health status.	Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Univ Calif San Francisco, Dept Med, Prevent Sci Grp, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Minnesota, Minneapolis, MN USA; Vet Affairs Med Ctr, Gen Internal Med Sect, Minneapolis, MN USA	Centers for Disease Control & Prevention - USA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Gregg, EW (corresponding author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS K-10, Atlanta, GA 30341 USA.	edg7@cdc.gov	Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Gregg, Edward/0000-0003-2381-6822; Ensrud, Kristine/0000-0002-9069-3036	NIAMS NIH HHS [AR35582, AR35584, AR35583] Funding Source: Medline; NIA NIH HHS [AG05407] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582, R01AR035584, R01AR035583] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bijnen FCH, 1998, ARCH INTERN MED, V158, P1499, DOI 10.1001/archinte.158.14.1499; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; CAULEY JA, 1987, AM J CLIN NUTR, V45, P14, DOI 10.1093/ajcn/45.1.14; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Erikssen G, 1998, LANCET, V352, P759, DOI 10.1016/S0140-6736(98)02268-5; Friedenreich CM, 2001, CANCER EPIDEM BIOMAR, V10, P287; Gregg EW, 1998, ANN INTERN MED, V129, P81, DOI 10.7326/0003-4819-129-2-199807150-00002; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Hein H. O., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P57; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Hu FB, 2000, JAMA-J AM MED ASSOC, V283, P2961, DOI 10.1001/jama.283.22.2961; Hu FB, 2001, ANN INTERN MED, V134, P96, DOI 10.7326/0003-4819-134-2-200101160-00009; Kamimoto L A, 1999, MMWR CDC Surveill Summ, V48, P89; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; Leveille SG, 1999, AM J EPIDEMIOL, V149, P654; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; Morgan K, 1997, J EPIDEMIOL COMMUN H, V51, P490, DOI 10.1136/jech.51.5.490; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Parker CJ, 1997, J EPIDEMIOL COMMUN H, V51, P494, DOI 10.1136/jech.51.5.494; Pereira M A, 1997, Med Sci Sports Exerc, V29, pS1; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; RAKOWSKI W, 1992, J GERONTOL, V47, pM122, DOI 10.1093/geronj/47.4.M122; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Stessman J, 2000, J AM GERIATR SOC, V48, P499, DOI 10.1111/j.1532-5415.2000.tb04995.x; Thune I, 2001, MED SCI SPORT EXER, V33, pS530, DOI 10.1097/00005768-200106001-00025; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; *US BUR CENS, 1999, STAT ABSTR US 1999; Wannamethee SG, 1998, LANCET, V351, P1603, DOI 10.1016/S0140-6736(97)12355-8; Wei M, 2000, ANN INTERN MED, V132, P605, DOI 10.7326/0003-4819-132-8-200004180-00002	43	254	260	2	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2379	2386		10.1001/jama.289.18.2379	http://dx.doi.org/10.1001/jama.289.18.2379			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677WF	12746361				2022-12-28	WOS:000182831200027
J	Lin, JJ; Zhou, JG; Shiu, WC; Liu, KP				Lin, JJ; Zhou, JG; Shiu, WC; Liu, KP			State-specific correlation of coincident product pairs in the F+CD4 reaction	SCIENCE			English	Article							DIFFERENTIAL CROSS-SECTIONS; MOLECULAR-BEAM; BIMOLECULAR REACTIONS; PHOTODISSOCIATION; RESONANCES; SCATTERING; MODE	When a chemical reaction forms two molecular products, even if the state-resolved differential cross section (DCS) for each product is obtained individually, the coincident attributes of the coproducts are still lacking. We exploit a method that provides coincidence information by measuring the state-resolved, pair-correlated DCS. Exemplified by the reaction F + CD4-->DF + CD3, a time-sliced ion velocity imaging technique was used to measure the velocity distribution of a state-selected CD3 product and to reveal the information of the coincident DF in a state-correlated manner. The correlation of different product state pairs shows a striking difference, which opens up a new way to unravel the complexity of a polyatomic reaction.	Acad Sinica, Inst Atom & Mol Sci, Taipei 106, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Liu, KP (corresponding author), Acad Sinica, Inst Atom & Mol Sci, POB 23-166, Taipei 106, Taiwan.	kpliu@gate.sinica.edu.tw	Lin, Jim/F-7916-2012; Liu, Kopin/F-7929-2012	Lin, Jim/0000-0002-8308-2552; Liu, Kopin/0000-0001-7499-2397				Althorpe SC, 2002, NATURE, V416, P67, DOI 10.1038/416067a; BRONIKOWSKI MJ, 1993, J PHYS CHEM-US, V97, P2194, DOI 10.1021/j100112a021; Corchado JC, 1996, J CHEM PHYS, V105, P3152, DOI 10.1063/1.472183; Crim FF, 1999, ACCOUNTS CHEM RES, V32, P877, DOI 10.1021/ar950046a; Dong F, 2000, J CHEM PHYS, V113, P3633, DOI 10.1063/1.1287840; Eppink ATJB, 1999, J CHEM PHYS, V110, P832, DOI 10.1063/1.478051; Eppink ATJB, 1997, REV SCI INSTRUM, V68, P3477, DOI 10.1063/1.1148310; Fernandez-Alonso F, 2002, ANNU REV PHYS CHEM, V53, P67, DOI 10.1146/annurev.physchem.53.091001.094554; Hall GE, 2000, ANNU REV PHYS CHEM, V51, P243, DOI 10.1146/annurev.physchem.51.1.243; Harich SA, 2002, NATURE, V419, P281, DOI 10.1038/nature01068; Hsieh CH, 1997, CHEM PHYS LETT, V277, P33, DOI 10.1016/S0009-2614(97)00884-1; Kim ZH, 2001, J AM CHEM SOC, V123, P12714, DOI 10.1021/ja017180c; Lee SH, 2002, J CHEM PHYS, V116, P7839, DOI 10.1063/1.1468880; LEVINE RD, 1987, MOL REACTION DYNAMIC; Lin JJ, 2003, REV SCI INSTRUM, V74, P2495, DOI 10.1063/1.1561604; Liu K, 2002, PHYSCHEMCOMM, V5, P27, DOI 10.1039/b110570a; Liu KP, 2001, ANNU REV PHYS CHEM, V52, P139, DOI 10.1146/annurev.physchem.52.1.139; Liu XH, 2000, SCIENCE, V289, P1536, DOI 10.1126/science.289.5484.1536; NEUMARK DM, 1985, J CHEM PHYS, V82, P3045, DOI 10.1063/1.448254; NEUMARK DM, 1985, J CHEM PHYS, V82, P3067, DOI 10.1063/1.448255; Schnieder L, 1997, J CHEM PHYS, V107, P6175, DOI 10.1063/1.474283; SIMPSON WR, 1995, J CHEM PHYS, V103, P7313, DOI 10.1063/1.470305; SINHA A, 1991, J CHEM PHYS, V94, P4928, DOI 10.1063/1.460578; SKODJE RT, 1993, ANNU REV PHYS CHEM, V44, P145, DOI 10.1146/annurev.physchem.44.1.145; Skodje RT, 2000, PHYS REV LETT, V85, P1206, DOI 10.1103/PhysRevLett.85.1206; Strazisar BR, 2000, SCIENCE, V290, P958, DOI 10.1126/science.290.5493.958; ZHOU J, IN PRESS J CHEM PHYS	27	211	214	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					966	969		10.1126/science.1083672	http://dx.doi.org/10.1126/science.1083672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738861				2022-12-28	WOS:000182719800053
J	Moore, JD; Kirk, JA; Hunt, T				Moore, JD; Kirk, JA; Hunt, T			Unmasking the S-phase-promoting potential of cyclin B1	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; CELL-CYCLE; NUCLEAR EXPORT; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; LOCALIZATION; MITOSIS; SPECIFICITY; ACTIVATION; KINASE	In higher eukaryotes, the S phase and M phase of the cell cycle are triggered by different cyclin-dependent kinases (CDKs). For example, in frog egg extracts, Cdk1-cyclin B catalyzes entry into mitosis but cannot trigger DNA replication. Two hypotheses can explain this observation: Either Cdk1-cyclin B fails to recognize the key substrates of its S-phase-promoting counterparts, or its activity is somehow regulated to prevent it from activating DNA synthesis. Here, we show that Cdk1-cyclin B1 has cryptic S-phase-promoting abilities that can be unmasked by relocating it from the cytoplasm to the nucleus and moderately stimulating its activity. Subcellular localization of vertebrate CDKs and the control of their activity are thus critical factors for determining their specificity.	Canc Res UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Hunt, T (corresponding author), Canc Res UK London Res Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.							AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BUENO A, 1993, MOL CELL BIOL, V13, P2286, DOI 10.1128/MCB.13.4.2286; Chen W, 2000, BIOCHEMISTRY-US, V39, P10781, DOI 10.1021/bi000909u; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Haase SB, 1999, NATURE, V401, P394, DOI 10.1038/43930; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Miller ME, 2000, MOL CELL BIOL, V20, P542, DOI 10.1128/MCB.20.2.542-555.2000; Miller ME, 2001, J CELL SCI, V114, P1811; Moore JD, 2002, MOL BIOL CELL, V13, P4388, DOI 10.1091/mbc.E02-07-0449; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MOORE JS, UNPUB; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Pomerening JR, 2003, NAT CELL BIOL, V5, P346, DOI 10.1038/ncb954; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Stern B, 1996, TRENDS GENET, V12, P345; Strausfeld UP, 1996, J CELL SCI, V109, P1555; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	30	108	108	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					987	990		10.1126/science.1081418	http://dx.doi.org/10.1126/science.1081418			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738867				2022-12-28	WOS:000182719800059
J	Connolly, SJ; Sheldon, R; Thorpe, KE; Roberts, RS; Ellenbogen, KA; Wilkoff, BL; Morillo, C; Gent, M				Connolly, SJ; Sheldon, R; Thorpe, KE; Roberts, RS; Ellenbogen, KA; Wilkoff, BL; Morillo, C; Gent, M		VPS II Investigators	Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope - Second Vasovagal Pacemaker Study (VPS II): A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TILT; MULTICENTER	Context Three previous small randomized trials have reported that pacemaker therapy is beneficial for patients with severe recurrent vasovagal syncope. However, because these trials were not double blind, they may have been biased in their assessment of outcomes and had a placebo effect of surgery. Objective To determine if pacing therapy reduces the risk of syncope in patients with vasovagal syncope. Design, Setting, and Patients A randomized double-blind trial of pacemaker therapy in outpatients referred to syncope specialists at 15 centers from September 1998 to April 2002. In the year prior to randomization,patients had had a median of 4 episodes of syncope. Patients were followed up for up to 6 months. Intervention After implantation of a dual chamber pacemaker, 100 patients were randomly assigned to receive dual-chamber pacing (DDD) with rate drop response or to have only sensing without pacing (ODO). Main Outcome Measure Time to first recurrence of syncope. Results No patients were lost to follow-up. Of the 52 patients randomized to ODO, 22 (42%) had recurrent syncope within 6 months compared with 16 (33%) of 48 patients in the DDD group. The cumulative risk of syncope at 6 months was 40% (95% confidence interval [CI], 25%-52%) for the ODO group and 31% (95% CI, 17%43%) for the DDD group. The relative risk reduction in time to syncope with DDD pacing was 30% (95% CI, -33% to 63%; 1-sided P=.14). Lead dislodgement or repositioning occurred in 7 patients. One patient had vein thrombosis, another had pericardial tamponade leading to removal of the pacemaker system, and a third had infection involving the pacemaker generator. Conclusions In this double-blind randomized trial, pacing therapy did not reduce the risk of recurrent syncope in patients with vasovagal syncope. Because of the weak evidence of efficacy of pacemaker therapy and the risk of complications, pacemaker therapy should not be recommended as first-line therapy for patients with recurrent vasovagal syncope.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Calgary, Dept Cardiovasc Med, Calgary, AB, Canada; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA; Inst Corazon, Dept Cardiol & Cardiovasc Sci, Floridablanca, Colombia	McMaster University; McMaster University; University of Calgary; Virginia Commonwealth University; Cleveland Clinic Foundation	Connolly, SJ (corresponding author), 237 Barton St E, Hamilton, ON L8L 2X2, Canada.		Ellenbogen, Kenneth/AAJ-3992-2021	Thorpe, Kevin/0000-0002-7586-3893; Wilkoff, Bruce/0000-0001-8905-9233				Ammirati F, 2001, CIRCULATION, V104, P52, DOI 10.1161/hc2601.091708; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; BENDITT DG, 1995, ANN INTERN MED, V122, P204, DOI 10.7326/0003-4819-122-3-199502010-00008; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; Horng S, 2002, NEW ENGL J MED, V347, P137, DOI 10.1056/NEJMsb021025; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; Morillo CA, 1997, CIRCULATION, V96, P2509, DOI 10.1161/01.CIR.96.8.2509; MosquedaGarcia R, 1997, J CLIN INVEST, V99, P2736, DOI 10.1172/JCI119463; Sutton R, 2000, CIRCULATION, V102, P294	11	315	339	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2224	2229		10.1001/jama.289.17.2224	http://dx.doi.org/10.1001/jama.289.17.2224			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675ET	12734133	Bronze			2022-12-28	WOS:000182680700024
J	Frey, JJ				Frey, JJ			Time to myself	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Williams William Carlos, 1968, SELECTED POEMS	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2185	2186		10.1001/jama.289.17.2185	http://dx.doi.org/10.1001/jama.289.17.2185			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675ET	12734116				2022-12-28	WOS:000182680700001
J	Lorenz, K; Lynn, J				Lorenz, K; Lynn, J			Moral and practical challenges of physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OREGON; EUTHANASIA; DEATH		Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA; Washington Home Ctr Palliat Care Studies, Washington, DC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lorenz, K (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.							Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; CRENSHAW A, 2000, WASHINGTON POST 0425, P1; Drought Theresa S, 2002, Gerontologist, V42 Spec No 3, P114; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; FIELD MJ, 1997, APPRAOCHING DEATH IM; Foley KM, 2001, IMPROVING PALLIATIVE; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Iwashyna TJ, 2002, HEALTH SERV RES, V37, P1531, DOI 10.1111/1475-6773.10562; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 2003, ANN INTERN MED, V138, P208, DOI 10.7326/0003-4819-138-3-200302040-00013; *RW JOHNS FDN, 2003, ACC REP; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Veldink JH, 2002, NEW ENGL J MED, V346, P1638, DOI 10.1056/NEJMsa012739; Virnig BA, 2000, J AM GERIATR SOC, V48, P1117, DOI 10.1111/j.1532-5415.2000.tb04789.x; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	17	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2282	2282		10.1001/jama.289.17.2282	http://dx.doi.org/10.1001/jama.289.17.2282			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675ET	12734143				2022-12-28	WOS:000182680700034
J	Takahashi, K; Mitsui, K; Yamanaka, S				Takahashi, K; Mitsui, K; Yamanaka, S			Role of ERas in promoting tumour-like properties in mouse embryonic stem cells	NATURE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN; KINASE; TRANSFORMATION; GENE; AKT; ESTABLISHMENT; SUPPRESSION; PTEN; LINE	Embryonic stem (ES) cells are pluripotent cells derived from early mammalian embryos(1,2). Their immortality and rapid growth make them attractive sources for stem cell therapies(3); however, they produce tumours (teratomas) when transplanted, which could preclude their therapeutic usage(4). Why ES cells, which lack chromosomal abnormalities, possess tumour-like properties is largely unknown. Here we show that mouse ES cells specifically express a Ras-like gene, which we have named ERas. We show that human HRasp, which is a recognized pseudogene, does not contain reported base substitutions and instead encodes the human orthologue of ERas. This protein contains amino-acid residues identical to those present in active mutants of Ras(5) and causes oncogenic transformation in NIH 3T3 cells. ERas interacts with phosphatidylinositol-3-OH kinase(6) but not with Raf(7,8). ERas-null ES cells maintain pluripotency but show significantly reduced growth and tumorigenicity, which are rescued by expression of ERas complementary DNA or by activated phosphatidylinositol-3-OH kinase. We conclude that the transforming oncogene ERas is important in the tumour-like growth properties of ES cells.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Lab Anim Mol Technol, Nara 6300192, Japan	Nara Institute of Science & Technology	Yamanaka, S (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Lab Anim Mol Technol, Nara 6300192, Japan.		Takahashi, Kazutoshi/ABE-5504-2020; Mitsui, Kaoru/E-1464-2011	Takahashi, Kazutoshi/0000-0002-5329-8395; Mitsui, Kaoru/0000-0003-0534-9845				Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Freed CR, 2002, P NATL ACAD SCI USA, V99, P1755, DOI 10.1073/pnas.062039699; GASSMANN M, 1995, P NATL ACAD SCI USA, V92, P1292, DOI 10.1073/pnas.92.5.1292; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MIYOSHI J, 1984, NUCLEIC ACIDS RES, V12, P1821, DOI 10.1093/nar/12.4.1821; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	272	305	3	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					541	545		10.1038/nature01646	http://dx.doi.org/10.1038/nature01646			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774123	Bronze			2022-12-28	WOS:000183162900044
J	Heritage, J				Heritage, J			Super sunflowers - Stopping the rot?	SCIENCE			English	Editorial Material									Univ Leeds, Sch Biochem & Mol Biol, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Heritage, J (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England.							Burke JM, 2003, SCIENCE, V300, P1250, DOI 10.1126/science.1084960; Cessna SG, 2000, PLANT CELL, V12, P2191, DOI 10.1105/tpc.12.11.2191; NOYES RD, 1981, PHYSIOL PLANT PATHOL, V18, P123	3	2	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1243	1244		10.1126/science.1085576	http://dx.doi.org/10.1126/science.1085576			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764182				2022-12-28	WOS:000183042400031
J	Eberhart-Phillips, D; Haeussler, PJ; Freymueller, JT; Frankel, AD; Rubin, CM; Craw, P; Ratchkovski, NA; Anderson, G; Carver, GA; Crone, AJ; Dawson, TE; Fletcher, H; Hansen, R; Harp, EL; Harris, RA; Hill, DP; Hreinsdottir, S; Jibson, RW; Jones, LM; Kayen, R; Keefer, DK; Larsen, CF; Moran, SC; Personius, SF; Plafker, G; Sherrod, B; Sieh, K; Sitar, N; Wallace, WK				Eberhart-Phillips, D; Haeussler, PJ; Freymueller, JT; Frankel, AD; Rubin, CM; Craw, P; Ratchkovski, NA; Anderson, G; Carver, GA; Crone, AJ; Dawson, TE; Fletcher, H; Hansen, R; Harp, EL; Harris, RA; Hill, DP; Hreinsdottir, S; Jibson, RW; Jones, LM; Kayen, R; Keefer, DK; Larsen, CF; Moran, SC; Personius, SF; Plafker, G; Sherrod, B; Sieh, K; Sitar, N; Wallace, WK			The 2002 Denali fault earthquake, Alaska: A large magnitude, slip-partitioned event	SCIENCE			English	Article							STRESS TRANSFER; HAZARD	The M-W (moment magnitude) 7.9 Denali fault earthquake on 3 November 2002 was associated with 340 kilometers of surface rupture and was the largest strike-slip earthquake in North America in almost 150 years. It illuminates earthquake mechanics and hazards of large strike-slip faults. It began with thrusting on the previously unrecognized Susitna Glacier fault, continued with right-slip on the Denali fault, then took a right step and continued with right-slip on the Totschunda fault. There is good correlation between geologically observed and geophysically inferred moment release. The earthquake produced unusually strong distal effects in the rupture propagation direction, including triggered seismicity.	US Geol Survey, Anchorage, AK 99508 USA; Univ Alaska, Inst Geophys, Fairbanks, AK 99775 USA; US Geol Survey, Denver, CO 80225 USA; Cent Washington Univ, Dept Geol Sci, Ellensburg, WA 98926 USA; Alaska Div Geol & Geophys Surveys, Fairbanks, AK 99709 USA; US Geol Survey, Pasadena, CA 91106 USA; Humboldt State Univ, Kodiak, AK 99615 USA; Carver Geol, Kodiak, AK 99615 USA; US Geol Survey, Menlo Pk, CA 94025 USA; Univ Washington, Dept Earth & Space Sci, US Geol Survey, Seattle, WA 98195 USA; CALTECH, Div Geol & Planetary Sci 100 23, Pasadena, CA 91106 USA; Univ Calif Berkeley, Dept Civil & Environm Engn, Berkeley, CA 94720 USA	United States Department of the Interior; United States Geological Survey; University of Alaska System; University of Alaska Fairbanks; United States Department of the Interior; United States Geological Survey; Central Washington University; United States Department of the Interior; United States Geological Survey; California State University System; California State Polytechnic University, Humboldt; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; University of Washington; University of Washington Seattle; California Institute of Technology; University of California System; University of California Berkeley	Eberhart-Phillips, D (corresponding author), US Geol Survey, 4200 Univ Dr, Anchorage, AK 99508 USA.		Sitar, Nicholas/AAY-3604-2020; Harris, Ruth A/C-4184-2013; Eberhart-Phillips, Donna/H-3233-2018	Sitar, Nicholas/0000-0001-7253-5985; Harris, Ruth A/0000-0002-9247-0768; Kayen, Robert/0000-0002-0356-072X; Eberhart-Phillips, Donna/0000-0003-0392-8659; Freymueller, Jeffrey/0000-0003-0614-0306; Haeussler, Peter/0000-0002-1503-6247				*AL PIP SERV CO, 2002, DES BAS DB180; Anderson G, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016724; BARBEROPOULOU A, 2002, EOS, V83; BHAT HS, 2002, EOS, V83; BOATWRIGHT J, COMMUNICATION; CASSIDY JF, 2002, EOS, V83; CLUFF LS, 2002, EOS, V83; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; DREGER D, 2002, EOS, V83; Eberhart-Phillips D, 1998, B SEISMOL SOC AM, V88, P1095; FLETCHER H, 2002, THESIS U ALASKA FAIR; GRANT LB, 1993, B SEISMOL SOC AM, V83, P619; Haeussler PJ, 2000, GEOL SOC AM BULL, V112, P1414, DOI 10.1130/0016-7606(2000)1125;1414:PSHATO3.440268E-266;2.0.CO;2; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24347, DOI 10.1029/98JB01576; HUSEN S, 2002, EOS, V83; JI C, 2002, EOS, V83; KEEFER DK, 1984, GEOL SOC AM BULL, V95, P406, DOI 10.1130/0016-7606(1984)95<406:LCBE>2.0.CO;2; KIKUCHI M., 2002, 129 EIC; LAHR JC, 1980, GEOLOGY, V8, P483, DOI 10.1130/0091-7613(1980)8<483:HPAPII>2.0.CO;2; LAHR JC, 1986, B SEISMOL SOC AM, V76, P967; Lerbekmo J.F., 1975, ROYAL SOC NZ B, V13, P203; MCNUTT SR, 2002, EOS, V83; Parsons T, 1999, J GEOPHYS RES-SOL EA, V104, P20183, DOI 10.1029/1999JB900056; PLAFKER G, 1977, US GEOL SURV CIRC B, V751, pB67; Plafker G., 1994, GEOLOGY ALASKA, P389; REASENBERG PA, 1989, SCIENCE, V243, P1173, DOI 10.1126/science.243.4895.1173; Reilinger RE, 2000, SCIENCE, V289, P1519, DOI 10.1126/science.289.5484.1519; RICHTER DH, 1971, GEOL SOC AM BULL, V82, P1529, DOI 10.1130/0016-7606(1971)82[1529:QFITEA]2.0.CO;2; Ridgway KD, 2002, GEOL SOC AM BULL, V114, P1480, DOI 10.1130/0016-7606(2002)114<1480:MACTOT>2.0.CO;2; ROYLANCE FD, 2002, BALTIMORE SUN   1129, pA1; SAIKIA CK, 1994, GEOPHYS J INT, V118, P142, DOI 10.1111/j.1365-246X.1994.tb04680.x; SIEH KE, 1975, GEOL SOC AM ABSTR, V7, P423; Somerville P.G., 2002, SEISMOLOGICAL RES LE, V73, P260; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; SYLVESTER AG, 1988, GEOL SOC AM BULL, V100, P1666, DOI 10.1130/0016-7606(1988)100<1666:SSF>2.3.CO;2; Thatcher W, 1997, J GEOPHYS RES-SOL EA, V102, P5353, DOI 10.1029/96JB03486; Thoms E. E, 2000, THESIS U ALASKA FAIR; VELASCO AA, 2002, EOS, V83; Waldhauser F, 2000, B SEISMOL SOC AM, V90, P1353, DOI 10.1785/0120000006; Ziv A, 2000, J GEOPHYS RES-SOL EA, V105, P13631, DOI 10.1029/2000JB900081; Zumberge JF, 1997, J GEOPHYS RES-SOL EA, V102, P5005, DOI 10.1029/96JB03860	41	300	309	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1113	1118		10.1126/science.1082703	http://dx.doi.org/10.1126/science.1082703			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750512				2022-12-28	WOS:000182886500035
J	Damasio, A				Damasio, A			The person within	NATURE			English	Editorial Material									Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA	University of Iowa	Damasio, A (corresponding author), Univ Iowa, Coll Med, Dept Neurol, 200 Hawkins Dr, Iowa City, IA 52242 USA.		Damasio, Antonio/AAD-1342-2019					Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Damasio A.R., 2000, FEELING WHAT HAPPENS; Damasio A.R., 2003, LOOKING SPINOZA JOY; Nossal GJV, 2001, NATURE, V412, P685, DOI 10.1038/35089152	4	93	96	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					227	227		10.1038/423227a	http://dx.doi.org/10.1038/423227a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748620				2022-12-28	WOS:000182853100022
J	Harada, S; Rodan, GA				Harada, S; Rodan, GA			Control of osteoblast function and regulation of bone mass	NATURE			English	Review							RECEPTOR-RELATED PROTEIN-5; SKELETAL DEVELOPMENT; CHONDROCYTE DIFFERENTIATION; CBFA1-DEFICIENT MICE; POSTMENOPAUSAL WOMEN; TRANSGENIC MICE; BETA INTERACTS; DENSITY; LEPTIN; CBFA1	The skeleton is an efficient 'servo' (feedback-controlled/steady-state) system that continuously integrates signals and responses which sustain its functions of delivering calcium while maintaining strength. In many individuals, bone mass homeostasis starts failing in midlife, leading to bone loss, osteoporosis and debilitating fractures. Recent advances, spearheaded by genetic information, offer the opportunity to stop or reverse this downhill course.	Merck Res Labs, Dept Bone Biol & Osteoporosis Res, W Point, PA 19002 USA	Merck & Company	Rodan, GA (corresponding author), Merck Res Labs, Dept Bone Biol & Osteoporosis Res, W Point, PA 19002 USA.							Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756-3282(99)00232-X; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095; Flier JS, 2002, NATURE, V420, P619, DOI 10.1038/420619a; Frost HM, 2001, AM J HUM BIOL, V13, P235, DOI 10.1002/1520-6300(200102/03)13:2<235::AID-AJHB1034>3.3.CO;2-D; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Khosla S, 2002, ENDOCRINOLOGY, V143, P4161, DOI 10.1210/en.2002-220843; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kontulainen S, 2001, J BONE MINER RES, V16, P195, DOI 10.1359/jbmr.2001.16.2.195; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Mahns DA, 1998, J AUTONOM NERV SYST, V73, P80, DOI 10.1016/S0165-1838(98)00086-1; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; MARTIN TJ, 2002, OSTEOPOROSIS, P361; MINKOWITZ B, 1991, J ORTHOPAED RES, V9, P869, DOI 10.1002/jor.1100090613; MOSEKILDE L, 1990, BONE MINER, V10, P13, DOI 10.1016/0169-6009(90)90046-I; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; Ralston SH, 2002, J CLIN ENDOCR METAB, V87, P2460, DOI 10.1210/jc.87.6.2460; Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; Rodan GA, 1997, BONE, V20, P1, DOI 10.1016/S8756-3282(96)00318-3; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SCHMIDT A, 2002, PRINCIPLES BONE BIOL, P1455; Schwartzman RJ, 2000, NEW ENGL J MED, V343, P654, DOI 10.1056/NEJM200008313430911; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; Smith-White MA, 2002, REGUL PEPTIDES, V103, P105, DOI 10.1016/S0167-0115(01)00368-8; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; Thorsell A, 2002, NEUROPEPTIDES, V36, P182, DOI 10.1054/npep.2002.0897; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Wallace BA, 2000, CALCIFIED TISSUE INT, V67, P10, DOI 10.1007/s00223001089; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	67	1016	1107	9	181	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					349	355		10.1038/nature01660	http://dx.doi.org/10.1038/nature01660			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748654				2022-12-28	WOS:000182853100056
J	Shu, YS; Hasenstaub, A; McCormick, DA				Shu, YS; Hasenstaub, A; McCormick, DA			Turning on and off recurrent balanced cortical activity	NATURE			English	Article							VISUAL-CORTEX; NEOCORTICAL NEURONS; PERSISTENT ACTIVITY; CAT; INHIBITION; INPUT; RAT; EXCITATION; MECHANISMS; COMPONENTS	The vast majority of synaptic connections onto neurons in the cerebral cortex arise from other cortical neurons, both excitatory and inhibitory, forming local and distant 'recurrent' networks. Although this is a basic theme of cortical organization, its study has been limited largely to theoretical investigations, which predict that local recurrent networks show a proportionality or balance between recurrent excitation and inhibition, allowing the generation of stable periods of activity(1-5). This recurrent activity might underlie such diverse operations as short-term memory(4,6,7), the modulation of neuronal excitability with attention(8,9), and the generation of spontaneous activity during sleep(5,10-14). Here we show that local cortical circuits do indeed operate through a proportional balance of excitation and inhibition generated through local recurrent connections, and that the operation of such circuits can generate self-sustaining activity that can be turned on and off by synaptic inputs. These results confirm the long-hypothesized role of recurrent activity as a basic operation of the cerebral cortex.	Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA	Yale University	McCormick, DA (corresponding author), Yale Univ, Sch Med, Dept Neurobiol, 333 Cedar St, New Haven, CT 06510 USA.		Kobelt, Liza/F-5926-2011; Shu, Yousheng/AAC-3881-2020	Shu, Yousheng/0000-0002-2834-2876				Anderson JS, 2000, J NEUROPHYSIOL, V84, P909, DOI 10.1152/jn.2000.84.2.909; Anderson JS, 2000, SCIENCE, V290, P1968, DOI 10.1126/science.290.5498.1968; BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; Borg-Graham LJ, 1998, NATURE, V393, P369, DOI 10.1038/30735; Brunel N, 2001, J COMPUT NEUROSCI, V11, P63, DOI 10.1023/A:1011204814320; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; Chance FS, 2002, NEURON, V35, P773, DOI 10.1016/S0896-6273(02)00820-6; Compte A, 2003, J NEUROPHYSIOL, V89, P2707, DOI 10.1152/jn.00845.2002; COMPTE A, UNPUB J NEUROPHYSIOL; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; Contreras D, 1996, J PHYSIOL-LONDON, V494, P251, DOI 10.1113/jphysiol.1996.sp021488; Cossart R, 2003, NATURE, V423, P283, DOI 10.1038/nature01614; COWAN RL, 1994, J NEUROPHYSIOL, V71, P17, DOI 10.1152/jn.1994.71.1.17; Durstewitz D, 2000, NAT NEUROSCI, V3, P1184, DOI 10.1038/81460; Egorov AV, 2002, NATURE, V420, P173, DOI 10.1038/nature01171; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster JM, 1995, MEMORY CEREBRAL CORT; Gutkin BS, 2001, J COMPUT NEUROSCI, V11, P121, DOI 10.1023/A:1012837415096; Hahnloser RHR, 2002, NEURAL COMPUT, V14, P1669, DOI 10.1162/08997660260028665; Hahnloser RHR, 2000, NATURE, V405, P947, DOI 10.1038/35016072; Hirsch JA, 1998, J NEUROSCI, V18, P9517; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; Mao BQ, 2001, NEURON, V32, P883, DOI 10.1016/S0896-6273(01)00518-9; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027, DOI 10.1038/79848; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969, DOI 10.1152/jn.2001.85.5.1969; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; van Vreeswijk C, 1998, NEURAL COMPUT, V10, P1321, DOI 10.1162/089976698300017214; Wang XJ, 2001, TRENDS NEUROSCI, V24, P455, DOI 10.1016/S0166-2236(00)01868-3	30	754	765	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					288	293		10.1038/nature01616	http://dx.doi.org/10.1038/nature01616			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748642				2022-12-28	WOS:000182853100043
J	MacGillivray, S; Arroll, B; Hatcher, S; Ogston, S; Reid, I; Sullivan, F; Williams, B; Crombie, I				MacGillivray, S; Arroll, B; Hatcher, S; Ogston, S; Reid, I; Sullivan, F; Williams, B; Crombie, I			Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS; DISCONTINUATION	Objective To compare the efficacy and tolerability of tricyclic antidepressants with selective serotonin reuptake inhibitors in depression in primary care. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Register of the Cochrane Collaboration's depression, anxiety, and neurosis group. Reference lists of initial studies and other relevant review papers. Selected authors and experts. Selection of studies Studies had to meet minimum requirements on: adequacy of sample size, adequate allocation concealment, clear description of treatment, representative source of subjects, use of diagnostic criteria or clear specification of inclusion criteria, details regarding number and reasons for withdrawal by group, and outcome measures described clearly or use of validated instruments. Main outcome measures Standardised mean difference of final mean depression scores and relative risk of response when using the clinical global impression score. Relative risk of withdrawing from treatment at any time, and the number withdrawing due to side effects. Results 11 studies (2951 participants) compared a selective serotonin reuptake inhibitor with a tricyclic antidepressant. Efficacy between selective serotonin reuptake inhibitors and tricyclics did not differ significantly (standardised weighted mean difference, fixed effects 0.07, 95% confidence interval -0.02 to 0.15; z=1.59, P<0.11). Significantly more patients receiving a tricyclic withdrew from treatment (relative risk 0.78, 95% confidence interval 0.68 to 0.90; z=3.37, P<0.0007) and withdrew specifically because of side effects (0.73, 0.60 to 0.88; z=3.24, P<0.001). Most studies included were small and supported by commercial funding. Many studies were of low methodological quality or did not Present adequate. data for analysis, or both, and were of short duration, typically six to eight weeks. Conclusion The evidence on the relative efficacy. of selective serotonin reuptake inhibitors and tricyclic antidepressants in primary care is sparse and of variable quality. The study setting is likely to be important factor in assessing the efficacy and tolerability of treatment with antidepressant drugs.	Univ Auckland, Fac Med & Hlth Sci, Dept Gen Practice, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Div Psychiat, Auckland 1, New Zealand; Ninewells Hosp & Med Sch, Tayside Ctr Gen Practice, Dundee, Scotland; Ninewells Hosp & Med Sch, Dept Psychiat, Dundee, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland	University of Auckland; University of Auckland; University of Dundee; University of Dundee; University of Dundee	MacGillivray, S (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland.	s.a.macgillivray@dundee.ac.uk	Williams, Brian/AAS-3714-2021; Sullivan, Frank m/A-7767-2009; Reid, Ian C/B-8326-2008; Williams, Brian/G-5736-2012; Sullivan, Frank/L-8286-2019; macgillivray, Steve/A-5595-2012	Williams, Brian/0000-0003-0000-4354; Williams, Brian/0000-0003-0000-4354; Sullivan, Frank/0000-0002-6623-4964; MacGillivray, Stephen/0000-0002-1933-6431				ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; ARYA R, 1999, CURR OPIN, V12, P103; Furukawa TA, 2002, BMJ-BRIT MED J, V325, P991, DOI 10.1136/bmj.325.7371.991; Gill D, 1997, BRIT MED J, V314, P826; Hotopf M, 1997, BRIT J PSYCHIAT, V170, P120, DOI 10.1192/bjp.170.2.120; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Mulrow CD, 1994, COCHRANE LIB; *N ENGL EV BAS GUI, 1998, CHOIC ANT DEPR PRIM; Ronalds G, 1997, BRIT J PSYCHIAT, V171, P427, DOI 10.1192/bjp.171.5.427; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; Steffens D C, 1997, Depress Anxiety, V6, P10, DOI 10.1002/(SICI)1520-6394(1997)6:1<10::AID-DA2>3.0.CO;2-9; Suh T, 1997, PSYCHOL MED, V27, P1051, DOI 10.1017/S0033291797005205; Williams JW, 2000, ANN INTERN MED, V132, P743, DOI 10.7326/0003-4819-132-9-200005020-00011	14	173	176	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2003	326	7397					1014	1017		10.1136/bmj.326.7397.1014	http://dx.doi.org/10.1136/bmj.326.7397.1014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	679KG	12742924	Green Published			2022-12-28	WOS:000182920500018
J	Scheper-Hughes, N				Scheper-Hughes, N			Keeping an eye on the global traffic in human organs	LANCET			English	Article									Univ Calif Berkeley, Dept Anthropol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Scheper-Hughes, N (corresponding author), Univ Calif Berkeley, Dept Anthropol, Berkeley, CA 94720 USA.								0	80	80	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1645	1648		10.1016/S0140-6736(03)13305-3	http://dx.doi.org/10.1016/S0140-6736(03)13305-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747896				2022-12-28	WOS:000182746300026
J	Foulger, GR; Natland, JH				Foulger, GR; Natland, JH			Is "hotspot" volcanism a consequence of plate tectonics?	SCIENCE			English	Editorial Material							MANTLE; CONVECTION; ICELAND		Univ Durham, Dept Geol Sci, Durham DH1 3LE, England; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA	Durham University; University of Miami	Foulger, GR (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.							Anderson DL, 2001, SCIENCE, V293, P2016, DOI 10.1126/science.1065448; [Anonymous], [No title captured]; Breddam K, 2002, J PETROL, V43, P345, DOI 10.1093/petrology/43.2.345; Christiansen RL, 2002, GEOL SOC AM BULL, V114, P1245, DOI 10.1130/0016-7606(2002)114<1245:UMOOTY>2.0.CO;2; Courtillot V, 2003, EARTH PLANET SC LETT, V205, P295, DOI 10.1016/S0012-821X(02)01048-8; FOULGER GR, ASTRON GEOPHYS, V43, P2; Hieronymus CF, 1999, NATURE, V397, P604, DOI 10.1038/17584; King SD, 1998, EARTH PLANET SC LETT, V160, P289, DOI 10.1016/S0012-821X(98)00089-2; Koppers AAP, 2001, EARTH PLANET SC LETT, V185, P237, DOI 10.1016/S0012-821X(00)00387-3; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; NATLAND JH, 1980, AM J SCI, V280, P709; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; SMITH AD, 1993, TERRA NOVA, V5, P452, DOI 10.1111/j.1365-3121.1993.tb00283.x; STEIN C, 2003, ASTRON GEOPHYS, V44	14	146	158	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					921	922		10.1126/science.1083376	http://dx.doi.org/10.1126/science.1083376			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738845				2022-12-28	WOS:000182719800037
J	Hunt, JH				Hunt, JH			Cryptic herbivores of the rainforest canopy	SCIENCE			English	Editorial Material							ANTS		Univ Missouri, Dept Biol, St Louis, MO 63121 USA	University of Missouri System; University of Missouri Saint Louis	Hunt, JH (corresponding author), Univ Missouri, Dept Biol, 8001 Nat Bridge Rd, St Louis, MO 63121 USA.	jimhunt@umsl.edu	Hunt, James/D-1740-2009					Bluthgen N, 2000, OECOLOGIA, V125, P229, DOI 10.1007/s004420000449; CLARK DA, IN PRESS P NATL ACAD; Davidson D. W., 1996, NEOTROPICAL BIODIVER, P127; Davidson DW, 2003, SCIENCE, V300, P969, DOI 10.1126/science.1082074; Holldobler B., 1990, pi; Huxley C.R., 1991, ANT PLANT INTERACTIO; JANZEN DH, 1966, EVOLUTION, V20, P249, DOI 10.1111/j.1558-5646.1966.tb03364.x; Lowman Margaret D., 1995, P431; TOBIN JE, 1991, ANT - PLANT INTERACTIONS, P536; Tobin John E., 1995, P129; Tobin John E., 1994, P279; Wilson E.O., 1987, Conservation Biology, V1, P344, DOI 10.1111/j.1523-1739.1987.tb00055.x	12	21	22	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					916	917		10.1126/science.1085065	http://dx.doi.org/10.1126/science.1085065			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738842				2022-12-28	WOS:000182719800034
J	Morel, FMM; Price, NM				Morel, FMM; Price, NM			The biogeochemical cycles of trace metals in the oceans	SCIENCE			English	Review							EQUATORIAL PACIFIC-OCEAN; NATURAL ORGANIC-LIGANDS; MULTICOPPER OXIDASE; COLLOIDAL IRON; PHYTOPLANKTON; COPPER; COMPLEXATION; CADMIUM; CYANOBACTERIA; TERRESTRIAL	Planktonic uptake of some essential metals results in extraordinarily low concentrations in surface seawater. To sequester or take up these micronutrients, various microorganisms apparently release strong complexing agents and catalyze redox reactions that modify the bioavailability of trace metals and promote their rapid cycling in the upper water column. In turn, the low availability of some metals controls the rate of photosynthesis in parts of the oceans and the transformation and uptake of major nutrients such as nitrogen. The extremely low concentrations of several essential metals are both the cause and the result of ultraefficient uptake systems in the plankton and of widespread replacement of metals by one another for various biochemical functions.	Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	Princeton University; McGill University	Morel, FMM (corresponding author), Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA.	morel@princeton.edu	Morel, Francois M M/A-8107-2008; Price, Neil M./A-8963-2008	Price, Neil M./0000-0001-9986-9213				AHNER BA, COMMUNICATION; Barbeau K, 2001, NATURE, V413, P409, DOI 10.1038/35096545; Berman-Frank I, 2001, LIMNOL OCEANOGR, V46, P1249, DOI 10.4319/lo.2001.46.6.1249; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; BRULAND KW, 1989, LIMNOL OCEANOGR, V34, P269, DOI 10.4319/lo.1989.34.2.0269; BRULAND KW, 1980, EARTH PLANET SC LETT, V47, P176, DOI 10.1016/0012-821X(80)90035-7; Cavender-Bares KK, 1999, LIMNOL OCEANOGR, V44, P237, DOI 10.4319/lo.1999.44.2.0237; CHENG MD, 1989, ATMOS ENVIRON, V23, P1373, DOI 10.1016/0004-6981(89)90160-1; COALE KH, 1988, LIMNOL OCEANOGR, V33, P1084, DOI 10.4319/lo.1988.33.5.1084; Donat John R., 1995, P247; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; Francis CA, 2001, APPL ENVIRON MICROB, V67, P4272, DOI 10.1128/AEM.67.9.4272-4278.2001; Granger J, 2003, LIMNOL OCEANOGR, V48, P313, DOI 10.4319/lo.2003.48.1.0313; Herbik A, 2002, PLANT PHYSIOL, V130, P2039, DOI 10.1104/pp.013060; HUDSON RJM, 1993, DEEP-SEA RES PT I, V40, P129, DOI 10.1016/0967-0637(93)90057-A; Johnson KS, 1997, MAR CHEM, V57, P137, DOI 10.1016/S0304-4203(97)00043-1; Kogut MB, 2001, ENVIRON SCI TECHNOL, V35, P1149, DOI 10.1021/es0014584; KUSTKA AB, IN PRESS LIMNOL OCEA; Lane TW, 2000, P NATL ACAD SCI USA, V97, P4627, DOI 10.1073/pnas.090091397; Lee JG, 1996, ENVIRON SCI TECHNOL, V30, P1814, DOI 10.1021/es950331p; Macrellis HM, 2001, MAR CHEM, V76, P175, DOI 10.1016/S0304-4203(01)00061-5; Maldonado MT, 2001, J PHYCOL, V37, P298, DOI 10.1046/j.1529-8817.2001.037002298.x; Mann EL, 2002, LIMNOL OCEANOGR, V47, P976, DOI 10.4319/lo.2002.47.4.0976; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MARTIN JH, 1989, DEEP-SEA RES, V36, P649, DOI 10.1016/0198-0149(89)90144-1; MARTIN JH, 1973, GEOCHIM COSMOCHIM AC, V37, P1639, DOI 10.1016/0016-7037(73)90154-3; Martinez JS, 2001, LIMNOL OCEANOGR, V46, P420, DOI 10.4319/lo.2001.46.2.0420; Martinez JS, 2000, SCIENCE, V287, P1245, DOI 10.1126/science.287.5456.1245; Moffett JW, 1996, LIMNOL OCEANOGR, V41, P388, DOI 10.4319/lo.1996.41.3.0388; MOFFETT JW, 1987, PHOTOCHEMISTRY ENV A, P116; PRICE NM, 1991, LIMNOL OCEANOGR, V36, P1071, DOI 10.4319/lo.1991.36.6.1071; PRICE NM, 1994, LIMNOL OCEANOGR, V39, P520, DOI 10.4319/lo.1994.39.3.0520; RUE EL, 1995, MAR CHEM, V50, P117, DOI 10.1016/0304-4203(95)00031-L; Rue EL, 1997, LIMNOL OCEANOGR, V42, P901, DOI 10.4319/lo.1997.42.5.0901; Saito MA, 2002, LIMNOL OCEANOGR, V47, P1629, DOI 10.4319/lo.2002.47.6.1629; Saito MA, 2002, GEOCHIM COSMOCHIM AC, V66, P1943, DOI 10.1016/S0016-7037(02)00829-3; SUNDA WG, 1991, NATURE, V351, P55, DOI 10.1038/351055a0; SUNDA WG, 1988, DEEP-SEA RES, V35, P1297, DOI 10.1016/0198-0149(88)90084-2; Tebo BM, 1997, REV MINERAL, V35, P225; Tortell PD, 2000, LIMNOL OCEANOGR, V45, P1485, DOI 10.4319/lo.2000.45.7.1485; Tortell PD, 1996, NATURE, V383, P330, DOI 10.1038/383330a0; WAITE TD, 1984, ENVIRON SCI TECHNOL, V18, P860, DOI 10.1021/es00129a010; Wu JF, 2001, SCIENCE, V293, P847, DOI 10.1126/science.1059251	44	740	777	27	430	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					944	947		10.1126/science.1083545	http://dx.doi.org/10.1126/science.1083545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738853				2022-12-28	WOS:000182719800045
J	McVernon, J; Andrews, N; Slack, MPE; Ramsay, ME				McVernon, J; Andrews, N; Slack, MPE; Ramsay, ME			Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis	LANCET			English	Article							CAPSULAR POLYSACCHARIDE	An increase in invasive Hib disease incidence in the UK has coincided with the distribution of combination vaccines that contain acellular pertussis (DTaP-Hib). These vaccines have been associated with reduced Immunogenicity of the Hib component, although there is little agreement on the clinical relevance of this finding. We retrospectively compared vaccine formulations given to fully vaccinated Hib cases with those administered to fully immunised age-matched controls Using conditional logistic regression. More cases than controls received all three doses of their infant primary course as DTaP-Hib, compared with two or three doses of another Hib vaccine (conditional odds ratio 6.77 [95% CI 3.26-14.07]).	Hlth Protect Agcy, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England; Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England; Hlth Protect Agcy, Haemophilus Reference Unit, Oxford, England	Health Protection Agency; University of Oxford; Health Protection Agency	McVernon, J (corresponding author), Hlth Protect Agcy, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England.		; Ramsay, Mary Elizabeth/S-8281-2016	McVernon, Jodie/0000-0001-9774-1961; Ramsay, Mary Elizabeth/0000-0002-7156-7640				Anderson P, 2000, PEDIATR INFECT DIS J, V19, P589, DOI 10.1097/00006454-200007000-00001; Daum RS, 2001, J INFECT DIS, V184, P1293, DOI 10.1086/324007; Eskola J, 1999, LANCET, V354, P2063, DOI 10.1016/S0140-6736(99)04377-9; RAMSAY ME, IN PRESS J INFECT DI; *UK CHIEF MED OFF, PLANN HIB VACC CATCH	5	133	137	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1521	1523		10.1016/S0140-6736(03)13171-6	http://dx.doi.org/10.1016/S0140-6736(03)13171-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737866				2022-12-28	WOS:000182658900014
J	Sheth, U; Parker, R				Sheth, U; Parker, R			Decapping and decay of messenger RNA occur in cytoplasmic processing bodies	SCIENCE			English	Article							YEAST; PROTEINS; COMPLEX; DEADENYLATION; TRANSLATION; HELICASE; DEGRADATION; MECHANISMS; PARTICLES; MUTATIONS	A major pathway of eukaryotic messenger RNA ( mRNA) turnover begins with deadenylation, followed by decapping and 5' to 3' exonucleolytic decay. We provide evidence that mRNA decapping and 5' to 3' degradation occur in discrete cytoplasmic foci in yeast, which we call processing bodies ( P bodies). First, proteins that activate or catalyze decapping are concentrated in P bodies. Second, inhibiting mRNA turnover before decapping leads to loss of P bodies; however, inhibiting turnover at, or after, decapping, increases the abundance and size of P bodies. Finally, mRNA degradation intermediates are localized to P bodies. These results de. ne the flux of mRNAs between polysomes and P bodies as a critical aspect of cytoplasmic mRNA metabolism and a possible site for regulation of mRNA degradation.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Howard Hughes Med Inst, Tucson, AZ 85721 USA	University of Arizona; Howard Hughes Medical Institute; University of Arizona	Parker, R (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.	rrparker@u.arizona.edu			NIGMS NIH HHS [GM45443, R01 GM045443] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045443, R37GM045443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson P, 2002, J CELL SCI, V115, P3227; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Bonnerot C, 2000, MOL CELL BIOL, V20, P5939, DOI 10.1128/MCB.20.16.5939-5946.2000; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; BRENGUES M, UNPUB; Coller JM, 2001, RNA, V7, P1717, DOI 10.1017/S135583820101994X; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221; Ladomery M, 1997, NUCLEIC ACIDS RES, V25, P965, DOI 10.1093/nar/25.5.965; LaGrandeur T, 1999, RNA, V5, P420, DOI 10.1017/S1355838299981748; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Nakamura A, 2001, DEVELOPMENT, V128, P3233; Navarro RE, 2001, DEVELOPMENT, V128, P3221; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Schwartz DC, 2000, MOL CELL BIOL, V20, P7933, DOI 10.1128/MCB.20.21.7933-7942.2000; Schwartz DC, 1999, MOL CELL BIOL, V19, P5247; SHETH U, UNPUB; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Tharun S, 2001, MOL CELL, V8, P1075, DOI 10.1016/S1097-2765(01)00395-1; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; van Hoof A, 2000, MOL CELL BIOL, V20, P8230, DOI 10.1128/MCB.20.21.8230-8243.2000	33	973	1010	5	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					805	808		10.1126/science.1082320	http://dx.doi.org/10.1126/science.1082320			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730603	Green Accepted			2022-12-28	WOS:000182579800053
J	Gupta, S; Hadzibabic, Z; Zwierlein, MW; Stan, CA; Dieckmann, K; Schunck, CH; van Kempen, EGM; Verhaar, BJ; Ketterle, W				Gupta, S; Hadzibabic, Z; Zwierlein, MW; Stan, CA; Dieckmann, K; Schunck, CH; van Kempen, EGM; Verhaar, BJ; Ketterle, W			Radio-frequency spectroscopy of ultracold fermions	SCIENCE			English	Article							COLLISION FREQUENCY-SHIFT; LASER; GAS	Radio-frequency techniques were used to study ultracold fermions. We observed the absence of mean-field "clock" shifts, the dominant source of systematic error in current atomic clocks based on bosonic atoms. This absence is a direct consequence of fermionic antisymmetry. Resonance shifts proportional to interaction strengths were observed in a three-level system. However, in the strongly interacting regime, these shifts became very small, reflecting the quantum unitarity limit and many-body effects. This insight into an interacting Fermi gas is relevant for the quest to observe superfluidity in this system.	MIT, Dept Phys, Harvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA; MIT, Dept Phys, Elect Res Lab, Cambridge, MA 02139 USA; Eindhoven Univ Technol, NL-5600 MB Eindhoven, Netherlands	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Eindhoven University of Technology	Gupta, S (corresponding author), MIT, Dept Phys, Harvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA.	deep@mit.edu	Dieckmann, Kai/G-2363-2012; Stan, Claudiu/AAV-8091-2021; Hadzibabic, Zoran/B-8102-2011; Schunck, Christian H/A-3625-2010	Dieckmann, Kai/0000-0002-5305-2571; Hadzibabic, Zoran/0000-0002-0118-9285; Schunck, Christian H/0000-0002-7917-8180; /0000-0001-8120-8548				Bloch I, 1999, PHYS REV LETT, V82, P3008, DOI 10.1103/PhysRevLett.82.3008; DeMarco B, 1999, SCIENCE, V285, P1703, DOI 10.1126/science.285.5434.1703; Dieckmann K, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.203201; Fertig C, 2000, PHYS REV LETT, V85, P1622, DOI 10.1103/PhysRevLett.85.1622; GIBBLE K, 1993, PHYS REV LETT, V70, P1771, DOI 10.1103/PhysRevLett.70.1771; GIBBLE K, 1995, PHYS REV A, V52, P3370, DOI 10.1103/PhysRevA.52.3370; Gorlitz A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.090401; Granade SR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.120405; Hadzibabic Z, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.160401; Harber DM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.053616; Heiselberg H, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.043606; Holland M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.120406; Houbiers M, 1999, PHYS REV A, V59, P1556, DOI 10.1103/PhysRevA.59.1556; Houbiers M, 1998, PHYS REV A, V57, pR1497, DOI 10.1103/PhysRevA.57.R1497; Killian TC, 1998, PHYS REV LETT, V81, P3807, DOI 10.1103/PhysRevLett.81.3807; MARTIN AG, 1988, PHYS REV LETT, V61, P2431, DOI 10.1103/PhysRevLett.61.2431; Matthews MR, 1998, PHYS REV LETT, V81, P243, DOI 10.1103/PhysRevLett.81.243; Mewes MO, 1997, PHYS REV LETT, V78, P582, DOI 10.1103/PhysRevLett.78.582; O'Hara KM, 2002, SCIENCE, V298, P2179, DOI 10.1126/science.1079107; O'Hara KM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.041401; Roati G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.150403; Schreck F, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.080403; Sortais Y, 2001, PHYS SCRIPTA, VT95, P50, DOI 10.1238/Physica.Topical.095a00050; Stenger J, 1998, NATURE, V396, P345, DOI 10.1038/24567; Stenger J, 1999, PHYS REV LETT, V82, P4569, DOI 10.1103/PhysRevLett.82.4569; Truscott AG, 2001, SCIENCE, V291, P2570, DOI 10.1126/science.1059318; VANKEMPEN EGM, UNPUB	27	235	236	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1723	1726		10.1126/science.1085335	http://dx.doi.org/10.1126/science.1085335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12738872	Green Submitted			2022-12-28	WOS:000183459700044
J	Dalton, R				Dalton, R			Legal row looms for gene-map firm	NATURE			English	News Item																		2001, NATURE, V412, P105	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					470	470		10.1038/423470b	http://dx.doi.org/10.1038/423470b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774085	Bronze			2022-12-28	WOS:000183162900010
J	Makalowski, W				Makalowski, W			Not junk after all	SCIENCE			English	Editorial Material							ALU; PROTEIN		Penn State Univ, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Makalowski, W (corresponding author), Penn State Univ, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA.		Makalowski, Wojciech/I-2843-2016	Makalowski, Wojciech/0000-0003-2303-9541				BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; Chua K, 2001, MOL CELL BIOL, V21, P1509, DOI 10.1128/MCB.21.5.1509-1514.2001; IWASHITA S, IN PRESS MOL BIOL EV; Lev-Maor G, 2003, SCIENCE, V300, P1288, DOI 10.1126/science.1082588; MAKALOWSKI W, 1994, TRENDS GENET, V10, P188, DOI 10.1016/0168-9525(94)90254-2; Makalowski W, 2000, GENE, V259, P61, DOI 10.1016/S0378-1119(00)00436-4; MITCHELL GA, 1991, P NATL ACAD SCI USA, V88, P815, DOI 10.1073/pnas.88.3.815; NEI M, 1969, NATURE, V221, P40, DOI 10.1038/221040a0; Nobukuni T, 1997, J BIOL CHEM, V272, P2801, DOI 10.1074/jbc.272.5.2801; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; Ohno S., 1970, EVOLUTION GENE DUPLI; Sorek R, 2002, GENOME RES, V12, P1060, DOI 10.1101/gr.229302	13	75	87	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1246	1247		10.1126/science.1085690	http://dx.doi.org/10.1126/science.1085690			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764185				2022-12-28	WOS:000183042400034
J	Santer, BD; Wigley, TML; Meehl, GA; Wehner, MF; Mears, C; Schabel, M; Wentz, FJ; Ammann, C; Arblaster, J; Bettge, T; Washington, WM; Taylor, KE; Boyle, JS; Bruggemann, W; Doutriaux, C				Santer, BD; Wigley, TML; Meehl, GA; Wehner, MF; Mears, C; Schabel, M; Wentz, FJ; Ammann, C; Arblaster, J; Bettge, T; Washington, WM; Taylor, KE; Boyle, JS; Bruggemann, W; Doutriaux, C			Influence of satellite data uncertainties on the detection of externally forced climate change	SCIENCE			English	Article							TEMPERATURE TRENDS; SIMULATIONS; FINGERPRINT	Two independent analyses of the same satellite-based radiative emissions data yield tropospheric temperature trends that differ by 0.1degreesC per decade over 1979 to 2001. The troposphere warms appreciably in one satellite data set, while the other data set shows little overall change. These satellite data uncertainties are important in studies seeking to identify human effects on climate. A model-predicted "fingerprint" of combined anthropogenic and natural effects is statistically detectable only in the satellite data set with a warming troposphere. Our findings show that claimed inconsistencies between model predictions and satellite tropospheric temperature data (and between the latter and surface data) may be an artifact of data uncertainties.	Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA; Natl Ctr Atmospher Res, Boulder, CO 80303 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Remote Sensing Syst, Santa Rosa, CA 95401 USA; Univ Birmingham, Birmingham B15 2TT, W Midlands, England	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; National Center Atmospheric Research (NCAR) - USA; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Birmingham	Santer, BD (corresponding author), Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA.		Ammann, Caspar M/A-4899-2011; Wehner, Michael/F-7841-2015; Arblaster, Julie/C-1342-2010; Taylor, Karl E/F-7290-2011; Wigley, Tom M.L./B-4705-2008; Santer, Benjamin D/F-9781-2011; Schabel, Matthias C./H-4647-2019; Santer, Ben/ABA-1099-2021	Wehner, Michael/0000-0001-5991-0082; Arblaster, Julie/0000-0002-4287-2363; Taylor, Karl E/0000-0002-6491-2135; 				Allen MR, 1999, CLIM DYNAM, V15, P419, DOI 10.1007/s003820050291; AMMANN C, GEOPHYS RES LETT, V30; Christy JR, 2000, J ATMOS OCEAN TECH, V17, P1153, DOI 10.1175/1520-0426(2000)017<1153:MTTDCA>2.0.CO;2; HANSEN J, 2002, J GEOPHYS RES, V107; Hasselmann KF., 1979, METEOROLOGY TROPICAL, P251; Hegerl GC, 1996, J CLIMATE, V9, P2281, DOI 10.1175/1520-0442(1996)009<2281:DGGICC>2.0.CO;2; Hurrell JW, 1997, NATURE, V386, P164, DOI 10.1038/386164a0; Lanzante JR, 2003, J CLIMATE, V16, P241, DOI 10.1175/1520-0442(2003)016<0241:THOMRT>2.0.CO;2; MEARS CA, UNPUB; Meehl GA, 2001, CLIM DYNAM, V17, P515, DOI 10.1007/PL00007929; Meehl GA, 2003, J CLIMATE, V16, P426, DOI [10.1175/1520-0442(2003)016<0426:SAGGFA>2.0.CO;2, 10.1175/1520-0442(2003)016&lt;0426:SAGGFA&gt;2.0.CO;2]; Mitchell JFB, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P695; Ramaswamy V, 1996, NATURE, V382, P616, DOI 10.1038/382616a0; Ramaswamy V, 2001, REV GEOPHYS, V39, P71, DOI 10.1029/1999RG000065; Ramaswamy V., 2001, CLIMATE CHANGE 2001, P349; Roeckner E, 1999, J CLIMATE, V12, P3004, DOI 10.1175/1520-0442(1999)012<3004:TCCSWA>2.0.CO;2; SANTER BD, 1995, J GEOPHYS RES-OCEANS, V100, P10693, DOI 10.1029/95JC00683; Santer BD, 1999, J GEOPHYS RES-ATMOS, V104, P6305, DOI 10.1029/1998JD200096; Santer BD, 2001, J GEOPHYS RES-ATMOS, V106, P28033, DOI 10.1029/2000JD000189; Santer BD, 2000, J GEOPHYS RES-ATMOS, V105, P7337, DOI 10.1029/1999JD901105; SANTER BD, 2003, J GEOPHYS RES, V108; Singer SF, 1999, EOS T AGU, V80, P183; SPENCER RW, 1992, J CLIMATE, V5, P847, DOI 10.1175/1520-0442(1992)005<0847:PARVOS>2.0.CO;2; Stott PA, 1998, J CLIMATE, V11, P3282, DOI 10.1175/1520-0442(1998)011<3282:SDDOCC>2.0.CO;2; Stott PA, 2000, SCIENCE, V290, P2133, DOI 10.1126/science.290.5499.2133; TETT SFB, 2002, J GEOPHYS RES, V107; WALLACE JM, 2000, RECONCILING OBSERVAT; Washington WM, 2000, CLIM DYNAM, V16, P755, DOI 10.1007/s003820000079; Wentz FJ, 2000, NATURE, V403, P414, DOI 10.1038/35000184; Wentz FJ, 1998, NATURE, V394, P661, DOI 10.1038/29267	30	53	54	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1280	1284		10.1126/science.1082393	http://dx.doi.org/10.1126/science.1082393			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12730497				2022-12-28	WOS:000183042400046
J	Earley, CJ				Earley, CJ			Restless legs syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIMB MOVEMENT DISORDER; DOUBLE-BLIND; NOCTURNAL-MYOCLONUS; UREMIC PATIENTS; IRON STATUS; L-DOPA; PERGOLIDE; SLEEP; TRIAL; CARBIDOPA/LEVODOPA		Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Earley, CJ (corresponding author), Johns Hopkins Bayview Med Ctr, 5501 Hopkins Bayview Circle,AAC-1B-82, Baltimore, MD 21224 USA.							Allen RP, 2000, SLEEP MED, V1, P11, DOI 10.1016/S1389-9457(99)00012-X; Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Allen RP, 2001, J CLIN NEUROPHYSIOL, V18, P128, DOI 10.1097/00004691-200103000-00004; Allen RP, 1996, SLEEP, V19, P205, DOI 10.1093/sleep/19.3.205; Baynes RD, 1996, CLIN BIOCHEM, V29, P209, DOI 10.1016/0009-9120(96)00010-K; BOTEZ MI, 1977, NEW ENGL J MED, V297, P670; Cheshire WP, 2000, NEUROLOGY, V55, P1923, DOI 10.1212/WNL.55.12.1923; Chesson AL, 1999, SLEEP, V22, P961, DOI 10.1093/sleep/22.7.961; COLEMAN RM, 1980, ANN NEUROL, V8, P416, DOI 10.1002/ana.410080413; Davis BJ, 2000, EUR NEUROL, V43, P70, DOI 10.1159/000008138; Desautels A, 2001, AM J HUM GENET, V69, P1266, DOI 10.1086/324649; Earley CJ, 1996, SLEEP, V19, P801, DOI 10.1093/sleep/19.10.801; Earley CJ, 2000, J NEUROSCI RES, V62, P623, DOI 10.1002/1097-4547(20001201)62:5<623::AID-JNR1>3.3.CO;2-8; Ekbom KA, 1960, NEUROLOGY, V10, P868, DOI 10.1212/WNL.10.9.868; GOODMAN JDS, 1988, BRIT MED J, V297, P1101, DOI 10.1136/bmj.297.6656.1101-a; Hening W, 1999, SLEEP, V22, P970; Hui DSC, 2000, AM J KIDNEY DIS, V36, P783, DOI 10.1053/ajkd.2000.17664; Lachenmayer L, 2000, J NEUROL, V247, P28; Lee KA, 2001, J WOMEN HEALTH GEN-B, V10, P335, DOI 10.1089/152460901750269652; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; Montplaisir J, 1999, NEUROLOGY, V52, P938, DOI 10.1212/WNL.52.5.938; Montplaisir J, 2000, PRINCIPLES PRACTICE, P742; NORDLANDER N B, 1954, Br J Phys Med, V17, P160; NORDLANDER NB, 1953, ACTA MED SCAND, V145, P453; OKEEFFE ST, 1994, AGE AGEING, V23, P200, DOI 10.1093/ageing/23.3.200; OKEEFFE ST, 1993, POSTGRAD MED J, V69, P701, DOI 10.1136/pgmj.69.815.701; Pieta J, 1998, SLEEP, V21, P617, DOI 10.1093/sleep/21.6.617; Polydefkis M, 2000, NEUROLOGY, V55, P1115, DOI 10.1212/WNL.55.8.1115; Rutkove SB, 1996, MUSCLE NERVE, V19, P670, DOI 10.1002/(SICI)1097-4598(199605)19:5<670::AID-MUS20>3.0.CO;2-Q; SANDYK R, 1987, INT J NEUROSCI, V35, P233, DOI 10.3109/00207458708987132; Silber MH, 1997, SLEEP, V20, P878, DOI 10.1093/sleep/20.10.878; Staedt J, 1998, J NEURAL TRANSM, V105, P265, DOI 10.1007/s007020050055; Stiasny K, 2001, NEUROLOGY, V56, P1399, DOI 10.1212/WNL.56.10.1399; Sun ER, 1998, SLEEP, V21, P371, DOI 10.1093/sleep/21.4.381; TRENKWALDER C, 1995, SLEEP, V18, P681, DOI 10.1093/sleep/18.8.681; Walker SL, 1996, SLEEP, V19, P214; Wetter TC, 1999, NEUROLOGY, V52, P944, DOI 10.1212/WNL.52.5.944; Winkelman JW, 1996, AM J KIDNEY DIS, V28, P372, DOI 10.1016/S0272-6386(96)90494-1	38	194	201	1	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2103	2109		10.1056/NEJMcp021288	http://dx.doi.org/10.1056/NEJMcp021288			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761367				2022-12-28	WOS:000183008300008
J	Milutinovich, M; Koshland, DE				Milutinovich, M; Koshland, DE			SMC complexes - Wrapped up in controversy	SCIENCE			English	Editorial Material							STRUCTURAL MAINTENANCE; CHROMOSOMES SMC; PROTEINS; DNA; CONDENSIN; COHESION; HINGE; LONG		Carnegie Inst Washington, Howard Hughes Med Inst, Baltimore, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute	Milutinovich, M (corresponding author), Carnegie Inst Washington, Howard Hughes Med Inst, Baltimore, MD 21210 USA.							Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Gillespie PJ, 2002, CURR BIOL, V12, pR513, DOI 10.1016/S0960-9822(02)01024-2; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Koshland DE, 2000, CURR OPIN CELL BIOL, V12, P297, DOI 10.1016/S0955-0674(00)00092-2; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x	13	50	53	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1101	1102		10.1126/science.1084478	http://dx.doi.org/10.1126/science.1084478			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750506				2022-12-28	WOS:000182886500029
J	Groet, J; McElwaine, S; Spinelli, M; Rinaldi, A; Burtscher, I; Mulligan, C; Mensah, A; Cavani, S; Dagna-Bricarelli, F; Basso, G; Cotter, FE; Nizetic, D				Groet, J; McElwaine, S; Spinelli, M; Rinaldi, A; Burtscher, I; Mulligan, C; Mensah, A; Cavani, S; Dagna-Bricarelli, F; Basso, G; Cotter, FE; Nizetic, D			Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder	LANCET			English	Editorial Material							LEUKEMIA	Transient myeloid disorder Is a unique self-regressing neoplasia specific to Down's syndrome. The transcription factor GATA1 is needed for normal growth and maturation of erythroid cells and megakaryocytes. Mutations in GATA1 have been reported in acute megakaryoblastic leukaemia In Down's syndrome. We aimed to investigate changes in GATA1 in patients with Down's syndrome and either transient myeloid disorder (n=10) or acute megakaryoblastic leukaemia (n=6). We recorded mutations eliminating exon 2 from GATA1 In all patients with transient myeloid disorder (age 0-24 days) and In all with acute megakaryoblastic leukaemia (age 14-38 months). The range of mutations did not differ between patients with each disorder. Patients with transient myeloid disorder with mutations in GATA1 can regress spontaneously to complete remission, and mutations do not necessarily predict later acute megakaryoblastic leukaemia.	Univ London, Queen Marys Sch Med, St Bartholomews & Royal London Hosp, Dept Haematol, London E1 2AD, England; Univ Padua, Fac Med, Dept Pediat, Italian Natl Assoc Pediat Haematooncol, Padua, Italy; Galliera Hosp, Inst Human Genet, Genoa, Italy	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; University of Padua; Ente Ospedaliero Ospedali Galliera	Nizetic, D (corresponding author), Univ London, Queen Marys Sch Med, St Bartholomews & Royal London Hosp, Dept Haematol, Med Coll Bldg,Turner St, London E1 2AD, England.		Nizetic, Dean/F-9509-2015	BASSO, GIUSEPPE/0000-0002-2634-9302; Mensah, Afua Adjeiwaa/0000-0001-8113-3689; Nizetic, Dean/0000-0001-5486-5761	Telethon [C.51] Funding Source: Medline	Telethon(Fondazione Telethon)		Al-Kasim F, 2002, J PEDIAT HEMATOL ONC, V24, P9, DOI 10.1097/00043426-200201000-00004; GARNIS AS, 2002, J PEDIAT HEMATOL ONC, V24, P2; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Taub JW, 2002, J PEDIAT HEMATOL ONC, V24, P6, DOI 10.1097/00043426-200201000-00003; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955	5	126	131	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1617	1620		10.1016/S0140-6736(03)13266-7	http://dx.doi.org/10.1016/S0140-6736(03)13266-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747884				2022-12-28	WOS:000182746300014
J	Hall, WD; Mant, A; Mitchell, PB; Rendle, VA; Hickie, IB; McManus, P				Hall, WD; Mant, A; Mitchell, PB; Rendle, VA; Hickie, IB; McManus, P			Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis	BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION; RATES	Objective To examine die association between trends in antidepressant prescribing and suicide rates in Australia for 1991-2000. Design Analysis of databases of suicide and rates of antidepressant prescribing according to age and sex. Setting Australian Bureau of Statistics data, sales data from the Australian pharmaceutical industry, prescribing data in general practice. Subjects Men and women aged 15 years and over in 10 year age groups. Main outcome measures Trends in suicide rates and trends in antidepressant prescribing. Association measured by Spearman's rank correlations. Results While overall national rates of suicide did not fall significantly, incidence decreased in older men and women and increased in younger adults. In both men (r(s)=-0.91; P<0.01) and women (r(s)=-.0.76; P<0.05) the higher the exposure to antidepressants the larger the decline in rate of suicide. Conclusions Changes in suicide rates and exposure to antidepressants in Australia for 1991-2000 are significantly associated. This effect is most apparent in older age groups, in which rates of suicide decreased substantially in association with exposure to antidepressants. The increase in antidepressant prescribing may be a proxy marker for improved overall management of depression. If so, increased prescribing of selective serotonin reuptake inhibitors in general practice may have produced a quantifiable benefit in population mental health.	Univ New S Wales, Sch Psychiat, Randwick, NSW 2031, Australia; Beyond Blue Natl Depress Initiat, Melbourne, Vic 3122, Australia; Dept Hlth & Ageing, Drug Utilisat Subcomm, Canberra, ACT 2601, Australia; Univ Queensland, Inst Mol Biosci, Off Publ Policy & Eth, Brisbane, Qld 4072, Australia; Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of Queensland; University of New South Wales Sydney	Mant, A (corresponding author), Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia.		Hickie, Ian B/K-8975-2015; anand, amit/A-7222-2009; Hall, Wayne D/A-3283-2008	Hickie, Ian B/0000-0001-8832-9895; Hall, Wayne D/0000-0003-1984-0096; Mitchell, Philip/0000-0002-7954-5235				*AUSTR BUR STAT, 2000, SUIC AUSTR; Australian Bureau of Statistics, AUSTR SOC TRENDS 200; Barbui C, 1999, SOC PSYCH PSYCH EPID, V34, P152, DOI 10.1007/s001270050127; Bridges-Webb C., 1992, MED J AUST S, V157, pS1; Bridges-Webb Charles, 1992, Medical Journal of Australia, V157, pS1; BRITT H, GEN PRACTICE SERIES, V8; BRITT H, 2001, GEN PRACTICE SERIES, V8; Britt H, 1999, GEN PRACTICE SERIES; Carlsten A, 2001, PHARMACOEPIDEM DR S, V10, P525, DOI 10.1002/pds.618; CATALANO P, 2001, NATL ALCOHOL INDICAT, V4; Cook T.C., 1979, QUASIEXPERIMENTATION; Headey B, 1999, AUSTRALAS J AGEING, V18, P32, DOI 10.1111/j.1741-6612.1999.tb00887.x; Hickie IB, 2002, MED J AUSTRALIA, V176, pS61; Hickie IB, 2001, MED J AUSTRALIA, V175, pS25; Isacsson G, 2000, ACTA PSYCHIAT SCAND, V102, P113, DOI 10.1034/j.1600-0447.2000.102002113.x; Isacsson G, 1996, J AFFECT DISORDERS, V41, P1, DOI 10.1016/0165-0327(96)00050-X; Jorm AF, 2000, AUST NZ J PSYCHIAT, V34, P619, DOI 10.1046/j.1440-1614.2000.00761.x; Mackay FR, 1999, BRIT J GEN PRACT, V49, P892; McManus P, 2000, MED J AUSTRALIA, V173, P458, DOI 10.5694/j.1326-5377.2000.tb139294.x; Morrell S, 2001, ECON LABOUR RELAT RE, V12, P4; Naismith SL, 2001, MED J AUSTRALIA, V175, pS42; PRESKORN SH, 1994, J CLIN PSYCHIAT, V55, P6; Rihmer Z, 2001, EUR PSYCHIAT, V16, P406, DOI 10.1016/S0924-9338(01)00598-3; Vagholkar S, 1996, Aust Fam Physician, V25, P370; Webb M., 2000, NATL ALCOHOL INDICAT, V2; *WHO COLL CTR DRUG, 1998, METH GUID ATC CLASS	26	215	222	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1008	1011		10.1136/bmj.326.7397.1008	http://dx.doi.org/10.1136/bmj.326.7397.1008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	679KG	12742921	Bronze, Green Published			2022-12-28	WOS:000182920500015
J	Nizak, C; Monier, S; del Nery, E; Moutel, S; Goud, B; Perez, F				Nizak, C; Monier, S; del Nery, E; Moutel, S; Goud, B; Perez, F			Recombinant antibodies to the small GTPase Rab6 as conformation sensors	SCIENCE			English	Article							TO-TGN TRANSPORT; IN-VIVO; COMPLEX; CELLS; GOLGI; SELECTION; PROTEINS; PATHWAY	Here we report an approach, based on antibody phage display, to generate molecular conformation sensors. Recombinant antibodies specific to the guanosine triphosphate (GTP)-bound conformation of the small guanosine triphosphatase (GTPase) Rab6, a regulator of membrane traffic, were generated and used to locate Rab6.GTP in fixed cells, and, after green fluorescent protein (GFP) tagging and intracellular expression, to follow Rab6.GTP in vivo. Rab6 was in its GTP-bound conformation on the Golgi apparatus and transport intermediates, and the geometry of transport intermediates was modulated by Rab6 activity. More generally, the same approach could be applied to other molecules that can be locked in a particular conformation in vitro.	Inst Curie, CNRS, UMR144, F-75248 Paris 05, France; Inst Curie, Translat Dept, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Perez, F (corresponding author), Inst Curie, CNRS, UMR144, 26 Rue Ulm, F-75248 Paris 05, France.		Tschöpe, Solange Monier/L-9120-2018; Perez, Franck/A-1558-2014; Nizak, Clement/L-1334-2013; Nizak, Clement/HGV-1085-2022; Goud, Bruno/GWC-4807-2022	Perez, Franck/0000-0002-9129-9401; Nizak, Clement/0000-0002-4591-8240; Nizak, Clement/0000-0002-4591-8240; Moutel, Sandrine/0000-0002-9585-4855; DEL NERY, Elaine/0000-0002-9654-5202				BIOCCA S, 1995, TRENDS CELL BIOL, V5, P59; Cohen Pascale A, 2002, Methods Mol Biol, V178, P367; Darchen F, 2000, BIOCHIMIE, V82, P375, DOI 10.1016/S0300-9084(00)00219-4; DEMAUR AA, 2002, J BIOL CHEM, V277, P45075; Echard A, 2000, MOL BIOL CELL, V11, P3819, DOI 10.1091/mbc.11.11.3819; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Matanis T, 2002, NAT CELL BIOL, V4, P986, DOI 10.1038/ncb891; Monier S, 2002, TRAFFIC, V3, P289, DOI 10.1034/j.1600-0854.2002.030406.x; MONIER S, UNPUB; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NIZAK C, UNPUB; Plafker K, 2002, J BIOL CHEM, V277, P30121, DOI 10.1074/jbc.M203006200; Short B, 2002, CURR BIOL, V12, P1792, DOI 10.1016/S0960-9822(02)01221-6; Smothers JF, 2002, SCIENCE, V298, P621, DOI 10.1126/science.298.5593.621; STAHL B, 1994, J BIOL CHEM, V269, P24770; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Worn A, 2001, J MOL BIOL, V305, P989, DOI 10.1006/jmbi.2000.4265	24	102	111	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					984	987		10.1126/science.1083911	http://dx.doi.org/10.1126/science.1083911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738866				2022-12-28	WOS:000182719800058
J	Starzl, TE; Murase, N; Abu-Elmagd, K; Gray, EA; Shapiro, R; Eghtesad, B; Corry, RJ; Jordan, ML; Fontes, P; Gayowski, T; Bond, G; Scantlebury, VP; Potdar, S; Randhawa, P; Wu, T; Zeevi, A; Nalesnik, MA; Woodward, J; Marcos, A; Trucco, M; Demetris, AJ; Fung, JJ				Starzl, TE; Murase, N; Abu-Elmagd, K; Gray, EA; Shapiro, R; Eghtesad, B; Corry, RJ; Jordan, ML; Fontes, P; Gayowski, T; Bond, G; Scantlebury, VP; Potdar, S; Randhawa, P; Wu, T; Zeevi, A; Nalesnik, MA; Woodward, J; Marcos, A; Trucco, M; Demetris, AJ; Fung, JJ			Tolerogenic immunosuppression for organ transplantation	LANCET			English	Article							BONE-MARROW; ALLOGRAFT RECIPIENTS; GRAFT ACCEPTANCE; CELL-MIGRATION; LIVER; TOLERANCE; DONOR; CHIMERISM; REJECTION; KIDNEY	Background Insight into the mechanisms of organ engraftment and acquired tolerance has made it possible to facilitate these mechanisms, by tailoring the timing and dosage of immunosuppression in accordance with two therapeutic principles: recipient pretreatment, and minimum use of post-transplant immunosuppression. We aimed to apply these principles in recipients of renal and extrarenal organ transplants. Methods 82 patients awaiting kidney, liver, pancreas, or intestinal transplantation were pretreated with about 5 mg/kg of a broadly reacting rabbit antithymocyte globulin during several hours. Post-transplant immunosuppression was restricted to tacrolimus unless additional drugs were needed to treat breakthrough rejection. After 4 months, patients on tacrolimus monotherapy were considered for dose-spacing to every other day or longer intervals. Findings We frequently saw evidence of immune activation in graft biopsy samples, but unless this was associated with graft dysfunction or serious immune destruction, treatment usually was not intensified. Immunosuppression-related morbidity was virtually eliminated. 78 (95%) of 82 patients survived at 1 year and at 13-18 months. Graft survival was 73 (89%) of 82 at 1 year and 72 (88%) of 82 at 13-18 months. Of the 72 recipients with surviving grafts, 43 are on spaced doses of tacrolimus monotherapy: every other day (n=6), three times per week (11), twice per week (15), or once per week (11). Interpretation The striking ability to wean immunosuppression in these recipients indicates variable induction of tolerance. The simple therapeutic principles are neither drug-specific nor organ-specific. Systematic application of these principles should allow improvements in quality of life and long-term survival after organ transplantation.	Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Dept Paediat, Div Immunogenet, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Starzl, TE (corresponding author), UPMC Montefiore, Inst Transplantat, 7th Floor,S 3459 5th Ave, Pittsburgh, PA 15213 USA.		FUNG, John Julian/A-2679-2012; Randhawa, Parmjeet/H-4285-2019	FUNG, John Julian/0000-0002-3038-0441; 	NIDDK NIH HHS [R01 DK029961-19, DK 29961] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Elmagd K, 2001, ANN SURG, V234, P404, DOI 10.1097/00000658-200109000-00014; BARBER WH, 1989, TRANSPLANTATION, V47, P66, DOI 10.1097/00007890-198901000-00015; CALNE R, 1994, LANCET, V343, P67, DOI 10.1016/S0140-6736(94)90809-5; Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4; Demetris AJ, 1997, HEPATOLOGY, V25, P658; FONTES P, 1994, LANCET, V344, P151, DOI 10.1016/S0140-6736(94)92756-1; Garcia-Morales R, 1998, TRANSPLANTATION, V65, P956, DOI 10.1097/00007890-199804150-00016; Ichikawa N, 2000, LIVER TRANSPLANT, V6, P686, DOI 10.1053/jlts.2000.19029; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; MURASE N, 1995, TRANSPLANTATION, V60, P158, DOI 10.1097/00007890-199507270-00009; MYBURGH JA, 1986, WORLD J SURG, V10, P369, DOI 10.1007/BF01655296; MYBURGH JA, 1991, PATHWAYS APPL IMMUNO, P87; Preville X, 2001, TRANSPLANTATION, V71, P460, DOI 10.1097/00007890-200102150-00021; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Sakamoto T, 1999, TRANSPLANTATION, V67, P833, DOI 10.1097/00007890-199903270-00009; Smiley ST, 2000, TRANSPLANTATION, V70, P415, DOI 10.1097/00007890-200008150-00005; STARZL TE, 1968, NEW ENGL J MED, V278, P642, DOI 10.1056/NEJM196803212781202; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385; Starzl TE, 2002, J AM COLL SURGEONS, V195, P587, DOI 10.1016/S1072-7515(02)01498-9; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Starzl TE, 2001, NAT REV IMMUNOL, V1, P233, DOI 10.1038/35105088; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; Starzl TE, 1998, NEW ENGL J MED, V339, P1905, DOI 10.1056/NEJM199812243392607; STARZL TE, 1985, CHRONIC RENAL DIS, P507; Takatsuki M, 2001, TRANSPLANTATION, V72, P449, DOI 10.1097/00007890-200108150-00016; Wang CM, 2001, TRANSPLANTATION, V72, P44, DOI 10.1097/00007890-200107150-00011	27	365	386	1	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1502	1510		10.1016/S0140-6736(03)13175-3	http://dx.doi.org/10.1016/S0140-6736(03)13175-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737859	Green Accepted			2022-12-28	WOS:000182658900008
J	Richard, C; Balavoine, F; Schultz, P; Ebbesen, TW; Mioskowski, C				Richard, C; Balavoine, F; Schultz, P; Ebbesen, TW; Mioskowski, C			Supramolecular self-assembly of lipid derivatives on carbon nanotubes	SCIENCE			English	Article							PROTEINS; CRYSTALLIZATION; FLUORESCENCE; ORGANIZATION; SURFACTANTS; MICROSCOPY; ELECTRODE	Images of the assembly of surfactants and synthetic lipids on the surface of carbon nanotubes were obtained by transmission electron microscopy. Above the critical micellar concentration, sodium dodecyl sulfate (SDS) forms supramolecular structures made of rolled-up half-cylinders on the nanotube surface. Depending on the symmetry and the diameter of the carbon nanotube, we observed rings, helices, or double helices. Similar self-assemblies were also obtained with several synthetic single-chain lipids designed for the immobilization of histidine-tagged proteins. At the nanotube-water interface, permanent assemblies were produced from mixed micelles of SDS and different water-insoluble double-chain lipids after dialysis of the surfactant. Such arrangements could be further exploited for the development of new biosensors and bioelectronic nanomaterials.	CEA Saclay, Serv Marquage Mol & Chim Bioorgan, F-91191 Gif Sur Yvette, France; Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Univ Strasbourg 1, ISIS, F-67000 Strasbourg, France; Fac Pharm, CNRS, UMR 7514, F-67401 Illkirch Graffenstaden, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mioskowski, C (corresponding author), CEA Saclay, Serv Marquage Mol & Chim Bioorgan, Bat 547, F-91191 Gif Sur Yvette, France.		Richard, Cyrille/O-6802-2017	Richard, Cyrille/0000-0003-4896-6675; schultz, patrick/0000-0002-7310-6186				Ajayan PM, 1999, CHEM REV, V99, P1787, DOI 10.1021/cr970102g; Aksay IA, 1996, SCIENCE, V273, P892, DOI 10.1126/science.273.5277.892; Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s; Bonard JM, 1997, ADV MATER, V9, P827, DOI 10.1002/adma.19970091014; Burghard M, 1998, ADV MATER, V10, P584, DOI 10.1002/(SICI)1521-4095(199805)10:8<584::AID-ADMA584>3.0.CO;2-9; Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95; Dieckmann GR, 2003, J AM CHEM SOC, V125, P1770, DOI 10.1021/ja029084x; Dorn IT, 1998, J AM CHEM SOC, V120, P2753, DOI 10.1021/ja9735620; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972; KUBALEK EW, 1994, J STRUCT BIOL, V113, P117, DOI 10.1006/jsbi.1994.1039; MANNE S, 1994, LANGMUIR, V10, P4409, DOI 10.1021/la00024a003; MANNE S, 1995, SCIENCE, V270, P1480, DOI 10.1126/science.270.5241.1480; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Paborsky LR, 1996, ANAL BIOCHEM, V234, P60, DOI 10.1006/abio.1996.0050; Patrick HN, 2000, COLLOID SURFACE A, V162, P149, DOI 10.1016/S0927-7757(99)00187-9; RICHARD C, 2000, THESIS U PARIS SUD O; Schmid EL, 1997, ANAL CHEM, V69, P1979, DOI 10.1021/ac9700033; Sigal GB, 1996, ANAL CHEM, V68, P490, DOI 10.1021/ac9504023; Wanless EJ, 1996, J PHYS CHEM-US, V100, P3207, DOI 10.1021/jp952439x; Yakobson BI, 1997, AM SCI, V85, P324; ZETTLEMO.AC, 1968, J COLLOID INTERF SCI, V28, P343, DOI 10.1016/0021-9797(68)90066-0	24	694	717	4	285	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					775	778		10.1126/science.1080848	http://dx.doi.org/10.1126/science.1080848			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730595				2022-12-28	WOS:000182579800043
J	Riley, S; Fraser, C; Donnelly, CA; Ghani, AC; Abu-Raddad, LJ; Hedley, AJ; Leung, GM; Ho, LM; Lam, TH; Thach, TQ; Chau, P; Chan, KP; Leung, PY; Tsang, T; Ho, W; Lee, KH; Lau, EMC; Ferguson, NM; Anderson, RM				Riley, S; Fraser, C; Donnelly, CA; Ghani, AC; Abu-Raddad, LJ; Hedley, AJ; Leung, GM; Ho, LM; Lam, TH; Thach, TQ; Chau, P; Chan, KP; Leung, PY; Tsang, T; Ho, W; Lee, KH; Lau, EMC; Ferguson, NM; Anderson, RM			Transmission dynamics of the etiological agent of SARS in Hong Kong: Impact of public health interventions	SCIENCE			English	Article							ACUTE RESPIRATORY SYNDROME; CORONAVIRUS	We present an analysis of the first 10 weeks of the severe acute respiratory syndrome (SARS) epidemic in Hong Kong. The epidemic to date has been characterized by two large clusters - initiated by two separate "super-spread" events (SSEs) - and by ongoing community transmission. By fitting a stochastic model to data on 1512 cases, including these clusters, we show that the etiological agent of SARS is moderately transmissible. Excluding SSEs, we estimate that 2.7 secondary infections were generated per case on average at the start of the epidemic, with a substantial contribution from hospital transmission. Transmission rates fell during the epidemic, primarily as a result of reductions in population contact rates and improved hospital infection control, but also because of more rapid hospital attendance by symptomatic individuals. As a result, the epidemic is now in decline, although continued vigilance is necessary for this to be maintained. Restrictions on longer range population movement are shown to be a potentially useful additional control measure in some contexts. We estimate that most currently infected persons are now hospitalized, which highlights the importance of control of nosocomial transmission.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London SW7 2AZ, England; Univ Hong Kong, Dept Community Med, Pokfulam, Hong Kong, Peoples R China; Govt Hong Kong Special Adm Reg, Hlth Welf & Food Bur, Res Off, Hong Kong, Hong Kong, Peoples R China; Govt Hong Kong Special Adm Reg, Dept Hlth, Wanchai, Hong Kong, Peoples R China; Hong Kong Hosp Author, Kowloon, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Sch Publ Hlth, Prince Wales Hosp, Dept Community & Family Med, Shatin, Hong Kong, Peoples R China	Imperial College London; University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital	Riley, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, Exhibit Rd, London SW7 2AZ, England.	s.riley@imperial.ac.uk	Ghani, Azra/B-8560-2009; Abu-Raddad, Laith J/AAY-1441-2020; Fraser, Christophe/A-8109-2008; Chan, King Pan/C-4523-2009; Hedley, Anthony/C-4305-2009; Thach, Thuan-Quoc/C-4416-2009; Leung, Gabriel Matthew/C-4336-2009; Ferguson, Neil/B-8578-2008; Hedley, Anthony J/A-9113-2013; Lam, Tai Hing/C-4317-2009	Abu-Raddad, Laith J/0000-0003-0790-0506; Fraser, Christophe/0000-0003-2399-9657; Thach, Thuan-Quoc/0000-0003-3404-3888; Ferguson, Neil/0000-0002-1154-8093; Ghani, Azra/0000-0002-0007-4910; Donnelly, Christl/0000-0002-0195-2463; Leung, Gabriel/0000-0002-2503-6283; Anderson, Roy/0000-0002-9528-3175; Lam, Tai Hing/0000-0002-2033-9971; ho, lm/0000-0002-2709-927X; Riley, Steven/0000-0001-7904-4804				ANDERSON R M, 1991; DIEKMANN O, 2002, MATH EPIDEMIOLOGY IN; DONNELLY CA, 2003, LANCET          0507; Ferguson NM, 2003, J ANTIMICROB CHEMOTH, V51, P977, DOI 10.1093/jac/dkg136; *HONG KONG DEP HLT, 2003, OUTBR SEV AC RESP SY; *HONG KONG POL DEC, UNPUB SEL DAIL REP S; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; PEIRIS JSM, 2003, LANCET          0509; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634	12	741	804	11	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1961	1966		10.1126/science.1086478	http://dx.doi.org/10.1126/science.1086478			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12766206				2022-12-28	WOS:000183619400052
J	Rota, PA; Oberste, MS; Monroe, SS; Nix, WA; Campagnoli, R; Icenogle, JP; Penaranda, S; Bankamp, B; Maher, K; Chen, MH; Tong, SX; Tamin, A; Lowe, L; Frace, M; DeRisi, JL; Chen, Q; Wang, D; Erdman, DD; Peret, TCT; Burns, C; Ksiazek, TG; Rollin, PE; Sanchez, A; Liffick, S; Holloway, B; Limor, J; McCaustland, K; Olsen-Rasmussen, M; Fouchier, R; Gunther, S; Osterhaus, ADME; Drosten, C; Pallansch, MA; Anderson, LJ; Bellini, WJ				Rota, PA; Oberste, MS; Monroe, SS; Nix, WA; Campagnoli, R; Icenogle, JP; Penaranda, S; Bankamp, B; Maher, K; Chen, MH; Tong, SX; Tamin, A; Lowe, L; Frace, M; DeRisi, JL; Chen, Q; Wang, D; Erdman, DD; Peret, TCT; Burns, C; Ksiazek, TG; Rollin, PE; Sanchez, A; Liffick, S; Holloway, B; Limor, J; McCaustland, K; Olsen-Rasmussen, M; Fouchier, R; Gunther, S; Osterhaus, ADME; Drosten, C; Pallansch, MA; Anderson, LJ; Bellini, WJ			Characterization of a novel coronavirus associated with severe acute respiratory syndrome	SCIENCE			English	Article							TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; TARGETED RECOMBINATION; SPIKE GENE; VIRUS; DETERMINANT; ENTRY	In March 2003, a novel coronavirus (SARS-CoV) was discovered in association with cases of severe acute respiratory syndrome (SARS). The sequence of the complete genome of SARS-CoV was determined, and the initial characterization of the viral genome is presented in this report. The genome of SARS-CoV is 29,727 nucleotides in length and has 11 open reading frames, and its genome organization is similar to that of other coronaviruses. Phylogenetic analyses and sequence comparisons showed that SARS-CoV is not closely related to any of the previously characterized coronaviruses.	Ctr Dis Control, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94143 USA; Erasmus Univ, Dept Virol, NL-3000 DR Rotterdam, Netherlands; Bernhard Nocht Inst Trop Med, Dept Virol, D-20359 Hamburg, Germany	Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Erasmus University Rotterdam; Bernhard Nocht Institut fur Tropenmedizin	Rota, PA (corresponding author), Ctr Dis Control, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.	prota@cdc.gov	Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869; Rollin, Pierre/0000-0002-4608-2641; Osterhaus, Albert/0000-0002-6074-1172; Campagnoli, Ray/0000-0003-0531-3893; Monroe, Stephan/0000-0002-5424-716X; Guan, Yi/0000-0001-6057-9243; Gunther, Stephan/0000-0002-6562-0230				Centers for Disease Control and Prevention (CDC), 2003, MMWR-MORBID MORTAL W, V52, P357; de Haan CAM, 2002, VIRUS RES, V82, P77; de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998; DROSTEN C, 2003, N ENGL J MED    0417; Escors D, 2001, J VIROL, V75, P1312, DOI 10.1128/JVI.75.3.1312-1324.2001; Fauquet C.M., 2000, VIRUS TAXONOMY CLASS, P835; Garoff H, 1998, MICROBIOL MOL BIOL R, V62, P1171, DOI 10.1128/MMBR.62.4.1171-1190.1998; HOLMES KV, 2001, FIELDS VIROLOGY, pCH36; LAI MMC, 2001, FIELDS VIROLOGY, pCH35; LEE N, 2003, N ENGL J MED    0417; Leparc-Goffart I, 1998, J VIROL, V72, P9628, DOI 10.1128/JVI.72.12.9628-9636.1998; LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; POUTANEN SM, 2003, N ENGL J MED    0417; Sanchez CM, 1999, J VIROL, V73, P7607; Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215; Siddell S, 1995, CORONAVIRIDAE; THIEL V, 1994, J GEN VIROL, V75, P3041, DOI 10.1099/0022-1317-75-11-3041; TSANG KW, 2003, N ENGL J MED    0417; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	23	1877	2204	4	297	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1394	1399		10.1126/science.1085952	http://dx.doi.org/10.1126/science.1085952			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12730500				2022-12-28	WOS:000183181800035
J	Puigserver, P; Rhee, J; Donovan, J; Walkey, CJ; Yoon, JC; Oriente, F; Kitamura, Y; Altomonte, J; Dong, HJ; Accili, D; Spiegelman, BM				Puigserver, P; Rhee, J; Donovan, J; Walkey, CJ; Yoon, JC; Oriente, F; Kitamura, Y; Altomonte, J; Dong, HJ; Accili, D; Spiegelman, BM			Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1 alpha interaction	NATURE			English	Article							FORKHEAD TRANSCRIPTION FACTOR; CARBOXYKINASE GTP GENE; PROTEIN-KINASE-B; PHOSPHOENOLPYRUVATE CARBOXYKINASE; COACTIVATOR PGC-1; FACTOR FOXO1; FACTOR FKHR; EXPRESSION; BETA; PHOSPHORYLATION	Hepatic gluconeogenesis is absolutely required for survival during prolonged fasting or starvation, but is inappropriately activated in diabetes mellitus. Glucocorticoids and glucagon have strong gluconeogenic actions on the liver. In contrast, insulin suppresses hepatic gluconeogenesis(1-3). Two components known to have important physiological roles in this process are the forkhead transcription factor FOXO1 (also known as FKHR) and peroxisome proliferative activated receptor-gamma co-activator 1 (PGC-1alpha; also known as PPARGC1), a transcriptional co-activator; whether and how these factors collaborate has not been clear. Using wild-type and mutant alleles of FOXO1, here we show that PGC-1alpha binds and co-activates FOXO1 in a manner inhibited by Akt-mediated phosphorylation. Furthermore, FOXO1 function is required for the robust activation of gluconeogenic gene expression in hepatic cells and in mouse liver by PGC-1alpha. Insulin suppresses gluconeogenesis stimulated by PGC-1alpha but co-expression of a mutant allele of FOXO1 insensitive to insulin completely reverses this suppression in hepatocytes or transgenic mice. We conclude that FOXO1 and PGC-1alpha interact in the execution of a programme of powerful, insulin-regulated gluconeogenesis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Columbia Univ, Coll Phys & Surg, Naomi Berrie Diabet Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Mt Sinai Sch Med, Inst Human Gene Therapy & Mol Med, New York, NY 10029 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Rhee, James/V-9973-2019; ORIENTE, Francesco/J-6652-2018	Altomonte, Jennifer/0000-0003-1079-3633; Dong, H. Henry/0000-0003-0279-5241; ORIENTE, Francesco/0000-0003-4375-4526				Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; Becard D, 2001, DIABETES, V50, P2425, DOI 10.2337/diabetes.50.11.2425; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; UNGER RH, 1985, DIABETOLOGIA, V28, P574, DOI 10.1007/BF00281991; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	22	1108	1158	6	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					550	555		10.1038/nature01667	http://dx.doi.org/10.1038/nature01667			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12754525	Bronze			2022-12-28	WOS:000183162900046
J	Scherer, K				Scherer, K			Neurologic manifestations of vitamin B-12 deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Duke Univ, Med Ctr, Durham, NC 27710 USA	Duke University	Scherer, K (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.								0	14	14	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2208	2208		10.1056/NEJMicm020588	http://dx.doi.org/10.1056/NEJMicm020588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773648				2022-12-28	WOS:000183134700007
J	Shumaker, SA; Legault, C; Rapp, SR; Thal, L; Wallace, RB; Ockene, JK; Hendrix, SL; Jones, BN; Assaf, AR; Jackson, RD; Kotchen, JM; Wassertheil-Smoller, S; Wactawski-Wende, J				Shumaker, SA; Legault, C; Rapp, SR; Thal, L; Wallace, RB; Ockene, JK; Hendrix, SL; Jones, BN; Assaf, AR; Jackson, RD; Kotchen, JM; Wassertheil-Smoller, S; Wactawski-Wende, J		WHIMS Investigators	Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women - The Women's Health Initiative Memory Study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; CEREBRAL-BLOOD-FLOW; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; OLDER WOMEN; RISK-FACTORS; POPULATION; ACQUISITION; PREVALENCE; ESTRADIOL	Context Postmenopausal women have a greater risk than men of developing Alzheimer disease, but studies of the effects of estrogen therapy on Alzheimer disease have been inconsistent. On July 8, 2002, the study drugs, estrogen plus progestin, in the Women's Health Initiative (WHI) trial were discontinued because of certain increased health risks in women receiving combined hormone therapy. Objective To evaluate the effect of estrogen plus progestin on the incidence of dementia and mild cognitive impairment compared with placebo. Design, Setting, and Participants The Women's Health Initiative Memory Study (WHIMS), a randomized, double-blind, placebo-controlled clinical trial, began enrolling participants from the Women's Health Initiative (WHI) estrogen plus progestin trial in May 1996. Of the 4894 eligible participants of the WHI study, 4532 (92.6%) postmenopausal women free of probable dementia, aged 65 years or older, and recruited from 39 of 40 WHI clinical centers were enrolled in the WHIMS. Intervention Participants received either 1 daily tablet of 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (n=2229), ora matching placebo (n=2303). Main Outcome Measures incidence of probable dementia (primary outcome) and mild cognitive impairment (secondary outcome) were identified through a structured clinical assessment. Results The mean (SD) time between the date of randomization into WHI and the last Modified Mini-Mental State Examination (3MSE) for all WHIMS participants was 4.05 (1.19) years. Overall, 61 women were diagnosed with probable dementia, 40 (66%) in the estrogen plus progestin group compared with 21 (34%) in the placebo group. The hazard ratio (HR) for probable dementia was 2.05 (95% confidence interval [CI], 1.21-3.48; 45 vs 22 per 10000 person-years; P=.01). This increased risk would result in an additional 23 cases of dementia per 10000 women per year. Alzheimer disease was the most common classification of dementia in both study groups. Treatment effects on mild cognitive impairment did not differ between groups (HR, 1.07; 95% CI, 0.74-1.55; 63 vs 59 cases per 10000 person-years; P=.72). Conclusions Estrogen plus progestin therapy increased the risk for probable dementia in postmenopausal women aged 65 years or older. In addition, estrogen plus progestin therapy did not prevent mild cognitive impairment in these women. These findings, coupled with previously reported WHI data, support the conclusion that the risks of estrogen plus progestin outweigh the benefits.	Wake Forest Univ Hlth Sci, Dept Publ Hlth Sci, Winston Salem, NC 27104 USA; Wake Forest Univ Hlth Sci, Dept Psychiat & Behav Med, Winston Salem, NC USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; Univ Iowa, Dept Epidemiol, Iowa City, IA USA; Univ Massachusetts, Div Prevent & Behav Med, Worcester, MA 01605 USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Obstet & Gynecol, Detroit, MI USA; Brown Univ, Ctr Primary Care & Div, Providence, RI 02912 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Med Coll Wisconsin, Dept Epidemiol & Med, Milwaukee, WI 53226 USA; Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; University of California System; University of California San Diego; University of Iowa; University of Massachusetts System; University of Massachusetts Worcester; Wayne State University; Brown University; University System of Ohio; Ohio State University; Medical College of Wisconsin; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Shumaker, SA (corresponding author), Wake Forest Univ Hlth Sci, Dept Publ Hlth Sci, 200 W 1st St,Piedmont Plaza 2, Winston Salem, NC 27104 USA.	sshumake@wfubmc.edu	Wactawski-Wende, Jean/AGH-5457-2022	Wactawski-Wende, Jean/0000-0003-3096-9595				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; ATKINSON RC, 1971, SCI AM, V225, P82, DOI 10.1038/scientificamerican0871-82; Baldereschi M, 1998, NEUROLOGY, V50, P996, DOI 10.1212/WNL.50.4.996; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; BIRGE SJ, 1997, AM J MED, V103, P15; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; Brinton RD, 2000, NEUROBIOL AGING, V21, P475, DOI 10.1016/S0197-4580(00)00109-3; Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; Chen JG, 2002, J NEUROPSYCH CLIN N, V14, P58, DOI 10.1176/appi.neuropsych.14.1.58; Chesler EJ, 2000, HORM BEHAV, V38, P234, DOI 10.1006/hbeh.2000.1626; Coker LH, 2003, J PSYCHOSOM RES, V54, P129, DOI 10.1016/S0022-3999(02)00523-8; COX DR, 1972, J R STAT SOC B, V34, P187; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; Gibbs RB, 1998, HORM BEHAV, V34, P98, DOI 10.1006/hbeh.1998.1451; Gibbs RB, 2000, NEUROSCIENCE, V101, P931, DOI 10.1016/S0306-4522(00)00433-4; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Hajjar L, 2002, J GERONTOL A-BIOL, V57, pM414, DOI 10.1093/gerona/57.7.M414; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HERBISON AE, 1995, NEUROENDOCRINOLOGY, V61, P1, DOI 10.1159/000126810; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; HOGERVORST E, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003799; ISAACS B, 1973, BRIT J PSYCHIAT, V123, P467, DOI 10.1192/bjp.123.4.467; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; Jellinger KA, 2002, J NEURAL TRANSM, V109, P329, DOI 10.1007/s007020200027; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; JUDD HL, 1974, J CLIN ENDOCR METAB, V39, P1020, DOI 10.1210/jcem-39-6-1020; Kalaria RN, 1996, NEUROBIOL AGING, V17, P687; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Kaplan EF., 1983, BOSTON NAMING TEST, V2; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kawas CH, 2003, NEUROLOGY, V60, P1089, DOI 10.1212/01.WNL.0000055813.36504.BF; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Leibson CL, 1997, AM J EPIDEMIOL, V145, P301; Maki PM, 2002, NEUROPSYCHOLOGIA, V40, P518, DOI 10.1016/S0028-3932(01)00126-9; Maki PM, 2000, NEUROBIOL AGING, V21, P373, DOI 10.1016/S0197-4580(00)00123-8; Marriott LK, 2002, BEHAV NEUROSCI, V116, P902, DOI 10.1037//0735-7044.116.5.902; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756-200205070-00018; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; REITAN RM, 1992, J CLIN PSYCHOL, V48, P521, DOI 10.1002/1097-4679(199207)48:4<521::AID-JCLP2270480414>3.0.CO;2-C; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 2002, JAMA-J AM MED ASSOC, V288, P2170, DOI 10.1001/jama.288.17.2170; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; Rodriguez EG, 2002, J AM GERIATR SOC, V50, P1852, DOI 10.1046/j.1532-5415.2002.50515.x; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Steffens DC, 1999, J AM GERIATR SOC, V47, P1171, DOI 10.1111/j.1532-5415.1999.tb05195.x; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TENG EL, 1990, PSYCHOGERIATRICS BIO, P189; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Wang PN, 2000, NEUROLOGY, V54, P2061, DOI 10.1212/WNL.54.11.2061; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123	82	1519	1560	1	90	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2651	2662		10.1001/jama.289.20.2651	http://dx.doi.org/10.1001/jama.289.20.2651			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	682DG	12771112				2022-12-28	WOS:000183075600024
J	Lodowski, DT; Pitcher, JA; Capel, WD; Lefkowitz, RJ; Tesmer, JJG				Lodowski, DT; Pitcher, JA; Capel, WD; Lefkowitz, RJ; Tesmer, JJG			Keeping G proteins at bay: A complex between G protein-coupled receptor kinase 2 and G beta gamma	SCIENCE			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C-BETA; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; G(BETA-GAMMA) SUBUNITS; STRUCTURAL BASIS; ALPHA-SUBUNITS; BINDING	The phosphorylation of heptahelical receptors by heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptor kinases (GRKs) is a universal regulatory mechanism that leads to desensitization of G protein signaling and to the activation of alternative signaling pathways. We determined the crystallographic structure of bovine GRK2 in complex with G protein beta(1)gamma(2) subunits. Our results show how the three domains of GRK2-the RGS (regulator of G protein signaling) homology, protein kinase, and pleckstrin homology domains-integrate their respective activities and recruit the enzyme to the cell membrane in an orientation that not only facilitates receptor phosphorylation, but also allows for the simultaneous inhibition of signaling by Galpha and Gbetagamma subunits.	Univ Texas, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA; UCL, Dept Pharmacol, MRC, Lab Mol & Cell Biol, London WC1E 6BT, England; UCL, Dept Pharmacol, Cell Biol Unit, London WC1E 6BT, England; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of Texas System; University of Texas Austin; University of London; University College London; University of London; University College London; Duke University; Duke University	Tesmer, JJG (corresponding author), Univ Texas, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	tesmer@mail.utexas.edu	Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021	Tesmer, John/0000-0003-1125-3727	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; Chestukhin A, 1996, J BIOL CHEM, V271, P10175, DOI 10.1074/jbc.271.17.10175; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Iaccarino G, 1999, P ASSOC AM PHYSICIAN, V111, P399, DOI 10.1111/paa.1999.111.5.399; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Lodowski DT, 2003, ACTA CRYSTALLOGR D, V59, P936, DOI 10.1107/S0907444903002622; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Narayana N, 1997, STRUCTURE, V5, P921, DOI 10.1016/S0969-2126(97)00246-3; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; PAO CS, 2002, SCI STKE, pPE42; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Touhara K, 1997, FEBS LETT, V417, P243, DOI 10.1016/S0014-5793(97)01294-5; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837	58	308	320	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1256	1262		10.1126/science.1082348	http://dx.doi.org/10.1126/science.1082348			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764189				2022-12-28	WOS:000183042400039
J	Wager, JF				Wager, JF			Transparent electronics	SCIENCE			English	Editorial Material									Oregon State Univ, Dept Elect Engn & Comp Sci, Corvallis, OR 97331 USA	Oregon State University	Wager, JF (corresponding author), Oregon State Univ, Dept Elect Engn & Comp Sci, Corvallis, OR 97331 USA.							Carcia PF, 2003, APPL PHYS LETT, V82, P1117, DOI 10.1063/1.1553997; Hoffman RL, 2003, APPL PHYS LETT, V82, P733, DOI 10.1063/1.1542677; Masuda S, 2003, J APPL PHYS, V93, P1624, DOI 10.1063/1.1534627; Nomura K, 2003, SCIENCE, V300, P1269, DOI 10.1126/science.1083212	4	733	753	2	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1245	1246		10.1126/science.1085276	http://dx.doi.org/10.1126/science.1085276			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764184	Green Published			2022-12-28	WOS:000183042400033
J	Jones, CH				Jones, CH			How faults accommodate plate motion	SCIENCE			English	Editorial Material							CONVERGENCE; DEFORMATION		Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Univ Colorado, CIRES, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Jones, CH (corresponding author), Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA.		Jones, Craig H/K-2224-2017	Jones, Craig H/0000-0002-1698-0408				Bilham R, 1998, GEOTIMES, V43, P4; Bowman D, 2003, SCIENCE, V300, P1121, DOI 10.1126/science.1082180; Eberhart-Phillips D, 2003, SCIENCE, V300, P1113, DOI 10.1126/science.1082703; FITCH TJ, 1972, J GEOPHYS RES, V77, P4432, DOI 10.1029/JB077i023p04432; JONES CH, 1992, SCIENCE, V256, P83, DOI 10.1126/science.256.5053.83; MCCAFFREY R, 1992, J GEOPHYS RES-SOL EA, V97, P8905, DOI 10.1029/92JB00483; MICHAEL AJ, 1990, GEOPHYS RES LETT, V17, P1453, DOI 10.1029/GL017i009p01453; Page BM, 1998, GEOL SOC AM BULL, V110, P846, DOI 10.1130/0016-7606(1998)110<0846:OLCTOT>2.3.CO;2; PLATT JP, 1993, J GEOPHYS RES-SOL EA, V98, P16239, DOI 10.1029/93JB00888; RICHARD P, 1989, CR ACAD SCI II, V308, P553	10	4	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1105	1106		10.1126/science.1084028	http://dx.doi.org/10.1126/science.1084028			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750509				2022-12-28	WOS:000182886500032
J	Yaman, I; Fernandez, J; Liu, HY; Caprara, M; Komar, AA; Koromilas, AE; Zhou, LY; Snider, MD; Scheuner, D; Kaufman, RJ; Hatzoglou, M				Yaman, I; Fernandez, J; Liu, HY; Caprara, M; Komar, AA; Koromilas, AE; Zhou, LY; Snider, MD; Scheuner, D; Kaufman, RJ; Hatzoglou, M			The zipper model of translational control: A small upstream ORF is the switch that controls structural remodeling of an mRNA leader	CELL			English	Article							RIBOSOME ENTRY SITE; MEDIATED TRANSLATION; INTERNAL INITIATION; REGION; ATTENUATION; PSEUDOKNOT; IRES	Transport of the essential amino acids arginine and lysine is critical for the survival of mammalian cells. The adaptive response to nutritional stress involves increased translation of the arginine/lysine transporter (cat-1) mRNA via an internal ribosome entry site (IRES) within the mRNA leader. Induction of cat-1 IRES activity requires both translation of a small upstream open reading frame (uORF) within the IRES and phosphorylation of the translation initiation factor eIF2alpha. We show here that translation of the upstream ORF unfolds an inhibitory structure in the mRNA leader, eliciting a conformational change that yields an active IRES. The IRES, whose activity is induced by amino acid starvation, is created by RNA-RNA interactions between the 5' end of the leader and downstream sequences. This study suggests that the structure of the IRES is dynamic and regulation of this RNA structure is a mechanism of translational control.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, Cleveland, OH 44106 USA; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Lady Davis Institute; McGill University; McGill University; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA.	mxh8@po.cwru.edu	yaman, ibrahim/A-7192-2016	yaman, ibrahim/0000-0002-3987-1984; Komar, Anton/0000-0003-4188-0633	NIAID NIH HHS [AI42394] Funding Source: Medline; NIDDK NIH HHS [R01 DK60596-01] Funding Source: Medline; NIGMS NIH HHS [GM62853, GM26796] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062853, R01GM026796] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Fletcher SP, 2002, J VIROL, V76, P5024, DOI 10.1128/JVI.76.10.5024-5033.2002; Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453; Garlapati S, 2002, RNA, V8, P601, DOI 10.1017/S135583820202071X; HAHN J, 1982, MOL GEN GENET, V186, P204, DOI 10.1007/BF00331851; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Rijnbrand RCA, 1996, VIROLOGY, V226, P47, DOI 10.1006/viro.1996.0626; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schlax PJ, 2001, J BIOL CHEM, V276, P38494, DOI 10.1074/jbc.M106934200; Schlegl J, 1997, RNA, V3, P1159; Vos S, 2002, BIOCHEMISTRY-US, V41, P5383, DOI 10.1021/bi0156310; WANG CY, 1995, RNA, V1, P526; Yanofsky C, 2000, J BACTERIOL, V182, P1, DOI 10.1128/JB.182.1.1-8.2000	23	168	178	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	2003	113	4					519	531		10.1016/S0092-8674(03)00345-3	http://dx.doi.org/10.1016/S0092-8674(03)00345-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757712	Bronze			2022-12-28	WOS:000182981500013
J	Bansal, D; Miyake, K; Vogel, SS; Groh, S; Chen, CC; Williamson, R; McNeil, PL; Campbell, KP				Bansal, D; Miyake, K; Vogel, SS; Groh, S; Chen, CC; Williamson, R; McNeil, PL; Campbell, KP			Defective membrane repair in dysferlin-deficient muscular dystrophy	NATURE			English	Article							MIYOSHI MYOPATHY; SKELETAL-MUSCLE; GENE; EXOCYTOSIS; EXPRESSION; COMPLEX; ACCUMULATION; DISRUPTIONS; MECHANISM; PROTEINS	Muscular dystrophy includes a diverse group of inherited muscle diseases characterized by wasting and weakness of skeletal muscle(1). Mutations in dysferlin are linked to two clinically distinct muscle diseases, limb-girdle muscular dystrophy type 2B and Miyoshi myopathy, but the mechanism that leads to muscle degeneration is unknown(2,3). Dysferlin is a homologue of the Caenorhabditis elegans fer-1 gene, which mediates vesicle fusion to the plasma membrane in spermatids(4). Here we show that dysferlin-null mice maintain a functional dystrophin glycoprotein complex but nevertheless develop a progressive muscular dystrophy. In normal muscle, membrane patches enriched in dysferlin can be detected in response to sarcolemma injuries. In contrast, there are sub-sarcolemmal accumulations of vesicles in dysferlin-null muscle. Membrane repair assays with a two-photon laser-scanning microscope demonstrated that wildtype muscle fibres efficiently reseal their sarcolemma in the presence of Ca2+. Interestingly, dysferlin-deficient muscle fibres are defective in Ca2+-dependent sarcolemma resealing. Membrane repair is therefore an active process in skeletal muscle fibres, and dysferlin has an essential role in this process. Our findings show that disruption of the muscle membrane repair machinery is responsible for dysferlin-deficient muscle degeneration, and highlight the importance of this basic cellular mechanism of membrane resealing in human disease.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Physiol & Biophys, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; NIAAA, Lab Mol Physiol, NIH, Rockville, MD 20852 USA; Univ Iowa, Coll Med, Dept Obstet & Gynecol, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University System of Georgia; Augusta University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Physiol & Biophys, Howard Hughes Med Inst, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Vogel, Steven/A-3585-2012; Chen, Chien-Chang/D-2023-2015	Chen, Chien-Chang/0000-0001-8850-4278; Campbell, Kevin/0000-0003-2066-5889; Vogel, Steven/0000-0002-3005-2667	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000452, Z01AA000452] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Achanzar WE, 1997, J CELL SCI, V110, P1073; Anderson LVB, 2000, NEUROMUSCULAR DISORD, V10, P553, DOI 10.1016/S0960-8966(00)00143-7; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; CLARKE MSF, 1993, J CELL SCI, V106, P121; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; McNeil PL, 2000, J CELL SCI, V113, P1891; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; McNeil PL, 2003, P NATL ACAD SCI USA, V100, P4592, DOI 10.1073/pnas.0736739100; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375	27	708	733	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					168	172		10.1038/nature01573	http://dx.doi.org/10.1038/nature01573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736685				2022-12-28	WOS:000182699600046
J	Lin, PH; Lumsden, AB				Lin, PH; Lumsden, AB			Abdominal aortic aneurysm as an incidental finding	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Lin, PH (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1884	1884		10.1056/NEJMicm020634	http://dx.doi.org/10.1056/NEJMicm020634			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12736281				2022-12-28	WOS:000182684100007
J	Yang, WY; Gruebele, M				Yang, WY; Gruebele, M			Folding at the speed limit	NATURE			English	Article							UNFOLDED CYTOCHROME-C; MICROSCOPIC THEORY; CONTACT FORMATION; LAMBDA-REPRESSOR; KINETICS; DYNAMICS; DIFFUSION; PROTEINS; RATES	Many small proteins seem to fold by a simple process explicable by conventional chemical kinetics and transition-state theory. This assumes an instant equilibrium between reactants and a high-energy activated state(1). In reality, equilibration occurs on timescales dependent on the molecules involved, below which such analyses break down(1). The molecular timescale, normally too short to be seen in experiments, can be of a significant length for proteins. To probe it directly, we studied very rapidly folding mutants of the five-helix bundle protein lambda(6-85), whose activated state is significantly populated during folding. A time-dependent rate coefficient below 2 mus signals the onset of the molecular timescale, and hence the ultimate speed limit for folding(2). A simple model shows that the molecular timescale represents the natural pre-factor for transition state models of folding.	Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gruebele, M (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.		Yang, Wei Yuan/B-4474-2011					Berne B. J., 1993, ACTIVATED BARRIER CR, P82; Bieri O, 1999, P NATL ACAD SCI USA, V96, P9597, DOI 10.1073/pnas.96.17.9597; Burton RE, 1997, NAT STRUCT BIOL, V4, P305, DOI 10.1038/nsb0497-305; Chang IJ, 2003, P NATL ACAD SCI USA, V100, P3838, DOI 10.1073/pnas.0637283100; Ervin J, 2000, J PHOTOCH PHOTOBIO B, V54, P1, DOI 10.1016/S1011-1344(00)00002-6; Garcia-Mira MM, 2002, SCIENCE, V298, P2191, DOI 10.1126/science.1077809; Ghaemmaghami S, 1998, BIOCHEMISTRY-US, V37, P9179, DOI 10.1021/bi980356b; Gruebele M, 1998, ACCOUNTS CHEM RES, V31, P699, DOI 10.1021/ar970083x; Hagen SJ, 1997, J PHYS CHEM B, V101, P2352, DOI 10.1021/jp9622997; Hagen SJ, 1996, P NATL ACAD SCI USA, V93, P11615, DOI 10.1073/pnas.93.21.11615; Lapidus LJ, 2000, P NATL ACAD SCI USA, V97, P7220, DOI 10.1073/pnas.97.13.7220; Mayor U, 2003, NATURE, V421, P863, DOI 10.1038/nature01428; Metzler R, 1999, P NATL ACAD SCI USA, V96, P11085, DOI 10.1073/pnas.96.20.11085; Myers JK, 1999, BIOCHEMISTRY-US, V38, P6761, DOI 10.1021/bi990088x; Pappenberger G, 2000, P NATL ACAD SCI USA, V97, P17, DOI 10.1073/pnas.97.1.17; Portman JJ, 2001, J CHEM PHYS, V114, P5082, DOI 10.1063/1.1334663; Portman JJ, 2001, J CHEM PHYS, V114, P5069, DOI 10.1063/1.1334662; Sabelko J, 1999, P NATL ACAD SCI USA, V96, P6031, DOI 10.1073/pnas.96.11.6031; Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060; Silow M, 1997, BIOCHEMISTRY-US, V36, P7633, DOI 10.1021/bi970210x; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Snow CD, 2002, NATURE, V420, P102, DOI 10.1038/nature01160; Thirumalai D, 1999, J PHYS CHEM B, V103, P608, DOI 10.1021/jp982362n; Yeh IC, 2002, J AM CHEM SOC, V124, P6563, DOI 10.1021/ja025789n	24	361	365	0	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					193	197		10.1038/nature01609	http://dx.doi.org/10.1038/nature01609			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736690				2022-12-28	WOS:000182699600052
J	Babu, AN; Kymes, SM; Fryer, SMC				Babu, AN; Kymes, SM; Fryer, SMC			Eponyms and the diagnosis of aortic regurgitation: What says the evidence?	ANNALS OF INTERNAL MEDICINE			English	Review							AUSTIN-FLINT MURMUR; PULSED DOPPLER-ECHOCARDIOGRAPHY; VALVULAR HEART-DISEASE; BLOOD-PRESSURE; ASYMPTOMATIC PATIENTS; CLINICAL-EFFICACY; DUROZIEZS MURMUR; FLOW DYNAMICS; INSUFFICIENCY; SIGN		St Louis Vet Adm Med Ctr, St Louis, MO 63106 USA; St Louis Univ, Sch Med, St Louis, MO USA; Washington Univ, Sch Med, St Louis, MO USA	Saint Louis University; Washington University (WUSTL)	Babu, AN (corresponding author), St Louis Vet Adm Med Ctr, 915 N Grand Blvd, St Louis, MO 63106 USA.	ajitbabu@hotmail.com						ABBAS F, 1987, SOUTHERN MED J, V80, P1051, DOI 10.1097/00007611-198708000-00027; ARONOW WS, 1989, AM J CARDIOL, V63, P128, DOI 10.1016/0002-9149(89)91098-9; BABU AN, 2001, J GEN INTERN MED S1, V16, P115; BICKLEY LS, 1999, BATES GUIDE PHYSICAL; BLOOMFIELD DA, 1973, SOUTH MED J, V66, P55, DOI 10.1097/00007611-197301000-00010; Blumgart HL, 1933, J AMER MED ASSOC, V100, P173, DOI 10.1001/jama.1933.02740030021007; Bonow RO, 1998, CIRCULATION, V98, P1949, DOI 10.1161/01.CIR.98.18.1949; Braunwald E., 2001, HARRISONS PRINCIPLES; Braunwald E., 2001, HEART DIS TXB CARDIO; Carabello BA, 1997, NEW ENGL J MED, V337, P32, DOI 10.1056/NEJM199707033370107; Cecil EL, 2000, CECIL TXB MED; Cheitlin MD, 2001, AM FAM PHYSICIAN, V64, P1709; Choudhry NK, 1999, JAMA-J AM MED ASSOC, V281, P2231, DOI 10.1001/jama.281.23.2231; COHN LH, 1967, AM J CARDIOL, V19, P177, DOI 10.1016/0002-9149(67)90530-9; Constant J., 1999, BEDSIDE CARDIOLOGY; Corrigan D J, 1832, Edinb Med Surg J, V37, P225; CRAIGE E, 1988, NEW ENGL J MED, V318, P1611, DOI 10.1056/NEJM198806163182409; CURRENS JH, 1953, NEW ENGL J MED, V248, P583, DOI 10.1056/NEJM195304022481403; Degowin, 2000, DEGOWINS DIAGNOSTIC; EMI S, 1993, J AM COLL CARDIOL, V21, P1399, DOI 10.1016/0735-1097(93)90316-S; Enghoff E, 1972, Acta Med Scand Suppl, V538, P3; FLINT A, 1862, AM J MED SCI, V44, P29; FOLTS JD, 1968, CIRCULATION, V38, P426, DOI 10.1161/01.CIR.38.2.426; FRANK MJ, 1965, ARCH INTERN MED, V116, P357, DOI 10.1001/archinte.1965.03870030037008; FUSTER V, 2001, HURSTS HEART; Gaasch WH, 1997, CHEST, V111, P1702, DOI 10.1378/chest.111.6.1702; GRAYBURN PA, 1986, ANN INTERN MED, V104, P599, DOI 10.7326/0003-4819-104-5-599; Hill L, 1909, HEART-J STUD CIRC, V1, P73; HILL L, 1911, HEART, V3, P219; Hughes M L Jr, 1969, Ala J Med Sci, V6, P72; Humes H.D., 2000, KELLEYS TXB INTERNAL; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; KINNEY EL, 1988, J GEN INTERN MED, V3, P429, DOI 10.1007/BF02595918; Kotte JR, 1944, AM HEART J, V28, P476, DOI 10.1016/S0002-8703(44)91009-4; Kutryk M, 1997, CAN J CARDIOL, V13, P237; LANDZBERG JS, 1992, J AM COLL CARDIOL, V20, P408, DOI 10.1016/0735-1097(92)90110-9; LANIADO S, 1982, CIRCULATION, V66, P226, DOI 10.1161/01.CIR.66.1.226; Lee D, 1995, Zhonghua Yi Xue Za Zhi (Taipei), V56, P152; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Luisada AA, 1943, AM HEART J, V26, P2; Mangione S, 1996, J GEN INTERN MED, V11, P490, DOI 10.1007/BF02599046; Murray JR, 1914, BRIT MED J, V1914, P697, DOI 10.1136/bmj.1.2778.697; NASSER W, 1966, NEW ENGL J MED, V275, P1007, DOI 10.1056/NEJM196611032751808; OBRIEN KP, 1969, AM HEART J, V77, P603, DOI 10.1016/0002-8703(69)90544-4; Orient JM., 2000, SAPIRAS ART SCI BEDS; PARKER E, 1971, CIRCULATION, V43, P349, DOI 10.1161/01.CIR.43.3.349; PASCARELLI EF, 1964, NEW ENGL J MED, V270, P693, DOI 10.1056/NEJM196404022701401; RAHKO PS, 1991, CIRCULATION, V83, P1940, DOI 10.1161/01.CIR.83.6.1940; Richardson W Scott, 2002, ACP J Club, V137, pA11; ROMAN MJ, 1987, ANN INTERN MED, V106, P800, DOI 10.7326/0003-4819-106-6-800; ROWE GG, 1965, NEW ENGL J MED, V272, P1207, DOI 10.1056/NEJM196506102722305; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAPIRA JD, 1981, SOUTHERN MED J, V74, P459, DOI 10.1097/00007611-198104000-00022; SCOGNAMIGLIO R, 1994, NEW ENGL J MED, V331, P689, DOI 10.1056/NEJM199409153311101; SEGAL BL, 1964, AM J CARDIOL, V14, P628, DOI 10.1016/0002-9149(64)90053-0; SHINE KI, 1968, AM HEART J, V76, P728, DOI 10.1016/0002-8703(68)90257-3; Sox HC, 1988, MED DECISION MAKING; Stewart HA, 1908, ARCH INTERN MED, V1, P102; SWARTZ MH, 1998, TXB PHYSICAL DIAGNOS; Thayer WS, 1901, AM J MED SCI, V122, P547; Tice F, 1911, ILLINOIS M J, V20, P271; UEDA H, 1965, JPN HEART J, V6, P294; WARNES CA, 1983, AM J CARDIOL, V51, P1551, DOI 10.1016/0002-9149(83)90675-6; Willius FA, 1941, CARDIAC CLASSICS; ZONERAICH S, 1995, CIRCULATION, V91, P2089, DOI 10.1161/01.CIR.91.7.2089; [No title captured]	68	22	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					736	742		10.7326/0003-4819-138-9-200305060-00010	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729428				2022-12-28	WOS:000182661400006
J	Larson, KM; Bodin, P; Gomberg, J				Larson, KM; Bodin, P; Gomberg, J			Using 1-Hz GPS data to measure deformations caused by the Denali fault earthquake	SCIENCE			English	Article							CALIFORNIA; MAGNITUDE	The 3 November 2002 moment magnitude 7.9 Denali fault earthquake generated large, permanent surface displacements in Alaska and large-amplitude surface waves throughout western North America. We find good agreement between strong ground-motion records integrated to displacement and 1-hertz Global Positioning System (GPS) position estimates collected similar to 140 kilometers from the earthquake epicenter. One-hertz GPS receivers also detected seismic surface waves 750 to 3800 kilometers from the epicenter, whereas these waves saturated many of the seismic instruments in the same region. High-frequency GPS increases the dynamic range and frequency bandwidth of ground-motion observations, providing another tool for studying earthquake processes.	Univ Colorado, Dept Aerosp Engn Sci, Boulder, CO 80309 USA; Memphis State Univ, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA; US Geol Survey, Memphis, TN 38152 USA	University of Colorado System; University of Colorado Boulder; University of Memphis; United States Department of the Interior; United States Geological Survey	Larson, KM (corresponding author), Univ Colorado, Dept Aerosp Engn Sci, Boulder, CO 80309 USA.	kristine.larson@colorado.edu	Larson, Kristine M/J-7623-2018	Larson, Kristine M/0000-0003-4666-8885				Eberhart-Phillips D, 2003, SCIENCE, V300, P1113, DOI 10.1126/science.1082703; Gomberg J, 1999, B SEISMOL SOC AM, V89, P1428; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; Mao AL, 1999, J GEOPHYS RES-SOL EA, V104, P2797, DOI 10.1029/1998JB900033; NIKOLAIDIS R, 2001, J GEOPHYS RES, DOI DOI 10.1029/2001JB00329; Segall P, 1997, ANNU REV EARTH PL SC, V25, P301, DOI 10.1146/annurev.earth.25.1.301; Zhang J, 1997, J GEOPHYS RES-SOL EA, V102, P18035, DOI 10.1029/97JB01380	7	241	276	5	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1421	1424		10.1126/science.1084531	http://dx.doi.org/10.1126/science.1084531			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12750480				2022-12-28	WOS:000183181800042
J	Aebischer, NJ; Baker, SE; Johnson, PJ; Macdonald, DW; Reynolds, JC				Aebischer, NJ; Baker, SE; Johnson, PJ; Macdonald, DW; Reynolds, JC			Hunting and fox numbers in the United Kingdom	NATURE			English	Article									Game Conservancy Trust, Fordingbridge SP6 1EF, Hants, England; Univ Oxford, Dept Zool, Wildlife Conservat Res Unit, Oxford OX1 3PS, England	University of Oxford	Aebischer, NJ (corresponding author), Game Conservancy Trust, Fordingbridge SP6 1EF, Hants, England.		Aebischer, Nicholas J/AAU-9285-2021; Reynolds, Jonathan/N-6079-2018	Reynolds, Jonathan/0000-0003-2443-0999				Baker PJ, 2002, NATURE, V419, P34, DOI 10.1038/419034a; Heydon MJ, 2000, J ZOOL, V251, P265, DOI 10.1111/j.1469-7998.2000.tb00609.x; MacDonald D. W., 2000, MANAGING BRIT MAMMAL	3	8	8	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					400	400		10.1038/423400a	http://dx.doi.org/10.1038/423400a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761539	Bronze			2022-12-28	WOS:000183012000030
J	Hunsaker, AR; Reilly, JJ				Hunsaker, AR; Reilly, JJ			Centrilobular emphysema with predominantly upper-lobe involvement	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Hunsaker, AR (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2091	2091		10.1056/NEJMicm030318	http://dx.doi.org/10.1056/NEJMicm030318			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761366				2022-12-28	WOS:000183008300006
J	Jacobsson, LTH; Jacobsson, ME; Askling, J; Knowler, WC				Jacobsson, LTH; Jacobsson, ME; Askling, J; Knowler, WC			Perinatal characteristics and risk of rheumatoid arthritis	BRITISH MEDICAL JOURNAL			English	Article									Malmo Univ Hosp, Dept Rheumatol, S-20502 Malmo, Sweden; Karolinska Hosp & Inst, Clin Epidemiol Unit, S-17176 Stockholm, Sweden; NIDDK, Diabet & Arthrit Epidemiol Sect, Phoenix, AZ 85014 USA	Lund University; Skane University Hospital; Karolinska Institutet; Karolinska University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Jacobsson, LTH (corresponding author), Malmo Univ Hosp, Dept Rheumatol, S-20502 Malmo, Sweden.							Enzer I, 2002, ARTHRITIS RHEUM, V46, P1729, DOI 10.1002/art.10360; KaipiainenSeppanen O, 1996, CLIN EXP RHEUMATOL, V14, P537; MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B; Symmons D, 2000, RHEUMATOLOGY, V39, P835, DOI 10.1093/rheumatology/39.8.835; Walker-Bone K, 2002, RHEUMATOLOGY, V41, P69	5	61	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2003	326	7398					1068	1069		10.1136/bmj.326.7398.1068	http://dx.doi.org/10.1136/bmj.326.7398.1068			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681ZD	12750209	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000183064700017
J	Chandok, MR; Ytterberg, AJ; van Wijk, KJ; Klessig, DF				Chandok, MR; Ytterberg, AJ; van Wijk, KJ; Klessig, DF			RETRACTED: The pathogen-inducible nitric oxide synthase (iNOS) in plants is a variant of the P protein of the glycine decarboxylase complex (Retracted Article. See vol 119, pg 445, 2004)	CELL			English	Article; Retracted Publication							SALICYLIC-ACID; NITRATE REDUCTASE; PHYTOALEXIN ACCUMULATION; MOLECULAR-CLONING; PURIFICATION; RESISTANCE; EXPRESSION; INDUCTION; SIGNAL; NO	A growing body of evidence indicates that nitric oxide (NO) plays important signaling roles in plants. However, the enzyme(s) responsible for its synthesis after infection was unknown. Here, we demonstrate that the pathogen-induced, NO-synthesizing enzyme is a variant form of the P protein of glycine decarboxylase (GDC). Inhibitors of the P protein of GDC block its NO synthase (NOS)-like activity, and variant P produced in E. coli or insect cells displays NOS activity. The plant enzyme shares many biochemical and kinetic properties with animal NOSs. However, only a few of the critical motifs associated with NO production in animals can be recognized in the variant P sequence, suggesting that it uses very different chemistry for NO synthesis. Since nitrate reductase is likely responsible for NO production in uninfected or nonelicited plants, our results suggest that plants, like animals, use multiple enzymes for the synthesis of this critical hormone.	Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA	Cornell University; Boyce Thompson Institute for Plant Research; Cornell University	Klessig, DF (corresponding author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.	dfk8@cornell.edu						Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Barroso JB, 1999, J BIOL CHEM, V274, P36729, DOI 10.1074/jbc.274.51.36729; Barroso JB, 2000, AM J PHYSIOL-REG I, V279, pR650, DOI 10.1152/ajpregu.2000.279.2.R650; Beligni MV, 2001, PLANT CELL ENVIRON, V24, P267, DOI 10.1046/j.1365-3040.2001.00672.x; Biswas TK, 2002, J BIOL CHEM, V277, P45704, DOI 10.1074/jbc.M202565200; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Brunori M, 1999, CELL MOL LIFE SCI, V56, P549, DOI 10.1007/s000180050452; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; CONRATH U, 1995, P NATL ACAD SCI USA, V92, P7143, DOI 10.1073/pnas.92.16.7143; Cueto M, 1996, FEBS LETT, V398, P159, DOI 10.1016/S0014-5793(96)01232-X; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; DEMPSEY DA, 1993, PHYTOPATHOLOGY, V83, P1021, DOI 10.1094/Phyto-83-1021; Dempsey DA, 1999, CRIT REV PLANT SCI, V18, P547, DOI 10.1080/07352689991309397; Desikan R, 2002, P NATL ACAD SCI USA, V99, P16314, DOI 10.1073/pnas.252461999; Dong XN, 2001, CURR OPIN PLANT BIOL, V4, P309, DOI 10.1016/S1369-5266(00)00178-3; Douce R, 2001, TRENDS PLANT SCI, V6, P167, DOI 10.1016/S1360-1385(01)01892-1; Durner J, 1998, P NATL ACAD SCI USA, V95, P10328, DOI 10.1073/pnas.95.17.10328; Durner J, 1999, CURR OPIN PLANT BIOL, V2, P369, DOI 10.1016/S1369-5266(99)00007-2; Foissner I, 2000, PLANT J, V23, P817, DOI 10.1046/j.1365-313X.2000.00835.x; FUJIWARA K, 1987, BIOCHEM BIOPH RES CO, V149, P621, DOI 10.1016/0006-291X(87)90413-X; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Garvey EP, 1996, METHOD ENZYMOL, V268, P339; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; Kaiser WM, 2002, J EXP BOT, V53, P875, DOI 10.1093/jexbot/53.370.875; Klessig DF, 2000, P NATL ACAD SCI USA, V97, P8849, DOI 10.1073/pnas.97.16.8849; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JS, 1999, J BIOL CHEM, V274, P27658, DOI 10.1074/jbc.274.39.27658; Mackerness SAH, 2001, FEBS LETT, V489, P237, DOI 10.1016/S0014-5793(01)02103-2; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MATA CG, 2002, PLANT PHYSIOL, V128, P790; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; Modolo LV, 2002, PLANT PHYSIOL, V130, P1288, DOI 10.1104/pp.005850; MURPHY ME, 1994, METHOD ENZYMOL, V233, P240; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Navarre DA, 1999, PLANT CELL, V11, P237; NAVARRE DA, 1995, PLANT CELL, V7, P463, DOI 10.1105/tpc.7.4.463; Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.010707; Noritake T, 1996, PLANT CELL PHYSIOL, V37, P113, DOI 10.1093/oxfordjournals.pcp.a028908; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; REIF DW, 1995, ARCH BIOCHEM BIOPHYS, V320, P170, DOI 10.1006/abbi.1995.1356; Ribeiro EA, 1999, FEBS LETT, V445, P283, DOI 10.1016/S0014-5793(99)00138-6; Rockel P, 2002, J EXP BOT, V53, P103, DOI 10.1093/jexbot/53.366.103; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; Shah J, 1999, PLANT CELL, V11, P191, DOI 10.1105/tpc.11.2.191; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirato M, 1998, BIOCHEM J, V333, P795, DOI 10.1042/bj3330795; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Torreilles J, 2001, FRONT BIOSCI-LANDMRK, V6, pD1161, DOI 10.2741/Torreill; Tun NN, 2001, FEBS LETT, V509, P174, DOI 10.1016/S0014-5793(01)03164-7; Van Camp W, 1998, TRENDS PLANT SCI, V3, P330, DOI 10.1016/S1360-1385(98)01297-7; Wendehenne D, 2001, TRENDS PLANT SCI, V6, P177, DOI 10.1016/S1360-1385(01)01893-3; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOLPERT TJ, 1994, PLANT CELL, V6, P1145, DOI 10.1105/tpc.6.8.1145; Yamasaki H, 1999, TRENDS PLANT SCI, V4, P128, DOI 10.1016/S1360-1385(99)01393-X; Yao N, 2002, PLANT J, V30, P567, DOI 10.1046/j.1365-313X.2002.01314.x	65	137	185	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	2003	113	4					469	482		10.1016/S0092-8674(03)00350-7	http://dx.doi.org/10.1016/S0092-8674(03)00350-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757708	Bronze			2022-12-28	WOS:000182981500009
J	Hytch, MJ; Putaux, JL; Penisson, JM				Hytch, MJ; Putaux, JL; Penisson, JM			Measurement of the displacement field of dislocations to 0.03 angstrom by electron microscopy	NATURE			English	Article							HREM; MICROGRAPHS; BOUNDARY; STRAIN	Defects and their associated long-range strain fields are of considerable importance in many areas of materials science(1,2). For example, a major challenge facing the semiconductor industry is to understand the influence of defects on device operation, a task made difficult by the fact that their interactions with charge carriers can occur far from defect cores, where the influence of the defect is subtle and difficult to quantify(3,4). The accurate measurement of strain around defects would therefore allow more detailed understanding of how strain fields affect small structures - in particular their electronic, mechanical and chemical properties and how such fields are modified when confined to nanometre-sized volumes. Here we report the measurement of displacements around an edge dislocation in silicon using a combination of high-resolution electron microscopy and image analysis inherited from optical interferometry. The agreement of our observations with anisotropic elastic theory calculations is better than 0.03 Angstrom. Indeed, the results can be considered as an experimental verification of anisotropic theory at the near-atomic scale. With the development of nanostructured materials and devices, we expect the use of electron microscopy as a metrological tool for strain analysis to become of increasing importance.	CNRS, Ctr Etud Chim Met, F-94407 Vitry Sur Seine, France; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France; Univ Grenoble 1, F-38041 Grenoble, France; CEA Grenoble, DRFMC, SP2M, ME, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Hytch, MJ (corresponding author), CNRS, Ctr Etud Chim Met, 15 Rue G Urbain, F-94407 Vitry Sur Seine, France.	martin.hytch@glvt-cnrs.fr	PUTAUX, Jean-Luc/ABC-5309-2020	PUTAUX, Jean-Luc/0000-0002-9760-5369				ALEXANDER H, 2000, HDB SEMICONDUCTOR TE, P293; BIERWOLF R, 1993, ULTRAMICROSCOPY, V49, P273, DOI 10.1016/0304-3991(93)90234-O; Gabor D., 1946, J I ELECT ENG LOND, V93, P429, DOI DOI 10.1049/JI-3-2.1946.0074; Hirth J.P., 1968, THEORY DISLOCATIONS; Hytch MJ, 1998, ULTRAMICROSCOPY, V74, P131, DOI 10.1016/S0304-3991(98)00035-7; Hytch MJ, 1997, MICROSC MICROANAL M, V8, P41, DOI 10.1051/mmm:1997105; Hytch MJ, 2001, ULTRAMICROSCOPY, V87, P199, DOI 10.1016/S0304-3991(00)00099-1; Jia CL, 1999, PHYS REV LETT, V82, P5052, DOI 10.1103/PhysRevLett.82.5052; Kret S, 2000, J PHYS-CONDENS MAT, V12, P10313, DOI 10.1088/0953-8984/12/49/334; LEPINOUX J, 2000, NATO SCI SERIES APPL, V367; Mobus G, 2000, ULTRAMICROSCOPY, V85, P183, DOI 10.1016/S0304-3991(00)00057-7; Nabarro F.R.N, 1979, DISLOCATIONS SOLIDS, V1; *SEM IND ASS, 2002, NAT TECHN ROAD MAP S; TAKEDA M, 1982, J OPT SOC AM, V72, P156, DOI 10.1364/JOSA.72.000156; Takeda M, 1996, J OPT SOC AM A, V13, P1495, DOI 10.1364/JOSAA.13.001495; THIBAULTDESSEAUX J, 1989, J PHYS-PARIS, V50, P2525, DOI 10.1051/jphys:0198900500180252500; TREACY MMJ, 1985, PHILOS MAG A, V51, P389, DOI 10.1080/01418618508237563; Weirich TE, 1996, NATURE, V382, P144, DOI 10.1038/382144a0	18	416	422	9	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					270	273		10.1038/nature01638	http://dx.doi.org/10.1038/nature01638			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748637				2022-12-28	WOS:000182853100038
J	Mounkes, LC; Kozlov, S; Hernandez, L; Sullivan, T; Stewart, CL				Mounkes, LC; Kozlov, S; Hernandez, L; Sullivan, T; Stewart, CL			A progeroid syndrome in mice is caused by defects in A-type lamins	NATURE			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; NUCLEAR-ENVELOPE; GENE; EXPRESSION; MUTATIONS; DISEASE; CELLS	Numerous studies of the underlying causes of ageing have been attempted by examining diseases associated with premature ageing, such as Werner's syndrome and Hutchinson - Gilford progeria syndrome (HGPS). HGPS is a rare genetic disorder resulting in phenotypes suggestive of accelerated ageing, including shortened stature, craniofacial disproportion, very thin skin, alopecia and osteoporosis, with death in the early teens predominantly due to atherosclerosis(1). However, recent reports suggest that developmental abnormalities may also be important in HGPS(1,2). Here we describe the derivation of mice carrying an autosomal recessive mutation in the lamin A gene (Lmna) encoding A-type lamins, major components of the nuclear lamina(3). Homozygous mice display defects consistent with HGPS, including a marked reduction in growth rate and death by 4 weeks of age. Pathologies in bone, muscle and skin are also consistent with progeria. The Lmna mutation resulted in nuclear morphology defects and decreased lifespan of homozygous fibroblasts, suggesting premature cell death. Here we present a mouse model for progeria that may elucidate mechanisms of ageing and development in certain tissue types, especially those developing from the mesenchymal cell lineage.	NCI, Canc & Dev Biol Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stewart, CL (corresponding author), NCI, Canc & Dev Biol Lab, Frederick, MD 21702 USA.				NATIONAL CANCER INSTITUTE [Z01BC010377] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackerman J, 2002, PEDIATR PATHOL MOL M, V21, P1, DOI 10.1080/15227950252774110; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Hoeffel JC, 2000, SKELETAL RADIOL, V29, P668, DOI 10.1007/s002560000280; Holaska JM, 2003, J BIOL CHEM, V278, P6969, DOI 10.1074/jbc.M208811200; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; Kirkland JL, 2002, EXP GERONTOL, V37, P757, DOI 10.1016/S0531-5565(02)00014-1; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; Lewis M, 2003, AGEING RES REV, V2, P95, DOI 10.1016/S1568-1637(02)00044-2; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; Morris GE, 2001, TRENDS MOL MED, V7, P572, DOI 10.1016/S1471-4914(01)02128-1; OZAKI T, 1994, ONCOGENE, V9, P2649; Raharjo WH, 2001, J CELL SCI, V114, P4447; Rodrigues GHD, 2002, ANN GENET-PARIS, V45, P151, DOI 10.1016/S0003-3995(02)01119-X; ROEBER R-A, 1990, Journal of Cell Science, V95, P587; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Sarkar PK, 2001, POSTGRAD MED J, V77, P312, DOI 10.1136/pmj.77.907.312; Spann TP, 2002, J CELL BIOL, V156, P603, DOI 10.1083/jcb.200112047; STEWART CL, 1993, METHOD ENZYMOL, V225, P823; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Taylor-Jones JM, 2002, MECH AGEING DEV, V123, P649, DOI 10.1016/S0047-6374(01)00411-0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Uitto Jouni, 2002, Trends in Endocrinology and Metabolism, V13, P140, DOI 10.1016/S1043-2760(02)00595-7; Upchurch DA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e69; Vigouroux C, 2001, J CELL SCI, V114, P4459; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7	26	267	278	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					298	301		10.1038/nature01631	http://dx.doi.org/10.1038/nature01631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748643	Green Published			2022-12-28	WOS:000182853100045
J	Dai, X; Savrasov, SY; Kotliar, G; Migliori, A; Ledbetter, H; Abrahams, E				Dai, X; Savrasov, SY; Kotliar, G; Migliori, A; Ledbetter, H; Abrahams, E			Calculated phonon spectra of plutonium at high temperatures	SCIENCE			English	Article							ELECTRONIC-STRUCTURE; DELTA-PU; METALS; APPROXIMATION; TRANSITION; SYSTEMS	We constructed computer-based simulations of the lattice dynamical properties of plutonium using an electronic structure method, which incorporates correlation effects among the f-shell electrons and calculates phonon spectra at arbitrary wavelengths. Our predicted spectrum for the face-centered cubic delta phase agrees well with experiments in the elastic limit and explains unusually large shear anisotropy of this material. The spectrum of the body-centered cubic phase shows an instability at zero temperature over a broad region of the wave vectors, indicating that this phase is highly anharmonic and can be stabilized at high temperatures by its phonon entropy.	New Jersey Inst Technol, Dept Phys, Newark, NJ 07102 USA; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Mat Theory, Piscataway, NJ 08854 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA	New Jersey Institute of Technology; Rutgers State University New Brunswick; Rutgers State University New Brunswick; United States Department of Energy (DOE); Los Alamos National Laboratory	Savrasov, SY (corresponding author), New Jersey Inst Technol, Dept Phys, Newark, NJ 07102 USA.	savrasov@oak.njit.edu	Dai, Xi/C-4236-2008; Migliori, Albert/F-6961-2015; Dai, Xi/HCG-9886-2022; Savrasov, Sergey Y/M-7157-2015	Dai, Xi/0000-0002-2396-0966; 				Allen PG, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.214107; ANDERSON PW, 1961, PHYS REV, V124, P41, DOI 10.1103/PhysRev.124.41; Anisimov VI, 1997, J PHYS-CONDENS MAT, V9, P767, DOI 10.1088/0953-8984/9/4/002; Bouchet J, 2000, J PHYS-CONDENS MAT, V12, P1723, DOI 10.1088/0953-8984/12/8/315; DESCLAUX JP, 1984, HDB PHYSICS CHEM ACT, V1; Freeman A.J., 1974, ACTINIDES ELECT STRU, V1; Freeman A.J., 1974, ACTINIDES ELECT STRU, V2; Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13; HECKER S.S., 2000, LOS ALAMOS SCI, V26, P244; Held K, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.276404; HUBBARD J, 1964, PROC R SOC LON SER-A, V281, P401, DOI 10.1098/rspa.1964.0190; JOHANSSON B, 1995, PHYS REV LETT, V74, P2335, DOI 10.1103/PhysRevLett.74.2335; JOHANSSON B, 1974, PHILOS MAG, V30, P469, DOI 10.1080/14786439808206574; Jones MD, 2000, PHYS REV B, V61, P4644, DOI 10.1103/PhysRevB.61.4644; Kotliar G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.046401; Kotliar G, 2001, NATO SCI SER II MATH, V23, P259; LEDBETTER HM, 1976, ACTA METALL MATER, V24, P891, DOI 10.1016/0001-6160(76)90037-7; Lundqvist S., 1983, THEORY INHOMOGENEOUS; Migliori A., 2000, LOS ALAMOS SCI, V26, P208; SAVRASOV SY, 1992, PHYS REV LETT, V69, P2819, DOI 10.1103/PhysRevLett.69.2819; Savrasov SY, 2000, PHYS REV LETT, V84, P3670, DOI 10.1103/PhysRevLett.84.3670; Savrasov SY, 2001, NATURE, V410, P793, DOI 10.1038/35071035; Savrasov SY, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.056401; SKRIVER HL, 1978, PHYS REV LETT, V41, P42, DOI 10.1103/PhysRevLett.41.42; SODERLIND P, 1994, PHYS REV B, V50, P7291, DOI 10.1103/PhysRevB.50.7291; SOLOVYEV IV, 1991, PHYS REV B, V43, P14414, DOI 10.1103/PhysRevB.43.14414; Turchi PEA, 1999, ELECTRON CORRELATIONS AND MATERIALS PROPERTIES, P531; Wallace DC, 1998, PHYS REV B, V58, P15433, DOI 10.1103/PhysRevB.58.15433	28	224	224	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					953	955		10.1126/science.1083428	http://dx.doi.org/10.1126/science.1083428			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738856				2022-12-28	WOS:000182719800048
J	Waxman, AB; Shepard, JO; Mark, EJ				Waxman, AB; Shepard, JO; Mark, EJ			Case 14-2003: A 73-year-old woman with pneumonia and progressive respiratory failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COMMUNITY-ACQUIRED PNEUMONIA; DIFFUSE ALVEOLAR DAMAGE; DISTRESS-SYNDROME; SURVEILLANCE; MANAGEMENT; TULAREMIA; PROGNOSIS; ETIOLOGY; DISEASE; LUNG		Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Thorac Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Waxman, AB (corresponding author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.		Waxman, Aaron/I-8659-2019; Waxman, Aaron/L-7450-2019	Waxman, Aaron/0000-0001-7797-0361; 				EVANS ME, 1985, MEDICINE, V64, P251, DOI 10.1097/00005792-198507000-00006; FARLEY MM, 1992, ANN INTERN MED, V116, P806, DOI 10.7326/0003-4819-116-10-806; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; GATTINONI L, 1994, JAMA-J AM MED ASSOC, V271, P1772, DOI 10.1001/jama.271.22.1772; Janz TG, 2000, CHEST, V117, P562, DOI 10.1378/chest.117.2.562; JOHNSON DH, 1993, POSTGRAD MED, V93, P69; Johnson DH, 1993, POSTGRAD MED, V93, P79; Johnson DH, 1993, POSTGRAD MED, V93, P75; Kauppinen M, 1995, CLIN INFECT DIS, V21, pS244, DOI 10.1093/clind/21.Supplement_3.S244; KOHLER RB, 1984, J CLIN MICROBIOL, V20, P605, DOI 10.1128/JCM.20.4.605-607.1984; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MATSUBARA O, 1995, PATHOL INT, V45, P473, DOI 10.1111/j.1440-1827.1995.tb03488.x; Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; Muder R R, 1987, Semin Respir Infect, V2, P242; Pache JC, 1998, MODERN PATHOL, V11, P1064; PACHON J, 1990, AM REV RESPIR DIS, V142, P369, DOI 10.1164/ajrccm/142.2.369; PIERCE AK, 1974, AM REV RESPIR DIS, V110, P647; Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045; SCHLOSSBERG D, 1993, ARCH INTERN MED, V153, P2594, DOI 10.1001/archinte.153.22.2594; Stout JE, 1997, NEW ENGL J MED, V337, P682, DOI 10.1056/NEJM199709043371006; Swartz MN, 2002, NEW ENGL J MED, V346, P634; Swartz MN, 2001, NEW ENGL J MED, V345, P1621, DOI 10.1056/NEJMra012892; TEUTSCH SM, 1979, NEW ENGL J MED, V301, P826, DOI 10.1056/NEJM197910113011507; TOMASHEFSKI JF, 1990, CLIN CHEST MED, V11, P593; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; WRIGHT L, 1997, CLIN PULM MED, V4, P152; Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X; YOUNG LS, 1969, NEW ENGL J MED, V280, P1253, DOI 10.1056/NEJM196906052802301	30	7	8	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1902	1912		10.1056/NEJMcpc030009	http://dx.doi.org/10.1056/NEJMcpc030009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12736284				2022-12-28	WOS:000182684100010
J	Palmer, RL				Palmer, RL			Death in anorexia nervosa	LANCET			English	Editorial Material							LONG-TERM SURVIVAL; ROCHESTER		Leicester Gen Hosp, Univ Dept Psychiat, Brandon Unit, Leicester LE5 4PW, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital	Palmer, RL (corresponding author), Leicester Gen Hosp, Univ Dept Psychiat, Brandon Unit, Gwendolen Rd, Leicester LE5 4PW, Leics, England.	postmaster@lgh1.u-net.com						Korndorfer SR, 2003, MAYO CLIN PROC, V78, P278, DOI 10.4065/78.3.278; LUCAS AR, 1991, AM J PSYCHIAT, V148, P917; Lucas AR, 1999, INT J EAT DISORDER, V26, P397; Nielsen S, 2001, PSYCHIAT CLIN N AM, V24, P201, DOI 10.1016/S0193-953X(05)70217-3; SULLIVAN PF, 1995, AM J PSYCHIAT, V152, P1073; Sullivan PF, 2003, MAYO CLIN PROC, V78, P273, DOI 10.4065/78.3.273; Van Furth EF, 1998, W S CLIN NEUROBIOL, V4, P315; Van Hoeken D, 2003, HDB EATING DISORDERS, P11; Wentz E, 2001, J CHILD PSYCHOL PSYC, V42, P613, DOI 10.1111/1469-7610.00757	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2003	361	9368					1490	1490		10.1016/S0140-6736(03)13221-7	http://dx.doi.org/10.1016/S0140-6736(03)13221-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674WB	12737856				2022-12-28	WOS:000182658900005
J	Grech, ED				Grech, ED			ABC of interventional cardiology - Percutaneous coronary intervention. II: The procedure	BRITISH MEDICAL JOURNAL			English	Review							ANGIOPLASTY		Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB, Canada; Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Grech, ED (corresponding author), Hlth Sci Ctr, Winnipeg, MB, Canada.							ALMOND DG, 2002, PRACTICAL INTERVENTI, P63; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Rensing BJ, 2001, EUR HEART J, V22, P2125, DOI 10.1053/euhj.2001.2892; Smith SC, 2001, J AM COLL CARDIOL, V37, P2215, DOI 10.1016/S0735-1097(01)01344-4; WAKSMAN R, 2002, PRACTICAL INTERVENTI, P295	6	64	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1137	1140		10.1136/bmj.326.7399.1137	http://dx.doi.org/10.1136/bmj.326.7399.1137			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763994	Green Published			2022-12-28	WOS:000183245000031
J	Hubner, K; Fuhrmann, G; Christenson, LK; Kehler, J; Reinbold, R; De La Fuente, R; Wood, J; Strauss, JF; Boiani, M; Scholer, HR				Hubner, K; Fuhrmann, G; Christenson, LK; Kehler, J; Reinbold, R; De La Fuente, R; Wood, J; Strauss, JF; Boiani, M; Scholer, HR			Derivation of oocytes from mouse embryonic stem cells	SCIENCE			English	Article							OCT-4 TRANSCRIPTION FACTOR; PRIMORDIAL GERM-CELLS; ZONA-PELLUCIDA GENES; H-Y ANTIGEN; CHROMOSOME SYNAPSIS; COORDINATE EXPRESSION; FIG-ALPHA; IN-VITRO; MICE; ACTIVATION	Continuation of mammalian species requires the formation and development of the sexually dimorphic germ cells. Cultured embryonic stem cells are generally considered pluripotent rather than totipotent because of the failure to detect germline cells under differentiating conditions. Here we show that mouse embryonic stem cells in culture can develop into oogonia that enter meiosis, recruit adjacent cells to form follicle-like structures, and later develop into blastocysts. Oogenesis in culture should contribute to various areas, including nuclear transfer and manipulation of the germ line, and advance studies on fertility treatment and germ and somatic cell interaction and differentiation.	Univ Penn, Sch Vet Med, Ctr Anim Transgenesis & Germ Cell Res, Germline Dev Grp,New Bolton Ctr, Kennett Sq, PA 19348 USA; Univ Penn, Sch Vet Med, Ctr Anim Transgenesis & Germ Cell Res, Female Germ Cell Biol Grp,New Bolton Ctr, Kennett Sq, PA 19348 USA; Ctr Neurochim, Lab Neurobiol Dev & Regenerat, CNRS, FRE 2373, F-67084 Strasbourg, France; Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Pennsylvania; Pennsylvania Medicine	Scholer, HR (corresponding author), Univ Penn, Sch Vet Med, Ctr Anim Transgenesis & Germ Cell Res, Germline Dev Grp,New Bolton Ctr, 382 W St Rd, Kennett Sq, PA 19348 USA.		Boiani, Michele/M-3519-2015; , HS/AAB-4434-2019; reinbold, rolland/AAW-8940-2020; Christenson, Lane K/G-6435-2013	Boiani, Michele/0000-0003-2765-2781; , HS/0000-0003-2643-5136; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007305, R01HD042011] Funding Source: NIH RePORTER; NICHD NIH HHS [HD06274, T32 HD07305, 1RO1HD42011-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson R, 2000, MECH DEVELOP, V91, P61, DOI 10.1016/S0925-4773(99)00271-3; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; CHISHOLM JC, 1987, DEVELOPMENT, V101, P565; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; Chuma S, 2001, DEV BIOL, V229, P468, DOI 10.1006/dbio.2000.9989; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Crawford PA, 1997, MOL CELL BIOL, V17, P3997, DOI 10.1128/MCB.17.7.3997; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; EAST IJ, 1984, DEV BIOL, V104, P49, DOI 10.1016/0012-1606(84)90035-6; EPIFANO O, 1995, DEVELOPMENT, V121, P1947; Eppig JJ, 1996, CANCER RES, V56, P5047; Eppig JJ, 1996, BIOL REPROD, V54, P197, DOI 10.1095/biolreprod54.1.197; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HUBNER K, UNPUB; LAWSON KA, 1994, CIBA F SYMP, V182, P68; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Liang LF, 1997, DEVELOPMENT, V124, P4939; Matzuk MM, 2000, MOL CELL ENDOCRINOL, V163, P61, DOI 10.1016/S0303-7207(99)00241-5; McLaren A, 1997, DEV BIOL, V187, P107, DOI 10.1006/dbio.1997.8584; Nordhoff V, 2001, MAMM GENOME, V12, P309, DOI 10.1007/s003350010279; OHNO S, 1978, CYTOGENET CELL GENET, V20, P351, DOI 10.1159/000130863; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;452::AID-MRD14&gt;3.0.CO;2-S; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Rankin T, 1999, DEVELOPMENT, V126, P3847; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Simpson E, 1997, ANNU REV IMMUNOL, V15, P39, DOI 10.1146/annurev.immunol.15.1.39; Soyal SM, 2000, DEVELOPMENT, V127, P4645; STEVENS LC, 1974, DEV BIOL, V37, P369, DOI 10.1016/0012-1606(74)90155-9; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tarsounas M, 1999, J CELL SCI, V112, P423; Tilmann C, 2002, RECENT PROG HORM RES, V57, P1, DOI 10.1210/rp.57.1.1; Toyooka Y, 2000, MECH DEVELOP, V93, P139, DOI 10.1016/S0925-4773(00)00283-5; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2; Yuan L, 2000, MOL CELL, V5, P73, DOI 10.1016/S1097-2765(00)80404-9; ZENZES MT, 1978, CYTOGENET CELL GENET, V20, P365, DOI 10.1159/000130864	41	793	888	2	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1251	1256		10.1126/science.1083452	http://dx.doi.org/10.1126/science.1083452			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12730498				2022-12-28	WOS:000183042400038
J	Pages, V; Fuchs, RP				Pages, V; Fuchs, RP			Uncoupling of leading- and lagging-strand DNA replication during lesion bypass in vivo	SCIENCE			English	Article							POLYMERASES POL-II; FRAMESHIFT MUTATIONS; MUTAGENESIS; CELLS; FORKS; IV	Numerous agents attack DNA, forming lesions that impair normal replication. Specialized DNA polymerases transiently replace the replicative polymerase and copy past lesions, thus generating mutations, the major initiating cause of cancer. We monitored, in Escherichia coli, the kinetics of replication of both strands of DNA molecules containing a single replication block in either the leading or lagging strand. Despite a block in the leading strand, lagging-strand synthesis proceeded further, implying transient uncoupling of concurrent strand synthesis. Replication through the lesion requires specialized DNA polymerases and is achieved with similar kinetics and efficiencies in both strands.	Ecole Super Biotechnol, CNRS, Unite Propre Rech 9003, F-67400 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Fuchs, RP (corresponding author), Ecole Super Biotechnol, CNRS, Unite Propre Rech 9003, Blvd S Brant, F-67400 Strasbourg, France.		Pagès, Vincent/L-8455-2016	Pagès, Vincent/0000-0002-3059-2903				Becherel OJ, 2001, P NATL ACAD SCI USA, V98, P8566, DOI 10.1073/pnas.141113398; Bresson A, 2002, EMBO J, V21, P3881, DOI 10.1093/emboj/cdf363; CORDEIROSTONE M, 1979, BIOPHYS J, V27, P287, DOI 10.1016/S0006-3495(79)85218-2; Courcelle J, 2003, SCIENCE, V299, P1064, DOI 10.1126/science.1081328; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Hoffmann GR, 1997, CHEM RES TOXICOL, V10, P347, DOI 10.1021/tx960128n; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; MILLER JA, 1970, CANCER RES, V30, P559; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Pages V, 2002, ONCOGENE, V21, P8957, DOI 10.1038/sj.onc.1206006; PAGES V, UNPUB; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; TOMIZAWA JI, 1974, P NATL ACAD SCI USA, V71, P2260, DOI 10.1073/pnas.71.6.2260; Wagner J, 2002, DNA REPAIR, V1, P159, DOI 10.1016/S1568-7864(01)00012-X	21	159	161	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1300	1303		10.1126/science.1083964	http://dx.doi.org/10.1126/science.1083964			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764199				2022-12-28	WOS:000183042400052
J	Prescott, ED; Julius, D				Prescott, ED; Julius, D			A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity	SCIENCE			English	Article							DIRECT ACTIVATION; CHANNELS; PAIN; HEAT; TRPV3; VR1	The capsaicin receptor (TRPV1), a heat-activated ion channel of the pain pathway, is sensitized by phosphatidylinositol-4,5-bisphosphate (PIP2) hydrolysis after phospholipase C activation. We identify a site within the C-terminal domain of TRPV1 that is required for PIP2-mediated inhibition of channel gating. Mutations that weaken PIP2-TRPV1 interaction reduce thresholds for chemical or thermal stimuli, whereas TRPV1 channels in which this region is replaced with a lipid-bindingdomain from PIP2-activated potassium channels remain inhibited by PIP2. The PIP2-interaction domain therefore serves as a critical determinant of thermal threshold and dynamic sensitivity range, tuning TRPV1, and thus the sensory neuron, to appropriately detect heat under normal or pathophysiological conditions.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	julius@cmp.ucsf.edu						Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; PRESCOTT ED, UNPUB; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	23	422	446	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1284	1288		10.1126/science.1083646	http://dx.doi.org/10.1126/science.1083646			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764195				2022-12-28	WOS:000183042400047
J	Wang, YY; Rogado, NS; Cava, RJ; Ong, NP				Wang, YY; Rogado, NS; Cava, RJ; Ong, NP			Spin entropy as the likely source of enhanced thermopower in NaxCo2O4	NATURE			English	Article							THERMOELECTRIC-POWER; NACO2O4; DENSITY	In an electric field, the flow of electrons in a solid produces an entropy current in addition to the familiar charge current. This is the Peltier effect, and it underlies all thermoelectric refrigerators. The increased interest in thermoelectric cooling applications has led to a search for more efficient Peltier materials and to renewed theoretical investigation into how electron-electron interaction may enhance the thermopower of materials such as the transition-metal oxides(1-4). An important factor in this enhancement is the electronic spin entropy, which is predicted(4-6) to dominate the entropy current. However, the crucial evidence for the spin-entropy term, namely its complete suppression in a longitudinal magnetic field, has not been reported until now. Here we report evidence for such suppression in the layered oxide NaxCo2O4, from thermopower and magnetization measurements in both longitudinal and transverse magnetic fields. The strong dependence of thermopower on magnetic field provides a rare, unambiguous example of how strong electron-electron interaction effects can qualitatively alter electronic behaviour in a solid. We discuss the implications of our finding-that spin-entropy dominates the enhancement of thermopower in transition-metal oxides-for the search for better Peltier materials.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Ong, NP (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.		Ong, N. Phuan/Z-1626-2019	Ong, N. Phuan/0000-0001-7166-1058				Ando Y, 1999, PHYS REV B, V60, P10580, DOI 10.1103/PhysRevB.60.10580; BENI G, 1974, PHYS REV B, V10, P2186, DOI 10.1103/PhysRevB.10.2186; CHAIKIN PM, 1976, PHYS REV B, V13, P647, DOI 10.1103/PhysRevB.13.647; Koshibae W, 2000, PHYS REV B, V62, P6869, DOI 10.1103/PhysRevB.62.6869; KWAK JF, 1976, PHYS REV B, V13, P652, DOI 10.1103/PhysRevB.13.652; KWAK JF, 1976, PHYS REV B, V13, P641, DOI 10.1103/PhysRevB.13.641; Mahan G, 1997, PHYS TODAY, V50, P42, DOI 10.1063/1.881752; Palsson G, 1998, PHYS REV LETT, V80, P4775, DOI 10.1103/PhysRevLett.80.4775; Ray R, 1999, PHYS REV B, V59, P9454, DOI 10.1103/PhysRevB.59.9454; Singh DJ, 2000, PHYS REV B, V61, P13397, DOI 10.1103/PhysRevB.61.13397; ZIMAN JM, 1972, PRINCIPLES THEORY SO, P235	12	593	604	9	232	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					425	428		10.1038/nature01639	http://dx.doi.org/10.1038/nature01639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761545	Green Submitted			2022-12-28	WOS:000183012000038
J	Ingrosso, D; Cimmino, A; Perna, AF; Masella, L; De Santo, NG; De Bonis, ML; Vacca, M; D'Esposito, M; D'Urso, M; Galletti, P; Zappia, V				Ingrosso, D; Cimmino, A; Perna, AF; Masella, L; De Santo, NG; De Bonis, ML; Vacca, M; D'Esposito, M; D'Urso, M; Galletti, P; Zappia, V			Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia	LANCET			English	Article							DNA METHYLTRANSFERASE GENE; CHRONIC-RENAL-FAILURE; S-ADENOSYLHOMOCYSTEINE; BECKWITH-WIEDEMANN; DISEASE; HYPOMETHYLATION; INACTIVATION; HOMOCYSTEINE; MUTATION; PROTEINS	Background Hyperhomocysteinaemia occurs in several genetically determined and acquired disorders and is highly prevalent in patients with uraemia. In these disorders, homocysteine precursor S-adenosylhomocysteine, a powerful competitive inhibitor of S-adenosylmethionine-dependent methyltransferases, is increased, suggesting unbalanced methylation. We aimed to investigate whether DNA hypomethylation is present in patients with uraemia who also have hyperhomocysteinaemia and whether regulation of specific classes of genes, dependent on DNA methylation, is compromised. Methods We selected men with hyperhomocysteinaemia and uraemia who were having standard haemodialysis treatment, and compared them with healthy male controls. We measured the homocysteine concentration from plasma samples and obtained DNA and RNA samples from peripheral mononuclear cells. DNA methylation was assessed by cytosine extension assay and by Southern blotting. Allelic expression of pseudoautosomal and imprinted genes was investigated by analysis of suitable restriction fragment length polymorphisms. Findings Total DNA hypomethylation was higher in patients than in controls (z score -4.593, p=0.0006) and allelic expression was changed in both sex-linked and imprinted genes. The shift from monoallelic to biallelic expression was dependent on homocysteine concentrations. Folate therapy, a common method to reduce hyperhomocysteinaemia, restored DNA methylation to normal levels and corrected the patterns of gene expression. Interpretation Our results suggest that hyperhomocysteinaemia affects epigenetic control of gene expression, which can be reverted by folate treatment. Our data support the hypothesis that the toxic action of homocysteine can be mediated by macromolecule hypomethylation.	Univ Naples 2, Sch Med & Surg, Dept Biochem & Biophys F Cedranglo, I-80138 Naples, Italy; Univ Naples 2, Sch Med & Surg, Div Nephrol 1, I-80138 Naples, Italy; Univ Naples 2, Sch Med & Surg, Dept Paediat, I-80138 Naples, Italy; Univ Naples 2, Sch Med & Surg, Cardiovasc Res Ctr, I-80138 Naples, Italy; CNR, Inst Genet & Biophys A Buzzati Traverso, I-80125 Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Ingrosso, D (corresponding author), Univ Naples 2, Sch Med & Surg, Dept Biochem & Biophys F Cedranglo, Via Costantinopoli 16, I-80138 Naples, Italy.	diego.ingrosso@unina2.it	Ingrosso, Diego/AHE-4980-2022; Vacca, Marcella/B-9513-2015; Perna, Alessandra F/AAC-3952-2022; D'Esposito, Maurizio/AAY-6376-2020	Vacca, Marcella/0000-0002-5495-9183; PERNA, Alessandra/0000-0003-4048-9392; Cimmino, Amelia/0000-0002-0004-9299				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027; Ciccodicola A, 2000, HUM MOL GENET, V9, P395, DOI 10.1093/hmg/9.3.395; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; DEsposito M, 1996, NAT GENET, V13, P227, DOI 10.1038/ng0696-227; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Hendrich B, 2001, HUM MOL GENET, V10, P2233, DOI 10.1093/hmg/10.20.2233; James SJ, 2002, J NUTR, V132, p2361S, DOI 10.1093/jn/132.8.2361S; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Matarazzo MR, 2002, HUM MOL GENET, V11, P3191, DOI 10.1093/hmg/11.25.3191; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; PERNA AF, 1993, J CLIN INVEST, V91, P2497; Perna AF, 1996, KIDNEY INT, V50, P358, DOI 10.1038/ki.1996.324; Perna AF, 1997, J AM SOC NEPHROL, V8, P1899; Perna AF, 2001, KIDNEY INT, V59, P2299, DOI 10.1046/j.1523-1755.2001.00747.x; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robinson K, 1996, CIRCULATION, V94, P2743, DOI 10.1161/01.CIR.94.11.2743; Sperandeo MP, 2000, AM J HUM GENET, V66, P841, DOI 10.1086/302811; SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; ZAPPIA V, 1969, J BIOL CHEM, V244, P4499	30	338	353	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1693	1699		10.1016/S0140-6736(03)13372-7	http://dx.doi.org/10.1016/S0140-6736(03)13372-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767735				2022-12-28	WOS:000182919700010
J	Nicholls, S; Trim, G; Hereford-Ashley, P; Leitch, J; Barlow, M				Nicholls, S; Trim, G; Hereford-Ashley, P; Leitch, J; Barlow, M			Pain in the neck	LANCET			English	Editorial Material							SYNCOPE		John Hunter Hosp, Dept Cardiovasc Med, Newcastle, NSW, Australia	John Hunter Hospital	Leitch, J (corresponding author), John Hunter Hosp, Dept Cardiovasc Med, Locked Bag 1,Hunter Reg Mail Ctr, Newcastle, NSW, Australia.			Nicholls, Stephen/0000-0002-9668-4368				CICOGNA R, 1993, EUR HEART J, V14, P1476, DOI 10.1093/eurheartj/14.11.1476; Macdonald D R, 1983, J Neurooncol, V1, P257, DOI 10.1007/BF00165610; Mathias CJ, 2001, LANCET, V357, P348, DOI 10.1016/S0140-6736(00)03642-4; ROTHSTEIN SG, 1987, HEAD NECK SURG, V9, P332, DOI 10.1002/hed.2890090605; Weisnberg TH., 1910, JAMA-J AM MED ASSOC, VLIV, P1600, DOI 10.1001/jama.1910.92550460001001g	5	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 17	2003	361	9370					1700	1700		10.1016/S0140-6736(03)13373-9	http://dx.doi.org/10.1016/S0140-6736(03)13373-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767736				2022-12-28	WOS:000182919700011
J	Becker, A; Grunewald, U				Becker, A; Grunewald, U			Disaster management - Flood risk in central Europe	SCIENCE			English	Editorial Material									Potsdam Inst Climate Impact Res, D-14473 Potsdam, Germany; Brandenburg Univ Technol, D-03013 Cottbus, Germany	Potsdam Institut fur Klimafolgenforschung	Becker, A (corresponding author), Potsdam Inst Climate Impact Res, D-14473 Potsdam, Germany.							*DTSCH WETT, 1997, MITT DTSCH VERB WASS, V29; GRUNEWALD U, 2002, NOTFALLVORSORGE 4 20, P14; Houghton J. T., 2001, CLIMATE CHANGE 2001; KUBAT J, 2002, 10 MAGD GEW 22 26 OC; KUNDZEWICZ ZW, IN PRESS NAT HAZARDS; *SACHS LAND UMW GE, 2002, VORL KURZB MET HYDR; SCHANZE J, 2002, GAIA, V11, P247; SCHELLNHUBER HJ, 2002, JAHRHUNDERTFLUT; *STAATSM UMW LANDW, 2002, HOCHW SACHS; HIST FLOOD PEAKS NEI	10	90	93	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1099	1099		10.1126/science.1083624	http://dx.doi.org/10.1126/science.1083624			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750504				2022-12-28	WOS:000182886500027
J	Rosenblum, A; Joseph, H; Fong, C; Kipnis, S; Cleland, C; Portenoy, RK				Rosenblum, A; Joseph, H; Fong, C; Kipnis, S; Cleland, C; Portenoy, RK			Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMBULATORY AIDS PATIENTS; OPIATE WITHDRAWAL; CANCER; MANAGEMENT; SEVERITY	Context Little is known about the prevalence and characteristics of chronic pain among patients with different types of chemical dependency. Objectives To estimate the prevalence and to examine the characteristics of chronic severe pain in chemically dependent populations receiving methadone maintenance or inpatient residential treatment. Design, Setting, and Particiloants Representative samples of 390 patients from 2 methadone maintenance treatment programs (MMTPs) and 531 patients from 13 short-term residential substance abuse treatment (inpatient) programs, all in New York State, were surveyed in late 2000 and early 2001. Main Outcome Measure Prevalence of chronic severe pain, defined as pain that persisted for more than 6 months and was of moderate to severe intensity or that significantly interfered with daily activities. Results Chronic severe pain was experienced by 37% of MMTP patients (95% confidence. interval [CI], 32%-41%) and 24% of inpatients (95% CI, 20%-28%; P=.03). Pain of any type or duration during the past week was reported by 80% of MMTP patients and 78% of inpatients. Among those with chronic severe pain, 65% of MMTP patients and 48% of inpatients reported high levels of pain-related interference in physical and psychosocial functioning. Among MMTP patients, correlates of chronic pain in a multivariate model were age (odds ratio [OR], 2.08; 95% CI, 1.17-3.70), chronic illness (OR, 1.88; 95% CI, 1.07-3.29), lifetime psychiatric illness (OR, 1.77; 95% CI, 1.06-2.97), psychiatric distress (OR, 1.63; 95% CI, 1.22-2.18), and time in treatment (OR, 2.23; 95% CI, 1.06-4.68). Among inpatients, the correlates of chronic pain were race (blacks vs whites: OR, 0.52; 95% CI, 0.31-6.90; Hispanics vs whites: OR, 0.48; 95% CI, 0.24-0.95), drug craving (OR, 2.78; 95% CI, 1.54-5.02), chronic illness (OR, 2.17; 95% CI, 1.37-3.43), and psychiatric distress (OR, 1.36; 95% CI, 1.03-1.81). Among those with chronic severe pain, inpatients were significantly more likely than MMTP patients to have used illicit drugs, as well as alcohol, to treat their pain complaint (51% vs 34%, P=.005) but were less likely to have been prescribed pain medications (52% vs 67%, P=.01). Conclusions Chronic severe pain is prevalent among patients in substance abuse treatment, especially MMTP patients. Pain is associated with functional impairment and correlates of pain vary with the population. Self-medication for pain with psychoactive drugs appears especially problematic among substance users who enroll in drug-free treatment programs. Substance abuse treatment programs need to develop comprehensive and structured pain management programs.	Natl Dev & Res Inst Inc, Inst Treatment & Serv Res, New York, NY 10010 USA; New York State Off Alcoholism & Subst Abuse Serv, New York, NY USA; New York State Off Alcoholism & Subst Abuse Serv, Albany, NY USA; Beth Israel Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA	National Development & Research Institutes, Inc; Harvard University; Beth Israel Deaconess Medical Center	Rosenblum, A (corresponding author), Natl Dev & Res Inst Inc, Inst Treatment & Serv Res, 71 W 23rd St,8th Floor, New York, NY 10010 USA.			Cleland, Charles/0000-0002-6931-9904	NATIONAL INSTITUTE ON DRUG ABUSE [P30DA011041] Funding Source: NIH RePORTER; NIDA NIH HHS [P30DA11041] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Breitbart W, 1996, PAIN, V68, P315, DOI 10.1016/S0304-3959(96)03215-0; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COMPTON MA, 1994, J PAIN SYMPTOM MANAG, V9, P462, DOI 10.1016/0885-3924(94)90203-8; Compton P, 2001, DRUG ALCOHOL DEPEN, V63, P139, DOI 10.1016/S0376-8716(00)00200-3; Derogatis LR., 1994, SCL 90 R ADM SCORING; FARRELL M, 1994, ADDICTION, V89, P1471, DOI 10.1111/j.1360-0443.1994.tb03745.x; FAUCETT J, 1994, J PAIN SYMPTOM MANAG, V9, P383, DOI 10.1016/0885-3924(94)90175-9; Ford B.L., 1983, INCOMPLETE DATA SAMP, P185; Galea S, 2002, NEW ENGL J MED, V346, P982, DOI 10.1056/NEJMsa013404; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; HANDELSMAN L, 1987, AM J DRUG ALCOHOL AB, V13, P293, DOI 10.3109/00952998709001515; Hosmer DW, 1980, COMMUNICATIONS STA A, V10, P1043; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jamison RN, 2000, J PAIN SYMPTOM MANAG, V19, P53, DOI 10.1016/S0885-3924(99)00144-X; Jordan MS, 1998, ARTHRIT CARE RES, V11, P80, DOI 10.1002/art.1790110203; MacLeod DB, 1996, AM J EMERG MED, V14, P323, DOI 10.1016/S0735-6757(96)90187-4; *OFF ALC SUBST AB, 1998, EXPL STUD PHEN STREE; PANKRATZ L, 1989, DRUG ALCOHOL DEPEN, V24, P115, DOI 10.1016/0376-8716(89)90073-2; PORTENOY RK, 1994, CANCER-AM CANCER SOC, V74, P907, DOI 10.1002/1097-0142(19940801)74:3<907::AID-CNCR2820740318>3.0.CO;2-#; PORTENOY RK, 1992, CANCER-AM CANCER SOC, V70, P1616, DOI 10.1002/1097-0142(19920915)70:6<1616::AID-CNCR2820700630>3.0.CO;2-7; Portenoy RK, 1997, JAMA-J AM MED ASSOC, V278, P592, DOI 10.1001/jama.278.7.592; PORTENOY RK, 1997, SUBSTANCE ABUSE COMP, P563; RETTIG RA, 1995, FED REG METHADONE TR; Rosen CS, 2000, ASSESSMENT, V7, P103, DOI 10.1177/107319110000700201; Sande IG, 1983, INCOMPLETE DATA SAMP, V3, P334; Savage SR, 1996, J PAIN SYMPTOM MANAG, V11, P274, DOI 10.1016/0885-3924(95)00202-2; Scimeca MM, 2000, MT SINAI J MED, V67, P412; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Verhaak PFM, 1998, PAIN, V77, P231, DOI 10.1016/S0304-3959(98)00117-1; Von Korff M, 2001, HDB PAIN ASSESSMENT, P603	32	353	357	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2370	2378		10.1001/jama.289.18.2370	http://dx.doi.org/10.1001/jama.289.18.2370			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	677WF	12746360	Bronze			2022-12-28	WOS:000182831200026
J	Hawton, K; Simkin, S; Deeks, J				Hawton, K; Simkin, S; Deeks, J			Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARACETAMOL; PREVENTION	Objectives To examine the incidence of suicides due to co-proxamol compared with tricyclic antidepressants and paracetamol, and to compare fatality rates for self poisonings with these drugs. Design Analysis of routinely collected national and local data on suicides and self poisonings. Setting Records of suicides in England and Wales 1997-9; non-fatal self poisonings in Oxford District 1997-9. Data sources Office for National Statistics and Oxford monitoring system for attempted suicide. Main outcome measures Incidence of suicides with co-proxamol or tricyclic antidepressants or paracetamol. Ratios of fatal to non-fatal self poisonings. Results Co-proxamol alone accounted for 5% of all suicides. Of 4162 drug related suicides, 18% (766) involved co-proxamol alone, 22% (927) tricyclic antidepressants alone, and 9% (368) paracetamol alone. A higher proportion of suicides in the 10-24 yearn age group were due to co-proxamol than in the other age groups. The odds of dying after overdose with co-proxamol was 2.3 times (95% confidence interval 2.1 to 2.5) that for tricyclic antidepressants and 28.1 times (24.9 to 32.9) that for paracetamol. Conclusions Self poisoning with co-proxamol is particularly dangerous and contributes substantially to drug related suicides. Restricting availability of co-proxamol could have an important role in suicide prevention.	Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England; Inst Hlth Sci, Ctr Stat Med, Oxford OX3 7LF, England	University of Oxford; University of Oxford	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England.	keith.hawton@psych.ox.ac.uk	Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				Bialas MC, 1996, QJM-INT J MED, V89, P893; *COMM SAF MED, 1985, CURR PROBL, V14; Department of Health, 2002, NAT SUIC PREV STRAT; Dollery C, 1999, THERAPEUTIC DRUGS, V2; Fishbain D A, 1999, Semin Clin Neuropsychiatry, V4, P221; Haigh S, 1996, LANCET, V347, P1840, DOI 10.1016/S0140-6736(96)91665-7; HAWTON K, 1995, BRIT MED J, V310, P164, DOI 10.1136/bmj.310.6973.164; Hawton K, 2001, BMJ-BRIT MED J, V322, P1203, DOI 10.1136/bmj.322.7296.1203; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Malmberg A, 1999, BRIT J PSYCHIAT, V175, P103, DOI 10.1192/bjp.175.2.103; OLIVER RG, 1972, MED J AUSTRALIA, V2, P919, DOI 10.5694/j.1326-5377.1972.tb103635.x; PENTTINEN J, 1995, AM J PUBLIC HEALTH, V85, P1452, DOI 10.2105/AJPH.85.10.1452-a; Po ALW, 1997, BRIT MED J, V315, P1565, DOI 10.1136/bmj.315.7122.1565; SELLAR C, 1990, J EPIDEMIOL COMMUN H, V44, P313, DOI 10.1136/jech.44.4.313; Sykes JV, 1996, LANCET, V348, P408, DOI 10.1016/S0140-6736(05)65028-3; Taylor SJ, 1997, ACTA PSYCHIAT SCAND, V95, P457, DOI 10.1111/j.1600-0447.1997.tb10132.x; YOUNG RJ, 1980, BRIT MED J, V280, P1045, DOI 10.1136/bmj.280.6220.1045	17	49	51	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2003	326	7397					1006	1008		10.1136/bmj.326.7397.1006	http://dx.doi.org/10.1136/bmj.326.7397.1006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	679KG	12742920	Green Published, Bronze			2022-12-28	WOS:000182920500014
J	Davidson, DW; Cook, SC; Snelling, RR; Chua, TH				Davidson, DW; Cook, SC; Snelling, RR; Chua, TH			Explaining the abundance of ants in lowland tropical rainforest canopies	SCIENCE			English	Article							CANDIDATUS-BLOCHMANNIA; SYMBIOTIC BACTERIA; NITROGEN ISOTOPES; ENDOSYMBIONTS; APHIDS	The extraordinary abundance of ants in tropical rainforest canopies has led to speculation that numerous arboreal ant taxa feed principally as "herbivores" of plant and insect exudates. Based on nitrogen (N) isotope ratios of plants, known herbivores, arthropod predators, and ants from Amazonia and Borneo, we find that many arboreal ant species obtain little N through predation and scavenging. Microsymbionts of ants and their hemipteran trophobionts might play key roles in the nutrition of taxa specializing on N-poor exudates. For plants, the combined costs of biotic defenses and herbivory by ants and tended Hemiptera are substantial, and forest losses to insect herbivores vastly exceed current estimates.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Nat Hist Museum Los Angeles, Entomol Sect, Los Angeles, CA 90007 USA; Univ Brunei Darussalam, Dept Biol, Bandar Seri Begawan, Brunei	Utah System of Higher Education; University of Utah; University Brunei Darussalam	Davidson, DW (corresponding author), Univ Utah, Dept Biol, 257 South,1400 East, Salt Lake City, UT 84112 USA.		Chua, Tock H./E-4157-2012	Chua, Tock H./0000-0002-8984-8723				BAKER HG, 1978, BOT GAZ, V139, P322, DOI 10.1086/337008; Bluthgen N, 2002, J ANIM ECOL, V71, P793, DOI 10.1046/j.1365-2656.2002.00647.x; BUCKLEY RC, 1987, ANNU REV ECOL SYST, V18, P111, DOI 10.1146/annurev.es.18.110187.000551; CAETANO F H, 1985, Naturalia (Rio Claro), V10, P37; CAETANO FH, 1994, LES INSECTES SOCIAUX, P391; Davidson D. W., 1996, NEOTROPICAL BIODIVER, P127; Davidson Diane W., 1993, Journal of Hymenoptera Research, V2, P13; Davidson DW, 1997, BIOL J LINN SOC, V61, P153, DOI 10.1006/bijl.1996.0128; Davidson DW, 1998, ECOL ENTOMOL, V23, P484, DOI 10.1046/j.1365-2311.1998.00145.x; DAVIDSON DW, UNPUB; Dejean A, 2000, SOCIOBIOLOGY, V35, P403; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; Douglas AE, 1998, ANNU REV ENTOMOL, V43, P17, DOI 10.1146/annurev.ento.43.1.17; Febvay G, 1999, J EXP BIOL, V202, P2639; Floren A, 2002, OECOLOGIA, V131, P137, DOI 10.1007/s00442-002-0874-z; FOLGARAIT PJ, 1995, OECOLOGIA, V104, P189, DOI 10.1007/BF00328584; Heil M, 1998, FUNCT ECOL, V12, P117, DOI 10.1046/j.1365-2435.1998.00158.x; Holldobler B., 1990, pi; Leigh Egbert G. Jr., 1996, P111; MACKO SA, 1986, GEOCHIM COSMOCHIM AC, V50, P2143, DOI 10.1016/0016-7037(86)90068-2; Moran NA, 2003, ENVIRON MICROBIOL, V5, P116, DOI 10.1046/j.1462-2920.2003.00391.x; Nakabachi A, 1997, INSECT BIOCHEM MOLEC, V27, P1057, DOI 10.1016/S0965-1748(97)00092-1; Sandstrom JP, 2001, PHYSIOL ENTOMOL, V26, P202, DOI 10.1046/j.0307-6962.2001.00235.x; Sauer C, 2000, INT J SYST EVOL MICR, V50, P1877, DOI 10.1099/00207713-50-5-1877; SCHUPP EW, 1991, ANT - PLANT INTERACTIONS, P175; Thao ML, 1998, CURR MICROBIOL, V36, P238, DOI 10.1007/s002849900301; Tobin John E., 1995, P129; Tobin John E., 1994, P279; van Borm S, 2002, P ROY SOC B-BIOL SCI, V269, P2023, DOI 10.1098/rspb.2002.2101; von Dohlen CD, 2001, NATURE, V412, P433, DOI 10.1038/35086563; Wernegreen JJ, 2002, MICROBIOL-SGM, V148, P2551, DOI 10.1099/00221287-148-8-2551; WHEELER GC, MEMOIRS ENTOMOLOGICA, V7; Wilkinson TL, 2001, J EXP BIOL, V204, P3027; Yoneyama T, 1997, NEW PHYTOL, V137, P205, DOI 10.1046/j.1469-8137.1997.00809.x	34	487	509	1	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					969	972		10.1126/science.1082074	http://dx.doi.org/10.1126/science.1082074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738862				2022-12-28	WOS:000182719800054
J	DePaolo, DJ; Manga, M				DePaolo, DJ; Manga, M			Deep origin of hotspots - The mantle plume model	SCIENCE			English	Editorial Material							GENERATION; CORE		Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	DePaolo, DJ (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.		Manga, Michael/D-3847-2013	Manga, Michael/0000-0003-3286-4682				Allen RM, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000595; Buffett BA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014649; Courtillot V, 2003, EARTH PLANET SC LETT, V205, P295, DOI 10.1016/S0012-821X(02)01048-8; DAVIES GF, 1993, GEOPHYS J INT, V115, P132, DOI 10.1111/j.1365-246X.1993.tb05593.x; GRIFFITHS RW, 1986, PHYS EARTH PLANET IN, V43, P261, DOI 10.1016/0031-9201(86)90016-6; Humphreys E. D., 2000, GSA TODAY, V10, P1; MCKENZIE D, 1984, J PETROL, V25, P713, DOI 10.1093/petrology/25.3.713; MONTELLI R, EGS AGU EUG JOINT AS; Morgan W.J., 1972, GEOL SOC AM MEM, V132, P7, DOI [DOI 10.1130/MEM132-P7, 10.1130/MEM132-p7]; NATAF HC, 1991, TECTONOPHYSICS, V187, P261; Ribe NM, 1999, EARTH PLANET SC LETT, V171, P517, DOI 10.1016/S0012-821X(99)00179-X; RICHARDS MA, 1989, SCIENCE, V246, P103, DOI 10.1126/science.246.4926.103; Romanowicz B, 2002, SCIENCE, V296, P513, DOI 10.1126/science.1069404; SLEEP NH, 1988, J GEOPHYS RES-SOLID, V93, P7672, DOI 10.1029/JB093iB07p07672; Tatsumi Y., 1995, SUBDUCTION ZONE MAGM; van Keken PE, 2002, ANNU REV EARTH PL SC, V30, P493, DOI 10.1146/annurev.earth.30.091201.141236	16	69	76	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					920	921		10.1126/science.1083623	http://dx.doi.org/10.1126/science.1083623			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738844				2022-12-28	WOS:000182719800036
J	Thompson, KH; Orvig, C				Thompson, KH; Orvig, C			Boon and bane of metal ions in medicine	SCIENCE			English	Review							COMPLEXES; AGENTS	In biological systems metal ions promote responses that range from deficiency to toxicity. Some, such as iron and zinc, have a known optimal intake range for normal, healthy individuals. Metal ions contained within well-designed molecules already constitute a great boon for the medicinal pharmacopoeia. However, whether essential or not, the threshold for toxicity can be very low. One of the challenges of designing metal-based drugs is to balance the potential toxicity of an active formulation with the substantial positive impact of these increasingly common therapeutic and diagnostic aids.	Univ British Columbia, Dept Chem, Med Inorgan Chem Grp, Vancouver, BC V6T 1Z1, Canada	University of British Columbia	Orvig, C (corresponding author), Univ British Columbia, Dept Chem, Med Inorgan Chem Grp, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	orvig@chem.ubc.ca	Orvig, Chris/A-4099-2010	Orvig, Chris/0000-0002-2830-5493				ABRAMS MJ, 1993, SCIENCE, V261, P725, DOI 10.1126/science.8102010; ANDREWS NC, 1999, NEW ENGL J MED, V341, P893; Briand GG, 1999, CHEM REV, V99, P2601, DOI 10.1021/cr980425s; Cameron Beth R., 2001, Journal of Inorganic Biochemistry, V83, P233, DOI 10.1016/S0162-0134(00)00184-7; Caravan P, 2002, J AM CHEM SOC, V124, P3152, DOI 10.1021/ja017168k; Dilworth JR, 1998, CHEM SOC REV, V27, P43; Doctrow SR, 2002, J MED CHEM, V45, P4549, DOI 10.1021/jm020207y; Farrell N. P., 1999, USES INORGANIC CHEM; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; Guo ZJ, 1999, ANGEW CHEM INT EDIT, V38, P1513; Heaney RP, 2001, J NUTR, V131, p1344S, DOI 10.1093/jn/131.4.1344S; Hepburn DDD, 2002, CHEM RES TOXICOL, V15, P93, DOI 10.1021/tx010091t; Institute of Medicine, 2001, DIETARY REFERENCE IN; Liu S, 1999, CHEM REV, V99, P2235, DOI 10.1021/cr980436l; MERTZ W, 1993, NUTR REV, V51, P287, DOI 10.1111/j.1753-4887.1993.tb03057.x; Mertz W., 1994, RISK ASSESSMENT ESSE; MORLEY JE, 1995, GERIATRIC NUTR; Navarro M, 2001, INORG CHEM, V40, P6879, DOI 10.1021/ic0103087; Nielsen FH, 2000, J TRACE ELEM EXP MED, V13, P113; Salvemini D, 2002, NAT REV DRUG DISCOV, V1, P367, DOI 10.1038/nrd796; Sanchez-Delgado RA, 1998, INORG CHIM ACTA, V276, P528; Sigerist H., 1996, 4 TREATISES THEOPHRA; Silverman AP, 2002, J BIOL CHEM, V277, P49743, DOI 10.1074/jbc.M206979200; Storr T, 2003, BIOCONJUGATE CHEM, V14, P212, DOI 10.1021/bc025606m; Subramanian Indu, 2002, Curr Neurol Neurosci Rep, V2, P317, DOI 10.1007/s11910-002-0007-4; Thompson KH, 2000, J CHEM SOC DALTON, P2885, DOI 10.1039/b002753g; Werbovetz KA, 1999, MOL BIOCHEM PARASIT, V98, P53, DOI 10.1016/S0166-6851(98)00146-7; Woo LCY, 1999, J INORG BIOCHEM, V76, P251, DOI 10.1016/S0162-0134(99)00152-X; Zeevaart JR, 1999, J INORG BIOCHEM, V73, P265, DOI 10.1016/S0162-0134(99)00027-6; [No title captured]	30	320	327	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					936	939		10.1126/science.1083004	http://dx.doi.org/10.1126/science.1083004			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738851				2022-12-28	WOS:000182719800043
J	Garlaschelli, D; Caldarelli, G; Pietronero, L				Garlaschelli, D; Caldarelli, G; Pietronero, L			Universal scaling relations in food webs	NATURE			English	Article							COMPLEX NETWORKS; CONNECTANCE; PATTERNS; SIZE	The structure of ecological communities is usually represented by food webs(1-3). In these webs, we describe species by means of vertices connected by links representing the predations. We can therefore study different webs by considering the shape (topology) of these networks(4,5). Comparing food webs by searching for regularities is of fundamental importance, because universal patterns would reveal common principles underlying the organization of different ecosystems. However, features observed in small food webs(1-3,6) are different from those found in large ones(7-15). Furthermore, food webs (except in isolated cases(16,17)) do not share(18,19) general features with other types of network (including the Internet, the World Wide Web and biological webs). These features are a small-world character(4,5) and a scale-free (power-law) distribution of the degree(4,5) (the number of links per vertex). Here we propose to describe food webs as transportation networks(20) by extending to them the concept of allometric scaling(20-22) (how branching properties change with network size). We then decompose food webs in spanning trees and loop-forming links. We show that, whereas the number of loops varies significantly across real webs, spanning trees are characterized by universal scaling relations.	Univ Roma La Sapienza, INFM, UdR Roma 1, I-00185 Rome, Italy; Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy; Univ Siena, INFM, UdR Siena, I-53100 Siena, Italy; Univ Siena, Dipartimento Fis, I-53100 Siena, Italy; CNR, Ist Acust OM Corbino, I-00133 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Siena; University of Siena; Consiglio Nazionale delle Ricerche (CNR)	Caldarelli, G (corresponding author), Univ Roma La Sapienza, INFM, UdR Roma 1, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Pietronero, Luciano/O-4473-2018; Garlaschelli, Diego/P-2795-2019; Caldarelli, Guido/A-5274-2010; Garlaschelli, Diego/O-4862-2014	Pietronero, Luciano/0000-0001-6424-8863; Caldarelli, Guido/0000-0001-9377-3616; Garlaschelli, Diego/0000-0001-6035-1783				Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Banavar JR, 1999, NATURE, V399, P130, DOI 10.1038/20144; Caldarelli G, 1998, J THEOR BIOL, V193, P345, DOI 10.1006/jtbi.1998.0706; Camacho J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.228102; Christian RR, 1999, ECOL MODEL, V117, P99, DOI 10.1016/S0304-3800(99)00022-8; Cohen J.E., 1990, COMMUNITY FOOD WEBS; Cohen J.E., 1989, ECOLOGISTS COOPERATI; COUSINS SH, 1991, TRENDS ECOL EVOL, V6, P190, DOI 10.1016/0169-5347(91)90212-G; Drossel B, 2001, J THEOR BIOL, V208, P91, DOI 10.1006/jtbi.2000.2203; Dunne JA, 2002, P NATL ACAD SCI USA, V99, P12917, DOI 10.1073/pnas.192407699; Dunne JA, 2002, ECOL LETT, V5, P558, DOI 10.1046/j.1461-0248.2002.00354.x; GOLDWASSER L, 1993, ECOLOGY, V74, P1216, DOI 10.2307/1940492; HALL SJ, 1991, J ANIM ECOL, V60, P823, DOI 10.2307/5416; Huxham M, 1996, OIKOS, V76, P284, DOI 10.2307/3546201; Lawton J.H., 1989, P43; MARTINEZ ND, 1991, ECOL MONOGR, V61, P367, DOI 10.2307/2937047; Martinez ND, 1999, ECOLOGY, V80, P1044, DOI 10.1890/0012-9658(1999)080[1044:EOSEOC]2.0.CO;2; MARTINEZ ND, 1992, AM NAT, V139, P1208, DOI 10.1086/285382; McMahon T.A., 1983, SIZE LIFE; Memmott J, 2000, J ANIM ECOL, V69, P1, DOI 10.1046/j.1365-2656.2000.00367.x; Montoya JM, 2002, J THEOR BIOL, V214, P405, DOI 10.1006/jtbi.2001.2460; PIMM SL, 1982, FOOD WEBS; POLIS GA, 1991, AM NAT, V138, P123, DOI 10.1086/285208; RODRIGUEZITURBE.I, 1996, FRACTAL RIVER BASINS; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; WARREN PH, 1989, OIKOS, V55, P299, DOI 10.2307/3565588; West GB, 1999, SCIENCE, V284, P1677, DOI 10.1126/science.284.5420.1677; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; Williams RJ, 2002, P NATL ACAD SCI USA, V99, P12913, DOI 10.1073/pnas.192448799; Williams RJ, 2000, NATURE, V404, P180, DOI 10.1038/35004572	30	207	214	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					165	168		10.1038/nature01604	http://dx.doi.org/10.1038/nature01604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736684				2022-12-28	WOS:000182699600045
J	O'Malley, PG; Feuerstein, IM; Taylor, AJ				O'Malley, PG; Feuerstein, IM; Taylor, AJ			Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	75th Annual Scientific Session of the American-Heart-Association	NOV 17-20, 2002	CHICAGO, IL	Amer Heart Assoc			CORONARY-HEART-DISEASE; HORMONE REPLACEMENT THERAPY; COMPUTED-TOMOGRAPHY; SMOKING-CESSATION; ARTERY CALCIUM; GENERAL-PRACTICE; INTERVENTION; EVENTS; MEN; ATHEROSCLEROSIS	Context Although the use of electron beam tomography (EBT) as a motivational tool to change behavior is practiced, its efficacy has not been studied. Objective To assess the effects of incorporating EBT as a motivational factor into a cardiovascular screening program in the context of either intensive case management (ICM) or usual care by assessing its impact over 1 year on a composite measure of projected risk. Design Randomized controlled trial with a 2 x 2 factorial design and 1 year of follow-up., Setting and Participants A consecutive sample of 450 asymptomatic active-duty US Army personnel aged 39 to 45 years stationed within the Washington, DC, area and scheduled to undergo a periodic Army-mandated physical examination were enrolled between January 1999 and March 2001 (mean age, 42 years; 79% male; 66 [15%] had coronary calcification; mean [SD] predicted 10-year coronary risk, 5.85% [3.85%]). Interventions Patients were randomly assigned to 1 of 4 intervention arms: EBT results provided in the setting of either ICM (n=111) or usual care (n=119) or EBT results withheld in the setting of either ICM (n=124) or usual care (n=96). Main Outcome Measure The primary outcome measure was change in a composite measure of risk, the 10-year Framingham Risk Score (FRS). Results Comparing the groups who received EBT results with those who did not, the mean absolute risk change in 10-year FRS was +0.30 vs +0.36 (P=.81). Comparing the groups who received ICM with those who received usual care, the mean absolute risk change in 10-year FRS was -0.06 vs +0.74 (P=.003). Improvement or stabilization of cardiovascular risk was noted in 157 patients (40.2%). In multivariable analyses predicting change in FRS, after controlling for knowledge of coronary calcification, motivation for change, and multiple psychological variables, only the number of risk factors (odds ratio, 1.42; 95% confidence interval, 1.16-1.75 for each additional risk factor) and receipt of ICM (odds ratio, 1.62; 95% confidence interval, 1.04-2.52) were associated with improved or stabilized projected risk. Conclusions Using coronary calcification screening to motivate patients to make evidence-based changes in risk factors was not associated with improvement in modifiable cardiovascular risk at 1 year. Case management was superior to usual care in the management of risk factors.	Walter Reed Army Med Ctr, Dept Med, Div Gen Internal Med, Washington, DC 20307 USA; Walter Reed Army Med Ctr, Dept Radiol, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA	O'Malley, PG (corresponding author), Walter Reed Army Med Ctr, Dept Med, Div Gen Internal Med, 6900 Georgia Ave, Washington, DC 20307 USA.	patrick.omalley@amedd.army.mil						AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; [Anonymous], 1994, BMJ, V308, P313; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BARRATT A, 1994, AM J PUBLIC HEALTH, V84, P779, DOI 10.2105/AJPH.84.5.779; BIENER L, 1991, HEALTH PSYCHOL, V10, P360, DOI 10.1037/0278-6133.10.5.360; Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013; Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; Dornelas EA, 2000, PREV MED, V30, P261, DOI 10.1006/pmed.2000.0644; EBRAHIM S, 2000, COCHRANE LIB; Elgin EE, 2002, AM J CARDIOL, V90, P543, DOI 10.1016/S0002-9149(02)02533-X; ELTON PJ, 1994, J EPIDEMIOL COMMUN H, V48, P22, DOI 10.1136/jech.48.1.22; Engberg M, 2002, J FAM PRACTICE, V51, P546; FELDMAN W, 1990, Journal of General Internal Medicine, V5, pS50, DOI 10.1007/BF02600842; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Greenland P, 2001, CIRCULATION, V104, P1863, DOI 10.1161/hc4201.097189; Grundy SM, 1998, CIRCULATION, V97, P1876, DOI 10.1161/01.CIR.97.18.1876; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HAVAS S, 1991, ARCH INTERN MED, V151, P113, DOI 10.1001/archinte.151.1.113; Hoeg JM, 1997, JAMA-J AM MED ASSOC, V277, P1387, DOI 10.1001/jama.277.17.1387; Horton KM, 2002, CIRCULATION, V106, P532, DOI 10.1161/01.CIR.0000027136.56615.DE; JANOWITZ WR, 1993, AM J CARDIOL, V72, P247, DOI 10.1016/0002-9149(93)90668-3; Kajinami K, 1997, J AM COLL CARDIOL, V29, P1549, DOI 10.1016/S0735-1097(97)00090-9; Lee TH, 2002, NEW ENGL J MED, V346, P529, DOI 10.1056/NEJM200202143460715; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; Murray C. J. L., 1996, GLOBAL BURDEN DIS; MURRAY DM, 1986, PREV MED, V15, P661, DOI 10.1016/0091-7435(86)90071-X; O'Malley PG, 2000, AM J CARDIOL, V85, P945, DOI 10.1016/S0002-9149(99)00906-6; O'Malley PG, 1999, AM HEART J, V137, P932, DOI 10.1016/S0002-8703(99)70419-9; Park R, 2002, CIRCULATION, V106, P2073, DOI 10.1161/01.CIR.0000033819.29662.09; ROBERTSON I, 1992, BRIT J GEN PRACT, V42, P469; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; Rumberger JA, 1997, J AM COLL CARDIOL, V29, P1542, DOI 10.1016/S0735-1097(97)00093-4; Schmermund A, 1997, CIRCULATION, V96, P1461, DOI 10.1161/01.CIR.96.5.1461; Shaw C, 1999, SOC SCI MED, V49, P1571, DOI 10.1016/S0277-9536(99)00244-0; SHAW LJ, IN PRESS RADIOLOGY; Shields J P, 1996, Am J Card Imaging, V10, P235; Silverman SL, 1997, OBSTET GYNECOL, V89, P321, DOI 10.1016/S0029-7844(97)85857-7; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; STEVENS VJ, 1993, MED CARE, V31, P65, DOI 10.1097/00005650-199301000-00005; Taylor AJ, 1998, NEW ENGL J MED, V339, P2018, DOI 10.1056/NEJM199812313392711; TAYLOR JA, 1953, J ABNORM SOC PSYCH, V48, P285, DOI 10.1037/h0056264; Torgerson DJ, 1997, ARCH INTERN MED, V157, P2121, DOI 10.1001/archinte.157.18.2121; Wang SJ, 1996, AM HEART J, V132, P550, DOI 10.1016/S0002-8703(96)90237-9; Wong ND, 1996, AM J CARDIOL, V78, P1220, DOI 10.1016/S0002-9149(96)00599-1	49	141	142	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2215	2223		10.1001/jama.289.17.2215	http://dx.doi.org/10.1001/jama.289.17.2215			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	675ET	12734132	Bronze			2022-12-28	WOS:000182680700023
J	Allen, RM; Kanamori, H				Allen, RM; Kanamori, H			The potential for earthquake early warning in southern California	SCIENCE			English	Article							SYSTEM	Earthquake mitigation efforts in the United States currently use long-term probabilistic hazard assessments and rapid post-earthquake notification to reduce the potential damage of earthquakes. Here we present the seismological design for and demonstrate the feasibility of a short-term hazard warning system. Using data from past earthquakes, we show that our Earthquake Alarm System (ElarmS) could, with current TriNet instrumentation, issue a warning a few to tens of seconds ahead of damaging ground motion. The system uses the frequency content of the P-wave arrival to determine earthquake magnitude, an approach that allows magnitude determination before any damaging ground motion occurs.	Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; CALTECH, Seismol Lab, Pasadena, CA 91125 USA	University of Wisconsin System; University of Wisconsin Madison; California Institute of Technology	Allen, RM (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.		Allen, Richard/H-8493-2016	Allen, Richard/0000-0003-4293-9772				Anderson J., 1995, SEISMOL RES LETT, V66, P11, DOI [10.1785/gssrl.66.6.11, DOI 10.1785/GSSRL.66.6.11]; Aranda J. M. E., 1995, SEISMOL RES LETT, V66, P42; BAKUN WH, 1994, B SEISMOL SOC AM, V84, P359; Frankel A., 1996, 96532 US GEOL SURV O; Hauksson E, 2001, SEISMOL RES LETT, V72, P690, DOI DOI 10.1785/GSSRL.72.6.690; HEATON TH, 1985, SCIENCE, V228, P987, DOI 10.1126/science.228.4702.987; Housner GW, 1997, J ENG MECH, V123, P897, DOI 10.1061/(ASCE)0733-9399(1997)123:9(897); JONES L, 1994, SCIENCE, V266, P389, DOI 10.1126/science.266.5184.398; Kanamori H, 1997, NATURE, V390, P461, DOI 10.1038/37280; Kanamori H., 1991, EOS, V72, P564; Nakamura Y., 1988, P 9 WORLD C EARTHQ E, P673; NAKAMURA Y, 1988, EARTHQUAKES VOLCANOE, V20, P140; Nakamura Y., 1988, CALIF GEOLOGY, P33; TOKSOZ MN, 1990, PURE APPL GEOPHYS, V133, P475, DOI 10.1007/BF00878001; Tsai YB, 2001, B SEISMOL SOC AM, V91, P1298, DOI 10.1785/0120000740; Wald DJ., 1999, EARTHQ SPECTRA, V15, P537, DOI [10.1193/1.1586057, DOI 10.1193/1.1586057]; Wu YM, 2002, B SEISMOL SOC AM, V92, P2008, DOI 10.1785/0120010217; Wu YM, 1998, B SEISMOL SOC AM, V88, P1254	18	377	422	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					786	789		10.1126/science.1080912	http://dx.doi.org/10.1126/science.1080912			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730599				2022-12-28	WOS:000182579800047
J	Heo, WD; Meyer, T				Heo, WD; Meyer, T			Switch-of-function mutants based on morphology classification of Ras superfamily small GTPases	CELL			English	Article							GTP-BINDING PROTEINS; ACTIN CYTOSKELETON; RHO-GTPASE; FAMILY; DOMAIN; PATHWAYS; CDC42; ACTIVATION; COMPLEX; MEMBER	Signaling proteins from the same family can have markedly different roles in a given cellular context. Here, we show that expression of one hundred constitutively active human small GTPases induced cell morphologies that fell into nine distinct classes. We developed an algorithm for pairs of classes that predicted amino acid positions that can be exchanged to create mutants with switched functionality. The algorithm was validated by creating switch-of-function mutants for Rac1, CDC42, H-Ras, RalA, Rap2B, and R-Ras3. Contrary to expectations, the relevant residues were mostly outside known interaction surfaces and were structurally far apart from each other. Our study shows that specificity in protein families can be explored by combining genome-wide experimental functional classification with the creation of switch-of-function mutants.	Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA	Stanford University	Meyer, T (corresponding author), Stanford Univ, Dept Mol Pharmacol, Sch Med, 269 Campus Dr,Room 3215, Stanford, CA 94305 USA.	tobias1@stanford.edu	Heo, Won-Do/C-1696-2011	Meyer, Tobias/0000-0003-4339-3804				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Foster R, 1996, MOL CELL BIOL, V16, P2689; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Krzanowski W. J., 1988, PRINCIPLES MULTIVARI; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sowa ME, 2001, NAT STRUCT BIOL, V8, P234, DOI 10.1038/84974; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanabe K, 2000, J NEUROSCI, V20, P4138; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	37	84	85	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					315	328						14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732140				2022-12-28	WOS:000182640800007
J	Marra, MA; Jones, SJM; Astell, CR; Holt, RA; Brooks-Wilson, A; Butterfield, YSN; Khattra, J; Asano, JK; Barber, SA; Chan, SY; Cloutier, A; Coughlin, SM; Freeman, D; Girn, N; Griffith, OL; Leach, SR; Mayo, M; McDonald, H; Montgomery, SB; Pandoh, PK; Petrescu, AS; Robertson, AG; Schein, JE; Siddiqui, A; Smailus, DE; Stott, JE; Yang, GS; Plummer, F; Andonov, A; Artsob, H; Bastien, N; Bernard, K; Booth, TF; Bowness, D; Czub, M; Drebot, M; Fernando, L; Flick, R; Garbutt, M; Gray, M; Grolla, A; Jones, S; Feldmann, H; Meyers, A; Kabani, A; Li, Y; Normand, S; Stroher, U; Tipples, GA; Tyler, S; Vogrig, R; Ward, D; Watson, B; Brunham, RC; Krajden, M; Petric, M; Skowronski, DM; Upton, C; Roper, RL				Marra, MA; Jones, SJM; Astell, CR; Holt, RA; Brooks-Wilson, A; Butterfield, YSN; Khattra, J; Asano, JK; Barber, SA; Chan, SY; Cloutier, A; Coughlin, SM; Freeman, D; Girn, N; Griffith, OL; Leach, SR; Mayo, M; McDonald, H; Montgomery, SB; Pandoh, PK; Petrescu, AS; Robertson, AG; Schein, JE; Siddiqui, A; Smailus, DE; Stott, JE; Yang, GS; Plummer, F; Andonov, A; Artsob, H; Bastien, N; Bernard, K; Booth, TF; Bowness, D; Czub, M; Drebot, M; Fernando, L; Flick, R; Garbutt, M; Gray, M; Grolla, A; Jones, S; Feldmann, H; Meyers, A; Kabani, A; Li, Y; Normand, S; Stroher, U; Tipples, GA; Tyler, S; Vogrig, R; Ward, D; Watson, B; Brunham, RC; Krajden, M; Petric, M; Skowronski, DM; Upton, C; Roper, RL			The genome sequence of the SARS-associated coronavirus	SCIENCE			English	Article							PROTEIN FAMILIES; VIRUS; TRANSCRIPTION; GENERATION; DATABASE	We sequenced the 29,751-base genome of the severe acute respiratory syndrome (SARS)-associated coronavirus known as the Tor2 isolate. The genome sequence reveals that this coronavirus is only moderately related to other known coronaviruses, including two human coronaviruses, HCoV-OC43 and HCoV-229E. Phylogenetic analysis of the predicted viral proteins indicates that the virus does not closely resemble any of the three previously known groups of coronaviruses. The genome sequence will aid in the diagnosis of SARS virus infection in humans and potential animal hosts (using polymerase chain reaction and immunological tests), in the development of antivirals (including neutralizing antibodies), and in the identification of putative epitopes for vaccine development.	British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada; Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada; British Columbia Ctr Dis Control, Vancouver, BC V5Z 4R4, Canada; Univ British Columbia, Ctr Dis Control, Vancouver, BC V5Z 4R4, Canada; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	British Columbia Cancer Agency; University of British Columbia; University of Victoria	Marra, MA (corresponding author), British Columbia Canc Agcy, Genome Sci Ctr, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	mmarra@bccgsc.ca	Jones, Steven J/C-3621-2009; Roper, Rachel/A-7935-2013; Upton, Chris/A-4670-2008; Schein, Jacquie E/G-3674-2015; Brooks-Wilson, Angela/E-9399-2012; Marra, Marco A/B-5987-2008; Holt, Robert A/C-3303-2009; Griffith, Obi/P-1286-2014	Jones, Steven J/0000-0003-3394-2208; Roper, Rachel/0000-0001-6971-7745; Brooks-Wilson, Angela/0000-0003-1009-6408; Marra, Marco A/0000-0001-7146-7175; Holt, Robert A/0000-0002-7259-1247; Upton, Chris/0000-0002-9019-8967; Griffith, Obi/0000-0002-0843-4271; Montgomery, Stephen/0000-0002-5200-3903				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; DONNELLY CA, 2003, LANCET          0507; Fauquet C.M., 2000, VIRUS TAXONOMY CLASS, P835; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fields B. N., 2001, FIELDS VIROLOGY, V4; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Jonassen CM, 1998, J GEN VIROL, V79, P715, DOI 10.1099/0022-1317-79-4-715; Krishnan R, 1996, VIROLOGY, V218, P400, DOI 10.1006/viro.1996.0210; KUO L, 2002, ANN M AM SOC VIR LEX; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6; Munch R, 2003, MICROBES INFECT, V5, P69, DOI 10.1016/S1286-4579(02)00053-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEIRIS JSM, 2003, LANCET          0408; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Sawicki DL, 2001, J GEN VIROL, V82, P385, DOI 10.1099/0022-1317-82-2-385; Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215; SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990; SCHAAD MC, 1994, J VIROL, V68, P8169, DOI 10.1128/JVI.68.12.8169-8179.1994; SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626; Siddell S.G., 1995, CORONAVIRIDAE, P389; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai JC, 2003, J VIROL, V77, P841, DOI 10.1128/JVI.77.2.841-850.2003; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	32	1577	1913	4	239	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1399	1404		10.1126/science.1085953	http://dx.doi.org/10.1126/science.1085953			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12730501				2022-12-28	WOS:000183181800036
J	Iwamoto, M; Jernigan, DB; Guasch, A; Trepka, MJ; Blackmore, CG; Hellinger, WC; Pham, SM; Zaki, S; Lanciotti, RS; Lance-Parker, SE; DiazGranados, CA; Winquist, AG; Perlino, CA; Wiersma, S; Hillyer, KL; Goodman, JL; Marfin, AA; Chamberland, ME; Petersen, LR; Blake, P; Bower, W; Dowdy, L; Fleming, J; Guarner, J; Jimenez, J; Kuehnert, M; Leguen, F; Luu, T; Mallon, S; Moseley, R; Nejman, A; Page, P; Pealer, L; Qi, XS; Rico, E; Roehrig, J; Rollin, P; Salameh, M; Shieh, WJ; Tso, P; Withum, D				Iwamoto, M; Jernigan, DB; Guasch, A; Trepka, MJ; Blackmore, CG; Hellinger, WC; Pham, SM; Zaki, S; Lanciotti, RS; Lance-Parker, SE; DiazGranados, CA; Winquist, AG; Perlino, CA; Wiersma, S; Hillyer, KL; Goodman, JL; Marfin, AA; Chamberland, ME; Petersen, LR; Blake, P; Bower, W; Dowdy, L; Fleming, J; Guarner, J; Jimenez, J; Kuehnert, M; Leguen, F; Luu, T; Mallon, S; Moseley, R; Nejman, A; Page, P; Pealer, L; Qi, XS; Rico, E; Roehrig, J; Rollin, P; Salameh, M; Shieh, WJ; Tso, P; Withum, D		West Nile Virus Transplant Recipie	Transmission of West Nile virus from an organ donor to four transplant recipients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; ENCEPHALITIS; OUTBREAK; INFECTION; EPIDEMIC; DIAGNOSIS	BACKGROUND: In August 2002, fever and mental-status changes developed in recipients of organs from a common donor. Transmission of West Nile virus through organ transplantation was suspected. METHODS: We reviewed medical records, conducted interviews, and collected blood and tissue samples for testing with a variety of assays. Persons who donated blood to the organ donor and associated blood components were identified and tested for West Nile virus. RESULTS: We identified West Nile virus infection in the organ donor and in all four organ recipients. Encephalitis developed in three of the organ recipients, and febrile illness developed in one. Three recipients became seropositive for West Nile virus IgM antibody; the fourth recipient had brain tissue that was positive for West Nile virus by isolation and nucleic acid and antigen assays. Serum specimens obtained from the organ donor before and immediately after blood transfusions showed no evidence of West Nile virus; however, serum and plasma samples obtained at the time of organ recovery were positive on viral nucleic acid testing and viral culture. The organ donor had received blood transfusions from 63 donors. A review of blood donors and follow-up testing identified one donor who had viremia at the time of donation and who became seropositive for West Nile virus IgM antibodies during the next two months. CONCLUSIONS: Our investigation of this cluster documents the transmission of West Nile virus by organ transplantation. Organ recipients receiving immunosuppressive drugs may be at high risk for severe disease after West Nile virus infection. Blood transfusion was the probable source of the West Nile virus viremia in the organ donor.	Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Appl Publ Hlth Training, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Emory Univ, Sch Med, Atlanta, GA USA; Florida Dept Hlth, Tallahassee, FL USA; Mayo Clin, Jacksonville, FL 32224 USA; Univ Miami, Miami, FL 33152 USA; Georgia Dept Human Resources, Div Publ Hlth, Atlanta, GA USA; Amer Red Cross, Blood Serv, Atlanta, GA USA; US FDA, Rockville, MD 20857 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Florida Department of Health; Mayo Clinic; University of Miami; American Red Cross; US Food & Drug Administration (FDA)	Iwamoto, M (corresponding author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, 1600 Clifton Rd,MS A35, Atlanta, GA 30333 USA.		Guarner, Jeannette/B-8273-2013; Guasch, Anna Maria/Y-7842-2019	Guarner, Jeannette/0000-0001-5610-3541; Trepka, Mary Jo/0000-0002-6585-1194				[Anonymous], 2001, W NIL VIR SURV CONTR, P20; [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P833; [Anonymous], 1997, MMWR MORB MORTAL WKL, V46, P1; Asnis DS, 2000, CLIN INFECT DIS, V30, P841; Asnis DS, 2000, CLIN INFECT DIS, V30, P413, DOI 10.1086/313737; Biggerstaff BJ, 2002, TRANSFUSION, V42, P1019, DOI 10.1046/j.1537-2995.2002.00167.x; Chowers MY, 2001, EMERG INFECT DIS, V7, P675; *CTR BIOL EV RES, 2003, GUID IND REV REC ASS; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066, DOI 10.1128/JCM.38.11.4066-4071.2000; Martin DA, 2002, CLIN DIAGN LAB IMMUN, V9, P544, DOI 10.1128/CDLI.9.3.544-549.2002; Mostashari F, 2001, LANCET, V358, P261, DOI 10.1016/S0140-6736(01)05480-0; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Petersen LR, 2002, ANN INTERN MED, V137, P173, DOI 10.7326/0003-4819-137-3-200208060-00009; Shieh WJ, 2000, EMERG INFECT DIS, V6, P370, DOI 10.3201/eid0604.000407; SOUTHAM CM, 1954, AM J TROP MED HYG, V3, P19, DOI 10.4269/ajtmh.1954.3.19; Tardei G, 2000, J CLIN MICROBIOL, V38, P2232; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; Weiss D, 2001, EMERG INFECT DIS, V7, P654, DOI 10.3201/eid0704.010409; 2002, MMWR MORB MORTAL WKL, V51, P884; 2001, MMWR MORB MORTAL WKL, V50, P37; 2002, MMWR MORB MORTAL WKL, V51, P895; 2000, MMWR MORB MORTAL WKL, V50, P101	22	448	477	2	22	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2196	2203		10.1056/NEJMoa022987	http://dx.doi.org/10.1056/NEJMoa022987			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773646	Bronze			2022-12-28	WOS:000183134700005
J	Oldfield, TEE; Smith, RJ; Harrop, SR; Leader-Williams, N				Oldfield, TEE; Smith, RJ; Harrop, SR; Leader-Williams, N			Field sports and conservation in the United Kingdom	NATURE			English	Article							AGRI-ENVIRONMENT SCHEMES; PROTECTED AREAS; BIODIVERSITY; COUNTRYSIDE; FARMERS; ENGLAND	Many natural habitats exist on privately owned land outside protected areas(1), but few governments can afford to enforce or subsidize conservation of this biodiversity. Even in some developed countries, conservation subsidy schemes have only achieved limited success(2-4). Fortunately, some landowners may be willing to accept management costs in return for other benefits(5), although this remains controversial when it involves the killing of charismatic species. For example, participants in British field sports, such as fox hunting and game-bird shooting, may voluntarily conserve important habitats that are required by quarry species(6-8). Here we report results from a multidisciplinary study that addressed this issue by focusing on three sites across central England. We found that landowners participating in field sports maintained the most established woodland and planted more new woodland and hedgerows than those who did not, despite the equal availability of subsidies. Therefore, voluntary habitat management appears to be important for biodiversity conservation in Britain. Current debates on the future of field sports in Britain, and similar activities globally, may benefit from considering their utility as incentives to conserve additional habitat on private land.	Univ Kent, Durrell Inst Conservat & Ecol, Canterbury CT2 7NS, Kent, England	University of Kent	Leader-Williams, N (corresponding author), Univ Kent, Durrell Inst Conservat & Ecol, Canterbury CT2 7NS, Kent, England.		Smith, Robert J/D-9660-2011	Smith, Robert J/0000-0003-1599-9171				Baker PJ, 2002, NATURE, V419, P34, DOI 10.1038/419034a; Barr C.J., 1990, COUNTRYSIDE SURVEY 1; Beedell JDC, 1999, J ENVIRON MANAGE, V57, P165, DOI 10.1006/jema.1999.0296; BENNETT AF, 1999, LINKAGE LANDSCAPE RO; BURNS L, 2000, REPORT COMMITTEE INQ; *ENGL NAT, 2002, ANN REP APR 1 2001 3; Garbutt RA, 2002, BIOL CONSERV, V106, P273, DOI 10.1016/S0006-3207(01)00253-1; GLOWKA L, 1994, GUID CONV BIOL DIV; Goodman P.S., 2002, MAINSTREAMING BIODIV, P21; Kleijn D, 2001, NATURE, V413, P723, DOI 10.1038/35099540; Krebs JR, 1999, NATURE, V400, P611, DOI 10.1038/23127; Langholz JA, 2001, BIOSCIENCE, V51, P1079, DOI 10.1641/0006-3568(2001)051[1079:PAPOPO]2.0.CO;2; Leader-Williams N, 2002, NATURE, V419, P878, DOI 10.1038/419878a; LEADERWILLIAMS N, 1990, SCI PROGRESS-UK, V74, P189; LOVELACE D, 2000, MONEY MAKES COUNTRY; Macdonald D. W, 1987, RUNNING FOX; Macdonald DW, 2000, BIOL CONSERV, V94, P221, DOI 10.1016/S0006-3207(99)00173-1; O'Connell M, 2002, BIOL CONSERV, V103, P115, DOI 10.1016/S0006-3207(01)00125-2; Ovenden GN, 1998, J APPL ECOL, V35, P955, DOI 10.1111/j.1365-2664.1998.tb00014.x; ROBERTSON PA, 1988, BIOL CONSERV, V45, P159, DOI 10.1016/0006-3207(88)90136-X; Robinson RA, 2002, J APPL ECOL, V39, P157, DOI 10.1046/j.1365-2664.2002.00695.x; Stoate C, 2002, BIODIVERS CONSERV, V11, P561, DOI 10.1023/A:1015564806990; Sutherland WJ, 2002, TRENDS ECOL EVOL, V17, P148, DOI 10.1016/S0169-5347(01)02421-1; Tapper S., 1999, QUESTION BALANCE GAM; Thomas RC, 1997, BIOL CONSERV, V82, P243, DOI 10.1016/S0006-3207(97)00039-6; *UK GOV, 2001, ACH BETT QUAL LIF GO	26	50	55	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					531	533		10.1038/nature01678	http://dx.doi.org/10.1038/nature01678			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774120	Bronze			2022-12-28	WOS:000183162900041
J	Lev-Maor, G; Sorek, R; Shomron, N; Ast, G				Lev-Maor, G; Sorek, R; Shomron, N; Ast, G			The birth of an alternatively spliced exon: 3 ' splice-site selection in Alu exons	SCIENCE			English	Article							MESSENGER-RNA; MEDIATED INSERTION; SEQUENCE; ELEMENTS; SUBUNIT; GENES; MUTATION; RECEPTOR; VARIANT; JUNK	Alu repetitive elements can be inserted into mature messenger RNAs via a splicing-mediated process termed exonization. To understand the molecular basis and the regulation of the process of turning intronic Alus into new exons, we compiled and analyzed a data set of human exonized Alus. We revealed a mechanism that governs 3' splice-site selection in these exons during alternative splicing. On the basis of these findings, we identified mutations that activated the exonization of a silent intronic Alu.	Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel; Compugen, IL-69512 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Ast, G (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel.	gilast@post.tau.ac.il						BROSIUS J, 1992, P NATL ACAD SCI USA, V89, P10706, DOI 10.1073/pnas.89.22.10706; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; Chua K, 1999, NATURE, V402, P207, DOI 10.1038/46086; Chua K, 2001, MOL CELL BIOL, V21, P1509, DOI 10.1128/MCB.21.5.1509-1514.2001; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KNEBELMANN B, 1995, HUM MOL GENET, V4, P675, DOI 10.1093/hmg/4.4.675; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEVMAOR G, UNPUB; MAKALOWSKI W, 1994, TRENDS GENET, V10, P188, DOI 10.1016/0168-9525(94)90254-2; Makalowski W, 2000, GENE, V259, P61, DOI 10.1016/S0378-1119(00)00436-4; MANROW RE, 1993, J MOL BIOL, V234, P281, DOI 10.1006/jmbi.1993.1583; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; MIHOVILOVIC M, 1993, BIOCHEM BIOPH RES CO, V197, P137, DOI 10.1006/bbrc.1993.2452; Miller M, 1997, GENE, V190, P309, DOI 10.1016/S0378-1119(97)00022-X; MITCHELL GA, 1991, P NATL ACAD SCI USA, V88, P815, DOI 10.1073/pnas.88.3.815; Nekrutenko A, 2001, TRENDS GENET, V17, P619, DOI 10.1016/S0168-9525(01)02445-3; Rowold DJ, 2000, GENETICA, V108, P57, DOI 10.1023/A:1004099605261; Roy-Engel AM, 2002, GENOME RES, V12, P1333, DOI 10.1101/gr.384802; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Slavov D, 2002, GENE, V299, P83, DOI 10.1016/S0378-1119(02)01016-8; Sorek R, 2002, GENOME RES, V12, P1060, DOI 10.1101/gr.229302; SOREK R, UNPUB; Svineng G, 1998, BIOCHEM J, V330, P1255, DOI 10.1042/bj3301255; Vervoort R, 1998, HUM GENET, V103, P686, DOI 10.1007/PL00008709	26	339	363	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1288	1291		10.1126/science.1082588	http://dx.doi.org/10.1126/science.1082588			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764196				2022-12-28	WOS:000183042400048
J	Lucadamo, G; Medlin, DL				Lucadamo, G; Medlin, DL			Geometric origin of hexagonal close packing at a grain boundary in gold	SCIENCE			English	Article							INCOHERENT TWIN BOUNDARY; ELECTRON-MICROSCOPY; COPPER; DISSOCIATION; ENERGY; METALS; FCC	Using electron microscopy, we identify local, intergranular regions of hexagonal close-packing at a grain boundary in gold. By analyzing the topological defects that connect this layer to the adjacent face-centered cubic grains, we explain the geometric origin of this interfacial reconstruction. We extend this analysis to predict the stacking arrangements found over a range of intergranular misorientations. These results help to unify our understanding of the defects that control the behavior of polycrystalline materials by showing how line defects that are already well understood in the bulk also can determine the atomic arrangements at grain boundaries.	Sandia Natl Labs, Dept Thin Film & Interface Sci, Livermore, CA 94551 USA	United States Department of Energy (DOE); Sandia National Laboratories	Medlin, DL (corresponding author), Sandia Natl Labs, Dept Thin Film & Interface Sci, POB 969, Livermore, CA 94551 USA.		Medlin, Douglas/T-3514-2019	Medlin, Douglas/0000-0002-4613-1335				Balk TJ, 2001, PHILOS MAG A, V81, P1507, DOI 10.1080/01418610108214360; BRANDON DG, 1966, ACTA METALL MATER, V14, P1479, DOI 10.1016/0001-6160(66)90168-4; Campbell GH, 1996, SCRIPTA MATER, V35, P837, DOI 10.1016/1359-6462(96)00220-5; Carter CB, 1996, MATER SCI FORUM, V207-, P209, DOI 10.4028/www.scientific.net/MSF.207-209.209; ERNST F, 1992, PHYS REV LETT, V69, P620, DOI 10.1103/PhysRevLett.69.620; FRANK FC, 1949, PROC R SOC LON SER-A, V198, P205, DOI 10.1098/rspa.1949.0095; GRIMMER H, 1974, ACTA CRYSTALLOGR A, VA 30, P197, DOI 10.1107/S056773947400043X; Heidenreich R. D., 1948, C STRENGTH SOLIDS, P57; JENKINS ML, 1972, PHILOS MAG, V26, P747, DOI 10.1080/14786437208230118; KRAKOW W, 1987, ULTRAMICROSCOPY, V22, P47, DOI 10.1016/0304-3991(87)90049-0; McFadden SX, 1999, NATURE, V398, P684, DOI 10.1038/19486; Medlin DL, 2001, ACTA MATER, V49, P3689, DOI 10.1016/S1359-6454(01)00284-1; Medlin DL, 1998, ACTA MATER, V46, P5135, DOI 10.1016/S1359-6454(98)00164-5; MERKLE KL, 1994, J PHYS CHEM SOLIDS, V55, P991, DOI 10.1016/0022-3697(94)90119-8; MERKLE KL, 1990, C PHYS, V51, P251; Radetic T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.085502; Rittner JD, 1996, PHYS REV B, V54, P6999, DOI 10.1103/PhysRevB.54.6999; Rittner JD, 1996, PHYS REV B, V53, pR4241, DOI 10.1103/PhysRevB.53.R4241; Schiotz J, 1998, NATURE, V391, P561, DOI 10.1038/35328; Sutton A. P., 1995, INTERFACES CRYSTALLI; THOMPSON N, 1953, P PHYS SOC LOND B, V66, P481, DOI 10.1088/0370-1301/66/6/304; Van Swygenhoven H, 1999, ACTA MATER, V47, P3117, DOI 10.1016/S1359-6454(99)00109-3; Van Swygenhoven H, 2002, SCIENCE, V296, P66; Wang YM, 2002, NATURE, V419, P912, DOI 10.1038/nature01133; WOLF U, 1992, PHILOS MAG A, V66, P991, DOI 10.1080/01418619208248003; Yamakov V, 2002, NAT MATER, V1, P45, DOI 10.1038/nmat700	26	42	42	3	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1272	1275		10.1126/science.1083890	http://dx.doi.org/10.1126/science.1083890			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764193				2022-12-28	WOS:000183042400043
J	Bonow, RO; Eckel, RH				Bonow, RO; Eckel, RH			Diet, obesity, and cardiovascular risk	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Northwestern University; Feinberg School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bonow, RO (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.							Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Diabetes Prevention Program Research Group, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801	3	79	84	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2057	2058		10.1056/NEJMp030053	http://dx.doi.org/10.1056/NEJMp030053			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761363				2022-12-28	WOS:000183008300002
J	Fishman, A; Martinez, F; Naumheim, K; Piantadosi, S; Wise, R; Ries, A; Weinmann, G; Wood, DE				Fishman, A; Martinez, F; Naumheim, K; Piantadosi, S; Wise, R; Ries, A; Weinmann, G; Wood, DE		Natl Emphysema Treatment Trial Res	A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-STATUS; REHABILITATION; TERM	BACKGROUND: Lung-volume-reduction surgery has been proposed as a palliative treatment for severe emphysema. Effects on mortality, the magnitude and durability of benefits, and criteria for the selection of patients have not been established. METHODS: A total of 1218 patients with severe emphysema underwent pulmonary rehabilitation and were randomly assigned to undergo lung-volume-reduction surgery or to receive continued medical treatment. RESULTS: Overall mortality was 0.11 death per person-year in both treatment groups (risk ratio for death in the surgery group, 1.01; P=0.90). After 24 months, exercise capacity had improved by more than 10 W in 15 percent of the patients in the surgery group, as compared with 3 percent of patients in the medical-therapy group (P<0.001). With the exclusion of a subgroup of 140 patients at high risk for death from surgery according to an interim analysis, overall mortality in the surgery group was 0.09 death per person-year, as compared with 0.10 death per person-year in the medical-therapy group (risk ratio, 0.89; P=0.31); exercise capacity after 24 months had improved by more than 10 W in 16 percent of patients in the surgery group, as compared with 3 percent of patients in the medical-therapy group (P<0.001). Among patients with predominantly upper-lobe emphysema and low exercise capacity, mortality was lower in the surgery group than in the medical-therapy group (risk ratio for death, 0.47; P=0.005). Among patients with non-upper-lobe emphysema and high exercise capacity, mortality was higher in the surgery group than in the medical-therapy group (risk ratio, 2.06; P=0.02). CONCLUSIONS: Overall, lung-volume-reduction surgery increases the chance of improved exercise capacity but does not confer a survival advantage over medical therapy. It does yield a survival advantage for patients with both predominantly upper-lobe emphysema and low base-line exercise capacity. Patients previously reported to be at high risk and those with non-upper-lobe emphysema and high base-line exercise capacity are poor candidates for lung-volume-reduction surgery, because of increased mortality and negligible functional gain.	NETT Coordinating Ctr, Baltimore, MD 21205 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Michigan, Ann Arbor, MI 48109 USA; St Louis Univ, St Louis, MO 63103 USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Calif San Diego, La Jolla, CA 92093 USA; NHLBI, Bethesda, MD 20892 USA; Univ Washington, Seattle, WA 98195 USA	University of Pennsylvania; University of Michigan System; University of Michigan; Saint Louis University; Johns Hopkins University; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Washington; University of Washington Seattle	Piantadosi, S (corresponding author), NETT Coordinating Ctr, 615 N Wolfe St,Rm 5010, Baltimore, MD 21205 USA.			Wise, Robert/0000-0002-8353-2349	DIVISION OF LUNG DISEASES [N01HR076113, N01HR076104, N01HR076108, N01HR076112, N01HR076107, N01HR076110, N01HR076106, N01HR076102, N01HR076116, N01HR076101, N01HR076115, N01HR076118, N01HR076111, N01HR076119, N01HR076109, N01HR076105, N01HR076103, N01HR076114] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01HR76104, N01HR76119, N01HR76105, N01HR76118, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76116, N01HR76115, N01HR76113, N01HR76114, N01HR76102, N01HR76101, N01HR76103] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agresti A., 1996, INTRO CATEGORICAL DA; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; Bloch KE, 2002, J THORAC CARDIOV SUR, V123, P845, DOI 10.1067/mtc.2002.120731; Brenner M, 1996, CHEST, V110, P205, DOI 10.1378/chest.110.1.205; Cooper JD, 1996, J THORAC CARDIOV SUR, V112, P1319, DOI 10.1016/S0022-5223(96)70147-2; Criner GJ, 1999, AM J RESP CRIT CARE, V160, P2018, DOI 10.1164/ajrccm.160.6.9902117; *CYT SOFTW, 2001, LOGX 4 WIND LOG REGR; Eakin EG, 1998, CHEST, V113, P619, DOI 10.1378/chest.113.3.619; Fishman A, 2001, NEW ENGL J MED, V345, P1075; Flaherty KR, 2001, CHEST, V119, P1337, DOI 10.1378/chest.119.5.1337; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; Gelb AF, 1999, CHEST, V116, P1608, DOI 10.1378/chest.116.6.1608; Ingenito EP, 2001, AM J RESP CRIT CARE, V163, P1068, DOI 10.1164/ajrccm.163.5.9911013; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702; KAPLAN RM, 1984, J CHRON DIS, V37, P85, DOI 10.1016/0021-9681(84)90050-X; *NTIS, 2002, SUB5251INQ NTIS; *NTIS, 2002, SUB5446INQ NTIS; Pompeo E, 2000, ANN THORAC SURG, V70, P948, DOI 10.1016/S0003-4975(00)01646-5; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278, DOI 10.1164/ajrccm.155.4.9105067; Rodarte J, 1999, J THORAC CARDIOV SUR, V118, P518; Sciurba FC, 1996, NEW ENGL J MED, V334, P1095, DOI 10.1056/NEJM199604253341704; Shih JH, 1995, CONTROL CLIN TRIALS, V16, P395, DOI 10.1016/S0197-2456(95)00132-8; Steele B, 1996, J Cardiopulm Rehabil, V16, P25; Wisser W, 2000, EUR J CARDIO-THORAC, V17, P666, DOI 10.1016/S1010-7940(00)00446-2; 2001, STATA REFERENCE MANU	27	1279	1364	2	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2059	2073						15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12759479				2022-12-28	WOS:000183008300003
J	Kurzrock, R; Kantarjian, HM; Druker, BJ; Talpaz, M				Kurzrock, R; Kantarjian, HM; Druker, BJ; Talpaz, M			Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics	ANNALS OF INTERNAL MEDICINE			English	Review							ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAKPOINT CLUSTER REGION; COLONY-STIMULATING FACTOR; FOCAL ADHESION KINASE; P210 BCR-ABL; C-ABL; IMATINIB MESYLATE	The Philadelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias. The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity. This abnormal enzymatic activation is critical to the oncogenic potential of Bcr-Abl. Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiologic processes. However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as ST1571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific. This agent has shown striking activity in chronic myelogenous leukemia. It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor. In addition, it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor. The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of molecular therapeutics. This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University	Kurzrock, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Box 422,1515 Holcombe Blvd, Houston, TX 77030 USA.	rkurzroc@mdanderson.org		Talpaz, Moshe/0000-0003-3361-3981; Druker, Brian/0000-0001-8331-8206				ABELSON HT, 1970, CANCER RES, V30, P2213; AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; Agami R, 1999, NATURE, V399, P809; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Arlinghaus RB, 1998, CRIT REV ONCOGENESIS, V9, P1; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beaupre DM, 1999, J CLIN ONCOL, V17, P1071, DOI 10.1200/JCO.1999.17.3.1071; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; BIERNAUX C, 1995, BLOOD, V86, P3118; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Cheng KD, 2002, CANCER, V95, P440, DOI 10.1002/cncr.10670; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cortes JE, 2002, BLOOD, V100, p95A; Cortez D, 1996, ONCOGENE, V13, P2589; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Deininger MWN, 1998, CANCER RES, V58, P421; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; DHINGRA K, 1991, LEUKEMIA, V5, P191; DHUT S, 1988, ONCOGENE, V3, P561; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; DRUKER B, 1992, BLOOD, V79, P2215; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GOTOH A, 1995, EXP HEMATOL, V23, P1153; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KANTARJIAN H, 1994, AM J MED, V96, P133, DOI 10.1016/0002-9343(94)90133-3; Kantarjian HM, 2002, BLOOD, V99, P3547, DOI 10.1182/blood.V99.10.3547; KANTARJIAN HM, 1993, BLOOD, V82, P691; Kantarjian HM, 2002, BLOOD, V100, P1590, DOI 10.1182/blood.V100.5.1590.h81702001590_1590_1595; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1987, BRIT J HAEMATOL, V67, P55, DOI 10.1111/j.1365-2141.1987.tb02296.x; KURZROCK R, 1990, BLOOD, V75, P445; KURZROCK R, 1986, ANN INTERN MED, V105, P673, DOI 10.7326/0003-4819-105-5-673; Kurzrock R, 2001, J CLIN ONCOL, V19, P2915, DOI 10.1200/JCO.2001.19.11.2915; KURZROCK R, 1987, BLOOD, V70, P233; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1987, BLOOD, V70, P1584; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Larson RA, 2002, BLOOD, V100, p4A; Laurent E, 2000, LEUKEMIA, V14, P1892, DOI 10.1038/sj.leu.2401923; Laurent E, 2001, CANCER RES, V61, P2343; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Maru Y, 1999, BIOCHEM BIOPH RES CO, V260, P309, DOI 10.1006/bbrc.1999.0822; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; *NAT CTR BIOT INF, ENTR; Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207; NOWELL PC, 1960, SCIENCE, V132, P1497; ODA T, 1994, J BIOL CHEM, V269, P22925; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RODENHUIS S, 1985, NEW ENGL J MED, V313, P51; RON D, 1991, NEW BIOL, V3, P372; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rubin BP, 2002, J CLIN ONCOL, V20, P3586, DOI 10.1200/JCO.2002.01.027; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHTALRID M, 1988, J CLIN ONCOL, V6, P1569, DOI 10.1200/JCO.1988.6.10.1569; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STEWART MJ, 1994, J BIOL CHEM, V269, P10820; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Tauchi T, 1998, INT J ONCOL, V12, P1269; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VANETTEN RA, 1995, ONCOGENE, V10, P1977; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WETZLER M, 1995, P NATL ACAD SCI USA, V92, P3488, DOI 10.1073/pnas.92.8.3488; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; WilsonRawls J, 1996, CANCER RES, V56, P3426; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799	124	229	259	2	45	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					819	830		10.7326/0003-4819-138-10-200305200-00010	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755554				2022-12-28	WOS:000182920700006
J	Wrenn, K				Wrenn, K			On being a doctor - Past and present	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Vanderbilt Univ, Med Ctr, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Wrenn, K (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, 703 Oxford House, Nashville, TN 37232 USA.	keith.wrenn@mcmail.vanderbilt.edu	Wrenn, Keith/AAI-7651-2020						0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					847	847		10.7326/0003-4819-138-10-200305200-00015	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755559				2022-12-28	WOS:000182920700011
J	Bowman, D; King, G; Tapponnier, P				Bowman, D; King, G; Tapponnier, P			Slip partitioning by elastoplastic propagation of oblique slip at depth	SCIENCE			English	Article							LOMA-PRIETA; FAULTS; GROWTH; TIBET; CALIFORNIA; MECHANICS; EVOLUTION; BASIN; ASIA	Oblique motion along tectonic boundaries is commonly partitioned into slip on faults with different senses of motion. The origin of slip partitioning is important to structural geology, tectonophysics, and earthquake mechanics. Partitioning can be explained by the upward elastoplastic propagation of oblique slip from a fault or shear zone at depth. The strain field ahead of the propagating fault separates into zones of predominantly normal, reverse, and strike-slip faulting. The model successfully predicts the distribution of fault types along parts of the San Andreas and Haiyuan faults.	Calif State Univ Fullerton, Dept Geol Sci, Fullerton, CA 92834 USA; Inst Phys Globe, Lab Tecton, F-75252 Paris 5, France	California State University System; California State University Fullerton; UDICE-French Research Universities; Universite Paris Cite	Bowman, D (corresponding author), Calif State Univ Fullerton, Dept Geol Sci, 800 State Coll Blvd, Fullerton, CA 92834 USA.	dbowman@fullerton.edu	Tapponnier, .Paul E/B-7033-2011	Tapponnier, .Paul E/0000-0002-7135-1962				Abelson M, 1997, EARTH PLANET SC LETT, V148, P405, DOI 10.1016/S0012-821X(97)00054-X; [Anonymous], 2002, SEISMOL RES LETT, DOI [DOI 10.1785/gssrl.73.2.125, DOI 10.1785/GSSRL.73.2.125]; ARMIJO R, 1986, J GEOPHYS RES-SOLID, V91, P13803, DOI 10.1029/JB091iB14p13803; COWIE PA, 1992, J GEOPHYS RES-SOL EA, V97, P11085, DOI 10.1029/92JB00586; COWIE PA, 1992, J STRUCT GEOL, V14, P1133, DOI 10.1016/0191-8141(92)90065-5; DESCHAMPS A, 1985, SEISMOL SOC AM B, V76, P2683; DIETZ LD, 1990, GEOPHYS RES LETT, V17, P1417, DOI 10.1029/GL017i009p01417; Dolan JF, 1997, GEOL SOC AM BULL, V109, P1595, DOI 10.1130/0016-7606(1997)109<1595:ATPASH>2.3.CO;2; FITCH TJ, 1972, J GEOPHYS RES, V77, P4432, DOI 10.1029/JB077i023p04432; GAUDEMER Y, 1995, GEOPHYS J INT, V120, P599, DOI 10.1111/j.1365-246X.1995.tb01842.x; HENYEY TL, 1971, J GEOPHYS RES, V76, P7924, DOI 10.1029/JB076i032p07924; Hubert-Ferrari A, 2003, GEOPHYS J INT, V153, P111, DOI 10.1046/j.1365-246X.2003.01872.x; JACKSON J, 1983, J STRUCT GEOL, V5, P471, DOI 10.1016/0191-8141(83)90053-6; KING GCP, 1981, NATURE, V292, P22, DOI 10.1038/292022a0; Lawn B.R., 1975, FRACTURE BRITTLE SOL; McClintock F. A., 1971, FRACTURE ADV TREATIS, P47, DOI DOI 10.1016/B978-0-12-449703-0.50007-2; Meade BJ, 2002, B SEISMOL SOC AM, V92, P208, DOI 10.1785/0120000837; Meyer B, 1998, GEOPHYS J INT, V135, P1, DOI 10.1046/j.1365-246X.1998.00567.x; MICHAEL AJ, 1990, GEOPHYS RES LETT, V17, P1453, DOI 10.1029/GL017i009p01453; MOLNAR P, 1992, FAULT MECH TRANSPORT, pCH18; PELTZER G, 1988, J GEOPHYS RES-SOLID, V93, P15085, DOI 10.1029/JB093iB12p15085; Poliakov ANB, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000572; Scholz CH, 2000, GEOLOGY, V28, P163, DOI 10.1130/0091-7613(2000)28<163:EFASSA>2.0.CO;2; STEIN RS, 1984, SCIENCE, V224, P869, DOI 10.1126/science.224.4651.869; Tapponnier P, 2001, SCIENCE, V294, P1671, DOI 10.1126/science.105978; WALLACE RE, 1984, J GEOPHYS RES, V89, P5763, DOI 10.1029/JB089iB07p05763; Wittlinger G, 1998, SCIENCE, V282, P74, DOI 10.1126/science.282.5386.74; Woodcock N.H., 1994, CONTINENTAL DEFORMAT, P251	28	89	98	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2003	300	5622					1121	1123		10.1126/science.1082180	http://dx.doi.org/10.1126/science.1082180			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750513				2022-12-28	WOS:000182886500037
J	Petersen, KF; Befroy, D; Dufour, S; Dziura, J; Ariyan, C; Rothman, DL; DiPietro, L; Cline, GW; Shulman, GI				Petersen, KF; Befroy, D; Dufour, S; Dziura, J; Ariyan, C; Rothman, DL; DiPietro, L; Cline, GW; Shulman, GI			Mitochondrial dysfunction in the elderly: Possible role in insulin resistance	SCIENCE			English	Article							FREE FATTY-ACIDS; SKELETAL-MUSCLE; MECHANISM; ACCUMULATION; SPECTROSCOPY; ACTIVATION; MUTATIONS; HUMANS; LIVER	Insulin resistance is a major factor in the pathogenesis of type 2 diabetes in the elderly. To investigate how insulin resistance arises, we studied healthy, lean, elderly and young participants matched for lean body mass and fat mass. Elderly study participants were markedly insulin-resistant as compared with young controls, and this resistance was attributable to reduced insulin-stimulated muscle glucose metabolism. These changes were associated with increased fat accumulation in muscle and liver tissue assessed by H-1 nuclear magnetic resonance (NMR) spectroscopy, and with a similar to40% reduction in mitochondrial oxidative and phosphorylation activity, as assessed by in vivo C-13/P-31 NMR spectroscopy. These data support the hypothesis that an age-associated decline in mitochondrial function contributes to insulin resistance in the elderly.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, John B Pierce Lab, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; The John B Pierce Laboratory, Inc; Howard Hughes Medical Institute; Yale University	Shulman, GI (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St, New Haven, CT 06520 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Ariyan, Charlotte/0000-0003-0818-3895	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049230, P30DK045735, K23DK002734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023686, R01AG009872, P60AG010469] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000125, M01 RR-00125] Funding Source: Medline; NIA NIH HHS [P60 AG-10469, R01 AG-09872, R01 AG023686-01A1, R01 AG023686] Funding Source: Medline; NIDDK NIH HHS [R01 DK049230, K-23 DK-02347, P30 DK045735, P30 DK-45735, R01 DK-49230, K23 DK002734-04, K23 DK002734] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HUSE DM, 1989, JAMA-J AM MED ASSOC, V262, P2708, DOI 10.1001/jama.262.19.2708; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; JOHNSON AB, 1992, CLIN SCI, V82, P219, DOI 10.1042/cs0820219; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Lebon V, 2001, J CLIN INVEST, V108, P733, DOI 10.1172/JCI11775; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; Luft R, 1993, Lakartidningen, V90, P2770; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Petersen KF, 1998, DIABETES, V47, P381, DOI 10.2337/diabetes.47.3.381; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914; SAAD MF, 1989, LANCET, V1, P1356; SASAKI A, 1982, DIABETOLOGIA, V22, P154, DOI 10.1007/BF00283743; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	30	1525	1585	4	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2003	300	5622					1140	1142		10.1126/science.1082889	http://dx.doi.org/10.1126/science.1082889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750520	Green Accepted			2022-12-28	WOS:000182886500044
J	Cossart, R; Aronov, D; Yuste, R				Cossart, R; Aronov, D; Yuste, R			Attractor dynamics of network UP states in the neocortex	NATURE			English	Article							SPONTANEOUS FIRING PATTERNS; LESS-THAN-1 HZ OSCILLATION; CAT VISUAL-CORTEX; FUNCTIONAL ARCHITECTURE; PREFRONTAL CORTEX; NEURONS; PROJECTIONS; MEMORY	The cerebral cortex receives input from lower brain regions, and its function is traditionally considered to be processing that input through successive stages to reach an appropriate output(1,2). However, the cortical circuit contains many interconnections, including those feeding back from higher centres(3-6), and is continuously active even in the absence of sensory inputs(7-9). Such spontaneous firing has a structure that reflects the coordinated activity of specific groups of neurons(10-12). Moreover, the membrane potential of cortical neurons fluctuates spontaneously between a resting ( DOWN) and a depolarized (UP) state(11,13-16), which may also be coordinated. The elevated firing rate in the UP state follows sensory stimulation(16) and provides a substrate for persistent activity, a network state that might mediate working memory(17-21). Using two-photon calcium imaging, we reconstructed the dynamics of spontaneous activity of up to 1,400 neurons in slices of mouse visual cortex. Here we report the occurrence of synchronized UP state transitions ('cortical flashes') that occur in spatially organized ensembles involving small numbers of neurons. Because of their stereotyped spatiotemporal dynamics, we conclude that network UP states are circuit attractors-emergent features of feedback neural networks(22) that could implement memory states or solutions to computational problems.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Cossart, R (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	rcossart@biology.columbia.edu	Cossart, Rosa/AAT-7934-2020; Cossart, Rosa/E-7674-2014	Cossart, Rosa/0000-0003-2111-6638; Cossart, Rosa/0000-0003-2111-6638				Anderson J, 2000, NAT NEUROSCI, V3, P617, DOI 10.1038/75797; Badea T, 2001, J NEUROBIOL, V48, P215, DOI 10.1002/neu.1052; BENYISHAI R, 1995, P NATL ACAD SCI USA, V92, P3844, DOI 10.1073/pnas.92.9.3844; Constantinidis C, 2001, J NEUROSCI, V21, P3646, DOI 10.1523/JNEUROSCI.21-10-03646.2001; COWAN RL, 1994, J NEUROPHYSIOL, V71, P17, DOI 10.1152/jn.1994.71.1.17; Creutzfeldt O., 1995, CORTEX CEREBRI; De No RL, 1938, J NEUROPHYSIOL, V1, P207; Douglas RJ, 1998, SYNAPTIC ORG BRAIN, P459; Durstewitz D, 2000, NAT NEUROSCI, V3, P1184, DOI 10.1038/81460; FUSTER JM, 1991, PROG BRAIN RES, V87, P201; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; Hebb Donald O., 1949, ORG BEHAV; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; Llinas R., 2002, I VORTEX NEURONS SEL; Majewska A, 2000, PFLUG ARCH EUR J PHY, V441, P398, DOI 10.1007/s004240000435; Mao BQ, 2001, NEURON, V32, P883, DOI 10.1016/S0896-6273(01)00518-9; Mountcastle V.B., 1998, PERCEPTUAL NEUROSCIE; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027, DOI 10.1038/79848; Seung HS, 2000, NEURON, V26, P259, DOI 10.1016/S0896-6273(00)81155-1; Shu YS, 2003, NATURE, V423, P288, DOI 10.1038/nature01616; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; STERIADE M, 1993, J NEUROSCI, V13, P3284; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; Tsodyks M, 1999, SCIENCE, V286, P1943, DOI 10.1126/science.286.5446.1943; Wang XJ, 2001, TRENDS NEUROSCI, V24, P455, DOI 10.1016/S0166-2236(00)01868-3; WILSON CJ, 1981, BRAIN RES, V220, P67, DOI 10.1016/0006-8993(81)90211-0	28	460	473	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					283	288		10.1038/nature01614	http://dx.doi.org/10.1038/nature01614			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748641				2022-12-28	WOS:000182853100042
J	Alford, MH				Alford, MH			Redistribution of energy available for ocean mixing by long-range propagation of internal waves	NATURE			English	Article							INERTIAL CURRENTS; TIDAL ENERGY; DEEP-OCEAN; WIND; ALTIMETRY; TIDES	Ocean mixing, which affects pollutant dispersal, marine productivity and global climate(1), largely results from the breaking of internal gravity waves-disturbances propagating along the ocean's internal stratification. A global map of internal-wave dissipation would be useful in improving climate models, but would require knowledge of the sources of internal gravity waves and their propagation. Towards this goal, I present here computations of horizontal internal-wave propagation from 60 historical moorings and relate them to the source terms of internal waves as computed previously(2,3). Analysis of the two most energetic frequency ranges-near-inertial frequencies and semidiurnal tidal frequencies-reveals that the fluxes in both frequency bands are of the order of 1 kW m(-1) (that is, 15-50% of the energy input) and are directed away from their respective source regions. However, the energy flux due to near-inertial waves is stronger in winter, whereas the tidal fluxes are uniform throughout the year. Both varieties of internal waves can thus significantly affect the space-time distribution of energy available for global mixing.	Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA; Univ Washington, Sch Oceanog, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Alford, MH (corresponding author), Univ Washington, Appl Phys Lab, 1013 NE 40th St, Seattle, WA 98105 USA.	malford@apl.washington.edu						Alford MH, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016614; Alford MH, 2001, J GEOPHYS RES-OCEANS, V106, P16947, DOI 10.1029/2000JC000370; Alford MH, 2001, J PHYS OCEANOGR, V31, P2359, DOI 10.1175/1520-0485(2001)031<2359:ISGTSD>2.0.CO;2; DASARO EA, 1985, J PHYS OCEANOGR, V15, P943, DOI 10.1175/1520-0485(1985)015<0943:UOTSIC>2.0.CO;2; DASARO EA, 1995, J PHYS OCEANOGR, V25, P2909, DOI 10.1175/1520-0485(1995)025<2909:UOICFB>2.0.CO;2; DASARO EA, 1991, P DYN OC INT GRAV WA, V2, P451; Doherty KW, 1999, J ATMOS OCEAN TECH, V16, P1816, DOI 10.1175/1520-0426(1999)016<1816:AMPI>2.0.CO;2; DUSHAW BD, 1995, J PHYS OCEANOGR, V25, P631, DOI 10.1175/1520-0485(1995)025<0631:BABTIT>2.0.CO;2; Egbert GD, 2000, NATURE, V405, P775, DOI 10.1038/35015531; FU LL, 1981, REV GEOPHYS, V19, P141, DOI 10.1029/RG019i001p00141; Ganachaud A, 2000, NATURE, V408, P453, DOI 10.1038/35044048; GARRETT C, 1975, J GEOPHYS RES, V80, P291, DOI 10.1029/JC080i003p00291; Garrett C, 2001, J PHYS OCEANOGR, V31, P962, DOI 10.1175/1520-0485(2001)031<0962:WITNIB>2.0.CO;2; GILL AE, 1984, J PHYS OCEANOGR, V14, P1129, DOI 10.1175/1520-0485(1984)014<1129:OTBOIW>2.0.CO;2; GREGG MC, 1987, J GEOPHYS RES-OCEANS, V92, P5249, DOI 10.1029/JC092iC05p05249; Kunze E, 2002, J PHYS OCEANOGR, V32, P1890, DOI 10.1175/1520-0485(2002)032<1890:IWIMSC>2.0.CO;2; LEDWELL JR, 1993, NATURE, V364, P701, DOI 10.1038/364701a0; Levitus S, 1994, WORLD OCEAN ATLAS 19; Manabe S, 1988, J CLIMATE, V1, P841, DOI 10.1175/1520-0442(1988)001<0841:TSEOAC>2.0.CO;2; Merrifield MA, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2001JC000996; Munk W, 1998, DEEP-SEA RES PT I, V45, P1977, DOI 10.1016/S0967-0637(98)00070-3; PINGREE RD, 1991, J PHYS OCEANOGR, V21, P28, DOI 10.1175/1520-0485(1991)021<0028:APABRO>2.0.CO;2; Polzin KL, 1997, SCIENCE, V276, P93, DOI 10.1126/science.276.5309.93; Ray RD, 2001, GEOPHYS RES LETT, V28, P1259, DOI 10.1029/2000GL012447; Ray RD, 1997, PROG OCEANOGR, V40, P135, DOI 10.1016/S0079-6611(97)00025-6; Samelson RM, 1998, J PHYS OCEANOGR, V28, P712, DOI 10.1175/1520-0485(1998)028<0712:LSCWLE>2.0.CO;2; St Laurent L, 2002, J PHYS OCEANOGR, V32, P2882, DOI 10.1175/1520-0485(2002)032<2882:TROITI>2.0.CO;2; Thorpe SA, 1999, J PHYS OCEANOGR, V29, P1085, DOI 10.1175/1520-0485(1999)029<1085:OIWG>2.0.CO;2; Webb DJ, 2001, NATURE, V409, P37, DOI 10.1038/35051171; Wunsch C, 1998, J PHYS OCEANOGR, V28, P2332, DOI 10.1175/1520-0485(1998)028<2332:TWDBTW>2.0.CO;2	30	278	284	5	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					159	162		10.1038/nature01628	http://dx.doi.org/10.1038/nature01628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736682				2022-12-28	WOS:000182699600043
J	Gould, MK; Sanders, GD; Barnett, PG; Rydzak, CE; Maclean, CC; McClellan, MB; Owens, DK				Gould, MK; Sanders, GD; Barnett, PG; Rydzak, CE; Maclean, CC; McClellan, MB; Owens, DK			Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules	ANNALS OF INTERNAL MEDICINE			English	Review							POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; TRANSTHORACIC NEEDLE-BIOPSY; ASSISTED THORACIC-SURGERY; QUALITY-OF-LIFE; NEGATIVE FIBEROPTIC BRONCHOSCOPY; IODINATED CONTRAST MATERIAL; POLYMERASE CHAIN-REACTION; CT-GUIDED BIOPSY; COMPUTED-TOMOGRAPHY	Background: Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) is a potentially useful but expensive test to diagnose solitary pulmonary nodules. Objective: To evaluate the cost-effectiveness of strategies for pulmonary nodule diagnosis and to specifically compare strategies that did and did not include FDG-PET. Design: Decision model. Data Sources: Accuracy and complications of diagnostic tests were estimated by using meta-analysis and literature review. Modeled survival was based on data from a large tumor registry. Cost estimates were derived from Medicare reimbursement and other sources. Target Population: All adult patients with a new, noncalcified pulmonary nodule seen on chest radiograph. Time Horizon: Patient lifetime. Perspective: Societal. Intervention: 40 clinically plausible combinations of 5 diagnostic interventions, including computed tomography, FDG-PET, transthoracic needle biopsy, surgery, and watchful waiting. Outcome Measures: Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Results of Base-Case Analysis: The cost-effectiveness of strategies depended critically on the pretest probability of malignancy. For patients with low pretest probability (26%), strategies that used FDG-PET selectively when computed tomography results were possibly malignant cost as little as $20 000 per QALY gained. For patients with high pretest probability (79%), strategies that used FDG-PET selectively when computed tomography results were benign cost as little as $16 000 per QALY gained. For patients with intermediate pretest probability (55%), FDG-PET strategies cost more than $220 000 per QALY gained because they were more costly but only marginally more effective than computed tomography-based strategies. Results of Sensitivity Analysis: The choice of strategy also depended on the risk for surgical complications, the probability of nondiagnostic needle biopsy, the sensitivity of computed tomography, and patient preferences for time spent in watchful waiting. In probabilistic sensitivity analysis, FDG-PET strategies were cost saving or cost less than $100 000 per QALY gained in 76.7%, 24.4%, and 99.9% of computer simulations for patients with low, intermediate, and high pretest probability, respectively. Conclusions: FDG-PET should be used selectively when pretest probability and computed tomography findings are discordant or in patients with intermediate pretest probability who are at high risk for surgical complications. In most other circumstances, computed tomography-based strategies result in similar quality-adjusted life-years and lower costs.	Vet Affairs Palo Alto Hlth Care Syst, Pulm Sect 111P, Palo Alto, CA 94304 USA; Stanford Univ, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Gould, MK (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Pulm Sect 111P, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	gould@stanford.edu						Asamura H, 1997, LUNG CANCER-J IASLC, V16, P183, DOI 10.1016/S0169-5002(96)00628-9; BALL J, 1998, AHCPR PUBLICATION; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BECKER GL, 1990, ARCH INTERN MED, V150, P557, DOI 10.1001/archinte.150.3.557; Bernard A, 1996, ANN THORAC SURG, V61, P202, DOI 10.1016/0003-4975(95)01014-9; BERQUIST TH, 1980, MAYO CLIN PROC, V55, P475; BROWN BW, 1984, J NATL CANCER I, V72, P31, DOI 10.1093/jnci/72.1.31; Brown W T, 1998, Semin Thorac Cardiovasc Surg, V10, P305; CONCES DJ, 1989, RADIOLOGY, V170, P643, DOI 10.1148/radiology.170.3.2916015; Cook GJR, 1996, CLIN RADIOL, V51, P603, DOI 10.1016/S0009-9260(96)80052-3; *CTR MED MED SERV, 1999 NAT PHYS FEE SC; *CTR MED MED SERV, MED PROV ANN REV EXP; CUMMINGS SR, 1986, AM REV RESPIR DIS, V134, P453; CUMMINGS SR, 1986, AM REV RESPIR DIS, V134, P449; Cutler DM, 1998, Q J ECON, V113, P991, DOI 10.1162/003355398555801; DALES RE, 1990, AM REV RESPIR DIS, V141, P1096, DOI 10.1164/ajrccm/141.5_Pt_1.1096; DALES RE, 1994, J CLIN EPIDEMIOL, V47, P1443, DOI 10.1016/0895-4356(94)90088-4; Dewan NA, 1997, CHEST, V112, P416, DOI 10.1378/chest.112.2.416; DEWAN NA, 1995, CHEST, V108, P441, DOI 10.1378/chest.108.2.441; DEWAN NA, 1993, CHEST, V104, P997, DOI 10.1378/chest.104.4.997; Dietlein M, 2000, EUR J NUCL MED, V27, P1441, DOI 10.1007/s002590000324; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; DUHAYLONGSOD FG, 1995, ANN THORAC SURG, V60, P1348, DOI 10.1016/0003-4975(95)00754-9; DUHAYLONGSOD FG, 1995, J THORAC CARDIOV SUR, V110, P130, DOI 10.1016/S0022-5223(05)80018-2; Dwamena BA, 1999, RADIOLOGY, V213, P530, DOI 10.1148/radiology.213.2.r99nv46530; *EX OFF PRES US, 2001, HIST TABL SPREADS 10; Ferguson MK, 1999, J THORAC CARDIOV SUR, V117, P37; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gambhir SS, 1998, J CLIN ONCOL, V16, P2113, DOI 10.1200/JCO.1998.16.6.2113; GEDDES DM, 1979, BRIT J DIS CHEST, V73, P1, DOI 10.1016/0007-0971(79)90002-0; Ginsberg RJ, 1995, ANN THORAC SURG, V60, P622, DOI [DOI 10.1016/0003-4975(95)00537-U, 10.1016/0003-4975]; Ginsberg Robert J., 1995, Annals of Thoracic Surgery, V60, P615, DOI 10.1016/0003-4975(95)00537-U; GODWIN JD, 1982, RADIOLOGY, V144, P349, DOI 10.1148/radiology.144.2.7089288; Gold MR, 1996, COST EFFECTIVENESS H; Gould MK, 2001, JAMA-J AM MED ASSOC, V285, P914, DOI 10.1001/jama.285.7.914; GOULD MK, 1998, AM J RESP CRIT CARE, V157, pA256; GRAVES WG, 1985, ANN THORAC SURG, V40, P57, DOI 10.1016/S0003-4975(10)61170-8; Gupta N, 1998, CHEST, V114, P1105, DOI 10.1378/chest.114.4.1105; Gupta NC, 1996, J NUCL MED, V37, P943; GUPTA NC, 1992, RADIOLOGY, V184, P441, DOI 10.1148/radiology.184.2.1620844; GURNEY JW, 1993, RADIOLOGY, V186, P415, DOI 10.1148/radiology.186.2.8421744; GURNEY JW, 1993, RADIOLOGY, V186, P405, DOI 10.1148/radiology.186.2.8421743; HARPOLE DH, 1995, CANCER-AM CANCER SOC, V76, P787, DOI 10.1002/1097-0142(19950901)76:5<787::AID-CNCR2820760512>3.0.CO;2-Q; Hau T, 1996, EUR J SURG, V162, P23; Hayashi N, 1998, AM J ROENTGENOL, V170, P329, DOI 10.2214/ajr.170.2.9456939; HEAVEY LR, 1986, AM J ROENTGENOL, V146, P285, DOI 10.2214/ajr.146.2.285; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Hermansson U, 1998, Semin Thorac Cardiovasc Surg, V10, P285; Hunink MGM, 1998, MED DECIS MAKING, V18, P337, DOI 10.1177/0272989X9801800312; HUSTON J, 1989, RADIOLOGY, V170, P653, DOI 10.1148/radiology.170.3.2916017; JACKMAN RJ, 1969, J THORAC CARDIOV SUR, V57, P1; Jancovici R, 1996, ANN THORAC SURG, V61, P533, DOI 10.1016/0003-4975(95)01060-2; JONES FA, 1989, CHEST, V96, P779, DOI 10.1378/chest.96.4.779; Kaseda S, 1998, Semin Thorac Cardiovasc Surg, V10, P300; Kelsey JL., 1996, METHODS OBSERVATIONA, V26; KENT DL, 1992, AM J ROENTGENOL, V158, P1135, DOI 10.2214/ajr.158.5.1533084; KHAN A, 1991, RADIOLOGY, V179, P477, DOI 10.1148/radiology.179.2.2014295; Kim S, 1999, CLIN NUCL MED, V24, P945, DOI 10.1097/00003072-199912000-00008; KUBOTA K, 1990, J NUCL MED, V31, P1927; Kubota K, 1989, Nihon Rinsho, V47, P1037; Landreneau RJ, 1997, J THORAC CARDIOV SUR, V113, P691, DOI 10.1016/S0022-5223(97)70226-5; LANDRENEAU RJ, 1992, ANN THORAC SURG, V54, P415, DOI 10.1016/0003-4975(92)90430-C; Laurent F, 2000, CLIN RADIOL, V55, P281, DOI 10.1053/crad.1999.0368; LEVINE MS, 1988, CHEST, V93, P1152, DOI 10.1378/chest.93.6.1152; Lewis R J, 1998, Semin Thorac Cardiovasc Surg, V10, P332; Li HQ, 1996, AM J ROENTGENOL, V167, P105, DOI 10.2214/ajr.167.1.8659351; LIBSHITZ HI, 1984, RADIOLOGY, V151, P295, DOI 10.1148/radiology.151.2.6709895; LILLINGTON GA, 1993, CLIN CHEST MED, V14, P111; Loscertales J, 1997, EUR J CARDIO-THORAC, V12, P892, DOI 10.1016/S1010-7940(97)00254-6; Lowe VJ, 1998, J CLIN ONCOL, V16, P1075, DOI 10.1200/JCO.1998.16.3.1075; Lowe VJ, 1998, THORAX, V53, P703, DOI 10.1136/thx.53.8.703; MACK MJ, 1993, ANN THORAC SURG, V56, P825, DOI 10.1016/0003-4975(93)90339-J; Martini N, 1999, J THORAC CARDIOV SUR, V117, P32, DOI 10.1016/S0022-5223(99)70467-8; MCKENNA RJ, 1985, CHEST, V88, P206, DOI 10.1378/chest.88.2.206; McKenna RJ, 1998, ANN THORAC SURG, V66, P1903, DOI 10.1016/S0003-4975(98)01166-7; MILLER DL, 1992, ANN THORAC SURG, V54, P410, DOI 10.1016/0003-4975(92)90429-8; MITRUKA S, 1995, SURGERY, V118, P676, DOI 10.1016/S0039-6060(05)80035-2; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; *NAT AER SPAC ADM, GROSS DOM PROD DEFL; NATHAN MH, 1962, RADIOLOGY, V79, P221, DOI 10.1148/79.2.221; National Cancer Institute, SURV EP END RES; Orino K, 1998, Jpn J Thorac Cardiovasc Surg, V46, P1267; Ost D, 2000, AM J RESP CRIT CARE, V162, P782, DOI 10.1164/ajrccm.162.3.9812152; Owens DK, 1996, JAMA-J AM MED ASSOC, V275, P1342, DOI 10.1001/jama.275.17.1342; Owens DK, 1996, ANN INTERN MED, V124, P803, DOI 10.7326/0003-4819-124-9-199605010-00004; PATZ EF, 1993, RADIOLOGY, V188, P487, DOI 10.1148/radiology.188.2.8327702; Patz EF, 2000, CHEST, V117, P1568, DOI 10.1378/chest.117.6.1568; PATZ EF, 1994, RADIOL CLIN N AM, V32, P811; PEARLBERG JL, 1985, RADIOLOGY, V157, P187, DOI 10.1148/radiology.157.1.4034964; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; Potente G, 1997, COMPUT MED IMAG GRAP, V21, P39, DOI 10.1016/S0895-6111(96)00071-7; POTOSKY AL, 1993, MED CARE, V31, P732; Prauer HW, 1998, BRIT J SURG, V85, P1506; PROTO AV, 1985, RADIOLOGY, V156, P149, DOI 10.1148/radiology.156.1.4001402; RIO FG, 1994, ACTA RADIOL, V35, P478; ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332; Roviaro G, 1998, Semin Thorac Cardiovasc Surg, V10, P313; Santambrogio L, 1997, CHEST, V112, P423, DOI 10.1378/chest.112.2.423; SEELY JM, 1993, RADIOLOGY, V186, P129, DOI 10.1148/radiology.186.1.8416552; Seemann MD, 1999, EUR RADIOL, V9, P409, DOI 10.1007/s003300050683; Shah R, 1996, J CARDIOVASC SURG, V37, P169; Shreve PD, 1998, RADIOLOGY, V207, P431, DOI 10.1148/radiology.207.2.9577492; SIEGELMAN SS, 1980, AM J ROENTGENOL, V135, P1; SIEGELMAN SS, 1986, RADIOLOGY, V160, P307, DOI 10.1148/radiology.160.2.3726105; Silvestri GA, 1998, CHEST, V114, P675, DOI 10.1378/chest.114.3.675; SMITH TJ, 1995, J CLIN ONCOL, V13, P2166, DOI 10.1200/JCO.1995.13.9.2166; Steele J D, 1966, Ann Thorac Surg, V2, P368; STEELE JD, 1973, J THORAC CARDIOV SUR, V65, P140; STEELE JD, 1963, J THORAC CARDIOV SUR, V46, P21, DOI 10.1016/S0022-5223(19)33683-9; Sugi K, 1998, SURG TODAY, V28, P41, DOI 10.1007/BF02483607; SWENSEN SJ, 1992, RADIOLOGY, V182, P343, DOI 10.1148/radiology.182.2.1732947; Swensen SJ, 1999, MAYO CLIN PROC, V74, P319, DOI 10.4065/74.4.319; Swensen SJ, 1997, ARCH INTERN MED, V157, P849, DOI 10.1001/archinte.157.8.849; Swensen SJ, 2000, RADIOLOGY, V214, P73, DOI 10.1148/radiology.214.1.r00ja1473; Swensen SJ, 1996, RADIOLOGY, V201, P447, DOI 10.1148/radiology.201.2.8888239; SWENSEN SJ, 1995, RADIOLOGY, V194, P393, DOI 10.1148/radiology.194.2.7824716; TAKANASHI N, 1995, LUNG CANCER-J IASLC, V13, P105, DOI 10.1016/0169-5002(95)00488-2; Tengs TO, 2000, MED CARE, V38, P583, DOI 10.1097/00005650-200006000-00004; Torrance GW, 1996, COST EFFECTIVENESS H, P276; TRAMPERT L, 1995, NUKLEARMED, V34, P79; *US CENS BUR, 1999 STAT ABSTR US; *US DEP HLTH HUM S, 1996, IMT ABR LIF TABL US; VANSONNENBERG E, 1988, RADIOLOGY, V167, P457, DOI 10.1148/radiology.167.2.3357956; Walker W S, 1998, Semin Thorac Cardiovasc Surg, V10, P291; WALLACE JM, 1982, CHEST, V81, P665, DOI 10.1378/chest.81.6.665; WARD HB, 1989, SURGERY, V106, P734; Weber W, 1999, J NUCL MED, V40, P574; Westcott JL, 1997, RADIOLOGY, V202, P97, DOI 10.1148/radiology.202.1.8988197; YAMASHITA K, 1995, RADIOLOGY, V194, P399, DOI 10.1148/radiology.194.2.7824717; Yankelevitz DF, 1998, CLIN IMAG, V22, P7, DOI 10.1016/S0899-7071(97)00067-3; Yankelevitz DF, 1997, CLIN IMAG, V21, P107, DOI 10.1016/S0899-7071(96)00011-3; Yim A P, 1998, Semin Thorac Cardiovasc Surg, V10, P326; Yim APC, 1996, CHEST, V109, P13, DOI 10.1378/chest.109.1.13; ZERHOUNI EA, 1986, RADIOLOGY, V160, P319, DOI 10.1148/radiology.160.2.3726107; ZERHOUNI EA, 1983, RADIOLOGY, V149, P767, DOI 10.1148/radiology.149.3.6647853; Zieren HU, 1996, EUR J CARDIO-THORAC, V10, P233, DOI 10.1016/S1010-7940(96)80144-8	137	129	141	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					724	735		10.7326/0003-4819-138-9-200305060-00009	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729427				2022-12-28	WOS:000182661400005
J	Salerno, SM; Alguire, PC; Waxman, HS				Salerno, SM; Alguire, PC; Waxman, HS			Training and competency evaluation for interpretation of 12-lead electrocardiograms: Recommendations from the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CLINICAL COMPETENCE; TASK-FORCE; CARDIOLOGY; STATEMENT; DIAGNOSIS; EMERGENCY; ACCIDENT; IMPACT	This paper is part 1 of a 2-part series on interpretation of 12-lead resting electrocardiograms (ECGs). Part 1 is a position paper that presents recommendations for initial competency, competency assessment and maintenance of competency on ECG interpretation, as well as recommendations for the role of computer-assisted ECG interpretation. Part 2 is a systematic review of detailed supporting evidence for the recommendations. Despite several earlier consensus-based recommendations on ECG interpretation, substantive evidence on the training needed to obtain and maintain ECG interpretation skills is not available. Some studies show that noncardiologist physicians have more ECG interpretation errors than do cardiologists, but the rate of adverse patient outcomes from ECG interpretation errors is low. Computers may decrease the time needed to interpret ECGs and can reduce ECG interpretation errors. However, they have shown less accuracy than physician interpreters and must be relied on only as an adjunct interpretation tool for a trained provider. Interpretation of ECGs varies greatly, even among expert electrocardiographers. Noncardiologists seem to be more influenced by patient history in interpreting ECGs than are cardiologists. Cardiologists also perform better than other specialists on standardized ECG examinations when minimal patient history is provided. Pending more definitive research, residency training in internal medicine with Advanced Cardiac Life Support instruction should continue to be sufficient for bedside interpretation of resting 12-lead ECGs in routine and emergency situations. Additional experience or training in ECG interpretation when the patient's clinical condition is unknown may be useful but requires further study.	Amer Coll Physicians, Customer Serv, Philadelphia, PA 19106 USA; Tripler Army Med Ctr, Honolulu, HI 96859 USA	American College of Physicians; United States Department of Defense; United States Army	Salerno, SM (corresponding author), Amer Coll Physicians, Customer Serv, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							*AM BOARD INT MED, 2002, POL PROC CERT; *AM MED ASS, 2002, GRAD MED ED DIR 2002, P86; Brailer DJ, 1997, MED DECIS MAKING, V17, P80, DOI 10.1177/0272989X9701700109; deBruyne MC, 1997, J CLIN EPIDEMIOL, V50, P947, DOI 10.1016/S0895-4356(97)00100-5; DUNN PM, 1990, ARCH INTERN MED, V150, P1917, DOI 10.1001/archinte.150.9.1917; FINCHER RME, 1988, SOUTH MED J, V81, P1291, DOI 10.1097/00007611-198810000-00020; FISCH C, 1995, CIRCULATION, V91, P2683, DOI 10.1161/01.CIR.91.10.2683; Goodacre S, 2001, POSTGRAD MED J, V77, P455, DOI 10.1136/pmj.77.909.455; Hatala R, 1999, J GEN INTERN MED, V14, P126, DOI 10.1046/j.1525-1497.1999.00298.x; Holmvang L, 1998, AM J CARDIOL, V82, P54, DOI 10.1016/S0002-9149(98)00226-4; Kadish AH, 2001, J AM COLL CARDIOL, V38, P2091, DOI 10.1016/S0735-1097(01)01680-1; Kastrati A, 1998, J AM COLL CARDIOL, V32, P970, DOI 10.1016/S0735-1097(98)00334-9; KINGSTON ME, 1979, J MED EDUC, V54, P107; Mason JW, 1997, J AM COLL CARDIOL, V29, P466; Salerno SM, 2003, ANN INTERN MED, V138, P751, DOI 10.7326/0003-4819-138-9-200305060-00013; SHIRATAKA M, 1992, J ELECTROCARDIOL, V25, P185, DOI 10.1016/0022-0736(92)90003-I; WHITE T, 1995, POSTGRAD MED J, V71, P132, DOI 10.1136/pgmj.71.833.132; Wickstrom GC, 2000, J GEN INTERN MED, V15, P361, DOI 10.1046/j.1525-1497.2000.04118.x; WIGTON RS, 1989, ANN INTERN MED, V111, P932, DOI 10.7326/0003-4819-111-11-932	19	62	62	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					747	750		10.7326/0003-4819-138-9-200305060-00012	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729430				2022-12-28	WOS:000182661400008
J	Lawn, SD; Planche, T; Riley, P; Holwill, S; Silman, N; Bewley, K; Rice, P; Wansbrough-Jones, MH				Lawn, SD; Planche, T; Riley, P; Holwill, S; Silman, N; Bewley, K; Rice, P; Wansbrough-Jones, MH			A black necrotic ulcer	LANCET			English	Editorial Material							ANTHRAX		St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England; St George Hosp, Sch Med, Dept Microbiol, London SW17 0RE, England; St George Hosp, Sch Med, Dept Histopathol, London SW17 0RE, England; Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England	St Georges University London; St Georges University London; St Georges University London	Lawn, SD (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England.			Bewley, Kevin/0000-0002-9078-6734; Planche, Timothy/0000-0002-0263-0888				Ala'Aldeen D, 2001, LANCET, V358, P1386, DOI 10.1016/S0140-6736(01)06492-3; Bartlett JG, 2002, CLIN INFECT DIS, V35, P851, DOI 10.1086/341902; BAXBY D, 1994, BRIT J DERMATOL, V131, P598, DOI 10.1111/j.1365-2133.1994.tb04969.x; ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995; WILLEMSE A, 1985, LANCET, V1, P1515	5	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1518	1518		10.1016/S0140-6736(03)13179-0	http://dx.doi.org/10.1016/S0140-6736(03)13179-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737863				2022-12-28	WOS:000182658900011
J	Groemping, Y; Lapouge, K; Smerdon, SJ; Rittinger, K				Groemping, Y; Lapouge, K; Smerdon, SJ; Rittinger, K			Molecular basis of phosphorylation-induced activation of the NADPH oxidase	CELL			English	Article							RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; PROTEIN-KINASE-C; CELL-FREE SYSTEM; SH3 DOMAIN; CRYSTAL-STRUCTURE; PX DOMAIN; P47(PHOX); BINDING; RECOGNITION	The multi-subunit NADPH oxidase complex plays a crucial role in host defense against microbial infection through the production of reactive oxygen species. Activation of the NADPH oxidase requires the targeting of a cytoplasmic p40-p47-p67(phox) complex to the membrane bound heterodimeric p22-gp91(phox) flavocytochrome. This interaction is prevented in the resting state due to an auto-inhibited conformation of p47(phox). The X-ray structure of the auto-inhibited form of p47(phox) reveals that tandem SH3 domains function together to maintain the cytoplasmic complex in an inactive form. Further structural and biochemical data show that phosphorylation of p47(phox) activates a molecular switch that relieves the inhibitory intramolecular interaction. This permits p47phox to interact with the cytoplasmic tail of p22(phox) and initiate formation of the active, membrane bound enzyme complex.	Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England	MRC National Institute for Medical Research	Rittinger, K (corresponding author), Natl Inst Med Res, Div Prot Struct, Mill Hill, London NW7 1AA, England.	katrin.rittinger@nimr.mrc.ac.uk	Rittinger, Katrin/D-2586-2014; Rittinger, Katrin/N-3344-2019	Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Lapouge, Karine/0000-0003-0620-9553; Smerdon, Stephen/0000-0001-5688-8465	Medical Research Council [MC_U117565398] Funding Source: Medline; MRC [MC_U117565398] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benard V, 1999, TRENDS PHARMACOL SCI, V20, P365, DOI 10.1016/S0165-6147(99)01367-X; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FINAN P, 1994, J BIOL CHEM, V269, P13752; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Leusen Jeanette H. W., 1996, Frontiers in Bioscience (online), V1, pD72; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; Lim WA, 1996, STRUCTURE, V4, P657; Mayer BJ, 2001, J CELL SCI, V114, P1253; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JW, 1997, J BIOL CHEM, V272, P11035; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Prehoda KE, 2001, NAT STRUCT BIOL, V8, P570, DOI 10.1038/89586; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wilson L, 1997, INFLAMM RES, V46, P265, DOI 10.1007/s000110050185; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	53	303	314	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					343	355		10.1016/S0092-8674(03)00314-3	http://dx.doi.org/10.1016/S0092-8674(03)00314-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732142	Bronze			2022-12-28	WOS:000182640800009
J	Ishitani, R; Nureki, O; Nameki, N; Okada, N; Nishimura, S; Yokoyama, S				Ishitani, R; Nureki, O; Nameki, N; Okada, N; Nishimura, S; Yokoyama, S			Alternative tertiary structure of tRNA for recognition by a posttranscriptional modification enzyme	CELL			English	Article							PHENYLALANINE TRANSFER-RNA; ARCHAEAL TRANSFER-RNA; MINIMAL TRANSFER-RNA; PSEUDOURIDINE SYNTHASE; GUANINE TRANSGLYCOSYLASE; MITOCHONDRIAL GENOMES; THERMOPHILIC ARCHAEA; CRYSTAL-STRUCTURE; WILD-TYPE; SEQUENCES	Transfer RNA (tRNA) canonically has the clover-leaf secondary structure with the acceptor, D, anticodon, and T arms, which are folded into the L-shaped tertiary structure. To strengthen the L form, posttranscriptional modifications occur on nucleotides buried within the core, but the modification enzymes are paradoxically inaccessible to them in the L form. In this study, we determined the crystal structure of tRNA bound with archaeosine tRNA-guanine transglycosylase, which modifies G15 of the D arm in the core. The bound tRNA assumes an alternative conformation ("lambda form") drastically different from the L form. All of the D-arm secondary base pairs and the canonical tertiary interactions are disrupted. Furthermore, a helical structure is reorganized, while the rest of the D arm is single stranded and protruded. Consequently, the enzyme precisely locates the exposed G15 in the active site, by counting the nucleotide number from G1 to G15 in the lambda form.	Univ Tokyo, Dept Biochem & Biophys, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; SPring 8, Harima Inst, RIKEN, Sayo, Hyogo 6795148, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; JST, PRESTO, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Banyu Tsukuba Res Inst Merck, Tsukuba, Ibaraki 3002611, Japan	University of Tokyo; Japan Synchrotron Radiation Research Institute; RIKEN; RIKEN; Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Merck & Company	Yokoyama, S (corresponding author), Univ Tokyo, Dept Biochem & Biophys, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Nameki, Nobukazu/H-1764-2013; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				AEBI M, 1990, J BIOL CHEM, V265, P16216; Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; Bai Y, 2000, J BIOL CHEM, V275, P28731, DOI 10.1074/jbc.M002174200; Bjork GR, 1999, FEBS LETT, V452, P47, DOI 10.1016/S0014-5793(99)00528-1; Bjork GR, 1995, TRNA STRUCTURE BIOSY, P165; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charette M, 2000, IUBMB LIFE, V49, P341; Davis DR., 1998, MODIFICATION EDITING, P85; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; Ferre-D'Amare AR, 2003, CURR OPIN STRUC BIOL, V13, P49, DOI 10.1016/S0959-440X(02)00002-7; Green R, 1999, BIOCHEMISTRY-US, V38, P1772, DOI 10.1021/bi982246a; GREGSON JM, 1993, J BIOL CHEM, V268, P10076; GUPTA R, 1984, J BIOL CHEM, V259, P9461; Gutgsell N, 2000, RNA, V6, P1870, DOI 10.1017/S1355838200001588; Gutgsell NS, 2001, RNA, V7, P990, DOI 10.1017/S1355838201000243; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; HORIE N, 1985, BIOCHEMISTRY-US, V24, P5711, DOI 10.1021/bi00342a004; Ishitani R, 2002, J MOL BIOL, V318, P665, DOI 10.1016/S0022-2836(02)00090-6; Ishitani R, 2001, ACTA CRYSTALLOGR D, V57, P1659, DOI 10.1107/S0907444901011994; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; Khaitovich P, 1999, BIOCHEMISTRY-US, V38, P1780, DOI 10.1021/bi9822473; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; McCloskey JA, 2001, NUCLEIC ACIDS RES, V29, P4699, DOI 10.1093/nar/29.22.4699; McCloskey JA, 1998, NUCLEIC ACIDS RES, V26, P196, DOI 10.1093/nar/26.1.196; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0; Ohtsuki T, 2002, FEBS LETT, V514, P37, DOI 10.1016/S0014-5793(02)02328-1; OKIMOTO R, 1990, EMBO J, V9, P3405, DOI 10.1002/j.1460-2075.1990.tb07542.x; OKIMOTO R, 1992, GENETICS, V130, P471; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROE BA, 1985, J BIOL CHEM, V260, P9759; SANNER MF, 1995, P 11 ACM S COMP GEOM, P104; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; WOLSTENHOLME DR, 1987, P NATL ACAD SCI USA, V84, P1324, DOI 10.1073/pnas.84.5.1324; Yokoyama Shigeyuki, 1995, P207	49	145	150	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					383	394		10.1016/S0092-8674(03)00280-0	http://dx.doi.org/10.1016/S0092-8674(03)00280-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732145	Bronze			2022-12-28	WOS:000182640800012
J	Miralles, F; Posern, G; Zaromytidou, AI; Treisman, R				Miralles, F; Posern, G; Zaromytidou, AI; Treisman, R			Actin dynamics control SRF activity by regulation of its coactivator MAL	CELL			English	Article							SERUM-RESPONSE-FACTOR; EMBRYONIC STEM-CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TERNARY COMPLEX; RHOA; FAMILY; SIGNAL; DIFFERENTIATION; POLYMERIZATION	Rho GTPases regulate the transcription factor SRF via their ability to induce actin polymerization. SRF activity responds to G actin, but the mechanism of this has remained unclear. We show that Rho-actin signaling regulates the subcellular localization of the myocardin-related SRF coactivator MAL, rearranged in t(1;22)(p13;q13) AML. The MAL-SRF interaction displays the predicted properties of a Rho-regulated SRF cofactor. MAL is predominantly cytoplasmic in serum-starved cells, but accumulates in the nucleus following serum stimulation. Activation of the Rho-actin signaling pathway is necessary and sufficient to promote MAL nuclear accumulation. MAL N-terminal sequences, including two RPEL motifs, are required for the response to signaling, while other regions mediate its nuclear export (or cytoplasmic retention) and nuclear import. MAL associates with unpolymerized actin through its RPEL motifs. Constitutively cytoplasmic MAL derivatives interfere with MAL redistribution and Rho-actin signaling to SRF. MAL associates with several SRF target promoters regulated via the Rho-actin pathway.	Canc Res UK London Res Inst, Transcript Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Canc Res UK London Res Inst, Transcript Lab, Lincolns Inn Fields Labs, Room 401,44 Lincolns Inn Fields, London WC2A 3PX, England.			Treisman, Richard/0000-0002-9658-0067; Miralles, Francesc/0000-0003-3069-2725				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; GROSSE R, 2003, IN PRESS EMBO J, V22; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Murai K, 2002, MOL CELL BIOL, V22, P7083, DOI 10.1128/MCB.22.20.7083-7092.2002; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Posern G, 2000, ONCOGENE, V19, P6361, DOI 10.1038/sj.onc.1204027; Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200; Sasazuki T, 2002, J BIOL CHEM, V277, P28853, DOI 10.1074/jbc.M203190200; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835	31	1014	1052	2	48	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 2	2003	113	3					329	342		10.1016/S0092-8674(03)00278-2	http://dx.doi.org/10.1016/S0092-8674(03)00278-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732141	Bronze			2022-12-28	WOS:000182640800008
J	Muller, A				Muller, A			The beauty of symmetry	SCIENCE			English	Editorial Material							CHEMISTRY		Univ Bielefeld, Fac Chem, D-33615 Bielefeld, Germany	University of Bielefeld	Muller, A (corresponding author), Univ Bielefeld, Fac Chem, D-33615 Bielefeld, Germany.	a.mueller@uni-bielefeld.de		Muller, Achim/0000-0003-0117-4021				Bai JF, 2003, SCIENCE, V300, P781, DOI 10.1126/science.1081119; Cronin L., 2003, INORGANIC EXPT, P340; Glanz J, 1997, SCIENCE, V276, P678; Moses MJ, 2003, SCIENCE, V300, P778, DOI 10.1126/science.1082342; Muller A, 2002, ANGEW CHEM INT EDIT, V41, P3604, DOI 10.1002/1521-3773(20021004)41:19<3604::AID-ANIE3604>3.0.CO;2-T; Muller A, 2002, ANGEW CHEM INT EDIT, V41, P1162, DOI 10.1002/1521-3773(20020402)41:7<1162::AID-ANIE1162>3.0.CO;2-8; Muller A, 2001, COORDIN CHEM REV, V222, P193, DOI 10.1016/S0010-8545(01)00391-5; OKEEFFE M, 1996, CRYSTAL STRUCTURES, V1; Schmid G, 2001, NANOSCALE MATERIALS IN CHEMISTRY, P15, DOI 10.1002/0471220620.ch2; Schnepf A, 2002, ANGEW CHEM INT EDIT, V41, P3533, DOI 10.1002/1521-3773(20021004)41:19<3532::AID-ANIE3532>3.0.CO;2-4; Tran NT, 2000, ANGEW CHEM INT EDIT, V39, P4121, DOI 10.1002/1521-3773(20001117)39:22<4121::AID-ANIE4121>3.0.CO;2-A; Voet D., 1995, BIOCHEMISTRY; Wang XJ, 2002, ANGEW CHEM INT EDIT, V41, P3818, DOI 10.1002/1521-3773(20021018)41:20<3818::AID-ANIE3818>3.0.CO;2-R; ZEE ANTHONY, 1999, FEARFUL SYMMETRY SEA	14	86	86	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					749	750		10.1126/science.1084991	http://dx.doi.org/10.1126/science.1084991			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730586				2022-12-28	WOS:000182579800032
J	Lazzarin, A; Clotet, B; Cooper, D; Reynes, J; Arasteh, K; Nelson, M; Katlama, C; Stellbrink, H; Delfraissy, J; Lange, J; Huson, L; DeMasi, R; Wat, C; Delehanty, J; Drobnes, C; Salgo, M				Lazzarin, A; Clotet, B; Cooper, D; Reynes, J; Arasteh, K; Nelson, M; Katlama, C; Stellbrink, H; Delfraissy, J; Lange, J; Huson, L; DeMasi, R; Wat, C; Delehanty, J; Drobnes, C; Salgo, M		TORO 2 Study Grp	Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; ANTIVIRAL ACTIVITY; PEPTIDE INHIBITOR; DETERMINANTS; MORBIDITY; MORTALITY; FAILURE; SAFETY; FUSION	BACKGROUND: The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of the optimized background regimen alone. METHODS: The patients had previous treatment with each of the three classes of antiretroviral drugs, documented resistance to each class, or both and a plasma level of human immunodeficiency virus type 1 (HIV-1) RNA of at least 5000 copies per milliliter. They were randomly assigned in a 2:1 ratio to receive either enfuvirtide (90 mg twice daily) plus a background regimen optimized with the aid of resistance testing (enfuvirtide group) or the background regimen alone (control group). RESULTS: Of the 512 patients who underwent randomization, 335 in the enfuvirtide group and 169 in the control group received at least one dose of study medication and had at least one follow-up measurement of plasma HIV-1 RNA. The median base-line plasma HIV-1 RNA level was 5.1 log(sub 10) copies per milliliter in both groups. The median CD4+ cell count was 98.0 cells per cubic millimeter in the enfuvirtide group and 101.5 cells per cubic millimeter in the control group. Patients had a median of seven years of previous treatment and had received a median of 12 antiretroviral drugs. The background regimen comprised a mean of four antiretroviral drugs in both groups. At 24 weeks, the least-squares mean change from base line in the plasma viral load (intention-to-treat, last observation carried forward) was a decrease of 1.429 log(sub 10) copies per milliliter in the enfuvirtide group and a decrease of 0.648 log(sub 10) copies per milliliter in the control group, a difference of 0.781 log(sub 10) copies per milliliter (P<0.001). The mean increase in the CD4+ cell count was greater in the enfuvirtide group (65.5 cells per cubic millimeter) than in the control group (38.0 cells per cubic millimeter, P=0.02). CONCLUSIONS: The addition of enfuvirtide to an optimized background regimen provided significant viral suppression and immunologic benefit over a 24-week period in HIV-1-infected patients who had previously received multiple antiretroviral drugs.	San Raffaele Vita Salute Univ, IRCCS, Clin Infect Dis, I-20127 Milan, Italy; Hosp Badalona Germans Trias & Pujol, Barcelona, Spain; SIDA Caixa Fdn, Inst Recerca, Barcelona, Spain; Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Univ Hosp Montpellier, Montpellier, France; Vivantes Auguste Viktoria Hosp, EPIMED, Berlin, Germany; Chelsea & Westminster Hosp, London, England; Hop La Pitie Salpetriere, Paris, France; Univ Hosp Eppendorf, Hamburg, Germany; Ctr Hosp Univ Bicetre, Assistance Publ Hop Paris, Paris, France; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Roche Prod Ltd, Welwyn Garden City, Herts, England; Trimeris, Durham, NC USA; Roche, Nutley, NJ USA	Vita-Salute San Raffaele University; Hospital Germans Trias i Pujol; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of New South Wales Sydney; Kirby Institute; Universite de Montpellier; CHU de Montpellier; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Hamburg; University Medical Center Hamburg-Eppendorf; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Amsterdam; Academic Medical Center Amsterdam; Roche Holding; Roche Holding	Lazzarin, A (corresponding author), San Raffaele Vita Salute Univ, IRCCS, Clin Infect Dis, Via Stamira Ancona 20, I-20127 Milan, Italy.	lazzarin.adriano@hsr.it	; LAZZARIN, Adriano/K-3607-2018	Oliva, Jesus/0000-0003-4080-7864; LAZZARIN, Adriano/0000-0003-2551-7754				Deeks SG, 2000, CLIN INFECT DIS, V30, pS177, DOI 10.1086/313855; DROBNES C, 2002, 42 INT C ANT AG CHEM, P262; GREENBERG ML, 2003, 10 C RETR OPP INF BO, P108; GROSSMAN H, 1999, 2 INT WORKSH SALV TH, P246; Hammer SM, 2002, JAMA-J AM MED ASSOC, V288, P169, DOI 10.1001/jama.288.2.169; Katlama C, 2003, 10 C RETR OPP INF BO; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; LALEZARI J, 2002, 42 INT C ANT AG CHEM, P266; Lalezari JP, 2003, AIDS, V17, P691, DOI 10.1097/00002030-200303280-00007; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; LALEZARI JP, IN PRESS ANTIVIRAL T; LANGE J, 2002, 6 INT C DRUG THER HI, P17; Miller V, 2001, AIDS, V15, P309, DOI 10.1097/00002030-200102160-00003; Murphy EL, 2001, ANN INTERN MED, V135, P17, DOI 10.7326/0003-4819-135-1-200107030-00005; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Race E, 1999, AIDS, V13, P2061, DOI 10.1097/00002030-199910220-00008; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Rousseau, 2001, J ACQ IMMUN DEF SYND, V26, P395; Rousseau MN, 2001, J ACQ IMMUN DEF SYND, V26, P36, DOI 10.1097/00126334-200101010-00005; Van Vaerenbergh K, 2000, ANTIMICROB AGENTS CH, V44, P2109, DOI 10.1128/AAC.44.8.2109-2117.2000; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051	22	531	555	1	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2186	2195		10.1056/NEJMoa035211	http://dx.doi.org/10.1056/NEJMoa035211			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773645	Green Published			2022-12-28	WOS:000183134700004
J	Korner, C				Korner, C			Slow in, rapid out - Carbon flux studies and Kyoto targets	SCIENCE			English	Editorial Material							TERRESTRIAL BIOSPHERE; DECIDUOUS FOREST; CO2 ENRICHMENT; BALANCE; EXCHANGE; VARIABILITY; ECOSYSTEMS		Univ Basel, Inst Bot, CH-4056 Basel, Switzerland	University of Basel	Korner, C (corresponding author), Univ Basel, Inst Bot, Schonbeinstr 6, CH-4056 Basel, Switzerland.		Körner, Christian/B-6592-2014	Körner, Christian/0000-0001-7768-7638				Canadell JG, 2000, ECOSYSTEMS, V3, P115, DOI 10.1007/s100210000014; DeLucia EH, 1999, SCIENCE, V284, P1177, DOI 10.1126/science.284.5417.1177; DIXON RK, 1994, SCIENCE, V263, P185, DOI 10.1126/science.263.5144.185; Ehman JL, 2002, GLOBAL CHANGE BIOL, V8, P575, DOI 10.1046/j.1365-2486.2002.00492.x; Frolking S, 1996, GLOBAL CHANGE BIOL, V2, P343, DOI 10.1111/j.1365-2486.1996.tb00086.x; Goulden ML, 1996, SCIENCE, V271, P1576, DOI 10.1126/science.271.5255.1576; Granados J, 2002, GLOBAL CHANGE BIOL, V8, P1109, DOI 10.1046/j.1365-2486.2002.00533.x; Korner C, 2000, ECOL APPL, V10, P1590, DOI 10.2307/2641226; Malhi Y, 1999, PLANT CELL ENVIRON, V22, P715, DOI 10.1046/j.1365-3040.1999.00453.x; Prentice IC, 2000, ECOL APPL, V10, P1553, DOI 10.1890/1051-0761(2000)010[1553:TCBOTT]2.0.CO;2; Schimel DS, 2001, NATURE, V414, P169, DOI 10.1038/35102500; Schulze ED, 2000, SCIENCE, V289, P2058, DOI 10.1126/science.289.5487.2058; Valentini R, 2000, NATURE, V404, P861, DOI 10.1038/35009084	13	173	182	4	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1242	1243		10.1126/science.1084460	http://dx.doi.org/10.1126/science.1084460			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764181				2022-12-28	WOS:000183042400030
J	Greenspan, SL; Resnick, NM; Parker, RA				Greenspan, SL; Resnick, NM; Parker, RA			Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN/PROGESTIN REPLACEMENT; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; VERTEBRAL FRACTURES; NONVERTEBRAL FRACTURES; ESTROGEN REPLACEMENT; DISEASE OUTCOMES; RISK; HEART; OSTEOPOROSIS	Context Therapy with individual antiresorptive agents has been shown to be effective for prevention and treatment of postmenopausal osteoporosis, but whether combination antiresorptive therapy with hormones and bisphosphonates is safe or efficacious or how these agents compare in elderly women is unknown. Objective To determine whether hormone replacement and the bisphosphonate alendronate sodium in combination are efficacious and safe, and how they compare with monotherapy in community-dwelling elderly women. Design Randomized, double-blind, placebo-controlled, clinical trial. Setting and Participants Five hundred seventy-three community-dwelling women age 65 years or older were screened: 485 completed screening and 373 (aged 65 to 90 years) were randomized following a 3-month, open-label, run-in phase with hormone replacement and alendronate placebo. The trial was conducted at a single academic US medical center from January 1996 to May 2001. Interventions Participants were randomly assigned in a 2 x 2 factorial design to receive hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without medroxyprogesterone, 2.5 mg/d) and alendronate, 10 mg daily, both agents, or neither. All participants received calcium and vitamin D supplements. Main Outcome Measures Annualized change in bone mineral density of the hip and spine and occurrence of adverse events. Results Bone mineral density at 3 years was significantly greater at all femoral and vertebral sites in women treated with combination therapy than with monotherapy, with mean (SD) increases of 5.9% (3.8) at the total hip, 10.4% (5.4) at the posteroanterior lumbar spine, and 11.8% (6.8) at the lateral lumbar spine. Mean (SD) increases in bone mass at the hip in women treated with alendronate alone were significantly greater than in those treated with hormone replacement therapy alone (4.2% [3.8] vs 3.0% [4.9]; P<.05, respectively), and alendronate resulted in more responders to therapy. All therapies were well tolerated and participant retention was 90% at 3 years. Conclusions Combination therapy with hormone replacement and alendronate was efficacious and well tolerated in this cohort. Alendronate was superior to hormone replacement, and combination therapy was superior to either therapy alone. Combination therapy may represent an option for women with more severe disease or for those who have failed to achieve an adequate response to monotherapy.	Univ Pittsburgh, Med Ctr, Div Endocrinol & Metab, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Div Geriatr Med, Pittsburgh, PA USA; Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard T.H. Chan School of Public Health	Greenspan, SL (corresponding author), Osteoporosis Prevent & Treatment Ctr, Kaufmann Med Bldg,Suite 1110,3471 5th Ave, Pittsburgh, PA 15213 USA.	griffithsd@msx.dept-med.pitt.edu			NCRR NIH HHS [M01-RR1032] Funding Source: Medline; NIA NIH HHS [R01 AG13069-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013069] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; DAWSONHUGHES B, 1987, AM J CLIN NUTR, V46, P685, DOI 10.1093/ajcn/46.4.685; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Faulkner KG, 2000, J BONE MINER RES, V15, P183, DOI 10.1359/jbmr.2000.15.2.183; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Greendale GA, 2000, ARCH INTERN MED, V160, P3065, DOI 10.1001/archinte.160.20.3065; Greenspan SL, 1998, J BONE MINER RES, V13, P1431, DOI 10.1359/jbmr.1998.13.9.1431; Greenspan SL, 1996, CALCIFIED TISSUE INT, V58, P409, DOI 10.1007/BF02509439; GREENSPAN SL, 1994, J BONE MINER RES, V9, P1959, DOI 10.1002/jbmr.5650091216; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Kuchel GA, 2001, J WOMEN HEALTH GEN-B, V10, P109, DOI 10.1089/152460901300039449; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LOOKER AC, 1995, J BONE MINER RES, V10, P796; Lu Y, 1996, J BONE MINER RES, V11, P626; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; *NIH CONS, 2000, OSTEOPOROSIS REP, V16, P1; Palomba S, 2002, J CLIN ENDOCR METAB, V87, P1502, DOI 10.1210/jc.87.4.1502; Regan MM, 2001, J WOMEN HEALTH GEN-B, V10, P343, DOI 10.1089/152460901750269661; Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Villareal DT, 2001, JAMA-J AM MED ASSOC, V286, P815, DOI 10.1001/jama.286.7.815; Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231; Wilson PWF, 2003, ANN INTERN MED, V138, P69, DOI 10.7326/0003-4819-138-1-200301070-00015	41	89	102	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2525	2533		10.1001/jama.289.19.2525	http://dx.doi.org/10.1001/jama.289.19.2525			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680KL	12759324	Bronze			2022-12-28	WOS:000182976500021
J	Myers, GJ; Davidson, PW; Cox, C; Shamlaye, CF; Palumbo, D; Cernichiari, E; Sloane-Reeves, J; Wilding, GE; Kost, J; Huang, LS; Clarkson, TW				Myers, GJ; Davidson, PW; Cox, C; Shamlaye, CF; Palumbo, D; Cernichiari, E; Sloane-Reeves, J; Wilding, GE; Kost, J; Huang, LS; Clarkson, TW			Prenatal methylmercury exposure from ocean fish consumption in the Seychelles child development study	LANCET			English	Article							IN-UTERO EXPOSURE; MATERNAL HAIR; OUTCOMES; MERCURY; DIET; AGE	Introduction Exposure to methylmercury (MeHg) before birth can adversely affect children's neurodevelopment. The most common form of prenatal exposure is maternal fish consumption, but whether such exposure harms the fetus is unknown. We aimed to identify adverse neurodevelopmental effects in a fish-consuming population. Methods We investigated 779 mother-infant pairs residing in the Republic of Seychelles. Mothers reported consuming fish on average 12 meals per week. Fish in Seychelles contain much the same concentrations of MeHg as commercial ocean fish elsewhere. Prenatal MeHg exposure was determined from maternal hair growing during pregnancy. We assessed neurocognitive, language, memory, motor, perceptual-motor, and behavioural functions in children at age 9 years. The association between prenatal MeHg exposure and the primary endpoints was investigated with multiple linear regression with adjustment for covariates that affect child development. Findings Mean prenatal MeHg exposure was 6.9 parts per million (SD 4.5ppm). Only two endpoints were associated with prenatal MeHg exposure. Increased exposure was associated with decreased performance in the grooved pegboard using the non-dominant hand in males and improved scores in the hyperactivity index of the Conner's teacher rating scale. Covariates affecting child development were appropriately associated with endpoints. Interpretation These data do not support the hypothesis that there is a neurodevelopmental risk from prenatal MeHg exposure resulting solely from ocean fish consumption.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biostat & Computat Biol, Rochester, NY 14620 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14620 USA; NICHD, Dept Neurol, NIH, US Dept HHS, Bethesda, MD USA; NICHD, Dept Pediat, NIH, US Dept HHS, Bethesda, MD USA; NICHD, Dept Epidemiol Stat & Prevent, NIH, US Dept HHS, Bethesda, MD USA; Minist Hlth, Victoria, Seychelles	University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Myers, GJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biostat & Computat Biol, 601 Elmwood Ave,Box 631, Rochester, NY 14620 USA.		Myers, Gary J/I-4901-2013	Myers, Gary J/0000-0003-4317-015X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, R01ES010219] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-01247, R01-ES10219, T32 ES-007] Funding Source: Medline; PHS HHS [R01-08442] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Axtell CD, 1998, ENVIRON HEALTH PERSP, V106, P559, DOI 10.2307/3434230; AXTELL CD, 2000, ENV RES A, V84, P12; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P705; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P613; CHOI BH, 1978, J NEUROPATH EXP NEUR, V37, P719, DOI 10.1097/00005072-197811000-00001; Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11, DOI 10.1289/ehp.02110s111; Cox C, 1989, ENV RES, V31, P640; DAVIDSON P, 1974, PERCEPT PSYCHOPHYS, V14, P539; Davidson PW, 1999, JAMA-J AM MED ASSOC, V281, P897; Davidson PW, 1998, JAMA-J AM MED ASSOC, V280, P701, DOI 10.1001/jama.280.8.701; Davidson PW, 1995, NEUROTOXICOLOGY, V16, P677; Davidson PW, 2000, ENVIRON RES, V84, P1, DOI 10.1006/enrs.2000.4084; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; Dourson ML, 2001, NEUROTOXICOLOGY, V22, P677, DOI 10.1016/S0161-813X(01)00060-2; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Harada Y., 1968, MINAMATA DISEASE, P93; IPCS, 1990, ENV HLTH CRIT 101 ME; JULSHAMN K, 1987, SCI TOTAL ENVIRON, V65, P53, DOI 10.1016/0048-9697(87)90160-4; KJELLSTROM T, 1986, 3080 NAT SWED ENV BO; KJELLSTROM T, 1989, 3642 NAT SWED ENV BO; Lapham LW, 1995, NEUROTOXICOLOGY, V16, P689; Marsh DO, 1995, NEUROTOXICOLOGY, V16, P583; MARSH DO, 1987, ARCH NEUROL-CHICAGO, V44, P1017, DOI 10.1001/archneur.1987.00520220023010; MCKEOWNEYSSEN GE, 1983, AM J EPIDEMIOL, V118, P470, DOI 10.1093/oxfordjournals.aje.a113652; MITCHELL JW, 1982, NEW ZEAL MED J, V95, P112; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P653; *NAT I ENV HLTH SC, 1998, WORKSH REP SCI ISS R; National Research Council (U.S.) Committee on the Toxicological Effects of Methylmercury, 2000, TOXICOLOGICAL EFFECT, P1; PHELPS RW, 1980, ARCH ENVIRON HEALTH, V35, P161, DOI 10.1080/00039896.1980.10667486; SAGER PR, 1984, DEV BRAIN RES, V12, P1, DOI 10.1016/0165-3806(84)90170-6	30	416	426	5	72	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 17	2003	361	9370					1686	1692		10.1016/S0140-6736(03)13371-5	http://dx.doi.org/10.1016/S0140-6736(03)13371-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767734				2022-12-28	WOS:000182919700009
J	Kitajima, TS; Yokobayashi, S; Yamamoto, M; Watanabe, Y				Kitajima, TS; Yokobayashi, S; Yamamoto, M; Watanabe, Y			Distinct cohesin complexes organize meiotic chromosome domains	SCIENCE			English	Article							SISTER-CHROMATID COHESION; FISSION YEAST; RECOMBINATION; PROTEIN; HETEROCHROMATIN; SEGREGATION; REQUIREMENT; REC8	Meiotic cohesin complexes at centromeres behave differently from those along chromosome arms, but the basis for these differences has remained elusive. The fission yeast cohesin molecule Rec8 largely replaces its mitotic counterpart, Rad21/Scc1, along the entire chromosome during meiosis. Here we show that Rec8 complexes along chromosome arms contain Rec11, whereas those in the vicinity of centromeres have a different partner subunit, Psc3. The arm-associated Rec8-Rec11 complexes are critical for meiotic recombination. The Rec8-Psc3 complexes comprise two different types of assemblies. First, pericentromeric Rec8-Psc3 complexes depend on histone methylation-directed heterochromatin for their localization and are required for cohesion during meiosis II. Second, central core Rec8-Psc3 complexes form independently of heterochromatin and are presumably required for establishing monopolar attachment at meiosis I. These findings define distinct modes of assembly and functions for cohesin complexes at different regions along chromosomes.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan; Japan Sci & Technol Corp, SORST, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Watanabe, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan.	ywatanab@ims.u-tokyo.ac.jp	Kitajima, Tomoya/A-7049-2016	Kitajima, Tomoya/0000-0002-6486-7143; Watanabe, Yoshinori/0000-0002-5488-4812				Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bernard P, 2002, TRENDS CELL BIOL, V12, P419, DOI 10.1016/S0962-8924(02)02344-9; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Cervantes MD, 2000, MOL CELL, V5, P883, DOI 10.1016/S1097-2765(00)80328-7; DEVEAUX LC, 1994, GENE DEV, V8, P203, DOI 10.1101/gad.8.2.203; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Krawchuk MD, 1999, GENETICS, V153, P57; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Li YF, 1997, MOL MICROBIOL, V23, P869, DOI 10.1046/j.1365-2958.1997.2691632.x; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; MCKEE B, COMMUNICATION; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Orr-Weaver TL, 1999, CELL, V99, P1, DOI 10.1016/S0092-8674(00)80055-0; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Pasierbek P, 2001, GENE DEV, V15, P1349, DOI 10.1101/gad.192701; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Uhlmann F, 2003, CURR BIOL, V13, pR104, DOI 10.1016/S0960-9822(03)00039-3; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Watanabe Y, 2001, NATURE, V409, P359, DOI 10.1038/35053103; Watanabe Y., UNPUB; YOKOBAYASHI S, IN PRESS MOL CELL BI	27	124	131	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2003	300	5622					1152	1155		10.1126/science.1083634	http://dx.doi.org/10.1126/science.1083634			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750522				2022-12-28	WOS:000182886500048
J	Myers, RA; Worm, B				Myers, RA; Worm, B			Rapid worldwide depletion of predatory fish communities	NATURE			English	Article							COLLAPSE; COD	Serious concerns have been raised about the ecological effects of industrialized fishing(1-3), spurring a United Nations resolution on restoring fisheries and marine ecosystems to healthy levels(4). However, a prerequisite for restoration is a general understanding of the composition and abundance of unexploited fish communities, relative to contemporary ones. We constructed trajectories of community biomass and composition of large predatory fishes in four continental shelf and nine oceanic systems, using all available data from the beginning of exploitation. Industrialized fisheries typically reduced community biomass by 80% within 15 years of exploitation. Compensatory increases in fast-growing species were observed, but often reversed within a decade. Using a meta-analytic approach, we estimate that large predatory fish biomass today is only about 10% of pre-industrial levels. We conclude that declines of large predators in coastal regions(5) have extended throughout the global ocean, with potentially serious consequences for ecosystems(5-7). Our analysis suggests that management based on recent data alone may be misleading, and provides minimum estimates for unexploited communities, which could serve as the 'missing baseline('8) needed for future restoration efforts.	Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada	Dalhousie University	Myers, RA (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada.	Ransom.Myers@dal.ca		Worm, Boris/0000-0002-5742-8716				Baum JK, 2003, SCIENCE, V299, P389, DOI 10.1126/science.1079777; BULLIS HARVEY R., 1955, COMMERCIAL FISH REV, V17, P1; Casey JM, 1998, SCIENCE, V281, P690, DOI 10.1126/science.281.5377.690; CASEY JM, 2000, FISH ASSEMBLAGES GRA; CATON AE, 1991, INTERAM TROP TUNA CO, V7, P181; *COMM CONS ANT MAR, 2002, STAT B CCAMLR, V14; Davidian M, 1995, NONLINEAR MODELS REP; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; Fogarty MJ, 1998, ECOL APPL, V8, pS6, DOI 10.2307/2641359; Hutchings J. A., 1995, N ATLANTIC FISHERIES, P38; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; KOCK KH, 1994, SOUTHERN OCEAN ECOLOGY: THE BIOMASS PERSPECTIVE, P287; LYNE V, 2000, DEV APPL EVALUATION; Myers RA, 1998, ECOL APPL, V8, pS165, DOI 10.1890/1051-0761(1998)8[S165:TLOEAP]2.0.CO;2; Myers RA, 1997, ECOL APPL, V7, P91, DOI 10.1890/1051-0761(1997)007[0091:WDFSCT]2.0.CO;2; Pauly D., 1988, P329; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; PAULY D, 1995, TRENDS ECOL EVOL, V10, P430, DOI 10.1016/S0169-5347(00)89171-5; PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0; Pauly D, 2002, NATURE, V418, P689, DOI 10.1038/nature01017; Roberts CM, 2002, TRENDS ECOL EVOL, V17, P242, DOI 10.1016/S0169-5347(02)02492-8; ROTHSCHILD BJ, 1967, J CONSEIL, V31, P102; SHOMURA RS, 1955, 157 USFWS; Steele JH, 2000, FISH RES, V44, P201, DOI 10.1016/S0165-7836(00)90003-1; Stevens JD, 2000, ICES J MAR SCI, V57, P476, DOI 10.1006/jmsc.2000.0724; Tegner MJ, 1999, TRENDS ECOL EVOL, V14, P261, DOI 10.1016/S0169-5347(99)01650-X; United Nations, 2002, WORLD SUMMIT SUSTAIN; Watson R, 2001, NATURE, V414, P534, DOI 10.1038/35107050; Worm B, 2002, NATURE, V417, P848, DOI 10.1038/nature00830; Worm B, 2003, ECOLOGY, V84, P162, DOI 10.1890/0012-9658(2003)084[0162:MAOCSI]2.0.CO;2	30	1946	2027	19	1081	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					280	283		10.1038/nature01610	http://dx.doi.org/10.1038/nature01610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748640				2022-12-28	WOS:000182853100041
J	Reilley, B; Van Herp, M; Sermand, D; Dentico, N				Reilley, B; Van Herp, M; Sermand, D; Dentico, N			SARS and Carlo Urbani	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Doctors Without Borders USA Inc, New York, NY 10016 USA; Med Sans Frontieres, Brussels, Belgium	Doctors Without Borders	Reilley, B (corresponding author), Doctors Without Borders USA Inc, New York, NY 10016 USA.								0	52	59	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					1951	1952		10.1056/NEJMp030080	http://dx.doi.org/10.1056/NEJMp030080			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12748315				2022-12-28	WOS:000182823400003
J	Priola, SA; Chesebro, B; Caughey, B				Priola, SA; Chesebro, B; Caughey, B			A view from the top - Prion diseases from 10,000 feet	SCIENCE			English	Editorial Material									NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Priola, SA (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, Hamilton, MT 59840 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000752, Z01AI000752, ZIAAI000580, Z01AI000580] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; 2003, KEYST S MOL ASP TRAN	2	24	24	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					917	+		10.1126/science.1085920	http://dx.doi.org/10.1126/science.1085920			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738843	Green Submitted			2022-12-28	WOS:000182719800035
J	Moses, MJ; Fettinger, JC; Eichhorn, BW				Moses, MJ; Fettinger, JC; Eichhorn, BW			Interpenetrating As-20 fullerene and Ni-12 icosahedra in the onion-skin [As@Ni-12@As-20](3-) ion	SCIENCE			English	Article							STRUCTURAL CHARACTERIZATION; CRYSTAL-STRUCTURE; CLUSTERS; CARBON; PHOSPHORUS; DIANIONS; SANDWICH; SILICON; C-60; RING	The [As@Ni-12@As-20](3-) ion was prepared from As-7(3-) and Ni(COD)(2) in ethylenediamine solutions and isolated as the Bu4P+ salt (As, arsenic; Ni, nickel; COD, cyclooctadiene; Bu, butyl; P, phosphorus). The anion contains an icosahedral [Ni-12(mu(12)-As)](3-) fragment that resides at the center of an As-20 dodecahedral (fullerene) cage to give an onion-skin-like [As@Ni-12@As-20](3-) cluster with 1 h point symmetry. The icosahedron and pentagonal dodecahedron are reciprocal platonic solids, and the 32 surface atoms form a dimpled geodesic sphere composed of 60 triangular faces. In the gas phase, the [As@Ni-12@As-20](3-) ion sequentially loses all 21 As atoms to form a series of Ni12As21-x clusters where 0 less than or equal to x less than or equal to 21, inclusively.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20782 USA	University System of Maryland; University of Maryland College Park	Eichhorn, BW (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20782 USA.		Moses-DeBusk, Melanie/P-4640-2016	Moses-DeBusk, Melanie/0000-0003-0382-0824; Fettinger, James/0000-0002-6428-4909				ALBANO VG, 1991, J CHEM SOC DALTON, P739, DOI 10.1039/dt9910000739; BERGMAN G, 1957, ACTA CRYSTALLOGR, V10, P254, DOI 10.1107/S0365110X57000808; Bobev S, 1999, J AM CHEM SOC, V121, P3795, DOI 10.1021/ja9844175; CERIOTTI A, 1989, J CHEM SOC CHEM COMM, P786, DOI 10.1039/c39890000786; Eichhorn BW, 1998, J AM CHEM SOC, V120, P9708, DOI 10.1021/ja9820700; Gausa M, 1996, J CHEM PHYS, V104, P9719, DOI 10.1063/1.471733; Goldshleger NF, 2001, FULLERENE SCI TECHN, V9, P255, DOI 10.1081/FST-100104493; Ha TK, 1999, CHEM PHYS LETT, V315, P327, DOI 10.1016/S0009-2614(99)01271-3; HASER M, 1992, J AM CHEM SOC, V114, P9551, DOI 10.1021/ja00050a039; HAWKINS JM, 1992, ACS SYM SER, V481, P91; Ho KM, 1998, NATURE, V392, P582, DOI 10.1038/33369; Kesanli B, 2002, J AM CHEM SOC, V124, P4779, DOI 10.1021/ja012528p; LAUHER JW, 1978, J AM CHEM SOC, V100, P5305, DOI 10.1021/ja00485a011; Lee CS, 2001, INORG CHEM, V40, P338, DOI 10.1021/ic0008363; MARGULIS L, 1993, NATURE, V365, P113, DOI 10.1038/365113b0; Mednikov EG, 2003, ANGEW CHEM INT EDIT, V42, P323, DOI 10.1002/anie.200390107; MINGOS DMP, 1972, NATURE-PHYS SCI, V236, P99, DOI 10.1038/physci236099a0; Moses MJ, 2002, J AM CHEM SOC, V124, P5944, DOI 10.1021/ja025627r; NESPER R, 1994, ANGEW CHEM INT EDIT, V33, P843, DOI 10.1002/anie.199408431; RHEINGOLD AL, 1982, J AM CHEM SOC, V104, P4727, DOI 10.1021/ja00381a060; RIECK DF, 1986, J AM CHEM SOC, V108, P1330, DOI 10.1021/ja00266a052; Scherer OJ, 2000, ANGEW CHEM INT EDIT, V39, P1029, DOI 10.1002/(SICI)1521-3773(20000317)39:6<1029::AID-ANIE1029>3.0.CO;2-6; Seifert G, 2001, EUR PHYS J D, V16, P341, DOI 10.1007/s100530170125; SEVOV SC, 1993, SCIENCE, V262, P880, DOI 10.1126/science.262.5135.880; SHEN MZ, 1994, J CHEM PHYS, V101, P2261, DOI 10.1063/1.467666; Sun Q, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.235417; Syamala MS, 2002, J AM CHEM SOC, V124, P6216, DOI 10.1021/ja012676f; Urnezius E, 2002, SCIENCE, V295, P832, DOI 10.1126/science.1067325; Wade K., 1976, ADV INORG CHEM RAD, V18, P1, DOI DOI 10.1016/S0065-2792(08)60027-8; Wang JL, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.205411; Ward J, 1984, ARTIFACTS RB FULLER, V3; York A, 2000, CHEM BRIT, V36, P40; Zak A, 2002, J AM CHEM SOC, V124, P4747, DOI 10.1021/ja012060q	33	158	161	5	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					778	780		10.1126/science.1082342	http://dx.doi.org/10.1126/science.1082342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730596				2022-12-28	WOS:000182579800044
J	Zeitlinger, J; Simon, I; Harbison, CT; Hannett, NM; Volkert, TL; Fink, GR; Young, RA				Zeitlinger, J; Simon, I; Harbison, CT; Hannett, NM; Volkert, TL; Fink, GR; Young, RA			Program-specific distribution of a transcription factor dependent on partner transcription factor and MAPK signaling	CELL			English	Article							YEAST STE12 PROTEIN; PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; FILAMENTOUS-GROWTH; INVASIVE GROWTH; GENE-EXPRESSION; KINASE CASCADE; DNA-BINDING; TRANSDUCTION	Specialized gene expression programs are induced by signaling pathways that act on transcription factors. Whether these transcription factors can function in multiple developmental programs through a global switch in promoter selection is not known. We have used genome-wide location analysis to show that the yeast Ste12 transcription factor, which regulates mating and filamentous growth, is bound to distinct program-specific target genes dependent on the developmental condition. This condition-dependent distribution of Ste12 requires concurrent binding of the transcription factor Tec1 during filamentation and is differentially regulated by the MAP kinases Fus3 and Kss1. Program-specific distribution across the genome may be a general mechanism by which transcription factors regulate distinct gene expression programs in response to signaling.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Zeitlinger, J (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Simon, Itamar/0000-0002-8517-1903				ANDRIANOPOULOS A, 1994, MOL CELL BIOL, V14, P2503, DOI 10.1128/MCB.14.4.2503; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Baur M, 1997, MOL CELL BIOL, V17, P4330, DOI 10.1128/MCB.17.8.4330; Breitkreutz A, 2002, TRENDS CELL BIOL, V12, P254, DOI 10.1016/S0962-8924(02)02284-5; Breitkreutz A, 2001, CURR BIOL, V11, P1266, DOI 10.1016/S0960-9822(01)00370-0; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Casamayor A, 2002, CURR OPIN MICROBIOL, V5, P179, DOI 10.1016/S1369-5274(02)00300-4; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Ciapponi L, 2001, GENE DEV, V15, P1540, DOI 10.1101/gad.886301; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; Crosby JA, 2000, YEAST, V16, P1365, DOI 10.1002/1097-0061(200011)16:15<1365::AID-YEA630>3.0.CO;2-S; Dickinson JR, 1996, MICROBIOL-UK, V142, P1391, DOI 10.1099/13500872-142-6-1391; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1991, COLD SPRING HARB SYM, V56, P41; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; Farley FW, 1999, GENETICS, V151, P1425; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; KIRKMANCORREIA C, 1993, MOL CELL BIOL, V13, P3765, DOI 10.1128/MCB.13.6.3765; Kohler T, 2002, EUKARYOT CELL, V1, P673, DOI 10.1128/EC.1.5.673-686.2002; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lorenz MC, 2000, MOL BIOL CELL, V11, P183, DOI 10.1091/mbc.11.1.183; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Michelson AM, 2002, P NATL ACAD SCI USA, V99, P546, DOI 10.1073/pnas.032685999; Nelson C, 2003, NATURE, V421, P187, DOI 10.1038/nature01243; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Olson KA, 2000, MOL CELL BIOL, V20, P4199, DOI 10.1128/MCB.20.12.4199-4209.2000; Pan XW, 2000, CURR OPIN MICROBIOL, V3, P567, DOI 10.1016/S1369-5274(00)00142-9; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; Pi HW, 1997, MOL CELL BIOL, V17, P6410, DOI 10.1128/MCB.17.11.6410; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; Pryciak PM, 2001, DEV CELL, V1, P449, DOI 10.1016/S1534-5807(01)00066-1; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rua D, 2001, CURR OPIN MICROBIOL, V4, P720, DOI 10.1016/S1369-5274(01)00274-0; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; van Drogen F, 2002, CURR BIOL, V12, pR53, DOI 10.1016/S0960-9822(01)00672-8; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; White LJ, 2001, SOFTW TEST VERIF REL, V11, P1, DOI 10.1002/stvr.220; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685	58	184	193	1	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 2	2003	113	3					395	404		10.1016/S0092-8674(03)00301-5	http://dx.doi.org/10.1016/S0092-8674(03)00301-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732146	Bronze			2022-12-28	WOS:000182640800013
J	Hoag, H				Hoag, H			BSE case rattles Canadian officials	NATURE			English	News Item																			0	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					467	467		10.1038/423467b	http://dx.doi.org/10.1038/423467b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774079	Bronze			2022-12-28	WOS:000183162900004
J	Hanauer, SB				Hanauer, SB			Immunogenicity of infliximab in Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Hanauer, SB (corresponding author), Univ Chicago, Chicago, IL 60637 USA.							Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Wagner C, 2002, GASTROENTEROLOGY, V122, pA613	5	10	10	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2155	2156						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761378				2022-12-28	WOS:000183008300031
J	Rands, SA; Cowlishaw, G; Pettifor, RA; Rowcliffe, JM; Johnstone, RA				Rands, SA; Cowlishaw, G; Pettifor, RA; Rowcliffe, JM; Johnstone, RA			Spontaneous emergence of leaders and followers in foraging pairs	NATURE			English	Article							DECISION-MAKING; PREDATION; RISK; BEHAVIOR; SEGREGATION; STRATEGIES; POSITION; RUTILUS; MODEL	Animals that forage socially(1) often stand to gain from coordination of their behaviour(2-5). Yet it is not known how group members reach a consensus on the timing of foraging bouts. Here we demonstrate a simple process by which this may occur. We develop a state-dependent, dynamic game model(6) of foraging by a pair of animals, in which each individual chooses between resting or foraging during a series of consecutive periods, so as to maximize its own individual chances of survival(6,7). We find that, if there is an advantage to foraging together(1,2,8), the equilibrium behaviour of both individuals becomes highly synchronized. As a result of this synchronization, differences in the energetic reserves of the two players spontaneously develop, leading them to adopt different behavioural roles. The individual with lower reserves emerges as the 'pace-maker' who determines when the pair should forage, providing a straightforward resolution to the problem of group coordination. Moreover, the strategy that gives rise to this behaviour can be implemented by a simple 'rule of thumb'(9) that requires no detailed knowledge of the state of other individuals.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Zool Soc London, Inst Zool, London NW1 4RY, England	University of Cambridge; Zoological Society of London	Rands, SA (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	s.rands@zoo.cam.ac.uk	Rowcliffe, Marcus/G-3713-2018; Rands, Sean A/B-2243-2008	Rowcliffe, Marcus/0000-0002-4286-6887; Rands, Sean A/0000-0002-7400-005X				Bednekoff PA, 1997, AM NAT, V150, P373, DOI 10.1086/286070; Camazine S., 2001, SELF ORG BIOL SYSTEM, DOI DOI 10.1515/9780691212920; CLARK CW, 1995, OIKOS, V72, P205, DOI 10.2307/3546222; CLARK CW, 1987, ANIM BEHAV, V35, P361, DOI 10.1016/S0003-3472(87)80259-2; Conradt L, 1998, P ROY SOC B-BIOL SCI, V265, P1359, DOI 10.1098/rspb.1998.0442; Conradt L, 2003, NATURE, V421, P155, DOI 10.1038/nature01294; Cuthill Innes C., 1997, P97; ENQUIST M, 1983, J THEOR BIOL, V102, P387, DOI 10.1016/0022-5193(83)90376-4; Giraldeau L.A., 2000, MG BEH ECOL; GOTCEITAS V, 1991, BEHAV ECOL SOCIOBIOL, V29, P255, DOI 10.1007/BF00163982; HAMILTON WD, 1971, J THEOR BIOL, V31, P295, DOI 10.1016/0022-5193(71)90189-5; HOUSTON A, 1988, NATURE, V332, P29, DOI 10.1038/332029a0; Houston AI, 1999, MODELS ADAPTIVE BEHA; Krause J, 1998, BEHAVIOUR, V135, P1031, DOI 10.1163/156853998792913519; KRAUSE J, 1993, OECOLOGIA, V93, P356, DOI 10.1007/BF00317878; KRAUSE J, 1992, BEHAV ECOL SOCIOBIOL, V30, P177, DOI 10.1007/BF00166700; Krause J, 2002, LIVING GROUPS; LEWONTIN RC, 1964, GENETICS, V49, P49; LIMA SL, 1986, ECOLOGY, V67, P377, DOI 10.2307/1938580; Lima SL, 1998, ADV STUD BEHAV, V27, P215; LIMA SL, 1990, CAN J ZOOL, V68, P619, DOI 10.1139/z90-092; MANGEL M, 1990, ANIM BEHAV, V39, P1163, DOI 10.1016/S0003-3472(05)80788-2; Mangel M., 1988, DYNAMIC MODELING BEH; MCNAMARA JM, 1990, ACTA BIOTHEOR, V38, P37, DOI 10.1007/BF00047272; McNamara JM, 1997, J THEOR BIOL, V189, P211, DOI 10.1006/jtbi.1997.0511; Richards SA, 2002, BEHAV ECOL, V13, P427, DOI 10.1093/beheco/13.3.427; ROOK AJ, 1991, APPL ANIM BEHAV SCI, V32, P157, DOI 10.1016/S0168-1591(05)80039-5; Ruckstuhl KE, 2002, BIOL REV, V77, P77, DOI 10.1017/S1464793101005814; Stephens D.W., 1986, pi; SZEKELY T, 1991, BEHAV ECOL SOCIOBIOL, V28, P203	30	235	237	1	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2003	423	6938					432	434		10.1038/nature01630	http://dx.doi.org/10.1038/nature01630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761547				2022-12-28	WOS:000183012000040
J	Bates, SM; Kearon, C; Crowther, M; Linkins, L; O'Donnell, M; Douketis, J; Lee, AYY; Weitz, JI; Johnston, M; Ginsberg, JS				Bates, SM; Kearon, C; Crowther, M; Linkins, L; O'Donnell, M; Douketis, J; Lee, AYY; Weitz, JI; Johnston, M; Ginsberg, JS			A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							WHOLE-BLOOD ASSAY; SUSPECTED PULMONARY-EMBOLISM; VEIN THROMBOSIS; NONINVASIVE DIAGNOSIS; CLINICAL-ASSESSMENT; THROMBOEMBOLISM; MANAGEMENT; EXCLUSION; COMPLICATIONS; ANGIOGRAPHY	Background: Because clinical diagnosis is inaccurate, objective testing is usually considered necessary when patients present with suspected deep venous thrombosis (DVT). Objective: To determine whether a negative result on a quantitative latex D-dimer assay eliminates the need for further investigation in patients with a low or moderate pretest probability of DVT. Design: Prospective cohort study. Setting: Three tertiary care hospitals in Canada. Patients: 556 consecutive outpatients with suspected first DVT. Intervention: Patients were categorized as having a low, moderate, or high pretest probability of DVT and then underwent D-dimer testing. Patients with low or moderate pretest probability and a negative D-dimer result had no further diagnostic testing and received no anticoagulant therapy. Serial compression ultrasonography was performed in all other patients. Patients who did not receive a diagnosis of DVT were followed for symptomatic venous thromboembolism. Measurements: Objectively confirmed symptomatic venous thromboembolic events during 3 months of follow-up. Results: 283 patients (51%) had low or moderate pretest probability and a negative D-dimer result. One of these patients had DVT during follow-up (negative likelihood ratio, 0.05 [CI, 0.01 to 0.23]). The negative likelihood ratio of the D-dimer test in all patients was 0.03 (CI, 0.01 to 0.16). Conclusion: A negative result on a quantitative latex D-dimer assay safely eliminates the need for further testing in patients with low or moderate pretest probability of DVT.	McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; Henderson Res Ctr, Hamilton, ON, Canada	McMaster University	Bates, SM (corresponding author), McMaster Univ, Med Ctr, HSC 3W11,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	batesm@mcmaster.ca	Weitz, Jeffrey/AAD-1929-2019; Douketis, James/AAO-5659-2021; O'Donnell, Martin/ABE-7459-2020; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; O'Donnell, Martin/0000-0002-7347-7761; 				Bates SM, 2001, ARCH INTERN MED, V161, P447, DOI 10.1001/archinte.161.3.447; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; Bernardi E, 1998, BRIT MED J, V317, P1037; BETTMANN MA, 1977, RADIOLOGY, V122, P101, DOI 10.1148/122.1.101; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BRENNER B, 1995, BLOOD COAGUL FIBRIN, V6, P219, DOI 10.1097/00001721-199505000-00004; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; CARTER CJ, 1993, THROMB HAEMOSTASIS, V69, P8; DAngelo A, 1996, THROMB HAEMOSTASIS, V75, P412; de Monye W, 1999, THROMB RES, V96, P293, DOI 10.1016/S0049-3848(99)00118-8; Farrell S, 2000, ANN EMERG MED, V35, P121, DOI 10.1016/S0196-0644(00)70130-2; Fiessinger JN, 1997, THROMB HAEMOSTASIS, V77, P1042; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; JOHN MA, 1990, THROMB RES, V58, P273, DOI 10.1016/0049-3848(90)90097-V; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Kearon C, 2001, ANN INTERN MED, V135, P108, DOI 10.7326/0003-4819-135-2-200107170-00011; KELLEY MA, 1991, ANN INTERN MED, V114, P300, DOI 10.7326/0003-4819-114-4-300; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Kraaijenhagen RA, 2002, ARCH INTERN MED, V162, P907, DOI 10.1001/archinte.162.8.907; Lee A Y, 1997, Curr Opin Pulm Med, V3, P275, DOI 10.1097/00063198-199707000-00007; Lee AYY, 1999, ANN INTERN MED, V131, P417, DOI 10.7326/0003-4819-131-6-199909210-00004; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; Leroyer C, 1997, THROMB HAEMOSTASIS, V77, P637; MANT MJ, 1977, LANCET, V1, P1133; Mauron T, 1998, THROMB HAEMOSTASIS, V79, P1217, DOI 10.1055/s-0037-1615046; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Sackett D.L., 1991, CLIN EPIDEMIOLOGY BA, P69; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; Turkstra F, 1996, THROMB HAEMOSTASIS, V76, P9; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010	43	96	99	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					787	794		10.7326/0003-4819-138-10-200305200-00006	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755550				2022-12-28	WOS:000182920700002
J	Jablonski, D; Roy, K; Valentine, JW; Price, RM; Anderson, PS				Jablonski, D; Roy, K; Valentine, JW; Price, RM; Anderson, PS			The impact of the pull of the recent on the history of marine diversity	SCIENCE			English	Article							BIODIVERSITY; ORIGINATION; EXTINCTION	Up to 50% of the increase in marine animal biodiversity through the Cenozoic at the genus level has been attributed to a sampling bias termed "the Pull of the Recent," the extension of stratigraphic ranges of fossil taxa by the relatively complete sampling of the Recent biota. However, 906 of 958 living genera and subgenera of bivalve mollusks having a fossil record occur in the Pliocene or Pleistocene. The Pull of the Recent thus accounts for only 5% of the Cenozoic increase in bivalve diversity, a major component of the marine record, suggesting that the diversity increase is likely to be a genuine biological pattern.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Univ Calif San Diego, Sect Ecol Behav & Evolut, La Jolla, CA 92903 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA	University of Chicago; University of California System; University of California San Diego; University of California System; University of California Berkeley	Jablonski, D (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	d-jablonski@uchicago.edu						Adrain JM, 2000, SCIENCE, V289, P110, DOI 10.1126/science.289.5476.110; Alroy J, 2001, P NATL ACAD SCI USA, V98, P6261, DOI 10.1073/pnas.111144698; BAMBACH RK, 1993, PALEOBIOLOGY, V19, P372, DOI 10.1017/S0094837300000336; Benton MJ, 2001, GEOL J, V36, P211, DOI 10.1002/gj.877.abs; Best MMR, 2000, PALEOBIOLOGY, V26, P103, DOI 10.1666/0094-8373(2000)026<0103:BTITMS>2.0.CO;2; Crame JA, 2002, GEOL SOC SPEC PUBL, V194, P153, DOI 10.1144/GSL.SP.2002.194.01.12; DARRAGH TA, 1985, ALCHERINGA, V9, P83, DOI 10.1080/03115518508618960; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; Foote M, 2000, PALEOBIOLOGY, V26, P74, DOI 10.1666/0094-8373(2000)26[74:OAECOT]2.0.CO;2; Gage J.D., 1991, DEEP SEA BIOL; GLOVER CP, 1993, J GEOL, V101, P729, DOI 10.1086/648271; Harper EM, 1998, ADEQUACY OF THE FOSSIL RECORD, P243; JABLONSKI D, 1995, SCIENCE, V268, P389, DOI 10.1126/science.11536722; Jackson JBC, 2001, SCIENCE, V293, P2401, DOI 10.1126/science.1063789; MARKOV AV, 2000, PALEONTOLOG J, V36, P121; MILLER AI, 1988, PALEOBIOLOGY, V14, P364, DOI 10.1017/S0094837300012100; MOORE RC, 1969, TREATISE INVERTEBRAT, VN; PEASE CM, 1992, PALEOBIOLOGY, V18, P89, DOI 10.1017/S0094837300012239; Peters SE, 2001, PALEOBIOLOGY, V27, P583, DOI 10.1666/0094-8373(2001)027<0583:BITPAR>2.0.CO;2; RAUP D M, 1979, Bulletin of Carnegie Museum of Natural History, P85; Sepkoski J.J., 1996, GLOBAL EVENT STRATIG, P35, DOI [10.1007/978-3-642-79634-0_4, DOI 10.1007/978-3-642-79634-0_4]; Sepkoski J.J., 2002, B AM PALEONTOL, V363, P1; Sepkoski JJ, 1997, J PALEONTOL, V71, P533, DOI 10.1017/S0022336000040026; SEPKOSKI JJ, 1981, NATURE, V293, P435, DOI 10.1038/293435a0; SEPKOSKI JJ, 1988, PALEOBIOLOGY, V14, P221, DOI 10.1017/S0094837300011969; Smith AB, 2001, PHILOS T R SOC B, V356, P351, DOI 10.1098/rstb.2000.0768; Smith Andrew B., 2000, Special Papers in Palaeontology, V63, P1; Valentine J. W., 1969, Palaeontology, V12, P684; VALENTINE JW, 1978, PALEOBIOLOGY, V4, P55, DOI 10.1017/S0094837300005686; VALENTINE JW, 1989, PALEOBIOLOGY, V15, P83, DOI 10.1017/S0094837300009295	30	125	130	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2003	300	5622					1133	1135		10.1126/science.1083246	http://dx.doi.org/10.1126/science.1083246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750517				2022-12-28	WOS:000182886500041
J	Krejci, L; Van Komen, S; Li, Y; Villemain, J; Reddy, MS; Klein, H; Ellenberger, T; Sung, P				Krejci, L; Van Komen, S; Li, Y; Villemain, J; Reddy, MS; Klein, H; Ellenberger, T; Sung, P			DNA helicase Srs2 disrupts the Rad51 presynaptic filament	NATURE			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; YEAST RAD51; STRAND EXCHANGE; REPAIR; RECOMBINATION; MUTATIONS; GENE; RECA; SGS1	Mutations in the Saccharomyces cerevisiae gene SRS2 result in the yeast's sensitivity to genotoxic agents, failure to recover or adapt from DNA damage checkpoint-mediated cell cycle arrest, slow growth, chromosome loss, and hyper-recombination(1,2). Furthermore, double mutant strains, with mutations in DNA helicase genes SRS2 and SGS1, show low viability that can be overcome by inactivating recombination, implying that untimely recombination is the cause of growth impairment(1,3,4). Here we clarify the role of SRS2 in recombination modulation by purifying its encoded product and examining its interactions with the Rad51 recombinase. Srs2 has a robust ATPase activity that is dependent on single-stranded DNA ( ssDNA) and binds Rad51, but the addition of a catalytic quantity of Srs2 to Rad51-mediated recombination reactions causes severe inhibition of these reactions. We show that Srs2 acts by dislodging Rad51 from ssDNA. Thus, the attenuation of recombination efficiency by Srs2 stems primarily from its ability to dismantle the Rad51 presynaptic filament efficiently. Our findings have implications for the basis of Bloom's and Werner's syndromes, which are caused by mutations in DNA helicases and are characterized by increased frequencies of recombination and a predisposition to cancers and accelerated ageing(5).	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Harvard University; Harvard Medical School; New York University	Krejci, L (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.		Krejci, Lumir/B-7842-2009	Krejci, Lumir/0000-0002-4732-1405; Klein, Hannah/0000-0003-4228-8535				ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Chanet R, 1996, MOL CELL BIOL, V16, P4782; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Klein HL, 2000, NAT GENET, V25, P132, DOI 10.1038/75957; Krejci L, 2001, MOL CELL BIOL, V21, P966, DOI 10.1128/MCB.21.3.966-976.2001; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Liberi G, 2000, EMBO J, V19, P5027, DOI 10.1093/emboj/19.18.5027; Mankouri HW, 2002, NUCLEIC ACIDS RES, V30, P1103, DOI 10.1093/nar/30.5.1103; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; MILNE GT, 1995, GENETICS, V139, P1189; Oakley TJ, 2002, DNA REPAIR, V1, P175, DOI 10.1016/S1568-7864(02)00002-2; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PALLADINO F, 1992, GENETICS, V132, P23; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 1999, J BIOL CHEM, V274, P33839, DOI 10.1074/jbc.274.48.33839; RONG L, 1993, J BIOL CHEM, V268, P1252; SCHILD D, 1995, GENETICS, V140, P115; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200	30	487	495	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					305	309		10.1038/nature01577	http://dx.doi.org/10.1038/nature01577			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748644				2022-12-28	WOS:000182853100047
J	Lunney, JR; Lynn, J; Foley, DJ; Lipson, S; Guralnik, JM				Lunney, JR; Lynn, J; Foley, DJ; Lipson, S; Guralnik, JM			Patterns of functional decline at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER PERSONS; DISABILITY; SERVICES; HOSPICE; DISEASE; HEALTH; ADULTS; HEART	Context Clinicians have observed various patterns of functional decline at the end of life, but few empirical data have tested these patterns in large populations. Objective To determine if functional decline differs among 4 types of illness trajectories: sudden death, cancer death, death from organ failure, and frailty. Design, Setting, and Participants Cohort analysis of data from 4 US regions in the prospective, longitudinal Established Populations for Epidemiologic Studies of the Elderly (EPESE) study. Of the 14456 participants aged 65 years or older who provided interviews at baseline (1981-1987), 4871 died during the first 6 years of follow-up; 4190 (86%) of these provided interviews within 1 year before dying. These decedents were evenly distributed in 12 cohorts based on the number of months between the final interview and death. Main Outcome Measures Self-or proxy-reported physical function (performance of 7 activities of daily living [ADLs]) within 1 year prior to death; predicted ADL dependency prior to death. Results Mean function declined across the 12 cohorts, simulating individual decline in the final year of life. Sudden death decedents were highly functional even in the last month before death (mean [95% confidence interval {CI}] numbers of ADL dependencies: 0.69 [0.19-1.19] at 12 months before death vs 1.22 [0.59-1.85] at the final month of life, P=.20); cancer decedents were highly functional early in their final year but markedly more disabled 3-months prior to death (0.77 [0.30-1.24] vs 4.09 [3.37-4.81], P<.001); organ failure decedents experienced a fluctuating. pattern of decline, with substantially poorer function during the last 3 months before death (2.10 [1.49-2.70] vs 3.66 [2.94-4.38], P<.001); and frail decedents were relatively more disabled in the final year and especially dependent during the last month (2.92 [2.24-3.60] vs 5.84 [5.33-6.35], P<.001). After controlling for age, sex, race, education, marital status, interval between final interview and death, and other demographic differences, frail decedents were more than 8 times more likely than sudden death decedents to be ADL dependent (OR, 8.32 [95% CI, 6.46-10.73); cancer decedents, one and a half times more likely (OR, 1.57 [95% CI, 1.25-1.96]); and organ failure decedents, 3 times more likely (OR, 3.00 [95% CI, 2.39-3.77]). Conclusions Trajectories of functional decline at the end of life are quite variable. Differentiating among expected trajectories and related needs would help shape tailored strategies and better programs of care prior to death.	NIA, Lab Epidemiol Demog & Biometry, NIH, Bethesda, MD 20892 USA; Washington Home Ctr Palliat Care Studies, Washington, DC USA; Hebrew Home Greater Washington, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Lunney, JR (corresponding author), NIA, Lab Epidemiol Demog & Biometry, NIH, Gateway Bldg,Suite 3C-309, Bethesda, MD 20892 USA.		Ram, Prem/K-4511-2012		NINR NIH HHS [K22-NR07967] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [K22NR007967] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		CORNONIHUNTLEY J, 1986, NIH PUBLICATION; CORNONIHUNTLEY J, NIH PUBLICATION, V2; *FED INT FOR AG RE, 2000, OLD AM 2000 KEY IND; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; Ferrucci L, 1996, J GERONTOL A-BIOL, V51, pM123, DOI 10.1093/gerona/51A.3.M123; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Glaser B., 1968, TIME DYING, DOI DOI 10.1097/00000446-196812000-00048; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; Guralnik JM, 2001, J AM GERIATR SOC, V49, pS12; Haan MN, 1997, J AM GERIATR SOC, V45, P667, DOI 10.1111/j.1532-5415.1997.tb01468.x; *I MED, 1997, APPR DEATH IMPR CAR; LAWTON MP, 1990, MILBANK Q, V68, P1, DOI 10.2307/3350075; Lunney JR, 2002, J AM GERIATR SOC, V50, P1108, DOI 10.1046/j.1532-5415.2002.50268.x; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; MCNEIL J, 2001, AM DISABILITIES 1997; Minino A M, 2001, Natl Vital Stat Rep, V49, P1; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; VERBRUGGE LM, 1994, J HEALTH SOC BEHAV, V35, P97, DOI 10.2307/2137359; Visser M, 1998, AM J CLIN NUTR, V68, P584, DOI 10.1093/ajcn/68.3.584; Wolinsky FD, 1997, MED CARE, V35, P1031, DOI 10.1097/00005650-199710000-00005; Wolinsky FD, 1998, J GERONTOL B-PSYCHOL, V53, pS336, DOI 10.1093/geronb/53B.6.S336; Wolinsky FD, 1996, J AGING HEALTH, V8, P155, DOI 10.1177/089826439600800201	23	819	827	1	61	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2387	2392		10.1001/jama.289.18.2387	http://dx.doi.org/10.1001/jama.289.18.2387			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	677WF	12746362	Bronze			2022-12-28	WOS:000182831200028
J	Golas, MM; Sander, B; Will, CL; Luhrmann, R; Stark, H				Golas, MM; Sander, B; Will, CL; Luhrmann, R; Stark, H			Molecular architecture of the multiprotein splicing factor SF3b	SCIENCE			English	Article							U2 SNRNP PROTEINS; BRANCH-SITE; CRYSTAL-STRUCTURE; ELECTRON CRYOMICROSCOPY; ANGSTROM RESOLUTION; RNA; DOMAIN; COMPLEX; BINDING; MICROSCOPY	The splicing factor SF3b is a multiprotein complex essential for the accurate excision of introns from pre-messenger RNA. As an integral component of the U2 small nuclear ribonucleoprotein (snRNP) and the U11/U12 di-snRNP, SF3b is involved in the recognition of the pre-messenger RNA's branch site within the major and minor spliceosomes. We have determined the three-dimensional structure of the human SF3b complex by single-particle electron cryomicroscopy at a resolution of less than 10 angstroms, allowing identification of protein domains with known structural folds. The best fit of a modeled RNA-recognition motif indicates that the protein p14 is located in the central cavity of the complex. The 22 tandem helical repeats of the protein SF3b155 are located in the outer shell of the complex enclosing p14.	Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	Max Planck Society	Stark, H (corresponding author), Max Planck Inst Biophys Chem, Fassberg 11, D-37077 Gottingen, Germany.	holger.stark@mpibpc.mpg.de	Sander, Bjoern/AAO-9021-2021	Sander, Bjoern/0000-0001-8495-2321; Holger, Stark/0000-0002-6161-1118				Bottcher C, 1999, FEBS LETT, V463, P255, DOI 10.1016/S0014-5793(99)01475-1; Burge CB, 1999, RNA WORLD, P525; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Das BK, 1999, MOL CELL BIOL, V19, P6796; De Carlo S, 2002, J STRUCT BIOL, V138, P216, DOI 10.1016/S1047-8477(02)00035-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Kramer A, 1999, J CELL BIOL, V145, P1355, DOI 10.1083/jcb.145.7.1355; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Query CC, 1996, EMBO J, V15, P1392, DOI 10.1002/j.1460-2075.1996.tb00481.x; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; TISCHENDORF GW, 1974, MOL GEN GENET, V134, P187, DOI 10.1007/BF00267715; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; Will CL, 1999, SCIENCE, V284, P2003, DOI 10.1126/science.284.5422.2003; Will CL, 2002, EMBO J, V21, P4978, DOI 10.1093/emboj/cdf480; Will CL, 2001, EMBO J, V20, P4536, DOI 10.1093/emboj/20.16.4536; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	30	201	217	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					980	984		10.1126/science.1084155	http://dx.doi.org/10.1126/science.1084155			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738865				2022-12-28	WOS:000182719800057
J	Huberman, AD; Wang, GY; Liets, LC; Collins, OA; Chapman, B; Chalupa, LM				Huberman, AD; Wang, GY; Liets, LC; Collins, OA; Chapman, B; Chalupa, LM			Eye-specific retinogeniculate segregation independent of normal neuronal activity	SCIENCE			English	Article								The segregation of initially intermingled left and right eye inputs to the dorsal lateral geniculate nucleus (DLGN) during development is thought to be in response to precise spatial and temporal patterns of spontaneous ganglion cell activity. To test this hypothesis, we disrupted the correlated activity of neighboring ganglion cells in the developing ferret retina through immunotoxin depletion of starburst amacrine cells. Despite the absence of this type of correlated activity, left and right eye inputs segregated normally in the DLGN. By contrast, when all spontaneous activity was blocked, the projections from the two eyes remained intermingled. Thus, certain features of normal neural activity patterns are not required for the formation of eye-specific projections to the DLGN.	Univ Calif Davis, Sch Med, Ctr Neurosci, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Ophthalmol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Chapman, B (corresponding author), Univ Calif Davis, Sch Med, Ctr Neurosci, Davis, CA 95616 USA.	bxchapman@ucdavis.edu; lmchalupa@ucdavis.edu			NATIONAL EYE INSTITUTE [R01EY011369, P30EY012576, R01EY013301, R01EY003991] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011369, EY12576, EY11369, EY03991, R01 EY011369-11, EY13301] Funding Source: Medline; NIMH NIH HHS [P20 MH6095] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		COOK PM, 1999, VISUAL NEUROSCI, V16, P3; Crowley JC, 2000, SCIENCE, V290, P1321, DOI 10.1126/science.290.5495.1321; Crowley JC, 1999, NAT NEUROSCI, V2, P1125, DOI 10.1038/16051; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Feller MB, 1999, NEURON, V22, P653, DOI 10.1016/S0896-6273(00)80724-2; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; Hahm JO, 1999, J COMP NEUROL, V412, P705, DOI 10.1002/(SICI)1096-9861(19991004)412:4<705::AID-CNE11>3.0.CO;2-D; Huberman AD, 2002, J NEUROSCI, V22, P9419; Jones EG, 1985, THALAMUS; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P7; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; Muir-Robinson G, 2002, J NEUROSCI, V22, P5259; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; RAKIC P, 1979, NATURE, V261, P5560; Rossi FM, 2001, P NATL ACAD SCI USA, V98, P6453, DOI 10.1073/pnas.101120998; SHATZ CJ, 1983, J NEUROSCI, V3, P482; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SKALIORA I, 1993, J NEUROSCI, V13, P313; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; Stellwagen D, 1999, NEURON, V24, P673, DOI 10.1016/S0896-6273(00)81121-6; Stellwagen D, 2002, NEURON, V33, P357, DOI 10.1016/S0896-6273(02)00577-9; Wang L, 1997, J NEUROPHYSIOL, V78, P689, DOI 10.1152/jn.1997.78.2.689; WONG RO, 1993, NEURON, V11, P5; WONG ROL, 1999, ANN REV NEUROSCI, V22; Zhou ZJ, 1998, J NEUROSCI, V18, P4155	26	92	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					994	998		10.1126/science.1080694	http://dx.doi.org/10.1126/science.1080694			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738869	Green Accepted			2022-12-28	WOS:000182719800061
J	Lenski, RE; Ofria, C; Pennock, RT; Adami, C				Lenski, RE; Ofria, C; Pennock, RT; Adami, C			The evolutionary origin of complex features	NATURE			English	Article							DESIGN; RATES; GENE	A long-standing challenge to evolutionary theory has been whether it can explain the origin of complex organismal features. We examined this issue using digital organisms-computer programs that self-replicate, mutate, compete and evolve. Populations of digital organisms often evolved the ability to perform complex logic functions requiring the coordinated execution of many genomic instructions. Complex functions evolved by building on simpler functions that had evolved earlier, provided that these were also selectively favoured. However, no particular intermediate stage was essential for evolving complex functions. The first genotypes able to perform complex functions differed from their non-performing parents by only one or two mutations, but differed from the ancestor by many mutations that were also crucial to the new functions. In some cases, mutations that were deleterious when they appeared served as stepping-stones in the evolution of complex features. These findings show how complex functions can originate by random mutation and natural selection.	Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Michigan State Univ, Dept Comp Sci & Engn, E Lansing, MI 48824 USA; Michigan State Univ, Lyman Briggs Sch, E Lansing, MI 48824 USA; Michigan State Univ, Dept Philosophy, E Lansing, MI 48824 USA; CALTECH, Digital Life Lab, Pasadena, CA 91125 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University; California Institute of Technology	Lenski, RE (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	lenski@msu.edu	Adami, Christoph/A-5181-2009; Adami, Chris/A-9675-2011	Adami, Chris/0000-0002-2915-9504; Ofria, Charles/0000-0003-2924-1732; Lenski, Richard/0000-0002-1064-8375				Adami C., 1998, INTRO ARTIFICIAL LIF; [Anonymous], 1861, ORIGIN SPECIES MEANS; Bedau MA, 1997, FROM ANIM ANIMAT, P125; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; Dawkins R., 1986, BLIND WATCHMAKER; Dean AM, 1997, P NATL ACAD SCI USA, V94, P3104, DOI 10.1073/pnas.94.7.3104; Dennett D., 2002, ENCY EVOLUTION, pE83; Dennett Daniel C., 1995, DARWINS DANGEROUS ID; Drake JW, 1998, GENETICS, V148, P1667; Foster JA, 2001, NAT REV GENET, V2, P428, DOI 10.1038/35076523; GOLDSMITH TH, 1990, Q REV BIOL, V65, P281, DOI 10.1086/416840; Holland J. H., 1992, ADAPTATION NATURAL A, DOI 10.7551/mitpress/1090.001.0001; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Koza JR, 1992, GENETIC PROGRAMMING; LAND MF, 1992, ANNU REV NEUROSCI, V15, P1, DOI 10.1146/annurev.ne.15.030192.000245; Lenski RE, 1999, NATURE, V400, P661, DOI 10.1038/23245; Lipson H, 2000, NATURE, V406, P974, DOI 10.1038/35023115; MelendezHevia E, 1996, J MOL EVOL, V43, P293, DOI 10.1007/PL00006089; Miller K., 1999, FINDING DARWINS GOD; Mortlock RP, 1984, MICROORGANISMS MODEL; Newcomb RD, 1997, P NATL ACAD SCI USA, V94, P7464, DOI 10.1073/pnas.94.14.7464; NILSSON DE, 1994, P ROY SOC B-BIOL SCI, V256, P53, DOI 10.1098/rspb.1994.0048; Ofria C, 2002, IEEE T EVOLUT COMPUT, V6, P420, DOI 10.1109/TEVC.2002.802442; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; RAY T., 1992, ARTIF LIFE, P371, DOI DOI 10.1016/S0040-4039(01)97473-8; SALVINIPLAWEN LV, 1977, EVOLUTIONARY BIOL, V10, P207; Wagenaar D, 2000, FROM ANIM ANIMAT, P216; Wilke CO, 2002, TRENDS ECOL EVOL, V17, P528, DOI 10.1016/S0169-5347(02)02612-5; Wilke CO, 2001, NATURE, V412, P331, DOI 10.1038/35085569; Wilkins A.S., 2002, EVOLUTION DEV PATHWA; Yedid G, 2002, NATURE, V420, P810, DOI 10.1038/nature01151; Yedid G, 2001, AM NAT, V157, P465, DOI 10.1086/319928; Yokoyama S, 2001, GENETICS, V158, P1697	33	403	409	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					139	144		10.1038/nature01568	http://dx.doi.org/10.1038/nature01568			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736677				2022-12-28	WOS:000182699600038
J	Rubenstein, LS				Rubenstein, LS			The medical community's response to torture	LANCET			English	Editorial Material									Phys Human Rights, Boston, MA 02116 USA		Rubenstein, LS (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.							*BRIT MED ASS, 1992, MED BETR; Heisler M, 2003, JAMA-J AM MED ASSOC, V289, P2135, DOI 10.1001/jama.289.16.2135; Physicians for Human Rights, 1996, TORT TURK ITS UNW AC; Physicians for Human Rights and University of Cape Town Health Sciences Faculty, 2003, DUAL LOYALT HUM RIGH; *UN OFF HIGH COMM, 2001, UN OFF HIGH COMM HUM, V8	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1556	1556		10.1016/S0140-6736(03)13161-3	http://dx.doi.org/10.1016/S0140-6736(03)13161-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737882				2022-12-28	WOS:000182658900029
J	Tomlinson, B; Cockram, C				Tomlinson, B; Cockram, C			SARS: experience at Prince of Wales Hospital, Hong Kong	LANCET			English	Editorial Material							CORONAVIRUS; VIRUS		Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Tomlinson, B (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.	btomlinson@cuhk.edu.hk	Tomlinson, Brian/P-5365-2015; Tomlinson, Brian/AAD-9404-2019	Tomlinson, Brian/0000-0001-6717-5444				Buckingham SC, 2002, J INFECT DIS, V185, P1222, DOI 10.1086/340024; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P241; *CDCP, 2003, CDC LAB AN SUGG NEW; *HONG KONG DEP HLT, MAIN FIND INV OUTBR; LEE N, 2003, N ENGL J MED; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; POUTANEN SM, 2003, N ENGL J MED; Storz J, 2000, J CLIN MICROBIOL, V38, P3291, DOI 10.1128/JCM.38.9.3291-3298.2000; TSANG KW, 2003, N ENGL J MED; *WHO, CAS DEF SURV SEV AC; World Health Organization, 2003, SEV AC RESP SYNDR SA; Yu M, 2000, AVIAN DIS, V44, P297, DOI 10.2307/1592543	12	114	116	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2003	361	9368					1486	1487		10.1016/S0140-6736(03)13218-7	http://dx.doi.org/10.1016/S0140-6736(03)13218-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737853	Bronze, Green Published			2022-12-28	WOS:000182658900002
J	Freemantle, N; Calvert, M; Wood, J; Eastaugh, J; Griffin, C				Freemantle, N; Calvert, M; Wood, J; Eastaugh, J; Griffin, C			Composite outcomes in randomized trials - Greater precision but with greater uncertainty?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLYCOPROTEIN IIB/IIIA INHIBITORS; CLINICAL-TRIALS	Composite outcomes, in which multiple end points are combined, are frequently used as primary outcome measures in randomized trials and are often associated with increased statistical efficiency. However, such measures may prove challenging for the interpretation of results. In this article, we examine the use of composite outcomes in major clinical trials, assess the arguments for and against them, and provide guidance on their application and reporting. To assess incidence and quality of reporting, we Systematically reviewed the use of composite end points in clinical trials in Annals of Internal Medicine, BMJ, Circulation, Clinical Infectious Diseases, Journal of the American College of Cardiology, JAMA, Lancet, New England Journal of Medicine, and Stroke from 1997 through 2001 using a sensitive search strategy. We selected for review 167 original reports of randomized trials (with a total of 300276 patients) that included a composite primary outcome that incorporated all-cause mortality. Sixty-three trials (38%) were neutral both for the primary end point and the mortality component Sixty trials (36%) reported significant results for the primary outcome measure but not for the mortality component Only 6 trials (4%) were significant for the mortality component but not for the primary composite outcome, whereas 19 trials (11%) were significant for both. Twenty-two trials (13%) were inadequately reported. Our review suggests that reporting of composite outcomes is generally inadequate, implying that the results apply to the individual components of the composite outcome rather than only to the overall composite. Current guidelines for the undertaking and reporting of clinical trials could be revised to reflect the common use of composite outcomes in clinical trials.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Freemantle, N (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Primary Care Clin Sci Bldg, Birmingham B15 2TT, W Midlands, England.	N.Freemantle@bham.ac.uk	Calvert, Melanie/F-7055-2011	Calvert, Melanie/0000-0002-1856-837X; Freemantle, Nick/0000-0001-5807-5740				[Anonymous], 1999, STAT MED, V18, P1905; Bhatt DL, 2000, JAMA-J AM MED ASSOC, V284, P1549, DOI 10.1001/jama.284.12.1549; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; Eccles M, 1998, BRIT MED J, V316, P1232, DOI 10.1136/bmj.316.7139.1232; Freemantle N, 2001, BRIT MED J, V322, P989, DOI 10.1136/bmj.322.7292.989; Hampton JR, 2000, BRIT MED J, V320, P244, DOI 10.1136/bmj.320.7229.244; Le May MR, 2001, J AM COLL CARDIOL, V37, P985, DOI 10.1016/S0735-1097(00)01213-4; Leon MB, 2001, NEW ENGL J MED, V344, P250, DOI 10.1056/NEJM200101253440402; Lincoff AM, 1999, NEW ENGL J MED, V341, P319, DOI 10.1056/NEJM199907293410503; Lindor KD, 1997, NEW ENGL J MED, V336, P691, DOI 10.1056/NEJM199703063361003; Martin DO, 2000, EPIDEMIOLOGY, V11, P255, DOI 10.1097/00001648-200005000-00005; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Rodriguez A, 2001, J AM COLL CARDIOL, V37, P51, DOI 10.1016/S0735-1097(00)01052-4; *SAS I INC, 2002, SAS COMP PROGR VERS; Shih JH, 1995, CONTROL CLIN TRIALS, V16, P395, DOI 10.1016/S0197-2456(95)00132-8; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; Yusuf S, 2000, NEW ENGL J MED, V342, P145	17	481	495	2	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2554	2559		10.1001/jama.289.19.2554	http://dx.doi.org/10.1001/jama.289.19.2554			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680KL	12759327				2022-12-28	WOS:000182976500024
J	Charge, S; Rudnicki, MA				Charge, S; Rudnicki, MA			Fusion with the fused: A new role for interleukin-4 in the building of muscle	CELL			English	Editorial Material							FIBER; CELL	In this issue of Cell, G. Pavlath and coworkers (Horsley et al., 2003) demonstrate a novel role for Interleukin-4 (IL-4) in regulating the fusion of myoblasts with differentiated myotubes. The authors demonstrate that NFATc2 signaling in newly formed myotubes induces IL-4 expression and secretion which promotes myoblast fusion with pre-existing myotubes.	Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute	Charge, S (corresponding author), Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON K1H 8L6, Canada.			Rudnicki, Michael/0000-0002-3866-5249				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; McNally AK, 2002, AM J PATHOL, V160, P621, DOI 10.1016/S0002-9440(10)64882-1; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Schiaffino S, 2002, TRENDS PHARMACOL SCI, V23, P569, DOI 10.1016/S0165-6147(02)02111-9	9	13	13	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	2003	113	4					422	423		10.1016/S0092-8674(03)00358-1	http://dx.doi.org/10.1016/S0092-8674(03)00358-1			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757701	Bronze			2022-12-28	WOS:000182981500002
J	Horsley, V; Jansen, KM; Mills, ST; Pavlath, GK				Horsley, V; Jansen, KM; Mills, ST; Pavlath, GK			IL-4 acts as a myoblast recruitment factor during mammalian muscle growth	CELL			English	Article							MEDIATED GENE-THERAPY; SKELETAL-MUSCLE; FUSION; CELLS; EXPRESSION; RECEPTOR; DIFFERENTIATION; TRANSCRIPTION; PATHWAY; HYPERTROPHY	Skeletal muscle formation and growth require the fusion of myoblasts to form multinucleated myofibers or myotubes, but few molecules are known to regulate myoblast fusion in mammals. The transcription factor NFATc2 controls myoblast fusion at a specific stage of myogenesis after the initial formation of a myotube and is necessary for further cell growth. By examining genes regulated by NFATc2 in muscle, this study identifies the cytokine IL-4 as a molecular signal that controls myoblast fusion with myotubes. Muscle cells lacking IL-4 or the IL-4alpha receptor subunit form normally but are reduced in size and myonuclear number. IL-4 is expressed by a subset of muscle cells in fusing muscle cultures and requires the IL-4alpha receptor subunit on myoblasts to promote fusion and growth. These data demonstrate that following myotube formation, myotubes recruit myoblast fusion by secretion of IL-4, leading to muscle growth.	Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Pavlath, GK (corresponding author), Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA.		Jansen, Kaspar/AAF-2762-2019		NIAMS NIH HHS [AR-48884, AR-47314] Funding Source: Medline; NIDCR NIH HHS [DE-13040] Funding Source: Medline; NIGMS NIH HHS [T32-GM08367] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047314, R01AR048884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Allen DL, 1999, MUSCLE NERVE, V22, P1350, DOI 10.1002/(SICI)1097-4598(199910)22:10<1350::AID-MUS3>3.0.CO;2-8; Barks JL, 1997, J IMMUNOL, V159, P4532; Barnoy S, 1996, BIOCHEM BIOPH RES CO, V220, P933, DOI 10.1006/bbrc.1996.0509; BLAU HM, 1995, NEW ENGL J MED, V333, P1554, DOI 10.1056/NEJM199512073332308; Constantin B, 1996, CELL CALCIUM, V19, P365, DOI 10.1016/S0143-4160(96)90109-8; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; DARR KC, 1989, J APPL PHYSIOL, V67, P1827, DOI 10.1152/jappl.1989.67.5.1827; DeFife KM, 1997, J IMMUNOL, V158, P3385; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; DOERING JL, 1977, EXP CELL RES, V105, P437, DOI 10.1016/0014-4827(77)90140-9; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Gorza L, 2000, FASEB J, V14, P461, DOI 10.1096/fasebj.14.3.461; HARRIS AJ, 1989, DEVELOPMENT, V107, P771; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Huerta L, 2002, CYTOMETRY, V47, P100, DOI 10.1002/cyto.10051; KITAZAWA S, 1995, J BIOL CHEM, V270, P4115, DOI 10.1074/jbc.270.8.4115; KONIGSBERG IR, 1971, DEV BIOL, V26, P133, DOI 10.1016/0012-1606(71)90113-8; LIND M, 1995, CYTOKINE, V7, P78, DOI 10.1006/cyto.1995.1010; Marino M, 2001, J NEUROIMMUNOL, V116, P94, DOI 10.1016/S0165-5728(01)00287-9; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; Mitchell PO, 2001, AM J PHYSIOL-CELL PH, V281, pC1706, DOI 10.1152/ajpcell.2001.281.5.C1706; MNALLY AK, 2002, AM J PATH9OL, V160, P621; Monticelli S, 2002, EUR J IMMUNOL, V32, P2971, DOI 10.1002/1521-4141(2002010)32:10<2971::AID-IMMU2971>3.0.CO;2-G; Murata T, 1998, BLOOD, V91, P3884; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Pavlath GK, 1998, DEV DYNAM, V212, P495, DOI 10.1002/(SICI)1097-0177(199808)212:4<495::AID-AJA3>3.3.CO;2-I; Phelan JN, 1997, ANAT REC, V247, P179, DOI 10.1002/(SICI)1097-0185(199702)247:2<179::AID-AR4>3.0.CO;2-T; Rahaman SO, 2002, CANCER RES, V62, P1103; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rau A, 2001, DEVELOPMENT, V128, P5061; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; ROSEN SD, 1992, TRENDS GLYCOSCI GLYC, V4, P1; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Taylor MV, 2002, CURR BIOL, V12, pR224, DOI 10.1016/S0960-9822(02)00757-1; WAKELAM MJO, 1985, BIOCHEM J, V228, P1; Wunschmann S, 2000, J CLIN MICROBIOL, V38, P3055; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YEOH GCT, 1977, EXP CELL RES, V104, P63, DOI 10.1016/0014-4827(77)90069-6; ZHANG M, 1995, DEV DYNAM, V204, P168, DOI 10.1002/aja.1002040207	44	371	400	1	13	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 16	2003	113	4					483	494		10.1016/S0092-8674(03)00319-2	http://dx.doi.org/10.1016/S0092-8674(03)00319-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757709	Bronze			2022-12-28	WOS:000182981500010
J	Boyle, WJ; Simonet, WS; Lacey, DL				Boyle, WJ; Simonet, WS; Lacey, DL			Osteoclast differentiation and activation	NATURE			English	Review							NF-KAPPA-B; FACTOR RECEPTOR FAMILY; BONE-RESORPTION; OSTEOPROTEGERIN LIGAND; INHIBITS OSTEOCLASTOGENESIS; TRANSCRIPTION FACTOR; SIGNALING COMPLEX; TERMINAL KINASE; KEY REGULATOR; RANK LIGAND	Osteoclasts are specialized cells derived from the monocyte/macrophage haematopoietic lineage that develop and adhere to bone matrix, then secrete acid and lytic enzymes that degrade it in a specialized, extracellular compartment. Discovery of the RANK signalling pathway in the osteoclast has provided insight into the mechanisms of osteoclastogenesis and activation of bone resorption, and how hormonal signals impact bone structure and mass. Further study of this pathway is providing the molecular basis for developing therapeutics to treat osteoporosis and other diseases of bone loss.	Amgen Inc, Thousand Oaks, CA 91320 USA; Prot Pathways Inc, Woodland Hills, CA 91367 USA	Amgen	Boyle, WJ (corresponding author), Prot Pathways Inc, Woodland Hills, CA 91367 USA.	bboyle@proteinpathways.com						Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763; Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348; Body JJ, 2003, CANCER-AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; CHAGRAOUI H, IN PRESS BLOOD; Chambers TJ, 2000, J PATHOL, V192, P4; Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Eghbali-Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hayashi T, 2002, J BIOL CHEM, V277, P27880, DOI 10.1074/jbc.M203836200; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Jimi E, 1999, J IMMUNOL, V163, P434; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Langdahl BL, 2002, J BONE MINER RES, V17, P1245, DOI 10.1359/jbmr.2002.17.7.1245; Lee SW, 2002, J BIOCHEM MOL BIOL, V35, P371; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047; Mak TW, 2002, NATURE, V418, P835, DOI 10.1038/418835a; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; McLean W, 2001, Trends Genet, V17, pS38, DOI 10.1016/S0168-9525(01)02458-1; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049; Morony S, 1999, J BONE MINER RES, V14, P1478, DOI 10.1359/jbmr.1999.14.9.1478; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; ODA H, 2002, J BONE MINER RES, V17, P612; Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA; Shui C, 2002, CALCIFIED TISSUE INT, V71, P437, DOI 10.1007/s00223-001-1138-3; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096; Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yan T, 2001, J CELL BIOCHEM, V83, P320, DOI 10.1002/jcb.1200; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	77	4488	4785	37	693	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					337	342		10.1038/nature01658	http://dx.doi.org/10.1038/nature01658			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748652				2022-12-28	WOS:000182853100054
J	Gabaix, X; Gopikrishnan, P; Plerou, V; Stanley, HE				Gabaix, X; Gopikrishnan, P; Plerou, V; Stanley, HE			A theory of power-law distributions in financial market fluctuations	NATURE			English	Article							STATISTICAL PROPERTIES; PRICE FLUCTUATIONS; ZIPFS LAW; TRADES; COMPANIES	Insights into the dynamics of a complex system are often gained by focusing on large fluctuations. For the financial system, huge databases now exist that facilitate the analysis of large fluctuations and the characterization of their statistical behaviour(1,2). Power laws appear to describe histograms of relevant financial fluctuations, such as fluctuations in stock price, trading volume and the number of trades(3-10). Surprisingly, the exponents that characterize these power laws are similar for different types and sizes of markets, for different market trends and even for different countries - suggesting that a generic theoretical basis may underlie these phenomena. Here we propose a model, based on a plausible set of assumptions, which provides an explanation for these empirical power laws. Our model is based on the hypothesis that large movements in stock market activity arise from the trades of large participants. Starting from an empirical characterization of the size distribution of those large market participants ( mutual funds), we show that the power laws observed in financial data arise when the trading behaviour is performed in an optimal way. Our model additionally explains certain striking empirical regularities that describe the relationship between large fluctuations in prices, trading volume and the number of trades.	MIT, Dept Econ, Cambridge, MA 02142 USA; Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Boston University; Boston University	Gabaix, X (corresponding author), MIT, Dept Econ, Cambridge, MA 02142 USA.		Gabaix, Xavier/B-8227-2008	Stanley, H./0000-0003-2800-4495				Axtell RL, 2001, SCIENCE, V293, P1818, DOI 10.1126/science.1062081; BAGWELL LS, 1992, J FINANC, V47, P71, DOI 10.2307/2329091; Bunde A., 2002, SCI DISASTERS CLIMAT; CHAN LKC, 1995, J FINANC, V50, P1147, DOI 10.2307/2329347; CUTLER DM, 1989, J PORTFOLIO MANAGE, V15, P4, DOI 10.3905/jpm.1989.409212; Daniel K, 1998, J FINANC, V53, P1839, DOI 10.1111/0022-1082.00077; Gabaix X, 1999, Q J ECON, V114, P739, DOI 10.1162/003355399556133; GABAIX X, 2003, POWER LAWS MUTUAL FU; Gopikrishnan P, 1999, PHYS REV E, V60, P5305, DOI 10.1103/PhysRevE.60.5305; Gopikrishnan P, 2000, PHYS REV E, V62, pR4493, DOI 10.1103/PhysRevE.62.R4493; GROSSMAN SJ, 1988, J FINANC, V43, P617, DOI 10.2307/2328186; Guillaume D, 1997, FINANC STOCH, V1, P95, DOI [10.1007/s007800050018, DOI 10.1007/S007800050018]; HASBROUCK J, 1991, J FINANC, V46, P179, DOI 10.2307/2328693; Keim DB, 1997, J FINANC ECON, V46, P265, DOI 10.1016/S0304-405X(97)00031-7; KYLE AS, 1985, ECONOMETRICA, V53, P1315, DOI 10.2307/1913210; LEE CMC, 1991, J FINANC, V46, P733, DOI 10.2307/2328845; Liu YH, 1999, PHYS REV E, V60, P1390, DOI 10.1103/PhysRevE.60.1390; Lux T., 1996, APPL FINANCIAL EC, V6, P463, DOI DOI 10.1080/096031096333917; MANDELBROT B, 1963, J BUS, V36, P394, DOI 10.1086/294632; O'Hara M., 1997, MARKET MICROSTRUCTUR; Okuyama K, 1999, PHYSICA A, V269, P125, DOI 10.1016/S0378-4371(99)00086-2; Plerou V, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.027104; Plerou V, 1999, PHYS REV E, V60, P6519, DOI 10.1103/PhysRevE.60.6519; Plerou V, 2000, PHYS REV E, V62, pR3023, DOI 10.1103/PhysRevE.62.R3023; Shleifer A., 2000, INEFFICIENT MARKETS; Wurgler J, 2002, J BUS, V75, P583, DOI 10.1086/341636; Zipf G. K., 1949, HUMAN BEHAV PRINCIPL; [No title captured]	28	792	809	3	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					267	270		10.1038/nature01624	http://dx.doi.org/10.1038/nature01624			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678EX	12748636				2022-12-28	WOS:000182853100037
J	Nisbet-Brown, E; Olivieri, NF; Giardina, PJ; Grady, RW; Neufeld, EJ; Sechaud, R; Krebs-Brown, AJ; Anderson, JR; Alberti, D; Sizer, KC; Nathan, DG				Nisbet-Brown, E; Olivieri, NF; Giardina, PJ; Grady, RW; Neufeld, EJ; Sechaud, R; Krebs-Brown, AJ; Anderson, JR; Alberti, D; Sizer, KC; Nathan, DG			Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial	LANCET			English	Article							CHELATION-THERAPY; DEFERIPRONE; PHARMACOKINETICS; FIBROSIS	Background Transfusional iron overload is a potentially fatal complication of the treatment of thalassaemia. We aimed to investigate short-term efficacy, pharmacokinetic/pharmacodynamic (PK/PD) relations, and safety of ICL670, a novel, tridentate, orally active iron chelator. Methods We enrolled 24 patients and divided them into three cohorts consisting of a minimum of seven individuals. Patients were admitted to a metabolic unit and consumed a diet with a defined content of iron. Two patients in each cohort were randomly allocated placebo. Five or more patients received one daily dose of ICL670 at 10, 20, or 40 mg kg(-1) day(-1), from day 1 to 12. Net iron excretion (NIE) was measured between days I and 12. Primary objectives included assessment of safety and tolerability (measured by adverse events and clinical laboratory monitoring), pharmacokinetics (measured as drug and drug-iron complex), and cumulative net iron excretion (measured by faecal and urine output minus food input). Analysis was for efficacy. Findings ICL670 was absorbed promptly and was detectable in the blood for 24 h. Exposure (area under the curve of plasma concentration) to ICL670 at pharmacokinetic steady state was proportional to dose. All three doses resulted in positive NIE. The NIE achieved at 20 mg kg-1 clays would prevent net iron accumulation in most patients transfused with 12-15 mL packed red-blood-cells kg(-1) month(-1), equivalent to 0.3-0.5 mg iron kg(-1) day(-1). A linear relation (PK/PD) was recorded between exposure to ICL670 and total iron excretion, by contrast with placebo (r(2)=0.54, p< 0.0001). Skin rashes were noted in four patients treated at 20 and 40 mg kg(-1) day(-1), and one patient also developed grade 2 transaminitis. Interpretation ICL670 given once daily at 20 mg/kg seems to be an effective orally active iron chelator and is reasonably well tolerated. Long-term studies are now necessary to establish the practical contribution of this drug.	Harvard Univ, Sch Med, Dept Paediat, Boston, MA USA; Weill Med Coll, Dept Paediat, New York, NY USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Toronto Gen Hosp, Toronto, ON, Canada; New York Presbyterian Hosp, New York, NY USA; Novartis Pharma AG, Basel, Switzerland	Harvard University; Harvard Medical School; Cornell University; University of Toronto; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; NewYork-Presbyterian Hospital; Novartis	Nathan, DG (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	david_nathan@dfci.harvard.edu	Olivieri, Nancy/AAI-2250-2020; Neufeld, Ellis J./F-9331-2011	Neufeld, Ellis J./0000-0001-8092-6281; safarikia, samira/0000-0002-7254-0634	NCRR NIH HHS [5M01-RR00047, 5M01 RR02172] Funding Source: Medline; NHLBI NIH HHS [HL04184, HL99016, P50 HL54785] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047, M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALREFAIE FN, 1995, BRIT J HAEMATOL, V89, P403, DOI 10.1111/j.1365-2141.1995.tb03318.x; Arnaiz-Villena A, 2001, TISSUE ANTIGENS, V57, P118, DOI 10.1034/j.1399-0039.2001.057002118.x; BADMAN DG, 2000, IRON CHELATORS NEW D; Breuer W, 2000, TRANSFUS SCI, V23, P185, DOI 10.1016/S0955-3886(00)00087-4; Cohen AR, 2000, BRIT J HAEMATOL, V108, P305; Del Vecchio GC, 2000, ACTA HAEMATOL-BASEL, V104, P99, DOI 10.1159/000039759; Heinz U, 1999, ANGEW CHEM INT EDIT, V38, P2568, DOI 10.1002/(SICI)1521-3773(19990903)38:17<2568::AID-ANIE2568>3.0.CO;2-C; HIDER RC, 1990, ANN NY ACAD SCI, V612, P327; Hoffbrand AV, 1998, BLOOD, V91, P295, DOI 10.1182/blood.V91.1.295.295_295_300; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mazza P, 1998, HAEMATOLOGICA, V83, P496; Naylor CD, 2002, CAN MED ASSOC J, V166, P452; NICK HP, 2000, IRON CHELATORS NEW D, P311; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; Olivieri NF, 1998, NEW ENGL J MED, V339, P417, DOI 10.1056/NEJM199808133390701; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056/NEJM199504063321404; Papassavas EC, 2000, HUM IMMUNOL, V61, P615, DOI 10.1016/S0198-8859(00)00115-4; Piga A, 2002, BLOOD, V100, p5A; Pippard MJ, 2000, BRIT J HAEMATOL, V111, P2, DOI 10.1046/j.1365-2141.2000.02406.x; Porter JB, 2001, BRIT J HAEMATOL, V115, P239, DOI 10.1046/j.1365-2141.2001.03195.x; Rouan MC, 2001, J CHROMATOGR B, V755, P203, DOI 10.1016/S0378-4347(01)00079-2; Ryabukhin YI, 1987, SOV J COORD CHEM, V13, P493; SINGH S, 1992, DRUG METAB DISPOS, V20, P256; Tondury P, 1998, BRIT J HAEMATOL, V101, P413, DOI 10.1046/j.1365-2141.1998.00725.x; VarnavidouNicolaidou A, 1997, TRANSPLANT P, V29, P2920, DOI 10.1016/S0041-1345(97)00729-X; Wanless IR, 2002, BLOOD, V100, P1566, DOI 10.1182/blood-2002-01-0306; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503	27	262	277	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	2003	361	9369					1597	1602		10.1016/S0140-6736(03)13309-0	http://dx.doi.org/10.1016/S0140-6736(03)13309-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747879				2022-12-28	WOS:000182746300009
J	Jeffcoate, WJ; Harding, KG				Jeffcoate, WJ; Harding, KG			Diabetic foot ulcers	LANCET			English	Review							LOWER-EXTREMITY AMPUTATIONS; COLONY-STIMULATING FACTOR; LOWER-LIMB AMPUTATIONS; MAJOR AMPUTATION; RISK-FACTORS; DECREASING INCIDENCE; VASCULAR-DISEASE; BYPASS-SURGERY; GROWTH-FACTOR; MANAGEMENT	Ulceration of the foot in diabetes is common and disabling and frequently leads to amputation of the leg. Mortality is high and healed ulcers often recur. The pathogenesis of foot ulceration is complex, clinical presentation variable, and management requires early expert assessment. Interventions should be directed at Infection, peripheral ischaemia, and abnormal pressure loading caused by peripheral neuropathy and limited joint mobility. Despite treatment, ulcers readily become chronic wounds. Diabetic foot ulcers have been neglected in health-care research and planning, and clinical practice is based more on opinion than scientific fact. Furthermore, the pathological processes are poorly understood and poorly taught and communication between the many specialties involved is disjointed and insensitive to the needs of patients.	City Hosp, Dept Endocrinol & Diabet, Nottingham NG5 1PB, England; Cardiff Univ, Wound Healing Res Unit, Cardiff CF4 4XN, S Glam, Wales	University of Nottingham; Cardiff University	Jeffcoate, WJ (corresponding author), City Hosp, Dept Endocrinol & Diabet, Nottingham NG5 1PB, England.	jeffcoate@bigfoot.com	Evans, Angela Margaret/Q-1981-2018; Harding, Keith/J-5605-2013	Evans, Angela Margaret/0000-0002-5527-1161; Harding, Keith/0000-0003-0048-3279				Abbott CA, 2002, DIABETIC MED, V19, P377, DOI 10.1046/j.1464-5491.2002.00698.x; Abbott CA, 1998, DIABETES CARE, V21, P1071, DOI 10.2337/diacare.21.7.1071; Abetz L., 2002, PRACT DIABETES INT, V19, P167, DOI [10.1002/pdi.356, DOI 10.1002/PDI.356]; Adler AI, 1999, DIABETES CARE, V22, P1029, DOI 10.2337/diacare.22.7.1029; Akbari CM, 1999, J VASC SURG, V30, P373, DOI 10.1016/S0741-5214(99)70154-0; Akbari CM, 2000, ARCH SURG-CHICAGO, V135, P452, DOI 10.1001/archsurg.135.4.452; Allenet B, 2000, DIABETES METAB, V26, P125; [Anonymous], 1990, Diabet Med, V7, P360; APELQVIST J, 1993, J INTERN MED, V233, P485, DOI 10.1111/j.1365-2796.1993.tb01003.x; Armstrong D G, 2001, Curr Diab Rep, V1, P233, DOI 10.1007/s11892-001-0039-1; Armstrong DG, 1998, DIABETES CARE, V21, P855, DOI 10.2337/diacare.21.5.855; Armstrong DG, 2001, J AM PODIAT MED ASSN, V91, P451, DOI 10.7547/87507315-91-9-451; Armstrong DG, 2001, DIABETES CARE, V24, P1019, DOI 10.2337/diacare.24.6.1019; Armstrong DG, 2000, ARCH SURG-CHICAGO, V135, P1405, DOI 10.1001/archsurg.135.12.1405; Association A.D., 1999, DIABETES CARE, V22, P1354, DOI DOI 10.2337/DIACARE.22.8.1354; BARTH R, 1991, DIABETIC MED, V8, P111, DOI 10.1111/j.1464-5491.1991.tb01555.x; BIRKE JA, 1992, LEPROSY REV, V63, P365; Blume PA, 2002, PLAST RECONSTR SURG, V109, P601, DOI 10.1097/00006534-200202000-00029; Boulton A., 2000, FOOT DIABETES, P19; Boyko EJ, 1996, DIABETIC MED, V13, P967, DOI 10.1002/(SICI)1096-9136(199611)13:11<967::AID-DIA266>3.0.CO;2-K; Bradbury AW, 1996, LANCET, V347, P277, DOI 10.1016/S0140-6736(96)90460-2; BRADLEY M, 1999, HLTH TECHNOL ASSES 1, V3; BRADLEY M, 1999, HLTH TECHNOL ASSES 2, V3; Bruckner M, 1999, AM J MANAG CARE, V5, P609; Calle-Pascual AL, 1997, DIABETES METAB, V23, P519; CALLEPASCUAL AL, DIAB CARE, V24, P1686; CANAVAN R, 2002, DIABETIC MED S2, V19, pA23; Caravaggi C, 2000, DIABETES CARE, V23, P1746, DOI 10.2337/diacare.23.12.1746; Carrington AL, 1996, DIABETES RES CLIN PR, V32, P19, DOI 10.1016/0168-8227(96)01198-9; Cavanagh, 2000, FOOT DIABETES, P33; CHANTELAU E, 1994, DIABETIC MED, V11, P114, DOI 10.1111/j.1464-5491.1994.tb00240.x; Chantelau E, 1996, DIABETIC MED, V13, P156, DOI 10.1002/(SICI)1096-9136(199602)13:2<156::AID-DIA59>3.0.CO;2-U; Chaturvedi N, 2002, DIABETIC MED, V19, P99, DOI 10.1046/j.1464-5491.2002.00583.x; Chaturvedi N, 2001, DIABETOLOGIA, V44, pS65, DOI 10.1007/PL00002941; COOPER DM, 1994, ANN SURG, V219, P688, DOI 10.1097/00000658-199406000-00012; daSilva AF, 1996, DIABETIC MED, V13, P726, DOI 10.1002/(SICI)1096-9136(199608)13:8<726::AID-DIA145>3.0.CO;2-P; de Lalla F, 2001, ANTIMICROB AGENTS CH, V45, P1094, DOI 10.1128/AAC.45.4.1094-1098.2001; DE P, 1999, PRACTICAL DIABETES I, V16, P179; Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; Embil JM, 2000, DIABETIC FOOT, V3, P76; Faglia E, 1998, J DIABETES COMPLICAT, V12, P96, DOI 10.1016/S1056-8727(97)98004-1; Faglia E, 2001, DIABETES CARE, V24, P78, DOI 10.2337/diacare.24.1.78; Falanga V, 2000, WOUND REPAIR REGEN, V8, P347; FEINGLASS J, RATES LOWER EXTREMIT; Gottrup F, 2001, ARCH SURG-CHICAGO, V136, P765, DOI 10.1001/archsurg.136.7.765; Gough A, 1997, LANCET, V350, P855, DOI 10.1016/S0140-6736(97)04495-4; GREENE SA, 1999, AM J MED, V107, pS2; HAMILTON AI, 1977, J ANAT, V124, P757; HARDING K, 2000, BRIT J NURS, V19, pS6; Harding KG, 2002, BRIT MED J, V324, P160, DOI 10.1136/bmj.324.7330.160; Harding KG, 2000, DIABETES-METAB RES, V16, pS47, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR133>3.0.CO;2-Q; Harrington C, 2000, DIABETES CARE, V23, P1333, DOI 10.2337/diacare.23.9.1333; Henriksson F, 2000, J INTERN MED, V248, P387, DOI 10.1046/j.1365-2796.2000.00749.x; Holstein P, 2000, DIABETOLOGIA, V43, P844, DOI 10.1007/s001250051459; Holstein PE, 1999, DIABETES CARE, V22, pB97; *INT WORK GROUP DI, 1909, INT CONS DIAB FOOT; ISAKSSON L, 1994, BRIT J SURG, V81, P517, DOI 10.1002/bjs.1800810410; Jeffcoate W, 2000, DIABETIC MED, V17, P253, DOI 10.1046/j.1464-5491.2000.00233.x; JEFFCOATE WJ, 1993, DIABETIC MED, V10, P676, DOI 10.1111/j.1464-5491.1993.tb00144.x; KUMAR S, 1994, DIABETIC MED, V11, P480, DOI 10.1111/j.1464-5491.1994.tb00310.x; LARSSON J, 1995, DIABETIC MED, V12, P770, DOI 10.1111/j.1464-5491.1995.tb02078.x; Lavery LA, 1996, DIABETIC MED, V13, P192, DOI 10.1002/(SICI)1096-9136(199602)13:2<192::AID-DIA35>3.0.CO;2-#; LEE JS, 1993, DIABETES, V42, P876, DOI 10.2337/diabetes.42.6.876; Lipsky, 1999, Curr Infect Dis Rep, V1, P253, DOI 10.1007/s11908-999-0027-1; Lipsky BA, 1997, CLIN INFECT DIS, V25, P1318, DOI 10.1086/516148; Lipsky BA, 2000, DIABETES-METAB RES, V16, pS42, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR109>3.3.CO;2-2; Litzelman DK, 1997, DIABETES CARE, V20, P1273, DOI 10.2337/diacare.20.8.1273; LOGERFO FW, 1984, NEW ENGL J MED, V311, P1615, DOI 10.1056/NEJM198412203112506; Loots MAM, 1998, J INVEST DERMATOL, V111, P850, DOI 10.1046/j.1523-1747.1998.00381.x; Macfarlane R, 1999, DIABETIC FOOT, V2, P123; Macfarlane RM, 1997, DIABETIC MED, V14, P867, DOI 10.1002/(SICI)1096-9136(199710)14:10<867::AID-DIA475>3.0.CO;2-L; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; Margolis DJ, 1999, DIABETES CARE, V22, P692, DOI 10.2337/diacare.22.5.692; Margolis DJ, 2001, DIABETES CARE, V24, P483, DOI 10.2337/diacare.24.3.483; Martin T A, 1999, Angiogenesis, V3, P69, DOI 10.1023/A:1009004212357; Mason J, 1999, DIABETIC MED, V16, P889, DOI 10.1046/j.1464-5491.1999.00137.x; Mayfield JA, 2000, J REHABIL RES DEV, V37, P23; MAYFIELD JA, 2000, J FAM PRACTICE, V49, P505; McCabe CJ, 1998, DIABETIC MED, V15, P80, DOI 10.1002/(SICI)1096-9136(199801)15:1<80::AID-DIA517>3.0.CO;2-K; McGee SR, 1998, ARCH INTERN MED, V158, P1357, DOI 10.1001/archinte.158.12.1357; Meijer JWG, 2001, DISABIL REHABIL, V23, P336; MOULIK P, 2002, DIABETIC FOOT, V5, P51; Muller IS, 2002, DIABETES CARE, V25, P570, DOI 10.2337/diacare.25.3.570; MUMCUOGLU KY, 2000, AM J CLIN DERMATOL, V2, P219; Nabuurs-Franssen MH, 2002, DIABETOLOGIA, V45, P1164, DOI 10.1007/s00125-002-0872-z; NORDEN CW, 1999, INFECT DIS, V2, P1; O'Meara S, 2000, HLTH TECHNOL ASSESS, V4; Oyibo SO, 2001, DIABETIC MED, V18, P133, DOI 10.1046/j.1464-5491.2001.00422.x; Patout CA, 2000, DIABETES CARE, V23, P1339, DOI 10.2337/diacare.23.9.1339; Piaggesi A, 1998, DIABETIC MED, V15, P412, DOI 10.1002/(SICI)1096-9136(199805)15:5<412::AID-DIA584>3.3.CO;2-T; Pittet D, 1999, ARCH INTERN MED, V159, P851, DOI 10.1001/archinte.159.8.851; Pollak RA, 1997, WOUNDS, V9, P175; Rajbhandari SM, 2002, DIABETOLOGIA, V45, P1085, DOI 10.1007/s00125-002-0885-7; Ramsey SD, 1999, DIABETES CARE, V22, P382, DOI 10.2337/diacare.22.3.382; Reiber GE, 1999, DIABETES CARE, V22, P157, DOI 10.2337/diacare.22.1.157; Reiber GE, 1998, AM J SURG, V176, p5S, DOI 10.1016/S0002-9610(98)00181-0; Reiber GE, 2002, JAMA-J AM MED ASSOC, V287, P2552, DOI 10.1001/jama.287.19.2552; Rith-Najarian S, 1998, J FAM PRACTICE, V47, P127; ROSS R, 1989, LANCET, V1, P1179; Spichler E R, 2001, Rev Panam Salud Publica, V10, P334, DOI 10.1590/S1020-49892001001100007; STEED DL, 1993, SURGERY, V114, P775; STEED DL, 1995, J VASC SURG, V21, P71, DOI 10.1016/S0741-5214(95)70245-8; Stiegler H, 1998, VASA-J VASCULAR DIS, V27, P10; STRANDNESS DE, 1964, DIABETES, V13, P366, DOI 10.2337/diab.13.4.366; Taylor RS, 1999, LANCET, V354, P1962, DOI 10.1016/S0140-6736(99)03164-5; TENGRUP L, 1998, SANC J PLAST RECONST, V22, P41; Tennvall GR, 2001, DIABETOLOGIA, V44, P2077; Tennvall GR, 2000, J DIABETES COMPLICAT, V14, P235; Tennvall GR, 2000, PHARMACOECONOMICS, V18, P225, DOI 10.2165/00019053-200018030-00003; Tentolouris N, 1999, DIABETIC MED, V16, P767, DOI 10.1046/j.1464-5491.1999.00132.x; Trautner C, 2001, DIABETES CARE, V24, P855, DOI 10.2337/diacare.24.5.855; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; Unwin N, 2000, BRIT J SURG, V87, P328, DOI 10.1046/j.1365-2168.2000.01344.x; Valk GD, 2002, ENDOCRIN METAB CLIN, V31, P633, DOI 10.1016/S0889-8529(02)00021-X; VALK GD, 2001, COCHRANE DB SYST REV, V4; vanHoutum WH, 1996, J INTERN MED, V240, P227, DOI 10.1046/j.1365-2796.1996.42868000.x; vanHoutum WH, 1996, DIABETES RES CLIN PR, V31, P125, DOI 10.1016/0168-8227(96)01199-0; vanHoutum WH, 1996, J DIABETES COMPLICAT, V10, P325, DOI 10.1016/1056-8727(95)00088-7; Venkatesan P, 1997, DIABETIC MED, V14, P487, DOI 10.1002/(SICI)1096-9136(199706)14:6<487::AID-DIA373>3.0.CO;2-Q; Veves A, 2001, DIABETES CARE, V24, P290, DOI 10.2337/diacare.24.2.290; Vileikyte L, 2001, DIABETES-METAB RES, V17, P246, DOI 10.1002/dmrr.216; Vinik Aaron I., 1999, American Journal of Medicine, V107, p17S; Vinik AI, 2001, DIABETES CARE, V24, P1468, DOI 10.2337/diacare.24.8.1468; Wagner A, 2001, DEUT MED WOCHENSCHR, V126, P1353, DOI 10.1055/s-2001-18655; WALTERS DP, 1992, DIABETIC MED, V9, P354, DOI 10.1111/j.1464-5491.1992.tb01796.x; Wieman TJ, 1998, DIABETES CARE, V21, P822, DOI 10.2337/diacare.21.5.822; Witso E, 2001, PROSTHET ORTHOT INT, V25, P181, DOI 10.1080/03093640108726600; Wrobel JS, 2001, DIABETES CARE, V24, P860, DOI 10.2337/diacare.24.5.860; Yonem A, 2001, DIABETES OBES METAB, V3, P332, DOI 10.1046/j.1463-1326.2001.00142.x; YUE DK, 1986, DIABETIC MED, V3, P221, DOI 10.1111/j.1464-5491.1986.tb00748.x; 2001, MMWR MORB MORTAL WKL, V50, P954	132	620	652	4	158	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2003	361	9368					1545	1551		10.1016/S0140-6736(03)13169-8	http://dx.doi.org/10.1016/S0140-6736(03)13169-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737879				2022-12-28	WOS:000182658900026
J	Bada, JL; Lazcano, A				Bada, JL; Lazcano, A			Prebiotic soup - Revisiting the Miller experiment	SCIENCE			English	Editorial Material									Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City 04510, DF, Mexico	University of California System; University of California San Diego; Scripps Institution of Oceanography; Universidad Nacional Autonoma de Mexico	Bada, JL (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.			Lazcano, Antonio/0000-0001-7365-8557				ANDERSON R, 1965, SCIENCE, V148, P1179, DOI 10.1126/science.148.3674.1179; GARRISON WM, 1951, SCIENCE, V114, P416, DOI 10.1126/science.114.2964.416; GEISON GL, 1969, ISIS, V60, P273, DOI 10.1086/350498; HOUGH L, 1956, J PHYSIOL-LONDON, V132, pP28; LAZCANO A, IN PRESS ORIGINS LIF; Lob W, 1913, BER DTSCH CHEM GES, V46, P684, DOI 10.1002/cber.19130460193; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; ORO J, 1961, NATURE, V191, P1193, DOI 10.1038/1911193a0; UREY HC, 1952, P NATL ACAD SCI USA, V38, P349	9	77	81	2	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					745	746		10.1126/science.1085145	http://dx.doi.org/10.1126/science.1085145			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730584				2022-12-28	WOS:000182579800030
J	Whitman, M; McKeon, F				Whitman, M; McKeon, F			p53 and TGF-beta in development: Prelude to tumor suppression?	CELL			English	Editorial Material							PROTEIN	Recent work in Xenopus embryos reveals an unexpected developmental role for the tumor suppressor gene p53. This finding may have implications for the evolution of p53, its interaction with Smads in TGF-beta dependent mesoderm specification, and the cooperation among p53 family members.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Whitman, M (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.							Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Landesman Y, 1997, CELL SIGNAL, V9, P291, DOI 10.1016/S0898-6568(97)89890-7; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WINKLBAUER R, 1986, DEV BIOL, V118, P70, DOI 10.1016/0012-1606(86)90074-6; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7	10	6	7	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					275	276		10.1016/S0092-8674(03)00317-9	http://dx.doi.org/10.1016/S0092-8674(03)00317-9			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732134				2022-12-28	WOS:000182640800001
J	Janssens, IA; Freibauer, A; Ciais, P; Smith, P; Nabuurs, GJ; Folberth, G; Schlamadinger, B; Hutjes, RWA; Ceulemans, R; Schulze, ED; Valentini, R; Dolman, AJ				Janssens, IA; Freibauer, A; Ciais, P; Smith, P; Nabuurs, GJ; Folberth, G; Schlamadinger, B; Hutjes, RWA; Ceulemans, R; Schulze, ED; Valentini, R; Dolman, AJ			Europe's terrestrial biosphere absorbs 7 to 12% of European anthropogenic CO2 emissions	SCIENCE			English	Article							CARBON-CYCLE; ATMOSPHERIC TRANSPORT; CLIMATE-CHANGE; FORESTS; LAND; SINK; EXCHANGES; BALANCE; FLUXES; OCEANS	Most inverse atmospheric models report considerable uptake of carbon dioxide in Europe's terrestrial biosphere. In contrast, carbon stocks in terrestrial ecosystems increase at a much smaller rate, with carbon gains in forests and grassland soils almost being offset by carbon losses from cropland and peat soils. Accounting for non-carbon dioxide carbon transfers that are not detected by the atmospheric models and for carbon dioxide fluxes bypassing the ecosystem carbon stocks considerably reduces the gap between the small carbon-stock changes and the larger carbon dioxide uptake estimated by atmospheric models. The remaining difference could be because of missing components in the stock-change approach, as well as the large uncertainty in both methods. With the use of the corrected atmosphere- and land-based estimates as a dual constraint, we estimate a net carbon sink between 135 and 205 teragrams per year in Europe's terrestrial biosphere, the equivalent of 7 to 12% of the 1995 anthropogenic carbon emissions.	Univ Antwerp, Dept Biol, B-2160 Antwerp, Belgium; Max Planck Inst Biogeochem, D-07701 Jena, Germany; Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France; Univ Aberdeen, Dept Plant & Soil Sci, Aberdeen AB24 3FX, Scotland; Alterra Green World Res, NL-6700 AC Wageningen, Netherlands; European Forest Inst, Joensuu 80100, Finland; Joanneum Res, A-8010 Graz, Austria; Univ Tuscia, Dept Forest Sci & Environm, I-01100 Viterbo, Italy; Free Univ Amsterdam, Dept Geoenvironm Sci, NL-1081 HV Amsterdam, Netherlands	University of Antwerp; Max Planck Society; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); University of Aberdeen; Wageningen University & Research; Tuscia University; Vrije Universiteit Amsterdam	Janssens, IA (corresponding author), Univ Antwerp, Dept Biol, B-2160 Antwerp, Belgium.	ijanssen@uia.ua.ac.be	Valentini, Riccardo/D-1226-2010; Smith, Pete/G-1041-2010; Nabuurs, Gert-Jan/D-8048-2015; Ciais, Philippe/A-6840-2011; Janssens, Ivan A/P-1331-2014; Folberth, Gerd A./F-7376-2010; Ceulemans, Reinhart J M/F-2109-2016; Schulze, Ernst-Detlef/K-9627-2014	Valentini, Riccardo/0000-0002-6756-5634; Smith, Pete/0000-0002-3784-1124; Ciais, Philippe/0000-0001-8560-4943; Janssens, Ivan A/0000-0002-5705-1787; Folberth, Gerd A./0000-0002-1075-440X; Ceulemans, Reinhart J M/0000-0003-4773-9358; Dolman, A.J./0000-0003-0099-0457				ARMENTANO TV, 1986, J ECOL, V74, P755, DOI 10.2307/2260396; ARMENTANO TV, 1990, WETLANDS SHALLOW CON, P281; BALDOCCHI DD, 1988, ECOLOGY, V69, P1331, DOI 10.2307/1941631; BOTCH MS, 1995, GLOBAL BIOGEOCHEM CY, V9, P37, DOI 10.1029/94GB03156; Bousquet P, 2000, SCIENCE, V290, P1342, DOI 10.1126/science.290.5495.1342; Bousquet P, 1999, J GEOPHYS RES-ATMOS, V104, P26161, DOI 10.1029/1999JD900342; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; Cox PM, 2000, NATURE, V408, P184, DOI 10.1038/35041539; Dersch G, 1997, BODENSCHUTZ OSTERREI, P411; Frankignoulle M, 1998, SCIENCE, V282, P434, DOI 10.1126/science.282.5388.434; FREIBAUER A, IN PRESS SOIL SCI RE; GUENTHER A, 1995, J GEOPHYS RES-ATMOS, V100, P8873, DOI 10.1029/94JD02950; Gurney KR, 2002, NATURE, V415, P626, DOI 10.1038/415626a; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Jackson RB, 2002, NATURE, V418, P623, DOI 10.1038/nature00910; Kaminski T, 1999, J GEOPHYS RES-ATMOS, V104, P18555, DOI 10.1029/1999JD900146; KAUPPI PE, 1992, SCIENCE, V256, P70, DOI 10.1126/science.256.5053.70; Lappalainen E., 1996, GLOBAL PEAT RESOURCE; Liski J, 2002, FOREST ECOL MANAG, V169, P159, DOI 10.1016/S0378-1127(02)00306-7; Liski J., 2000, ENVIRON SCI POLICY, V3, P91, DOI [10.1016/S1462-9011(00)00020-4, DOI 10.1016/S1462-9011(00)00020-4]; Ludwig W, 1998, AM J SCI, V298, P265, DOI 10.2475/ajs.298.4.265; MILNE R, 2001, UK EMISSIONS SOURCES; MUCHER CA, 2000, PELCOM PAN EUROPEAN; Nabuurs GJ, 2003, GLOBAL CHANGE BIOL, V9, P152, DOI 10.1046/j.1365-2486.2003.00570.x; Nabuurs GJ, 1997, BIOMASS BIOENERG, V13, P345, DOI 10.1016/S0961-9534(97)00036-6; Nabuurs GJ, 2001, THESIS U JOENSUU FIN; NABUURS GJ, 2001, LONG TERM EFFECTS CL, P220; Olivier J. G. J., 1999, ENVIRON SCI POLICY, V2, P241, DOI DOI 10.1016/S1462-9011(99)00027-1; OLIVIER JGJ, 2002, THESIS U UTRECHT NET; Pacala SW, 2001, SCIENCE, V292, P2316, DOI 10.1126/science.1057320; Papale D, 2003, GLOBAL CHANGE BIOL, V9, P525, DOI 10.1046/j.1365-2486.2003.00609.x; Penman J., 2000, IPCC GOOD PRACTICE G; PISARENKO AI, 2000, DEV FOREST RESOURCES; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; Schulze E.D., 2000, CARBON NITROGEN CYCL; Schulze E.D., 1998, IGBP SERIES, P145; Schulze ED, 2000, SCIENCE, V289, P2058, DOI 10.1126/science.289.5487.2058; Shvidenko A, 2002, CLIMATIC CHANGE, V55, P5, DOI 10.1023/A:1020243304744; SLEUTEL S, IN PRESS SOIL USE MA; Smith P, 2000, GLOB CHANGE BIOL, V6, P525, DOI 10.1046/j.1365-2486.2000.00331.x; Stallard RF, 1998, GLOBAL BIOGEOCHEM CY, V12, P231, DOI 10.1029/98GB00741; *TBFRA UN ECE FAO, 2000, TIMB FOR STUD PAP, V17; Valentini R, 2000, NATURE, V404, P861, DOI 10.1038/35009084; Vleeshouwers LM, 2002, GLOBAL CHANGE BIOL, V8, P519, DOI 10.1046/j.1365-2486.2002.00485.x	44	454	522	8	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1538	1542		10.1126/science.1083592	http://dx.doi.org/10.1126/science.1083592			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12764201				2022-12-28	WOS:000183333100045
J	Houston, F; Goldmann, W; Chong, A; Jeffrey, M; Gonzalez, L; Foster, J; Parnham, D; Hunter, N				Houston, F; Goldmann, W; Chong, A; Jeffrey, M; Gonzalez, L; Foster, J; Parnham, D; Hunter, N			Prion diseases: BSE in sheep bred for resistance to infection	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; PRP; SCRAPIE; AGENT; ONSET		Inst Anim Hlth, Newbury RG20 7NN, Berks, England; IAH Neuropathogenesis Unit, Edinburgh EH9 3JF, Midlothian, Scotland; Vet Labs Agcy Lasswade, Penicuik EH26 0PZ, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Houston, F (corresponding author), Inst Anim Hlth, Newbury RG20 7NN, Berks, England.		Jeffrey, Martin/D-2251-2009; González, Lorenzo/A-5325-2010; Houston, Eleanor/A-8036-2011	González, Lorenzo/0000-0003-4199-4526; 				Bossers A, 2000, J VIROL, V74, P1407, DOI 10.1128/JVI.74.3.1407-1414.2000; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; Hope J, 2000, J GEN VIROL, V81, P851, DOI 10.1099/0022-1317-81-3-851; Hunter N, 1997, TRENDS MICROBIOL, V5, P331, DOI 10.1016/S0966-842X(97)01081-0; IKEDA T, 1995, J GEN VIROL, V76, P2577, DOI 10.1099/0022-1317-76-10-2577; Jeffrey M, 2002, J COMP PATHOL, V127, P264, DOI 10.1053/jcpa.2002.0592; Jeffrey M, 2001, J COMP PATHOL, V125, P271, DOI 10.1053/jcpa.2001.0499; Jeffrey M, 2001, J COMP PATHOL, V124, P280, DOI 10.1053/jcpa.2001.0465; Kao RR, 2002, SCIENCE, V295, P332, DOI 10.1126/science.1067475; ORourke KI, 1997, J GEN VIROL, V78, P975, DOI 10.1099/0022-1317-78-4-975; Ryder SJ, 2000, J COMP PATHOL, V122, P131, DOI 10.1053/jcpa.1999.0349; VONKEULEN LJ, 1996, J CLIN MICROBIOL, V34, P1228	12	121	125	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					498	498		10.1038/423498a	http://dx.doi.org/10.1038/423498a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774113				2022-12-28	WOS:000183162900033
J	Mizuguchi, S; Uyama, T; Kitagawa, H; Nomura, KH; Dejima, K; Gengyo-Ando, K; Mitani, S; Sugahara, K; Nomura, K				Mizuguchi, S; Uyama, T; Kitagawa, H; Nomura, KH; Dejima, K; Gengyo-Ando, K; Mitani, S; Sugahara, K; Nomura, K			Chondroitin proteoglycans are involved in cell division of Caenorhabditis elegans	NATURE			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PROTEIN LINKAGE REGION; MOLECULAR-CLONING; IN-VIVO; BIOSYNTHESIS; DROSOPHILA; GLYCOSAMINOGLYCANS; EXPRESSION; INITIATION; ELONGATION	Glycosaminoglycans such as heparan sulphate and chondroitin sulphate are extracellular sugar chains involved in intercellular signalling. Disruptions of genes encoding enzymes that mediate glycosaminoglycan biosynthesis have severe consequences in Drosophila and mice(1-5). Mutations in the Drosophila gene sugarless, which encodes a UDP-glucose dehydrogenase, impair developmental signalling through the Wnt family member Wingless, and signalling by the fibroblast growth factor and Hedgehog pathways. Heparan sulphate is involved in these pathways(6-8), but little is known about the involvement of chondroitin. Undersulphated and oversulphated chondroitin sulphate chains have been implicated in other biological processes, however, including adhesion of erythrocytes infected with malaria parasite to human placenta and regulation of neural development(9,10). To investigate chondroitin functions, we cloned a chondroitin synthase homologue of Caenorhabditis elegans and depleted expression of its product by RNA-mediated interference and deletion mutagenesis. Here we report that blocking chondroitin synthesis results in cytokinesis defects in early embryogenesis. Reversion of cytokinesis is often observed in chondroitin-depleted embryos, and cell division eventually stops, resulting in early embryonic death. Our findings show that chondroitin is required for embryonic cytokinesis and cell division.	Kyushu Univ, Fac Sci 33, Dept Biol, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, SORST, Kawaguchi, Saitama 3320012, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Tokyo Womens Med Univ Sch Med, Dept Physiol, Tokyo 1628666, Japan	Kyushu University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Kobe Pharmaceutical University; Tokyo Women's Medical University	Nomura, K (corresponding author), Kyushu Univ, Fac Sci 33, Dept Biol, Fukuoka 8128581, Japan.	k-sugar@kobepharma-u.ac.jp; knomuscb@mbox.nc.kyushu-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020; Gengyo-Ando, Keiko/B-2753-2012; Gengyo-Ando, Keiko/AAC-4504-2019	Kitagawa, Hiroshi/0000-0002-9307-7079; 				Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; Christensen M, 2001, J BIOL CHEM, V276, P45024, DOI 10.1074/jbc.M107652200; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; Hacker U, 1997, DEVELOPMENT, V124, P3565; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Miller DM, 1995, METHOD CELL BIOL, V48, P365; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	30	194	207	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2003	423	6938					443	448		10.1038/nature01635	http://dx.doi.org/10.1038/nature01635			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761550				2022-12-28	WOS:000183012000043
J	Lecossier, D; Bouchonnet, F; Clavel, F; Hance, AJ				Lecossier, D; Bouchonnet, F; Clavel, F; Hance, AJ			Hypermutation of HIV-1 DNA in the absence of the Vif protein	SCIENCE			English	Article									INSERM, U552, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Hance, AJ (corresponding author), INSERM, U552, Paris, France.							HANCE AJ, UNPUB; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; MARTINEZ MA, 1994, P NATL ACAD SCI USA, V91, P11787, DOI 10.1073/pnas.91.25.11787; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939	5	560	588	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1112	1112		10.1126/science.1083338	http://dx.doi.org/10.1126/science.1083338			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750511				2022-12-28	WOS:000182886500034
J	Staddon, PL; Ramsey, CB; Ostle, N; Ineson, P; Fitter, AH				Staddon, PL; Ramsey, CB; Ostle, N; Ineson, P; Fitter, AH			Rapid turnover of hyphae of mycorrhizal fungi determined by AMS microanalysis of C-14	SCIENCE			English	Article							GLOBAL CLIMATE-CHANGE; PHOSPHORUS INFLOW; UPLAND GRASSLAND; EXTERNAL HYPHAE; ATMOSPHERIC CO2; PLANT-GROWTH; CARBON; SOIL; RADIOCARBON; MYCELIUM	Processes in the soil remain among the least well-characterized components of the carbon cycle. Arbuscular mycorrhizal (AM) fungi are ubiquitous root symbionts in many terrestrial ecosystems and account for a large fraction of photosynthate in a wide range of ecosystems; they therefore play a key role in the terrestrial carbon cycle. A large part of the fungal mycelium is outside the root ( the extraradical mycelium, ERM) and, because of the dispersed growth pattern and the small diameter of the hyphae (<5 micrometers), exceptionally difficult to study quantitatively. Critically, the longevity of these. ne hyphae has never been measured, although it is assumed to be short. To quantify carbon turnover in these hyphae, we exposed mycorrhizal plants to fossil ("carbon-14 - dead") carbon dioxide and collected samples of ERM hyphae ( up to 116 micrograms) over the following 29 days. Analyses of their carbon-14 content by accelerator mass spectrometry (AMS) showed that most ERM hyphae of AM fungi live, on average, 5 to 6 days. This high turnover rate reveals a large and rapid mycorrhizal pathway of carbon in the soil carbon cycle.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ Oxford, Archaeol & Hist Art Res Lab, Radiocarbon Accelerator Unit, Oxford OX1 3QJ, England; Inst Terr Ecol, Merlewood Res Stn, Ctr Ecol & Hydrol, Grange Over Sands LA11 6JU, Cumbria, England	University of York - UK; University of Oxford; UK Centre for Ecology & Hydrology (UKCEH)	Staddon, PL (corresponding author), Riso Natl Lab, Plant Res Dept, Bldg 313,Postbox 49, DK-4000 Roskilde, Denmark.		Ramsey, Christopher Bronk/A-3277-2012; Ostle, Nicholas J/E-4847-2014; Ostle, Nick J/K-6891-2012; Ramsey, Christopher Bronk/AAQ-2227-2021	Ramsey, Christopher Bronk/0000-0002-8641-9309; Ostle, Nicholas J/0000-0003-3263-3702; Ramsey, Christopher Bronk/0000-0002-8641-9309				Atkinson D, 2000, APPL SOIL ECOL, V15, P99, DOI 10.1016/S0929-1393(00)00084-6; Bago B, 1998, NEW PHYTOL, V139, P375, DOI 10.1046/j.1469-8137.1998.00199.x; Bever JD, 2002, PLANT SOIL, V244, P281, DOI 10.1023/A:1020221609080; BRONKRAMSEY C, 1997, NUCL INSTR METHODS P, V123, P539; Cao MK, 1998, NATURE, V393, P249, DOI 10.1038/30460; Fitter AH, 2000, NEW PHYTOL, V147, P179, DOI 10.1046/j.1469-8137.2000.00680.x; Fitter AH, 1997, NEW PHYTOL, V137, P247, DOI 10.1046/j.1469-8137.1997.00804.x; FRIESE CF, 1991, MYCOLOGIA, V83, P409, DOI 10.2307/3760351; Gange A, 2000, TRENDS ECOL EVOL, V15, P369, DOI 10.1016/S0169-5347(00)01940-6; Gaudinski JB, 2001, OECOLOGIA, V129, P420, DOI 10.1007/s004420100746; Hewitt E.J., 1975, PLANT MINERAL NUTR; Hobbie EA, 2002, NEW PHYTOL, V156, P129, DOI 10.1046/j.1469-8137.2002.00496.x; Hodge A, 2001, NATURE, V413, P297, DOI 10.1038/35095041; JAKOBSEN I, 1990, NEW PHYTOL, V115, P77, DOI 10.1111/j.1469-8137.1990.tb00924.x; JAKOBSEN I, 1992, NEW PHYTOL, V120, P371, DOI 10.1111/j.1469-8137.1992.tb01077.x; Johnson D, 2002, NEW PHYTOL, V153, P327, DOI 10.1046/j.0028-646X.2001.00316.x; Johnson D, 2002, SOIL BIOL BIOCHEM, V34, P1521, DOI 10.1016/S0038-0717(02)00126-8; Luo YQ, 2001, NATURE, V413, P622, DOI 10.1038/35098065; Oechel WC, 2000, NATURE, V406, P978, DOI 10.1038/35023137; Ostle N, 2000, RAPID COMMUN MASS SP, V14, P1345, DOI 10.1002/1097-0231(20000815)14:15<1345::AID-RCM22>3.0.CO;2-B; Radajewski S, 2000, NATURE, V403, P646, DOI 10.1038/35001054; Schlesinger WH, 2001, NATURE, V411, P466, DOI 10.1038/35078060; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; Sokal R. R, 1981, BIOMETRY; Staddon PL, 1999, SOIL BIOL BIOCHEM, V31, P1067, DOI 10.1016/S0038-0717(99)00020-6; Staddon PL, 1999, GLOBAL CHANGE BIOL, V5, P347, DOI 10.1046/j.1365-2486.1999.00230.x; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932	27	270	292	12	178	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1138	1140		10.1126/science.1084269	http://dx.doi.org/10.1126/science.1084269			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750519	Green Accepted			2022-12-28	WOS:000182886500043
J	Leucht, S; Wahlbeck, K; Hamann, J; Kissling, W				Leucht, S; Wahlbeck, K; Hamann, J; Kissling, W			New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-manalysis	LANCET			English	Review							CLOZAPINE LEPONEX; CHLORPROMAZINE; SCHIZOPHRENIA; METAANALYSIS; REMOXIPRIDE; EFFICACY; DRUGS; THIORIDAZINE; ZOTEPINE; QUALITY	Background The clearest advantage of new generation, atypical antipsychotics is a reduced risk of extrapyramidal side-effects (EPS), compared with conventional compounds. These findings might have been biased by the use of the high-potency antipsychotic haloperidol as a comparator in most of the trials. We aimed to establish whether the new drugs induce fewer EPS than low-potency conventional antipsychotics. Methods We did a meta-analysis of all randomised controlled trials in which new generation antipsychotics had been compared with low-potency (equivalent or less potent than chlorpromazine) conventional drugs. We included studies that met quality criteria A or B in the Cochrane Collaboration Handbook, and assessed quality with the Jadad scale. The primary outcome of interest was the number of patients who had at least one EPS. We used risk differences and 95% Cls as measures of effect size. Findings We identified 31 studies with a total of 2320 participants. Of the new generation drugs, only clozapine was associated with significantly fewer EPS (RD=-0.15, 95% Cl -0.26 to -0.4, p=0.008) and higher efficacy than low-potency conventional drugs. Reduced frequency of EPS seen with olanzapine was of borderline significance (-0.15, -0.31 to -0.01, p=0.07). Only one inconclusive trial of amisulpride, quetiapine, and risperidone and no investigations of ziprasidone and sertindole were identified, but some evidence indicates that zotepine and remoxipride do not lead to fewer EPS than low-potency antipsychotics. Mean doses less than 600 mg/day of chlorpromazine or its equivalent had no higher risk of EPS than new generation drugs. As a group, new generation drugs were moderately more efficacious than low-potency antipsychotics, largely irrespective of the comparator doses used. Interpretation Optimum doses of low-potency conventional antipsychotics might not induce more EPS than new generation drugs. Potential advantages in efficacy of the new generation drugs should be a factor in clinical treatment decisions to use these rather than conventional drugs.	Tech Univ Munich, Klin & Poliklin Psychiat & Psychotherapie, Klinikum Rechts Isar, D-81675 Munich, Germany; Zucker Hillside Hosp, Glen Oaks, NY 11004 USA; STAKES Natl Res & Dev Ctr Welf & Hlth, Helsinki, Finland	Technical University of Munich; Northwell Health	Leucht, S (corresponding author), Tech Univ Munich, Klin & Poliklin Psychiat & Psychotherapie, Klinikum Rechts Isar, Ismaningerstr 22, D-81675 Munich, Germany.	Stefan.Leucht@Lrz.tum.de	Wahlbeck, Kristian/F-8394-2011; Leucht, Stefan/Y-2408-2019	Wahlbeck, Kristian/0000-0003-3754-3933; Leucht, Stefan/0000-0002-4934-4352				ADAMS CE, 2003, COCHRANE DB SYST REV, V6; BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79; Blin O, 1996, J CLIN PSYCHOPHARM, V16, P38, DOI 10.1097/00004714-199602000-00007; BOLLINI P, 1994, PSYCHOL MED, V24, P307, DOI 10.1017/S003329170002729X; Butler A, 2000, INT J PSYCHIAT CLIN, V4, P19, DOI 10.1080/13651500052048460; CHIU E, 1976, AUST NZ J PSYCHIAT, V10, P343, DOI 10.3109/00048677609159524; CHOUINARD G, 1990, ACTA PSYCHIAT SCAND, V82, P111, DOI 10.1111/j.1600-0447.1990.tb05301.x; CLAGHORN J, 1987, J CLIN PSYCHOPHARM, V7, P377; Clarke M, 2000, COCHRANE LIB; *COCHR COLL, 2002, COCHR LIB; Conley RR, 1998, AM J PSYCHIAT, V155, P914, DOI 10.1176/ajp.155.7.914; Cooper SJ, 2000, ACTA PSYCHIAT SCAND, V101, P218, DOI 10.1046/j.0902-4441.2000.ap90086.x; DAVIS JM, 1989, COMPREHENSIVE TXB PS, P1591; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIETERLE D M, 1991, Fortschritte der Neurologie Psychiatrie, V59, P18, DOI 10.1055/s-2007-1000730; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FISCHERC.K, 1974, ARZNEIMITTEL-FORSCH, V24, P1706; Geddes J, 2000, BRIT MED J, V321, P1371, DOI 10.1136/bmj.321.7273.1371; GELENBERG AJ, 1979, J CLIN PSYCHIAT, V40, P238; GUIRGUIS E, 1977, CURR THER RES CLIN E, V21, P707; Herz MI, 1997, AM J PSYCHIAT, V154, P1; Hong CJ, 1997, INT CLIN PSYCHOPHARM, V12, P123, DOI 10.1097/00004850-199705000-00001; Howanitz E, 1999, J CLIN PSYCHIAT, V60, P41, DOI 10.4088/JCP.v60n0109; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KEKS N, 1994, ACTA PSYCHIAT SCAND, V90, P358, DOI 10.1111/j.1600-0447.1994.tb01607.x; KENNEDY E, 2003, COCHRANE DB SYST REV, V4; KOSTAKOGLU E, 2001, EUR NEUROPSYCHOPHA S, V11, pS369; Leon CA., 1974, REV COLOMB PSIQUIATR, V3, P309; Leucht S, 2002, AM J PSYCHIAT, V159, P180, DOI 10.1176/appi.ajp.159.2.180; LEUCHT S, 2003, IN PRESS AM J PSYCHI; Lieberman JA, 2001, SCHIZOPHR RES, V49, P236; LIU BL, 1994, CHIN J NEUROL PSYCHI, V27, P364; Loza N, 1999, EUR NEUROPSYCHOPHA S, V9, pS291; MCCREADIE RG, 1988, ACTA PSYCHIAT SCAND, V78, P49, DOI 10.1111/j.1600-0447.1988.tb06300.x; NISHIZONO M, 1994, NEUROPSYCHOPHARMAC S, V10, pS30; Peuskens J, 1997, ACTA PSYCHIAT SCAND, V96, P265, DOI 10.1111/j.1600-0447.1997.tb10162.x; PHANJOO AL, 1990, ACTA PSYCHIAT SCAND, V82, P181, DOI 10.1111/j.1600-0447.1990.tb05314.x; POTTER WZ, 1989, PSYCHOPHARMACOLOGY, V99, pS87, DOI 10.1007/BF00442568; RUTHER E, 1988, THERAPIE NEUROLEPTIK, P65; SEEMAN P, 1975, SCIENCE, V188, P1217, DOI 10.1126/science.1145194; SHOPSIN B, 1979, ARCH GEN PSYCHIAT, V36, P657; SINGER K, 1974, J INT MED RES, V2, P433; Thornley B, 1998, BRIT MED J, V317, P1181, DOI 10.1136/bmj.317.7167.1181; WADWORTH AN, 1990, DRUGS, V40, P863, DOI 10.2165/00003495-199040060-00008; WAHLBECK K, 2003, COCHRANE DB SYST REV, V3; WETZEL H, 1991, Fortschritte der Neurologie Psychiatrie, V59, P23, DOI 10.1055/s-2007-1000731; *WHO, 1999, WHO DRUG INFORMATION, V13, P249; Xu WE, 1985, CHINESE J NERVOUS ME, V11, P222	49	386	404	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	2003	361	9369					1581	1589		10.1016/S0140-6736(03)13306-5	http://dx.doi.org/10.1016/S0140-6736(03)13306-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	676HY	12747876				2022-12-28	WOS:000182746300006
J	Maxwell, J; Rosell, S; Forest, PG				Maxwell, J; Rosell, S; Forest, PG			Giving citizens a voice in healthcare policy in Canada	BRITISH MEDICAL JOURNAL			English	Article									Univ Laval, CAAP Dept Sci Polit, Quebec City, PQ G1S 2R3, Canada; Viewpoint Learning Inc, La Jolla, CA 92037 USA; Canadian Policy Res Networks, Ottawa, ON K1S 2B7, Canada	Laval University	Forest, PG (corresponding author), Univ Laval, CAAP Dept Sci Polit, Quebec City, PQ G1S 2R3, Canada.							ABELSON J, IN PRESS SOC SCI MED; Commission on the Future of Health Care in Canada, 2002, BUILD VAL FUT HLTH C; *EK RES ASS, 2002, FUT HLTH CAR CAN GEN; MAXWELL J, 2001, 4 CPRN; Maxwell Judith, 2002, REPORT CITIZENS DIAL; Mendelsohn M., 2001, CANADIANS THOUGHTS T; *NAT FOR HLTH, 1997, CAN HLTH ACT BUILD L, V2; ROSELL S, 2000, CHANGING FRAMES; Rosell Steven A., 1999, RENEWING GOVERNANCE; Yankelovich D, 1999, MAGIC DIALOGUE; Yankelovich D., 1991, COMING PUBLIC JUDGME	11	52	52	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1031	1033		10.1136/bmj.326.7397.1031	http://dx.doi.org/10.1136/bmj.326.7397.1031			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KG	12742930	Green Published			2022-12-28	WOS:000182920500025
J	Groisman, A; Enzelberger, M; Quake, SR				Groisman, A; Enzelberger, M; Quake, SR			Microfluidic memory and control devices	SCIENCE			English	Article							FLOW; DYNAMICS	We demonstrate microscopic fluidic control and memory elements through the use of an aqueous viscoelastic polymer solution as a working fluid. By exploiting the fluid's non-Newtonian rheological properties, we were able to demonstrate both a flux stabilizer and a bistable flip-flop memory. These circuit elements are analogous to their solid-state electronic counterparts and could be used as components of control systems for integrated microfluidic devices. Such miniaturized fluidic circuits are insensitive to electromagnetic interference and may also find medical applications for implanted drug-delivery devices.	CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA	California Institute of Technology	Quake, SR (corresponding author), CALTECH, Dept Appl Phys, MS 128-95, Pasadena, CA 91125 USA.		Groisman, Alexander/AAU-7843-2021					[Anonymous], 1987, DYNAMICS POLYM LIQUI; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; Bird RB, 1987, DYNAMICS POLYMERIC L, V1; Boger D.V., 1993, RHEOLOGICAL PHENOMEN; CARTALOS U, 1992, J NON-NEWTON FLUID, V45, P231, DOI 10.1016/0377-0257(92)85005-H; Foster K., 1970, FLUIDICS COMPONENTS; Groisman A, 2000, NATURE, V405, P53, DOI 10.1038/35011019; HUMPHREY EF, 1965, FLUIDICS; MULLER SJ, 1989, RHEOL ACTA, V28, P499, DOI 10.1007/BF01332920; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; Rothstein JP, 2001, J NON-NEWTON FLUID, V98, P33, DOI 10.1016/S0377-0257(01)00094-5; Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163; TIRTAATMADJA V, 1993, J RHEOL, V37, P1081, DOI 10.1122/1.550372; Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113	14	307	323	7	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					955	958		10.1126/science.1083694	http://dx.doi.org/10.1126/science.1083694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738857				2022-12-28	WOS:000182719800049
J	Venkitaraman, AR				Venkitaraman, AR			A growing network of cancer-susceptibility genes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FANCONI-ANEMIA; BRCA1		Univ Cambridge, Canc Res UK Dept Oncol, MRC, Canc Cell Unit, Cambridge, England	Cancer Research UK; University of Cambridge	Venkitaraman, AR (corresponding author), Univ Cambridge, Canc Res UK Dept Oncol, MRC, Canc Cell Unit, Cambridge, England.							Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	4	47	52	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1917	1919		10.1056/NEJMcibr023150	http://dx.doi.org/10.1056/NEJMcibr023150			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12736286				2022-12-28	WOS:000182684100012
J	Claas, FHJ				Claas, FHJ			Towards clinical transplantation tolerance	LANCET			English	Editorial Material							DISEASE		Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Claas, FHJ (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands.							Buhler LH, 2002, TRANSPLANTATION, V74, P1405, DOI 10.1097/01.TP.0000034627.37442.A4; BURLINGHAM WJ, 1995, TRANSPLANTATION, V59, P1147, DOI 10.1097/00007890-199504270-00013; Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4; Hayden-Martinez K, 2000, J IMMUNOL, V165, P3713, DOI 10.4049/jimmunol.165.7.3713; Hricik DE, 2001, TRANSPLANTATION, V72, pS32; Lan FS, 2000, TRANSPLANTATION, V69, P649, DOI 10.1097/00007890-200002270-00029; SAYEGH MH, 1991, ANN INTERN MED, V114, P954, DOI 10.7326/0003-4819-114-11-954; Smiley ST, 2000, TRANSPLANTATION, V70, P415, DOI 10.1097/00007890-200008150-00005; van Besouw NM, 2000, TRANSPLANTATION, V70, P136; VanBuskirk AM, 2000, J CLIN INVEST, V106, P145, DOI 10.1172/JCI9171; Wu DY, 1999, J IMMUNOL, V162, P6926	11	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1489	1490		10.1016/S0140-6736(03)13220-5	http://dx.doi.org/10.1016/S0140-6736(03)13220-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737855				2022-12-28	WOS:000182658900004
J	Laux, T				Laux, T			The stem cell concept in plants: A matter of debate	CELL			English	Review							SHOOT MERISTEM; ARABIDOPSIS; DIFFERENTIATION; WUSCHEL; GENES; FATE; LOOP	Throughout their life, which can last for over a thousand years, plants have the fascinating ability to give rise to new organs from founder cells in their apical meristems. Whether these founder cells are equivalent to the pluripotent stem cells in animals has been a long-standing controversy amongst plant scientists. Here, this controversy will be addressed in light of classical observations and recent findings.	Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	University of Freiburg	Laux, T (corresponding author), Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany.	laux@biologie.uni-freiburg.de						Brand U, 2002, PLANT PHYSIOL, V129, P565, DOI 10.1104/pp.001867; Brand U, 2000, SCIENCE, V289, P617, DOI 10.1126/science.289.5479.617; Clark SE, 2001, NAT REV MOL CELL BIO, V2, P276, DOI 10.1038/35067079; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Malamy JE, 1997, DEVELOPMENT, V124, P33; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; NEWMAN I. V., 1965, J LINN SOC LONDON BOT, V59, P185; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Schoof H, 2000, CELL, V100, P635, DOI 10.1016/S0092-8674(00)80700-X; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STEWART RN, 1970, AM J BOT, V57, P816, DOI 10.2307/2441339; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387	18	120	138	6	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					281	283		10.1016/S0092-8674(03)00312-X	http://dx.doi.org/10.1016/S0092-8674(03)00312-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732137	Bronze			2022-12-28	WOS:000182640800004
J	McQuibban, GA; Saurya, S; Freeman, M				McQuibban, GA; Saurya, S; Freeman, M			Mitochondrial membrane remodelling regulated by a conserved rhomboid protease	NATURE			English	Article							CYTOCHROME-C PEROXIDASE; DROSOPHILA EGF RECEPTOR; DOMINANT OPTIC ATROPHY; DYNAMIN-RELATED GTPASE; INTERMEMBRANE SPACE; OUTER-MEMBRANE; YEAST; SEQUENCE; FAMILY; GENE	Rhomboid proteins are intramembrane serine proteases that activate epidermal growth factor receptor (EGFR) signalling in Drosophila(1). Rhomboids are conserved throughout evolution(2-5), and even in eukaryotes their existence in species with no EGFRs implies that they must have additional roles. Here we report that Saccharomyces cerevisiae has two rhomboids, which we have named Rbd1p and Rbd2p. RBD1 deletion results in a respiratory defect; consistent with this, Rbd1p is localized in the inner mitochondrial membrane and mutant cells have disrupted mitochondria. We have identified two substrates of Rbd1p: cytochrome c peroxidase (Ccp1p); and a dynamin-like GTPase (Mgm1p), which is involved in mitochondrial membrane fusion(6-10). Rbd1p mutants are indistinguishable from Mgm1p mutants, indicating that Mgm1p is a key substrate of Rbd1p and explaining the rbd1Delta mitochondrial phenotype. Our data indicate that mitochondrial membrane remodelling is regulated by cleavage of Mgm1p and show that intramembrane proteolysis by rhomboids controls cellular processes other than signalling. In addition, mitochondrial rhomboids are conserved throughout eukaryotes and the mammalian homologue, PARL(11), rescues the yeast mutant, suggesting that these proteins represent a functionally conserved subclass of rhomboid proteases.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Freeman, Matthew/0000-0003-0410-5451				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Church C, 1996, J BIOL CHEM, V271, P18499, DOI 10.1074/jbc.271.31.18499; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; DAUM G, 1982, J BIOL CHEM, V257, P3028; Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; Ghiglione C, 2002, DEVELOPMENT, V129, P175; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Guthrie C., 2002, GUIDE YEAST GENETICS; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KAPUT J, 1982, J BIOL CHEM, V257, P5054; Klambt C, 2002, CURR BIOL, V12, pR21, DOI 10.1016/S0960-9822(01)00642-X; Koonin EV, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r19; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Muratsubaki H, 1998, ARCH BIOCHEM BIOPHYS, V352, P175, DOI 10.1006/abbi.1998.0583; Pascall JC, 1998, FEBS LETT, V429, P337, DOI 10.1016/S0014-5793(98)00622-X; Pellegrini L, 2001, J ALZHEIMERS DIS, V3, P181; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Tsruya R, 2002, GENE DEV, V16, P222, DOI 10.1101/gad.214202; Urban S, 2002, EMBO J, V21, P4277, DOI 10.1093/emboj/cdf434; Urban S, 2002, CURR BIOL, V12, P1507, DOI 10.1016/S0960-9822(02)01092-8; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; URBAN S, IN PRESS MOL CELL; Wasserman JD, 2000, GENE DEV, V14, P1651; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yaffe MP, 1999, NAT CELL BIOL, V1, pE149, DOI 10.1038/14101	30	309	323	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					537	541		10.1038/nature01633	http://dx.doi.org/10.1038/nature01633			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774122				2022-12-28	WOS:000183162900043
J	Jabbour, S				Jabbour, S			Health and development in the Arab world: which way forward?	BRITISH MEDICAL JOURNAL			English	Article									Amer Univ Beirut, Fac Hlth Sci, Beirut, Lebanon; Amer Univ Beirut, Fac Med, Beirut, Lebanon	American University of Beirut; American University of Beirut	Jabbour, S (corresponding author), Amer Univ Beirut, Fac Hlth Sci, Beirut, Lebanon.		Jabbour, Samer/Y-6860-2018	Jabbour, Samer/0000-0002-7150-6856				[Anonymous], 2002, LANCET, V359, P1261; Chelala C, 2002, LANCET, V359, P161, DOI 10.1016/S0140-6736(02)07377-4; FREIDMAN TL, 2000, NY TIMES        0403; IVKER R, 1997, LANCET, V349, P38; Kandela P, 1999, LANCET, V354, P1979, DOI 10.1016/S0140-6736(05)76750-7; Popal G R, 2000, East Mediterr Health J, V6, P791; SMITH R, 2003, BMJ, V326; *UN DEV PROGR AR F, 2002, AR HUM DEV REP 2002; *WORLD BANK, 2002, PUBL HLTH MIDDL E N; 2002, FORUM, V9; 2002, WEGHAT NAZAR	11	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1141	1143		10.1136/bmj.326.7399.1141	http://dx.doi.org/10.1136/bmj.326.7399.1141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763995	Green Published			2022-12-28	WOS:000183245000032
J	Ng, HT; Li, J; Smith, MK; Nguyen, P; Cassell, A; Han, J; Meyyappan, M				Ng, HT; Li, J; Smith, MK; Nguyen, P; Cassell, A; Han, J; Meyyappan, M			Growth of epitaxial nanowires at the junctions of nanowalls	SCIENCE			English	Article									NASA, Ctr Nanotechnol, Ames Res Ctr, Moffett Field, CA 94035 USA; NASA, Eloret Corp, Ames Res Ctr, Moffett Field, CA 94035 USA; San Jose State Univ, Dept Chem Engn, San Jose, CA 95192 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California State University System; San Jose State University	Ng, HT (corresponding author), NASA, Ctr Nanotechnol, Ames Res Ctr, Moffett Field, CA 94035 USA.		Li, Jun/H-7771-2013	Li, Jun/0000-0002-3689-8946				Huang MH, 2001, SCIENCE, V292, P1897, DOI 10.1126/science.1060367; Ng HT, 2003, APPL PHYS LETT, V82, P2023, DOI 10.1063/1.1564870; Semiconductor Industry Association, 2001, INT TECHN ROADM SEM; Wu YH, 2002, ADV MATER, V14, P64, DOI 10.1002/1521-4095(20020104)14:1<64::AID-ADMA64>3.0.CO;2-G	4	395	404	0	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1249	1249		10.1126/science.1082542	http://dx.doi.org/10.1126/science.1082542			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764187				2022-12-28	WOS:000183042400036
J	Schenck, CH; Mahowald, MW; Sack, RL				Schenck, CH; Mahowald, MW; Sack, RL			Assessment and management of insomnia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RESTLESS LEGS SYNDROME; LONG-TERM; SLEEP; DISORDERS; PARASOMNIAS; TOLERABILITY; MELATONIN; ZOLPIDEM; EFFICACY; THERAPY		Hennepin Cty Med Ctr, Minnesota Reg Sleep Disorders Ctr, Dept Psychiat 844, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Minnesota Reg Sleep Disorders Ctr, Dept Neurol, Minneapolis, MN 55415 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA	Hennepin County Medical Center; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Oregon Health & Science University	Schenck, CH (corresponding author), Hennepin Cty Med Ctr, Minnesota Reg Sleep Disorders Ctr, Dept Psychiat 844, 701 Pk Ave S, Minneapolis, MN 55415 USA.							Ayas NT, 2003, ARCH INTERN MED, V163, P205, DOI 10.1001/archinte.163.2.205; Burgess HJ, 2002, SLEEP MED REV, V6, P407, DOI 10.1053/smrv.2001.0215; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Dagan Y, 2002, SLEEP MED REV, V6, P45, DOI 10.1053/smrv.2001.0190; Diagnostic Classification Steering Committee American Sleep Disorders Association., 1990, INT CLASS SLEEP DIS; Drewes AM, 2001, SLEEP RES ONLINE, V4, P67; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6; Hajak G, 1998, INT CLIN PSYCHOPHARM, V13, P157, DOI 10.1097/00004850-199807000-00002; Holm KJ, 2000, DRUGS, V59, P865, DOI 10.2165/00003495-200059040-00014; HORNE J A, 1976, International Journal of Chronobiology, V4, P97; Mahowald ML, 2000, SLEEP MED, V1, P179, DOI 10.1016/S1389-9457(00)00029-0; Mahowald MW, 1998, CLIN CHEST MED, V19, P183, DOI 10.1016/S0272-5231(05)70441-X; Marcus DM, 2002, NEW ENGL J MED, V347, P2073, DOI 10.1056/NEJMsb022858; Martinez-Gonzalez D., 2002, PRIM PSYCHIAT, V9, P37; Moul DE, 2002, SLEEP, V25, P553; Nowell PD, 2001, DEPRESS ANXIETY, V14, P7, DOI 10.1002/da.1042; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Ohayon MM, 2003, J PSYCHIAT RES, V37, P9, DOI 10.1016/S0022-3956(02)00052-3; Richard S, 2000, NEUROSURG REV, V23, P1, DOI 10.1007/s101430050024; Sack RL, 1998, ANN MED, V30, P115, DOI 10.3109/07853899808999393; Sateia MJ, 2002, SLEEP MEDICINE, P151; Schenck CH, 2000, POSTGRAD MED, V107, P145, DOI 10.3810/pgm.2000.03.937; Schenck CH, 1996, AM J MED, V100, P333, DOI 10.1016/S0002-9343(97)89493-4; Senior BA, 2001, LARYNGOSCOPE, V111, P2144, DOI 10.1097/00005537-200112000-00012; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; TERMAN M, 2000, PRINCIPLES PRACTICE, P1258; Walters AS, 2001, MOVEMENT DISORD, V16, P1105, DOI 10.1002/mds.1214; Wing Y. K., 2001, Hong Kong Medical Journal, V7, P392; Ziegler G, 2002, EUR J MED RES, V7, P480; Zorick F, 2000, PRINCIPLES PRACTICE, P615	31	44	44	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2475	2479		10.1001/jama.289.19.2475	http://dx.doi.org/10.1001/jama.289.19.2475			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680KL	12759306				2022-12-28	WOS:000182976500001
J	Swift, RM				Swift, RM			Topiramate for the treatment of alcohol dependence: initiating abstinence	LANCET			English	Editorial Material							PREVENTION; RELAPSE		Providence VA Med Ctr, Providence, RI 02908 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Swift, RM (corresponding author), Providence VA Med Ctr, Providence, RI 02908 USA.	Robert_Swift@brown.edu						Brady KT, 2002, DRUG ALCOHOL DEPEN, V67, P323, DOI 10.1016/S0376-8716(02)00105-9; Johnson BA, 2000, JAMA-J AM MED ASSOC, V284, P963, DOI 10.1001/jama.284.8.963; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; LITTLETON J, 1995, ADDICTION, V90, P1179, DOI 10.1046/j.1360-0443.1995.90911793.x; Malcolm R, 2001, AM J ADDICTION, V10, P16, DOI 10.1080/10550490190942489; Mueller TI, 1997, ALCOHOL CLIN EXP RES, V21, P86; Murray C.J.L., 1996, GLOBAL BURDEN DIS CO, P295; Pettinati HM, 2000, ALCOHOL CLIN EXP RES, V24, P1041, DOI 10.1111/j.1530-0277.2000.tb04648.x; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SHAW GK, 1994, BRIT J PSYCHIAT, V165, P515, DOI 10.1192/bjp.165.4.515; SWIFT RM, 1994, AM J PSYCHIAT, V151, P1463	11	17	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1666	1667		10.1016/S0140-6736(03)13378-8	http://dx.doi.org/10.1016/S0140-6736(03)13378-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	679KB	12767727				2022-12-28	WOS:000182919700002
J	Cho, GY; Wu, YT; Ackerman, JL				Cho, GY; Wu, YT; Ackerman, JL			Detection of hydroxyl ions in bone mineral by solid-state NMR spectroscopy	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CALCIUM PHOSPHATES; HYDROXYAPATITE; TEMPERATURE; CARBONATE; CRYSTALS; PHASES; ENAMEL	Previous measurements of the hydroxyl (OH-) ion content of the calcium phosphate crystals of bone mineral have indicated a substantial depletion or near-absence of OH-, despite its presumed status as a constituent of the hydroxyapatite lattice. Analytical methods for determining bone crystal OH content have depended on procedures or assumptions that may have biased the results, such as chemical pretreatment to eliminate interference from the organic matrix. We demonstrate a two-dimensional solid-state nuclear magnetic resonance (NMR) spectroscopy technique that detects the proton spectrum of bone crystals while suppressing the interfering matrix signals, eliminating the need for specimen pretreatment other than cryogenic grinding. Results on fresh-frozen and ground whole bone of several mammalian species show that the bone crystal OH- is readily detectable; a rough estimate yields an OH- content of human cortical bone of about 20% of the amount expected in stoichiometric hydroxyapatite. This finding sheds light on the biochemical processes underlying normal and abnormal bone mineral metabolism.	Massachusetts Gen Hosp, Dept Radiol, NMR Ctr, Biomat Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Dept Orthopaed Surg, Lab Study Skeletal Disorders & Rehabil, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Ackerman, JL (corresponding author), Massachusetts Gen Hosp, Dept Radiol, NMR Ctr, Biomat Lab, Room 2301,149 13th St, Charlestown, MA 02129 USA.		Ackerman, Jerome L./E-2646-2015	Ackerman, Jerome L./0000-0001-5176-7496	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042258] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03264] Funding Source: Medline; NIAMS NIH HHS [AR42258] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARENDS J, 1987, J CRYST GROWTH, V84, P515, DOI 10.1016/0022-0248(87)90284-3; AUE WP, 1984, BIOCHEMISTRY-US, V23, P6110, DOI 10.1021/bi00320a032; BERRY EE, 1967, J INORG NUCL CHEM, V29, P317, DOI 10.1016/0022-1902(67)80033-2; BESHAH K, 1990, J SOLID STATE CHEM, V84, P71, DOI 10.1016/0022-4596(90)90185-Z; BILTZ RM, 1971, CALC TISS RES, V7, P259, DOI 10.1007/BF02062614; BLUMENTHAL NC, 1973, CALC TISS RES, V13, P235, DOI 10.1007/BF02015413; Elliott J. C., 1994, STRUCTURE CHEM APATI; Glimcher M. J, 1998, METABOLIC BONE DIS C, P23, DOI [DOI 10.1007/S10641-010-9735-5, 10.1021/cr60164a001, DOI 10.1016/B978-012068700-8/50003-7]; KIM HM, 1995, J BONE MINER RES, V10, P1589; Loong CK, 2000, BONE, V26, P599, DOI 10.1016/S8756-3282(00)00273-8; Ramanathan C, 1999, MAGNET RESON MED, V41, P1214, DOI 10.1002/(SICI)1522-2594(199906)41:6<1214::AID-MRM18>3.0.CO;2-H; REY C, 1995, BONE, V16, P583, DOI 10.1016/8756-3282(95)00101-I; ROTHWELL WP, 1980, J AM CHEM SOC, V102, P2637, DOI 10.1021/ja00528a020; SANTOS RA, 1994, J MAGN RESON SER B, V105, P183, DOI 10.1006/jmrb.1994.1120; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; TERMINE JD, 1973, CALC TISS RES, V13, P73, DOI 10.1007/BF02013723; TOMAZIC BB, 1993, J BIOMED MATER RES, V27, P217, DOI 10.1002/jbm.820270211; VATASSER.GT, 1970, CALC TISS RES, V5, P183, DOI 10.1007/BF02017547; WU Y, IN PRESS CALCIF TISS; WU YT, 1994, J MOL BIOL, V244, P423, DOI 10.1006/jmbi.1994.1740; Wu YT, 2002, J BONE MINER RES, V17, P472, DOI 10.1359/jbmr.2002.17.3.472; YESINOWSKI JP, 1987, J AM CHEM SOC, V109, P6274, DOI 10.1021/ja00255a009	22	234	243	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1123	1127		10.1126/science.1078470	http://dx.doi.org/10.1126/science.1078470			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750514				2022-12-28	WOS:000182886500038
J	Ledingham, KWD; McKenna, P; Singhal, RP				Ledingham, KWD; McKenna, P; Singhal, RP			Applications for nuclear phenomena generated by ultra-intense lasers	SCIENCE			English	Review							HIGH-ENERGY ELECTRONS; PROTON-BEAMS; HEAVY-ION; PLASMA; PULSE; EXCITATION; TRANSITION; DRIVEN; ACCELERATION; PHYSICS	The amplification of laser light to generate powers large enough to affect the nucleus has been the desire of scientists since the invention of the laser 40 years ago. Many lasers, including tabletop varieties, now have pulse powers greater than the electrical power generated by all the world's power plants combined. When this power is focused to dimensions of a few microns, laser-driven nuclear phenomena can occur. Here we review the developments in this research field and describe the potential of laser-produced proton, neutron, and heavy ion beams, together with isotope and isomer production.	Univ Strathclyde, Dept Phys, Glasgow G4 0NG, Lanark, Scotland; Univ Glasgow, Dept Phys & Astron, Glasgow G12 8QQ, Lanark, Scotland; Atom Weap Estab, Reading RG7 4PR, Berks, England	University of Strathclyde; University of Glasgow	Ledingham, KWD (corresponding author), Univ Strathclyde, Dept Phys, Glasgow G4 0NG, Lanark, Scotland.		McKenna, Paul/B-9764-2009; McKenna, Paul/P-5259-2019	McKenna, Paul/0000-0001-8061-7091; McKenna, Paul/0000-0001-8061-7091				Andreev AV, 2001, QUANTUM ELECTRON+, V31, P941, DOI 10.1070/QE2001v031n11ABEH002081; Andreev AV, 2000, J EXP THEOR PHYS+, V91, P1163, DOI 10.1134/1.1342882; Badziak J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.215001; BOYER K, 1988, PHYS REV LETT, V60, P557, DOI 10.1103/PhysRevLett.60.557; Bulanov SV, 2002, PHYS LETT A, V299, P240, DOI 10.1016/S0375-9601(02)00521-2; Carroll JJ, 2001, HYPERFINE INTERACT, V135, P3, DOI 10.1023/A:1013967219408; Clark EL, 2000, PHYS REV LETT, V84, P670, DOI 10.1103/PhysRevLett.84.670; Clark EL, 2000, PHYS REV LETT, V85, P1654, DOI 10.1103/PhysRevLett.85.1654; Cowan TE, 1999, LASER PART BEAMS, V17, P773, DOI 10.1017/S0263034699174238; Cowan TE, 2000, PHYS REV LETT, V84, P903, DOI 10.1103/PhysRevLett.84.903; DUBIETIS A, 1992, OPT COMMUN, V88, P437, DOI 10.1016/0030-4018(92)90070-8; Esirkepov TZ, 1999, JETP LETT+, V70, P82, DOI 10.1134/1.568134; Esirkepov TZ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.175003; FLOUX F, 1970, PHYS REV A, V1, P821, DOI 10.1103/PhysRevA.1.821; FRITZLER S, IN PRESS; GALY J, 2002, CENTRAL LASER FACILI, P29; GALY J, 2002, P 11 INT C EM NUCL E, P347; Hatchett SP, 2000, PHYS PLASMAS, V7, P2076, DOI 10.1063/1.874030; Hegelich M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.085002; IZAWA Y, 1979, PHYS LETT B, V88, P59, DOI 10.1016/0370-2693(79)90113-8; KEKEZ D, 1985, PHYS REV LETT, V55, P1366, DOI 10.1103/PhysRevLett.55.1366; Krushelnick K, 2000, IEEE T PLASMA SCI, V28, P1184, DOI 10.1109/27.893296; Ledingham KWD, 2000, PHYS REV LETT, V84, P899, DOI 10.1103/PhysRevLett.84.899; Letokhov V. S., 1974, Soviet Journal of Quantum Electronics, V3, P360, DOI 10.1070/QE1974v003n04ABEH005524; Mackinnon AJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.215006; Malka V, 2002, SCIENCE, V298, P1596, DOI 10.1126/science.1076782; McKenna P, 2002, REV SCI INSTRUM, V73, P4176, DOI 10.1063/1.1516855; MCKENNA PB, IN PRESS; MORITA M, 1973, PROG THEOR PHYS, V49, P1574, DOI 10.1143/PTP.49.1574; Norreys PA, 1999, PHYS PLASMAS, V6, P2150, DOI 10.1063/1.873466; OTOZAI K, 1973, PROG THEOR PHYS, V50, P1771, DOI 10.1143/PTP.50.1771; Perkins LJ, 2000, NUCL FUSION, V40, P1, DOI 10.1088/0029-5515/40/1/301; Phillips TW, 1999, REV SCI INSTRUM, V70, P1213, DOI 10.1063/1.1149337; Ross IN, 1999, LASER PART BEAMS, V17, P331, DOI 10.1017/S0263034699172203; Santala MIK, 2000, PHYS REV LETT, V84, P1459, DOI 10.1103/PhysRevLett.84.1459; Schwoerer H, 2003, EUROPHYS LETT, V61, P47, DOI 10.1209/epl/i2003-00243-1; Snavely RA, 2000, PHYS REV LETT, V85, P2945, DOI 10.1103/PhysRevLett.85.2945; Spencer I, 2002, REV SCI INSTRUM, V73, P3801, DOI 10.1063/1.1511802; Spencer I, 2001, NUCL INSTRUM METH B, V183, P449, DOI 10.1016/S0168-583X(01)00771-6; Stoyer MA, 2001, REV SCI INSTRUM, V72, P767, DOI 10.1063/1.1319355; STRICKLAND D, 1985, OPT COMMUN, V56, P219, DOI 10.1016/0030-4018(85)90120-8; Tajima T, 2002, PHYS REV SPEC TOP-AC, V5, DOI 10.1103/PhysRevSTAB.5.031301; TAJIMA T, 1979, PHYS REV LETT, V43, P267, DOI 10.1103/PhysRevLett.43.267; TAKABE H, 2001, J PLASMA FUSION RES, V77, P1097; Umstadter D, 2001, PHYS PLASMAS, V8, P1774, DOI 10.1063/1.1364515; Zepf M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.064801; Zweiback J, 2000, PHYS REV LETT, V85, P3640, DOI 10.1103/PhysRevLett.85.3640	47	314	319	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2003	300	5622					1107	1111		10.1126/science.1080552	http://dx.doi.org/10.1126/science.1080552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750510				2022-12-28	WOS:000182886500033
J	Stevenson, DJ				Stevenson, DJ			Mission to Earth's core - a modest proposal	NATURE			English	Article									CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Stevenson, DJ (corresponding author), CALTECH, Pasadena, CA 91125 USA.							ANDERSON DL, 1982, J GEOPHYS RES, V87, P3893, DOI 10.1029/JB087iB05p03893; Landau L. D., 1976, MECHANICS, V1; SCHUBERT G, 2001, MANTLE CONVECTION EA, P166; TURCOTTE DL, 1983, J GEOPHYS RES, V88, pB91, DOI [10.1029/JB088iS01p00B91, 10.1029/JB088iS02p0A585]; WEERTMAN J, 1971, J GEOPHYS RES, V76, P1171, DOI 10.1029/JB076i005p01171	5	21	21	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					239	240		10.1038/423239a	http://dx.doi.org/10.1038/423239a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748631				2022-12-28	WOS:000182853100031
J	Douek, M; Smith, G; Oshowo, A; Stoker, DL; Wellwood, JM				Douek, M; Smith, G; Oshowo, A; Stoker, DL; Wellwood, JM			Prospective randomised controlled trial of laparoscopic versus open inguinal hernia mesh repair: five year follow up	BRITISH MEDICAL JOURNAL			English	Article							GROIN HERNIA		N Middlesex Univ Hosp, Dept Surg, London N18 1QX, England; Whipps Cross Univ Hosp, Dept Surg, London E11 1NR, England; UCL Royal Free & Univ Coll Med Sch, Dept Surg, London W1W 7EJ, England	University of London; Queen Mary University London; University of London; University College London; UCL Medical School	Stoker, DL (corresponding author), N Middlesex Univ Hosp, Dept Surg, London N18 1QX, England.							Grant A, 2000, BRIT J SURG, V87, P860, DOI 10.1046/j.1365-2168.2000.01540.x; Grant AM, 2002, ANN SURG, V235, P322; National Institute for Clinical Excellence, 2001, GUID US LAP SURG ING; STOKER D, 1994, LANCET, V343, P1243, DOI 10.1016/S0140-6736(94)92148-2; Wellwood J, 1998, BRIT MED J, V317, P103, DOI 10.1136/bmj.317.7151.103	5	92	97	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1012	1013		10.1136/bmj.326.7397.1012	http://dx.doi.org/10.1136/bmj.326.7397.1012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KG	12742923	Bronze, Green Published			2022-12-28	WOS:000182920500017
J	Chen, Y; Au, J; Kazlas, P; Ritenour, A; Gates, H; McCreary, M				Chen, Y; Au, J; Kazlas, P; Ritenour, A; Gates, H; McCreary, M			Flexible active-matrix electronic ink display	NATURE			English	Article							TRANSISTORS; PAPER		E Ink Corp, Cambridge, MA 02138 USA	E Ink Corporation	Chen, Y (corresponding author), E Ink Corp, 733 Concord Ave, Cambridge, MA 02138 USA.			Ritenour, Andrew/0000-0002-7370-0273				Baeuerie R., 1999, Society for Information Display 1999 International Symposium, P14; CHEN Y, 2001, SID, P157; Comiskey B, 1998, NATURE, V394, P253, DOI 10.1038/28349; Huitema HEA, 2001, NATURE, V414, P599, DOI 10.1038/414599a; Kane MG, 2000, IEEE ELECTR DEVICE L, V21, P534, DOI 10.1109/55.877202; Polach S., 2000, IDW '00. Proceedings of the Seventh International Display Workshops, P203; Rogers JA, 2001, P NATL ACAD SCI USA, V98, P4835, DOI 10.1073/pnas.091588098; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; Suo Z, 1999, APPL PHYS LETT, V74, P1177, DOI 10.1063/1.123478; Theiss SD, 1997, MATER RES SOC SYMP P, V424, P65, DOI 10.1557/PROC-424-65	10	492	551	9	220	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					136	136		10.1038/423136a	http://dx.doi.org/10.1038/423136a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736673	Bronze			2022-12-28	WOS:000182699600034
J	Schwarz-Linek, U; Werner, JM; Pickford, AR; Gurusiddappa, S; Kim, JH; Pilka, ES; Briggs, JAG; Gough, TS; Hook, M; Campbell, ID; Potts, JR				Schwarz-Linek, U; Werner, JM; Pickford, AR; Gurusiddappa, S; Kim, JH; Pilka, ES; Briggs, JAG; Gough, TS; Hook, M; Campbell, ID; Potts, JR			Pathogenic bacteria attach to human fibronectin through a tandem beta-zipper	NATURE			English	Article							F1 MODULE PAIR; STAPHYLOCOCCUS-AUREUS; BINDING-PROTEIN; STREPTOCOCCUS-PYOGENES; MEDIATE ADHERENCE; CHEMICAL-SHIFT; NMR; SEQUENCE; DYSGALACTIAE; RESIDUES	Staphylococcus aureus and Streptococcus pyogenes, two important human pathogens, target host fibronectin (Fn) in their adhesion to and invasion of host cells(1,2). Fibronectin-binding proteins (FnBPs), anchored in the bacterial cell wall, have multiple Fn-binding repeats(3) in an unfolded(4,5) region of the protein. The bacterium-binding site in the amino-terminal domain ((1-5)F1) of Fn contains five sequential Fn type 1 (F1) modules. Here we show the structure of a streptococcal (S. dysgalactiae) FnBP peptide (B3)(6,7) in complex with the module pair (1)F1(2)F1. This identifies (1)F1-and (2)F1-binding motifs in B3 that form additional antiparallel beta-strands on sequential F1 modules-the first example of a tandem beta-zipper. Sequence analyses of larger regions of FnBPs from S. pyogenes and S. aureus reveal a repeating pattern of F1-binding motifs that match the pattern of F1 modules in (1-5)F1 of Fn. In the process of Fn-mediated invasion of host cells, therefore, the bacterial proteins seem to exploit the modular structure of Fn by forming extended tandem beta-zippers. This work is a vital step forward in explaining the full mechanism of the integrin-dependent(2,8) FnBP-mediated invasion of host cells.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Texas A&M Univ Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Univ Oxford, Cent Chem Lab, Oxford Ctr Mol Sci, Oxford OX1 3QH, England	University of Oxford; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Oxford	Potts, JR (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	jennifer.potts@bioch.ox.ac.uk	Briggs, John/J-3096-2012; Pickford, Andy/AGB-6901-2022; Werner, Joern/E-1148-2013	Schwarz-Linek, Ulrich/0000-0003-0526-223X; Werner, Jorn/0000-0002-4712-1833; Pickford, Andy/0000-0002-7237-0030; Briggs, John/0000-0003-3990-6910				Brunger A.T., 1993, X PLOR VERSION 3 1 S; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DERRICK JP, 1992, NATURE, V359, P752, DOI 10.1038/359752a0; GREENE C, 1995, MOL MICROBIOL, V17, P1143, DOI 10.1111/j.1365-2958.1995.mmi_17061143.x; Hashimoto Y, 2000, J BIOMOL NMR, V17, P203, DOI 10.1023/A:1008341609461; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; HUFF S, 1994, J BIOL CHEM, V269, P15563; Ing M, 1997, STAPHYLOCOCCI HUMAN, P331; Jaffe J, 1996, MOL MICROBIOL, V21, P373, DOI 10.1046/j.1365-2958.1996.6331356.x; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Knodler LA, 2001, NAT REV MOL CELL BIO, V2, P578, DOI 10.1038/35085062; Massey RC, 2001, CELL MICROBIOL, V3, P839, DOI 10.1046/j.1462-5822.2001.00157.x; MCGAVIN MJ, 1993, J BIOL CHEM, V268, P23946; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Peacock SJ, 1999, MICROBIOL-SGM, V145, P3477, DOI 10.1099/00221287-145-12-3477; Penkett CJ, 2000, BIOCHEMISTRY-US, V39, P2887, DOI 10.1021/bi992267k; Penkett CJ, 1998, BIOCHEMISTRY-US, V37, P17054, DOI 10.1021/bi9814080; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; Sass HJ, 2000, J BIOMOL NMR, V18, P303, DOI 10.1023/A:1026703605147; Schwarz-Linek U, 2001, FEBS LETT, V497, P137, DOI 10.1016/S0014-5793(01)02418-8; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010	30	296	308	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					177	181		10.1038/nature01589	http://dx.doi.org/10.1038/nature01589			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736686				2022-12-28	WOS:000182699600048
J	DeWitt, DE; Hirsch, IB				DeWitt, DE; Hirsch, IB			Outpatient insulin therapy in type 1 and type 2 diabetes mellitus - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BLOOD-GLUCOSE CONTROL; BEDTIME NPH INSULIN; SECONDARY SULFONYLUREA FAILURE; IMPROVED GLYCEMIC CONTROL; GLARGINE HOE 901; BASAL INSULIN; DOUBLE-BLIND; NOCTURNAL HYPOGLYCEMIA; ACTING INSULIN; DEPENDENT DIABETICS	Context Newer insulin therapies, including the concept of physiologic basal-prandial insulin and the availability of insulin analogues, are changing clinical diabetes care. The key to effective insulin therapy is an understanding of principles that, when implemented, can result in improved diabetes control. Objective To systematically review the literature regarding insulin use in patients with type 1 and type 2 diabetes mellitus (DM). Data Sources A MEDLINE search was performed to identify all English-language articles of randomized controlled trials involving insulin use in adults with type 1 or type 2 DM from January 1, 1980, to January 8, 2003. Bibliographies and experts were used to identify additional studies. Study Selection and Data Extraction Studies were included (199 for type 1 DM and 144 for type 2 DM, and 38 from other sources) if they involved human insulins or insulin analogues, were at least 4 weeks long with at least 10 patients in each group, and glycemic control and hypoglycemia were reported. Studies of insulin-oral combination were similarly selected. Data Synthesis Twenty-eight studies for type 1 DM, 18 for type 2 DM, and 48 for insulin-oral combination met the selection criteria. In patients with type 1 DM, physiologic replacement, with bedtime basal insulin and a mealtime rapid-acting insulin analogue, results in fewer episodes of hypoglycemia than conventional regimens. Rapid-acting insulin analogues are preferred over regular insulin in patients with type 1 DM since they improve HbA(1c) and reduce episodes of hypoglycemia. In patients with type 2 DM, adding bedtime neutral protamine Hagedorn (isophane) insulin to oral therapy significantly improves glycemic control, especially when started early in the course of disease. Bedtime use of insulin glargine results in fewer episodes of nighttime hypoglycemia than neutral protamine Hagedorn regimens. For patients with more severe insulin deficiency, a physiologic insulin regimen should allow lower glycemic targets in the majority of patients. Adverse events associated with insulin therapy include hypoglycemia, weight gain, and worsening diabetic retinopathy if hemoglobin A(1c) levels decrease rapidly. Conclusions Many options for insulin therapy are now available. Physiologic insulin therapy with insulin analogues is now relatively simple to use and is associated with fewer episodes of hypoglycemia.	Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA; Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Diabet Care Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	DeWitt, DE (corresponding author), Univ Melbourne, Rural Clin Sch, POB 6500, Shepparton, Vic 3632, Australia.	ddewitt@unimelb.edu.au	DeWitt, Dawn E/ABX-0983-2022	DeWitt, Dawn E/0000-0002-9352-3104				ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; Abraira C, 1998, DIABETES CARE, V21, P574, DOI 10.2337/diacare.21.4.574; *AM DIAB ASS, 2002, PRACT INS HDB PRESCR; American Diabetes Association, 1999, DIABETES CARE, V22, pS1; Amiel S, 2002, BRIT MED J, V325, P746, DOI 10.1136/bmj.325.7367.746; Annuzzi G, 2001, NUTR METAB CARDIOVAS, V11, P168; Aviles-Santa L, 1999, ANN INTERN MED, V131, P182, DOI 10.7326/0003-4819-131-3-199908030-00004; BACHMANN W, 1988, DEUT MED WOCHENSCHR, V113, P631, DOI 10.1055/s-2008-1067696; Bastyr EJ, 2000, DIABETES OBES METAB, V2, P39, DOI 10.1046/j.1463-1326.2000.00066.x; Bastyr EJ, 1999, CLIN THER, V21, P1703, DOI 10.1016/S0149-2918(99)80049-6; Bastyr EJ, 2000, DIABETES CARE, V23, P1236, DOI 10.2337/diacare.23.9.1236; Biermann E, 2000, ST HEAL T, V77, P327; Bode BW, 2002, DIABETES-METAB RES, V18, pS14, DOI 10.1002/dmrr.205; Bode BW, 2001, DIABETES CARE, V24, P69, DOI 10.2337/diacare.24.1.69; Boehm BO, 2002, DIABETIC MED, V19, P393, DOI 10.1046/j.1464-5491.2002.00733.x; Bolli GB, 2000, LANCET, V356, P443, DOI 10.1016/S0140-6736(00)02546-0; Brunelle RL, 1998, DIABETES CARE, V21, P1726, DOI 10.2337/diacare.21.10.1726; CASNER PR, 1988, CLIN PHARMACOL THER, V44, P594, DOI 10.1038/clpt.1988.199; Chantelau E, 1997, BMJ-BRIT MED J, V315, P1105; Chen H S, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P455; CHIASSON JL, 1994, ANN INTERN MED, V121, P928, DOI 10.7326/0003-4819-121-12-199412150-00004; CHOW CC, 1995, DIABETES CARE, V18, P307, DOI 10.2337/diacare.18.3.307; Clauson P, 1996, DIABETIC MED, V13, P471; Colombel A, 1999, DIABETIC MED, V16, P319, DOI 10.1046/j.1464-5491.1999.00077.x; Colwell JA, 1996, ANN INTERN MED, V124, P131, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00010; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; Daniels AR, 1997, NEW ZEAL MED J, V110, P435; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; Del Sindaco P, 1998, DIABETIC MED, V15, P592; Delea T, 2002, J AM COLL CARDIOL, V39, p184A; Diabet Control Complications Trial Res Grp, 1998, ANN INTERN MED, V128, P517, DOI 10.7326/0003-4819-128-7-199804010-00001; DUNBAR JM, 1994, DIABETES CARE, V17, P874, DOI 10.2337/diacare.17.8.874; FALKO JM, 1985, AM J MED, V79, P92, DOI 10.1016/S0002-9343(85)80014-0; Fanelli CG, 2002, ANN INTERN MED, V136, P504, DOI 10.7326/0003-4819-136-7-200204020-00007; Feinglos MN, 1998, DIABETES RES CLIN PR, V39, P193, DOI 10.1016/S0168-8227(98)00003-5; Ferguson SC, 2001, DIABETES-METAB RES, V17, P285, DOI 10.1002/dmrr.202; Franciosi M, 2001, DIABETES CARE, V24, P1870, DOI 10.2337/diacare.24.11.1870; FRANCIS AJ, 1983, BRIT MED J, V286, P1173, DOI 10.1136/bmj.286.6372.1173; FRAZIER LM, 1987, ARCH INTERN MED, V147, P1085, DOI 10.1001/archinte.147.6.1085; Fritsche A, 2000, ACTA DIABETOL, V37, P13, DOI 10.1007/s005920070030; Fritsche A, 2002, DIABETES, V51, pA54; Gabbe SG, 2000, AM J OBSTET GYNECOL, V182, P1283, DOI 10.1067/mob.2000.106182; Gale EAM, 2000, DIABETIC MED, V17, P209; GALLOWAY JA, 1973, DIABETES, V22, P471, DOI 10.2337/diab.22.6.471; Gray A, 2000, BMJ-BRIT MED J, V320, P1373, DOI 10.1136/bmj.320.7246.1373; GROOP L, 1991, DIABETES METAB, V17, P218; GROOP L, 1985, ACTA MED SCAND, V217, P33; GROOP L, 1984, ACTA ENDOCRINOL-COP, V106, P97, DOI 10.1530/acta.0.1060097; GROOP LC, 1992, DIABETES CARE, V15, P831, DOI 10.2337/diacare.15.7.831; GUTNIAK M, 1987, DIABETES CARE, V10, P545, DOI 10.2337/diacare.10.5.545; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; Heller SR, 1999, DIABETES CARE, V22, P1607, DOI 10.2337/diacare.22.10.1607; HELVE E, 1987, ACTA ENDOCRINOL-COP, V115, P313, DOI 10.1530/acta.0.1150313; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; Holleman F, 1997, DIABETES CARE, V20, P1827, DOI 10.2337/diacare.20.12.1827; HOLMAN RR, 1987, DIABETIC MED, V4, P457, DOI 10.1111/j.1464-5491.1987.tb00909.x; Holmboe ES, 2002, JAMA-J AM MED ASSOC, V287, P373, DOI 10.1001/jama.287.3.373; Home PD, 2000, DIABETIC MED, V17, P762, DOI 10.1046/j.1464-5491.2000.00380.x; Home PD, 1998, DIABETES CARE, V21, P1904, DOI 10.2337/diacare.21.11.1904; *INS ADM, 2000, DIABETES CARE S1, V23, pS86; Inzucchi SE, 2002, JAMA-J AM MED ASSOC, V287, P360, DOI 10.1001/jama.287.3.360; Jehle PM, 1999, LANCET, V354, P1604, DOI 10.1016/S0140-6736(98)12459-5; JENNINGS AM, 1991, DIABETES CARE, V14, P738, DOI 10.2337/diacare.14.8.738; Johnson JA, 2002, DIABETES CARE, V25, P2244, DOI 10.2337/diacare.25.12.2244; Juneja R, 2001, METABOLISM, V50, P1008, DOI 10.1053/meta.2001.25654; Kalergis M, 2000, DIABETES OBES METAB, V2, P299, DOI 10.1046/j.1463-1326.2000.00107.x; Kelley DE, 1998, DIABETES CARE, V21, P2056, DOI 10.2337/diacare.21.12.2056; Kelly JL, 2002, DIABETES, V51, pA123; KITABCHI AE, 1987, AM J MED SCI, V294, P10, DOI 10.1097/00000441-198707000-00002; KLEIN W, 1991, DIABETES METAB, V17, P235; Lalli C, 1999, DIABETES CARE, V22, P468, DOI 10.2337/diacare.22.3.468; LANDSTEDTHALLIN L, 1995, DIABETES CARE, V18, P1183, DOI 10.2337/diacare.18.8.1183; LAWRENCE AM, 1988, AM J MED, V85, P153, DOI 10.1016/0002-9343(88)90409-3; LEAN MEJ, 1985, BRIT MED J, V290, P105, DOI 10.1136/bmj.290.6462.105; Lebovitz HE, 1999, DIABETES REV, V7, P139; LEWITT MS, 1989, DIABETES CARE, V12, P379, DOI 10.2337/diacare.12.6.379; Linn T, 1996, METABOLISM, V45, P1508, DOI 10.1016/S0026-0495(96)90180-8; LINS PE, 1988, ACTA MED SCAND, V223, P171; Lopez-Alvarenga JC, 1999, DIABETES OBES METAB, V1, P29, DOI 10.1046/j.1463-1326.1999.00007.x; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MAUERHOFF T, 1986, DIABETES METAB, V12, P34; Melki V, 1998, DIABETES CARE, V21, P977, DOI 10.2337/diacare.21.6.977; Murphy NP, 2002, DIABETES, V51, pA54; MURRAY DP, 1988, DIABETIC MED, V5, P750, DOI 10.1111/j.1464-5491.1988.tb01102.x; Nathan DM, 2001, DIABETES CARE, V24, P1711; Niazi R, 1998, J Pak Med Assoc, V48, P336; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; OSEI K, 1984, AM J MED, V77, P1002, DOI 10.1016/0002-9343(84)90179-7; Palmer JP, 2003, DIABETES CARE, V26, P536, DOI 10.2337/diacare.26.2.536; PATERSON KR, 1991, DIABETIC MED, V8, P40, DOI 10.1111/j.1464-5491.1991.tb01514.x; PETERS A, 1991, DIABETES CARE, V14, P875, DOI 10.2337/diacare.14.10.875; Petersen M, 2003, DIABETES CARE, V26, P917; Pfutzner A, 1996, EXP CLIN ENDOCR DIAB, V104, P25; Pickup J, 2002, BMJ-BRIT MED J, V324, P705, DOI 10.1136/bmj.324.7339.705; Pieber TR, 2000, DIABETES CARE, V23, P157, DOI 10.2337/diacare.23.2.157; Ponssen HH, 2000, CLIN THER, V22, P709, DOI 10.1016/S0149-2918(00)90005-5; Porcellati F, 2002, DIABETES, V51, pA53; QUATRARO A, 1986, DIABETES METAB, V12, P315; Rabasa-Lhoret R, 2001, DIABETES CARE, V24, P625, DOI 10.2337/diacare.24.4.625; Raskin P, 2000, DIABETES CARE, V23, P1666, DOI 10.2337/diacare.23.11.1666; Raskin P, 2001, J DIABETES COMPLICAT, V15, P295, DOI 10.1016/S1056-8727(01)00168-4; Ratner RE, 2000, DIABETES CARE, V23, P639, DOI 10.2337/diacare.23.5.639; RavnikOblak M, 1995, DIABETES RES CLIN PR, V30, P27, DOI 10.1016/0168-8227(95)01137-4; REICH A, 1987, DIABETES RES CLIN EX, V6, P99; Relimpio F, 1998, DIABETIC MED, V15, P997, DOI 10.1002/(SICI)1096-9136(1998120)15:12<997::AID-DIA716>3.0.CO;2-B; Renner R, 1999, DIABETES CARE, V22, P784, DOI 10.2337/diacare.22.5.784; RIDDLE M, 1992, AM J MED SCI, V303, P151, DOI 10.1097/00000441-199203000-00003; Riddle MC, 1998, DIABETES CARE, V21, P1052, DOI 10.2337/diacare.21.7.1052; Riddle MC, 2002, DIABETES, V51, pA113; RIDDLE MC, 1989, DIABETES CARE, V12, P623, DOI 10.2337/diacare.12.9.623; Rivellese AA, 2000, J CLIN ENDOCR METAB, V85, P4188, DOI 10.1210/jc.85.11.4188; Roach P, 2001, INT J CLIN PRACT, V55, P177; Robinson AC, 1998, DIABETES CARE, V21, P701, DOI 10.2337/diacare.21.5.701; RODIER M, 1995, DIABETES RES CLIN PR, V28, P19, DOI 10.1016/0168-8227(95)96798-8; Romano G, 1997, DIABETES, V46, P1601, DOI 10.2337/diabetes.46.10.1601; ROPER ASW, 2002, US DIABETES PATIENT; Rosenstock J, 2001, DIABETES CARE, V24, P631, DOI 10.2337/diacare.24.4.631; Rosenstock J, 2000, DIABETES CARE, V23, P1137, DOI 10.2337/diacare.23.8.1137; Rossetti P, 2002, DIABETES, V51, pA54; Saaddine JB, 2002, ANN INTERN MED, V136, P565, DOI 10.7326/0003-4819-136-8-200204160-00005; SACKEY AH, 1994, ARCH DIS CHILD, V71, P248, DOI 10.1136/adc.71.3.248; SAMANTA A, 1987, DIABETES RES CLIN EX, V4, P183; Saudek CD, 1996, JAMA-J AM MED ASSOC, V276, P1322, DOI 10.1001/jama.276.16.1322; SAURBREY N, 1988, DIABETIC MED, V5, P150, DOI 10.1111/j.1464-5491.1988.tb00962.x; SCHADE DS, 1987, JAMA-J AM MED ASSOC, V257, P2441, DOI 10.1001/jama.257.18.2441; Schrezenmeir J, 2002, COMPUT METH PROG BIO, V69, P97, DOI 10.1016/S0169-2607(02)00034-2; SEIGLER DE, 1992, DIABETIC MED, V9, P826; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHANK ML, 1995, DIABETES, V44, P165, DOI 10.2337/diabetes.44.2.165; Shichiri M, 2000, DIABETES CARE, V23, pB21; SMALL M, 1988, DIABETES RES CLIN EX, V8, P85; SONERU IL, 1993, DIABETES CARE, V16, P896, DOI 10.2337/diacare.16.6.896; Stades AME, 2002, DIABETES CARE, V25, P712, DOI 10.2337/diacare.25.4.712; STENMAN S, 1988, DIABETOLOGIA, V31, P206, DOI 10.1007/BF00290586; Strowig SM, 2002, DIABETES CARE, V25, P1691, DOI 10.2337/diacare.25.10.1691; Tabak AG, 2000, DIABETES CARE, V23, P1284, DOI 10.2337/diacare.23.9.1284; Tamas G, 2001, DIABETES RES CLIN PR, V54, P105, DOI 10.1016/S0168-8227(01)00262-5; TAYLOR R, 1994, DIABETIC MED, V11, P551, DOI 10.1111/j.1464-5491.1994.tb02034.x; Taylor R, 2000, DIABETES CARE, V23, P1612, DOI 10.2337/diacare.23.11.1612; Thompson DM, 1999, CAN MED ASSOC J, V161, P959; TINDALL H, 1988, DIABETIC MED, V5, P533, DOI 10.1111/j.1464-5491.1988.tb01046.x; TRISCHITTA V, 1992, DIABETES CARE, V15, P539, DOI 10.2337/diacare.15.4.539; Tsui E, 2001, DIABETES CARE, V24, P1722, DOI 10.2337/diacare.24.10.1722; TUNBRIDGE FKE, 1989, DIABETIC MED, V6, P496, DOI 10.1111/j.1464-5491.1989.tb01216.x; TUOMINEN JA, 1995, DIABETOLOGIA, V38, P106, DOI 10.1007/BF02369359; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Van der Does FEE, 1998, DIABETES CARE, V21, P2085, DOI 10.2337/diacare.21.12.2085; Vignati L, 1997, CLIN THER, V19, P1408, DOI 10.1016/S0149-2918(97)80014-8; VIGNERI R, 1991, DIABETES METAB, V17, P232; Wake N, 2000, DIABETES RES CLIN PR, V48, P201, DOI 10.1016/S0168-8227(00)00122-4; Witthaus E, 2001, DIABETIC MED, V18, P619, DOI 10.1046/j.1464-5491.2001.00529.x; Wolffenbuttel BHR, 1996, DIABETES CARE, V19, P1326, DOI 10.2337/diacare.19.12.1326; WOLFFENBUTTEL BHR, 1989, DIABETIC MED, V6, P520, DOI 10.1111/j.1464-5491.1989.tb01220.x; Wright A, 2002, DIABETES CARE, V25, P330, DOI 10.2337/diacare.25.2.330; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001; Wulffele MG, 2002, NETH J MED, V60, P249; Yki-Jarvinen H, 1999, ANN INTERN MED, V130, P389, DOI 10.7326/0003-4819-130-5-199903020-00002; Yki-Jarvinen H, 2000, DIABETES CARE, V23, P1130, DOI 10.2337/diacare.23.8.1130; Yki-Jarvinen H, 2001, DIABETES CARE, V24, P758, DOI 10.2337/diacare.24.4.758; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005; YKIJARVINEN H, 2000, CURR OPIN ENDOCRINOL, V7, P175; Zinman B, 1997, DIABETES, V46, P440, DOI 10.2337/diabetes.46.3.440	163	353	375	2	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2254	2264		10.1001/jama.289.17.2254	http://dx.doi.org/10.1001/jama.289.17.2254			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675ET	12734137	Bronze			2022-12-28	WOS:000182680700028
J	Gormley, L				Gormley, L			Visiting detainees to prevent torture	LANCET			English	Editorial Material									Amnesty Int British Sect, Int Secretariat, London WC1X 0DW, England		Gormley, L (corresponding author), Amnesty Int British Sect, Int Secretariat, Peter Benenson House,1 Easton St, London WC1X 0DW, England.							Summerfield D, 2003, BRIT MED J, V326, P773, DOI 10.1136/bmj.326.7393.773; 2001, A56156 UN	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1557	1557		10.1016/S0140-6736(03)13162-5	http://dx.doi.org/10.1016/S0140-6736(03)13162-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737883				2022-12-28	WOS:000182658900030
J	Leventhal, AG; Wang, YC; Pu, ML; Zhou, YF; Ma, YY				Leventhal, AG; Wang, YC; Pu, ML; Zhou, YF; Ma, YY			GABA and its agonists improved visual cortical function in senescent monkeys	SCIENCE			English	Article							CONTRAST SENSITIVITY; AGE; PERCEPTION; NEURONS; CORTEX	Human cerebral cortical function degrades during old age. Much of this change may result from a degradation of intracortical inhibition during senescence. We used multibarreled microelectrodes to study the effects of electrophoretic application of gamma-aminobutyric acid (GABA), the GABA type a (GABAa) receptor agonist muscimol, and the GABAa receptor antagonist bicuculline, respectively, on the properties of individual V1 cells in old monkeys. Bicuculline exerted a much weaker effect on neuronal responses in old than in young animals, confirming a degradation of GABA-mediated inhibition. On the other hand, the administration of GABA and muscimol resulted in improved visual function. Many treated cells in area V1 of old animals displayed responses typical of young cells. The present results have important implications for the treatment of the sensory, motor, and cognitive declines that accompany old age.	Univ Utah, Sch Med, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Chinese Acad Sci, Kunming Inst Zool, Lab Primate Cognit Neurosci, Kunming 650223, Yunnan, Peoples R China	Utah System of Higher Education; University of Utah; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; Kunming Institute of Zoology	Leventhal, AG (corresponding author), Univ Utah, Sch Med, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA.	audie.leventhal@m.cc.utah.edu			NIA NIH HHS [AG-17922] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG017922] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Caspary DM, 1999, NEUROSCIENCE, V93, P307, DOI 10.1016/S0306-4522(99)00121-9; CASPARY DM, 1995, EXP GERONTOL, V30, P349, DOI 10.1016/0531-5565(94)00052-5; Eysel UT, 1998, NEUROSCIENCE, V84, P25, DOI 10.1016/S0306-4522(97)00378-3; Galarreta M, 2001, SCIENCE, V292, P2295, DOI 10.1126/science.1061395; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; KASAMATSU T, 1982, EXP BRAIN RES, V45, P317, DOI 10.1007/BF01208591; KLINE DW, 1983, J GERONTOL, V38, P211, DOI 10.1093/geronj/38.2.211; KLINE DW, 1991, VISION VISUAL DYSFUN, V16, P150; KLINE DW, 1985, HDB PSYCHOL AGING, P296; Letinic K, 2002, NATURE, V417, P645, DOI 10.1038/nature00779; MATSUMURA M, 1990, NEUROSCI RES, V8, P138, DOI 10.1016/0168-0102(90)90066-N; Ordy J. M., 1991, EFFECTS AGING ENV VI, P1; OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791; OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362; Porciatti V, 1999, VISION RES, V39, P2157, DOI 10.1016/S0042-6989(98)00288-0; Schmolesky MT, 2000, NAT NEUROSCI, V3, P384, DOI 10.1038/73957; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P287, DOI 10.1113/jphysiol.1975.sp011055; SPEAR PD, 1993, VISION RES, V33, P2589, DOI 10.1016/0042-6989(93)90218-L; Tran DB, 1998, GRAEF ARCH CLIN EXP, V236, P269, DOI 10.1007/s004170050076; WESTON HC, 1948, BRIT J OPHTHALMOL, V32, P645, DOI 10.1136/bjo.32.9.645	20	409	476	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					812	815		10.1126/science.1082874	http://dx.doi.org/10.1126/science.1082874			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730605				2022-12-28	WOS:000182579800055
J	Li, RH; Mitra, N; Gratkowski, H; Vilaire, G; Litvinov, R; Nagasami, C; Weisel, JW; Lear, JD; DeGrado, WF; Bennett, JS				Li, RH; Mitra, N; Gratkowski, H; Vilaire, G; Litvinov, R; Nagasami, C; Weisel, JW; Lear, JD; DeGrado, WF; Bennett, JS			Activation of integrin alpha IIb beta 3 by modulation of transmembrane helix associations	SCIENCE			English	Article							IIB-IIIA COMPLEX; INSIDE-OUT ACTIVATION; FIBRINOGEN BINDING; ELECTRON-MICROSCOPY; PLATELETS; MODEL; ALPHA(IIB)BETA(3); REARRANGEMENTS; TRANSDUCTION; PEPTIDES	Transmembrane helices of integrin alpha and beta subunits have been implicated in the regulation of integrin activity. Two mutations, glycine-708 to asparagine-708 (G708N) and methionine-701 to asparagine-701, in the transmembrane helix of the beta3 subunit enabled integrin alphaIIbbeta3 to constitutively bind soluble fibrinogen. Further characterization of the G708N mutant revealed that it induced alphaIIbbeta3 clustering and constitutive phosphorylation of focal adhesion kinase. This mutation also enhanced the tendency of the transmembrane helix to form homotrimers. These results suggest that homomeric associations involving transmembrane domains provide a driving force for integrin activation. They also suggest a structural basis for the coincidence of integrin activation and clustering.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	DeGrado, WF (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.		Litvinov, Rustem/E-5291-2011; Li, Renhao/B-1257-2012	Litvinov, Rustem/0000-0003-0643-1496; Li, Renhao/0000-0002-5806-5080	NATIONAL CANCER INSTITUTE [K01CA096706] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, P50HL054500] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA096706] Funding Source: Medline; NHLBI NIH HHS [HL40387, HL54500] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; [Anonymous], UNPUB; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Basani RB, 2001, J BIOL CHEM, V276, P13975, DOI 10.1074/jbc.M011511200; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; Bennett JS, 2001, BLOOD, V97, P3093, DOI 10.1182/blood.V97.10.3093; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Calzada MJ, 2002, J BIOL CHEM, V277, P39899, DOI 10.1074/jbc.M205886200; Choma C, 2000, NAT STRUCT BIOL, V7, P161; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Hantgan RR, 2003, J BIOL CHEM, V278, P3417, DOI 10.1074/jbc.M208869200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Litvinov RI, 2002, P NATL ACAD SCI USA, V99, P7426, DOI 10.1073/pnas.112194999; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; SHATTIL SJ, 1985, BLOOD, V66, P92; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	30	243	251	2	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					795	798		10.1126/science.1079441	http://dx.doi.org/10.1126/science.1079441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730600				2022-12-28	WOS:000182579800050
J	van der Wal, CH; Eisaman, MD; Andre, A; Walsworth, RL; Phillips, DF; Zibrov, AS; Lukin, MD				van der Wal, CH; Eisaman, MD; Andre, A; Walsworth, RL; Phillips, DF; Zibrov, AS; Lukin, MD			Atomic memory for correlated photon states	SCIENCE			English	Article							ELECTROMAGNETICALLY INDUCED TRANSPARENCY; QUANTUM-NOISE-REDUCTION; SINGLE PHOTONS; LIGHT; ENSEMBLES; COMMUNICATION; ENTANGLEMENT; GENERATION; COHERENCE; STORAGE	We experimentally demonstrate emission of two quantum-mechanically correlated light pulses with a time delay that is coherently controlled via temporal storage of photonic states in an ensemble of rubidium atoms. The experiment is based on Raman scattering, which produces correlated pairs of spin-flipped atoms and photons, followed by coherent conversion of the atomic states into a different photon beam after a controllable delay. This resonant nonlinear optical process is a promising technique for potential applications in quantum communication.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; PN Lebedev Phys Inst, Moscow 117924, Russia	Harvard University; Russian Academy of Sciences; Russian Academy of Science Lebedev Physical Institute	Lukin, MD (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	lukin@physics.harvard.edu	Zibrov, Alexander S/G-7419-2014; van der Wal, Caspar H./D-9206-2013; Eisaman, Matthew/E-8006-2011	van der Wal, Caspar H./0000-0002-9843-3220; Eisaman, Matthew/0000-0002-3814-6430				AYTUR O, 1990, PHYS REV LETT, V65, P1551, DOI 10.1103/PhysRevLett.65.1551; BOLLER KJ, 1991, PHYS REV LETT, V66, P2593, DOI 10.1103/PhysRevLett.66.2593; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; FLEISCHHAUER M, 1992, PHYS REV A, V46, P5856, DOI 10.1103/PhysRevA.46.5856; Fleischhauer M, 2000, PHYS REV LETT, V84, P5094, DOI 10.1103/PhysRevLett.84.5094; GHERI KM, 1994, PHYS REV A, V50, P1871, DOI 10.1103/PhysRevA.50.1871; Hald J, 1999, PHYS REV LETT, V83, P1319, DOI 10.1103/PhysRevLett.83.1319; HARRIS SE, 1967, PHYS REV LETT, V18, P732, DOI 10.1103/PhysRevLett.18.732; Harris SE, 1997, PHYS TODAY, V50, P36, DOI 10.1063/1.881806; HARRIS SE, 1990, PHYS REV LETT, V64, P1107, DOI 10.1103/PhysRevLett.64.1107; Hau LV, 1999, NATURE, V397, P594, DOI 10.1038/17561; HEIDMANN A, 1987, PHYS REV LETT, V59, P2555, DOI 10.1103/PhysRevLett.59.2555; HEMMER PR, 1995, OPT LETT, V20, P982, DOI 10.1364/OL.20.000982; HONG CK, 1987, PHYS REV LETT, V59, P2044, DOI 10.1103/PhysRevLett.59.2044; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; Imamoglu A, 1998, PHYS REV LETT, V81, P2836, DOI 10.1103/PhysRevLett.81.2836; Imamoglu A, 1997, PHYS REV LETT, V79, P1467, DOI 10.1103/PhysRevLett.79.1467; Julsgaard B, 2001, NATURE, V413, P400, DOI 10.1038/35096524; Kash MM, 1999, PHYS REV LETT, V82, P5229, DOI 10.1103/PhysRevLett.82.5229; Kuzmich A, 2000, PHYS REV LETT, V85, P1594, DOI 10.1103/PhysRevLett.85.1594; Kuzmich A, 2003, NATURE, V423, P731, DOI 10.1038/nature01714; Kuzmich A, 1997, PHYS REV LETT, V79, P4782, DOI 10.1103/PhysRevLett.79.4782; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; Lukin MD, 2000, ADV ATOM MOL OPT PHY, V42, P347, DOI 10.1016/S1049-250X(08)60190-1; Lukin MD, 1999, PHYS REV LETT, V82, P1847, DOI 10.1103/PhysRevLett.82.1847; Lukin MD, 2003, REV MOD PHYS, V75, P457, DOI 10.1103/RevModPhys.75.457; Lukin MD, 2000, PHYS REV LETT, V84, P4232, DOI 10.1103/PhysRevLett.84.4232; Phillips DF, 2001, PHYS REV LETT, V86, P783, DOI 10.1103/PhysRevLett.86.783; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; RAYMER MG, 1990, PROG OPTICS, V28, P181, DOI 10.1016/S0079-6638(08)70290-7; Scully M.O., 1997, QUANTUM OPT; SMITHEY DT, 1992, PHYS REV LETT, V69, P2650, DOI 10.1103/PhysRevLett.69.2650; VANDERWAL CH, IN PRESS FLUCTUATION; Zibrov AS, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.103601; [No title captured]	37	397	397	4	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					196	200		10.1126/science.1085946	http://dx.doi.org/10.1126/science.1085946			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12764202				2022-12-28	WOS:000184056200037
J	Loayza, D; de Lange, T				Loayza, D; de Lange, T			POT1 as a terminal transducer of TRF1 telomere length control	NATURE			English	Article							MAMMALIAN TELOMERES; HUMAN-CELLS; PROTEIN; CANCER; END; CHROMOSOMES; PROTECTION; TANKYRASE; BINDING; YEAST	Human telomere maintenance is essential for the protection of chromosome ends, and changes in telomere length have been implicated in ageing and cancer(1-4). Human telomere length is regulated by the TTAGGG-repeat-binding protein TRF1 and its interacting partners tankyrase 1, TIN2 and PINX1 ( refs 5-9). As the TRF1 complex binds to the duplex DNA of the telomere, it is unclear how it can affect telomerase, which acts on the single-stranded 30 telomeric overhang. Here we show that the TRF1 complex interacts with a single-stranded telomeric DNA-binding protein - protection of telomeres 1 (POT1) - and that human POT1 controls telomerase-mediated telomere elongation. The presence of POT1 on telomeres was diminished when the amount of single-stranded DNA was reduced. Furthermore, POT1 binding was regulated by the TRF1 complex in response to telomere length. A mutant form of POT1 lacking the DNA-binding domain abrogated TRF1-mediated control of telomere length, and induced rapid and extensive telomere elongation. We propose that the interaction between the TRF1 complex and POT1 affects the loading of POT1 on the single-stranded telomeric DNA, thus transmitting information about telomere length to the telomere terminus, where telomerase is regulated.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.		de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X				Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; de Lange T, 2001, SCIENCE, V292, P1075; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Evans SK, 2000, J CELL SCI, V113, P3357; Granger MP, 2002, CRIT REV ONCOL HEMAT, V41, P29, DOI 10.1016/S1040-8428(01)00188-3; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Sprung CN, 1999, EXP CELL RES, V247, P29, DOI 10.1006/excr.1998.4293; Sprung CN, 1999, P NATL ACAD SCI USA, V96, P6781, DOI 10.1073/pnas.96.12.6781; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	29	523	560	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					1013	1018		10.1038/nature01688	http://dx.doi.org/10.1038/nature01688			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12768206				2022-12-28	WOS:000183753900056
J	Dye, C; Gay, N				Dye, C; Gay, N			Modeling the SARS epidemic	SCIENCE			English	Editorial Material									WHO, CH-1211 Geneva 27, Switzerland; Hlth Protect Agcy, Ctr Communicable Dis Surveillance, London NW9 5EQ, England	World Health Organization; Health Protection Agency	Dye, C (corresponding author), WHO, CH-1211 Geneva 27, Switzerland.							Keeling MJ, 1997, SCIENCE, V275, P65, DOI 10.1126/science.275.5296.65; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478	3	181	206	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1884	1885		10.1126/science.1086925	http://dx.doi.org/10.1126/science.1086925			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12766208				2022-12-28	WOS:000183619400024
J	Abbott, A				Abbott, A			Anthropologists cast doubt on human DNA evidence	NATURE			English	News Item																			0	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					468	468		10.1038/423468b	http://dx.doi.org/10.1038/423468b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774081	Bronze			2022-12-28	WOS:000183162900006
J	Sodeck, G; Partik, B; Domanovits, H				Sodeck, G; Partik, B; Domanovits, H			Interactive case report - A 42 year old man with acute chest pain: case outcome	BRITISH MEDICAL JOURNAL			English	Article									Vienna Gen Hosp, Dept Emergency Med, A-1093 Vienna, Austria; Vienna Gen Hosp, Dept Radiol, Vienna, Austria		Domanovits, H (corresponding author), Vienna Gen Hosp, Dept Emergency Med, Wahringer Gurtel 18-20, A-1093 Vienna, Austria.								0	0	0	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1133	1133		10.1136/bmj.326.7399.1133	http://dx.doi.org/10.1136/bmj.326.7399.1133			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763989	Green Published			2022-12-28	WOS:000183245000025
J	Lu, W; Ji, ZQ; Pfeiffer, L; West, KW; Rimberg, AJ				Lu, W; Ji, ZQ; Pfeiffer, L; West, KW; Rimberg, AJ			Real-time detection of electron tunnelling in a quantum dot	NATURE			English	Article							TRANSISTOR; CHARGE; JUNCTIONS; OSCILLATIONS; STATISTICS; STATES; NOISE	Nanostructures in which strong (Coulomb) interactions exist between electrons are predicted to exhibit temporal electronic correlations(1). Although there is ample experimental evidence that such correlations exist(2), electron dynamics in engineered nanostructures have been observed directly only on long timescales(3). The faster dynamics associated with electrical currents or charge fluctuations(4) are usually inferred from direct (or quasi-direct) current measurements. Recently, interest in electron dynamics has risen, in part owing to the realization that additional information about electronic interactions can be found in the shot noise(5) or higher statistical moments(6,7) of a direct current. Furthermore, interest in quantum computation has stimulated investigation of quantum bit (qubit) readout techniques(8,9), which for many condensed-matter systems ultimately reduce to single-shot measurements of individual electronic charges. Here we report real-time observation of individual electron tunnelling events in a quantum dot using an integrated radio-frequency single-electron transistor(10,11). We use electron counting to measure directly the quantum dot's tunnelling rate and the occupational probabilities of its charge state. Our results provide evidence in favour of long (10 mus or more) inelastic scattering times in nearly isolated dots.	Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA; Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA; Lucent Technol Inc, Bell Labs, Murray Hill, NJ 07974 USA	Rice University; Rice University; Alcatel-Lucent; Lucent Technologies; AT&T	Rimberg, AJ (corresponding author), Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA.		Rimberg, Alexander/B-8076-2010; Lu, Wei D./E-8388-2011; Lu, Wei/AAE-2921-2022	Lu, Wei D./0000-0003-4731-1976; Lu, Wei/0000-0002-4150-8674				Aassime A, 2001, PHYS REV LETT, V86, P3376, DOI 10.1103/PhysRevLett.86.3376; Altshuler BL, 1997, PHYS REV LETT, V78, P2803, DOI 10.1103/PhysRevLett.78.2803; BASSEVILLE M, 1993, DETECTION ABRUPT CHA; BEENAKKER CWJ, 1991, PHYS REV B, V44, P1646, DOI 10.1103/PhysRevB.44.1646; BENJACOB E, 1985, PHYS LETT A, V108, P289, DOI 10.1016/0375-9601(85)90750-9; Berman D, 1999, PHYS REV LETT, V82, P161, DOI 10.1103/PhysRevLett.82.161; Blanter YM, 2000, PHYS REP, V336, P1, DOI 10.1016/S0370-1573(99)00123-4; DELSING P, 1989, PHYS REV LETT, V63, P1861, DOI 10.1103/PhysRevLett.63.1861; DRESSELHAUS PD, 1994, PHYS REV LETT, V72, P3226, DOI 10.1103/PhysRevLett.72.3226; Eisenberg E, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.136801; Folk JA, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.206802; FULTON TA, 1987, PHYS REV LETT, V59, P109, DOI 10.1103/PhysRevLett.59.109; KIRTON MJ, 1989, ADV PHYS, V38, P367, DOI 10.1080/00018738900101122; Levitov LS, 1996, J MATH PHYS, V37, P4845, DOI 10.1063/1.531672; LEVITOV LS, 1992, JETP LETT+, V55, P555; LIKHAREV KK, 1987, IEEE T MAGN, V23, P1142, DOI 10.1109/TMAG.1987.1065001; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Lu W, 2000, APPL PHYS LETT, V77, P2746, DOI 10.1063/1.1320455; Schoelkopf RJ, 1998, SCIENCE, V280, P1238, DOI 10.1126/science.280.5367.1238; Shnirman A, 1998, PHYS REV B, V57, P15400, DOI 10.1103/PhysRevB.57.15400	21	314	318	4	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					422	425		10.1038/nature01642	http://dx.doi.org/10.1038/nature01642			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761544				2022-12-28	WOS:000183012000037
J	Pan, JW; Gasparoni, S; Ursin, R; Weihs, G; Zeilinger, A				Pan, JW; Gasparoni, S; Ursin, R; Weihs, G; Zeilinger, A			Experimental entanglement purification of arbitrary unknown states	NATURE			English	Article							QUANTUM CRYPTOGRAPHY; TELEPORTATION; COMMUNICATION; COMPUTATION	Distribution of entangled states between distant locations is essential for quantum communication(1-3) over large distances. But owing to unavoidable decoherence in the quantum communication channel, the quality of entangled states generally decreases exponentially with the channel length. Entanglement purification(4,5) - a way to extract a subset of states of high entanglement and high purity from a large set of less entangled states - is thus needed to overcome decoherence. Besides its important application in quantum communication, entanglement purification also plays a crucial role in error correction for quantum computation, because it can significantly increase the quality of logic operations between different qubits(6). Here we demonstrate entanglement purification for general mixed states of polarization-entangled photons using only linear optics(7). Typically, one photon pair of fidelity 92% could be obtained from two pairs, each of fidelity 75%. In our experiments, decoherence is overcome to the extent that the technique would achieve tolerable error rates for quantum repeaters in long-distance quantum communication(8). Our results also imply that the requirement of high-accuracy logic operations in fault-tolerant quantum computation can be considerably relaxed(6).	Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria	University of Vienna	Pan, JW (corresponding author), Univ Vienna, Inst Expt Phys, Boltzmanngasse 5, A-1090 Vienna, Austria.	pan@ap.univie.ac.at; zeilinger-office@exp.univie.ac.at	Ursin, Rupert/E-9548-2012; Zeilinger, Anton/A-1170-2011; Weihs, Gregor/G-2564-2013; Pan, Jian-Wei/A-2332-2010	Ursin, Rupert/0000-0002-9403-269X; Weihs, Gregor/0000-0003-2260-3008; Pan, Jian-Wei/0000-0002-6100-5142				BENNETT CH, 1992, PHYS REV LETT, V69, P2881, DOI 10.1103/PhysRevLett.69.2881; Bennett CH, 1999, PHYS REV LETT, V83, P3081, DOI 10.1103/PhysRevLett.83.3081; Bennett CH, 1996, PHYS REV LETT, V76, P722, DOI 10.1103/PhysRevLett.76.722; Bennett CH, 1996, PHYS REV A, V53, P2046, DOI 10.1103/PhysRevA.53.2046; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Chen ZB, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.160408; Deutsch D, 1996, PHYS REV LETT, V77, P2818, DOI 10.1103/PhysRevLett.77.2818; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; Dur W, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.067901; EKERT AK, 1991, PHYS REV LETT, V67, P661, DOI 10.1103/PhysRevLett.67.661; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; Jones J, 2003, NATURE, V421, P28, DOI 10.1038/421028a; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kwiat PG, 2001, NATURE, V409, P1014, DOI 10.1038/35059017; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Mattle K, 1996, PHYS REV LETT, V76, P4656, DOI 10.1103/PhysRevLett.76.4656; Pan JW, 2003, NATURE, V421, P721, DOI 10.1038/nature01412; Pan JW, 2001, NATURE, V410, P1067, DOI 10.1038/35074041; Pittman TB, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.257902; RUDOLPH T, 2001, SAMPLE GATE LINEAR O; Simon C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.257901; Yamamoto T, 2003, NATURE, V421, P343, DOI 10.1038/nature01358; ZHAO Z, 2002, DETERMINISTIC HIGHLY; ZHAO ZX, IN PRESS PHYS REV LE, P32301; ZUKOWSKI M, 1995, ANN NY ACAD SCI, V755, P91, DOI 10.1111/j.1749-6632.1995.tb38959.x; ZUKOWSKI M, 1993, PHYS REV LETT, V71, P4287, DOI 10.1103/PhysRevLett.71.4287	30	390	403	3	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2003	423	6938					417	422		10.1038/nature01623	http://dx.doi.org/10.1038/nature01623			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761543				2022-12-28	WOS:000183012000036
J	Zhou, XJ; Yoshida, T; Lanzara, A; Bogdanov, PV; Kellar, SA; Shen, KM; Yang, WL; Ronning, F; Sasagawa, T; Kakeshita, T; Noda, T; Eisaki, H; Uchida, S; Lin, CT; Zhou, F; Xiong, JW; Ti, WX; Zhao, ZX; Fujimori, A; Hussain, Z; Shen, ZX				Zhou, XJ; Yoshida, T; Lanzara, A; Bogdanov, PV; Kellar, SA; Shen, KM; Yang, WL; Ronning, F; Sasagawa, T; Kakeshita, T; Noda, T; Eisaki, H; Uchida, S; Lin, CT; Zhou, F; Xiong, JW; Ti, WX; Zhao, ZX; Fujimori, A; Hussain, Z; Shen, ZX			Universal nodal Fermi velocity	NATURE			English	Article							ELECTRONIC-STRUCTURE; NORMAL-STATE; SUPERCONDUCTORS; BI2SR2CACU2O8+DELTA; LA2-XSRXCUO4; TEMPERATURE; PSEUDOGAP; PLANE; GAP; TC		Stanford Univ, Dept Phys Appl Phys & SSRL, Stanford, CA 94305 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA; Univ Tokyo, Dept Phys, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Dept Superconduct, Bunkyo Ku, Tokyo 113, Japan; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; Chinese Acad Sci, Inst Phys, Natl Lab Superconduct, Beijing 100080, Peoples R China	Stanford University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Tokyo; University of Tokyo; Max Planck Society; Chinese Academy of Sciences; Institute of Physics, CAS	Zhou, XJ (corresponding author), Stanford Univ, Dept Phys Appl Phys & SSRL, Stanford, CA 94305 USA.	xjzhou@lbl.gov	lanzara, alessandra/AAC-9535-2020; Fujimori, Atsushi/U-1971-2019; Eisaki, Hiroshi/F-6317-2018; Sasagawa, Takao/E-6666-2014; Shen, Kyle/B-3693-2008; Fujimori, Atsushi/G-5099-2014; Yang, Wanli/D-7183-2011	Eisaki, Hiroshi/0000-0002-8299-6416; Sasagawa, Takao/0000-0003-0149-6696; Fujimori, Atsushi/0000-0003-4876-0634; Yang, Wanli/0000-0003-0666-8063				Ando Y, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.017001; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; HOEFNER S, 1995, PHOTOEMISSION SPECTR; Lanzara A, 2001, NATURE, V412, P510, DOI 10.1038/35087518; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; Loram JW, 2000, PHYSICA C, V341, P831, DOI 10.1016/S0921-4534(00)00706-1; SHEN ZX, 1993, PHYS REV LETT, V70, P1553, DOI 10.1103/PhysRevLett.70.1553; THRUSK T, 1999, REP PROG PHYS, V62, P61; UCHIDA S, 1991, PHYS REV B, V43, P7942, DOI 10.1103/PhysRevB.43.7942; UEMURA YJ, 1989, PHYS REV LETT, V62, P2317, DOI 10.1103/PhysRevLett.62.2317; Yamada K, 1998, PHYS REV B, V57, P6165, DOI 10.1103/PhysRevB.57.6165; Zhou XJ, 2001, PHYS REV LETT, V86, P5578, DOI 10.1103/PhysRevLett.86.5578	13	279	284	2	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					398	398		10.1038/423398a	http://dx.doi.org/10.1038/423398a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761537	Bronze			2022-12-28	WOS:000183012000028
J	Psaty, BN; Lumley, T; Furberg, CD; Schellenbaum, G; Pahor, M; Alderman, MH; Weiss, NS				Psaty, BN; Lumley, T; Furberg, CD; Schellenbaum, G; Pahor, M; Alderman, MH; Weiss, NS			Health outcomes associated with various antihypertensive therapies used as first-line agents - A network meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRACTICE GUIDELINES COMMITTEE; CONVERTING-ENZYME-INHIBITORS; CHRONIC STABLE ANGINA; RANDOMIZED-TRIAL; BLOOD-PRESSURE; BETA-BLOCKERS; MILD HYPERTENSION; HEART-FAILURE; CARDIOVASCULAR MORBIDITY; CALCIUM-ANTAGONISTS	Context Establishing relative benefit or harm from specific antihypertensive agents is limited by the complex array of studies that compare treatments. Network meta-analysis combines direct and indirect evidence to better define risk or benefit. Objective To summarize the available clinical trial evidence concerning the safety and efficacy of various antihypertensive therapies used as first-line agents and evaluated in terms of major cardiovascular disease end points and all-cause mortality. Data Sources and Study Selection We used previous meta-analyses, MEDLINE searches, and journal reviews from January 1995 through December 2002. We identified long-term randomized controlled trials that assessed major cardiovascular disease end points as an outcome, Eligible studies included both those with placebo-treated or untreated controls and those with actively treated controls. Data Extraction Network meta-analysis was used to combine direct within-trial between-drug comparisons with indirect evidence from the other trials, The indirect comparisons, which preserve the within-trial randomized findings, were constructed from trials that had one treatment in common. Data Synthesis Data were combined from 42 clinical trials that included 192478 patients randomized to 7 major treatment strategies, including placebo. For all outcomes, low-dose diuretics were superior to placebo: coronary heart disease (CHD; RR, 0.79; 95% confidence interval [CI], 0.69-0.92); congestive heart failure (CHF; RR, 0.51; 95% CI, 0.42-0.62); stroke (RR, 0.71; 0.63-0.81); cardiovascular disease events (RR, 0.76, 95% CI, 0.69-0.83); cardiovascular disease mortality (RR, 021, 95% CI, 0.73-092); and total mortality (RR, 0.90; 95% CI, 0.84-0.96). None of the first-line treatment strategies-beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers; (CCBs), alpha-blockers, and angiotensin receptor blockers-was significantly better than low-dose diuretics for any outcome. Compared with CCBs, low-dose diuretics were associated with reduced risks of cardiovascular disease event (RR, 0.94; 95% CI 0.89-1.00) and CHF (RR, 0.74; 95% CI, 0.67-0.81). Compared with ACE inhibitors, low-dose diuretics were associated with reduced risks of CHF (RR, 0.88; 95% CI, 0.80-0.96), cardiovascular disease events (RR, 0.94; 95% CI, 0.89-1.00), and stroke (RR, 0.86; 0.77-0.97). Compared with beta-blockers, low-dose diuretics were associated with a reduced risk of cardiovascular disease events (RR, 0.89; 95% CI, 0.80-0.98). Compared with alpha-blockers, low-dose diuretics were associated with reduced risks of CHF (RR, 0.51; 95% CI, 0.43-0.60) and cardiovascular disease events (RR, 0.84; 95 % CI, 0.75-0.93) Blood pressure changes were similar between comparison treatments. Conclusions Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality. Clinical practice and treatment guidelines should reflect this evidence, and, future trials should use low-dose diuretics as the standard for clinically useful comparisons.	Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Biostat, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Wake Forest Univ Hlth Sci, Dept Publ Hlth Sci, Winston Salem, NC USA; Wake Forest Univ Hlth Sci, Dept Med, Winston Salem, NC USA; Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; Yeshiva University; Albert Einstein College of Medicine	Psaty, BN (corresponding author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Suite 1360,1730 Minor Ave, Seattle, WA 98101 USA.	psaty@u.washington.edu	Lovasi, Gina/C-2781-2009	Lovasi, Gina/0000-0003-2613-9599	NHLBI NIH HHS [HL68639, HL40628, HL43201] Funding Source: Medline; NIA NIH HHS [AG09556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043201, R01HL068639, R01HL040628, R29HL040628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Alderman MH, 2002, AM J HYPERTENS, V15, P917, DOI 10.1016/S0895-7061(02)03001-7; AMERY A, 1985, LANCET, V1, P1349; *ANBP2 INV, 2002, INT SOC HYP JUN 23 2; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1973, BMJ-BRIT MED J, V3, P434; [Anonymous], 1982, NEW ENGL J MED, V307, P976; [Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1993, Stroke, V24, P543; [Anonymous], 1982, JAMA-J AM MED ASSOC, V247, P633; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BLACK HR, 2002, AM SOC HYP MAY 18 20; BLACKWELDER WC, 1984, CONTROL CLIN TRIALS, V5, P97, DOI 10.1016/0197-2456(84)90116-8; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; Braunwald E, 2000, CIRCULATION, V102, P1193, DOI 10.1161/01.CIR.102.10.1193; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; CARTER AB, 1970, LANCET, V1, P485; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; CUPPLES LA, 1987, FARMINGHAM STUDY EPI; Cutler Jeffrey A., 1995, P253; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; EKBOM T, 1992, J HYPERTENS, V10, P1525, DOI 10.1097/00004872-199210120-00013; ERIKSSON S, 1995, CEREBROVASC DIS, V5, P21, DOI 10.1159/000107813; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Gibbons RJ, 1999, CIRCULATION, V99, P2829, DOI 10.1161/01.CIR.99.21.2829; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hansson L, 1999, BLOOD PRESSURE, V8, P177; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HEGELAND A, 1980, AM J MED, V0069, P00725; Heidenreich PA, 1999, JAMA-J AM MED ASSOC, V281, P1927, DOI 10.1001/jama.281.20.1927; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; Julian DG, 1997, EUR HEART J, V18, P394; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; KURAMOTO K, 1981, JPN HEART J, V22, P75; Kuramoto K, 1999, HYPERTENSION, V34, P1129; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; MacMahon S, 2000, LANCET, V356, P352, DOI 10.1016/S0140-6736(00)02521-6; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; Neal B, 2000, LANCET, V356, P1955; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; Pahor M, 2000, DIABETES CARE, V23, P888, DOI 10.2337/diacare.23.7.888; Pahor M, 2000, LANCET, V356, P1949, DOI 10.1016/S0140-6736(00)03306-7; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; PERRY HM, 1989, STROKE, V20, P4, DOI 10.1161/01.STR.20.1.4; PERRY HM, 1978, ANN NY ACAD SCI, V304, P267; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Rosei EA, 1997, J HYPERTENS, V15, P1337, DOI 10.1097/00004872-199715110-00019; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Schrier RW, 2000, NEW ENGL J MED, V343, P1969, DOI 10.1056/NEJM200012283432614; *SCOPE TRIAL INV, 2002, INT SOC HYP JUN 27 P; SEWESTER CS, 1996, DRUG FACTS COMPARISO; SMITH WM, 1977, CIRC RES, V40, P98; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Soriano JB, 1997, PROG CARDIOVASC DIS, V39, P445, DOI 10.1016/S0033-0620(97)80039-4; SPRACKLING ME, 1981, BRIT MED J, V283, P1151, DOI 10.1136/bmj.283.6300.1151; Staessen JA, 1999, HYPERTENSION, V33, P1476, DOI 10.1161/01.HYP.33.6.1476; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Veterans Administration Cooperative Study Group on Antihypertensive Agents, 1967, JAMA-J AM MED ASSOC, V202, P116, DOI DOI 10.1001/JAMA.1967.03130150084015; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; Williams SV, 2001, ANN INTERN MED, V135, P530, DOI 10.7326/0003-4819-135-7-200110020-00014; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; WOLFF FW, 1966, J CHRON DIS, V19, P227, DOI 10.1016/0021-9681(66)90128-7; WRIGHT J, 2002, AM SOC HYP MAY 18 20; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zanchetti A, 2002, CIRCULATION, V106, P2422, DOI 10.1161/01.CIR.0000039288.86470.DD	95	664	713	3	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2534	2544		10.1001/jama.289.19.2534	http://dx.doi.org/10.1001/jama.289.19.2534			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680KL	12759325				2022-12-28	WOS:000182976500022
J	Blank, L; Kimball, H; McDonald, W; Merino, J				Blank, L; Kimball, H; McDonald, W; Merino, J		ABIM Fdn; ACP Fdn; EFIM	Medical professionalism in the new millennium: A physician charter 15 months later	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									ABIM Fdn, Philadelphia, PA 19106 USA; ACP Fdn, Philadelphia, PA USA; European Federat Internal Med, Maastricht, Netherlands	American Board of Internal Medicine; Maastricht University	Blank, L (corresponding author), ABIM Fdn, 510 Walnut St,Suite 1700, Philadelphia, PA 19106 USA.	lblank@abim.org						Brennan T, 2002, LANCET, V359, P520, DOI 10.1016/s0140-6736(02)07684-5; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012	2	94	101	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					839	841		10.7326/0003-4819-138-10-200305200-00012	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755556				2022-12-28	WOS:000182920700008
J	Hon, KLE; Leung, CW; Cheng, WTF; Chan, PKS; Chu, WCW; Kwan, YW; Li, AM; Fong, NC; Ng, PC; Chiu, MC; Li, CK; Tam, JS; Fok, TF				Hon, KLE; Leung, CW; Cheng, WTF; Chan, PKS; Chu, WCW; Kwan, YW; Li, AM; Fong, NC; Ng, PC; Chiu, MC; Li, CK; Tam, JS; Fok, TF			Clinical presentations and outcome of severe acute respiratory syndrome in children	LANCET			English	Article								Hong Kong has been severely affected by severe acute respiratory syndrome (SARS). Contact in households and healthcare settings Is thought to be important for transmission, putting children at particular risk. Most data so far, however, have been for adults. We prospectively followed up the first ten children with SARS managed during the early phase of the epidemic in Hong Kong. All the children had been in close contact with infected adults. Persistent fever, cough, progressive radiographic changes of chest and lymphopenia were noted in all patients. The children were treated with high-dose ribavirin, oral prednisolone, or intravenous methylprednisolone, with no short-term adverse effects. Four teenagers required oxygen therapy and two needed assisted ventilation. None of the younger children required oxygen supplementation. Compared with adults and teenagers, SARS seems to have a less aggressive clinical course In younger children.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Diagnost Radiol & Organ Imaging, Shatin, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Fok, TF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, 6-F,Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.		Chu, Winnie CW/F-8449-2014; Chan, Paul KS/J-9360-2013; Li, Chi-kong/J-8456-2013; Li, Albert/AAF-2079-2019	Chu, Winnie CW/0000-0003-4962-4132; Chan, Paul KS/0000-0002-6360-4608; Li, Chi-kong/0000-0002-2810-5758; Kwan, Mike Yat Wah/0000-0002-1476-9625				CAIRO M, 2002, RUDOLPHS PEDIAT, P1548; LEE N, MAJOR OUTBREAK SEVER; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; SMITH DW, 1991, NEW ENGL J MED, V325, P24, DOI 10.1056/NEJM199107043250105; *WHO, CAS DEF SURV SEV AC	5	259	276	1	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 17	2003	361	9370					1701	1703		10.1016/S0140-6736(03)13364-8	http://dx.doi.org/10.1016/S0140-6736(03)13364-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767737	Green Published, Bronze			2022-12-28	WOS:000182919700012
J	Baenziger, JU				Baenziger, JU			A major step on the road to understanding a unique posttranslational modification and its role in a genetic disease	CELL			English	Editorial Material							MULTIPLE SULFATASE DEFICIENCY	The posttranslational conversion of cysteine to Calpha-formylglycine in the catalytic site of mammalian sulfatases is deficient in the rare but devastating disorder multiple sulfatase deficiency (MSD). Two papers in this issue of Cell (Dierks et al., 2003; Cosma et al., 2003) report the cloning of a gene responsible for this activity.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave, St Louis, MO 63110 USA.							BALLABIO A, 1985, HUM GENET, V70, P315, DOI 10.1007/BF00295367; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K	7	15	20	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 16	2003	113	4					421	422		10.1016/S0092-8674(03)00354-4	http://dx.doi.org/10.1016/S0092-8674(03)00354-4			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757700	Bronze			2022-12-28	WOS:000182981500001
J	Osterfield, M; Kirschner, MW; Flanagan, JG				Osterfield, M; Kirschner, MW; Flanagan, JG			Graded positional information: Interpretation for both fate and guidance	CELL			English	Review							SONIC HEDGEHOG; AXON GUIDANCE; NEURONS; SIGNAL	Recent evidence indicates that gradients of the same extracellular molecules can act as both morphogens, specifying cell differentiation, and guidance cues, directing axon movement. We discuss how cells may use common mechanisms to convert graded information into discrete responses; and how extracellular signals provide coordinate systems that can be linked to highly diverse cellular outputs.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Flanagan, JG (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.		Flanagan, John/AAM-2995-2020					Augsburger A, 1999, NEURON, V24, P127, DOI 10.1016/S0896-6273(00)80827-2; CAJAL SR, 1892, STRUCTURE RETINA; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Flanagan JG, 1999, NATURE, V401, P747, DOI 10.1038/44471; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; Krylova O, 2002, NEURON, V35, P1043, DOI 10.1016/S0896-6273(02)00860-7; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; Meinhardt H, 2000, BIOESSAYS, V22, P753, DOI 10.1002/1521-1878(200008)22:8<753::AID-BIES9>3.3.CO;2-Q; Peifer M, 2002, CELL, V109, P271, DOI 10.1016/S0092-8674(02)00739-0; Sanson B, 2001, EMBO REP, V2, P1083, DOI 10.1093/embo-reports/kve255; Steward O, 2002, CELL, V110, P537, DOI 10.1016/S0092-8674(02)00934-0; Trousse F, 2001, DEVELOPMENT, V128, P3927; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522	20	41	41	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 16	2003	113	4					425	428		10.1016/S0092-8674(03)00359-3	http://dx.doi.org/10.1016/S0092-8674(03)00359-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757702	Bronze			2022-12-28	WOS:000182981500003
J	Veaute, X; Jeusset, J; Soustelle, C; Kowalczykowski, SC; Le Cam, E; Fabre, F				Veaute, X; Jeusset, J; Soustelle, C; Kowalczykowski, SC; Le Cam, E; Fabre, F			The Srs2 helicase prevents recombination by disrupting Rad51 nucleoprotein filaments	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA HELICASE; HOMOLOGOUS RECOMBINATION; YEAST RAD51; MUTATIONS; REPAIR; GENE; SEQUENCE; MUTANTS; PROTEIN	Homologous recombination is a ubiquitous process with key functions in meiotic and vegetative cells for the repair of DNA breaks. It is initiated by the formation of single-stranded DNA on which recombination proteins bind to form a nucleoprotein filament that is active in searching for homology, in the formation of joint molecules and in the exchange of DNA strands(1). This process contributes to genome stability but it is also potentially dangerous to cells if intermediates are formed that cannot be processed normally and thus are toxic or generate genomic rearrangements. Cells must therefore have developed strategies to survey recombination and to prevent the occurrence of such deleterious events. In Saccharomyces cerevisiae, genetic data have shown that the Srs2 helicase negatively modulates recombination(2,3), and later experiments suggested that it reverses intermediate recombination structures(4-7). Here we show that DNA strand exchange mediated in vitro by Rad51 is inhibited by Srs2, and that Srs2 disrupts Rad51 filaments formed on single-stranded DNA. These data provide an explanation for the antirecombinogenic role of Srs2 in vivo and highlight a previously unknown mechanism for recombination control.	CNRS, CEA, DSV,Dept Radiobiol & Radiopathol, UMR 217, F-92265 Fontenay Aux Roses, France; Inst Gustave Roussy, IGR,UPS, CNRS, UMR 81126, F-94805 Villejuif, France; Univ Calif Davis, Ctr Genet & Dev, Sect Microbiol & Mol & Cellular Biol, Davis, CA 95616 USA	CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of California System; University of California Davis	Veaute, X (corresponding author), CNRS, CEA, DSV,Dept Radiobiol & Radiopathol, UMR 217, BP6, F-92265 Fontenay Aux Roses, France.	xavier.veaute@cea.fr; francis.fabre@cea.fr		Le cam, Eric/0000-0002-6832-6117				ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; AGUILERA A, 1988, GENETICS, V119, P779; Beloin C, 2003, J BIOL CHEM, V278, P5333, DOI 10.1074/jbc.M207489200; Chanet R, 1996, MOL CELL BIOL, V16, P4782; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; HEUDE M, 1995, MOL GEN GENET, V248, P59, DOI 10.1007/BF02456614; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; KAYTOR MD, 1995, GENETICS, V140, P1441; Klein H, 2001, GENETICS, V157, P557; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; LOVETT ST, 1987, GENETICS, V116, P547; MILNE GT, 1995, GENETICS, V139, P1189; PALLADINO F, 1992, GENETICS, V132, P23; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RONG L, 1993, J BIOL CHEM, V268, P1252; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SCHILD D, 1995, GENETICS, V140, P115; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2	24	471	475	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					309	312		10.1038/nature01585	http://dx.doi.org/10.1038/nature01585			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748645				2022-12-28	WOS:000182853100048
J	Verstappen, WHJM; van der Weijden, T; Sijbrandij, J; Smeele, I; Hermsen, J; Grimshaw, J; Grol, RPTM				Verstappen, WHJM; van der Weijden, T; Sijbrandij, J; Smeele, I; Hermsen, J; Grimshaw, J; Grol, RPTM			Effect of a practice-based strategy on test ordering performance of primary care physicians - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERAL-PRACTITIONERS; DIAGNOSTIC-TESTS; TEST REQUESTS; GUIDELINES; FEEDBACK; INTERVENTIONS; REFERRALS	Context Numbers of diagnostic tests ordered by primary care physicians are growing and many of these tests seem to be unnecessary according to established, evidence-based guidelines. An innovative strategy that focused on clinical problems and associated tests was developed. Objective To determine the effects of a multifaceted strategy aimed at improving the performance of primary tare physicians' test ordering. Design Multicenter, randomized controlled trial with a balanced, incomplete block design and randomization at group level. Thirteen groups of primary care physicians underwent the strategy for 3 clinical problems (arm A; cardiovascular topics, upper and lower abdominal complaints), while 13 other groups underwent the strategy for 3 other clinical problems (arm B; chronic obstructive-pulmonary disease and asthma, general complaints, degenerative joint complaints). Each arm acted as a control for the other. Setting: Primary care physician groups in 5 regions in the Netherlands with diagnostic centers recruited from May to September 1998. Study Participants: Twenty-six primary care physician groups, including 174 primary care physicians. Intervention During the 6 months of intervention, physicians discussed 3 consecutive, personal feedback reports in 3 small group meetings, related them to 3 evidence-based clinical guidelines, and made plans for change. Main Outcome Measure According to existing national, evidence-based guide, lines, a decrease in the total numbers of tests ordered per clinical problem and of some, defined inappropriate tests, is considered a quality improvement. Results For clinical problems allocated to arm A, the mean total number of requested tests per 6 months per physician was reduced from baseline to follow-up by 12% among physicians in the arm A intervention, but was unchanged in the arm B control, with a mean reduction of 67 more tests per physician per 6 months in arm A than in arm B (P=.01). For clinical problems allocated to arm 13, the mean total number of requested tests per 6 months per physician was reduced from baseline to follow-up by 8% among physicians in the arm B intervention, and by 3% in the arm A control, with a mean reduction of 28 more tests per physician per 6 months in arm B than in arm A (P=.22). Physicians in arm A had a significant reduction in mean total number of inappropriate tests ordered for problems allocated to arm A, whereas the reduction in inappropriate test ordered physicians in arm B for problems allocated to arm B was not statistically significant. Conclusion In this study, a practice-based, multifaceted strategy using guidelines, feedback, and social interaction resulted in modest improvements in test ordering by primary care physicians.	Maastricht Univ, Dept Gen Practice, Ctr Qual Care Res, NL-6200 MD Maastricht, Netherlands; Maxima Med Ctr, Med Integrat Ctr Kempenland, Veldhoven, Netherlands; Maastricht Univ, Dept Methodol & Stat, Maastricht, Netherlands; Elkerliek Hosp, Ctr Diagnost & Consultat, Helmond, Netherlands; Canisius Wilhelmina Hosp Nijmegen, Med Diagnost Ctr, Nijmegen, Netherlands; Univ Ottawa, Inst Populat Hlth, Ctr Best Practice, Ottawa Hlth Res Inst, Ottawa, ON K1N 6N5, Canada	Maastricht University; Maxima Medical Center; Maastricht University; Radboud University Nijmegen; University of Ottawa; Ottawa Hospital Research Institute	Verstappen, WHJM (corresponding author), Maastricht Univ, Dept Gen Practice, Ctr Qual Care Res, POB 616, NL-6200 MD Maastricht, Netherlands.		Grol, Richard/C-8523-2013; Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243				AYANIAN JZ, 1991, MED DECIS MAKING, V11, P154, DOI 10.1177/0272989X9101100302; BRADY WJ, 1988, J GEN INTERN MED, V3, P560, DOI 10.1007/BF02596100; BugterMaessen AMA, 1996, FAM PRACT, V13, P254, DOI 10.1093/fampra/13.3.254; Eccles M, 2001, LANCET, V357, P1406, DOI 10.1016/S0140-6736(00)04564-5; Ferrier BM, 1996, CAN FAM PHYSICIAN, V42, P463; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Grol R, 1990, Qual Assur Health Care, V2, P119; Hoffrage U, 2000, SCIENCE, V290, P2261, DOI 10.1126/science.290.5500.2261; KRISTIANSEN IS, 1992, FAM PRACT, V9, P22, DOI 10.1093/fampra/9.1.22; LEURQUIN P, 1995, BRIT J GEN PRACT, V45, P21; Little P, 1998, FAM PRACT, V15, P264, DOI 10.1093/fampra/15.3.264; McDonald IG, 1996, BRIT MED J, V313, P329, DOI 10.1136/bmj.313.7053.329; MITTMAN BS, 1992, QUALITY REV B, P413; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; Wensing M, 1998, BRIT J GEN PRACT, V48, P991; Wensing M, 1994, Int J Qual Health Care, V6, P115; WINKENS RAG, 1995, LANCET, V345, P498, DOI 10.1016/S0140-6736(95)90588-X; WINKENS RAG, 1995, BRIT J GEN PRACT, V45, P289; WONG ET, 1995, CLIN CHEM, V41, P1241; ZAAT JOM, 1992, MED CARE, V30, P846, DOI 10.1097/00005650-199209000-00008	21	110	111	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2407	2412		10.1001/jama.289.18.2407	http://dx.doi.org/10.1001/jama.289.18.2407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	677WF	12746365	Bronze			2022-12-28	WOS:000182831200031
J	Harding, S				Harding, S			Extracts from "concise clinical evidence" - Diabetic retinopathy	BRITISH MEDICAL JOURNAL			English	Article									Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Harding, S (corresponding author), Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.			Harding, Simon/0000-0003-4676-1158					0	9	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1023	1024		10.1136/bmj.326.7397.1023	http://dx.doi.org/10.1136/bmj.326.7397.1023			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KG	12742927	Green Published			2022-12-28	WOS:000182920500021
J	Fine, RL; Mayo, TW				Fine, RL; Mayo, TW			Resolution of futility by due process: Early experience with the Texas advance directives	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MEDICAL FUTILITY; LIMITS	Every U.S. state has developed legal rules to address end-of-life decision making. No law to date has effectively dealt with medical futility-an issue that has engendered significant debate in the medical and legal literature, many court cases, and a formal opinion from the American Medical Association's Council on Ethical and Judicial Affairs. In 1999, Texas was the first state to adopt a law regulating end-of-life decisions, providing a legislatively sanctioned, extrajudicial, due process mechanism for resolving medical futility disputes and other end-of-life ethical disagreements. After 2 years of practical experience with this law, data collected at a large tertiary care teaching hospital strongly suggest that the law represents a first step toward practical resolution of this controversial area of modern health care. As such, the law may be of interest to practitioners, patients, and legislators elsewhere.	Baylor Hlth Care Syst, Off Clin Eth, Dallas, TX 75204 USA; So Methodist Univ, Dedman Sch Law, Dallas, TX 75275 USA	Baylor Health Care System; Southern Methodist University	Fine, RL (corresponding author), Baylor Hlth Care Syst, Off Clin Eth, 3434 Swiss Ave,Suite 330, Dallas, TX 75204 USA.	robertf@baylorhealth.edu		Mayo, Thomas/0000-0002-5601-129X				Basta L, 1996, J AM COLL CARDIOL, V28, P1623, DOI 10.1016/S0735-1097(96)00341-5; Fine R L, 2001, HEC Forum, V13, P59, DOI 10.1023/A:1011249928196; Fine R L, 1999, Tex Med, V95, P64; Halevy A, 1996, JAMA-J AM MED ASSOC, V276, P571, DOI 10.1001/jama.276.7.571; Heitman E, 2001, HEC Forum, V13, P82, DOI 10.1023/A:1011202012266; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; JECKER NS, 1991, HASTINGS CENT REP, V21, P5, DOI 10.2307/3563315; Johnson S H, 1997, J Health Hosp Law, V30, P21; LO B, 1995, RESOLVING ETHICAL DI, P73; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; Plows CW, 1999, JAMA-J AM MED ASSOC, V281, P937; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHUSTER DP, 1992, AM REV RESPIR DIS, V145, P508, DOI 10.1164/ajrccm/145.3.508; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094	15	95	96	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					743	746		10.7326/0003-4819-138-9-200305060-00011	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729429				2022-12-28	WOS:000182661400007
J	Steinbrook, R				Steinbrook, R			HIV infection - A new drug and new costs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	14	14	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2171	2172		10.1056/NEJMp030043	http://dx.doi.org/10.1056/NEJMp030043			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773643				2022-12-28	WOS:000183134700001
J	Wu, JG; Huang, JH; Han, XG; Xie, ZQ; Gao, XM				Wu, JG; Huang, JH; Han, XG; Xie, ZQ; Gao, XM			Three-Gorges Dam - Experiment in habitat fragmentation?	SCIENCE			English	Editorial Material							FOREST FRAGMENTS; ECOLOGY		Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA; Chinese Acad Sci, Inst Bot, Beijing, Peoples R China	Arizona State University; Arizona State University-Tempe; Chinese Academy of Sciences; Institute of Botany, CAS	Wu, JG (corresponding author), Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA.	jingle.wu@asu.edu	Wu, Jianguo/G-6267-2010; Han, Xingguo/K-7552-2016	Wu, Jianguo/0000-0002-1182-3024; Han, Xingguo/0000-0002-1836-975X				[Anonymous], 2000, DAMS DEV NEW FRAM DE; da Fonseca GAB, 2002, SCIENCE, V295, P1835; Diamond J, 2001, SCIENCE, V294, P1847, DOI 10.1126/science.1067012; DIAMOND JM, 1972, P NATL ACAD SCI USA, V69, P3199, DOI 10.1073/pnas.69.11.3199; EDMONDS RL, 1992, GLOBAL ECOL BIOGEOGR, V2, P105, DOI 10.2307/2997637; Haila Y, 2002, ECOL APPL, V12, P321, DOI 10.1890/1051-0761(2002)012[0321:ACGOFR]2.0.CO;2; Hubbell Stephen P., 2001, V32, pi; Laurance WF, 2002, CONSERV BIOL, V16, P605, DOI 10.1046/j.1523-1739.2002.01025.x; Laurance WF, 2001, SCIENCE, V291, P438, DOI 10.1126/science.291.5503.438; Lei X, 1998, SCIENCE, V280, P25, DOI 10.1126/science.280.5360.25; LOVEJOY TE, 1986, CONSERVATION BIOL SC, P251; ROBINSON GR, 1992, SCIENCE, V257, P524, DOI 10.1126/science.257.5069.524; ROBINSON SK, 1995, SCIENCE, V267, P1987, DOI 10.1126/science.267.5206.1987; Schrope M, 2000, NATURE, V408, P395, DOI 10.1038/35044245; Shen Z H, 2000, J WUHAN BOT RES, V18, P99; TERBORGH J, 1974, BIOSCIENCE, V24, P715, DOI 10.2307/1297090; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; Wu J., 1995, ENCY ENV BIOL, P371; Wu J.G., 2000, CHINESE J ECOL, V19, P42, DOI [10.13292/j.1000-4890.2000.0008, DOI 10.13292/J.1000-4890.2000.0008]; Wu JG, 1995, Q REV BIOL, V70, P439, DOI 10.1086/419172; XIAO W, 2000, ECOLOGY TERRESTRIAL; Zhenli H., 2001, BIODIVERS SCI, V9, P472, DOI [DOI 10.3321/J.ISSN:1005-0094.2001.04.021, 10.17520/biods.2001068, DOI 10.17520/BIODS.2001068]	22	282	357	18	278	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1239	1240		10.1126/science.1083312	http://dx.doi.org/10.1126/science.1083312			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764179				2022-12-28	WOS:000183042400028
J	Platt, T; Fuentes-Yaco, C; Frank, KT				Platt, T; Fuentes-Yaco, C; Frank, KT			Spring algal bloom and larval fish survival	NATURE			English	Article									Fisheries & Oceans Canada, Bedford Inst Oceanog, Ocean Sci Div, Dartmouth, NS B2Y 4A2, Canada; Dalhousie Univ, Dept Oceanog, Halifax, NS B3H 4J1, Canada	Bedford Institute of Oceanography; Fisheries & Oceans Canada; Dalhousie University	Platt, T (corresponding author), Fisheries & Oceans Canada, Bedford Inst Oceanog, Ocean Sci Div, Box 1006, Dartmouth, NS B2Y 4A2, Canada.							Cushing D.H., 1974, P399; CUSHING DH, 1990, ADV MAR BIOL, V26, P249, DOI 10.1016/S0065-2881(08)60202-3; Hjort J., 1914, RAPP P V REUN CONS I, V20, P1; KANE J, 1984, MAR ECOL PROG SER, V16, P9, DOI 10.3354/meps016009; MOHN RK, 2002, 2002102 CSAS RES; PLATT T, 1996, O3 CM INT COUN EXPL; Sverdrup H.U., 1953, J CONSEILCONSEIL PER, V18, P287, DOI [10.1093/icesjms/18.3.287, DOI 10.1093/ICESJMS/18.3.287]	7	424	436	8	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					398	399		10.1038/423398b	http://dx.doi.org/10.1038/423398b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761538				2022-12-28	WOS:000183012000029
J	Coffey, C; Veit, F; Wolfe, R; Cini, E; Patton, GC				Coffey, C; Veit, F; Wolfe, R; Cini, E; Patton, GC			Mortality in young offenders: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-HEALTH; ADOLESCENTS; CUSTODY; ABUSE	Objectives To estimate overall and cause specific standardised mortality ratios in young offenders. Design Comparison of mortality data in cohort of young offenders. Settings State of Victoria, Australia. Subjects Cohort of young offenders aged 10-20 years with a first custodial sentence from 1 January 1988 to 31 December 1999. Main outcome measures Deaths ascertained by matching with the national death index, a database containing records of all deaths in Australia since 1980. Death rates in the reference Victorian population used to calculate standardised mortality ratios. Results The offender cohort comprised 2621 men and 228 women with 11 333 person years of observation. The median age of first detention was 17.9 years for men and 18.4 years for women. Median follow up was 3.3 years for men and 1.4 years for women. Overall standardised mortality ratio adjusted for age (expressed as a ratio) was 9.4 (95% confidence interval 7.4 to 11.9) for men and 41.3 (20.2 to 84.7) for women. Cause specific standardised mortality ratios for men were 25.7 (17.9 to 36.9) for drug related causes, 9.2 (5.8 to 15) for suicide, and 5.7 (3.6 to 9.2) for non-intentional injury. A quarter of drug related deaths in men aged 15-19 years were in offenders. Conclusions Social policies for young offenders should address both the prevalent drug and mental health problems as well the high levels of social disadvantage.	Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Parkville, Vic 3052, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3000, Australia	Murdoch Children's Research Institute; Monash University	Coffey, C (corresponding author), Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Parkville, Vic 3052, Australia.		Ribeiro, Ana Cristina/HHN-7466-2022; Patton, George C/B-5246-2013	Ribeiro, Ana Cristina/0000-0002-0493-8376; Patton, George C/0000-0001-5039-8326; Wolfe, Rory/0000-0002-2126-1045				ANDERSON B, 2001, 5 YOUTH JUST BOARD; Bickel R, 2002, AUST NZ J PSYCHIAT, V36, P603, DOI 10.1046/j.1440-1614.2002.01073.x; FARRINGTON DP, 1995, CRIM BEHAV MENT HEAL, V0005; Fasher AM, 1997, J PAEDIATR CHILD H, V33, P426; HALL W, 1999, 67 NDARC U NEW S WAL; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; Kalland M, 2001, BRIT MED J, V323, P207, DOI 10.1136/bmj.323.7306.207; KOSKY RJ, 1990, MED J AUSTRALIA, V153, P24, DOI 10.5694/j.1326-5377.1990.tb125458.x; Kosky RJ, 1996, AUST NZ J PSYCHIAT, V30, P326, DOI 10.3109/00048679609064994; LEFFERT N, 1995, PSYCHOSOCIAL DISORDE, P37; Oyefeso A, 1999, SOC PSYCH PSYCH EPID, V34, P437, DOI 10.1007/s001270050166; Rothman K., 1998, MODERN EPIDEMIOLOGY; RYDELIUS PA, 1988, ACTA PSYCHIAT SCAND, V77, P398, DOI 10.1111/j.1600-0447.1988.tb05141.x; SILBEREISEN RK, 1995, PSYCHOSOCIAL DISORDE; SMITH DJ, 1995, PSYCHOSOCIAL DISORDE; Stattin H., 1995, CRIM BEHAV MENT HEAL, V5, P279, DOI [10.1002/cbm.1995.5.4.279, DOI 10.1002/CBM.1995.5.4.279]; Thompson SC, 1998, AUST NZ J PUBL HEAL, V22, P573, DOI 10.1111/j.1467-842X.1998.tb01441.x; Thompson SC, 1998, MED J AUSTRALIA, V169, P306, DOI 10.5694/j.1326-5377.1998.tb140281.x; Veit F, 2000, DRUG ALCOHOL REV, V19, P457, DOI 10.1080/713659429; Weinberg NZ, 1998, J AM ACAD CHILD PSY, V37, P252, DOI 10.1097/00004583-199803000-00009; YAEGER CA, 1990, AM J PSYCHIAT, V147, P612	21	78	78	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2003	326	7398					1064	1066		10.1136/bmj.326.7398.1064	http://dx.doi.org/10.1136/bmj.326.7398.1064			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681ZD	12750207	Green Published, Bronze			2022-12-28	WOS:000183064700015
J	Morton, V; Torgerson, DJ				Morton, V; Torgerson, DJ			Effect of regression to the mean on decision making in health care	BRITISH MEDICAL JOURNAL			English	Article							THERAPY		Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England	University of York - UK	Torgerson, DJ (corresponding author), Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; Cummings SR, 2000, JAMA-J AM MED ASSOC, V283, P1318, DOI 10.1001/jama.283.10.1318; Galton F., 1886, J ANTHR I, V15, P246, DOI 10.2307%2F2841583; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; PEARCE J, 1995, BRIT J PSYCHIAT, V167, P163, DOI 10.1192/bjp.167.2.163; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; Wise J, 2001, BRIT MED J, V322, P70	8	181	184	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2003	326	7398					1083	1084		10.1136/bmj.326.7398.1083	http://dx.doi.org/10.1136/bmj.326.7398.1083			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681ZD	12750214	Green Accepted, Green Published			2022-12-28	WOS:000183064700023
J	Stohr, K				Stohr, K		World Hlth Org Multicentre Coll	A multicentre collaboration to investigate the cause of severe acute respiratory syndrome	LANCET			English	Article							NIPAH VIRUS; INFECTIONS	Severe acute respiratory syndrome is a new disease In human beings, first recognised in late February, 2003, in Hanoi, Vietnam. The severity of the disease, combined with its rapid spread along international air-travel routes, prompted WHO to set up a network of scientists from 11 laboratories around the world to try to identify the causal agent and develop a diagnostic test. The network unites laboratories with different methods and capacities to rapidly fulfil all postulates for establishing a virus as the cause of a disease. Results are shared in real time via a secure website, on which microscopy pictures, protocols for testing, and PCR primer sequences are also posted. Findings are discussed in daily teleconferences. Progress is further facilitated through sharing between laboratories of samples and test materials. The network has identified a new coronavirus, consistently detected in samples of SARS patients from several countries, and conclusively named it as the causative agent of SARS; the strain Is unlike any other known member of the genus Coronavirus. Three diagnostic tests are now available, but all have limitations.	WHO, Communicable Dis, CH-1211 Geneva 27, Switzerland	World Health Organization	Stohr, K (corresponding author), WHO, Communicable Dis, CH-1211 Geneva 27, Switzerland.	SARSetiology@who.int						Almond J, 1997, NATURE, V389, P437, DOI 10.1038/38876; [Anonymous], 2003, Wkly Epidemiol Rec, V78, P73; [Anonymous], 1985, World Health Organ Tech Rep Ser, V719, P1; [Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P81; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; DROSTEN C, IDENTIFICATION NOVEL; Enserink M, 2003, SCIENCE, V300, P224, DOI 10.1126/science.300.5617.224; FENG P, 1995, EMERG INFECT DIS, V1, P47, DOI 10.3201/eid0102.950202; Goh KJ, 2000, NEW ENGL J MED, V342, P1229, DOI 10.1056/NEJM200004273421701; Gubler DJ, 2001, ANN NY ACAD SCI, V951, P13; Heymann DL, 1999, J INFECT DIS, V179, pS283, DOI 10.1086/514287; KSIAZEK TG, NOVEL CORONAVIRUS AS; LEE N, MAJOR OUTBREAK SEVER; McCormack JG, 2002, MED J AUSTRALIA, V177, P45, DOI 10.5694/j.1326-5377.2002.tb04637.x; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Petersen LR, 2001, EMERG INFECT DIS, V7, P611; Rivers TM, 1937, J BACTERIOL, V33, P1; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Wells RM, 1997, EMERG INFECT DIS, V3, P361, DOI 10.3201/eid0303.970314; *WHO, WHO COLL MULT RES PR; *WHO, SEV AC RESP SYNDR WH; *WHO, AC RESP SYNDR CHIN U; *WHO, SIT UPD SEV AC RESP; WHO, WHO ISS GLOB AL CAS; *WHO, WHO ISS EM TRAV ADV; World Health Organization, CUM NUMB REP PROB CA; 2003, MORB MORTAL WKLY REP, V52, P226; 2003, WKLY EPIDEMIOL REC, V78, P49; 2001, WKLY EPIDEMIOL REC, V76, P41; 2003, WKLY EPIDEMIOL REC, V78, P41; 2002, WKLY EPIDEMIOL REC, V77, P152	33	123	136	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1730	1733		10.1016/S0140-6736(03)13376-4	http://dx.doi.org/10.1016/S0140-6736(03)13376-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767752	Green Published, Bronze			2022-12-28	WOS:000182919700026
J	Holmes, KV				Holmes, KV			SARS-associated coronavirus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Holmes, KV (corresponding author), Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA.							Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2	1	216	271	0	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					1948	1951		10.1056/NEJMp030078	http://dx.doi.org/10.1056/NEJMp030078			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12748314	Bronze			2022-12-28	WOS:000182823400002
J	Kronenberg, HM				Kronenberg, HM			Developmental regulation of the growth plate	NATURE			English	Review							HORMONE-RELATED PEPTIDE; ENDOCHONDRAL BONE-DEVELOPMENT; PARATHYROID-HORMONE; INDIAN HEDGEHOG; CHONDROCYTE DIFFERENTIATION; CBFA1-DEFICIENT MICE; TARGETED DISRUPTION; FACTOR RECEPTOR-3; JOINT FORMATION; MOUSE LIMB	Vertebrates do not look like jellyfish because the bones of their skeletons are levers that allow movement and protect vital organs. Bones come in an enormous variety of shapes and sizes to accomplish these goals, but, with few exceptions, use one process endochondral bone formation to generate the skeleton. The past few years have seen an enormous increase in understanding of the signalling pathways and the transcription factors that control endochondral bone development.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kronenberg, HM (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.							Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Baur ST, 2000, DEVELOPMENT, V127, P605; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Chung UI, 1998, P NATL ACAD SCI USA, V95, P13030, DOI 10.1073/pnas.95.22.13030; Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Karp SJ, 2000, DEVELOPMENT, V127, P543; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Long FX, 2001, DEVELOPMENT, V128, P5099; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Minina E, 2001, DEVELOPMENT, V128, P4523; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Naski MC, 1998, DEVELOPMENT, V125, P4977; Noonan KJ, 1998, J ORTHOPAED RES, V16, P500, DOI 10.1002/jor.1100160416; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Rosen V., 2002, PRINCIPLES BONE BIOL, P919; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; St-Jacques B, 1999, GENE DEV, V13, P2617; Storm EE, 1999, DEV BIOL, V209, P11, DOI 10.1006/dbio.1999.9241; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; Yi SE, 2000, DEVELOPMENT, V127, P621	38	1948	2058	3	185	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					332	336		10.1038/nature01657	http://dx.doi.org/10.1038/nature01657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748651				2022-12-28	WOS:000182853100053
J	Nicolaou, S; Al-Nakshabandi, NA; Muller, NL				Nicolaou, S; Al-Nakshabandi, NA; Muller, NL			Radiologic manifestations of severe acute respiratory syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Nicolaou, S (corresponding author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.								0	7	11	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					2006	2006		10.1056/NEJMicm030360	http://dx.doi.org/10.1056/NEJMicm030360			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12748316				2022-12-28	WOS:000182823400009
J	Zelzer, E; Olsen, BR				Zelzer, E; Olsen, BR			The genetic basis for skeletal diseases	NATURE			English	Review							GROWTH-FACTOR RECEPTOR-3; RECESSIVE ROBINOW-SYNDROME; AUTOSOMAL SEX REVERSAL; TGF-BETA-SUPERFAMILY; BRACHYDACTYLY TYPE-B; SRY-RELATED GENE; TYROSINE KINASE; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS; BONE-DEVELOPMENT	We walk, run, work and play, paying little attention to our bones, their joints and their muscle connections, because the system works. Evolution has refined robust genetic mechanisms for skeletal development and growth that are able to direct the formation of a complex, yet wonderfully adaptable organ system. How is it done? Recent studies of rare genetic diseases have identified many of the critical transcription factors and signalling pathways specifying the normal development of bones, confirming the wisdom of William Harvey when he said: "nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten path".	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Olsen, BR (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.							Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Belin V, 1998, NAT GENET, V19, P67, DOI 10.1038/ng0198-67; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; BOBER E, 1994, DEVELOPMENT, V120, P603; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Gong YQ, 1999, NAT GENET, V21, P302, DOI 10.1038/6821; Hall CM, 2002, AM J MED GENET, V113, P65, DOI 10.1002/ajmg.10828; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hopyan S, 2002, NAT GENET, V30, P306, DOI 10.1038/ng844; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Jobert AS, 1998, J CLIN INVEST, V102, P34, DOI 10.1172/JCI2918; Johnson KR, 1998, HUM MOL GENET, V7, P1033, DOI 10.1093/hmg/7.6.1033; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Mansouri A, 2001, DEVELOPMENT, V128, P1995; McCready ME, 2002, HUM GENET, V111, P368, DOI 10.1007/s00439-002-0815-2; McCright B, 2002, DEVELOPMENT, V129, P1075; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Munns C F, 2001, Hand Surg, V6, P13, DOI 10.1142/S0218810401000424; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Polinkovsky A, 1997, NAT GENET, V17, P18, DOI 10.1038/ng0997-18; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; Ross JL, 2003, AM J MED GENET A, V116A, P61, DOI 10.1002/ajmg.a.10807; Royce PM, 2002, CONNECTIVE TISSUE IT; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Shears DJ, 2002, AM J MED GENET, V110, P153, DOI 10.1002/ajmg.10421; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Thien H, 1999, MAMM GENOME, V10, P205, DOI 10.1007/s003359900973; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Wilkie A O, 2001, Novartis Found Symp, V232, P122; Wilkie AO, 2001, NOVART FDN SYMP, V232, P133; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	75	196	204	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					343	348		10.1038/nature01659	http://dx.doi.org/10.1038/nature01659			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748653				2022-12-28	WOS:000182853100055
J	Baker, L; Wagner, TH; Singer, S; Bundorf, MK				Baker, L; Wagner, TH; Singer, S; Bundorf, MK			Use of the Internet and e-mail for health care information - Results from a national survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORLD-WIDE-WEB; METASTATIC BREAST-CANCER; CROSS-SECTIONAL SURVEY; PATIENT E-MAIL; MEDICAL INFORMATION; QUALITY; ADVICE	Context The Internet has attracted considerable attention as a means to improve health and health care delivery, but it is not clear how prevalent Internet use for health care really is or what impact it has on health care utilization. Available estimates of use and impact vary widely. Without accurate estimates of use and effects, it is difficult to focus policy discussions. or design appropriate policy activities. Objectives To measure the extent of Internet use for health care among a representative sample of the US population, to examine the prevalence of e-mail use for health care, and to examine the effects that Internet and e-mail use has on users, knowledge about health care matters and their use of the health care system. Design, Setting, and Participants Survey conducted in December 2001. and January 2002 among a sample drawn from a research panel of more than 60000 US households developed and maintained by Knowledge Networks. Responses were analyzed from 4764 individuals aged 21 years or older who were self-reported Internet users. Main Outcome Measures Self-reported rates in the past year of Internet and e-mail use to obtain information related to health, contact health care professionals, and obtain prescriptions; perceived effects of Internet and e-mail use on health care use. Results Approximately 40% of respondents with Internet access reported using the Internet to look for advice or information about health or health care in 2001. Six percent reported using e-mail to contact a physician or other health care professional. About one third of those using the Internet for health reported that using the Internet affected a decision about health or their health care, but very few reported impacts on measurable health care utilization; 94% said that Internet use had no effect on the number of physician visits they had and 93% said it had no effect on the number of telephone contacts. Five percent or less reported use of the Internet to obtain prescriptions or. purchase pharmaceutical products. Conclusions Although many people use the Internet for health information, use is not as common as is sometimes reported. Effects on actual health care utilization are also less substantial than some have claimed. Discussions of the role of the Internet in health care and the development of policies that might influence this role should not presume that use of the Internet for health information is universal or that the Internet strongly influences health care utilization.	Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA; Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA; VA Palo Alto Hlth Care Syst, VA Hlth Serv Res & Dev Hlth Econ Resource Ctr, Palo Alto, CA USA	Stanford University; Stanford University; Stanford University; National Bureau of Economic Research; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Baker, L (corresponding author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, HRP Redwood Bldg,Room 253, Stanford, CA 94305 USA.			Singer, Sara/0000-0002-3374-1177; Baker, Laurence/0000-0001-5032-794X; Bundorf, M. Kate/0000-0002-9824-4868; Wagner, Todd/0000-0001-7625-3504	NATIONAL INSTITUTE ON AGING [P30AG017253] Funding Source: NIH RePORTER; NIA NIH HHS [AG17253] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blumenthal D, 2002, MILBANK Q, V80, P525, DOI 10.1111/1468-0009.00021; BLY L, 1999, US TODAY        0514, pD1; Borowitz SM, 1998, JAMA-J AM MED ASSOC, V280, P1321, DOI 10.1001/jama.280.15.1321; Brodie M, 2000, HEALTH AFFAIR, V19, P255, DOI 10.1377/hlthaff.19.6.255; CAREY B, 2001, LOS ANGELES TIM 0402, pS3; Classen C, 2001, ARCH GEN PSYCHIAT, V58, P494, DOI 10.1001/archpsyc.58.5.494; Couchman GR, 2001, J FAM PRACTICE, V50, P414; Culver JD, 1997, J GEN INTERN MED, V12, P466, DOI 10.1046/j.1525-1497.1997.00084.x; *DEP COMM NAT TEL, 2002, NAT ONL AR EXP THEIR; ELIAS M, 2001, USA TODAY       0319, pD7; Eysenbach G, 1998, JAMA-J AM MED ASSOC, V280, P1333, DOI 10.1001/jama.280.15.1333; Fogel J, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e9; FOX S, 2000, ONLINE HLTH CARE REV; Gingrich N, 2000, HEALTH AFFAIR, V19, P33; Griffiths KM, 2000, BMJ-BRIT MED J, V321, P1511, DOI 10.1136/bmj.321.7275.1511; HORRIGAN J, 2002, GETTING SERIOUS ONLI; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; Kleinke JD, 2000, HEALTH AFFAIR, V19, P57, DOI 10.1377/hlthaff.19.6.57; LANDRO L, 2002, WALL STREET J   0425, pD4; Lorig KR, 2002, ARCH INTERN MED, V162, P792, DOI 10.1001/archinte.162.7.792; Mandl KD, 2000, ARCH PEDIAT ADOL MED, V154, P508, DOI 10.1001/archpedi.154.5.508; MARTIN JP, 1999, WASH POST       0831, pZ10; Meric F, 2002, BMJ-BRIT MED J, V324, P577, DOI 10.1136/bmj.324.7337.577; National Research Council, 2000, NETW HLTH PRESCR INT; Pealer LN, 1997, J SCHOOL HEALTH, V67, P232, DOI 10.1111/j.1746-1561.1997.tb06311.x; Pennbridge J, 1999, WESTERN J MED, V171, P302; Potts HWW, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.1.e5; Purcell GP, 2002, BMJ-BRIT MED J, V324, P557, DOI 10.1136/bmj.324.7337.557; REID B, 2002, WASH POST       1105, pF1; SCHOROW S, 2002, BOSTON HERALD   0123, P45; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Sittig DF, 2001, INT J MED INFORM, V61, P71, DOI 10.1016/S1386-5056(00)00134-9; SPIEGEL D, 1989, LANCET, V2, P888; Spielberg AR, 1998, JAMA-J AM MED ASSOC, V280, P1353, DOI 10.1001/jama.280.15.1353; TAYLOR H, 2000, EXPLOSIVE GROWTH CYB; TAYLOR H, 2001, CYBERCHONDRIACS UPDA; TAYLOR H, 2003, CYBERCHONDRIACS UPDA; WAGNER TH, 2003, USE INTERNET CHRONIC; WATSON R, 2001, NEWSWEEK, P54; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879	41	804	811	3	93	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2400	2406		10.1001/jama.289.18.2400	http://dx.doi.org/10.1001/jama.289.18.2400			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	677WF	12746364	Bronze			2022-12-28	WOS:000182831200030
J	So, LKY; Lau, ACW; Yam, LYC; Cheung, TMT; Poon, E; Yung, RWH; Yuen, KY				So, LKY; Lau, ACW; Yam, LYC; Cheung, TMT; Poon, E; Yung, RWH; Yuen, KY			Development of a standard treatment protocol for severe acute respiratory syndrome	LANCET			English	Editorial Material								A series of 31 patients with probable SARS, diagnosed from WHO criteria, were treated according to a treatment protocol consisting of antibacterials and a combination of ribavirin and methylprednisolone. Through experience with the first 11 patients, we were able to finalise standard dose regimens, including pulsed methylprednisolone. One patient recovered on antibacterial treatment alone, 17 showed rapid and sustained responses, and 13 achieved Improvement with step-up or pulsed methylprednisolone. Four patients required short periods of non-invasive ventilation. No patient required intubation or mechanical ventilation. There was no mortality or treatment morbidity in this series.	Pamela Youde Nethersole Eastern Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Pamela Youde Nethersole Eastern Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	Pamela Youde Nethersole Eastern Hospital; Pamela Youde Nethersole Eastern Hospital; University of Hong Kong	So, LKY (corresponding author), Dept Med, 3 Lok Man Rd, Chaiwan, Hong Kong, Peoples R China.	drewlau@hkstar.com		Yuen, Kwok-yung/0000-0002-2083-1552				Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; LEE N, MAJOR OUTBREAK SEVER; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; TSANG KW, CLUSTER CASES SEVERE; *WHO, CAS DEF SURV SEV AC	5	229	262	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	2003	361	9369					1615	1617		10.1016/S0140-6736(03)13265-5	http://dx.doi.org/10.1016/S0140-6736(03)13265-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747883	Bronze, Green Published			2022-12-28	WOS:000182746300013
J	Bardelli, A; Parsons, DW; Silliman, N; Ptak, J; Szabo, S; Saha, S; Markowitz, S; Willson, JKV; Parmigiani, G; Kinzler, KW; Vogelstein, B; Velculescu, VE				Bardelli, A; Parsons, DW; Silliman, N; Ptak, J; Szabo, S; Saha, S; Markowitz, S; Willson, JKV; Parmigiani, G; Kinzler, KW; Vogelstein, B; Velculescu, VE			Mutational analysis of the tyrosine kinome in colorectal cancers	SCIENCE			English	Article							KINASE		Johns Hopkins, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins, Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Univ Hosp Cleveland, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University	Velculescu, VE (corresponding author), Johns Hopkins, Howard Hughes Med Inst, Baltimore, MD 21231 USA.		Velculescu, Victor/ABF-4846-2020; BARDELLI, Alberto/J-9721-2018	Velculescu, Victor/0000-0003-1195-438X; Parsons, Donald/0000-0002-8775-3501; BARDELLI, Alberto/0000-0003-1647-5070	NATIONAL CANCER INSTITUTE [R37CA057345, R01CA057345, R37CA043460, R01CA043460, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924, CA43460, CA57345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762	3	397	480	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					949	949		10.1126/science.1082596	http://dx.doi.org/10.1126/science.1082596			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738854				2022-12-28	WOS:000182719800046
J	Priori, SG; Schwartz, PJ; Napolitano, C; Bloise, R; Ronchetti, E; Grillo, M; Vicentini, A; Spazzolini, C; Nastoli, J; Bottelli, G; Folli, R; Cappelletti, D				Priori, SG; Schwartz, PJ; Napolitano, C; Bloise, R; Ronchetti, E; Grillo, M; Vicentini, A; Spazzolini, C; Nastoli, J; Bottelli, G; Folli, R; Cappelletti, D			Risk stratification in the long-QT syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC-ARRHYTHMIAS; MUTATIONS; REGISTRY; GENOTYPE; CHANNEL; THERAPY; KVLQT1; IMPACT; SCN5A; GENES	BACKGROUND: Mutations in potassium-channel genes KCNQ1 (LQT1 locus) and KCNH2 (LQT2 locus) and the sodium-channel gene SCN5A (LQT3 locus) are the most common causes of the long-QT syndrome. We stratified risk according to the genotype, in conjunction with other clinical variables such as sex and the length of the QT interval. METHODS: We evaluated 647 patients (386 with a mutation at the LQT1 locus, 206 with a mutation at the LQT2 locus, and 55 with a mutation at the LQT3 locus) from 193 consecutively genotyped families with the long-QT syndrome. The cumulative probability of a first cardiac event, defined as the occurrence of syncope, cardiac arrest, or sudden death before the age of 40 years and before the initiation of therapy, was determined according to genotype, sex, and the QT interval corrected for heart rate (QTc). Within each genotype we also assessed risk in the four categories derived from the combination of sex and QTc (<500 msec or greater/equal 500 msec). RESULTS: The incidence of a first cardiac event before the age of 40 years and before the initiation of therapy was lower among patients with a mutation at the LQT1 locus (30 percent) than among those with a mutation at the LQT2 locus (46 percent) or those with a mutation at the LQT3 locus (42 percent) (P<0.001 by Fisher's exact test). Multivariate analysis showed that the genetic locus and the QTc, but not sex, were independent predictors of risk. The QTc was an independent predictor of risk among patients with a mutation at the LQT1 locus and those with a mutation at the LQT2 locus but not among those with a mutation at the LQT3 locus, whereas sex was an independent predictor of events only among those with a mutation at the LQT3 locus. CONCLUSIONS: The locus of the causative mutation affects the clinical course of the long-QT syndrome and modulates the effects of the QTc and sex on clinical manifestations. We propose an approach to risk stratification based on these variables.	Univ Pavia, Maugeri Fdn, I-27100 Pavia, Italy; Fdn S Maugeri, Ist Ric & Cura Carattere Sci, Dept Mol Cardiol, Pavia, Italy; Policlin San Matteo, Ist Ric & Cura Carattere, Dept Cardiol, I-27100 Pavia, Italy	Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS; IRCCS Fondazione San Matteo	Priori, SG (corresponding author), Univ Pavia, Maugeri Fdn, Via Ferrata 8, I-27100 Pavia, Italy.		Priori, Silvia G/ABH-6894-2020; napolitano, carlo/ABI-4608-2020; bloise, raffaella/AAC-2922-2020; Spazzolini, Carla/AAA-5023-2020; Schwartz, Peter J./J-4267-2016	Priori, Silvia G/0000-0001-6877-0288; napolitano, carlo/0000-0002-7643-4628; bloise, raffaella/0000-0003-3485-9596; Spazzolini, Carla/0000-0003-1209-0157; Schwartz, Peter J./0000-0003-0367-1048; Nastoli, janni/0000-0002-5888-5951; ronchetti, elena/0000-0002-9185-7848	Telethon [GP0227Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Locati EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237; Moss AJ, 2002, CIRCULATION, V105, P794, DOI 10.1161/hc0702.105124; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; Moss AJ, 2000, CIRCULATION, V101, P616, DOI 10.1161/01.CIR.101.6.616; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; Priori SG, 2001, EUR HEART J, V22, P1374, DOI 10.1053/euhj.2001.2824; Priori SG, 1999, CIRCULATION, V99, P518, DOI 10.1161/01.CIR.99.4.518; Priori SG, 2002, EUR HEART J, V23, P257; Priori SG, 1999, CIRCULATION, V99, P529, DOI 10.1161/01.CIR.99.4.529; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; Schwartz PJ, 2001, CIRCULATION, V103, P89; SCHWARTZ PJ, 1983, EUR HEART J, V4, P529, DOI 10.1093/oxfordjournals.eurheartj.a061517; SCHWARTZ PJ, 2000, CARDIAC ELECTROPHYSI, P597; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; WARD O C, 1964, J Ir Med Assoc, V54, P103; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404	20	965	1006	2	34	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1866	1874		10.1056/NEJMoa022147	http://dx.doi.org/10.1056/NEJMoa022147			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12736279				2022-12-28	WOS:000182684100005
J	Wasan, DT; Nikolov, AD				Wasan, DT; Nikolov, AD			Spreading of nanofluids on solids	NATURE			English	Article							COLLOIDAL CRYSTALS; WETTING FILMS; DYNAMICS; SURFACE; FORCES; FLUID	Suspensions of nanometre-sized particles (nanofluids) are used in a variety of technological contexts. For example, their spreading and adhesion behaviour on solid surfaces can yield materials with desirable structural and optical properties(1). Similarly, the spreading behaviour of nanofluids containing surfactant micelles has implications for soil remediation, oily soil removal, lubrication and enhanced oil recovery. But the well-established concepts of spreading and adhesion of simple liquids do not apply to nanofluids(2-7). Theoretical investigations have suggested that a solid-like ordering of suspended spheres will occur in the confined three-phase contact region at the edge of the spreading fluid, becoming more disordered and fluid-like towards the bulk phase(8,9). Calculations have also suggested that the pressure arising from such colloidal ordering in the confined region will enhance the spreading behaviour of nanofluids(10,11). Here we use video microscopy to demonstrate both the two-dimensional crystal-like ordering of charged nanometre-sized polystyrene spheres in water, and the enhanced spreading dynamics of a micellar fluid, at the three-phase contact region. Our findings suggest a new mechanism for oily soil removal-detergency.	IIT, Dept Environm Chem & Engn, Chicago, IL 60616 USA	Illinois Institute of Technology	Wasan, DT (corresponding author), IIT, Dept Environm Chem & Engn, Chicago, IL 60616 USA.							Boda D, 1999, LANGMUIR, V15, P4311, DOI 10.1021/la981013h; Brauman JI, 1996, SCIENCE, V273, P855, DOI 10.1126/science.273.5277.855; CAZABAT AM, 1991, COLLOID SURFACE, V52, P1, DOI 10.1016/0166-6622(91)80002-6; CHURAEV NV, 1993, COLLOID SURFACE A, V79, P25, DOI 10.1016/0927-7757(93)80156-9; Churaev NV, 2001, LANGMUIR, V17, P1338, DOI 10.1021/la000789r; De Coninck J, 2001, CURR OPIN COLLOID IN, V6, P49, DOI 10.1016/S1359-0294(00)00087-X; DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827; DIMITROV AS, 1990, COLLOID SURFACE, V47, P299, DOI 10.1016/0166-6622(90)80080-N; KAO RL, 1989, COLLOID SURFACE, V34, P389, DOI 10.1016/0166-6622(88)80163-X; LOBO LA, 1990, LANGMUIR, V6, P995, DOI 10.1021/la00095a019; MURRAY CA, 1995, AM SCI, V83, P238; Neimark AV, 2000, LANGMUIR, V16, P5526, DOI [10.1021/la000267b, 10.1021/1a000267b]; NIKOLOV AD, 1986, OPT ACTA, V33, P1359, DOI 10.1080/713821887; NIKOLOV AD, 1986, S SERIES AM I CHEM E, V252, P82; NIKOLOV AD, 1995, HDB SURFACE IMAGING, P209; PIERANSKI P, 1983, PHYS REV LETT, V50, P900, DOI 10.1103/PhysRevLett.50.900; PIERANSKI P, 1983, CONTEMP PHYS, V24, P25, DOI 10.1080/00107518308227471; Ruckenstein E, 1996, J COLLOID INTERF SCI, V179, P136, DOI 10.1006/jcis.1996.0195; Tata BVR, 2000, PHYS REV E, V62, P3875, DOI 10.1103/PhysRevE.62.3875; Trokhymchuk A, 2001, LANGMUIR, V17, P4940, DOI 10.1021/la010047d; VANWINKLE DH, 1988, J CHEM PHYS, V89, P3885, DOI 10.1063/1.454864; Wasan DT, 1999, ACS SYM SER, V736, P40	22	620	655	16	319	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					156	159		10.1038/nature01591	http://dx.doi.org/10.1038/nature01591			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736681				2022-12-28	WOS:000182699600042
J	Epshtein, V; Nudler, E				Epshtein, V; Nudler, E			Cooperation between RNA polymerase molecules in transcription elongation	SCIENCE			English	Article							ESCHERICHIA-COLI; II ELONGATION; FACTOR-SII; MECHANISM; TERMINATION; COMPLEX; DNA; TRANSLOCATION; PROMOTER; PROTEIN	Transcription elongation is responsible for rapid synthesis of RNA chains of thousands of nucleotides in vivo. In contrast, a single round of transcription performed in vitro is frequently interrupted by pauses and arrests that drastically reduce the elongation rate and the yield of the full-length transcript. Here we demonstrate that most transcriptional delays disappear if more than one RNA polymerase (RNAP) molecule initiates from the same promoter. Anti-arrest and anti-pause effects of trailing RNAP are due to forward translocation of leading (backtracked) complexes. Such cooperation between RNAP molecules links the rate of elongation to the rate of initiation and explains why elongation is still fast and processive in vivo even without anti-arrest factors.	NYU Med Ctr, Dept Biochem, New York, NY 10016 USA	New York University	Nudler, E (corresponding author), NYU Med Ctr, Dept Biochem, New York, NY 10016 USA.	evgeny.nudler@med.nyu.edu		Nudler, Evgeny/0000-0002-8811-3071	NIGMS NIH HHS [GM58750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; EPSHTEIN V, UNPUB; FOE VE, 1977, COLD SPRING HARB SYM, V42, P723, DOI 10.1101/SQB.1978.042.01.074; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; GIARDINA C, 1993, J BIOL CHEM, V268, P23806; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; HAMMING J, 1981, NUCLEIC ACIDS RES, V9, P1339, DOI 10.1093/nar/9.6.1339; Hirayoshi K, 1999, METHOD ENZYMOL, V304, P351; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JACQUET MA, 1992, MOL MICROBIOL, V6, P1681, DOI 10.1111/j.1365-2958.1992.tb00893.x; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Toulme F, 2000, EMBO J, V19, P6853, DOI 10.1093/emboj/19.24.6853; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	30	168	174	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					801	805		10.1126/science.1083219	http://dx.doi.org/10.1126/science.1083219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730602				2022-12-28	WOS:000182579800052
J	Groisman, R; Polanowska, J; Kuraoka, I; Sawada, J; Saijo, M; Drapkin, R; Kisselev, AF; Tanaka, K; Nakatani, Y				Groisman, R; Polanowska, J; Kuraoka, I; Sawada, J; Saijo, M; Drapkin, R; Kisselev, AF; Tanaka, K; Nakatani, Y			The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage	CELL			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION-COUPLED REPAIR; COCKAYNE-SYNDROME; PROTEIN; DEGRADATION; PROTEASOME; CELLS; NEDD8; PATHWAY; DEUBIQUITINATION	Nucleotide excision repair (NER) is a major cellular defense against the carcinogenic effects of ultraviolet light from the sun. Mutational inactivation of NER proteins, like DDB and CSA, leads to hereditary diseases such as xeroderma pigmentosum (XP) and Cockayne syndrome (CS). Here, we show that DDB2 and CSA are each integrated into nearly identical complexes via interaction with DDB1. Both complexes contain cullin 4A and Roc1 and display ubiquitin ligase activity. They also contain the COP9 signalosome (CSN), a known regulator of cullin-based ubiquitin ligases. Strikingly, CSN differentially regulates ubiquitin ligase activity of the DDB2 and CSA complexes in response to UV irradiation. Knockdown of CSN with RNA interference leads to defects in NER. These results suggest that the distinct UV response of the DDB2 and CSA complexes is involved in diverse mechanisms of NER.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Osaka Univ, Grad Sch Frontier Biosci, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Osaka 5650871, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Osaka University; Japan Science & Technology Agency (JST)	Nakatani, Y (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Polanowska, Jolanta/P-9117-2016; Drapkin, Ronny/E-9944-2016	Polanowska, Jolanta/0000-0001-7666-7010; Drapkin, Ronny/0000-0002-6912-6977; Groisman, Sonia/0000-0003-1153-3841; Groisman, Regina/0000-0003-3990-7622; Kuraoka, Isao/0000-0001-6391-3411				Bootsma D., 1998, GENETIC BASIS HUMAN, P254; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CARREAU M, 1992, MUTAT RES, V274, P57, DOI 10.1016/0921-8777(92)90043-3; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lee SK, 2002, CELL, V109, P823, DOI 10.1016/S0092-8674(02)00795-X; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nakatsu Y, 2000, J BIOL CHEM, V275, P34931, DOI 10.1074/jbc.M004936200; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wakasugi M, 2001, J BIOL CHEM, V276, P15434, DOI 10.1074/jbc.M011177200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	39	575	612	2	18	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 2	2003	113	3					357	367		10.1016/S0092-8674(03)00316-7	http://dx.doi.org/10.1016/S0092-8674(03)00316-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732143	Bronze			2022-12-28	WOS:000182640800010
J	Hartl, P				Hartl, P			A 42 year old man with acute chest pain: case outcome - Commentary: Patient's view	BRITISH MEDICAL JOURNAL			English	Editorial Material									Vienna Gen Hosp, Dept Emergency Med, A-1093 Vienna, Austria; Vienna Gen Hosp, Dept Radiol, A-1093 Vienna, Austria		Hartl, P (corresponding author), Vienna Gen Hosp, Dept Emergency Med, Wahringer Gurtel 18-20, A-1093 Vienna, Austria.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1133	1134		10.1136/bmj.326.7399.1133-a	http://dx.doi.org/10.1136/bmj.326.7399.1133-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763988	Green Published			2022-12-28	WOS:000183245000026
J	Caro, G; Bourdon, B; Birck, JL; Moorbath, S				Caro, G; Bourdon, B; Birck, JL; Moorbath, S			Sm-146-Nd-142 evidence from Isua metamorphosed sediments for early differentiation of the Earth's mantle	NATURE			English	Article							ND-ISOTOPE HETEROGENEITY; RAPID ACCRETION; NORTHERN CANADA; WEST GREENLAND; CASE-HISTORIES; SM-ND; SYSTEMATICS; CRUST; EVOLUTION; NEODYMIUM	Application of the Sm-147-Nd-143 chronometer (half-life of 106 Gyr) suggests that large-scale differentiation of the Earth's mantle may have occurred during the first few hundred million years of its history(1). However, the signature of mantle depletion found in early Archaean rocks is often obscured by uncertainties resulting from open-system behaviour of the rocks during later high-grade metamorphic events(2). Hence, although strong hints exist regarding the presence of differentiated silicate reservoirs before 4.0 Gyr ago, both the nature and age of early mantle differentiation processes remain largely speculative(3-5). Here we apply short-lived Sm-146-Nd-142 chronometry (half-life of 103 Myr) to early Archaean rocks using ultraprecise measurement of Nd isotope ratios. The analysed samples are well-preserved metamorphosed sedimentary rocks from the 3.7-3.8-Gyr Isua greenstone belt of West Greenland. All display well-resolved Nd-142 anomalies averaging 15 +/- 4 p.p.m. (2sigma). Using the initial epsilon(143)Nd value from ref. 6 coupled Sm-146-Sm-147 chronometry constrains the mean age of mantle differentiation to 4,460 +/- 115 Myr. This early Sm/Nd fractionation probably reflects differentiation of the Earth's mantle during the final stage of terrestrial accretion.	Univ Paris 07, Inst Phys Globe Paris, Lab Geochim & Cosmochim, CNRS,UMR 7579, F-75252 Paris 05, France; Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Oxford	Caro, G (corresponding author), Univ Paris 07, Inst Phys Globe Paris, Lab Geochim & Cosmochim, CNRS,UMR 7579, 4 Pl Jussieu, F-75252 Paris 05, France.	caro@jpgp.jussieu.fr	Bourdon, Bernard/A-3303-2008; BIRCK, Jean Louis/A-6127-2011					ALLEGRE CJ, 1987, EARTH PLANET SC LETT, V81, P127, DOI 10.1016/0012-821X(87)90151-8; ARMSTRONG RL, 1981, PHILOS T R SOC A, V301, P443, DOI 10.1098/rsta.1981.0122; BOAK JL, 1982, EARTH PLANET SC LETT, V59, P155, DOI 10.1016/0012-821X(82)90123-6; Borg LE, 1997, GEOCHIM COSMOCHIM AC, V61, P4915, DOI 10.1016/S0016-7037(97)00276-7; Boyet M, 2002, GEOCHIM COSMOCHIM AC, V66, pA99; Caro G, 2002, GEOCHIM COSMOCHIM AC, V66, pA120; Chambers JE, 2001, ICARUS, V152, P205, DOI 10.1006/icar.2001.6639; CHASE CG, 1988, EARTH PLANET SC LETT, V91, P66, DOI 10.1016/0012-821X(88)90151-3; Choblet G, 2000, PHYS EARTH PLANET IN, V119, P321, DOI 10.1016/S0031-9201(00)00136-9; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; GOLDSTEIN SJ, 1988, EARTH PLANET SC LETT, V87, P249, DOI 10.1016/0012-821X(88)90013-1; GOLDSTEIN SL, 1992, EOS T AGU, V73, pS323; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; HOFMANN AW, 1988, EARTH PLANET SC LETT, V90, P297, DOI 10.1016/0012-821X(88)90132-X; Kamber BS, 1998, CHEM GEOL, V148, P219, DOI 10.1016/S0009-2541(98)00032-1; Kleine T, 2002, NATURE, V418, P952, DOI 10.1038/nature00982; LUGMAIR GW, 1983, SCIENCE, V222, P1015, DOI 10.1126/science.222.4627.1015; MCCULLOCH MT, 1993, LITHOS, V30, P237, DOI 10.1016/0024-4937(93)90038-E; Moorbath S, 1997, CHEM GEOL, V135, P213, DOI 10.1016/S0009-2541(96)00117-9; Nutman AP, 1997, CHEM GEOL, V141, P271, DOI 10.1016/S0009-2541(97)00084-3; PRINZHOFER A, 1992, GEOCHIM COSMOCHIM AC, V56, P797, DOI 10.1016/0016-7037(92)90099-5; Regelous M, 1996, GEOCHIM COSMOCHIM AC, V60, P3513, DOI 10.1016/0016-7037(96)00203-7; Rehkamper M, 1996, CHEM GEOL, V129, P201, DOI 10.1016/0009-2541(95)00143-3; Schoenberg R, 2002, GEOCHIM COSMOCHIM AC, V66, P3151, DOI 10.1016/S0016-7037(02)00911-0; Schoenberg R, 2002, NATURE, V418, P403, DOI 10.1038/nature00923; Sharma M, 1996, GEOCHIM COSMOCHIM AC, V60, P2037, DOI 10.1016/0016-7037(96)00082-8; SMITH AD, 1989, EARTH PLANET SC LETT, V93, P14, DOI 10.1016/0012-821X(89)90180-5; TONKS WB, 1993, J GEOPHYS RES-PLANET, V98, P5319, DOI 10.1029/92JE02726; Vance D, 2002, CHEM GEOL, V185, P227, DOI 10.1016/S0009-2541(01)00402-8; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995	31	231	237	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2003	423	6938					428	432		10.1038/nature01668	http://dx.doi.org/10.1038/nature01668			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761546				2022-12-28	WOS:000183012000039
J	Laing, R; Waning, B; Gray, A; Ford, N; 't Hoen, E				Laing, R; Waning, B; Gray, A; Ford, N; 't Hoen, E			25 years of the WHO essential medicines lists: progress and challenges	LANCET			English	Review								The first WHO essential drugs list, published in 1977, was described as a peaceful revolution in international public health. The list helped to establish the principle that some medicines were more useful than others and that essential medicines were often inaccessible to many populations. Since then, the essential medicines list (EML) has increased in size; defining an essential medicine has moved from an experience to an evidence-based process, including criteria such as public-health relevance, efficacy, safety, and cost-effectiveness. High priced medicines such as antiretrovirals are now included. Differences exist between the WHO model EML and national EMLs since countries face varying challenges relating to costs, drug effectiveness, morbidity patterns, and rationality of prescribing. Ensuring equitable access to and rational use of essential medicines has been promoted through WHO's revised drug strategy. This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines.	Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA; Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA; Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Expt & Clin Pharmacol, Congella, South Africa; Med Sans Frontieres, London, England; Med Sans Frontieres, Paris, France	Boston University; University of Kwazulu Natal; Doctors Without Borders; Doctors Without Borders	Laing, R (corresponding author), Boston Univ, Sch Publ Hlth, 715 Albany St,T4W, Boston, MA 02118 USA.	richardl@bu.edu	Gray, Andrew/F-2104-2013	Gray, Andrew/0000-0001-7815-8180; 't Hoen, Ellen/0000-0003-4477-6866; Waning, Brenda/0000-0001-5773-1558				CHETLEY A, 1990, HLTH BUSINESS WORLD, P75; *DEP HLTH S AFR, 1996, NAT DRUG POL S AFR; *DEP HLTH S AFR, POL GUID MAN TRANSM; Gray A, 1999, S AFRICAN HLTH REV 1, P161; GRAY A, 1997, S AFRICAN HLTH REV 1, P99; GRAY A, POLICY CHANGE CONTEX; HOGERZEIL HV, 1984, TROPICAL DOCTOR, V16, P113; HOWARD NJ, 1991, LANCET, V338, P743, DOI 10.1016/0140-6736(91)91455-4; *INT FED PHARM MAN, 1997, ESS DRUGS; Kanji N, 1992, DRUGS POLICY DEV COU; MARITOUX J, 2002, ESSENTIAL DRUGS PRAC; QUICK JD, 1981, MANAGING DRUG SUPPLY; Quick JD, 1997, DC2018020003 DEP EN; SCHOLTZ M, 1999, C AIDS ESS MED COMP; STEIGER W, 2001, COMMENTS RECOMMENDAT; t Hoen Ellen F. M., 2002, CHICAGO J INT LAW, V3, P27; THOEN E, 1993, LANCET, V342, P308, DOI 10.1016/0140-6736(93)91856-H; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Velasquez G., 1999, GLOBALIZATION ACCESS; *WHO, 2001, IPCW305ADD3 WHO; WHO, 1986, WHA3927 WHO; WHO, 2000, WHO MED STRAT 2000 2; *WHO, 1987, RAT US DRUGS REP; *WHO, 2001, WHOCDSRBM200135; *WHO, 2002, EB1098 WHO; *WHO, 1997, TECH REP SER WHO, V867; *WHO, 1977, TECH REP SER WHO, V615; *WHO, 1997, WHOMAL961075; *WHO, 2002, REP 12 EXP COMM SEL; *WHO, 1996, 4914 WHO WHA; *WHO, 1988, TECH REP SER WHO, V770; *WHO, 2002, WHO MOD FORM; *WHO, 2000, TECHN REP SERI WHO, V895; *WHO, 1979, TECH REP SER WHO, V641; *WHO, 2001, 54102001 WHO WHA; *WHO, 2001, 5411 WHO WHA; *WHO, 2002, TECH REP SER WHO, V914; *WHO, 1990, TECH REP SER WHO, V805; *WHO, 2002, WHO CHILD AD HLTH DE; *WHO, 2002, DRUG PRIC INF SERV W; *WHO EDM DEP ESS D, 2001, UPD DISS WHO MOD LIS; *WHO EX BOARD, 2001, EB108INFDOC2 WHO; *WHO UNICEF, 1978, HLTH ALL SER, V1; WHO (World Health Organization), 1988, WORLD DRUG SIT; *WORLD HLTH ASS, 1975, WHA2866 WHO; World Trade Organization, 2001, WTMIN01DEC2 WTO; 1998, DEV ESSENTIAL DRUGS; 2003, LANCET, V361, P269; 1999, COMMON WORKING PAPER, V3; 1998, 1D3BWD98 EUR COMM DG; 1999, WTGCW282; 1987, SCRIP, V256, P1; 2001, WHO ESSEN DRUGS MON, P23	53	191	214	2	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1723	1729		10.1016/S0140-6736(03)13375-2	http://dx.doi.org/10.1016/S0140-6736(03)13375-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767751				2022-12-28	WOS:000182919700025
J	Plunkett, A; Hulse, JA; Mishra, B; Gill, J				Plunkett, A; Hulse, JA; Mishra, B; Gill, J			Variable presentation of Brugada syndrome: lessons from three generations with syncope	BRITISH MEDICAL JOURNAL			English	Review							ST-SEGMENT ELEVATION; BUNDLE-BRANCH BLOCK; CARDIOMYOPATHY; DEATH		Maidstone Hlth Author, Dept Paediat, Maidstone ME16 9QQ, Kent, England; Maidstone Hlth Author, Dept Cardiol, Maidstone ME16 9QQ, Kent, England; St Thomas Hosp, Dept Cardiol, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Plunkett, A (corresponding author), Maidstone Hlth Author, Dept Paediat, Maidstone ME16 9QQ, Kent, England.			Plunkett, Adrian/0000-0003-0703-2649				Brugada J, 1998, CIRCULATION, V97, P457; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; Brugada P, 2000, Curr Cardiol Rep, V2, P507, DOI 10.1007/s11886-000-0035-0; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; Corrado D, 1999, Cardiol Rev, V7, P191, DOI 10.1097/00045415-199907000-00010; Izumi T, 2000, INTERNAL MED, V39, P28, DOI 10.2169/internalmedicine.39.28; Naccarelli GV, 2001, AM J MED, V110, P573, DOI 10.1016/S0002-9343(01)00625-8; Towbin JA, 2000, J CARDIOVASC ELECTR, V11, P601, DOI 10.1111/j.1540-8167.2000.tb00016.x	8	7	8	2	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2003	326	7398					1078	1079		10.1136/bmj.326.7398.1078	http://dx.doi.org/10.1136/bmj.326.7398.1078			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681ZD	12750212	Green Published			2022-12-28	WOS:000183064700020
J	Wenzel, RP; Edmond, MB				Wenzel, RP; Edmond, MB			Managing SARS amidst uncertainty	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA	Virginia Commonwealth University	Wenzel, RP (corresponding author), Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA.			Edmond, Michael/0000-0002-4144-8974					0	86	95	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					1947	1948		10.1056/NEJMp030072	http://dx.doi.org/10.1056/NEJMp030072			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12748313	Bronze			2022-12-28	WOS:000182823400001
J	Kakavanos, R; Turner, CT; Hopwood, JJ; Kakkis, ED; Brooks, DA				Kakavanos, R; Turner, CT; Hopwood, JJ; Kakkis, ED; Brooks, DA			Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I	LANCET			English	Article							ALPHA-L-IDURONIDASE; GAUCHER-DISEASE TYPE-1; FELINE MODEL; ANTIBODIES; EFFICACY; VI	Background Enzyme-replacement therapy has been assessed as a treatment for patients who have mucopolysaccharidosis I (alpha-L-iduronidase deficiency). We aimed to investigate the humoral immune response to recombinant human alpha-L-iduronidase among these patients. Methods We characterised the antibody titres and specific linear sequence epitope reactivity of serum antibodies to alpha-L-iduronidase for ten patients with mucopolysaccharidosis 1, at the start of treatment and after 6, 12, 26, 52, and 104 weeks. We compared the values for patients' samples with those for samples from normal human controls. Findings Before enzyme-replacement therapy, all patients had low serum antibody titres to recombinant human alpha-L-iduronidase that were within the control range. Five of the ten patients produced higher-than-normal titres of antibody to the replacement protein during the treatment course (serum antibody titres 130 000-500 000 and high-affinity epitope reactivity). However, by week 26, antibody reactivity was reduced, and by week 104 all patients had low antibody titres and only low-affinity epitope reactivity. Patients who had mucopolysaccharidosis I with antibody titres within the normal range at 6-12 weeks did not subsequently develop immune responses. Interpretation After 2 years of treatment, patients who initially had an immune reaction developed immune tolerance to alpha-L-iduronidase. This finding has positive implications for long-term enzyme-replacement therapy in patients who have mucopolysaccharidosis I.	Womens & Childrens Hosp, Dept Clin Pathol, Lysosomal Dis Res Unit, Adelaide, SA 5006, Australia; Univ Adelaide, Dept Paediat, Adelaide, SA, Australia; Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA	Womens & Childrens Hospital Australia; University of Adelaide; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Brooks, DA (corresponding author), Womens & Childrens Hosp, Dept Clin Pathol, Lysosomal Dis Res Unit, Adelaide, SA 5006, Australia.	douglas.brooks@adelaide.edu.au	Brooks, Doug A/K-6714-2012; Turner, Chris/AAC-9775-2021; Turner, Christopher T/F-4434-2013; Kakavanos-Plew, Revecca/D-4233-2011	Turner, Chris/0000-0001-7409-4386; Turner, Christopher T/0000-0001-7409-4386; Brooks, Doug/0000-0001-9098-3626				ASHTON LJ, 1992, AM J HUM GENET, V50, P787; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; Beutler E, 1997, BAILLIERE CLIN HAEM, V10, P751, DOI 10.1016/S0950-3536(97)80038-8; Brady RO, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e11; BRADY RO, 1966, NEW ENGL J MED, V275, P312, DOI 10.1056/NEJM196608112750606; Brooks DA, 1999, MOL GENET METAB, V68, P268, DOI 10.1006/mgme.1999.2894; Brooks DA, 1998, BBA-MOL BASIS DIS, V1407, P163, DOI 10.1016/S0925-4439(98)00034-9; Brooks DA, 1997, BBA-MOL BASIS DIS, V1361, P203, DOI 10.1016/S0925-4439(97)00036-7; Brooks DA, 2001, GLYCOBIOLOGY, V11, P741, DOI 10.1093/glycob/11.9.741; Clarke LA, 1999, AM J HUM GENET, V65, pA25; Clarke LA, 1997, HUM MOL GENET, V6, P503, DOI 10.1093/hmg/6.4.503; Crawley AC, 1997, J CLIN INVEST, V99, P651, DOI 10.1172/JCI119208; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; DEDUVE C, 1964, FED PROC, V23, P1045; Durand P, 2000, HUM MOL GENET, V9, P967, DOI 10.1093/hmg/9.6.967; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; Grabowski GA, 1996, DRUGS, V52, P159, DOI 10.2165/00003495-199652020-00001; Grabowski GA, 1998, BLOOD REV, V12, P115, DOI 10.1016/S0268-960X(98)90023-6; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HOLCENBERG JS, 1982, ANNU REV BIOCHEM, V51, P795, DOI 10.1146/annurev.bi.51.070182.004051; HOPWOOD JJ, 1989, HEPARIN CHEM BIOL PR, P181; Kakkis ED, 1996, BIOCHEM MOL MED, V58, P156, DOI 10.1006/bmme.1996.0044; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; PASTORES GM, 1993, BLOOD, V82, P408; Ponce E, 1997, BLOOD, V90, P43; Rosenberg M, 1999, BLOOD, V93, P2081, DOI 10.1182/blood.V93.6.2081.406k07_2081_2088; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; Turner CT, 1999, MOL GENET METAB, V67, P194, DOI 10.1006/mgme.1999.2859; Turner CT, 2000, MOL GENET METAB, V69, P277, DOI 10.1006/mgme.2000.2979	32	74	80	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	2003	361	9369					1608	1613		10.1016/S0140-6736(03)13311-9	http://dx.doi.org/10.1016/S0140-6736(03)13311-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747881				2022-12-28	WOS:000182746300011
J	Staessen, JA; Wang, JG; Bianchi, G; Birkenhager, WH				Staessen, JA; Wang, JG; Bianchi, G; Birkenhager, WH			Essential hypertension	LANCET			English	Review							AMBULATORY BLOOD-PRESSURE; RENIN-ANGIOTENSIN SYSTEM; CONVERTING-ENZYME-INHIBITOR; URINARY SODIUM-EXCRETION; 3 CANDIDATE GENES; ANTIHYPERTENSIVE TREATMENT; PULSE PRESSURE; OLDER PATIENTS; MYOCARDIAL-INFARCTION; BETA-BLOCKERS	Hypertension is a frequent, chronic, age-related disorder, which often entails debilitating cardiovascular and renal complications. Blood pressure is usually noted in combination with other cardiovascular risk factors. Diagnosis of hypertension increasingly relies on automated techniques of blood pressure measurement. The pathophysiology of essential hypertension depends on the primary or secondary inability of the kidney to excrete sodium at a normal blood pressure. The central nervous system, endocrine factors, the large arteries, and the microcirculation also have roles in the disorder. Although monogenic forms of blood pressure dysregulation exist, hypertension mostly arises as a complex quantitative trait that is affected by varying combinations of genetic and environmental factors. Non-pharmacological strategies can reduce blood pressure. Antihypertensive drug treatment diminishes the complications of hypertension. The concept that a few major genes will provide the final clue to the pathogenesis of essential hypertension is an oversimplification that contradicts the heterogeneous nature of this disorder. Further integration of genetic, molecular, clinical, and epidemiological research could disclose subsets of patients in whom specific combinations of genetic and environmental factors raise blood pressure, and might lead to more individualised treatment.	Katholieke Univ Leuven, Dept Mol Cardiovasc Onderzoek, Studiecoordinatiectr, Louvain, Belgium; Univ Vita Salute, Dipartimento Sci & Technol Biomed, Osped San Raffaele, Div Nefrol Dialisi & Ipertens, Milan, Italy; Erasmus Univ, Rotterdam, Netherlands	KU Leuven; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Erasmus University Rotterdam	Staessen, JA (corresponding author), Univ Leuven, Lab Hypertens, Study Coordinating Ctr, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	jan.staessen@med.kuleuven.ac.be	Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637; Bianchi, Giuseppe/0000-0002-8365-3618				Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; *ALLHAT OFF COORD, 2003, JAMA-J AM MED ASSOC, V288, P2981; [Anonymous], 1991, JAMA, V265, P3255; Aviv A, 2002, HYPERTENSION, V40, P229, DOI 10.1161/01.HYP.0000027280.91984.1B; Balkestein EJ, 2002, J HYPERTENS, V20, P1551, DOI 10.1097/00004872-200208000-00018; Barker D J, 1997, Rev Reprod, V2, P105, DOI 10.1530/ror.0.0020105; Barlassina C, 2000, KIDNEY INT, V57, P1083, DOI 10.1046/j.1523-1755.2000.00935.x; BEILIN LJ, 1995, J HYPERTENS, V13, P939, DOI 10.1097/00004872-199509000-00001; BERETTAPICCOLI C, 1984, J CARDIOVASC PHARM, V6, pS134, DOI 10.1097/00005344-198400061-00023; BIANCHI G, 1994, P NATL ACAD SCI USA, V91, P3999, DOI 10.1073/pnas.91.9.3999; BIANCHI G, 1992, COLLOQ INSE, V218, P447; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Chatellier G, 1996, AM J HYPERTENS, V9, P644, DOI 10.1016/0895-7061(96)00018-0; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; Cooper RS, 2002, HYPERTENSION, V40, P629, DOI 10.1161/01.HYP.0000035708.02789.39; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; De Angelis C, 1998, AM J PHYSIOL-RENAL, V274, pF182, DOI 10.1152/ajprenal.1998.274.1.F182; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; DiBona GF, 2000, HYPERTENSION, V36, P1083, DOI 10.1161/01.HYP.36.6.1083; Dickerson JEC, 1999, LANCET, V353, P2008, DOI 10.1016/S0140-6736(98)07614-4; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Executive Committee of the Hypertension Society of Southern Africa, 1995, S AFR MED J, V85, P1321; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Fagard RH, 2001, MED SCI SPORT EXER, V33, pS484, DOI 10.1097/00005768-200106001-00018; Fagard RH, 2000, CIRCULATION, V102, P1139, DOI 10.1161/01.CIR.102.10.1139; Ferguson AV, 1998, PROG NEUROBIOL, V54, P169, DOI 10.1016/S0301-0082(97)00065-8; Ferrandi M, 2000, ACTA PHYSIOL SCAND, V168, P187; Ferrari P, 1999, J PHARMACOL EXP THER, V288, P1074; FERRARI P, IN PRESS ANN NY ACAD; Fink GD, 1997, CLIN EXP PHARMACOL P, V24, P91, DOI 10.1111/j.1440-1681.1997.tb01789.x; FLECKENSTEIN A, 1990, CARDIOVASC DRUG THER, V4, P1005, DOI 10.1007/BF02018309; Forette F, 2002, ARCH INTERN MED, V162, P2046, DOI 10.1001/archinte.162.18.2046; Franklin SS, 2001, CIRCULATION, V103, P1245; Frossard PM, 1995, CLIN GENET, V48, P284; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; Geller DS, 2000, SCIENCE, V289, P119, DOI 10.1126/science.289.5476.119; Gerstein HC, 2000, LANCET, V355, P253; Gheorghiade M, 2002, CIRCULATION, V106, P394, DOI 10.1161/01.CIR.0000019582.39797.EF; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; Glorioso N, 2001, HYPERTENSION, V38, P204, DOI 10.1161/01.HYP.38.2.204; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; *GUID COMM, 2003, IN PRESS J HYPERTENS; Guidi E, 1996, J AM SOC NEPHROL, V7, P1131; GUYTON AC, 1990, AM J PHYSIOL, V259, pR865, DOI 10.1152/ajpregu.1990.259.5.R865; Higaki J, 2000, CIRCULATION, V101, P2060, DOI 10.1161/01.CIR.101.17.2060; Hopkins PN, 2002, CIRCULATION, V105, P1921, DOI 10.1161/01.CIR.0000014684.75359.68; IWAI N, 1994, HYPERTENSION, V23, P375, DOI 10.1161/01.HYP.23.3.375; Iwai N, 2002, J AM SOC NEPHROL, V13, P80, DOI 10.1681/ASN.V13180; Julier C, 1997, HUM MOL GENET, V6, P2077, DOI 10.1093/hmg/6.12.2077; Kario K, 2001, HYPERTENSION, V38, P852, DOI 10.1161/hy1001.092640; Keller G, 2003, NEW ENGL J MED, V348, P101, DOI 10.1056/NEJMoa020549; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kvist S, 2001, CARDIOVASC RES, V52, P136, DOI 10.1016/S0008-6363(01)00366-2; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LICHTLEN PR, 1990, CARDIOVASC DRUG THER, V4, P1047, DOI 10.1007/BF02018315; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Liu JE, 1999, ANN INTERN MED, V131, P564, DOI 10.7326/0003-4819-131-8-199910190-00003; LUFT FC, 1991, HYPERTENSION, V17, pI102, DOI 10.1161/01.HYP.17.1_Suppl.I102; Luft FC, 2001, HYPERTENSION, V37, P350, DOI 10.1161/01.HYP.37.2.350; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; MacMahon S, 2000, J AM COLL CARDIOL, V36, P438, DOI 10.1016/S0735-1097(00)00736-1; Magyar CE, 2001, J AM SOC NEPHROL, V12, P2231, DOI 10.1681/ASN.V12112231; Mancia G, 1999, HYPERTENSION, V34, P724, DOI 10.1161/01.HYP.34.4.724; Manunta P, 2001, HYPERTENSION, V38, P198, DOI 10.1161/01.HYP.38.2.198; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; Mikkelsen KL, 1997, AM J HYPERTENS, V10, P483, DOI 10.1016/S0895-7061(96)00487-6; Mitchell GF, 1997, CIRCULATION, V96, P4254; Morimoto A, 1997, LANCET, V350, P1734, DOI 10.1016/S0140-6736(97)05189-1; Morris AAM, 2000, LANCET, V355, P1290; Mulvany MJ, 1999, CARDIOVASC RES, V41, P9, DOI 10.1016/S0008-6363(98)00289-2; Muntau AC, 2002, NEW ENGL J MED, V347, P2122, DOI 10.1056/NEJMoa021654; Nakayama T, 1997, ADV EXP MED BIOL, V433, P127; Neal B, 2000, LANCET, V356, P1955; O'Brien E, 2002, BLOOD PRESS MONIT, V7, P3, DOI 10.1097/00126097-200202000-00002; O'Rourke MF, 2002, AM J HYPERTENS, V15, P426, DOI 10.1016/S0895-7061(01)02319-6; Ohkubo T, 1998, J HYPERTENS, V16, P971, DOI 10.1097/00004872-199816070-00010; Ohkubo T, 2000, J HYPERTENS, V18, P847, DOI 10.1097/00004872-200018070-00005; OMVIK P, 1986, J HYPERTENS, V4, P535, DOI 10.1097/00004872-198610000-00004; Orlov SN, 1999, AM J PHYSIOL-CELL PH, V276, pC511, DOI 10.1152/ajpcell.1999.276.3.C511; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; PICKERING TG, 1994, LANCET, V344, P31; Pitt B, 2000, CIRCULATION, V102, P1503, DOI 10.1161/01.CIR.102.13.1503; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Price DA, 2002, HYPERTENSION, V40, P186, DOI 10.1161/01.HYP.0000024349.85680.87; Prince MJ, 1996, BMJ-BRIT MED J, V312, P801; Psaty BM, 2002, JAMA-J AM MED ASSOC, V287, P1680, DOI 10.1001/jama.287.13.1680; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Rapp JP, 2000, PHYSIOL REV, V80, P135, DOI 10.1152/physrev.2000.80.1.135; RETTIG R, 1990, HYPERTENSION, V15, P429, DOI 10.1161/01.HYP.15.4.429; Rice T, 2000, CIRCULATION, V102, P1956, DOI 10.1161/01.CIR.102.16.1956; Rice T, 2002, HYPERTENSION, V39, P1037, DOI 10.1161/01.HYP.0000018911.46067.6E; ROSSI GP, 1995, J HYPERTENS, V13, P1181, DOI 10.1097/00004872-199510000-00013; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Safar ME, 2002, HYPERTENSION, V39, P735, DOI 10.1161/hy0202.098325; Sareli P, 2001, ARCH INTERN MED, V161, P965, DOI 10.1001/archinte.161.7.965; SCHMIEDER RE, 1994, HYPERTENSION, V23, P351, DOI 10.1161/01.HYP.23.3.351; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350; Sega R, 2001, CIRCULATION, V104, P1385, DOI 10.1161/hc3701.096100; Serne EH, 2001, HYPERTENSION, V38, P238, DOI 10.1161/01.HYP.38.2.238; Sharma P, 1998, HYPERTENSION, V32, P676, DOI 10.1161/01.HYP.32.4.676; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; Simon A, 2001, CIRCULATION, V103, P2949, DOI 10.1161/01.CIR.103.24.2949; Sorof JM, 2000, J PEDIATR-US, V136, P578, DOI 10.1067/mpd.2000.106230; STAESSEN J, 1989, J HYPERTENS, V7, pS19, DOI 10.1097/00004872-198902001-00006; Staessen JA, 2000, LANCET, V355, P865, DOI 10.1016/S0140-6736(99)07330-4; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; Staessen JA, 1997, JAMA-J AM MED ASSOC, V278, P1065, DOI 10.1001/jama.278.13.1065; Staessen JA, 1999, JAMA-J AM MED ASSOC, V282, P539, DOI 10.1001/jama.282.6.539; Staessen JA, 2002, AM J HYPERTENS, V15, P835, DOI 10.1016/S0895-7061(02)02987-4; Staessen JA, 2002, AM J HYPERTENS, V15, p85S, DOI 10.1016/S0895-7061(02)02949-7; Staessen JA, 2001, J HYPERTENS, V19, P1349, DOI 10.1097/00004872-200108000-00002; Stevenson LW, 2002, NEW ENGL J MED, V346, P1346, DOI 10.1056/NEJM200205023461802; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; Teo KK, 2000, CIRCULATION, V102, P1748; Thijs L, 1999, Blood Press Monit, V4, P77, DOI 10.1097/00126097-199902000-00004; Thomas F, 2002, EUR HEART J, V23, P528, DOI 10.1053/euhj.2001.2888; Tribut Olivier, 2002, Med Sci Monit, V8, pRA152; Tripodi G, 1996, J CLIN INVEST, V97, P2815, DOI 10.1172/JCI118737; Tsujita Y, 2001, J HYPERTENS, V19, P1941, DOI 10.1097/00004872-200111000-00003; Tuomilehto J, 2001, LANCET, V357, P848, DOI 10.1016/S0140-6736(00)04199-4; Turner ST, 2001, J HYPERTENS, V19, P1, DOI 10.1097/00004872-200101000-00001; Uzu T, 1997, CIRCULATION, V96, P1859, DOI 10.1161/01.CIR.96.6.1859; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417; Vasan RS, 2001, LANCET, V358, P1682, DOI 10.1016/S0140-6736(01)06710-1; Verdecchia P, 2002, EUR HEART J, V23, P106, DOI 10.1053/euhj.2001.2657; Verdecchia P, 1998, HYPERTENSION, V32, P983, DOI 10.1161/01.HYP.32.6.983; Wang JG, 2001, AM J KIDNEY DIS, V38, P1158, DOI 10.1053/ajkd.2001.29205; Wang JG, 2000, EUR J PHARMACOL, V410, P289, DOI 10.1016/S0014-2999(00)00822-0; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; Weinberger MH, 2001, HYPERTENSION, V37, P429, DOI 10.1161/01.HYP.37.2.429; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; WILSON AF, 1991, AM J HUM GENET, V48, P862; Wu DA, 1996, J CLIN INVEST, V97, P2111, DOI 10.1172/JCI118648; Wu K, 1997, J HUM HYPERTENS, V11, P95, DOI 10.1038/sj.jhh.1000403; YING LH, 1991, BIOCHEM BIOPH RES CO, V181, P486, DOI 10.1016/S0006-291X(05)81445-7; YOUNG LE, 2002, TWIN RES, V4, P307; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zanchetti A, 1998, J HYPERTENS, V16, P1667, DOI 10.1097/00004872-199816110-00014; Zanchetti A, 2002, CIRCULATION, V106, P2422, DOI 10.1161/01.CIR.0000039288.86470.DD; Zimdahl H, 2002, HYPERTENSION, V39, P1050, DOI 10.1161/01.HYP.0000018909.50074.45; Zipfel GJ, 1999, NEW ENGL J MED, V341, P1543, DOI 10.1056/NEJM199911113412011	146	349	382	2	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	2003	361	9369					1629	1641		10.1016/S0140-6736(03)13302-8	http://dx.doi.org/10.1016/S0140-6736(03)13302-8			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747893				2022-12-28	WOS:000182746300023
J	Rees, DC; Howard, JB				Rees, DC; Howard, JB			The interface between the biological and inorganic worlds: Iron-sulfur metalloclusters	SCIENCE			English	Review							DEHYDROGENASE/ACETYL-COA SYNTHASE; CARBON-MONOXIDE DEHYDROGENASE; ANGSTROM RESOLUTION; NITROGEN-FIXATION; CRYSTAL-STRUCTURE; AZOTOBACTER-VINELANDII; PROTEIN STRUCTURES; EVOLUTION; LIFE; HYDROGENASE	Complex iron-sulfur metalloclusters form the active sites of the enzymes that catalyze redox transformations of N-2, CO, and H-2, which are likely components of Earth's primordial atmosphere. Although these centers reflect the organizational principles of simpler iron-sulfur clusters, they exhibit extensive elaborations that confer specific ligand-binding and catalytic properties. These changes were probably achieved through evolutionary processes, including the fusion of small clusters, the addition of new metals, and the development of cluster assembly pathways, driven by selective pressures resulting from changes in the chemical composition of the biosphere.	CALTECH, Howard Hughes Med Inst, Div Chem & Chem Engn 114 96, Pasadena, CA 91125 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA	California Institute of Technology; Howard Hughes Medical Institute; University of Minnesota System; University of Minnesota Twin Cities	Rees, DC (corresponding author), CALTECH, Howard Hughes Med Inst, Div Chem & Chem Engn 114 96, Pasadena, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045162, R01GM045162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MWW, 2000, CURR OPIN CHEM BIOL, V4, P214, DOI 10.1016/S1367-5931(99)00077-0; Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Berg J.M., 1982, IRON SULFUR PROTEINS, P1; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; Catling DC, 2001, SCIENCE, V293, P839, DOI 10.1126/science.1061976; Cody GD, 2000, SCIENCE, V289, P1337, DOI 10.1126/science.289.5483.1337; Darnault C, 2003, NAT STRUCT BIOL, V10, P271, DOI 10.1038/nsb912; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Dorr M, 2003, ANGEW CHEM INT EDIT, V42, P1540, DOI 10.1002/anie.200250371; Doukov TI, 2002, SCIENCE, V298, P567, DOI 10.1126/science.1075843; Drennan CL, 2001, P NATL ACAD SCI USA, V98, P11973, DOI 10.1073/pnas.211429998; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Fani R, 2000, J MOL EVOL, V51, P1; Frazzon J, 2002, MET IONS BIOL SYST, V39, P163; HOLM RH, 1992, ADV INORG CHEM, V38, P1, DOI 10.1016/S0898-8838(08)60061-6; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; Kasting JF, 2002, SCIENCE, V296, P1066, DOI 10.1126/science.1071184; Kasting JF, 2001, SCIENCE, V293, P819, DOI 10.1126/science.1063811; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Navarro-Gonzalez R, 2001, NATURE, V412, P61, DOI 10.1038/35083537; Parisini E, 1999, ACTA CRYSTALLOGR D, V55, P1773, DOI 10.1107/S0907444999009129; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Postgate J. R, 1982, FUNDAMENTALS NITROGE; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; Stout CD, 1998, J MOL BIOL, V278, P629, DOI 10.1006/jmbi.1998.1732; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Wiechert UH, 2002, SCIENCE, V298, P2341, DOI 10.1126/science.1079894; Yeh AP, 2002, J BIOL CHEM, V277, P34499, DOI 10.1074/jbc.M205096200	34	182	186	4	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					929	931		10.1126/science.1083075	http://dx.doi.org/10.1126/science.1083075			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738849				2022-12-28	WOS:000182719800041
J	Child, JA; Morgan, GJ; Davies, FE; Owen, RG; Bell, SE; Hawkins, K; Brown, J; Drayson, MT; Selby, PJ				Child, JA; Morgan, GJ; Davies, FE; Owen, RG; Bell, SE; Hawkins, K; Brown, J; Drayson, MT; Selby, PJ		Med Res Council Adult Leukaemia Wo	High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; AUTOLOGOUS TRANSPLANTATION; INTRAVENOUS MELPHALAN; THERAPY; IMPACT; REMISSION; LEUKEMIA; SURVIVAL; TRIAL	BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta(sub 2)-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.	Leukaemia Res Fund Unit, Leeds, W Yorkshire, England; Canc Res UK Clin Ctr, Acad Unit Haematol & Oncol, Leeds, W Yorkshire, England; Univ Leeds, Acad Unit Epidemiol & Hlth Serv Res, No & Yorkshire Clin Trials & Res Unit, Leeds, W Yorkshire, England; Univ Birmingham, Dept Immunol, Birmingham, W Midlands, England	University of Leeds; Cancer Research UK; University of Leeds; University of Leeds; University of Birmingham	Child, JA (corresponding author), Gen Infirm, Dept Haematol, Great George St, Leeds LS1 3EX, W Yorkshire, England.			Davies, Faith/0000-0002-3971-2393; brown, julia/0000-0002-2719-7064; Cocks, Kim/0000-0003-2595-708X; Drayson, Mark/0000-0002-1528-7564; morgan, gareth/0000-0002-4271-6360				Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; ATTAL M, 2001, P 8 INT MYEL WORKSH, P28; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; Barlogie B, 1999, BLOOD, V93, P55, DOI 10.1182/blood.V93.1.55.401k04_55_65; Blade J, 1996, J CLIN ONCOL, V14, P2167, DOI 10.1200/JCO.1996.14.7.2167; Blade J, 2001, BLOOD, V98, p815A; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; CAVO M, 2001, P 8 INT MYEL WORKSH, P29; CHILD JA, 1994, BRIT J HAEMATOL, V88, P672, DOI 10.1111/j.1365-2141.1994.tb05103.x; *COCHR COLL, 2000, REV MAN REVM VERS 4; CUNNINGHAM D, 1994, J CLIN ONCOL, V12, P759, DOI 10.1200/JCO.1994.12.4.759; CUZICK J, 1985, BRIT J CANCER, V52, P1, DOI 10.1038/bjc.1985.140; Davies FE, 2001, BRIT J HAEMATOL, V112, P814, DOI 10.1046/j.1365-2141.2001.02530.x; Facon T, 2001, BLOOD, V97, P1566, DOI 10.1182/blood.V97.6.1566; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; Fermand JP, 2001, BLOOD, V98, p815A; Fermand JP, 1999, BLOOD, V94, p396A; GORE ME, 1989, LANCET, V2, P879; Lahuerta JJ, 2000, BRIT J HAEMATOL, V109, P438, DOI 10.1046/j.1365-2141.2000.02012.x; Lenhoff S, 2000, BLOOD, V95, P7; MACLENNAN IC, 1992, LANCET, V340, P200; MCELWAIN TJ, 1983, LANCET, V2, P822; MORGAN G, 2001, OXFORD TXB ONCOLOGY, V2, P2419; SAMSON D, 1989, LANCET, V2, P882; Segeren CM, 2001, BLOOD, V98, p815A; SELBY PJ, 1987, BRIT J HAEMATOL, V66, P55, DOI 10.1111/j.1365-2141.1987.tb06890.x; Simnett SJ, 2000, CLIN LAB HAEMATOL, V22, P61, DOI 10.1046/j.1365-2257.2000.00270.x; SINGER CRJ, 2001, P 8 INT MYEL WORKSH, P140; Tricot G, 2002, BRIT J HAEMATOL, V116, P211, DOI 10.1046/j.1365-2141.2002.03231.x	29	1402	1455	0	75	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1875	1883		10.1056/NEJMoa022340	http://dx.doi.org/10.1056/NEJMoa022340			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12736280	Bronze			2022-12-28	WOS:000182684100006
J	Powell, JT; Greenhalgh, RM				Powell, JT; Greenhalgh, RM			Small abdominal aortic aneurysms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; RISK-FACTORS; OLDER ADULTS; REPAIR; ULTRASOUND; PREVALENCE; GROWTH; MEN; ATHEROSCLEROSIS; RUPTURE		Univ Hosp Coventry & Warwickshire, NHS Trust, Coventry CV2 2DX, W Midlands, England; Imperial Coll Charing Cross, Dept Vasc Surg, London, England	University of Warwick; Imperial College London	Powell, JT (corresponding author), Univ Hosp Coventry & Warwickshire, NHS Trust, Clifford Bridge Rd, Coventry CV2 2DX, W Midlands, England.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				Alcorn HG, 1996, ARTERIOSCL THROM VAS, V16, P963, DOI 10.1161/01.ATV.16.8.963; ALLARDICE JT, 1988, BRIT J SURG, V75, P240, DOI 10.1002/bjs.1800750318; Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135; Baxter BT, 2002, J VASC SURG, V36, P1, DOI 10.1067/mva.2002.125018; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; Brady AR, 2003, BRIT J SURG, V90, P492; Brady AR, 2000, BRIT J SURG, V87, P742, DOI 10.1046/j.1365-2168.2000.01410.x; Brady AR, 2002, NEW ENGL J MED, V346, P1445; Brown LC, 1999, ANN SURG, V230, P289, DOI 10.1097/00000658-199909000-00002; Chang JB, 1997, SURGERY, V121, P117, DOI 10.1016/S0039-6060(97)90279-8; Crow P, 2001, BRIT J SURG, V88, P941, DOI 10.1046/j.0007-1323.2001.01822.x; DAngelo AJ, 1997, J VASC SURG, V25, P152, DOI 10.1016/S0741-5214(97)70332-X; Forbes JF, 1998, LANCET, V352, P1656; Harris PL, 2000, J VASC SURG, V32, P739, DOI 10.1067/mva.2000.109990; HENNEY AM, 1993, LANCET, V341, P215, DOI 10.1016/0140-6736(93)90077-T; Jones K, 2002, EUR J VASC ENDOVASC, V23, P421, DOI 10.1053/ejvs.2002.1633; Jones KG, 2001, CIRCULATION, V103, P2260; Laupacis A, 2002, J VASC SURG, V35, P72, DOI 10.1067/mva.2002.121308; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; Lee AJ, 1997, EUR HEART J, V18, P671; MACSWEENEY STR, 1994, LANCET, V344, P651, DOI 10.1016/S0140-6736(94)92087-7; Marian AJ, 2001, CIRCULATION, V103, P2222; McWilliams RG, 2002, J ENDOVASC THER, V9, P170, DOI 10.1583/1545-1550(2002)009<0170:DOEWEU>2.0.CO;2; Olsen MF, 1997, BRIT J SURG, V84, P1535, DOI 10.1002/bjs.1800841111; Pleumeekers HJCM, 1995, AM J EPIDEMIOL, V142, P1291, DOI 10.1093/oxfordjournals.aje.a117596; POWELL JT, 1993, LANCET, V342, P1473, DOI 10.1016/0140-6736(93)92939-Q; Powell JT, 1998, LANCET, V352, P1649; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; REED D, 1992, CIRCULATION, V85, P205, DOI 10.1161/01.CIR.85.1.205; Reed WW, 1997, ARCH INTERN MED, V157, P2064, DOI 10.1001/archinte.157.18.2064; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; Scott RAP, 2001, EUR J VASC ENDOVASC, V21, P535, DOI 10.1053/ejvs.2001.1368; Shah PK, 1997, CIRCULATION, V96, P2115; Singh K, 2001, AM J EPIDEMIOL, V154, P236, DOI 10.1093/aje/154.3.236; STEYERBERG EW, 1995, ARCH INTERN MED, V155, P1998, DOI 10.1001/archinte.155.18.1998; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407; Teufelsbauer H, 2002, CIRCULATION, V106, P782, DOI 10.1161/01.CIR.0000028603.73287.7D; TILSON MD, 1992, CIRCULATION, V85, P378, DOI 10.1161/01.CIR.85.1.378; Tornwall ME, 2001, ATHEROSCLEROSIS, V157, P167, DOI 10.1016/S0021-9150(00)00694-8; Vammen S, 2002, BRIT J SURG, V89, P120; Vammen S, 2001, BRIT J SURG, V88, P1066, DOI 10.1046/j.0007-1323.2001.01845.x; Vardulaki KA, 1999, BRIT J SURG, V86, P280; Vardulaki KA, 1998, BRIT J SURG, V85, P1674; VOLODOS NL, 1986, VESTN KHIR IM GREKOV, V137, P123; Wilmink TBM, 1999, J VASC SURG, V30, P1099, DOI 10.1016/S0741-5214(99)70049-2; Wolf YG, 2000, J VASC SURG, V32, P1142, DOI 10.1067/mva.2000.109210; Yasuhara H, 1999, BRIT J SURG, V86, P1047, DOI 10.1046/j.1365-2168.1999.01187.x	50	120	131	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1895	1901		10.1056/NEJMcp012641	http://dx.doi.org/10.1056/NEJMcp012641			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12736283				2022-12-28	WOS:000182684100009
J	Vincent, GM				Vincent, GM			The long-QT syndrome - Bedside to bench to bedside	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Latter Day St Hosp, Dept Internal Med, Salt Lake City, UT 84143 USA; Univ Utah, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah	Vincent, GM (corresponding author), Latter Day St Hosp, Dept Internal Med, Salt Lake City, UT 84143 USA.							Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178	2	15	15	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1837	1838		10.1056/NEJMp030039	http://dx.doi.org/10.1056/NEJMp030039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12736277				2022-12-28	WOS:000182684100002
J	Seto, WH; Tsang, D; Yung, RWH; Ching, TY; Ng, TK; Ho, M; Ho, LM; Peiris, JSM				Seto, WH; Tsang, D; Yung, RWH; Ching, TY; Ng, TK; Ho, M; Ho, LM; Peiris, JSM		Advisors Expert SARS Grp Hosp Auth	Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)	LANCET			English	Article								We did a case-control study in five Hong Kong hospitals, with 241 non-infected and 13 infected staff with documented exposures to 31 index patients with severe acute respiratory syndrome (SARS) during patient care. All participants were surveyed about use of mask, gloves, gowns, and hand-washing, as recommended under droplets and contact precautions when caring for index patients with SARS. 69 staff who reported use of all four measures were not infected, whereas all Infected staff had omitted at least one measure (p=0.0224). Fewer staff who wore masks (p=0.0001), gowns (p=0.006), and washed their hands (p=0.047) became infected compared with those who didn't, but stepwise logistic regression was significant only for masks (p=0.011). Practice of droplets precaution and contact precaution is adequate in significantly reducing the risk of infection after exposures to patients with SARS. The protective role of the mask suggests that in hospitals, infection is transmitted by droplets.	Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Pamela Nethersole Youde Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Kwong Wah Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Kwong Wah Hospital; University of Hong Kong; University of Hong Kong	Seto, WH (corresponding author), Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		; Peiris, Joseph Sriyal Malik/C-4380-2009	ho, lm/0000-0002-2709-927X; Seto, Wing Hong/0000-0002-1139-9200; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995	PHS HHS [A95357] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Garner JS, 1996, AM J INFECT CONTROL, V24, P24; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Rosling L, 2003, BRIT MED J, V326, P416, DOI 10.1136/bmj.326.7386.416; *US CDC, 2003, INF CONTR PREC AER G; World Health Organization, 2003, WHO ISS GLOB AL CAS	5	552	591	2	54	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1519	1520		10.1016/S0140-6736(03)13168-6	http://dx.doi.org/10.1016/S0140-6736(03)13168-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737864	Green Published, Bronze			2022-12-28	WOS:000182658900012
J	Bibikova, M; Beumer, K; Trautman, JK; Carroll, D				Bibikova, M; Beumer, K; Trautman, JK; Carroll, D			Enhancing gene targeting with designed zinc finger nucleases	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; RESTRICTION ENZYMES; DROSOPHILA; CLEAVAGE; MUTAGENESIS; REPLACEMENT; SELECTION; DOMAINS		Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Carroll, D (corresponding author), Univ Utah, Sch Med, Dept Biochem, 20 North 1900 East, Salt Lake City, UT 84132 USA.		Wilson, Matthew H/K-3193-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058504] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58504] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bibikova M, 2001, MOL CELL BIOL, V21, P289, DOI 10.1128/MCB.21.1.289-297.2001; Bibikova M, 2002, GENETICS, V161, P1169; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; Cohen-Tannoudji M, 1998, MOL CELL BIOL, V18, P1444, DOI 10.1128/MCB.18.3.1444; Donoho G, 1998, MOL CELL BIOL, V18, P4070, DOI 10.1128/MCB.18.7.4070; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Rong YS, 2000, SCIENCE, V288, P2013, DOI 10.1126/science.288.5473.2013; Segal DJ, 2002, METHODS, V26, P76, DOI 10.1016/S1046-2023(02)00009-9; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Smih F, 1995, NUCLEIC ACIDS RES, V23, P5012, DOI 10.1093/nar/23.24.5012; Smith J, 2000, NUCLEIC ACIDS RES, V28, P3361, DOI 10.1093/nar/28.17.3361; WONG WJ, 2003, P NATL ACAD SCI USA, V100, P2556	16	598	736	4	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					764	764		10.1126/science.1079512	http://dx.doi.org/10.1126/science.1079512			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730594				2022-12-28	WOS:000182579800040
J	Kuo, AL; Gulbis, JM; Antcliff, JF; Rahman, T; Lowe, ED; Zimmer, J; Cuthbertson, J; Ashcroft, FM; Ezaki, T; Doyle, DA				Kuo, AL; Gulbis, JM; Antcliff, JF; Rahman, T; Lowe, ED; Zimmer, J; Cuthbertson, J; Ashcroft, FM; Ezaki, T; Doyle, DA			Crystal structure of the potassium channel KirBac1.1 in the closed state	SCIENCE			English	Article							RECTIFIER K+ CHANNEL; ACETYLCHOLINE-RECEPTOR; RECTIFICATION; PERMEATION; PORE; RESOLUTION; MECHANISM; DYNAMICS; SPERMINE; DOMAINS	The KirBac1.1 channel belongs to the inward-rectifier family of potassium channels. Here we report the structure of the entire prokaryotic Kir channel assembly, in the closed state, refined to a resolution of 3.65 angstroms. We identify the main activation gate and structural elements involved in gating. On the basis of structural evidence presented here, we suggest that gating involves coupling between the intracellular and membrane domains. This further suggests that initiation of gating by membrane or intracellular signals represents different entry points to a common mechanistic pathway.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Walter & Eliza Hall Inst Med Res, Struct Biol Div, Parkville, Vic 3050, Australia; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Gifu Univ, Grad Sch Med Regenerat & Adv Med Sci, Dept Microbiol & Bioinformat, Gifu 5008705, Japan	University of Oxford; Walter & Eliza Hall Institute; University of Oxford; Gifu University	Doyle, DA (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England.		Lowe, Edward/AAP-5381-2021	Lowe, Edward/0000-0002-1757-0208; Zimmer, Jochen/0000-0002-8423-2882				Ashcroft FM, 2000, ION CHANNELS DIS; Beckstein O, 2001, J PHYS CHEM B, V105, P12902, DOI 10.1021/jp012233y; Bright JN, 2002, BIOPOLYMERS, V64, P303, DOI 10.1002/bip.10197; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 2001, BMC EVOL BIOL, V1, DOI 10.1186/1471-2148-1-14; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Hille B., 2001, IONIC CHANNELS EXCIT, P814; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kubo Y, 2001, J PHYSIOL-LONDON, V531, P645, DOI 10.1111/j.1469-7793.2001.0645h.x; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAM SC, 1984, J CHEM SOC FARAD T 1, V80, P2255, DOI 10.1039/f19848002255; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	27	632	650	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1922	1926		10.1126/science.1085028	http://dx.doi.org/10.1126/science.1085028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12738871				2022-12-28	WOS:000183619400039
J	Desiraju, GR				Desiraju, GR			In search of clarity	NATURE			English	Editorial Material									Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India	University of Hyderabad	Desiraju, GR (corresponding author), Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India.		Desiraju, Gautam R./AAQ-6388-2021; Desiraju, Gautam R/B-1565-2009					Desiraju G. R., 1989, CRYSTAL ENG DESIGN O; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Sayre D, 2002, STRUCT CHEM, V13, P81, DOI 10.1023/A:1013477415486	3	27	28	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2003	423	6939					485	485		10.1038/423485a	http://dx.doi.org/10.1038/423485a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774103	Bronze			2022-12-28	WOS:000183162900025
J	Osborn, DPJ; King, MB; Nazareth, I				Osborn, DPJ; King, MB; Nazareth, I			Participation in screening for cardiovascular risk by people with schizophrenia or similar mental illnesses: cross sectional study in general practice	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL HEALTH		UCL, Dept Psychiat & Behav Sci, London NW3 2PF, England; UCL, Dept Primary Care & Populat, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Osborn, DPJ (corresponding author), UCL, Dept Psychiat & Behav Sci, London NW3 2PF, England.	dosborn@rfc.ucl.ac.uk	Osborn, David/B-8165-2009; King, Michael B/D-7477-2011	Osborn, David/0000-0003-2519-1539; King, Michael B/0000-0003-4715-7171; Nazareth, Irwin/0000-0003-2146-9628				National Institute for Clinical Excellence, 2002, SCHIZ COR INT TREATM; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; Osborn DPJ, 2001, WESTERN J MED, V175, P329, DOI 10.1136/ewjm.175.5.329; Phelan M, 2001, BRIT MED J, V322, P443, DOI 10.1136/bmj.322.7284.443; Yardley L, 1998, BRIT J GEN PRACT, V48, P1131	5	49	49	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1122	1123		10.1136/bmj.326.7399.1122	http://dx.doi.org/10.1136/bmj.326.7399.1122			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763984	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000183245000020
J	Enstrom, JE; Kabat, GC				Enstrom, JE; Kabat, GC			Environmental tobacco smoke and tobacco related mortality in a prospective study of Californians, 1960-98	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PASSIVE SMOKING; LUNG-CANCER; METAANALYSIS; EXPOSURE; TRENDS	Objective To measure the relation between environmental tobacco smoke, as estimated by smoking in Spouses, and long term mortality from tobacco related disease. Design Prospective Cohort Study covering 39 years. Setting Adult population of California, United States. Participants 118 094 adults enrolled in late 1959 in the American Cancer Society cancer prevention study, who were followed until 1998. Particular focus is on the 35 561 never smokers who had a spouse in the study with known smoking habits. Main outcome measures Relative risks and 95% confidence intervals for deaths from coronary heart disease, lung cancer, and chronic obstructive pulmonary disease related to smoking in spouses and active cigarette smoking. Results For participants followed from 1960 until 1998 the age adjusted relative risk (95% confidence interval) for never smokers married to ever smokers compared with never smokers married to never smokers was 0.94 (0.85 to 1.05) for coronary heart disease, 0.75 (0.42 to 135) for lung cancer, and 1.27 (0.78 to 2.08) for chronic obstructive pulmonary disease among 9619 men, mid 1.01 (0.94 to 1.08), 0.99 (0.72 to 1.37), mid 1.13 (0.80 to 1.58), respectively, among 25 942 women. No significant associations were found for current or former exposure to environmental tobacco smoke before or after adjusting for seven confounders and before or after excluding participants with pre-existing disease. No significant associations were found during tire shorter follow tip periods of 1960-5, 1966-72, 1973-85 mid 1973-98. Conclusions The results do not support a causal relation between environmental tobacco smoke and tobacco related mortality, although they do not rule out a small effect. The association between exposure to environmental tobacco smoke and coronary heart disease and lung, cancer may be considerably weaker than generally believed.	Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA	University of California System; University of California Los Angeles; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Enstrom, JE (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA.	jenstrom@ucla.edu						Bailar JC, 1999, NEW ENGL J MED, V340, P958, DOI 10.1056/NEJM199903253401211; BURNS DM, 1997, SMOKING TOBACCO CONT, V8, P113; Enstrom JE, 1999, EPIDEMIOLOGY, V10, P500, DOI 10.1097/00001648-199909000-00007; ENSTROM JE, 1980, J NATL CANCER I, V65, P1175; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P127, DOI 10.1016/0895-4356(91)90261-7; GARFINKEL L, 1981, JNCI-J NATL CANCER I, V66, P1061, DOI 10.1093/jnci/66.6.1061; GORI GB, 1999, PASSIVE SMOKE EPAS B; Green CR, 1997, J HEALTH POLIT POLIC, V22, P1279, DOI 10.1215/03616878-22-5-1279; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; Johnson NJ, 2000, ANN EPIDEMIOL, V10, P224, DOI 10.1016/S1047-2797(99)00052-6; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; LEE PN, 1992, ENV TOBACCO SMOKE MO; LEVOIS ME, 1995, REGUL TOXICOL PHARM, V21, P184, DOI 10.1006/rtph.1995.1023; LeVois ME, 1998, BRIT MED J, V317, P344, DOI 10.1136/bmj.317.7154.344; *NAT CANC I, 1999, NIH PUBL; *NAT CANC I, 1999, SMOK TOB CONTR MON, V10; SCHAAD UB, 1995, PEDIATR INFECT DIS J, V14, P1, DOI 10.1097/00006454-199501000-00001; SCHAEFER C, 1995, AM J EPIDEMIOL, V141, P1142, DOI 10.1093/oxfordjournals.aje.a117387; Schall LC, 2001, ANN EPIDEMIOL, V11, P292, DOI 10.1016/S1047-2797(00)00217-9; SO Y, 1992, SAS STAT SOFTWARE; TAYLOR AE, 1992, CIRCULATION, V86, P1; Thun M, 1999, ENVIRON HEALTH PERSP, V107, P841, DOI 10.2307/3434563; *US DEP HHS, 2001, WOM SMOK REP SURG GE, P343; *US EPA, 1992, 600690006F EPA; *US EPA, 1992, NIH PUBL	27	125	130	2	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	2003	326	7398					1057	+		10.1136/bmj.326.7398.1057	http://dx.doi.org/10.1136/bmj.326.7398.1057			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681ZD	12750205	Bronze, Green Published			2022-12-28	WOS:000183064700013
J	Hay, SI; Were, EC; Renshaw, M; Noor, AM; Ochola, SA; Olusanmi, L; Alipui, N; Snow, RW				Hay, SI; Were, EC; Renshaw, M; Noor, AM; Ochola, SA; Olusanmi, L; Alipui, N; Snow, RW			Forecasting, warning, and detection of malaria epidemics: a case study	LANCET			English	Article							HIGHLANDS; KENYA	Our aim was to assess whether a combination of seasonal climate forecasts, monitoring of meteorological conditions, and early detection of cases could have helped to prevent the 2002 malaria emergency In the highlands of western Kenya. Seasonal climate forecasts did not anticipate the heavy rainfall. Rainfall data gave timely and reliable early warnings; but monthly surveillance of malaria out-patients gave no effective alarm, though it did help to confirm that normal rainfall conditions in Kisii Central and Gucha led to typical resurgent outbreaks whereas exceptional rainfall in Nandi and Kericho led to true malaria epidemics. Management of malaria in the highlands, including improved planning for the annual resurgent outbreak, augmented by simple central nationwide early warning, represents a feasible strategy for increasing epidemic preparedness in Kenya.	Univ Oxford, Dept Zool, TALA Res Grp, Oxford OX1 3PS, England; Minist Hlth, Div Malaria Control, Nairobi, Kenya; UNICEF, ESARO, Nairobi, Kenya; UNICEF, KCO, Nairobi, Kenya; UN Complex Gigiri, Nairobi, Kenya; Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Programme, Nairobi, Kenya; Univ Oxford, John Radcliffe Hosp, Ctr Trop Med, Oxford OX3 9DU, England	University of Oxford; Kenya Medical Research Institute; University of Oxford	Hay, SI (corresponding author), Univ Oxford, Dept Zool, TALA Res Grp, S Parks Rd, Oxford OX1 3PS, England.	simon.hay@zoo.ox.ac.uk	Snow, Robert William/AFR-1436-2022; Hay, Simon Iain/F-8967-2015	Snow, Robert William/0000-0003-3725-6088; Hay, Simon Iain/0000-0002-0611-7272	Wellcome Trust [081829, 056642] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Guyatt HL, 2002, TROP MED INT HEALTH, V7, P298, DOI 10.1046/j.1365-3156.2002.00874.x; Hay SI, 2002, EMERG INFECT DIS, V8, P555, DOI 10.3201/eid0806.010310; NAJERA JA, 1998, MALARIA EPIDEMICS DE, P81; ROBERTS JMD, 1964, J TROP MED HYG, V67, P230; *WHO, 2001, MAL EARL WARN SYST C, P80	5	78	83	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1705	1706		10.1016/S0140-6736(03)13366-1	http://dx.doi.org/10.1016/S0140-6736(03)13366-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767739	Green Accepted			2022-12-28	WOS:000182919700014
J	Fredrick, K; Noller, HF				Fredrick, K; Noller, HF			Catalysis of ribosomal translocation by sparsomycin	SCIENCE			English	Article							ANTITUMOR ANTIBIOTIC SPARSOMYCIN; PEPTIDYL TRANSFERASE CENTER; TRANSFER-RNA; PROTEIN-SYNTHESIS; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; STRUCTURAL BASIS; P-SITE; BINDING; INTERMEDIATE	During protein synthesis, transfer RNAs (tRNAs) are translocated from the aminoacyl to peptidyl to exit sites of the ribosome, coupled to the movement of messenger RNA ( mRNA), in a reaction catalyzed by elongation factor G (EF-G) and guanosine triphosphate (GTP). Here, we show that the peptidyl transferase inhibitor sparsomycin triggers accurate translocation in vitro in the absence of EF-G and GTP. Our results provide evidence that translocation is a function inherent to the ribosome and that the energy to drive this process is stored in the tRNA-mRNA-ribosome complex after peptide-bond formation. These findings directly implicate the peptidyl transferase center of the 50S subunit in the mechanism of translocation, a process involving large-scale movement of tRNA and mRNA in the 30S subunit, some 70 angstroms away.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Noller, HF (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.				NIGMS NIH HHS [GM17129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bashan A, 2003, MOL CELL, V11, P91, DOI 10.1016/S1097-2765(03)00009-1; BILGIN N, 1990, EMBO J, V9, P735, DOI 10.1002/j.1460-2075.1990.tb08167.x; CABANAS MJ, 1978, BIOCHEM BIOPH RES CO, V83, P991; CUNDLIFFE E, 1990, RIBOSOME, P479; Feinberg JS, 2001, P NATL ACAD SCI USA, V98, P11120, DOI 10.1073/pnas.211184098; Fredrick K, 2002, MOL CELL, V9, P1125, DOI 10.1016/S1097-2765(02)00523-3; FREDRICK K, UNPUB; GAVRILOV.LP, 1971, FEBS LETT, V17, P324, DOI 10.1016/0014-5793(71)80177-1; GAVRILOV.LP, 1972, FEBS LETT, V22, P91, DOI 10.1016/0014-5793(72)80227-8; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; Hansen JL, 2002, P NATL ACAD SCI USA, V99, P11670, DOI 10.1073/pnas.172404099; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; HISHIZAW.T, 1970, P NATL ACAD SCI USA, V66, P523, DOI 10.1073/pnas.66.2.523; Jerinic O, 2000, J MOL BIOL, V304, P707, DOI 10.1006/jmbi.2000.4269; LAZARO E, 1991, BIOCHEMISTRY-US, V30, P9642, DOI 10.1021/bi00104a011; LAZARO E, 1991, ANTIMICROB AGENTS CH, V35, P10, DOI 10.1128/AAC.35.1.10; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MONRO RE, 1969, NATURE, V222, P356, DOI 10.1038/222356a0; Noller HF, 2002, FEBS LETT, V514, P11, DOI 10.1016/S0014-5793(02)02327-X; PESTKA S, 1969, J BIOL CHEM, V244, P1533; PESTKA S, 1971, J BIOL CHEM, V246, P7715; PESTKA S, 1969, P NATL ACAD SCI USA, V64, P709, DOI 10.1073/pnas.64.2.709; Porse BT, 1999, P NATL ACAD SCI USA, V96, P9003, DOI 10.1073/pnas.96.16.9003; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; Semenkov YP, 2000, NAT STRUCT BIOL, V7, P1027; Southworth DR, 2002, J MOL BIOL, V324, P611, DOI 10.1016/S0022-2836(02)01196-8; THEOCHARIS DA, 1992, BIOCHEMISTRY-US, V31, P5861, DOI 10.1021/bi00140a023; THOMPSON J, 1991, BIOCHIMIE, V73, P1131, DOI 10.1016/0300-9084(91)90156-U; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	35	113	116	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1159	1162		10.1126/science.1084571	http://dx.doi.org/10.1126/science.1084571			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750524				2022-12-28	WOS:000182886500050
J	Garcia-Barros, M; Paris, F; Cordon-Cardo, C; Lyden, D; Rafii, S; Haimovitz-Friedman, A; Fuks, Z; Kolesnick, R				Garcia-Barros, M; Paris, F; Cordon-Cardo, C; Lyden, D; Rafii, S; Haimovitz-Friedman, A; Fuks, Z; Kolesnick, R			Tumor response to radiotherapy regulated by endothelial cell apoptosis	SCIENCE			English	Article							IONIZING-RADIATION; STEM-CELLS; IN-VITRO; SPHINGOMYELINASE; CERAMIDE; CANCER; GROWTH; DEATH; MICE; ANGIOGENESIS	About 50% of cancer patients receive radiation therapy. Here we investigated the hypothesis that tumor response to radiation is determined not only by tumor cell phenotype but also by microvascular sensitivity. MCA/129 fibrosarcomas and B16F1 melanomas grown in apoptosis-resistant acid sphingomyelinase (asmase) -deficient or Bax-deficient mice displayed markedly reduced baseline microvascular endothelial apoptosis and grew 200 to 400% faster than tumors on wild-type microvasculature. Thus, endothelial apoptosis is a homeostatic factor regulating angiogenesis-dependent tumor growth. Moreover, these tumors exhibited reduced endothelial apoptosis upon irradiation and, unlike tumors in wild-type mice, they were resistant to single-dose radiation up to 20 grays (Gy). These studies indicate that microvascular damage regulates tumor cell response to radiation at the clinically relevant dose range.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Hematol Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.		Paris, francois E/L-4915-2015	Paris, francois E/0000-0002-0176-7348	NATIONAL CANCER INSTITUTE [R01CA085704] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85704, CA 52462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; ELLIS F, 1969, Clinical Radiology, V20, P1, DOI 10.1016/S0009-9260(69)80043-7; Folkman J, 2000, NAT REV MOL CELL BIO, V1, P76, DOI 10.1038/35036100; Folkman J, 2002, CANCER CELL, V1, P113, DOI 10.1016/S1535-6108(02)00038-7; FUKS Z, 1994, CANCER RES, V54, P2582; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HENDRY JH, 1994, RADIOTHER ONCOL, V30, P11, DOI 10.1016/0167-8140(94)90004-3; Jensen JM, 1999, J CLIN INVEST, V104, P1761, DOI 10.1172/JCI5307; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KIM JH, 1986, CANCER RES, V46, P1120; Kozin SV, 2001, CANCER RES, V61, P39; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Muller AM, 2002, EXP MOL PATHOL, V72, P221, DOI 10.1006/exmp.2002.2424; MUNRO TR, 1961, BRIT J RADIOL, V34, P246, DOI 10.1259/0007-1285-34-400-246; Ning SC, 2002, RADIAT RES, V157, P45, DOI 10.1667/0033-7587(2002)157[0045:TAASAS]2.0.CO;2; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Platt J, 2000, EUR J CANCER, V36, P2397, DOI 10.1016/S0959-8049(00)00336-1; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; St Croix B, 2000, SCIENCE, V289, P1197; Stewart FM, 2001, BLOOD, V98, P1246, DOI 10.1182/blood.V98.4.1246; TEICHER BA, 1992, CANCER RES, V52, P6702; TROTT KR, 1994, RADIOTHER ONCOL, V30, P1, DOI 10.1016/0167-8140(94)90002-7; WHELDON TE, 1977, BRIT J RADIOL, V50, P843, DOI 10.1259/0007-1285-50-599-843; WITHERS HR, 1970, INT J RADIAT BIOL RE, V17, P261, DOI 10.1080/09553007014550291	31	1195	1270	3	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1155	1159		10.1126/science.1082504	http://dx.doi.org/10.1126/science.1082504			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750523				2022-12-28	WOS:000182886500049
J	Weill, M; Lutfalla, G; Mogensen, K; Chandre, F; Berthomieu, A; Berticat, C; Pasteur, N; Philips, A; Fort, P; Raymond, M				Weill, M; Lutfalla, G; Mogensen, K; Chandre, F; Berthomieu, A; Berticat, C; Pasteur, N; Philips, A; Fort, P; Raymond, M			Insecticide resistance in mosquito vectors	NATURE			English	Article							ACETYLCHOLINESTERASE		Univ Montpellier 2, Inst Sci Evolut, UMR 5554, F-34095 Montpellier, France; CNRS, Def Antivirales & Tumorales UMR 5124, F-34293 Montpellier, France; CNRS, Ctr Rech Biochim Macromol, UPR1086, F-34293 Montpellier, France; IRD, LIN, F-34394 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut de Recherche pour le Developpement (IRD)	Weill, M (corresponding author), Univ Montpellier 2, Inst Sci Evolut, UMR 5554, CC 065, F-34095 Montpellier, France.	weill@isem.univ-montp2.fr	Chandre, Fabrice/Q-3429-2019; Fort, Philippe/M-9498-2015; Lutfalla, Georges/AAW-9386-2021; PHILIPS, Alexandre/AAB-6047-2020; Raymond, Michel/C-9049-2015	Chandre, Fabrice/0000-0002-1994-9705; Fort, Philippe/0000-0001-5997-8722; LUTFALLA, Georges/0000-0002-6591-7894; Weill, Mylene/0000-0002-4043-1601; Raymond, Michel/0000-0002-1714-6984				Bourguet D, 1996, PESTIC BIOCHEM PHYS, V55, P122, DOI 10.1006/pest.1996.0041; MUTERO A, 1994, P NATL ACAD SCI USA, V91, P5922, DOI 10.1073/pnas.91.13.5922; N'Guessan R, 2003, MED VET ENTOMOL, V17, P19, DOI 10.1046/j.1365-2915.2003.00406.x; TOUTANT JP, 1989, PROG NEUROBIOL, V32, P423, DOI 10.1016/0301-0082(89)90031-2; Weill M, 2002, P ROY SOC B-BIOL SCI, V269, P2007, DOI 10.1098/rspb.2002.2122	5	344	372	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					136	137		10.1038/423136b	http://dx.doi.org/10.1038/423136b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736674				2022-12-28	WOS:000182699600035
J	Wu, EB; Sung, JJY				Wu, EB; Sung, JJY			Haemorrhagic-fever-like changes and normal chest radiograph in a doctor with SARS	LANCET			English	Article								A 33-year-old doctor contracted severe acute respiratory syndrome presenting with features of disseminated intravascular coagulopathy without changes in the chest radiograph initially. A CT scan of his chest showed marked lung changes. His condition improved with intravenous methylprednisolone 500 mg daily and ribavirin 1.2 g orally thrice daily. The case illustrates the importance of a break in fever between the viraemic and lung inflammatory phases of the illness that occurs before radiographic changes and which may obscure diagnosis. Careful quarantine and follow-up of these patients are necessary. Coagulopathy is usually uncomplicated and early CT of the chest may elucidate hidden lung changes and facilitate a rapid diagnosis.	Prince Wales Hosp, Dept Med, Shatin, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Therapeut, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Wu, EB (corresponding author), Prince Wales Hosp, Dept Med, Shatin, Hong Kong, Peoples R China.		Sung, Joseph J. Y./R-3203-2018	Sung, Joseph J. Y./0000-0003-3125-5199				*CDCP, 2003, SEV AC RESP SYNDR SA; LEE N, MAJOR OUTBREAK SEVER; 2003, MORB MORTAL WKLY REP, V52, P241	3	17	23	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1520	1521		10.1016/S0140-6736(03)13170-4	http://dx.doi.org/10.1016/S0140-6736(03)13170-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737865	Green Published, Bronze			2022-12-28	WOS:000182658900013
J	Calhoun, VC; Levine, M				Calhoun, VC; Levine, M			Coordinate regulation of an extended chromosome domain	CELL			English	Editorial Material							TRANSCRIPTION; ACTIVATION; GENES		Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Calhoun, VC (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA.			Calhoun, Vincent/0000-0003-0957-5567; Levine, Michael/0000-0001-7629-0081				Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Calhoun VC, 2002, P NATL ACAD SCI USA, V99, P9243, DOI 10.1073/pnas.142291299; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; Fraser P, 1998, CURR OPIN CELL BIOL, V10, P361, DOI 10.1016/S0955-0674(98)80012-4; Kmita M, 2002, NATURE, V420, P145, DOI 10.1038/nature01189; Smallwood PM, 2002, P NATL ACAD SCI USA, V99, P1008, DOI 10.1073/pnas.022629799; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6	8	3	3	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 2	2003	113	3					278	280		10.1016/S0092-8674(03)00309-X	http://dx.doi.org/10.1016/S0092-8674(03)00309-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732136	Bronze			2022-12-28	WOS:000182640800003
J	Hafezparast, M; Klocke, R; Ruhrberg, C; Marquardt, A; Ahmad-Annuar, A; Bowen, S; Lalli, G; Witherden, AS; Hummerich, H; Nicholson, S; Morgan, PJ; Oozageer, R; Priestley, JV; Averill, S; King, VR; Ball, S; Peters, J; Toda, T; Yamamoto, A; Hiraoka, Y; Augustin, M; Korthaus, D; Wattler, S; Wabnitz, P; Dickneite, C; Lampel, S; Boehme, F; Peraus, G; Popp, A; Rudelius, M; Schlegel, J; Fuchs, H; de Angelis, MH; Schiavo, G; Shima, DT; Russ, AP; Stumm, G; Martin, JE; Fisher, EMC				Hafezparast, M; Klocke, R; Ruhrberg, C; Marquardt, A; Ahmad-Annuar, A; Bowen, S; Lalli, G; Witherden, AS; Hummerich, H; Nicholson, S; Morgan, PJ; Oozageer, R; Priestley, JV; Averill, S; King, VR; Ball, S; Peters, J; Toda, T; Yamamoto, A; Hiraoka, Y; Augustin, M; Korthaus, D; Wattler, S; Wabnitz, P; Dickneite, C; Lampel, S; Boehme, F; Peraus, G; Popp, A; Rudelius, M; Schlegel, J; Fuchs, H; de Angelis, MH; Schiavo, G; Shima, DT; Russ, AP; Stumm, G; Martin, JE; Fisher, EMC			Mutations in dynein link motor neuron degeneration to defects in retrograde transport	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; INTERMEDIATE-CHAIN BINDING; AXONAL-TRANSPORT; CYTOPLASMIC DYNEIN; HEAVY-CHAIN; MICE; GENE; DYNACTIN; DISEASE; SOD1	Degenerative disorders of motor neurons include a range of progressive fatal diseases such as amyotrophic lateral sclerosis (ALS), spinal-bulbar muscular atrophy (SBMA), and spinal muscular atrophy (SMA). Although the causative genetic alterations are known for some cases, the molecular basis of many SMA and SBMA-like syndromes and most ALS cases is unknown. Here we show that missense point mutations in the cytoplasmic dynein heavy chain result in progressive motor neuron degeneration in heterozygous mice, and in homozygotes this is accompanied by the formation of Lewy-like inclusion bodies, thus resembling key features of human pathology. These mutations exclusively perturb neuron-specific functions of dynein.	Ingenium Pharmaceut AG, D-82152 Martinsried, Germany; UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England; Canc Res UK, Lab Endothelial Cell Biol, London WC2A 3PX, England; Canc Res UK, Lab Cell Regulat, London WC2A 3PX, England; Canc Res UK, Lab Mol Neuropathobiol, London WC2A 3PX, England; Queen Mary Univ London, Royal London Hosp, Dept Histopathol, London E1 1BB, England; Queen Mary Univ London, Barts & London, Dept Neurosci, London E1 4NS, England; MRC, Mammalian Genet Unit, Harwell OX11 0RD, Berks, England; Commun Res Labs, Kansai Adv Res Ctr, CREST Res Project, Cell Biol Grp, Kobe, Hyogo 6512492, Japan; Tech Univ Munich, Inst Pathol, Div Neuropathol, D-81675 Munich, Germany; Gesell Strahlenforsch Natl Res Ctr Environm & Hlt, Inst Expt Genet, D-85764 Neuherberg, Germany	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Cancer Research UK; Cancer Research UK; Cancer Research UK; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; University of London; Queen Mary University London; Japan Science & Technology Agency (JST); National Institute of Information & Communications Technology (NICT) - Japan; Technical University of Munich	Stumm, G (corresponding author), Ingenium Pharmaceut AG, Fraunhoferstr 13, D-82152 Martinsried, Germany.	e.fisher@prion.ucl.ac.uk	AHMAD-ANNUAR, AZLINA/B-8305-2010; Yamamoto, Ayumu/AAN-4565-2021; Fisher, Elizabeth MC/C-2168-2008; Hiraoka, Yasushi/B-5111-2009; Ruhrberg, Christiana/C-6404-2009; Hafezparast, Majid/H-6728-2018; Hafezparast, Majid/N-8292-2019; de Angelis, Martin Hrabe/F-5531-2012	AHMAD-ANNUAR, AZLINA/0000-0001-6329-4366; Yamamoto, Ayumu/0000-0001-6960-9461; Fisher, Elizabeth MC/0000-0003-2850-9936; Hiraoka, Yasushi/0000-0001-9407-8228; Ruhrberg, Christiana/0000-0002-3212-9381; Hafezparast, Majid/0000-0002-5262-7150; de Angelis, Martin Hrabe/0000-0002-7898-2353; Schiavo, Giampietro/0000-0002-4319-8745; Schlegel, Jurgen/0000-0002-5544-2717				Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; Asai DJ, 2001, TRENDS CELL BIOL, V11, P196, DOI 10.1016/S0962-8924(01)01970-5; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Eaton BA, 2002, NEURON, V34, P729, DOI 10.1016/S0896-6273(02)00721-3; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; HAFEZPARAST M, UNPUB; Harada A, 1998, J CELL BIOL, V141, P51, DOI 10.1083/jcb.141.1.51; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; King SM, 2000, J CELL SCI, V113, P2521; LA SA, 1991, NATURE, V352, P77; Lalli G, 2002, J CELL BIOL, V156, P233, DOI 10.1083/jcb.200106142; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; Murakami T, 2001, NEUROSCI LETT, V308, P149, DOI 10.1016/S0304-3940(01)02036-5; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Rogers DC, 2001, NEUROSCI LETT, V306, P89, DOI 10.1016/S0304-3940(01)01885-7; Shah JV, 2002, CURR OPIN CELL BIOL, V14, P58, DOI 10.1016/S0955-0674(01)00294-0; Stieber A, 2000, J NEUROL SCI, V173, P63, DOI 10.1016/S0022-510X(99)00301-9; Terada S, 2000, CURR OPIN NEUROBIOL, V10, P566, DOI 10.1016/S0959-4388(00)00129-X; Tsuchiya K, 2000, ACTA NEUROPATHOL, V100, P603, DOI 10.1007/s004010000237; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Vallee RB, 2001, TRENDS CELL BIOL, V11, P155, DOI 10.1016/S0962-8924(01)01956-0; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Witherden AS, 2002, GENE, V283, P71, DOI 10.1016/S0378-1119(01)00853-8; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4	30	530	548	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					808	812		10.1126/science.1083129	http://dx.doi.org/10.1126/science.1083129			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730604				2022-12-28	WOS:000182579800054
J	Coburn, W; Boggs, SE				Coburn, W; Boggs, SE			Polarization of the prompt gamma-ray emission from the gamma-ray burst of 6 December 2002	NATURE			English	Article							MAGNETIC-FIELDS; BLACK-HOLES; GRB 990510; AFTERGLOW; FIREBALL; POLARIMETRY; ENERGY; SHOCKS; MODEL	Observations of the afterglows of g-ray bursts (GRBs) have revealed that they lie at cosmological distances, and so correspond to the release of an enormous amount of energy(1,2). The nature of the central engine that powers these events and the prompt gamma-ray emission mechanism itself remain enigmatic because, once a relativistic fireball is created, the physics of the afterglow is insensitive to the nature of the progenitor. Here we report the discovery of linear polarization in the prompt gamma-ray emission from GRB021206, which indicates that it is synchrotron emission from relativistic electrons in a strong magnetic field. The polarization is at the theoretical maximum, which requires a uniform, large-scale magnetic field over the gamma-ray emission region. A large-scale magnetic field constrains possible progenitors to those either having or producing organized fields. We suggest that the large magnetic energy densities in the progenitor environment (comparable to the kinetic energy densities of the fireball), combined with the large-scale structure of the field, indicate that magnetic fields drive the GRB explosion.	Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Boggs, SE (corresponding author), Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA.	boggs@ssl.berkeley.edu	Boggs, Steven E/E-4170-2015	Boggs, Steven E/0000-0001-9567-4224				Bersier D, 2003, ASTROPHYS J, V583, pL63, DOI 10.1086/368158; BLANDFORD R, 1987, PHYS REP, V154, P1, DOI 10.1016/0370-1573(87)90134-7; BLANDFORD RD, 1977, MON NOT R ASTRON SOC, V179, P433, DOI 10.1093/mnras/179.3.433; Covino S, 1999, ASTRON ASTROPHYS, V348, pL1; Derishev EV, 2001, ASTRON ASTROPHYS, V372, P1071, DOI 10.1051/0004-6361:20010586; Frail DA, 2000, ASTROPHYS J, V537, P191, DOI 10.1086/309024; Freedman DL, 2001, ASTROPHYS J, V547, P922, DOI 10.1086/318386; Galama TJ, 1999, NATURE, V398, P394, DOI 10.1038/18828; Gruzinov A, 2001, ASTROPHYS J, V563, pL15, DOI 10.1086/324223; Gruzinov A, 1999, ASTROPHYS J, V511, P852, DOI 10.1086/306720; Guetta D, 2001, ASTROPHYS J, V557, P399, DOI 10.1086/321543; HURLEY K, 2002, 1727 GCN; HURLEY K, 2002, 1728 GCN; Lei F, 1997, SPACE SCI REV, V82, P309, DOI 10.1023/A:1005027107614; LIN RP, IN PRESS SOL PHYS; MCCONNELL M, 1996, AIP C P, V384, P851; Medvedev MV, 1999, ASTROPHYS J, V526, P697, DOI 10.1086/308038; Meszaros P, 2002, ANNU REV ASTRON ASTR, V40, P137, DOI 10.1146/annurev.astro.40.060401.093821; Meszaros P, 1997, ASTROPHYS J, V482, pL29, DOI 10.1086/310692; NOVICK R, 1975, SPACE SCI REV, V18, P389, DOI 10.1007/BF00212912; REES MJ, 1994, ASTROPHYS J, V430, pL93, DOI 10.1086/187446; Rol E, 2000, ASTROPHYS J, V544, P707, DOI 10.1086/317256; RYBICKI GB, 1979, RAD PROCESSES ASTROP, P180; Sari R, 1996, ASTROPHYS J, V473, P204, DOI 10.1086/178136; Spruit HC, 2001, ASTRON ASTROPHYS, V369, P694, DOI 10.1051/0004-6361:20010131; THOMPSON C, 1994, MON NOT R ASTRON SOC, V270, P480, DOI 10.1093/mnras/270.3.480; USOV VV, 1992, NATURE, V357, P472, DOI 10.1038/357472a0; van Paradijs J, 2000, ANNU REV ASTRON ASTR, V38, P379, DOI 10.1146/annurev.astro.38.1.379; Waxman E, 1997, ASTROPHYS J, V489, pL33, DOI 10.1086/310960; Wijers RAMJ, 1999, ASTROPHYS J, V523, pL33, DOI 10.1086/312262	30	326	329	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					415	417		10.1038/nature01612	http://dx.doi.org/10.1038/nature01612			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12761542	Green Submitted			2022-12-28	WOS:000183012000035
J	Ramsey, SD; Berry, K; Etzioni, R; Kaplan, RM; Sullivan, SD; Wood, DE				Ramsey, SD; Berry, K; Etzioni, R; Kaplan, RM; Sullivan, SD; Wood, DE		Natl Emphysema Treatment Trial	Cost effectiveness of lung-volume - Reduction surgery for patients with severe emphysema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; TRANSPLANTATION; NETHERLANDS; HEALTH	BACKGROUND: The National Emphysema Treatment Trial, a randomized clinical trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, included a prospective economic analysis. METHODS: After pulmonary rehabilitation, 1218 patients at 17 medical centers were randomly assigned to lung-volume-reduction surgery or continued medical treatment. Costs for the use of medical care, medications, transportation, and time spent receiving treatment were derived from Medicare claims and data from the trial. Cost effectiveness was calculated over the duration of the trial and was estimated for 10 years of follow-up with the use of modeling based on observed trends in survival, cost, and quality of life. RESULTS: Interim analyses identified a group of patients with excess mortality and little chance of improved functional status after surgery. When these patients were excluded, the cost-effectiveness ratio for lung-volume-reduction surgery as compared with medical therapy was $190,000 per quality-adjusted life-year gained at 3 years and $53,000 per quality-adjusted life-year gained at 10 years. Subgroup analyses identified patients with predominantly upper-lobe emphysema and low exercise capacity after pulmonary rehabilitation who had lower mortality and better functional status than patients who received medical therapy. The cost-effectiveness ratio in this subgroup was $98,000 per quality-adjusted life-year gained at 3 years and $21,000 at 10 years. Bootstrap analysis revealed substantial uncertainty for the subgroup and 10-year estimates. CONCLUSIONS: Given its cost and benefits over three years of follow-up, lung-volume-reduction surgery is costly relative to medical therapy. Although the predictions are subject to substantial uncertainty, the procedure may be cost effective if benefits can be maintained over time.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Washington, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Ramsey, SD (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,MP-900, Seattle, WA 98109 USA.	sramsey@fhcrc.org	KAPLAN, Robert/AAK-7342-2021		NHLBI NIH HHS [N01HR76109, N01HR76108, N01HR76107, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76106, N01HR76105, N01HR76116, N01HR76119, N91HR76115, N01HR76101, N01HR76102, N01HR76103, N91HR76118, N01HR76104] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR076106, N01HR076111, N01HR076102, N01HR076105, N01HR076104, N01HR076110, N01HR076109, N01HR076115, N01HR076118, N01HR076116, N01HR076119, N01HR076113, N01HR076108, N01HR076103, N01HR076112, N01HR076101, N01HR076114, N01HR076107] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al MJ, 1998, CHEST, V113, P124, DOI 10.1378/chest.113.1.124; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; Briggs AH, 2002, ANNU REV PUBL HEALTH, V23, P377, DOI 10.1146/annurev.publhealth.23.100901.140534; *BUR LAB STAT, 2003, CONS PRIC IND; *BUR LAB STAT, 2002, OV BLS STAT WAG EARN; Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W; Chaudhary MA, 1996, STAT MED, V15, P1447; Drazen JM, 2001, NEW ENGL J MED, V345, P1126, DOI 10.1056/NEJM200110113451511; Fein AM, 1998, CHEST, V113, p277S, DOI 10.1378/chest.113.4_Supplement.277S; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Fishman A, 2001, NEW ENGL J MED, V345, P1075; Flaherty KR, 2001, CHEST, V119, P1337, DOI 10.1378/chest.119.5.1337; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; Gelb AF, 1999, CHEST, V116, P1608, DOI 10.1378/chest.116.6.1608; *GEN SERV ADM, 2003, PRIV OWN VEH REIMB P; *HARV CTR RISK AN, 2003, CEA REG STAND METH P; HOLOHAN TV, 1996, AHCPR PUBLICATION; KAPLAN RM, 1984, J CHRON DIS, V37, P85, DOI 10.1016/0021-9681(84)90050-X; KAPLAN RM, 1993, CANCER TREAT REV, V19, P85, DOI 10.1016/0305-7372(93)90061-U; KAPLAN RM, 1996, QUALITY LIFE PHARMAC, P309; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lin DY, 1997, BIOMETRICS, V53, P419, DOI 10.2307/2533947; *MED EC, 2002, PHYS DESK REF; ORENSTEIN DM, 1990, CHEST, V98, P1081, DOI 10.1378/chest.98.5.1081; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Pliskin J S, 1981, Med Decis Making, V1, P10, DOI 10.1177/0272989X8100100104; Pompeo E, 2000, ANN THORAC SURG, V70, P948, DOI 10.1016/S0003-4975(00)01646-5; RAMSEY SD, 1995, CHEST, V108, P1594, DOI 10.1378/chest.108.6.1594; Ramsey SD, 2001, ANN THORAC SURG, V71, P995, DOI 10.1016/S0003-4975(00)02283-9; Rodarte J, 1999, J THORAC CARDIOV SUR, V118, P518; *SAS I, 2002, SAS VERS 8; Sciurba FC, 1996, NEW ENGL J MED, V334, P1095, DOI 10.1056/NEJM199604253341704; SQUIER HC, 1995, AM J RESP CRIT CARE, V152, P2032, DOI 10.1164/ajrccm.152.6.8520772; Steele B, 1996, J Cardiopulm Rehabil, V16, P25; *THOM MED EC, 2002, DRUG TOP RED BOOK; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; VANHOUT B, 1993, J HEALTH ECON, V12, P73, DOI 10.1016/0167-6296(93)90041-C; Wagner, 2000, JNCI-J NATL CANCER I, V92, P164; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WEINSTEIN MC, 1982, CIRCULATION, V66, P56	40	139	142	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2092	2102						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680YU	12759480				2022-12-28	WOS:000183008300007
J	Ylinen, J; Takala, EP; Nykanen, M; Hakkinen, A; Malkia, E; Pohjolainen, T; Karppi, SL; Kautiainen, H; Airaksinen, O				Ylinen, J; Takala, EP; Nykanen, M; Hakkinen, A; Malkia, E; Pohjolainen, T; Karppi, SL; Kautiainen, H; Airaksinen, O			Active neck muscle training in the treatment of chronic neck pain in women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; ISOMETRIC STRENGTH; CERVICAL-SPINE; HEALTHY-VOLUNTEERS; SHOULDER PAIN; MRI CHANGES; PHYSIOTHERAPY; DISABILITY; REHABILITATION; INTERVENTION	Context Active physical training is commonly recommended for patients with chronic neck pain; however, its efficacy has not been demonstrated in randomized studies. Objective To evaluate the efficacy of intensive isometric neck strength training and lighter endurance training of neck muscles on pain and disability in women with chronic, nonspecific neck pain. Design Examiner-blinded randomized controlled trial conducted between February 2000 and March 2002. Setting Participants were recruited from occupational health care systems in southern and eastern Finland. Patients A total of 180 female office workers between the ages of 25 and 53 years with chronic, nonspecific neck pain. Interventions Patients were randomly assigned to either 2 training groups or to a control group, with 60 patients in each group. The endurance training group performed dynamic neck exercises, which included lifting the head up from the supine and prone positions. The strength training group performed high-intensity isometric neck strengthening and stabilization exercises with an elastic band. Both training groups performed dynamic exercises for the shoulders and upper extremities with dumbbells. All groups were advised to do aerobic and stretching exercises regularly 3 times a week. Main Outcome Measures Neck pain and disability were assessed by a visual ana, log scale, the neck and shoulder pain and disability index, and the Vernon neck disability index. Intermediate outcome measures included mood assessed by a short depression inventory and by maximal isometric neck strength and range of motion measures. Results At the 12-month follow-up visit, both neck pain and disability had decreased in both training groups compared with the control group (P<.001). Maximal isometric neck strength had improved flexion by 110%, rotation by 76%, and extension by 69% in the strength training group. The respective improvements in the endurance training group were 28%, 29%, and 16% and in the control group were 10%, 10%, and 7%. Range of motion had also improved statistically significantly in both training groups compared with the control group in rotation, but only the strength training group had statistically significant improvements in lateral flexion and in flexion and extension. Conclusions Both strength and endurance training for 12 months were effective methods for decreasing pain and disability in women with chronic, nonspecific neck pain. Stretching and fitness training are commonly advised for patients with chronic neck pain, but stretching and aerobic exercising alone proved to be a much less effective form of training than strength training.	Jyvaskyla Cent Hosp, Dept Phys Med & Rehabil, Jyvaskyla 40620, Finland; Finnish Inst Occupat Hlth, Helsinki, Finland; Punkaharju Rehabil Ctr, Punkaharju, Finland; Univ Jyvaskyla, Dept Hlth Sci, Jyvaskyla, Finland; Social Insurance Inst, Helsinki, Finland; Rheumatism Fdn Hosp, SF-18120 Heinola, Finland; Kuopio Univ Hosp, Dept Phys Med & Rehabil, SF-70210 Kuopio, Finland	Central Finland Central Hospital; Finnish Institute of Occupational Health; University of Jyvaskyla; Rheumatism Foundation Hospital; Kuopio University Hospital; University of Eastern Finland	Ylinen, J (corresponding author), Jyvaskyla Cent Hosp, Dept Phys Med & Rehabil, Keskussairaalantie 19, Jyvaskyla 40620, Finland.	jari.ylinen@ksshp.fi		Hakkinen, Arja/0000-0002-5779-1259				Aker PD, 1996, BMJ-BRIT MED J, V313, P1291; ANDERSSEN KL, 1971, FUNDAMENTALS EXERCIS; AROMAA A, 2002, PUBLICATION NATL PUB; Chiu TTW, 2002, CLIN REHABIL, V16, P772, DOI 10.1191/0269215502cr552oa; Conley MS, 1997, J APPL PHYSIOL, V83, P2105, DOI 10.1152/jappl.1997.83.6.2105; Cote P, 2000, SPINE, V25, P1109; Ertzgaard S., 2000, PHYSIOTHER CAN, V52, P233; FORSETH KO, 1992, SCAND J RHEUMATOL, V21, P74, DOI 10.3109/03009749209095071; FRIEDENBERG ZB, 1963, J BONE JOINT SURG AM, V45, P1171, DOI 10.2106/00004623-196345060-00004; GOLDIE I, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P117; Gore DR, 2001, SPINE, V26, P2463, DOI 10.1097/00007632-200111150-00013; GORE DR, 1987, SPINE, V12, P1, DOI 10.1097/00007632-198701000-00001; GROSS AR, 1996, ONLINE J CURR C0730; Horneij E, 2002, J REHABIL MED, V34, P176, DOI 10.1080/16501970213235; Jordan A, 1998, SPINE, V23, P311, DOI 10.1097/00007632-199802010-00005; Jordan A, 1999, SPINE, V24, P1343, DOI 10.1097/00007632-199907010-00012; Karjalainen K, 2001, SPINE, V26, P174, DOI 10.1097/00007632-200101150-00012; KELTIKANGASJARVINEN L, 1987, PSYCHOL REP, V60, P111, DOI 10.2466/pr0.1987.60.1.111; LEHTO IJ, 1994, NEURORADIOLOGY, V36, P49, DOI 10.1007/BF00599196; LEVOSKA S, 1993, ARCH PHYS MED REHAB, V74, P425; Lundblad I, 1999, J OCCUP REHABIL, V9, P179, DOI 10.1023/A:1021301801292; Mantyselka PT, 2002, EUR J PAIN, V6, P141, DOI 10.1053/eujp.2001.0311; MANTYSELKA PT, 1998, PATIENT PAIN GEN PRA; Mathiowetz Virgil, 2002, Occup Ther Int, V9, P201, DOI 10.1002/oti.165; Randlov A, 1998, CLIN REHABIL, V12, P200, DOI 10.1191/026921598666881319; REKOLA K, 1993, ACTA U OUL D, V259, P53; RUSH PJ, 1994, BRIT J RHEUMATOL, V33, P566; Siivola SM, 2002, EUR SPINE J, V11, P358, DOI 10.1007/s00586-001-0370-x; Sjogaard G, 2000, EUR J APPL PHYSIOL, V83, P99, DOI 10.1007/s004210000285; Staudte H W, 1994, Eur Spine J, V3, P155, DOI 10.1007/BF02190578; Taimela S, 2000, SPINE, V25, P1021, DOI 10.1097/00007632-200004150-00018; TAKALA EP, 1994, SCAND J REHABIL MED, V26, P17; TAKALA EP, 1992, SCAND J WORK ENV HEA, V18, P257, DOI 10.5271/sjweh.1580; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; VIIKARIJUNTURA E, 1988, SCAND J REHABIL MED, V20, P167; Waling K, 2002, SPINE, V27, P789, DOI 10.1097/00007632-200204150-00002; WULFF HR, 1981, ANN RHEUM DIS, V40, P87; YLINEN J, 1994, ARCH PHYS MED REHAB, V75, P465, DOI 10.1016/0003-9993(94)90173-2; Ylinen JJ, 1999, CLIN BIOMECH, V14, P217, DOI 10.1016/S0268-0033(98)00063-1	39	330	343	0	62	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2509	2516		10.1001/jama.289.19.2509	http://dx.doi.org/10.1001/jama.289.19.2509			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680KL	12759322	Bronze			2022-12-28	WOS:000182976500019
J	Wilson, JF				Wilson, JF			The vaccine crossroads	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					857	860		10.7326/0003-4819-138-10-200305200-00037	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755580				2022-12-28	WOS:000182920700029
J	Cosma, MP; Pepe, S; Annunziata, I; Newbold, RF; Grompe, M; Parenti, G; Ballabio, A				Cosma, MP; Pepe, S; Annunziata, I; Newbold, RF; Grompe, M; Parenti, G; Ballabio, A			The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases	CELL			English	Article							ENZYME REPLACEMENT THERAPY; METACHROMATIC LEUKODYSTROPHY; ARYLSULFATASE-A; STEROID SULFATASE; FELINE MODEL; COMPLEMENTATION; FORMYLGLYCINE; FIBROBLASTS; EXPRESSION; SYSTEM	In multiple sulfatase deficiency (MSD), a human inherited disorder, the activities of all sulfatases are impaired due to a defect in posttranslational modification. Here we report the identification, by functional complementation using microcell-mediated chromosome transfer, of a gene that is mutated in MSD and is able to rescue the enzymatic deficiency in patients' cell lines. Functional conservation of this gene was observed among distantly related species, suggesting a critical biological role. Coexpression of SUMF1 with sulfatases results in a strikingly synergistic increase of enzymatic activity, indicating that SUMF1 is both an essential and a limiting factor for sulfatases. These data have profound implications on the feasibility of enzyme replacement therapy for eight distinct inborn errors of metabolism.	Telethon Inst Genet & Med, I-80131 Naples, Italy; Univ Naples Federico 2, Dept Pediat, I-80131 Naples, Italy; Brunel Univ, Brunel Inst Canc Genet & Pharmacogenom, Uxbridge UB8 4SP, Middx, England; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Univ Naples 2, I-80131 Naples, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Naples Federico II; Brunel University; Oregon Health & Science University; Universita della Campania Vanvitelli	Ballabio, A (corresponding author), Telethon Inst Genet & Med, I-80131 Naples, Italy.	ballabio@tigem.it	BALLABIO, Andrea/AAL-2672-2020; Cosma, Maria Pia/E-8731-2015	BALLABIO, Andrea/0000-0003-1381-4604; Cosma, Maria Pia/0000-0003-4207-5097; parenti, giancarlo/0000-0002-6287-5748; Grompe, Markus/0000-0002-6616-4345	Telethon [TGM03S01, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		BALLABIO A, 1985, HUM GENET, V70, P315, DOI 10.1007/BF00295367; BALLABIO A, 2001, METABOLIC MOL BASIS, P4241; BISCHEL M, 1966, ARCH NEUROL-CHICAGO, V15, P13, DOI 10.1001/archneur.1966.00470130017002; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BURCH M, 1986, CLIN GENET, V30, P409; BURK R, 1981, AM J HUM GENET, V33, pA72; Byers S, 2000, PEDIATR RES, V47, P743, DOI 10.1203/00006450-200006000-00010; CHANG PL, 1980, P NATL ACAD SCI-BIOL, V77, P6166, DOI 10.1073/pnas.77.10.6166; CONARY JT, 1988, BIOL CHEM H-S, V369, P297, DOI 10.1515/bchm3.1988.369.1.297; Consiglio A, 2001, NAT MED, V7, P310, DOI 10.1038/85454; COUCHOT J, 1974, ARCH FR PEDIATR, V31, P775; Crawley AC, 1997, J CLIN INVEST, V99, P651, DOI 10.1172/JCI119208; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; Ferrante P, 2002, EUR J HUM GENET, V10, P813, DOI 10.1038/sj.ejhg.5200887; Fey J, 2001, J BIOL CHEM, V276, P47021, DOI 10.1074/jbc.M108943200; FRANCA JRD, 1995, J ATMOS CHEM, V22, P81; Ho TT, 2002, J GENE MED, V4, P613, DOI 10.1002/jgm.302; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; HORWITZ AL, 1979, P NATL ACAD SCI USA, V76, P6496, DOI 10.1073/pnas.76.12.6496; Hunt JD, 1996, ANAL BIOCHEM, V238, P107, DOI 10.1006/abio.1996.0263; Imreh S, 1997, GENE CHROMOSOME CANC, V20, P224; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Matzner U, 2000, GENE THER, V7, P1250, DOI 10.1038/sj.gt.3301232; Matzner U, 2002, GENE THER, V9, P53, DOI 10.1038/sj.gt.3301593; Meroni G, 1996, HUM MOL GENET, V5, P423, DOI 10.1093/hmg/5.4.423; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Saeki Y, 2001, MOL THER, V3, P591, DOI 10.1006/mthe.2001.0294; Schiller NG, 1998, IDENTITIES-GLOB STUD, V5, P1; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; STEIN C, 1989, J BIOL CHEM, V264, P1252; Toietta G, 2001, HUM GENE THER, V12, P2007, DOI 10.1089/104303401753204571; VONFIGURA K, 2001, METABOLIC MOL BASES, P3695; Wade-Martins R, 2001, NAT BIOTECHNOL, V19, P1067, DOI 10.1038/nbt1101-1067; ZENGER J L, 1989, American Journal of Human Genetics, V45, pA70	40	258	292	2	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 16	2003	113	4					445	456		10.1016/S0092-8674(03)00348-9	http://dx.doi.org/10.1016/S0092-8674(03)00348-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757706	Bronze			2022-12-28	WOS:000182981500007
J	Dierks, T; Schmidt, B; Borissenko, LV; Peng, JH; Preusser, A; Mariappan, M; von Figura, K				Dierks, T; Schmidt, B; Borissenko, LV; Peng, JH; Preusser, A; Mariappan, M; von Figura, K			Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C-alpha-formylglycine generating enzyme	CELL			English	Article							HUMAN ARYLSULFATASE-A; ENDOPLASMIC-RETICULUM; POSTTRANSLATIONAL FORMATION; EUKARYOTIC SULFATASES; PROTEIN MODIFICATION; CRYSTAL-STRUCTURE; CYSTEINE; CONVERSION; FIBROBLASTS; MECHANISM	C-alpha-formylglycine (FGly) is the catalytic residue in the active site of eukaryotic sulfatases. It is posttranslationally generated from a cysteine in the endoplasmic reticulum. The genetic defect of FGly formation causes multiple sulfatase deficiency (MSD), a lysosomal storage disorder. We purified the FGly generating enzyme (FGE) and identified its gene and nine mutations in seven MSD patients. In patient fibroblasts, the activity of sulfatases is partially restored by transduction of FGE encoding cDNA, but not by cDNA carrying an MSD mutation. The gene encoding FGE is highly conserved among pro- and eukaryotes and has a paralog of unknown function in vertebrates. FGE is localized in the endoplasmic reticulum and is predicted to have a tripartite domain structure.	Univ Gottingen, D-37073 Gottingen, Germany	University of Gottingen	von Figura, K (corresponding author), Univ Gottingen, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	kfigura@gwdg.de	mariappan, malaiyalam/K-9024-2012; Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANSON DS, 1993, BIOCHEM J, V294, P657, DOI 10.1042/bj2940657; ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BASNER R, 1979, PEDIATR RES, V13, P1316, DOI 10.1203/00006450-197912000-00002; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; BURCH M, 1986, CLIN GENET, V30, P409; BURK RD, 1984, J PEDIATR-US, V104, P574, DOI 10.1016/S0022-3476(84)80550-8; CHANG PL, 1983, J INHERIT METAB DIS, V6, P167, DOI 10.1007/BF02310875; CONARY JT, 1988, BIOL CHEM H-S, V369, P297, DOI 10.1515/bchm3.1988.369.1.297; COUCHOT J, 1974, ARCH FR PEDIATR, V31, P775; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Fey J, 2001, J BIOL CHEM, V276, P47021, DOI 10.1074/jbc.M108943200; FLUHARTY AL, 1979, AM J HUM GENET, V31, P574; FLUHARTY AL, 1978, AM J HUM GENET, V30, P249; GLOSSL J, 1978, CLIN CHIM ACTA, V88, P111, DOI 10.1016/0009-8981(78)90157-2; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; Hansske B, 2002, J CLIN INVEST, V109, P725, DOI 10.1172/JCI200214010; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; KRESSE H, 1980, BIOCHEM BIOPH RES CO, V97, P41, DOI 10.1016/S0006-291X(80)80131-8; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Meyer HA, 2000, J BIOL CHEM, V275, P14550, DOI 10.1074/jbc.275.19.14550; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; Peng JH, 2003, J MASS SPECTROM, V38, P80, DOI 10.1002/jms.404; Rampini S, 1970, Helv Paediatr Acta, V25, P436; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROMMERSKIRCH W, 1992, P NATL ACAD SCI USA, V89, P2561, DOI 10.1073/pnas.89.7.2561; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; STECKEL F, 1985, EUR J BIOCHEM, V151, P141, DOI 10.1111/j.1432-1033.1985.tb09078.x; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; Thiel C, 2002, BIOCHEM J, V367, P195, DOI 10.1042/BJ20020794; VAMOS E, 1981, J INHERIT METAB DIS, V4, P103, DOI 10.1007/BF02263612; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13; YUTAKA T, 1981, CLIN GENET, V20, P296	44	269	304	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	2003	113	4					435	444		10.1016/S0092-8674(03)00347-7	http://dx.doi.org/10.1016/S0092-8674(03)00347-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	680MG	12757705	Bronze			2022-12-28	WOS:000182981500006
J	Garfield, CF; Chung, PJ; Rathouz, PJ				Garfield, CF; Chung, PJ; Rathouz, PJ			Alcohol advertising in magazines and adolescent readership	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRINKING; SCHOOL	Context Adolescent drinking is a major public health concern. The federal government does not restrict alcohol advertising to adolescents, but relies on the alcohol industry for self-regulation. Objectives To investigate recent alcohol advertising in magazines and to determine whether advertising frequency is associated with adolescent readership. Design, Setting, and Subjects All alcohol advertisements were counted that appeared from 1997-2001 in 35 of 48 major US magazines, which tracked their adolescent readership (3 refused all alcohol advertisements; and advertisement counts were unavailable for 10). Variation was assessed in the advertisement placement frequency for each major category of alcohol (beer, wine and wine coolers, and distilled liquor) by a magazine's adolescent readership (age 12-19 years), young adult readership (age 20-24 years), and older adult readership (age greater than or equal to25 years); readership demographics (sex, race, and income); year; frequency of publication; and cost per advertisement. Main Outcome Measure Variation in alcohol advertising frequency by adolescent readership. Results Adolescent readership ranged from 1.0 to 7.1 million. The alcohol industry placed 9148 advertisements at a cost of $696 million. Of the 9148 advertisements, 1201 (13%) were for beer, 443 (5%) for wine, and 7504 (82%) for liquor. After adjustment for other magazine characteristics, the advertisement rate ratio was 1.6 times more for beer (95% confidence interval [CI], 1.0-2.6; P=.05) and liquor (95% CI, 1.1-2.3; P=.01) for every additional million adolescent readers. Wine industry advertising was not associated with adolescent readership. Conclusions Magazine advertising by the beer and liquor industries is associated with adolescent readership. industry and federal policymakers should examine ways to regulate advertising that reaches large numbers of adolescents.	Evanston NW Healthcare Res Inst, Dept Pediat, Evanston, IL 60202 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Chicago	Garfield, CF (corresponding author), Evanston NW Healthcare Res Inst, Dept Pediat, 2650 Ridge Ave, Evanston, IL 60202 USA.	c-garfield@northwestern.edu	Garfield, Craig/AAE-2525-2020	Garfield, Craig/0000-0002-6512-6005				*AM COLL EM PHYS, 2001, ANN EMERG MED, V37, P557; [Anonymous], 1999, Pediatrics, V104, P341; Atkin, 1993, Adolesc Med, V4, P527; ATKIN CK, 1990, J ADOLESCENT HEALTH, V11, P10, DOI 10.1016/0197-0070(90)90125-L; ATKIN CK, 1984, J COMMUN, V28, P71; Chung PJ, 2002, HEALTH AFFAIR, V21, P254, DOI 10.1377/hlthaff.21.2.254; *COMP MED REP, 2001, TARG 2 CONS MAG OCC; *FED TRAD COMM, SELF REG ALC IND REV; Foster SE, 2003, JAMA-J AM MED ASSOC, V289, P989, DOI 10.1001/jama.289.8.989; *GEORG U CTR ALC M, 2002, OV YOUTH TARG ALC AD; GRUBE JW, 1994, AM J PUBLIC HEALTH, V84, P254, DOI 10.2105/AJPH.84.2.254; Grube JW, 1995, EFFECTS MASS MEDIA U, V28, P105; IACOBUCCI D, 2001, KELLOGG MARKETING; Jacobs EA, 2001, PEDIATRICS, V108, P185, DOI 10.1542/peds.108.1.185; Johnston L, 2003, MONITORING FUTURE NA; JOHNSTON LD, 1996, NIH PUBLICATION, V1; MADDEN PA, 1994, AM J PUBLIC HEALTH, V84, P297, DOI 10.2105/AJPH.84.2.297; Martin SE, 2002, ALCOHOL CLIN EXP RES, V26, P900, DOI 10.1097/00000374-200206000-00021; *MED RES INC, 2000, MED REP; *NAT HIGHW TRAFF S, 1998, TRAFF SAF FACTS 1997; *NAT I ALC AB ALC, 1997, YOUTH DRINK RISK FAC; *NAT I ALC AB ALC, 1996, ALC AL 31 DRINK DRIV; *OFF INSP GEN, 1992, YOUTH ALC DANG DEADL; SHELOV S, 1995, PEDIATRICS, V95, P295; Snyder LB, 2000, J STUD ALCOHOL, V61, P896, DOI 10.15288/jsa.2000.61.896; Strasburger, 1993, Adolesc Med, V4, P391; Strasburger VC, 2002, PEDIATR CLIN N AM, V49, P353, DOI 10.1016/S0031-3955(01)00009-8; STRUNIN L, 1992, INT J ADDICT, V27, P129, DOI 10.3109/10826089209068734; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; *US DEP HHS, 1997, 9 SPEC REP US C ALC; Valois RF, 1999, J ADOLESCENT HEALTH, V25, P328, DOI 10.1016/S1054-139X(99)00051-8; Wechsler H, 1998, J AM COLL HEALTH, V47, P57, DOI 10.1080/07448489809595621; 1991, MMWR MORB MORTAL WKL, V40, P178; 2001, US WINE MARKET IMPAC; 2002, US BEER MARKET IMPAC; 2001, US SPIRITS MARKET IM	36	48	49	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2424	2429		10.1001/jama.289.18.2424	http://dx.doi.org/10.1001/jama.289.18.2424			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	677WF	12746369				2022-12-28	WOS:000182831200035
J	Prager, KM				Prager, KM			Alice's husband	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2333	2333		10.1001/jama.289.18.2333	http://dx.doi.org/10.1001/jama.289.18.2333			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677WF	12746339				2022-12-28	WOS:000182831200001
J	Wardle, DA; Hornberg, G; Zackrisson, O; Kalela-Brundin, M; Coomes, DA				Wardle, DA; Hornberg, G; Zackrisson, O; Kalela-Brundin, M; Coomes, DA			Long-term effects of wildfire on ecosystem properties across an island area gradient	SCIENCE			English	Article							TERRESTRIAL ECOSYSTEMS; CARBON STORAGE; BOREAL FOREST; FIRE; GRASSLAND; BUDGET; SINK	Boreal forest soils play an important role in the global carbon cycle by functioning as a large terrestrial carbon sink or source, and the alteration of fire regime through global change phenomena may influence this role. We studied a system of forested lake islands in the boreal zone of Sweden for which fire frequency increases with increasing island size. Large islands supported higher plant productivity and litter decomposition rates than did smaller ones, and, with increasing time since fire, litter decomposition rates were suppressed sooner than was ecosystem productivity. This contributes to greater carbon storage with increasing time since fire; for every century without a major fire, an additional 0.5 kilograms per square meter of carbon becomes stored in the humus.	Swedish Univ Agr Sci, Fac Forestry, Dept Forest Vegetat Ecol, SE-90183 Umea, Sweden; Landcare Res, Lincoln, New Zealand; Museum Forestry, SE-92123 Lycksele, Sweden; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	Swedish University of Agricultural Sciences; Landcare Research - New Zealand; University of Cambridge	Wardle, DA (corresponding author), Swedish Univ Agr Sci, Fac Forestry, Dept Forest Vegetat Ecol, SE-90183 Umea, Sweden.		Coomes, David/H-5630-2011; Wardle, David A./F-6031-2011	Wardle, David A./0000-0002-0476-7335				ANDERSON JM, 1991, ECOL APPL, V1, P326, DOI 10.2307/1941761; BONAN GB, 1989, ANNU REV ECOL SYST, V20, P1, DOI 10.1146/annurev.es.20.110189.000245; Fang JY, 2001, SCIENCE, V292, P2320, DOI 10.1126/science.1058629; FLANNIGAN MD, 1991, CANADIAN J FOREST RE, V21, P61; Goodale CL, 2002, ECOL APPL, V12, P891, DOI 10.2307/3060997; HAAPASAARI M, 1998, ACTA FOR FENN, V135, P1; Harden JW, 2000, GLOBAL CHANGE BIOL, V6, P174, DOI 10.1046/j.1365-2486.2000.06019.x; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Houghton RA, 2000, GLOBAL ECOL BIOGEOGR, V9, P145, DOI 10.1046/j.1365-2699.2000.00164.x; Hurtt GC, 2002, P NATL ACAD SCI USA, V99, P1389, DOI 10.1073/pnas.012249999; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Larsen CPS, 1997, J BIOGEOGR, V24, P663, DOI 10.1111/j.1365-2699.1997.tb00076.x; OJIMA DS, 1994, BIOGEOCHEMISTRY, V24, P67, DOI 10.1007/BF02390180; PAYETTE S, 1992, P144, DOI 10.1017/CBO9780511565489.006; Schimel DS, 2001, NATURE, V414, P169, DOI 10.1038/35102500; SCHIMEL DS, 1995, GLOBAL CHANGE BIOL, V1, P77, DOI 10.1111/j.1365-2486.1995.tb00008.x; Scurlock JMO, 1998, GLOBAL CHANGE BIOL, V4, P229, DOI 10.1046/j.1365-2486.1998.00151.x; SIREN GUSTAF, 1955, ACTA FOREST FENNICA, V62, P1; Tilman D, 2000, ECOLOGY, V81, P2680, DOI 10.1890/0012-9658(2000)081[2680:FSAECS]2.0.CO;2; Wardle DA, 2002, J BIOGEOGR, V29, P583, DOI 10.1046/j.1365-2699.2002.00708.x; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296; ZACKRISSON O, 1977, OIKOS, V29, P22, DOI 10.2307/3543289	22	223	232	10	139	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					972	975		10.1126/science.1082709	http://dx.doi.org/10.1126/science.1082709			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738863				2022-12-28	WOS:000182719800055
J	Colombo, K; Grill, SW; Kimple, RJ; Willard, FS; Siderovski, DP; Gonczy, P				Colombo, K; Grill, SW; Kimple, RJ; Willard, FS; Siderovski, DP; Gonczy, P			Translation of polarity cues into asymmetric spindle positioning in Caenorhabditis elegans embryos	SCIENCE			English	Article							C-ELEGANS; CELL-DIVISION; G-ALPHA; DISSOCIATION INHIBITOR; BINDING PROTEIN; GERM-LINE; DROSOPHILA; LOCALIZATION; ORIENTATION; SEGREGATION	Asymmetric divisions are crucial for generating cell diversity; they rely on coupling between polarity cues and spindle positioning, but how this coupling is achieved is poorly understood. In one-cell stage Caenorhabditis elegans embryos, polarity cues set by the PAR proteins mediate asymmetric spindle positioning by governing an imbalance of net pulling forces acting on spindle poles. We found that the GoLoco-containing proteins GPR-1 and GPR-2, as well as the Galpha subunits GOA-1 and GPA-16, were essential for generation of proper pulling forces. GPR-1/2 interacted with guanosine diphosphate-bound GOA-1 and were enriched on the posterior cortex in a par-3- and par-2-dependent manner. Thus, the extent of net pulling forces may depend on cortical Galpha activity, which is regulated by anterior-posterior polarity cues through GPR-1/2.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	Swiss Institute Experimental Cancer Research; Max Planck Society; University of North Carolina; University of North Carolina Chapel Hill	Gonczy, P (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Siderovski, David Peter/AAA-9603-2019; Grill, Stephan/D-9427-2012; Kimple, Randall/L-6460-2019	Siderovski, David Peter/0000-0002-0688-8210; Kimple, Randall/0000-0001-8336-8000; Gonczy, Pierre/0000-0002-6305-6883	NIGMS NIH HHS [GM62338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyd L, 1996, DEVELOPMENT, V122, P3075; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; COLOMBO K, UNPUB; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Gonczy P, 2002, TRENDS CELL BIOL, V12, P332, DOI 10.1016/S0962-8924(02)02306-1; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; GRILL SW, UNPUB; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hung TJ, 1999, DEVELOPMENT, V126, P127; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Miller KG, 2000, GENETICS, V156, P1649; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; Pellettieri J, 2002, SCIENCE, V298, P1946, DOI 10.1126/science.1072162; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; Rose LS, 1998, DEVELOPMENT, V125, P1337; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; Tsou MFB, 2002, DEVELOPMENT, V129, P4469; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297	26	225	235	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1957	1961		10.1126/science.1084146	http://dx.doi.org/10.1126/science.1084146			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12750478				2022-12-28	WOS:000183619400051
J	Lipsitch, M; Cohen, T; Cooper, B; Robins, JM; Ma, S; James, L; Gopalakrishna, G; Chew, SK; Tan, CC; Samore, MH; Fisman, D; Murray, M				Lipsitch, M; Cohen, T; Cooper, B; Robins, JM; Ma, S; James, L; Gopalakrishna, G; Chew, SK; Tan, CC; Samore, MH; Fisman, D; Murray, M			Transmission dynamics and control of severe acute respiratory syndrome	SCIENCE			English	Article							CORONAVIRUS	Severe acute respiratory syndrome (SARS) is a recently described illness of humans that has spread widely over the past 6 months. With the use of detailed epidemiologic data from Singapore and epidemic curves from other settings, we estimated the reproductive number for SARS in the absence of interventions and in the presence of control efforts. We estimate that a single infectious case of SARS will infect about three secondary cases in a population that has not yet instituted control measures. Public-health efforts to reduce transmission are expected to have a substantial impact on reducing the size of the epidemic.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Minist Hlth, Epidemiol & Dis Control Div, Singapore 169854, Singapore; Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; City Hamilton Publ Hlth & Community Serv Dept, Hamilton, ON L8R 3L5, Canada; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Ministry of Health-Singapore; Utah System of Higher Education; University of Utah; McMaster University; Harvard University; Massachusetts General Hospital	Murray, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	mmurray@hsph.harvard.edu	Cooper, Ben/HGC-7082-2022; Cohen, Ted/G-8101-2011	Cohen, Ted/0000-0002-8091-7198; Lipsitch, Marc/0000-0003-1504-9213; Cooper, Ben/0000-0002-9445-7217	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048935, T32AI007433, R21AI055825, R01AI032475, R01AI046669, K08AI055985] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07433, K08 AI055985-01A1, R21 AI 55825, R01 AI 46669, R01 AI 48935, R01 AI 32475, K08 AI055985] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON R M, 1991; CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019; DONNELLY CA, 2003, LANCET, V361; Dowell SF, 2001, EMERG INFECT DIS, V7, P369; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799; Karlin S., 1975, 1 COURSE STOCHASTIC, V2; LIPSITCH M, UNPUB; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; *US CDCP, 2003, MMWR-MORBID MORTAL W, V52, P405	11	923	1000	2	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1966	1970		10.1126/science.1086616	http://dx.doi.org/10.1126/science.1086616			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12766207	Green Accepted, Green Submitted			2022-12-28	WOS:000183619400053
J	Booth, CM; Matukas, LM; Tomlinson, GA; Rachlis, AR; Rose, DB; Dwosh, HA; Walmsley, SL; Mazzulli, T; Avendano, M; Derkach, P; Ephtimios, IE; Kitai, I; Mederski, BD; Shadowitz, SB; Gold, WL; Hawryluck, LA; Rea, E; Chenkin, JS; Cescon, DW; Poutanen, SM; Detsky, AS				Booth, CM; Matukas, LM; Tomlinson, GA; Rachlis, AR; Rose, DB; Dwosh, HA; Walmsley, SL; Mazzulli, T; Avendano, M; Derkach, P; Ephtimios, IE; Kitai, I; Mederski, BD; Shadowitz, SB; Gold, WL; Hawryluck, LA; Rea, E; Chenkin, JS; Cescon, DW; Poutanen, SM; Detsky, AS			Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Severe acute respiratory syndrome (SARS) is an emerging infectious disease that first manifested in humans in China in November 2002 and has subsequently spread worldwide. Objectives To describe the clinical characteristics and short-term outcomes of SARS in the first large group of patients in North America; to describe how these patients were treated and the variables associated with poor outcome. Design, Setting, and Patients Retrospective case series involving 144 adult patients admitted to 10 academic and community hospitals in the greater Toronto, Ontario, area between March 7 and April 10, 2003, with a diagnosis of suspected or probable SARS. Patients were included if they had fever, a known exposure to SARS, and respiratory symptoms or infiltrates observed on chest radiograph. Patients were excluded if an alternative diagnosis was determined. Main Outcome Measures Location of exposure to SARS; features of the history, physical examination, and laboratory tests at admission to the hospital; and 21-day outcomes such as death or intensive care unit (ICU) admission with or without mechanical ventilation. Results Of the 144 patients, 111 (77%) were exposed to SARS in the hospital setting. Features of the clinical examination most commonly found in these patients at admission were self-reported fever (99%), documented elevated temperature (85%), nonproductive cough (69%), myalgia (49%), and dyspnea (42%). Common laboratory features included elevated lactate dehydrogenase (87%), hypocalcemia (60%), and lymphopenia,(54%). Only 2% of patients had rhinorrhea. A total of 126 patients (88%) were treated with ribavirin, although its use was associated with significant toxicity, including hemolysis (in 76%) and decrease in hemoglobin of 2 g/dL (in 49%). Twenty-nine patients (20%) were admitted to the ICU with or without mechanical ventilation, and 8 patients died (21-day mortality, 6.5%; 95% confidence interval [CI], 1.9%-11.8%). Multivariable analysis showed that the presence of diabetes (relative risk [RR], 3.1; 95% CI, 1.4-7.2; P=.01) or other comorbid conditions (RR, 2.5; 95% CI, 1.1-5.8; P=.03) were independently associated with poor outcome (death, ICU admission, or mechanical ventilation). Conclusions The majority of cases in the SARS outbreak in the greater Toronto area were related to hospital exposure. In the event that contact history becomes unreliable, several features of the clinical presentation will be useful in raising the suspicion of SARS. Although SARS is associated with significant morbidity and mortality, especially in patients with diabetes or other comorbid conditions, the vast majority (93.5%) of patients in our cohort survived.	Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Scarborough Gen Hosp, Toronto, ON, Canada; York Cent Hosp, Toronto, ON, Canada; Univ Hlth Network, Toronto, ON, Canada; Westpk Healthcare Ctr, Toronto, ON, Canada; Markham Stouffville Hosp, Toronto, ON, Canada; RougeValley Hlth Syst, Toronto, ON, Canada; N York Gen Hosp, Toronto, ON, Canada; Toronto Publ Hlth, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Scarborough Hospital; University of Toronto; University Toronto Affiliates; North York General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; North York General Hospital	Detsky, AS (corresponding author), Mt Sinai Hosp, Suite 427,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	allan.detsky@uhn.on.ca	Poutanen, Susan M/F-9640-2012; Poutanen, Susan M./N-8066-2019; Tomlinson, George A/L-5432-2016	Poutanen, Susan M/0000-0003-4747-2550; Poutanen, Susan M./0000-0003-4747-2550; Tomlinson, George A/0000-0002-9328-6399; Walmsley, Sharon/0000-0002-3959-5692				Borio L, 2002, JAMA-J AM MED ASSOC, V287, P2391, DOI 10.1001/jama.287.18.2391; *BRIT COL GEN SCI, SARS ASS COR; *CDCP, 2003, SEV AC RESP SYNDR CO; *CDCP, SARS COR SEQ; Centers for Disease Control and Prevention, 2003, UPD OUTBR SEV AC RES; CONOVER WJ, 1980, PRACTICAL NON PARAME; Cox D. R., 1984, ANAL SURVIVAL DATA; DROSTEN C, N ENGL J MED; DWOSH HA, IN PRESS CMAJ; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; *HLTH CAN, SEV AC RESP SYNDR CA; KSIAZEK TG, N ENGL J MED; LEE N, N ENGL J MED; Mandell LA, 2000, CLIN INFECT DIS, V31, P422, DOI 10.1086/313965; *ONT MIN HLTH LONG, 2003, SEV AC RESP SYNDR; POUTANEN SM, N ENGL J MED; TSANG KW, N ENGL J MED; Tukey John W., 1990, STAT SCI, V5, P327, DOI [10.1214/ss/1177012101, DOI 10.1214/SS/1177012101]; WHO, WHO ISS GLOB AL CAS; *WHO, CAS DEF SURV SEV AC; World Health Organization, CUM NUMB REP PROB CA	22	919	1006	1	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2801	2809		10.1001/jama.289.21.JOC30885	http://dx.doi.org/10.1001/jama.289.21.JOC30885			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KH	12734147	Bronze			2022-12-28	WOS:000183205500028
J	Jha, AK; Perlin, JB; Kizer, KW; Dudley, RA				Jha, AK; Perlin, JB; Kizer, KW; Dudley, RA			Effect of the transformation of the Veterans Affairs health care system on the quality of care.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICARE BENEFICIARIES; FEE SCHEDULE; VA; DISPARITIES	BACKGROUND: In the mid-1990s, the Department of Veterans Affairs (VA) health care system initiated a systemwide reengineering to, among other things, improve its quality of care. We sought to determine the subsequent change in the quality of health care and to compare the quality with that of the Medicare fee-for-service program. METHODS: Using data from an ongoing performance-evaluation program in the VA, we evaluated the quality of preventive, acute, and chronic care. We assessed the change in quality-of-care indicators from 1994 (before reengineering) through 2000 and compared the quality of care with that afforded by the Medicare fee- for-service system, using the same indicators of quality. RESULTS: In fiscal year 2000, throughout the VA system, the percentage of patients receiving appropriate care was 90 percent or greater for 9 of 17 quality-of-care indicators and exceeded 70 percent for 13 of 17 indicators. There were statistically significant improvements in quality from 1994-1995 through 2000 for all nine indicators that were collected in all years. As compared with the Medicare fee-for-service program, the VA performed significantly better on all 11 similar quality indicators for the period from 1997 through 1999. In 2000, the VA outperformed Medicare on 12 of 13 indicators. CONCLUSIONS: The quality of care in the VA health care system substantially improved after the implementation of a systemwide reengineering and, during the period from 1997 through 2000, was significantly better than that in the Medicare fee-for-service program. These data suggest that the quality-improvement initiatives adopted by the VA in the mid-1990s were effective.	Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94118 USA; Vet Hlth Adm, Off Qual & Performance, Washington, DC USA; San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA; Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; Natl Qual Forum, Washington, DC USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; Harvard University; Brigham & Women's Hospital	Dudley, RA (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Box 0936,333 Calif St,Suite 265, San Francisco, CA 94118 USA.	adudley@itsa.ucsf.edu	Greiver, Michelle/N-8764-2015; Young, Alexander/A-1523-2009	Greiver, Michelle/0000-0001-8957-0285; Young, Alexander/0000-0002-9367-9213				[Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Asch SM, 2000, JAMA-J AM MED ASSOC, V284, P2325, DOI 10.1001/jama.284.18.2325; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; *COMM VET AFF, 1997, VET EQ RES ALL SYST; Demakis JG, 2000, MED CARE, V38, pS17; *DEP VET AFF, 1997, JOURN CHANG; Doebbeling BN, 2002, MED CARE, V40, P540, DOI 10.1097/00005650-200206000-00011; *FED INT FOR AG RE, 2003, OLD AM 2000 KEY IND; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Gardner J, 1998, Mod Healthc, V28, P39; HOLLOWAY JJ, 1990, HEALTH SERV RES, V25, P213; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Jha AK, 2001, JAMA-J AM MED ASSOC, V285, P297, DOI 10.1001/jama.285.3.297; Kazis LE, 1999, AM J MED QUAL, V14, P28, DOI 10.1177/106286069901400105; Kazis LE, 1998, ARCH INTERN MED, V158, P626, DOI 10.1001/archinte.158.6.626; KENT C, 1991, F GRAYS MED HLTH S, V45, pP4; Kizer KW, 1999, AM J MED QUAL, V14, P3, DOI 10.1177/106286069901400103; Kizer KW, 2001, HLTH INFORMAT SER, P79; KIZER KW, 1998, STRAIGHT CEO WORLDS; Klein R., 2001, DATA SOCIOECONOMIC S; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728; *MIDW BUS GROUP HL, 2002, RED COSTS POOR QUAL; MITCHELL JB, 1990, INQUIRY-J HEALTH CAR, V27, P108; Palmer RH, 1998, INT J QUAL HEALTH C, V10, P477; *PRES ADV COMM CON, 1998, QUAL 1ST BETT HLTH C; Schneider EC, 2001, JAMA-J AM MED ASSOC, V286, P1455, DOI 10.1001/jama.286.12.1455; Schneider EC, 2002, JAMA-J AM MED ASSOC, V287, P1288, DOI 10.1001/jama.287.10.1288; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Trude S, 1997, J HEALTH POLIT POLIC, V22, P49, DOI 10.1215/03616878-22-1-49; *VET HLTH ADM OFF, 2000, VHA PERF MEAS SYST T; Wennberg JE, 1998, DARTMOUTH ATLAS HLTH; Wilson NJ, 1997, HEALTH AFFAIR, V16, P200, DOI 10.1377/hlthaff.16.4.200; ZOOK CJ, 1980, MILBANK FUND Q, V58, P454, DOI 10.2307/3349734	35	507	509	2	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2218	2227		10.1056/NEJMsa021899	http://dx.doi.org/10.1056/NEJMsa021899			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	683EK	12773650				2022-12-28	WOS:000183134700009
J	Transue, ER				Transue, ER			What I have seen	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2619	2620		10.1001/jama.289.20.2619	http://dx.doi.org/10.1001/jama.289.20.2619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682DG	12771095	Bronze			2022-12-28	WOS:000183075600001
J	Hawkins, G; McMahon, AD; Twaddle, S; Wood, SF; Ford, I; Thomson, NC				Hawkins, G; McMahon, AD; Twaddle, S; Wood, SF; Ford, I; Thomson, NC			Stepping down inhaled corticosteroids in asthma: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FLUTICASONE PROPIONATE; ADOLESCENTS; SALMETEROL; REDUCTION; MODERATE; ADULTS	Objectives To determine whether the dose of inhaled corticosteroids can be stepped down in patients with chronic stable asthma while maintaining control. Design One year, randomised controlled, double blind, parallel group trial. Setting General practices throughout western and central Scotland. Participants 259 adult patients with asthma receiving regular treatment with inhaled corticosteroids at high dose (mean dose 1430 mug beclomethasone dipropionate). Interventions Participants were allocated to receive either no alteration to their dose of inhaled corticosteroid (control) or a 50% reduction in their dose if they met criteria for stable asthma (stepdown). Main outcome measures Comparison of asthma exacerbation rates, asthma related visits to general practice and hospital, health status measures, and corticosteroid dosage between the two groups. Results The proportions of subjects with asthma exacerbations were not significantly different (stepdown 31%, control 26%, P = 0.354). Similarly, the numbers of visits to general practice or hospital and the disease specific and generic measures of health status over die one year period were not significantly different. On average the stepdown group received 348 mug (95% confidence interval 202 mug to 494 mug) of beclomethasone dipropionate less per day than the controls (a difference of 25%), with no difference in the annual dose of oral corticosteroids between the two treatment regimens. Conclusions By adopting a stepdown approach to the use of inhaled steroids at high doses in asthma a reduction in the dose can be achieved without compromising asthma control.	Univ Glasgow, Western Infirm, Dept Resp Med, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland; Stobhill Gen Hosp, Dept Res & Dev, Glasgow G21 3UT, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Thomson, NC (corresponding author), Univ Glasgow, Western Infirm, Dept Resp Med, Glasgow G11 6NT, Lanark, Scotland.	n.c.thomson@clinmed.gla.ac.uk	Ford, Ian/ABE-6145-2020; McMahon, Alex D/C-4304-2008	Thomson, Neil/0000-0003-1632-6630				Althuis MD, 1999, J ASTHMA, V36, P257, DOI 10.3109/02770909909075409; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bousquet J, 2002, CLIN THER, V24, P1, DOI 10.1016/S0149-2918(02)85002-0; DEKKER FW, 1993, EUR RESPIR J, V6, P886; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; Gershman NH, 2000, EUR RESPIR J, V15, P11, DOI 10.1183/09031936.00.15101100; *GLOB IN ASTHM, 1995, PUBL GLOB IN ASTHM; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; McMahon AD, 2002, STAT MED, V21, P1365, DOI 10.1002/sim.1120; Rimmington LD, 1997, EUR RESPIR J, V11, P1289; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Tattersfield AE, 1999, THORAX, V54, P753, DOI 10.1136/thx.54.9.753; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; 2003, THORAX S1, V58, pS1	23	97	98	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2003	326	7399					1115	1118		10.1136/bmj.326.7399.1115	http://dx.doi.org/10.1136/bmj.326.7399.1115			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763981	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000183245000017
J	Froy, O; Gotter, AL; Casselman, AL; Reppert, SM				Froy, O; Gotter, AL; Casselman, AL; Reppert, SM			Illuminating the circadian clock in monarch butterfly migration	SCIENCE			English	Article								Migratory monarch butterflies use a time-compensated Sun compass to navigate to their overwintering grounds in Mexico. Here, we report that constant light, which disrupts circadian clock function at both the behavioral and molecular levels in monarchs, also disrupts the time-compensated component of flight navigation. We further show that ultraviolet light is important for flight navigation but is not required for photic entrainment of circadian rhythms. Tracing these distinct light-input pathways into the brain should aid our understanding of the clock-compass mechanisms necessary for successful migration.	Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Reppert, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, LRB-728,364 Plantat St, Worcester, MA 01605 USA.	steven.reppert@umassmed.edu	Froy, Oren/C-3550-2009					Brower LP, 1996, J EXP BIOL, V199, P93; Emery P, 2000, NEURON, V26, P493, DOI 10.1016/S0896-6273(00)81181-2; FROY O, UNPUB; Labhart T, 1999, MICROSC RES TECHNIQ, V47, P368, DOI 10.1002/(SICI)1097-0029(19991215)47:6<368::AID-JEMT2>3.3.CO;2-H; Mouritsen H, 2002, P NATL ACAD SCI USA, V99, P10162, DOI 10.1073/pnas.152137299; Perez SM, 1997, NATURE, V387, P29, DOI 10.1038/387029a0; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; Saunders DS, 1982, INSECT CLOCKS; URQUHART F, 1960, MONARCH BUTTERLY; Wehner R, 2001, J EXP BIOL, V204, P2589; White R.C., UNPUB; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	12	130	140	7	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1303	1305		10.1126/science.1084874	http://dx.doi.org/10.1126/science.1084874			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764200				2022-12-28	WOS:000183042400053
J	Guo, B; Zhai, DY; Cabezas, E; Welsh, K; Nouraini, S; Satterthwait, AC; Reed, JC				Guo, B; Zhai, DY; Cabezas, E; Welsh, K; Nouraini, S; Satterthwait, AC; Reed, JC			Humanin peptide suppresses apoptosis by interfering with Bax activation	NATURE			English	Article							CELL-DEATH; PROTEINS	Bax (Bcl2-associated X protein) is an apoptosis-inducing protein that participates in cell death during normal development and in various diseases(1). Bax resides in an inactive state in the cytosol of many cells. In response to death stimuli, Bax protein undergoes conformational changes that expose membrane-targeting domains, resulting in its translocation to mitochondrial membranes, where Bax inserts and causes release of cytochrome c and other apoptogenic proteins(2). It is unknown what controls conversion of Bax from the inactive to active conformation. Here we show that Bax interacts with humanin (HN), an anti-apoptotic peptide of 24 amino acids encoded in mammalian genomes(3,4). HN prevents the translocation of Bax from cytosol to mitochondria. Conversely, reducing HN expression by small interfering RNAs sensitizes cells to Bax and increases Bax translocation to membranes. HN peptides also block Bax association with isolated mitochondria, and suppress cytochrome c release in vitro. Notably, the mitochondrial genome contains an identical open reading frame, and the mitochondrial version of HN can also bind and suppress Bax. We speculate therefore that HN arose from mitochondria and transferred to the nuclear genome, providing a mechanism for protecting these organelles from Bax.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org						Atherton E., 1989, SOLID PHASE SYNTHESI; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Gray MW, 2001, GENOME BIOL, V2; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kermer P, 2002, CELL DEATH DIFFER, V9, P405, DOI 10.1038/sj.cdd.4400972; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; Stryer L., 1988, BIOCHEMISTRY-US; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tajima H, 2002, NEUROSCI LETT, V324, P227, DOI 10.1016/S0304-3940(02)00199-4; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xu QL, 2000, METHOD ENZYMOL, V322, P283; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	23	444	501	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2003	423	6938					456	461		10.1038/nature01627	http://dx.doi.org/10.1038/nature01627			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12732850				2022-12-28	WOS:000183012000046
J	Bobrowski, N; Honninger, G; Galle, B; Platt, U				Bobrowski, N; Honninger, G; Galle, B; Platt, U			Detection of bromine monoxide in a volcanic plume	NATURE			English	Article							OZONE; CHLORINE; DESTRUCTION; ERUPTION; FLUXES; RATIOS; GASES; OXIDE; BRO	The emission of volcanic gases usually precedes eruptive activity(1), providing both a warning signal and an indication of the nature of the lava soon to be erupted. Additionally, volcanic emissions are a significant source of gases and particles to the atmosphere, influencing tropospheric and stratospheric trace-gas budgets(2). Despite some halogen species having been measured in volcanic plumes(3) (mainly HCl and HF), little is known about bromine compounds(4) and, in particular, gas-phase reactive bromine species. Such species are especially important in the stratosphere(5), as reactive bromine - despite being two orders of magnitude less abundant than chlorine - accounts for about one-third of halogen-catalysed ozone depletion(6). In the troposphere, bromine-catalysed complete ozone destruction has been observed to occur regularly during spring in the polar boundary layers(7-11) as well as in the troposphere above the Dead Sea basin(12). Here we report observations of BrO and SO2 abundances in the plume of the Soufriere Hills volcano ( Montserrat) in May 2002 by ground-based multi-axis differential optical absorption spectroscopy. Our estimate of BrO emission leads us to conclude that local ozone depletion and small ozone 'holes' may occur in the vicinity of active volcanoes, and that the amount of bromine emitted from volcanoes might be sufficiently large to play a role not only in the stratosphere, but also in tropospheric chemistry.	Heidelberg Univ, Inst Umweltphys, INF 229, D-69120 Heidelberg, Germany; Chalmers Univ Technol, S-41296 Gothenburg, Sweden	Ruprecht Karls University Heidelberg; Chalmers University of Technology	Bobrowski, N (corresponding author), Heidelberg Univ, Inst Umweltphys, INF 229, D-69120 Heidelberg, Germany.	Nicole.Bobrowski@iup.uni-heidelberg.de	Galle, Bo/F-7996-2016; Putaux, Jean-Luc/A-3488-2012; Hytch, Martin/N-6911-2019	Galle, Bo/0000-0001-9989-809X; Putaux, Jean-Luc/0000-0002-9760-5369; 				ANDERSON AT, 1975, REV GEOPHYS, V13, P37, DOI 10.1029/RG013i001p00037; Barrie L, 1997, TELLUS B, V49, P450, DOI 10.1034/j.1600-0889.49.issue5.2.x; BLUTH GJS, 1992, GEOPHYS RES LETT, V19, P151, DOI 10.1029/91GL02792; Bureau H, 2000, EARTH PLANET SC LETT, V183, P51, DOI 10.1016/S0012-821X(00)00258-2; Butler J. H., 1996, METHYL BROMIDE ISSUE, P28; CADLE RD, 1980, REV GEOPHYS, V18, P746, DOI 10.1029/RG018i004p00746; FISH DJ, 1995, GEOPHYS RES LETT, V22, P811, DOI 10.1029/95GL00392; Francis P, 1998, NATURE, V396, P567, DOI 10.1038/25115; FRANCIS P, 1995, GEOPHYS RES LETT, V22, P1717, DOI 10.1029/95GL01657; Galle B, 2003, J VOLCANOL GEOTH RES, V119, P241, DOI 10.1016/S0377-0273(02)00356-6; Graf HF, 1997, J GEOPHYS RES-ATMOS, V102, P10727, DOI 10.1029/96JD03265; HAUSMANN M, 1994, J GEOPHYS RES-ATMOS, V99, P25399, DOI 10.1029/94JD01314; Hebestreit K, 1999, SCIENCE, V283, P55, DOI 10.1126/science.283.5398.55; Honninger G, 2002, ATMOS ENVIRON, V36, P2481, DOI 10.1016/s1352-2310(02)00104-8; KRAFFT K, 1976, CR ACAD SCI D NAT, V282, P341; Kraus S., 2001, P 1 INT DOAS WORKSH; Leser H, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL015811; MCCORMICK MP, 1995, NATURE, V373, P399, DOI 10.1038/373399a0; MCELROY MB, 1986, NATURE, V321, P759, DOI 10.1038/321759a0; MILLAN M, 1969, THESIS U TORONTO; MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0; Oppenheimer C, 1998, APPL PHYS B-LASERS O, V67, P505, DOI 10.1007/s003400050536; PINTO JP, 1989, J GEOPHYS RES-ATMOS, V94, P11165, DOI 10.1029/JD094iD08p11165; PLATT U, 1994, MONITORING SPECTROSC, P27; Stutz J, 1996, APPL OPTICS, V35, P6041, DOI 10.1364/AO.35.006041; SUGIURA T, 1963, J EARTH SCI-NAGOYA U, V11, P272; Tuckermann M, 1997, TELLUS B, V49, P533, DOI 10.1034/j.1600-0889.49.issue5.9.x; Van Roozendael M., 2001, WINDOAS 2 1 SOFTWARE; Wagner T, 1998, NATURE, V395, P486, DOI 10.1038/26723; Young SR, 1998, GEOPHYS RES LETT, V25, P3389, DOI 10.1029/98GL01405	30	240	243	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					273	276		10.1038/nature01625	http://dx.doi.org/10.1038/nature01625			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748638				2022-12-28	WOS:000182853100039
J	Jessup, M; Brozena, S				Jessup, M; Brozena, S			Medical progress: Heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONVERTING ENZYME-INHIBITORS; LEFT-VENTRICULAR DYSFUNCTION; BUNDLE-BRANCH-BLOCK; RANDOMIZED-TRIAL; CARDIAC RESYNCHRONIZATION; MYOCARDIAL-INFARCTION; DILATED CARDIOMYOPATHY; MITRAL REGURGITATION; THERAPEUTIC OPTIONS; ENALAPRIL THERAPY		Hosp Univ Penn, Dept Med, Div Cardiovasc, Heart Failure Cardiac Transplantat Program, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Jessup, M (corresponding author), Heart Failure Cardiac Transplantat Program, 6 Penn Tower,3400 Spruce St, Philadelphia, PA 19104 USA.	jessupm@uphs.upenn.edu		Jessup, Mariell/0000-0002-3010-0112				Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Adams KF, 2002, J AM COLL CARDIOL, V39, P946, DOI 10.1016/S0735-1097(02)01708-4; American Heart Association, 2000, 2001 HEART STROK STA; [Anonymous], 1999, BMJ-BRIT MED J, V318, P29; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; Banerjee P, 2002, J AM COLL CARDIOL, V39, P138, DOI 10.1016/S0735-1097(01)01704-1; Baumgartner WA, 2001, J AM COLL SURGEONS, V192, P345, DOI 10.1016/S1072-7515(01)00777-3; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Bishay ES, 2000, EUR J CARDIO-THORAC, V17, P213, DOI 10.1016/S1010-7940(00)00345-6; Bitran D, 2001, J CARDIAC SURG, V16, P79, DOI 10.1111/j.1540-8191.2001.tb00488.x; Bouchart F, 2001, EUR J CARDIO-THORAC, V20, P1157, DOI 10.1016/S1010-7940(01)00982-4; Brater DC, 1998, NEW ENGL J MED, V339, P387, DOI 10.1056/NEJM199808063390607; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; Bristow MR, 1996, CIRCULATION, V94, P2807, DOI 10.1161/01.CIR.94.11.2807; Brutsaert D L, 1997, J Card Fail, V3, P225, DOI 10.1016/S1071-9164(97)90019-1; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Coats AJS, 1999, CIRCULATION, V99, P1138, DOI 10.1161/01.CIR.99.9.1138; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Deedwania PC, 2000, ARCH INTERN MED, V160, P1585, DOI 10.1001/archinte.160.11.1585; Drazner MH, 2001, NEW ENGL J MED, V345, P574, DOI 10.1056/NEJMoa010641; Eichhorn EJ, 1996, CIRCULATION, V94, P2285, DOI 10.1161/01.CIR.94.9.2285; ELLISON DH, 1994, AM J KIDNEY DIS, V23, P623, DOI 10.1016/S0272-6386(12)70272-X; Farrell MH, 2002, JAMA-J AM MED ASSOC, V287, P890, DOI 10.1001/jama.287.7.890; Foody JM, 2002, JAMA-J AM MED ASSOC, V287, P883, DOI 10.1001/jama.287.7.883; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GARG R, 1995, JAMA-J AM MED ASSOC, V274, P462; Gerber TC, 2001, MAYO CLIN PROC, V76, P803; Gerstein HC, 2000, LANCET, V355, P253; Gibelin P, 2001, EUR J HEART FAIL, V3, P739, DOI 10.1016/S1388-9842(01)00206-9; Gomberg-Maitland M, 2001, ARCH INTERN MED, V161, P342, DOI 10.1001/archinte.161.3.342; GREENBERG B, 1995, CIRCULATION, V91, P2573, DOI 10.1161/01.CIR.91.10.2573; Groenning BA, 2000, J AM COLL CARDIOL, V36, P2072, DOI 10.1016/S0735-1097(00)01006-8; Gullestad L, 1999, J AM COLL CARDIOL, V34, P2061, DOI 10.1016/S0735-1097(99)00495-7; HALL SA, 1995, J AM COLL CARDIOL, V25, P1154, DOI 10.1016/0735-1097(94)00543-Y; Hambrecht R, 2000, JAMA-J AM MED ASSOC, V283, P3095, DOI 10.1001/jama.283.23.3095; Havranek EP, 1999, J AM COLL CARDIOL, V33, P1174, DOI 10.1016/S0735-1097(98)00695-0; He SQ, 1997, CIRCULATION, V96, P1826, DOI 10.1161/01.CIR.96.6.1826; *HEART OUTC PREV E, 2000, LANCET, V356, P860; HULTGREN HN, 1983, AM J CARDIOL, V52, P755, DOI 10.1016/0002-9149(83)90411-3; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; Jessup M, 2001, NEW ENGL J MED, V345, P1490, DOI 10.1056/NEJMed010109; KEELING PJ, 1994, HERZ, V19, P91; Kerwin WF, 2000, J AM COLL CARDIOL, V35, P1221, DOI 10.1016/S0735-1097(00)00555-6; Khalil ME, 2001, J AM COLL CARDIOL, V37, P1757, DOI 10.1016/S0735-1097(01)01229-3; Khand A, 2000, J AM COLL CARDIOL, V36, P2284, DOI 10.1016/S0735-1097(00)00995-5; Konstam MA, 2000, CIRCULATION, V102, P1076, DOI 10.1161/01.CIR.102.10.1076; Mann DL, 1999, CIRCULATION, V100, P999, DOI 10.1161/01.CIR.100.9.999; Massie BM, 2000, AM J MED, V109, P431, DOI 10.1016/S0002-9343(00)00579-9; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; McMurray J, 2002, CIRCULATION, V105, P2223, DOI 10.1161/01.CIR.0000014771.38666.22; McMurray J, 2002, CIRCULATION, V105, P2099, DOI 10.1161/01.CIR.0000014763.63528.9D; Mestroni L, 1997, CURR OPIN CARDIOL, V12, P303, DOI 10.1097/00001573-199705000-00012; Morrison LK, 2002, J AM COLL CARDIOL, V39, P202, DOI 10.1016/S0735-1097(01)01744-2; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; Munzel T, 2001, CIRCULATION, V104, P1571, DOI 10.1161/hc3801.095585; Nanas JN, 2000, J AM COLL CARDIOL, V36, P2090, DOI 10.1016/S0735-1097(00)01025-1; Otsuji Y, 1998, J AM COLL CARDIOL, V32, P398, DOI 10.1016/S0735-1097(98)00237-X; Packer M, 1999, CIRCULATION, V100, P2312, DOI 10.1161/01.CIR.100.23.2312; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; Perry G, 1997, NEW ENGL J MED, V336, P525; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; RABKIN SW, 1982, BRIT HEART J, V47, P546; Raman J S, 2001, Ann Thorac Cardiovasc Surg, V7, P278; Roberts R, 2000, AM J MED GENET, V97, P310, DOI 10.1002/1096-8628(200024)97:4<310::AID-AJMG1282>3.0.CO;2-7; Sadaniantz A, 1998, AM J CARDIOL, V81, P643, DOI 10.1016/S0002-9149(97)00982-X; Saxon LA, 2002, CIRCULATION, V105, P1304, DOI 10.1161/hc1102.105730; Saxon LA, 2001, J AM COLL CARDIOL, V38, P1971, DOI 10.1016/S0735-1097(01)01638-2; SCHNEIDER JF, 1985, AM J CARDIOL, V55, P1332, DOI 10.1016/0002-9149(85)90499-0; Senni M, 2001, J AM COLL CARDIOL, V38, P1277, DOI 10.1016/S0735-1097(01)01567-4; Shah NB, 1998, AM HEART J, V135, P373, DOI 10.1016/S0002-8703(98)70310-2; Starling RC, 2000, J AM COLL CARDIOL, V36, P2098, DOI 10.1016/S0735-1097(00)01034-2; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stellbrink C, 2001, J AM COLL CARDIOL, V38, P1957, DOI 10.1016/S0735-1097(01)01637-0; Stevenson WG, 2001, J CARDIOVASC ELECTR, V12, P112, DOI 10.1046/j.1540-8167.2001.00112.x; Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981; Taegtmeyer H, 2002, CIRCULATION, V105, P1727, DOI 10.1161/01.CIR.0000012466.50373.E8; Tang WHW, 2002, J AM COLL CARDIOL, V39, P746; Tang WHW, 2002, J AM COLL CARDIOL, V39, P70; Touiza A, 2001, J AM COLL CARDIOL, V38, P1966, DOI 10.1016/S0735-1097(01)01648-5; VanDantzig JM, 1996, AM HEART J, V131, P865, DOI 10.1016/S0002-8703(96)90166-0; Vasan RS, 2000, CIRCULATION, V101, P2118, DOI 10.1161/01.CIR.101.17.2118; Weber KT, 2001, NEW ENGL J MED, V345, P1689, DOI 10.1056/NEJMra000050; Wenger Nanette K., 1996, Am J Geriatr Cardiol, V5, P78; XIAO HB, 1991, BRIT HEART J, V66, P443; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zile MR, 2002, CIRCULATION, V105, P1503, DOI 10.1161/hc1202.105290; 1997, ARCH INTERN MED, V157, P2413	95	1385	1465	3	115	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					2007	2018		10.1056/NEJMra021498	http://dx.doi.org/10.1056/NEJMra021498			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12748317				2022-12-28	WOS:000182823400010
J	Kellis, M; Patterson, N; Endrizzi, M; Birren, B; Lander, ES				Kellis, M; Patterson, N; Endrizzi, M; Birren, B; Lander, ES			Sequencing and comparison of yeast species to identify genes and regulatory elements	NATURE			English	Article							TRANSCRIPTION FACTOR; HEMIASCOMYCETOUS YEASTS; GENOMIC EXPLORATION; BINDING SITES; DNA-SEQUENCE; SACCHAROMYCES; EVOLUTION; DATABASE; IDENTIFICATION; ADAPTATION	Identifying the functional elements encoded in a genome is one of the principal challenges in modern biology. Comparative genomics should offer a powerful, general approach. Here, we present a comparative analysis of the yeast Saccharomyces cerevisiae based on high-quality draft sequences of three related species (S. paradoxus, S. mikatae and S. bayanus). We first aligned the genomes and characterized their evolution, defining the regions and mechanisms of change. We then developed methods for direct identification of genes and regulatory motifs. The gene analysis yielded a major revision to the yeast gene catalogue, affecting approximately 15% of all genes and reducing the total count by about 500 genes. The motif analysis automatically identified 72 genome-wide elements, including most known regulatory motifs and numerous new motifs. We inferred a putative function for most of these motifs, and provided insights into their combinatorial interactions. The results have implications for genome analysis of diverse organisms, including the human.	Whitehead MIT Ctr Genome Res, Cambridge, MA 02142 USA; MIT, Dept Comp Sci, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Kellis, M (corresponding author), Whitehead MIT Ctr Genome Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	manoli@mit.edu; lander@wi.mit.edu	Kellis, Manolis/ABE-7385-2020; Peng, Bo/A-6920-2009	Kellis, Manolis/0000-0001-7113-9630; Peng, Bo/0000-0001-8225-2284	NHGRI NIH HHS [R01 HG004037] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004037] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Anderson JSJ, 2000, NUCLEIC ACIDS RES, V28, P1604, DOI 10.1093/nar/28.7.1604; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Batzoglou S, 2002, GENOME RES, V12, P177, DOI 10.1101/gr.208902; Blanchette M, 2002, GENOME RES, V12, P739, DOI 10.1101/gr.6902; Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; Bon E, 2000, FEBS LETT, V487, P37, DOI 10.1016/S0014-5793(00)02276-6; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; Dunham MJ, 2002, P NATL ACAD SCI USA, V99, P16144, DOI 10.1073/pnas.242624799; Dwight SS, 2002, NUCLEIC ACIDS RES, V30, P69, DOI 10.1093/nar/30.1.69; Fischer G, 2000, NATURE, V405, P451, DOI 10.1038/35013058; Fischer G, 2001, GENOME RES, V11, P2009, DOI 10.1101/gr.212701; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gasch AP, 2002, GENOME BIOL, V3; Gelfand MS, 2000, NUCLEIC ACIDS RES, V28, P695, DOI 10.1093/nar/28.3.695; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Hampson S, 2002, BIOINFORMATICS, V18, P513, DOI 10.1093/bioinformatics/18.4.513; Harrison PM, 2002, NUCLEIC ACIDS RES, V30, P1083, DOI 10.1093/nar/30.5.1083; Hurst LD, 2002, TRENDS GENET, V18, P486, DOI 10.1016/S0168-9525(02)02722-1; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; Koufopanou V, 2002, MOL BIOL EVOL, V19, P239, DOI 10.1093/oxfordjournals.molbev.a004077; Kowalczuk M, 1999, YEAST, V15, P1031, DOI 10.1002/(SICI)1097-0061(199908)15:11<1031::AID-YEA431>3.0.CO;2-G; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lindgren A, 2000, EMBO J, V19, P6489, DOI 10.1093/emboj/19.23.6489; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; McClelland M, 2000, NUCLEIC ACIDS RES, V28, P4974, DOI 10.1093/nar/28.24.4974; McCue LA, 2001, NUCLEIC ACIDS RES, V29, P774, DOI 10.1093/nar/29.3.774; McGuire AM, 2000, GENOME RES, V10, P744, DOI 10.1101/gr.10.6.744; Mewes HW, 1999, NUCLEIC ACIDS RES, V27, P44, DOI 10.1093/nar/27.1.44; Morillon S, 2000, MOL CELL BIOL, V20, P5766, DOI 10.1128/MCB.20.15.5766-5776.2000; Mosley AL, 2003, J BIOL CHEM, V278, P10322, DOI 10.1074/jbc.M212802200; Oeltjen JC, 1997, GENOME RES, V7, P315, DOI 10.1101/gr.7.4.315; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Perrin A, 2002, INFECT IMMUN, V70, P7063, DOI 10.1128/IAI.70.12.7063-7072.2002; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wood V, 2001, COMP FUNCT GENOM, V2, P143, DOI 10.1002/cfg.86; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	50	1379	1556	1	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					241	254		10.1038/nature01644	http://dx.doi.org/10.1038/nature01644			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748633				2022-12-28	WOS:000182853100033
J	Sheppard, SS; Jewitt, DC				Sheppard, SS; Jewitt, DC			An abundant population of small irregular satellites around Jupiter	NATURE			English	Article							JOVIAN SATELLITES; SIZE DISTRIBUTION; GIANT PLANETS; ASTEROIDS; DISCOVERY; CAPTURE; URANUS; SATURN; GAS	Irregular satellites have eccentric orbits that can be highly inclined or even retrograde relative to the equatorial planes of their planets. These objects cannot have formed by circumplanetary accretion, unlike the regular satellites that follow uninclined, nearly circular and prograde orbits(1). Rather, they are probably products of early capture from heliocentric orbits(2-5). Although the capture mechanism remains uncertain, the study of irregular satellites provides a window on processes operating in the young Solar System. Families of irregular satellites recently have been discovered around Saturn ( thirteen members, refs 6, 7), Uranus ( six, ref. 8) and Neptune ( three, ref. 9). Because Jupiter is closer than the other giant planets, searches for smaller and fainter irregular satellites can be made. Here we report the discovery of 23 new irregular satellites of Jupiter, so increasing the total known population to 32. There are five distinct satellite groups, each dominated by one relatively large body. The groups were most probably produced by collisional shattering of precursor objects after capture by Jupiter.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA	University of Hawaii System	Sheppard, SS (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.			Sheppard, Scott/0000-0003-3145-8682				Boss AP, 2002, ICARUS, V156, P291, DOI 10.1006/icar.2002.6816; Carruba V, 2002, ICARUS, V158, P434, DOI 10.1006/icar.2002.6896; CELLINO A, 1991, MON NOT R ASTRON SOC, V253, P561, DOI 10.1093/mnras/253.4.561; COLOMBO G, 1971, ICARUS, V15, P186, DOI 10.1016/0019-1035(71)90073-X; CRUIKSHANK DP, 1977, ICARUS, V30, P224, DOI 10.1016/0019-1035(77)90136-1; DOHNANYI JS, 1969, J GEOPHYS RES, V74, P2531, DOI 10.1029/JB074i010p02531; GEHRELS T, 1977, COMETS ASTEROIDS MET, P323; Gladman B, 2000, ICARUS, V147, P320, DOI 10.1006/icar.2000.6463; Gladman B, 2001, NATURE, V412, P163, DOI 10.1038/35084032; Hartmann W. K., 2000, ORIGIN EARTH MOON, P493; HEPPENHEIMER TA, 1977, ICARUS, V30, P385, DOI 10.1016/0019-1035(77)90173-7; HOLMAN M, 2003, 8047 IAU; KESSLER DJ, 1981, ICARUS, V48, P39, DOI 10.1016/0019-1035(81)90151-2; Kuiper G.P., 1956, VA, V2, P1631, DOI [10.1016/0083-6656(56)90090-3, DOI 10.1016/0083-6656(56)90090-3]; MELOSH HJ, 1989, IMPACT CRATERING, P46; NAKAMURA T, 1995, ICARUS, V116, P113, DOI 10.1006/icar.1995.1115; Peale SJ, 1999, ANNU REV ASTRON ASTR, V37, P533, DOI 10.1146/annurev.astro.37.1.533; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; POLLACK JB, 1979, ICARUS, V37, P587, DOI 10.1016/0019-1035(79)90016-2; Rettig TW, 2001, ICARUS, V154, P313, DOI 10.1006/icar.2001.6715; SAHA P, 1993, ICARUS, V106, P549, DOI 10.1006/icar.1993.1192; SHEPPARD SS, 2003, 8089 IAU; SHEPPARD SS, 2001, 7555 IAU; SHEPPARD SS, 2002, 7900 IAU; SHEPPARD SS, 2003, 8116 IAU; Tanga P, 1999, ICARUS, V141, P65, DOI 10.1006/icar.1999.6148; Thomas PC, 1997, SCIENCE, V277, P1492, DOI 10.1126/science.277.5331.1492; Thommes EW, 2002, ASTRON J, V123, P2862, DOI 10.1086/339975	28	72	72	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					261	263		10.1038/nature01584	http://dx.doi.org/10.1038/nature01584			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748634				2022-12-28	WOS:000182853100035
J	Clayton, PT; Surtees, RAH; DeVile, C; Hyland, K; Heales, SJR				Clayton, PT; Surtees, RAH; DeVile, C; Hyland, K; Heales, SJR			Neonatal epileptic encephalopathy	LANCET			English	Editorial Material							ACID DECARBOXYLASE DEFICIENCY		Great Ormond St Hosp Sick Children, Dept Metab Med, London WC1N 1EH, England; Great Ormond St Hosp Sick Children, Dept Neurol, London WC1N 1EH, England; Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX USA; UCL Natl Hosp Neurol & Neurosurg, Neurometab Unit, London WC1N 3BG, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Baylor University; Baylor University Medical Center; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Clayton, PT (corresponding author), Great Ormond St Hosp Sick Children, Dept Metab Med, London WC1N 1EH, England.	p.clayton@ich.ucl.ac.uk	Clayton, Peter T/C-1523-2008	Clayton, Peter/0000-0001-7592-4302				Brautigam C, 2002, NEUROPEDIATRICS, V33, P113, DOI 10.1055/s-2002-33673; HYLAND K, 1992, NEUROLOGY, V42, P1980; Kuo MF, 2002, PEDIATR NEUROL, V26, P146, DOI 10.1016/S0887-8994(01)00357-5; Ngo EO, 1998, BIOCHEMISTRY-US, V37, P7741, DOI 10.1021/bi972983r	4	59	59	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1614	1614		10.1016/S0140-6736(03)13312-0	http://dx.doi.org/10.1016/S0140-6736(03)13312-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747882				2022-12-28	WOS:000182746300012
J	Ramaswamy, S; Perou, CM				Ramaswamy, S; Perou, CM			DNA microarrays in breast cancer: the promise of personalised medicine	LANCET			English	Editorial Material							GENE-EXPRESSION; PREDICTION; CLASSIFICATION; DISCOVERY; SURVIVAL		Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Whitehead MIT Ctr Genome Res, Cambridge, MA USA; Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of North Carolina; University of North Carolina Chapel Hill	Ramaswamy, S (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Cole BF, 2001, LANCET, V358, P277, DOI 10.1016/S0140-6736(01)05483-6; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	14	41	43	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1576	1577		10.1016/S0140-6736(03)13322-3	http://dx.doi.org/10.1016/S0140-6736(03)13322-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747872				2022-12-28	WOS:000182746300002
J	Kawakami, R; Shinohara, Y; Kato, Y; Sugiyama, H; Shigemoto, R; Ito, I				Kawakami, R; Shinohara, Y; Kato, Y; Sugiyama, H; Shigemoto, R; Ito, I			Asymmetrical allocation of NMDA receptor epsilon 2 subunits in hippocampal circuitry	SCIENCE			English	Article							RAT-BRAIN; LOCALIZATION; EXPRESSION; DIVERSITY; SUBTYPES; POTENT	Despite its implications for higher order functions of the brain, little is currently known about the molecular basis of left-right asymmetry of the brain. Here we report that synaptic distribution of N-methyl-D-aspartate (NMDA) receptor GluRepsilon2 (NR2B) subunits in the adult mouse hippocampus is asymmetrical between the left and right and between the apical and basal dendrites of single neurons. These asymmetrical allocations of epsilon2 subunits differentiate the properties of NMDA receptors and synaptic plasticity between the left and right hippocampus. These results provide a molecular basis for the structural and functional asymmetry of the mature brain.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Grad Univ Adv Studies, Sch Life Sci, Natl Inst Physiol Sci, Div Cerebral Struct, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Japan	Kyushu University; Kyushu University; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Japan Science & Technology Agency (JST)	Ito, I (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan.	isitoscb@mbox.nc.kyushu-u.ac.jp	Shigemoto, Ryuichi/E-3628-2013; Kawakami, Ryosuke/AAU-6087-2020; 良介, 川上/E-2029-2012	Shigemoto, Ryuichi/0000-0001-8761-9444; 				Amaral David G., 1995, P443; Chizh BA, 2001, TRENDS PHARMACOL SCI, V22, P636, DOI 10.1016/S0165-6147(00)01863-0; Contractor A, 2000, J NEUROSCI, V20, P8269, DOI 10.1523/JNEUROSCI.20-22-08269.2000; Corballis MC, 1998, TRENDS COGN SCI, V2, P152, DOI 10.1016/S1364-6613(98)01156-5; COTMAN CW, 1974, J CELL BIOL, V62, P236, DOI 10.1083/jcb.62.1.236; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Gottmann K, 1997, J NEUROSCI, V17, P2766; Hollmann M, 1999, HANDB EXP PHARM, V141, P3; Ito I, 1996, NEUROSCI LETT, V203, P69, DOI 10.1016/0304-3940(95)12258-3; Ito I, 2000, NEUROPHARMACOLOGY, V39, P943, DOI 10.1016/S0028-3908(99)00217-8; Kilbride J, 1998, EUR J PHARMACOL, V356, P149, DOI 10.1016/S0014-2999(98)00526-3; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; Mutel V, 1998, J NEUROCHEM, V70, P2147; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; Rogers LJ, 2002, COMP VERTEBRATE LATE; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Springer SP, 1997, LEFT BRAIN RIGHT BRA; Vicini S, 1998, J NEUROPHYSIOL, V79, P555, DOI 10.1152/jn.1998.79.2.555; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WATANABE M, 1993, J COMP NEUROL, V338, P377, DOI 10.1002/cne.903380305; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K	26	172	173	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					990	994		10.1126/science.1082609	http://dx.doi.org/10.1126/science.1082609			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738868	Green Accepted			2022-12-28	WOS:000182719800060
J	Marshall, BT; Long, M; Piper, JW; Yago, T; McEver, RP; Zhu, C				Marshall, BT; Long, M; Piper, JW; Yago, T; McEver, RP; Zhu, C			Direct observation of catch bonds involving cell-adhesion molecules	NATURE			English	Article							RECEPTOR-LIGAND BONDS; P-SELECTIN; HUMAN NEUTROPHILS; FORCE; KINETICS; LEUKOCYTES; TRANSIENT; LIFETIME; REQUIRES; BINDING	Bonds between adhesion molecules are often mechanically stressed. A striking example is the tensile force applied to selectin-ligand bonds, which mediate the tethering and rolling of flowing leukocytes on vascular surfaces(1-3). It has been suggested that force could either shorten bond lifetimes, because work done by the force could lower the energy barrier between the bound and free states(4) ('slip'), or prolong bond lifetimes by deforming the molecules such that they lock more tightly(5,6) ('catch'). Whereas slip bonds have been widely observed(7-14), catch bonds have not been demonstrated experimentally. Here, using atomic force microscopy and flow-chamber experiments, we show that increasing force first prolonged and then shortened the lifetimes of P-selectin complexes with P-selectin glycoprotein ligand-1, revealing both catch and slip bond behaviour. Transitions between catch and slip bonds might explain why leukocyte rolling on selectins first increases and then decreases as wall shear stress increases(,)(9,15)(16). This dual response to force provides a mechanism for regulating cell adhesion under conditions of variable mechanical stress.	Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Coulter Sch Biomed Engn, Atlanta, GA 30332 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zhu, C (corresponding author), Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.	cheng.zhu@me.gatech.edu	Zhu, Cheng/A-5724-2011					Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Dembo Micah, 1994, V24, P51; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Isberg RR, 2002, CELL, V110, P1, DOI 10.1016/S0092-8674(02)00821-8; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Pierres A, 1996, P NATL ACAD SCI USA, V93, P15114, DOI 10.1073/pnas.93.26.15114; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; Smith MJ, 1999, BIOPHYS J, V77, P3371, DOI 10.1016/S0006-3495(99)77169-9; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wong JY, 1999, BIOPHYS J, V77, P1445, DOI 10.1016/S0006-3495(99)76992-4; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041	30	727	755	11	156	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					190	193		10.1038/nature01605	http://dx.doi.org/10.1038/nature01605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736689	Green Published			2022-12-28	WOS:000182699600051
J	Batlle, JC				Batlle, JC			Legal status of physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; EUTHANASIA; CONSULTATION; OREGON; DEATH		Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Batlle, JC (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							BAILE WF, 1993, CANCER, V72, P2786, DOI 10.1002/1097-0142(19931101)72:9<2786::AID-CNCR2820720942>3.0.CO;2-2; Cantor NL, 2001, J LAW MED ETHICS, V29, P182; Cohen-Almagor R, 2002, J LAW MED ETHICS, V30, P95, DOI 10.1111/j.1748-720X.2002.tb00725.x; *DEP JUST OFF ATT, 2001, 25342001 AG DEP JUST; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2002, ARCH INTERN MED, V162, P142, DOI 10.1001/archinte.162.2.142; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Hamerly JP, 1998, AM J HEALTH-SYST PH, V55, P543, DOI 10.1093/ajhp/55.6.543; Lindsay RA, 2002, J LAW MED ETHICS, V30, P6, DOI 10.1111/j.1748-720X.2002.tb00714.x; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; Onwuteaka-Philipsen BD, 2001, J MED ETHICS, V27, P331; PRETTY D, RIGHT DIE CASE EUROP; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811	14	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2279	2281		10.1001/jama.289.17.2279	http://dx.doi.org/10.1001/jama.289.17.2279			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675ET	12734142				2022-12-28	WOS:000182680700033
J	McCarthy, EP; Burns, RB; Ngo-Metzger, Q; Davis, RB; Phillips, RS				McCarthy, EP; Burns, RB; Ngo-Metzger, Q; Davis, RB; Phillips, RS			Hospice use among Medicare managed care and fee-for-service patients dying with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	25th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 2002	ATLANTA, GEORGIA	Soc Gen Internal Med			ILL PATIENTS; PALLIATIVE CARE; LIFE; HMO; REIMBURSEMENT; OUTCOMES; SYSTEMS; DEATH; END	Context For most patients aged 65 years or older with cancer, hospice services are uniformly covered by Medicare. Hospice care is believed to improve care for patients at the end of life. However, few patients use hospice and others enroll too late to maximize the benefits of hospice services. Objectives Because type of insurance may affect use, we examined whether patients with Medicare managed care insurance enrolled in hospice earlier and had longer hospice stays than patients with Medicare fee-for-service (FFS) insurance. Design and Setting Retrospective analysis of the last year of life using the Linked Medicare-Tumor Registry Database in 1 of 9 Surveillance, Epidemiology, and End Results program coverage areas. Patients A total of 260090 Medicare beneficiaries aged 66 years or older diagnosed with first primary lung (n=62 117), colorectal (n=57 260), prostate (n=59 826), female breast (n =37 609), bladder (n =19 598), pancreatic (n =11 378), gastric (n =9599), or liver (n=2703) cancer between January 1, 1973, and December 31, 1996, and who died between January 1, 1988, and December 31, 1998. Main Outcome Measures Time from diagnosis to hospice entry and hospice length of stay for patients enrolled in FFS vs managed care plans after adjusting for patient demographics, tumor registry, year of hospice entry, and type and cancer stage. Results Of the 260090 patients, most were men (59%), white (85%), and enrolled in FFS (89.7%). Only 54937 patients (21.1%) received hospice care before death. Hospice use varied by type of primary cancer ranging from 31.8% of patients with pancreatic cancer to 15.6% with bladder cancer. Managed care patients were more likely to use hospice than FFS patients (32.4% vs 19.8%, P<.001). Among hospice patients, median (interquartile range) length of stay was longer for managed care vs FFS patients (32 days [11-82] vs 25 days [9-66], P<.001). After adjustment, managed care patients had higher rates of hospice enrollment (adjusted hazard ratio [HR], 1.38; 95% CI, 1.35-1.42) and had a longer length of stay (adjusted HR, 0.91; 95% CI, 0.88-0.94) vs FFS patients. Managed care patients were less likely to enroll in hospice within 7 days of their death (18.6% vs 22.6%, P<.001) and somewhat more likely to enroll in hospice more than 180 days before death (7.8% vs 6.1 %, P<.001); the results for each of the 8 cancer diagnoses were similar. Hospice enrollment and length of stay among managed care vs FFS patients differed significantly by region. Conclusion Medicare beneficiaries enrolled in managed care had consistently higher rates of hospice use and significantly longer hospice stays than those enrolled in FFS. Although these differences may reflect patient and family preferences, our findings raise the possibility that some managed care plans are more successful at facilitating or encouraging hospice use for patients dying with cancer.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	McCarthy, EP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, 330 Brookline Ave,Rose 139, Boston, MA 02215 USA.				NCI NIH HHS [5R29 CA79052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA079052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American Cancer Society, 2002, CANC FACTS FIG 2002; BULKIN W, 1988, NEW ENGL J MED, V318, P376, DOI 10.1056/NEJM198802113180609; Cher DJ, 1997, JAMA-J AM MED ASSOC, V278, P1001, DOI 10.1001/jama.278.12.1001; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Cleary JF, 1997, CANCER, V80, P1335, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1335::AID-CNCR21>3.3.CO;2-5; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; *CTR MED MED SERV, 2002, FACT SHEET PROT MED; *CTR MED MED SERV, 2002, US DEP HLTH HUM SERV; *CTR MED MED SERV, 2000, US DEP HLTH HUM SERV; Curtis JR, 1997, JAMA-J AM MED ASSOC, V278, P1025, DOI 10.1001/jama.278.12.1025; Emanuel EJ, 2002, ARCH INTERN MED, V162, P1722, DOI 10.1001/archinte.162.15.1722; *GEN ACC OFF, 2000, MED MOR BEN US HOSP; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; Kinzbrunner B M, 1998, J Palliat Med, V1, P127, DOI 10.1089/jpm.1998.1.127; Lamont EB, 2002, CANCER, V94, P2733, DOI 10.1002/cncr.10530; Lee E, 2013, STAT METHODS SURVIVA; LEVY MH, 1993, J NATL CANCER I, V85, P1283, DOI 10.1093/jnci/85.16.1283; McCarthy EP, 2003, J CLIN ONCOL, V21, P728, DOI 10.1200/JCO.2003.06.142; MILES SH, 1995, WESTERN J MED, V163, P302; Morgan RO, 1997, NEW ENGL J MED, V337, P169, DOI 10.1056/NEJM199707173370306; *NAT HOSP PALL CAR, 2002, DEV QUAL CAR COST EF; Neuman P, 1998, HEALTH AFFAIR, V17, P132, DOI 10.1377/hlthaff.17.4.132; POTOSKY AL, 1993, MED CARE, V31, P732; Randal J, 1996, J NATL CANCER I, V88, P860, DOI 10.1093/jnci/88.13.860; Riley G, 1996, HEALTH CARE FINANC R, V17, P65; Steinberg S M, 1998, J Palliat Med, V1, P387, DOI 10.1089/jpm.1998.1.387; SULMASY DP, 1995, ARCH INTERN MED, V155, P133, DOI 10.1001/archinte.155.2.133; Virnig B A, 1999, Hosp J, V14, P1; Virnig BA, 2001, AM J MANAG CARE, V7, P777; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027	32	107	108	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2238	2245		10.1001/jama.289.17.2238	http://dx.doi.org/10.1001/jama.289.17.2238			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675ET	12734135	Bronze			2022-12-28	WOS:000182680700026
J	Runo, JR; Loyd, JE				Runo, JR; Loyd, JE			Primary pulmonary hypertension	LANCET			English	Review							VASCULAR SMOOTH-MUSCLE; HEREDITARY HEMORRHAGIC TELANGIECTASIA; EPOPROSTENOL PROSTACYCLIN THERAPY; MORPHOGENETIC PROTEIN-RECEPTOR; ANGIOTENSIN-CONVERTING ENZYME; HEART-LUNG TRANSPLANTATION; CONTINUOUS INTRAVENOUS EPOPROSTENOL; ENDOTHELIAL-CELL PROLIFERATION; DILATION ATRIAL SEPTOSTOMY; PLACEBO-CONTROLLED TRIAL	Primary pulmonary hypertension (PPH) is a rare disorder characterised by raised pulmonary-artery pressure in the absence of secondary causes. Precapillary pulmonary arteries are affected by medial hypertrophy, intimal fibrosis, microthrombosis, and plexiform lesions. Most individuals present with dyspnoea or evidence of right heart failure. Echocardiography is the best non-invasive test to screen for suspected pulmonary hypertension. The discovery of mutations In the coding region of the gene for bone morphogenetic protein receptor 2 in patients with familial and sporadic PPH may help not only to elucidate pathogenesis but also to direct future treatment options. The pathogenesis is not completely understood, but recent investigations have revealed many possible candidate modifier genes. Without treatment, the disorder progresses in most cases to right heart failure and death. With current therapies such as epoprostenol, progression of disease is slowed, but not halted. Many promising new therapeutic options, including prostacyclin analogues, endothelin-l-receptor antagonists, and phosphodiesterase inhibitors, improve clinical function and haemodynamic measures and may prolong survival.	Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA	Vanderbilt University	Loyd, JE (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, T-1217 Med Ctr N, Nashville, TN 37232 USA.			Loyd, James/0000-0002-5042-7390	NHLBI NIH HHS [HL 07123, HL 48164] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007123, R01HL048164] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Aguilar RV, 2000, AM J RESP CRIT CARE, V162, P1846, DOI 10.1164/ajrccm.162.5.2004042; Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; Aris R, 1998, AM J RESP CRIT CARE, V158, P335; Atkinson C, 2002, CIRCULATION, V105, P1672, DOI 10.1161/01.CIR.0000012754.72951.3D; Badesch DB, 2000, ANN INTERN MED, V132, P425, DOI 10.7326/0003-4819-132-6-200003210-00002; BANDO K, 1994, J THORAC CARDIOV SUR, V108, P1056, DOI 10.1016/S0022-5223(94)70148-2; Barst RJ, 2002, CHEST, V121, P1860, DOI 10.1378/chest.121.6.1860; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; BAUDOUIN SV, 1993, BRIT J CLIN PHARMACO, V36, P45, DOI 10.1111/j.1365-2125.1993.tb05890.x; BENZA RL, 2002, CARDIOPULM CRIT  SPR, P7; BJORNSSON J, 1985, MAYO CLIN PROC, V60, P16, DOI 10.1016/S0025-6196(12)65277-X; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blumberg FC, 2002, CHEST, V121, P1566, DOI 10.1378/chest.121.5.1566; Bogdan M, 1998, THORAX, V53, P1059, DOI 10.1136/thx.53.12.1059; Boger RH, 1996, INT J CLIN PHARM TH, V34, P323; Campbell AIM, 2001, CIRCULATION, V104, P2242, DOI 10.1161/hc4201.097838; Castelain V, 2002, AM J RESP CRIT CARE, V165, P338, DOI 10.1164/ajrccm.165.3.2106033; Channick RN, 2001, LANCET, V358, P1119, DOI 10.1016/S0140-6736(01)06250-X; CHANNICK RN, 2002, PULM HYPERTENS, V1, P13; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Clapp LH, 2002, AM J RESP CELL MOL, V26, P194, DOI 10.1165/ajrcmb.26.2.4695; Cool CD, 1997, HUM PATHOL, V28, P434, DOI 10.1016/S0046-8177(97)90032-0; Cowan KN, 2000, NAT MED, V6, P698, DOI 10.1038/76282; Cowan KN, 2000, J CLIN INVEST, V105, P21, DOI 10.1172/JCI6539; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; DALONZO GE, 1987, CHEST, V92, P57, DOI 10.1378/chest.92.1.57; DALONZO GE, 1984, CHEST, V85, P457, DOI 10.1378/chest.85.4.457; Davie N, 2002, AM J RESP CRIT CARE, V165, P398, DOI 10.1164/ajrccm.165.3.2104059; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Deng ZM, 2000, AM J RESP CRIT CARE, V161, P1055, DOI 10.1164/ajrccm.161.3.9906051; Dorai H, 2000, J CELL PHYSIOL, V184, P37, DOI 10.1002/(SICI)1097-4652(200007)184:1<37::AID-JCP4>3.0.CO;2-M; DRESDALE DT, 1954, B NEW YORK ACAD MED, V30, P195; DRESDALE DT, 1951, AM J MED, V11, P686, DOI 10.1016/0002-9343(51)90020-4; Eddahibi S, 2000, AM J RESP CRIT CARE, V162, P1493, DOI 10.1164/ajrccm.162.4.2003124; Eddahibi S, 2000, J CLIN INVEST, V105, P1555, DOI 10.1172/JCI8678; Eddahibi S, 1999, CIRC RES, V84, P329, DOI 10.1161/01.RES.84.3.329; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; ELLIOTT G, 1995, CHEST, V108, P973, DOI 10.1378/chest.108.4.973; Friedman R, 1997, CIRCULATION, V96, P2782, DOI 10.1161/01.CIR.96.9.2782; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Gaine SP, 1998, LANCET, V352, P719, DOI 10.1016/S0140-6736(98)02111-4; Galie N., 1996, European Journal of Clinical Investigation, V26, pA48; Galie N, 2002, J AM COLL CARDIOL, V39, P1496, DOI 10.1016/S0735-1097(02)01786-2; Gammie JS, 1998, J THORAC CARDIOV SUR, V115, P397, DOI 10.1016/S0022-5223(98)70284-3; GARCIADORADO D, 1983, J AM COLL CARDIOL, V1, P1216, DOI 10.1016/S0735-1097(83)80133-8; Geraci MW, 1999, J CLIN INVEST, V103, P1509, DOI 10.1172/JCI5911; Ghofrani HA, 2002, ANN INTERN MED, V136, P515, DOI 10.7326/0003-4819-136-7-200204020-00008; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Girgis R. E., 2002, Journal of Heart and Lung Transplantation, V21, P149, DOI 10.1016/S1053-2498(01)00695-7; Grunig E, 2000, CIRCULATION, V102, P1145, DOI 10.1161/01.CIR.102.10.1145; HAMILTON G, 2001, AM J RESP CRIT CARE, V163, pA540; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HERVE P, 1990, AM J MED, V89, P117, DOI 10.1016/0002-9343(90)90111-P; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Herve P, 1998, EUR RESPIR J, V11, P1153, DOI 10.1183/09031936.98.11051153; HIGENBOTTAM TW, 1993, BRIT HEART J, V70, P366; Hoeper MM, 2000, J AM COLL CARDIOL, V35, P176, DOI 10.1016/S0735-1097(99)00494-5; Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; Hoeper MM, 2002, AM J RESP CRIT CARE, V165, P1209, DOI 10.1164/rccm.200110-028PP; HOEPER MM, 1997, AM J RESP CELL MOL B, V17, P748; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HUBER K, 1994, AM J RESP CRIT CARE, V150, P929, DOI 10.1164/ajrccm.150.4.7921465; Ichida F, 1997, AM J CARDIOL, V80, P662, DOI 10.1016/S0002-9149(97)00447-5; Indolfi C, 2000, J AM COLL CARDIOL, V35, P214, DOI 10.1016/S0735-1097(99)00526-4; INGLESBY TV, 1973, AM J MED, V55, P5, DOI 10.1016/0002-9343(73)90144-7; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KAY JM, 1971, THORAX, V26, P262, DOI 10.1136/thx.26.3.262; Kereveur A, 2000, ARTERIOSCL THROM VAS, V20, P2233, DOI 10.1161/01.ATV.20.10.2233; Kshettry VR, 1996, CHEST, V110, P704, DOI 10.1378/chest.110.3.704; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Langleben D, 1999, CIRCULATION, V99, P3266, DOI 10.1161/01.CIR.99.25.3266; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; Laufs U, 1997, J BIOL CHEM, V272, P31725, DOI 10.1074/jbc.272.50.31725; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; LEE SL, 1991, CIRC RES, V68, P1362, DOI 10.1161/01.RES.68.5.1362; LEVINE SM, 1992, CHEST, V101, P401, DOI 10.1378/chest.101.2.401; LOYD JE, 1988, AM REV RESPIR DIS, V138, P952, DOI 10.1164/ajrccm/138.4.952; LOYD JE, 1995, AM J RESP CRIT CARE, V152, P93, DOI 10.1164/ajrccm.152.1.7599869; LOYD JE, 1984, AM REV RESPIR DIS, V129, P194; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; MacLean MR, 2000, BRIT J PHARMACOL, V131, P161, DOI 10.1038/sj.bjp.0703570; Mark EJ, 1997, NEW ENGL J MED, V337, P602, DOI 10.1056/NEJM199708283370904; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; McCaffrey TA, 1997, J CLIN INVEST, V100, P2182, DOI 10.1172/JCI119754; MCGOON MD, 1984, J CLIN INVEST, V74, P828, DOI 10.1172/JCI111499; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; McLaughlin VV, 1999, ANN INTERN MED, V130, P740, DOI 10.7326/0003-4819-130-9-199905040-00014; MEHTA S, 1995, CIRCULATION, V92, P1539, DOI 10.1161/01.CIR.92.6.1539; Mitani Y, 1997, CIRCULATION, V96, P689; Mitani Y, 2000, FASEB J, V14, P805, DOI 10.1096/fasebj.14.5.805; Miyamoto S, 2000, AM J RESP CRIT CARE, V161, P487, DOI 10.1164/ajrccm.161.2.9906015; Morrell NW, 1999, AM J PHYSIOL-LUNG C, V277, pL440, DOI 10.1152/ajplung.1999.277.3.L440; Morrell NW, 2001, CIRCULATION, V104, P790, DOI 10.1161/hc3201.094152; Morse JH, 1999, CHEST, V116, P847, DOI 10.1378/chest.116.3.847; Nagaya N, 2000, CIRCULATION, V102, P2005, DOI 10.1161/01.CIR.102.16.2005; Nagaya N, 1999, J AM COLL CARDIOL, V34, P1188, DOI 10.1016/S0735-1097(99)00312-5; Nagaya N, 2001, AM J RESP CRIT CARE, V163, P887, DOI 10.1164/ajrccm.163.4.2007116; Nakaoka T, 1997, J CLIN INVEST, V100, P2824, DOI 10.1172/JCI119830; Newman JH, 2001, NEW ENGL J MED, V345, P319, DOI 10.1056/NEJM200108023450502; NICOD P, 1987, ANN INTERN MED, V107, P565, DOI 10.7326/0003-4819-107-4-565; Nishihara A, 2002, MOL BIOL CELL, V13, P3055, DOI 10.1091/mbc.E02-02-0063; Okada K, 1998, AM J RESP CRIT CARE, V158, P939, DOI 10.1164/ajrccm.158.3.9710007; Olschewski H, 2000, ANN INTERN MED, V132, P435, DOI 10.7326/0003-4819-132-6-200003210-00003; Olschewski H, 1998, INTENS CARE MED, V24, P631, DOI 10.1007/s001340050628; Olschewski H, 2002, NEW ENGL J MED, V347, P322, DOI 10.1056/NEJMoa020204; Opravil M, 1997, AM J RESP CRIT CARE, V155, P990, DOI 10.1164/ajrccm.155.3.9117037; Orte C, 2000, J PATHOL, V192, P379, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q; Palmer SM, 1998, CHEST, V113, P237, DOI 10.1378/chest.113.1.237; PASQUE MK, 1995, CIRCULATION, V92, P2252, DOI 10.1161/01.CIR.92.8.2252; Pearson DL, 2001, NEW ENGL J MED, V344, P1832, DOI 10.1056/NEJM200106143442404; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; Prasad S, 2000, NEW ENGL J MED, V343, P1342, DOI 10.1056/NEJM200011023431814; REITZ BA, 1982, NEW ENGL J MED, V306, P557, DOI 10.1056/NEJM198203113061001; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1986, ANN INTERN MED, V105, P499, DOI 10.7326/0003-4819-105-4-499; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 1991, CHEST, V99, P1208, DOI 10.1378/chest.99.5.1208; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; Rich S, 1997, AM J CARDIOL, V80, P369, DOI 10.1016/S0002-9149(97)00370-6; Rich S, 1998, WORLD S PRIM PULM HY; Robbins IM, 2000, CHEST, V117, P14, DOI 10.1378/chest.117.1.14; Rosenzweig EB, 1999, CIRCULATION, V99, P1858, DOI 10.1161/01.CIR.99.14.1858; ROTHMAN A, 1993, AM HEART J, V125, P1763, DOI 10.1016/0002-8703(93)90769-6; Rothman RB, 1999, CIRCULATION, V100, P869, DOI 10.1161/01.CIR.100.8.869; ROZKOVEC A, 1986, BRIT HEART J, V55, P449; Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212; Rudarakanchana N, 2002, HUM MOL GENET, V11, P1517, DOI 10.1093/hmg/11.13.1517; Rudarakanchana N, 2001, THORAX, V56, P888, DOI 10.1136/thorax.56.11.888; Saji T, 1996, AM J CARDIOL, V78, P244, DOI 10.1016/S0002-9149(96)90408-7; SANDOVAL J, 1994, CIRCULATION, V89, P1733, DOI 10.1161/01.CIR.89.4.1733; Sandoval J, 1998, J AM COLL CARDIOL, V32, P297, DOI 10.1016/S0735-1097(98)00238-1; Schumacher YO, 2001, AIDS, V15, P1747, DOI 10.1097/00002030-200109070-00026; Schuster DP, 1996, AM J RESP CRIT CARE, V154, P1087, DOI 10.1164/ajrccm.154.4.8887612; Shekerdemian LS, 2002, AM J RESP CRIT CARE, V165, P1098, DOI 10.1164/ajrccm.165.8.2107097; Simonneau G, 2002, AM J RESP CRIT CARE, V165, P800, DOI 10.1164/ajrccm.165.6.2106079; SMITH P, 1990, J PATHOL, V160, P111, DOI 10.1002/path.1711600204; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; Thomson JR, 2000, J MED GENET, V37, P741, DOI 10.1136/jmg.37.10.741; Trembath RC, 2001, NEW ENGL J MED, V345, P325, DOI 10.1056/NEJM200108023450503; Tuder RM, 1999, AM J RESP CRIT CARE, V159, P1925, DOI 10.1164/ajrccm.159.6.9804054; Tuder RM, 2001, J PATHOL, V195, P367, DOI 10.1002/path.953; TUDER RM, 1994, AM J PATHOL, V144, P275; Vachiery JL, 2002, CHEST, V121, P1561, DOI 10.1378/chest.121.5.1561; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; WAGENVOORT CA, 1980, CHEST, V77, P614, DOI 10.1378/chest.77.5.614; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; Weir EK, 1996, CIRCULATION, V94, P2216, DOI 10.1161/01.CIR.94.9.2216; Yeager ME, 2001, CIRC RES, V88, pE2; Yi ES, 2000, AM J RESP CRIT CARE, V162, P1577, DOI 10.1164/ajrccm.162.4.9912131; Yuan JXJ, 1998, CIRCULATION, V98, P1400, DOI 10.1161/01.CIR.98.14.1400; Yuan XJ, 1998, LANCET, V351, P726, DOI 10.1016/S0140-6736(05)78495-6; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	156	393	436	0	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1533	1544		10.1016/S0140-6736(03)13167-4	http://dx.doi.org/10.1016/S0140-6736(03)13167-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737878				2022-12-28	WOS:000182658900025
J	Bai, JF; Virovets, AV; Scheer, M				Bai, JF; Virovets, AV; Scheer, M			Synthesis of inorganic fullerene-like molecules	SCIENCE			English	Article							CAGES; PHASE; FORMS	The reaction of [Cp*Fe(eta(5)-P-5)] with Cu(I)Cl in solvent mixtures of CH2Cl2/CH3CN leads to the formation of entirely inorganic fullerene-like molecules of the formula [{Cp*Fe(eta(5):eta(1):eta(1):eta(1):eta(1):eta(1)-P-5)}(12){CuCl}(10){Cu2Cl3}(5){Cu(CH3CN)(2)}(5)] (1) possessing 90 inorganic core atoms. This compound represents a structural motif similar to that of C-60: cyclo-P-5 rings of [Cp*Fe(eta(5)-P-5)] molecules are surrounded by six-membered P4Cu2 rings that result from the coordination of each of the phosphorus lone pairs to CuCl metal centers, which are further coordinated by P atoms of other cyclo-P-5 rings. Thus, five- and six-membered rings alternate in a manner comparable to that observed in the fullerene molecules. The so-formed half shells are joined by [Cu2Cl3](-) as well as by [Cu(CH3CN)(2)](+) units. The spherical body has an inside diameter of 1.25 nanometers and an outside diameter of 2.13 nanometers, which is about three times as large as that of C-60.	Univ Karlsruhe, Inst Anorgan Chem, D-76128 Karlsruhe, Germany; Nanjing Univ, Inst Coordinat Chem, Nanjing 210093, Peoples R China; Nanjing Univ, State Key Lab Coordinat Chem, Nanjing 210093, Peoples R China; Russian Acad Sci, Inst Inorgan Chem, Siberian Div, Novosibirsk 630090, Russia	Helmholtz Association; Karlsruhe Institute of Technology; Nanjing University; Nanjing University; Russian Academy of Sciences; Nikolaev Institute of Inorganic Chemistry of the Russian Academy of Sciences	Scheer, M (corresponding author), Univ Karlsruhe, Inst Anorgan Chem, Kaiserstr 12, D-76128 Karlsruhe, Germany.	mascheer@chemie.uni-karlsruhe.de	Virovets, Alexander V/H-2545-2012; Scheer, Manfred/J-3232-2016	Virovets, Alexander V/0000-0002-8843-8503; Scheer, Manfred/0000-0003-2182-5020				Bai JF, 2002, ANGEW CHEM INT EDIT, V41, P783, DOI 10.1002/1521-3773(20020301)41:5<783::AID-ANIE783>3.0.CO;2-J; Bai JF, 2002, ANGEW CHEM INT EDIT, V41, P1737, DOI 10.1002/1521-3773(20020517)41:10<1737::AID-ANIE1737>3.0.CO;2-4; Balch AL, 1998, CHEM REV, V98, P2123, DOI 10.1021/cr960040e; BLOM R, 1989, ACTA CHEM SCAND, V43, P458, DOI 10.3891/acta.chem.scand.43-0458; Hirsch A, 1999, ACCOUNTS CHEM RES, V32, P795, DOI 10.1021/ar980113b; Kadish K.M., 2000, FULLERENES CHEM PHYS; Moschel C, 1999, Z ANORG ALLG CHEM, V625, P175, DOI 10.1002/(SICI)1521-3749(199902)625:2<175::AID-ZAAC175>3.0.CO;2-2; Muller A, 2002, ANGEW CHEM INT EDIT, V41, P3604, DOI 10.1002/1521-3773(20021004)41:19<3604::AID-ANIE3604>3.0.CO;2-T; Muller A, 1998, ANGEW CHEM INT EDIT, V37, P3360, DOI 10.1002/(SICI)1521-3773(19981231)37:24<3359::AID-ANIE3359>3.0.CO;2-J; SCHERER OJ, 1987, ANGEW CHEM INT EDIT, V26, P59, DOI 10.1002/anie.198700591; SCHERER OJ, 1988, CHEM BER-RECL, V121, P935, DOI 10.1002/cber.19881210518; SEVOV SC, 1993, SCIENCE, V262, P880, DOI 10.1126/science.262.5135.880; Sevov SC, 1996, J SOLID STATE CHEM, V123, P344, DOI 10.1006/jssc.1996.0190; SilaghiDumitrescu I, 1996, J MOL STRUC-THEOCHEM, V367, P47, DOI 10.1016/S0166-1280(96)04555-1; SilaghiDumitrescu I, 1996, J MOL STRUC-THEOCHEM, V370, P17, DOI 10.1016/S0166-1280(96)04677-5; Tozzini V, 2001, J PHYS CHEM B, V105, P12477, DOI 10.1021/jp0134087	16	285	292	0	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					781	783		10.1126/science.1081119	http://dx.doi.org/10.1126/science.1081119			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730597				2022-12-28	WOS:000182579800045
J	Kilby, JM; Eron, JJ				Kilby, JM; Eron, JJ			Novel therapies based on mechanisms of HIV-1 cell entry	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; DEFICIENCY SYNDROME AIDS; SMALL-MOLECULE INHIBITOR; RECOMBINANT SOLUBLE CD4; SCH-C SCH-351125; CHEMOKINE RECEPTOR; PHASE-I; ENVELOPE GLYCOPROTEINS; DEXTRAN SULFATE		Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA	University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill	Kilby, JM (corresponding author), Univ Alabama, Dept Med, 908 20th St S, Birmingham, AL 35294 USA.			Kilby, J. Michael/0000-0003-3222-1003	NCRR NIH HHS [5M01 RR00032-38] Funding Source: Medline; NIAID NIH HHS [AI32775-07, AI41530-05, AI50410, AI27767] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032775, P30AI027767, P30AI050410, U01AI041530] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dean M, 1996, SCIENCE, V274, P1069; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DELWART EL, 1990, AIDS RES HUM RETROV, V6, P703, DOI 10.1089/aid.1990.6.703; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; DeVreese K, 1996, J VIROL, V70, P689, DOI 10.1128/JVI.70.2.689-696.1996; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Doranz BJ, 2001, AIDS RES HUM RETROV, V17, P475, DOI 10.1089/08892220151126508; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; ERON J, 2001, 8 C RETR OPP INF CHI; Este JA, 1997, MOL PHARMACOL, V52, P98, DOI 10.1124/mol.52.1.98; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferrer M, 1999, NAT STRUCT BIOL, V6, P953; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; GREENBERG M, 2001, 8 C RETR OPP INF CHI; Greenberg ML, 2002, ANTIVIR THER, V7, pS140; Greenberg ML, 2002, ANTIVIR THER, V7, pS14; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; Hoxie JA, 1998, J REPROD IMMUNOL, V41, P197, DOI 10.1016/S0165-0378(98)00059-X; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; Jacobson JM, 2000, J INFECT DIS, V182, P326, DOI 10.1086/315698; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kilby JM, 2003, AIDS RES HUM RETROV, V19, P83, DOI 10.1089/08892220360474014; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KURITZKES DR, 2003, 10 C RETR OPP INF BO, P62; LALEZARI J, 2001, 8 C RETR OPP INF FEB, P277; Lalezari JP, 2003, AIDS, V17, P691, DOI 10.1097/00002030-200303280-00007; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Lin PF, 2002, ANTIVIR THER, V7, pS8; LIN PF, 2001, IDENTIFICATION CHARA, V2, P56; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu J, 2002, ANTIVIR THER, V7, pS74; MENG TC, 1995, J ACQ IMMUN DEF SYND, V8, P152; MEYLAN PRA, 1994, ANTIMICROB AGENTS CH, V38, P2910, DOI 10.1128/AAC.38.12.2910; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; MIRALLES G, 2003, 10 C RETR OPP INF BO, P63; MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; MORELAND LW, 1995, NEW ENGL J MED, V332, P1651; Mori T, 2001, ANTIMICROB AGENTS CH, V45, P664, DOI 10.1128/AAC.45.3.664-672.2001; Mosier DE, 1999, J VIROL, V73, P3544, DOI 10.1128/JVI.73.5.3544-3550.1999; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nagashima KA, 2001, J INFECT DIS, V183, P1121, DOI 10.1086/319284; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; REYES G, 2001, 8 C RETR OPP INF CHI, P285; REYNES J, 2002, 9 C RETR OPP INF SEA, P53; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Rusconi S, 1996, ANTIMICROB AGENTS CH, V40, P234, DOI 10.1128/AAC.40.1.234; Rusconi S, 2000, J VIROL, V74, P9328, DOI 10.1128/JVI.74.19.9328-9332.2000; SCHACKER T, 1995, J ACQ IMMUN DEF SYND, V9, P145; Schols D, 2002, 9 C RETR OPP INF SEA, P53; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; Shearer MH, 1998, J INFECT DIS, V177, P1727, DOI 10.1086/517432; Shearer WT, 2000, J INFECT DIS, V182, P1774, DOI 10.1086/317622; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Singh A, 2000, J VIROL, V74, P10229, DOI 10.1128/JVI.74.21.10229-10235.2000; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398; TREMBLAY C, 2001, 7 C RETR OPP INF SAN, P170; Tremblay CL, 2002, ANTIMICROB AGENTS CH, V46, P1336, DOI 10.1128/AAC.46.5.1336-1339.2002; Trkola A, 2001, J VIROL, V75, P579, DOI 10.1128/JVI.75.2.579-588.2001; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 2002, P NATL ACAD SCI USA, V99, P395, DOI 10.1073/pnas.012519099; Van Damme L, 2000, SEX TRANSM INFECT, V76, P126, DOI 10.1136/sti.76.2.126; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; Wofsy D, 1993, Immunol Ser, V59, P221; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zhang LQ, 2002, SCIENCE, V298, P995, DOI 10.1126/science.1076185	100	205	220	0	22	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2228	2238		10.1056/NEJMra022812	http://dx.doi.org/10.1056/NEJMra022812			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773651	Green Published			2022-12-28	WOS:000183134700010
J	Petersen, LA; Normand, ST; Leape, LL; McNeil, BJ				Petersen, LA; Normand, ST; Leape, LL; McNeil, BJ			Regionalization and the underuse of angiography in the veterans affairs health care system as compared with a fee-for-service system.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; CORONARY-ANGIOGRAPHY; CARDIAC PROCEDURES; MEDICARE PATIENTS; ELDERLY PATIENTS; HOSPITAL VOLUME; UNITED-STATES; ASSOCIATION; MORTALITY	BACKGROUND: Policies to concentrate or regionalize invasive procedures at high-volume medical centers are under active consideration. Such policies could improve outcomes among those who undergo procedures while increasing their underuse among those who never reach such centers. We compared the underuse of needed angiography after acute myocardial infarction in a traditional Medicare fee-for-service system with underuse in the regionalized Department of Veterans Affairs (VA) health care system. METHODS: We studied 1665 veterans from 81 VA hospitals and 19,305 Medicare patients from 1530 non-VA hospitals, all of whom were elderly men. We compared adjusted angiography use and one-year mortality among patients for whom angiography was rated as clinically needed. We compared underuse in models before and after controlling for the on-site availability of cardiac procedures. RESULTS: After adjustment for the need for angiography, underuse was present in both groups, but VA patients remained significantly less likely than Medicare patients to undergo angiography (43.9 percent vs. 51.0 percent; odds ratio, 0.75; 95 percent confidence interval, 0.57 to 0.96). After also controlling for on-site availability of cardiac procedures at the admitting hospital, we found no significant difference in the underuse of angiography among VA patients as compared with Medicare patients (odds ratio, 1.02; 95 percent confidence interval, 0.82 to 1.26) or in one-year mortality (odds ratio, 1.08; 95 percent confidence interval, 0.89 to 1.28). CONCLUSIONS: There is underuse of needed angiography after acute myocardial infarction in both the VA and Medicare systems, but the rate of underuse is significantly higher in the VA. These differences appear to be associated with limited on-site availability of cardiac procedures in the regionalized VA health care system. Further work should focus on how regionalization policies could be improved with effective referral and triage processes.	Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA; Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Petersen, LA (corresponding author), Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA.			Normand, Sharon-Lise/0000-0001-7027-4769	AHRQ HHS [R01-HS08071] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008071] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], CORONARY ANGIOGRAPHY; Ayanian JZ, 1998, NEW ENGL J MED, V338, P1896, DOI 10.1056/NEJM199806253382608; Birkmeyer J D, 1999, Eff Clin Pract, V2, P277; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Cannon CP, 2002, JAMA-J AM MED ASSOC, V287, P1987, DOI 10.1001/jama.287.15.1987; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Epstein AM, 2002, NEW ENGL J MED, V346, P1161, DOI 10.1056/NEJM200204113461512; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; GILKS WR, 1994, STATISTICIAN, V43, P169, DOI 10.2307/2348941; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V273, P160; Guadagnoli E, 2000, NEW ENGL J MED, V343, P1460, DOI 10.1056/NEJM200011163432006; Hannan EL, 1999, NEW ENGL J MED, V340, P1677, DOI 10.1056/NEJM199905273402112; Laouri M, 1997, INT J QUAL HEALTH C, V9, P15, DOI 10.1093/intqhc/9.1.15; Leape LL, 1999, ANN INTERN MED, V130, P183, DOI 10.7326/0003-4819-130-3-199902020-00003; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1990, HOSP VOLUME PHYSICIA; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Normand SLT, 1997, J AM STAT ASSOC, V92, P803, DOI 10.2307/2965545; Petersen LA, 2000, NEW ENGL J MED, V343, P1934, DOI 10.1056/NEJM200012283432606; Petersen LA, 2001, CIRCULATION, V104, P2898, DOI 10.1161/hc4901.100524; Petersen LA, 1999, J GEN INTERN MED, V14, P555, DOI 10.1046/j.1525-1497.1999.10198.x; Peterson ED, 1997, ANN INTERN MED, V126, P561, DOI 10.7326/0003-4819-126-7-199704010-00012; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; ROBINSON JC, 1987, NEW ENGL J MED, V317, P85, DOI 10.1056/NEJM198707093170205; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SPERTUS JA, 1995, ARCH INTERN MED, V155, P2309, DOI 10.1001/archinte.155.21.2309; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Tu JV, 1997, NEW ENGL J MED, V337, P139; Wennberg DE, 1996, JAMA-J AM MED ASSOC, V275, P1161, DOI 10.1001/jama.275.15.1161; Wright SM, 1999, MED CARE, V37, P529, DOI 10.1097/00005650-199906000-00002	35	86	87	1	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2209	2217		10.1056/NEJMsa021725	http://dx.doi.org/10.1056/NEJMsa021725			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773649				2022-12-28	WOS:000183134700008
J	Kaplan, JB; Bennett, T				Kaplan, JB; Bennett, T			Use of race and ethnicity in biomedical publication	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HEALTH-SERVICES RESEARCH; AMERICAN-INDIANS; DEATH CERTIFICATES; RACIAL MISCLASSIFICATION; RESIDENTIAL SEGREGATION; ALASKA NATIVES; SOCIAL-CLASS; 2000 CENSUS; RACE/ETHNICITY; EPIDEMIOLOGY	Researchers, clinicians, and policy makers face 3 challenges in writing about race and ethnicity: accounting for the limitations of race/ethnicity data; distinguishing between race/ethnicity as a risk factor or as a risk marker; and finding a way to write about race/ethnicity that does not stigmatize and does not imply a we/they dichotomy between health professionals and populations of color. Journals play an important role in setting standards for research and policy literature. The authors outline guidelines that might be used when race and ethnicity are addressed in biomedical publications.	Univ N Carolina, Sch Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Bennett, T (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Maternal & Child Hlth, C7445, Chapel Hill, NC 27599 USA.	trude_bennet@unc.edu						Acevedo-Garcia D, 2000, SOC SCI MED, V51, P1143, DOI 10.1016/S0277-9536(00)00016-2; Ahdieh L, 1996, Ethn Health, V1, P95; *AM ANTHR ASS, 1998, AM ANTHR ASS RESP OM; Amaro H, 2000, AM J PUBLIC HEALTH, V90, P1724, DOI 10.2105/AJPH.90.11.1724; Anderson M R, 1998, Fam Med, V30, P224; Anderson MR, 2001, FAM MED, V33, P430; [Anonymous], 1996, BRIT MED J, V312, P1094; [Anonymous], 1996, AM J PHYS ANTHROPOL, V101, P569; [Anonymous], 2000, NAT GENET, V24, P97; Azuonye IO, 1996, BRIT MED J, V313, P426; BAGLEY C, 1995, SOC SCI MED, V40, P1017, DOI 10.1016/0277-9536(94)00318-N; Baumeister L, 2000, HEALTH SERV RES, V35, P869; Bennett T, 1997, PUBLIC HEALTH REP, V112, P477; Bennett T, 1998, J NATL MED ASSOC, V90, P401; Bhopal R, 1997, BRIT MED J, V314, P1751, DOI 10.1136/bmj.314.7096.1751; Bhopal R, 2002, AM J PUBLIC HEALTH, V92, P156, DOI 10.2105/AJPH.92.2.156-a; Bhopal R, 1998, AM J PUBLIC HEALTH, V88, P1303, DOI 10.2105/AJPH.88.9.1303; Bhopal R, 1997, Ethn Health, V2, P223; BHOPAL R, 2000, SCI EDITOR, V23, P75; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P244; Blumenthal DS, 1999, ACAD MED, V74, P1259, DOI 10.1097/00001888-199912000-00001; Boehmer U, 2002, AM J PUBLIC HEALTH, V92, P1471, DOI 10.2105/AJPH.92.9.1471; BOGUE G, 1971, SOC BIOL, V18, P387, DOI 10.1080/19485565.1971.9987946; Braveman P, 2001, PUBLIC HEALTH REP, V116, P449, DOI 10.1093/phr/116.5.449; BRAVEMAN P, 2002, 130 ANN M AM PUBL HL; Burhansstipanov L, 2000, AM J PUBLIC HEALTH, V90, P1720, DOI 10.2105/AJPH.90.11.1720; COOPER RS, 1994, PUBLIC HEALTH REP, V109, P46; *COUNC BIOL ED STY, 1994, SCI STYL FORM CBE MA; CULEBRAS A, 1995, ARCH NEUROL-CHICAGO, V52, P533, DOI 10.1001/archneur.1995.00540290123029; Davis MM, 2001, ARCH PEDIAT ADOL MED, V155, P973; Drevdahl D, 2001, NURS RES, V50, P305, DOI 10.1097/00006199-200109000-00009; Flores G, 2001, ARCH PEDIAT ADOL MED, V155, P1178; Friedman DJ, 2000, AM J PUBLIC HEALTH, V90, P1714, DOI 10.2105/AJPH.90.11.1714; FROST F, 1994, AM J PREV MED, V10, P290, DOI 10.1016/S0749-3797(18)30581-6; FROST F, 1992, J NATL CANCER I, V84, P957, DOI 10.1093/jnci/84.12.957; Fullilove MT, 1998, AM J PUBLIC HEALTH, V88, P1297, DOI 10.2105/AJPH.88.9.1297; Fustinoni O, 2000, STROKE, V31, P1013, DOI 10.1161/01.STR.31.5.1013; Geronimus A T, 2001, J Am Med Womens Assoc (1972), V56, P133; Geronimus AT, 2000, AM J PUBLIC HEALTH, V90, P867, DOI 10.2105/AJPH.90.6.867; Geronimus AT., 2001, J AM MED WOMENS ASS, V56, P149, DOI DOI 10.1080/19397030902947041; GIMENEZ ME, 1989, INT J HEALTH SERV, V19, P557, DOI 10.2190/HN6N-P1TH-8CHL-KW5X; Goodman AH, 2000, AM J PUBLIC HEALTH, V90, P1699, DOI 10.2105/AJPH.90.11.1699; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P268, DOI 10.1001/jama.267.2.268; Hahn RA, 1996, EPIDEMIOLOGY, V7, P75, DOI 10.1097/00001648-199601000-00013; HAHN RA, 1994, PUBLIC HEALTH REP, V109, P7; Hahn RA, 2002, PUBLIC HEALTH REP, V117, P37, DOI 10.1016/S0033-3549(04)50106-1; Hahn RA, 1999, EPIDEMIOLOGY, V10, P108, DOI 10.1097/00001648-199903000-00004; Harwell TS, 2002, PUBLIC HEALTH REP, V117, P44, DOI 10.1093/phr/117.1.44; HAYESBAUTISTA DE, 1980, AM J PUBLIC HEALTH, V70, P353, DOI 10.2105/AJPH.70.4.353; Herman Allen A., 1996, Ethnicity and Disease, V6, P7; HUTH EJ, 1995, ANN INTERN MED, V122, P619, DOI 10.7326/0003-4819-122-8-199504150-00012; Institute of Medicine Committee on Cancer Research Among Minorities and the Medically Underserved, 1999, UN BURD CANC ASS NIH; International Committee of Medical Journal Editors, UN REQ MAN SUBM BIOM; Iverson C, 1998, AM MED ASS MANUAL ST; JAMES SA, 1994, CULT MED PSYCHIAT, V18, P163, DOI 10.1007/BF01379448; JONES CP, 1991, AM J EPIDEMIOL, V134, P1079, DOI 10.1093/oxfordjournals.aje.a116011; Jones CP, 2001, AM J EPIDEMIOL, V154, P299, DOI 10.1093/aje/154.4.299; Jones CP, 2000, AM J PUBLIC HEALTH, V90, P1212, DOI 10.2105/AJPH.90.8.1212; Kaufman JS, 1995, PUBLIC HEALTH REP, V110, P662; Kaufman JS, 1999, EPIDEMIOLOGY, V10, P101, DOI 10.1097/00001648-199903000-00001; Kaufman JS, 2001, AM J EPIDEMIOL, V154, P291, DOI 10.1093/aje/154.4.291; Kaufman JS, 2001, AM J EPIDEMIOL, V154, P305, DOI 10.1093/aje/154.4.305; KENNEDY RD, 1991, PUBLIC HEALTH REP, V106, P97; Krieger N, 2000, AM J PUBLIC HEALTH, V90, P1687, DOI 10.2105/AJPH.90.11.1687; Krieger N, 2000, EPIDEMIOLOGY, V11, P237, DOI 10.1097/00001648-200005000-00001; KRIEGER N, 1994, INT J HEALTH SERV, V24, P25, DOI 10.2190/2JG7-YMD5-WCP2-XXNT; Krieger N, 1999, AM J PUBLIC HEALTH, V89, P782, DOI 10.2105/AJPH.89.5.782; Krieger N, 1999, INT J HEALTH SERV, V29, P295, DOI 10.2190/M11W-VWXE-KQM9-G97Q; Krieger N, 2000, INT J HEALTH SERV, V30, P211, DOI 10.2190/672J-1PPF-K6QT-9N7U; KRIEGER N, 1993, AM J PREV MED, V9, P82, DOI 10.1016/S0749-3797(18)30666-4; KRIEGER N, 2002, 130 ANN M AM PUBL HL; LaVeist TA, 2000, INT J HEALTH SERV, V30, P217, DOI 10.2190/LKDF-UJQ5-W1KU-GLR1; LAVEIST TA, 1994, HEALTH SERV RES, V29, P1; Laveist Thomas A., 1996, Ethnicity and Disease, V6, P21; Laws MB, 2002, PUBLIC HEALTH REP, V117, P50, DOI 10.1093/phr/117.1.50; Laws MB, 2001, ARCH PEDIAT ADOL MED, V155, P972, DOI 10.1001/archpedi.155.8.972; LillieBlanton M, 1996, ANNU REV PUBL HEALTH, V17, P411; LillieBlanton M, 1996, SOC SCI MED, V43, P83, DOI 10.1016/0277-9536(95)00337-1; McAuley J, 1996, BRIT MED J, V313, P425; McKenzie K, 1996, BRIT MED J, V312, P1054; MCKENZIE KJ, 1994, BRIT MED J, V309, P286, DOI 10.1136/bmj.309.6950.286; MOSCOU S, IN PRESS VALIDITY RA; NAVARRO V, 1991, INT J HEALTH SERV, V21, P229, DOI 10.2190/5WXM-QK9K-PTMQ-T1FG; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Oppenheimer GM, 2001, AM J PUBLIC HEALTH, V91, P1049, DOI 10.2105/AJPH.91.7.1049; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; PEROT RT, 2001, RACIAL ETHNIC PRIMAR; Rankin J, 1999, BRIT MED J, V318, P1696, DOI 10.1136/bmj.318.7199.1696; Rivara F, 2001, ARCH PEDIAT ADOL MED, V155, P1179; Rivara FP, 2001, ARCH PEDIAT ADOL MED, V155, P973; Rivara FP, 2001, ARCH PEDIAT ADOL MED, V155, P119, DOI 10.1001/archpedi.155.2.119; Schwartz RS, 2001, NEW ENGL J MED, V344, P1392, DOI 10.1056/NEJM200105033441810; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; Sondik EJ, 2000, AM J PUBLIC HEALTH, V90, P1709, DOI 10.2105/AJPH.90.11.1709; SORLIE PD, 1992, EPIDEMIOLOGY, V3, P181, DOI 10.1097/00001648-199203000-00018; Srinivasan S, 2000, AM J PUBLIC HEALTH, V90, P1731, DOI 10.2105/AJPH.90.11.1731; Stehr-Green P, 2002, AM J PUBLIC HEALTH, V92, P443, DOI 10.2105/AJPH.92.3.443; Stolley PD, 1999, INT J HEALTH SERV, V29, P905, DOI 10.2190/QAAH-P5DT-WMP8-8HNL; Sugarman Jonathan R., 1996, Cancer, V78, P1564, DOI 10.1002/(SICI)1097-0142(19961001)78:7+<1564::AID-CNCR7>3.3.CO;2-Q; SUGARMAN JR, 1993, AM J PUBLIC HEALTH, V83, P681, DOI 10.2105/AJPH.83.5.681; SUGARMAN JR, 1993, AM J KIDNEY DIS, V21, P383, DOI 10.1016/S0272-6386(12)80265-4; TERRIS M, 1973, AM J PUBLIC HEALTH, V63, P477, DOI 10.2105/AJPH.63.6.477; Thomas NM, 2002, AM J PUBLIC HEALTH, V92, P156, DOI 10.2105/AJPH.92.2.156; THOMAS S, 1996, CURR ISSUES PUBLIC H, V2, P5; Thomas SB, 2001, AM J PUBLIC HEALTH, V91, P1046, DOI 10.2105/AJPH.91.7.1046; TREVINO FM, 1987, AM J PUBLIC HEALTH, V77, P69, DOI 10.2105/AJPH.77.1.69; *US OFF MAN BUDG, 1977, OFFICE MANAGEMENT BU; *US OFF MAN BUDG, 1977, A46 OFF MAN BUDG US; US Office of Management and Budget, 1997, FED REGISTER, V62, P58781; Wallman KK, 2000, AM J PUBLIC HEALTH, V90, P1704, DOI 10.2105/AJPH.90.11.1704; WARREN RC, 1994, PUBLIC HEALTH REP, V109, P4; WILKINSON DY, 1987, MILBANK Q, V65, P56, DOI 10.2307/3349951; Williams D.R., 2001, AM BECOMING RACIAL T, P371; Williams DR, 2000, AM J PUBLIC HEALTH, V90, P1728, DOI 10.2105/AJPH.90.11.1728; Williams DR, 1997, ANN EPIDEMIOL, V7, P322, DOI 10.1016/S1047-2797(97)00051-3; Williams DR, 1996, INT J HEALTH SERV, V26, P483, DOI 10.2190/U9QT-7B7Y-HQ15-JT14; WILLIAMS DR, 1994, HEALTH SERV RES, V29, P261; Williams DR, 2002, AM J PUBLIC HEALTH, V92, P588, DOI 10.2105/AJPH.92.4.588; Williams DR, 2001, PUBLIC HEALTH REP, V116, P404, DOI 10.1016/S0033-3549(04)50068-7; WILLIAMS DR, 1994, PUBLIC HEALTH REP, V109, P26; WING B, 2001, COLOR LINES, V4, P24; Witzig R, 1996, ANN INTERN MED, V125, P675, DOI 10.7326/0003-4819-125-8-199610150-00008; Zuberi T, 2001, THICKER BLOOD RACIAL, V1st; Zubizarreta P, 1999, LANCET, V354, P780, DOI 10.1016/S0140-6736(05)76026-8; 1993, MMWR MORB MORTAL WKL, V42, P16; PAEDIAT PERINATAL EP; 2000, PAEDIAT PERINAT EPID, V14, P13	128	387	399	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2709	2716		10.1001/jama.289.20.2709	http://dx.doi.org/10.1001/jama.289.20.2709			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	682DG	12771118				2022-12-28	WOS:000183075600030
J	Brown, PJB; Warmington, V; Laurence, M; Prevost, AT				Brown, PJB; Warmington, V; Laurence, M; Prevost, AT			Randomised crossover trial comparing the performance of Clinical Terms Version 3 and Read Codes 5 byte set coding schemes in general practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BOOTSTRAP CONFIDENCE-INTERVALS; TERMINOLOGY; COVERAGE	Objective To determine whether Clinical Terms Version 3 provides greater accuracy and consistency in coding electronic patient records than the Read Codes 5 byte set. Design Randomised crossover trial. Clinicians coded patient records using both schemes after being randomised in pairs to use one scheme before the other. Setting 10 general practices in urban, suburban, and rural environments in Norfolk. Participants 10 general practitioners. Source of data Concepts were collected from records of 100 patient encounters. Main outcome measures Percentage of coded choices ranked as being exact representations of the original terms; percentage of cases where coding choice of paired general practitioners was identical; length of time taken to find a code. Results A total of 995 unique concepts were collected. Exact matches were more common with Clinical Terms (70% (95% confidence interval 67% to 73%)) than with Read Codes (50% (47% to 53%)) (P < 0.001), and this difference was significant for each of the 10 participants individually. The pooled proportion with exact and identical matches by paired participants was greater for Clinical Terms (0.58 (0.55 to 0.61)) than Read Codes (0.36 (0.33 to 0.39)) (P < 0.001). The time taken to code with Clinical Terms (30 seconds per term) was not significantly longer than that for Read Codes. Conclusions Clinical Terms Version 3 performed significantly better than Read Codes 5 byte set in capturing the meaning of concepts. These findings suggest that improved coding accuracy in primary care electronic patient records can be achieved with the use of such a clinical terminology.	Univ E Anglia, Sch Informat Syst, Norwich NR4 7TJ, Norfolk, England; Humbleyard Practice, Hethersett NR9 3AB, Norfolk, England; Bacon Rd Med Ctr, Norwich NR2 3QX, Norfolk, England; Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England	University of East Anglia; University of Cambridge	Brown, PJB (corresponding author), Humbleyard Practice, Hethersett NR9 3AB, Norfolk, England.	Pjbb@hicomm.demon.co.uk		Prevost, A. Toby/0000-0003-1723-0796				ALTMAN DG, 1996, PRACTICAL STAT MED R; Brown PJB, 2001, J AM MED INFORM ASSN, P71; Brown PJB, 2000, J AM MED INFORM ASSN, V7, P392, DOI 10.1136/jamia.2000.0070392; Campbell JR, 1997, J AM MED INFORM ASSN, V4, P238, DOI 10.1136/jamia.1997.0040238; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; Chute CG, 1996, J AM MED INFORM ASSN, V3, P224, DOI 10.1136/jamia.1996.96310636; Cimino JJ, 2001, J AM MED INFORM ASSN, V8, P163, DOI 10.1136/jamia.2001.0080163; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; EVANS DA, 1994, J AM MED INFORM ASSN, V1, P207, DOI 10.1136/jamia.1994.95236153; Fisher R.A., 1963, STAT TABLES BIOL AGR, V6th; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Hausam R R, 1995, Proc Annu Symp Comput Appl Med Care, P426; Humphreys BL, 1997, J AM MED INFORM ASSN, V4, P484, DOI 10.1136/jamia.1997.0040484; Mullins H C, 1996, Proc AMIA Annu Fall Symp, P135; NHS Executive, 1998, INF HLTH INF STRAT M; ONEIL M, 1995, METHOD INFORM MED, V34, P187; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SEVERS MP, 1993, B ROYAL COLL PHYSICI, V27, P9; Stearns MQ, 2001, J AM MED INFORM ASSN, P662	19	19	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2003	326	7399					1127	1130		10.1136/bmj.326.7399.1127	http://dx.doi.org/10.1136/bmj.326.7399.1127			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763986	Green Published, Bronze			2022-12-28	WOS:000183245000023
J	Aitman, TJ				Aitman, TJ			Genetic medicine and obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hammersmith Hosp, Imperial Coll Fac Med, MRC, Clin Sci Ctr,Physiol Genom & Med Grp, London, England	Imperial College London	Aitman, TJ (corresponding author), Hammersmith Hosp, Imperial Coll Fac Med, MRC, Clin Sci Ctr,Physiol Genom & Med Grp, London, England.			Aitman, Timothy/0000-0002-7875-4502				Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434	2	10	11	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2138	2139		10.1056/NEJMcibr035202	http://dx.doi.org/10.1056/NEJMcibr035202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761372				2022-12-28	WOS:000183008300014
J	Brophy, JM; Belisle, P; Joseph, L				Brophy, JM; Belisle, P; Joseph, L			Evidence for use of coronary Stents - A hierarchical Bayesian meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article							BALLOON ANGIOPLASTY; RANDOMIZED-TRIAL; ARTERY-DISEASE; HEART-DISEASE; FOLLOW-UP; MEDICAL STATISTICS; TOTAL OCCLUSION; WIKTOR STENT; IMPLANTATION; PLACEMENT	Background: Coronary stents are widely used in interventionall cardiology, but a current quantitative systematic overview comparing routine coronary stenting with standard percutaneous transluminal coronary angioplasty (PTCA) and restricted stenting (provisional stenting) has not been published. Purpose: To summarize results from all randomized clinical trials comparing routine coronary stenting with standard PTCA. Data Sources: Electronic databases were searched by using the key words angioplasty and stent. References from identified articles were also reviewed. In addition, several prominent general medical and cardiology journals were searched and agencies known to perform systematic reviews were consulted. Study Selection: All comparative randomized clinical trials were included, except those involving primary angioplasty for the treatment of acute myocardial infarction. Data Extraction: A specified protocol was followed, and two of the authors independently extracted the data. Outcomes assessed were total mortality, myocardial infarction, angiographic restenosis, coronary artery bypass surgery, repeated PTCA, and freedom from angina. Data Synthesis: The results were synthesized by using a Bayesian hierarchical random-effects model. A total of 29 trials involving 9918 patients were identified. There was no evidence for a difference between routine coronary stenting and standard PTCA in terms of deaths or myocardial infarctions (odds ratio, 0.90 [95% credible interval [CrI], 0.72 to 1.11]) or the need for coronary artery bypass surgery (odds ratio, 1.01 [CrI, 0.79 to 1.31]). Coronary stenting reduced the rate of restenosis (odds ratio, 0.52 [CrI, 0.37 to 0.69]) and the need for repeated PTCA (odds ratio, 0.59 [CrI, 0.50 to 0.68]). The trials showed a wide range of crossover rates from PTCA to stenting. By use of a multiplicative model, each 10% increase in crossover rate decreased the need for repeated angioplasty by approximately 8% (odds ratio multiplying factor, 1.08 [CrI, 0.98 to 1.18]). Routine stenting probably reduces the need for repeated angioplasty by fewer than 4 to 5 per 100 treated persons compared with PTCA with provisional stenting. Studies were not blinded and suggest a bias with a possible overestimation of this benefit. Conclusions: in the controlled environment of randomized clinical trials, routine coronary stenting is safe but probably not associated with important reductions in rates of mortality, acute myocardial infarction, or coronary artery bypass surgery compared with standard PTCA with provisional stenting. Coronary stenting is associated with substantial reductions in angiographic restenosis rates and the subsequent need for repeated PTCA, although this benefit may be overestimated because of trial designs. The incremental benefit of routine stenting for reducing repeated angioplasty diminishes as the crossover rate of stenting with conventional PTCA increases.	McGill Univ, Montreal, PQ, Canada	McGill University	Brophy, JM (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Div Epidemiol, 687 Pine Ave W,Room 4-12, Montreal, PQ H3A 1A1, Canada.	james.brophy@mcxgill.ca	brophy, james/H-6673-2019	brophy, james/0000-0001-8049-6875				ABELSON R, 2003, NY TIMES        0103; Al Suwaidi J, 2000, JAMA-J AM MED ASSOC, V284, P1828, DOI 10.1001/jama.284.14.1828; Al Suwaidi J, 2000, CIRCULATION, V101, P948, DOI 10.1161/01.CIR.101.9.948; Anderson HV, 2000, CIRCULATION, V102, P2910; Betriu A, 1999, J AM COLL CARDIOL, V34, P1498, DOI 10.1016/S0735-1097(99)00366-6; Brophy JM, 2001, ANN INTERN MED, V134, P550, DOI 10.7326/0003-4819-134-7-200104030-00008; Bucher HC, 2000, BMJ-BRIT MED J, V321, P73, DOI 10.1136/bmj.321.7253.73; Buller CE, 1999, CIRCULATION, V100, P236, DOI 10.1161/01.CIR.100.3.236; Cantor WJ, 2000, J AM COLL CARDIOL, V36, P1142, DOI 10.1016/S0735-1097(00)00854-8; Caramori PRA, 1999, J AM COLL CARDIOL, V34, P1675, DOI 10.1016/S0735-1097(99)00411-8; Dangas G, 2000, AM J CARDIOL, V85, P957, DOI 10.1016/S0002-9149(99)00909-1; Di Mario C, 2000, CIRCULATION, V102, P2938; Doucet S, 2001, CIRCULATION, V104, P2029, DOI 10.1161/circ.104.17.2029; Eeckhout E, 1996, AM HEART J, V132, P263, DOI 10.1016/S0002-8703(96)90420-2; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Fluck DS, 2000, HEART, V84, P522, DOI 10.1136/heart.84.5.522; Gelman Andrew, 1995, BAYESIAN DATA ANAL; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Hancock J, 1998, HEART, V79, P18, DOI 10.1136/hrt.79.1.18; Hannan EL, 2000, J AM COLL CARDIOL, V36, P395, DOI 10.1016/S0735-1097(00)00752-X; Higginson L, 1997, CAN J CARDIOL, V13, P731; Hoher M, 1999, J AM COLL CARDIOL, V34, P722, DOI 10.1016/S0735-1097(99)00254-5; Inoue T, 2000, AM J CARDIOL, V86, P1057, DOI 10.1016/S0002-9149(00)01159-0; Karsch KR, 2000, HEART, V84, P469, DOI 10.1136/heart.84.5.469; Kastrati A, 2000, CIRCULATION, V102, P2593; Koning R, 2001, CIRCULATION, V104, P1604, DOI 10.1161/hc3901.096695; Lafont A, 2000, J AM COLL CARDIOL, V36, P404, DOI 10.1016/S0735-1097(00)00747-6; Lincoff AM, 1999, NEW ENGL J MED, V341, P319, DOI 10.1056/NEJM199907293410503; Lotan C, 2000, EUR HEART J, V21, P1960, DOI 10.1053/euhj.2000.2295; Meads C, 2000, Health Technol Assess, V4, P1; Moer R, 2001, J AM COLL CARDIOL, V38, P1598, DOI 10.1016/S0735-1097(01)01602-3; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; *NAT I CLIN EXC, COR ART STENTS TREAT; Park SW, 2000, EUR HEART J, V21, P1785, DOI 10.1053/euhj.1999.1947; Ritchie JL, 1999, AM HEART J, V138, P437, DOI 10.1016/S0002-8703(99)70144-4; Rodriguez A, 1998, J AM COLL CARDIOL, V32, P1351, DOI 10.1016/S0735-1097(98)00388-X; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; Rubartelli P, 1998, J AM COLL CARDIOL, V32, P90, DOI 10.1016/S0735-1097(98)00193-4; Ruygrok PN, 1999, J AM COLL CARDIOL, V34, P1507, DOI 10.1016/S0735-1097(99)00380-0; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Serruys PW, 2000, CIRCULATION, V102, P2930; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Sievert H, 1999, AM J CARDIOL, V84, P386, DOI 10.1016/S0002-9149(99)00320-3; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; SIMES PA, 1996, J AM COLL CARDIOL, V28, P1444; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; Weaver WD, 2000, LANCET, V355, P2199, DOI 10.1016/S0140-6736(00)02403-X; Williams DO, 2000, CIRCULATION, V102, P2945; Witkowski A, 2000, AM HEART J, V140, P264, DOI 10.1067/mhj.2000.107555	55	148	159	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					777	786		10.7326/0003-4819-138-10-200305200-00005	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755549	Green Submitted			2022-12-28	WOS:000182920700001
J	Helms, JA; Schneider, RA				Helms, JA; Schneider, RA			Cranial skeletal biology	NATURE			English	Review							NEURAL CREST CELLS; HOX GENE-EXPRESSION; TIME-LAPSE ANALYSIS; SONIC HEDGEHOG; MICE LACKING; HOMEOTIC TRANSFORMATION; ZEBRAFISH; SPECIFICATION; MIGRATION; GROWTH	To artists, the face is a mirror of the soul. To biologists, the face reflects remarkable structural diversity think of bulldogs and wolfhounds or galapagos finches. How do such variations in skeletal form arise? Do the same mechanisms control skeletogenesis elsewhere in the body? The answers lie in the molecular machinery that generates neural crest cells, controls their migration, and guides their differentiation to cartilage and bone.	Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Helms, JA (corresponding author), Univ Calif San Francisco, Room U-453,533 Parnassus Ave, San Francisco, CA 94143 USA.	helms@itsa.ucsf.edu		Helms, Jill/0000-0002-0463-396X; Schneider, Richard/0000-0002-2626-3111				Ahlgren SC, 2002, P NATL ACAD SCI USA, V99, P10476, DOI 10.1073/pnas.162356199; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Aybar MJ, 2003, DEVELOPMENT, V130, P483, DOI 10.1242/dev.00238; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; Beverdam A, 2002, GENESIS, V34, P221, DOI 10.1002/gene.10156; BIRGBAUER E, 1995, DEVELOPMENT, V121, P935; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Carter DR, 1998, CLIN ORTHOP RELAT R, pS41; CARTER DR, 1991, BONE-BIOMATERIAL INTERFACE, P367; Chai Y, 2003, MICROSC RES TECHNIQ, V60, P469, DOI 10.1002/jemt.10287; Chai Y, 2000, DEVELOPMENT, V127, P1671; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cohen MM, 2000, J CRAN GENET DEV BIO, V20, P19; Cole F, 2003, CURR BIOL, V13, P411, DOI 10.1016/S0960-9822(03)00088-5; COLNOT C, IN PRESS DEVELOPMENT; Cooper KL, 2003, DEV BIOL, V253, P200, DOI 10.1016/S0012-1606(02)00018-0; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Cordero D. R., 2002, CRANIOFACIAL SURG SC, P75; CORDERO DR, UNPUB NATURE MED; Couly G, 2002, DEVELOPMENT, V129, P1061; Couly G, 1998, DEVELOPMENT, V125, P3445; Creuzet S, 2002, DEVELOPMENT, V129, P4301; Depew MJ, 2002, SCIENCE, V298, P381, DOI 10.1126/science.1075703; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Garg V, 2001, DEV BIOL, V235, P62, DOI 10.1006/dbio.2001.0283; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; Golding JP, 1999, DEV BIOL, V216, P85, DOI 10.1006/dbio.1999.9497; Golding JP, 2000, NAT CELL BIOL, V2, P103, DOI 10.1038/35000058; Gorlin RJ, 1997, J CRANIO MAXILL SURG, V25, P69, DOI 10.1016/S1010-5182(97)80048-0; Groves AK, 2000, DEVELOPMENT, V127, P3489; Holder N, 1999, DEVELOPMENT, V126, P2033; Hu D, 1999, DEVELOPMENT, V126, P4873; Hu D, 2003, DEVELOPMENT, V130, P1749, DOI 10.1242/dev.00397; Hunter MP, 2002, DEV BIOL, V247, P367, DOI 10.1006/dbio.2002.0701; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487; KEELER RF, 1968, TERATOLOGY, V1, P5, DOI 10.1002/tera.1420010103; Kendrick KM, 2001, NATURE, V414, P165, DOI 10.1038/35102669; Kimmel CB, 2001, DEV BIOL, V233, P239, DOI 10.1006/dbio.2001.0201; Kulesa P, 2000, DEVELOPMENT, V127, P2843; Kulesa PM, 2000, DEVELOPMENT, V127, P1161; Lee SH, 2001, NATURE, V414, P909, DOI 10.1038/414909a; Levine JP, 1998, PLAST RECONSTR SURG, V101, P1441, DOI 10.1097/00006534-199805000-00002; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; Lucas A., 1972, AVIAN ANATOMY INTEGU; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; Mavrogiannis LA, 2001, NAT GENET, V27, P17, DOI 10.1038/83703; McGonnell IM, 2002, CURR BIOL, V12, P767, DOI 10.1016/S0960-9822(02)00818-7; Miller CT, 2000, DEVELOPMENT, V127, P3815; NAKAMURA H, 1982, J EMBRYOL EXP MORPH, V70, P1; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Noden D. M., 1982, FACTORS MECH INFLUEN, P168; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1978, DEV BIOL, V67, P296, DOI 10.1016/0012-1606(78)90201-4; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; Picasso Pablo, 1972, PICASSO ART SELECTIO; Popperl H, 2000, MOL CELL, V6, P255, DOI 10.1016/S1097-2765(00)00027-7; PRINCE V, 1994, DEVELOPMENT, V120, P911; Prince VE, 1998, DEVELOPMENT, V125, P393; Probst A, 1997, J INVEST SURG, V10, P77, DOI 10.3109/08941939709032137; Remuzzi G, 2002, NAT REV DRUG DISCOV, V1, P986, DOI 10.1038/nrd962; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schilling TF, 1996, DEVELOPMENT, V123, P329; SCHILLING TF, 1994, DEVELOPMENT, V120, P483; Schneider RA, 2003, SCIENCE, V299, P565, DOI 10.1126/science.1077827; Schneider RA, 2001, DEVELOPMENT, V128, P2755; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; Trainor PA, 2002, SCIENCE, V295, P1288, DOI 10.1126/science.1064540; Trainor PA, 2000, NAT REV NEUROSCI, V1, P116, DOI 10.1038/35039056; Vitelli F, 2002, HUM MOL GENET, V11, P915, DOI 10.1093/hmg/11.8.915; Wagner W, 2002, HEAD NECK-J SCI SPEC, V24, P482, DOI 10.1002/hed.10083; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; Wilson C, 2002, NEW SCI, V175, P32; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	81	180	187	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					326	331		10.1038/nature01656	http://dx.doi.org/10.1038/nature01656			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748650				2022-12-28	WOS:000182853100052
J	Evans, AV; Child, FJ; Russell-Jones, R				Evans, AV; Child, FJ; Russell-Jones, R			Lesson of the week - Zosteriform metastasis from melanoma	BRITISH MEDICAL JOURNAL			English	Review							KAPOSIS-SARCOMA; HERPES-ZOSTER; CARCINOMA		St Thomas Hosp, St Johns Inst Dermatol, Skin Tumour Unit, London SE1 7EH, England; St Marys Hosp, London W2 1NY, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London	Evans, AV (corresponding author), St Thomas Hosp, St Johns Inst Dermatol, Skin Tumour Unit, London SE1 7EH, England.							ALOI FG, 1990, J AM ACAD DERMATOL, V22, P130, DOI 10.1016/S0190-9622(08)80015-1; BLUEFARB SM, 1957, ARCH DERMATOL, V76, P402, DOI 10.1001/archderm.1957.01550220010002; BRAVERMAN IM, 1981, SKIN SIGNS SYSTEMIC, P1; HODGE SJ, 1979, INT J DERMATOL, V18, P142, DOI 10.1111/j.1365-4362.1979.tb04492.x; ITIN PH, 1995, J AM ACAD DERMATOL, V32, P854, DOI 10.1016/0190-9622(95)91546-X; JAWORSKY C, 1986, ARCH DERMATOL, V122, P1357, DOI 10.1001/archderm.122.12.1357; LOOKINGBILL DP, 1993, J AM ACAD DERMATOL, V29, P228, DOI 10.1016/0190-9622(93)70173-Q; MANTEAUX A, 1992, J DERMATOL SURG ONC, V18, P97, DOI 10.1111/j.1524-4725.1992.tb02440.x; MATARASSO SL, 1988, J DERMATOL SURG ONC, V14, P774, DOI 10.1111/j.1524-4725.1988.tb01162.x; NIEDT GW, 1988, J AM ACAD DERMATOL, V18, P448; North S, 1998, CUTIS, V62, P143; ROTH JS, 1993, J AM ACAD DERMATOL, V29, P488, DOI 10.1016/S0190-9622(08)82003-8	12	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1025	1026		10.1136/bmj.326.7397.1025	http://dx.doi.org/10.1136/bmj.326.7397.1025			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KG	12742928	Green Published			2022-12-28	WOS:000182920500023
J	Fletcher, CV				Fletcher, CV			Enfuvirtide, a new drug for HIV infection	LANCET			English	Editorial Material							PEPTIDE INHIBITOR; VIRUS; PHARMACOKINETICS; FUSION; T-20		Univ Colorado, Hlth Sci Ctr, Dept Clin Pharm, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Fletcher, CV (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Clin Pharm, 4200 E 9th Ave, Denver, CO 80262 USA.							CLOTET B, 2002, 14 INT AIDS C BARC S; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; LaBranche CC, 2001, ANTIVIR RES, V50, P95, DOI 10.1016/S0166-3542(01)00130-9; LALEZARI JP, 2003, N ENGL J MED; *ROCH PHARM, 2003, FUZEONTM PACK INS; Zhang XP, 2002, CLIN PHARMACOL THER, V72, P10, DOI 10.1067/mcp.2002.125945	7	35	37	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 10	2003	361	9369					1577	1578		10.1016/S0140-6736(03)13323-5	http://dx.doi.org/10.1016/S0140-6736(03)13323-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676HY	12747873				2022-12-28	WOS:000182746300003
J	Dror, I; Amitay, T; Yaron, B; Berkowitz, B				Dror, I; Amitay, T; Yaron, B; Berkowitz, B			Salt-pump mechanism for contaminant intrusion into coastal aquifers	SCIENCE			English	Article									Weizmann Inst Sci, Dept Environm Sci & Energy Res, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Berkowitz, B (corresponding author), Weizmann Inst Sci, Dept Environm Sci & Energy Res, IL-76100 Rehovot, Israel.		BERKOWITZ, BRIAN/K-1497-2012	BERKOWITZ, BRIAN/0000-0003-3078-1859				Brendel ML, 1999, FLUID PHASE EQUILIBR, V165, P87, DOI 10.1016/S0378-3812(99)00267-8; Lipiatou E, 1997, DEEP-SEA RES PT II, V44, P881, DOI 10.1016/S0967-0645(96)00093-8; Setschenow J., 1889, Z PHYS CHEM, V4, P117, DOI DOI 10.1515/ZPCH-1889-0109; Tkalich P, 2002, MAR POLLUT BULL, V44, P1219, DOI 10.1016/S0025-326X(02)00178-9; Xie WH, 1997, MAR ENVIRON RES, V44, P429, DOI 10.1016/S0141-1136(97)00017-2; Zhang Q, 2001, J CONTAM HYDROL, V49, P201, DOI 10.1016/S0169-7722(00)00194-7	6	17	17	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					950	950		10.1126/science.1080075	http://dx.doi.org/10.1126/science.1080075			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738855				2022-12-28	WOS:000182719800047
J	Zerhouni, E				Zerhouni, E			Embryonic stem cells - Stem cell programs	SCIENCE			English	Editorial Material									NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Zerhouni, E (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.								0	4	5	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					911	912		10.1126/science.1084819	http://dx.doi.org/10.1126/science.1084819			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738840				2022-12-28	WOS:000182719800032
J	Bagri, A; Cheng, HJ; Yaron, A; Pleasure, SJ; Tessier-Lavigne, M				Bagri, A; Cheng, HJ; Yaron, A; Pleasure, SJ; Tessier-Lavigne, M			Stereotyped pruning of long hippocampal axon branches triggered by retraction inducers of the semaphorin family	CELL			English	Article							PROJECTION; CELLS; NEURONS	Like naturally occurring neuronal cell death, stereotyped pruning of long axon branches to temporary targets is a widespread regressive phenomenon in the developing mammalian brain that helps sculpt the pattern of neuronal connections. The mechanisms controlling stereotyped pruning are, however, poorly understood. Here, we provide evidence that semaphorins, activating the Plexin-A3 receptor, function as retraction inducers to trigger-stereotyped pruning of specific hippocampal mossy fiber and pyramidal axon branches. Both pruning events are defective in Plexin-A3 mutants, reflecting a cell-autonomous requirement for Plexin-A3. The distribution of mRNAs for Sema3F and Sema3A makes them candidates for triggering the pruning. In vitro, hippocampal neurons respond to semaphorins by retracting axon branches. These results implicate semaphorins as retraction inducers controlling stereotyped pruning in the mammalian brain.	Univ Calif San Francisco, Dept Neurol, Program Neurosci, San Francisco, CA 94143 USA; Stanford Univ, Dept Biol Sci, Howard Hughes Med Inst, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University	Pleasure, SJ (corresponding author), Univ Calif San Francisco, Dept Neurol, Program Neurosci, San Francisco, CA 94143 USA.	samuelp@itsa.ucsf.edu; marctl@stanford.edu	Cheng, Hwai-Jong/AAY-5067-2021	Cheng, Hwai-Jong/0000-0003-0647-0567				Albright TD, 2000, NEURON, V25, pS1, DOI 10.1016/S0896-6273(00)80912-5; ALTMAN J, 1990, J COMP NEUROL, V301, P343, DOI 10.1002/cne.903010303; BANKER GA, 1979, J COMP NEUROL, V187, P469, DOI 10.1002/cne.901870302; Bernstein M, 1999, CURR OPIN NEUROBIOL, V9, P364, DOI 10.1016/S0959-4388(99)80053-1; Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chedotal A, 1998, DEVELOPMENT, V125, P4313; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; Hadjantonakis AK, 2001, GENESIS, V29, P133, DOI 10.1002/gene.1016; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; HERRMANN K, 1995, P NATL ACAD SCI USA, V92, P11244, DOI 10.1073/pnas.92.24.11244; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1998, PROG BRAIN RES, V117, P115; LINKE R, 1995, J COMP NEUROL, V351, P602, DOI 10.1002/cne.903510409; Martin LA, 2002, J NEUROSCI, V22, P3520; Murakami Y, 2001, DEV DYNAM, V220, P246, DOI 10.1002/1097-0177(20010301)220:3<246::AID-DVDY1112>3.0.CO;2-2; OLEARY DDM, 1986, DEV BRAIN RES, V27, P87, DOI 10.1016/0165-3806(86)90235-X; OLEARY DDM, 1990, COLD SH Q B, V55, P453; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; STANFIELD BB, 1985, J COMP NEUROL, V238, P236, DOI 10.1002/cne.902380210; SUPER H, 1994, J COMP NEUROL, V344, P101, DOI 10.1002/cne.903440108; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Weimann JM, 1999, NEURON, V24, P819, DOI 10.1016/S0896-6273(00)81030-2	26	247	249	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					285	299		10.1016/S0092-8674(03)00267-8	http://dx.doi.org/10.1016/S0092-8674(03)00267-8			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732138	Bronze			2022-12-28	WOS:000182640800005
J	Fan, XH				Fan, XH			Black holes at the cosmic dawn	SCIENCE			English	Editorial Material							DIGITAL SKY SURVEY; QUASARS; DISCOVERY; GALAXY		Univ Arizona, Steward Observ, Tucson, AZ 85721 USA	University of Arizona	Fan, XH (corresponding author), Univ Arizona, Steward Observ, Tucson, AZ 85721 USA.	fan@as.arizona.edu						Ajiki M, 2002, ASTROPHYS J, V576, pL25, DOI 10.1086/343026; BUNKER A, UNPUB; Carilli CL, 2003, SCIENCE, V300, P773, DOI 10.1126/science.1082600; Carilli CL, 2001, ASTROPHYS J, V555, P625, DOI 10.1086/321519; Elvis M, 2002, ASTROPHYS J, V567, pL107, DOI 10.1086/340006; Fan XH, 2001, ASTRON J, V122, P2833, DOI 10.1086/324111; Fan XH, 2003, ASTRON J, V125, P1649, DOI 10.1086/368246; Ferrarese L, 2000, ASTROPHYS J, V539, pL9, DOI 10.1086/312838; FREUDLING W, IN PRESS ASTROPHYS J; GERBHARDT K, 2001, ASTROPHYS J LETT, V539, pL13; Hu EM, 2002, ASTROPHYS J, V568, pL75, DOI 10.1086/340424; Hu EM, 1996, ASTROPHYS J, V459, pL53, DOI 10.1086/309958; Ohta K, 1996, NATURE, V382, P426, DOI 10.1038/382426a0; Omont A, 1996, ASTRON ASTROPHYS, V315, P1; Yu QJ, 2002, MON NOT R ASTRON SOC, V335, P965, DOI 10.1046/j.1365-8711.2002.05532.x	15	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					752	753		10.1126/science.1084469	http://dx.doi.org/10.1126/science.1084469			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730588				2022-12-28	WOS:000182579800034
J	Naber, N; Minehardt, TJ; Rice, S; Chen, XR; Grammer, J; Matuska, M; Vale, RD; Kollman, PA; Car, R; Yount, RG; Cooke, R; Pate, E				Naber, N; Minehardt, TJ; Rice, S; Chen, XR; Grammer, J; Matuska, M; Vale, RD; Kollman, PA; Car, R; Yount, RG; Cooke, R; Pate, E			Closing of the nucleotide pocket of kinesin-family motors upon binding to microtubules	SCIENCE			English	Article							CRYSTAL-STRUCTURE; G-PROTEINS; MOLECULAR MOTORS; MECHANISM; MYOSIN; DOMAIN; ATPASE; ACTIVATION; SWITCHES; REVEALS	We have used adenosine diphosphate analogs containing electron paramagnetic resonance (EPR) spin moieties and EPR spectroscopy to show that the nucleotide-binding site of kinesin-family motors closes when the motor.diphosphate complex binds to microtubules. Structural analyses demonstrate that a domain movement in the switch 1 region at the nucleotide site, homologous to domain movements in the switch 1 region in the G proteins [heterotrimeric guanine nucleotide-binding proteins], explains the EPR data. The switch movement primes the motor both for the free energy-yielding nucleotide hydrolysis reaction and for subsequent conformational changes that are crucial for the generation of force and directed motion along the microtubule.	Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Washington State Univ, Dept Chem, Pullman, WA 99164 USA; Washington State Univ, Dept Math, Pullman, WA 99164 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Princeton University; Washington State University; Washington State University; Washington State University	Naber, N (corresponding author), Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA.		Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir I/0000-0002-6361-2798	NCRR NIH HHS [RR1081] Funding Source: Medline; NIAMS NIH HHS [AR42895, AR39643] Funding Source: Medline; NIDDK NIH HHS [DK05915] Funding Source: Medline; NIGMS NIH HHS [GM29072] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039643, P01AR042895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029072] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CROWDER MS, 1987, BIOPHYS J, V51, P323, DOI 10.1016/S0006-3495(87)83338-6; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Griffith O.H., 1976, SPIN LABELING THEORY, P454; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; KOZIELSKI F, 1997, CELL, V7, P1407; Kull FJ, 2002, J CELL SCI, V115, P15; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Minehardt TJ, 2001, BIOPHYS J, V80, P1151, DOI 10.1016/S0006-3495(01)76092-4; Naber N, 2003, BIOPHYS J, V84, P3190, DOI 10.1016/S0006-3495(03)70043-5; Pate E, 1997, BIOCHEMISTRY-US, V36, P12155, DOI 10.1021/bi970996z; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sack S, 1999, EUR J BIOCHEM, V262, P1, DOI 10.1046/j.1432-1327.1999.00341.x; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; YOUNT RG, 1995, BIOPHYS J, V68, pS44; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	27	49	50	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					798	801		10.1126/science.1082374	http://dx.doi.org/10.1126/science.1082374			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730601				2022-12-28	WOS:000182579800051
J	Drinkwater, MJ; Gregg, MD; Hilker, M; Bekki, K; Couch, WJ; Ferguson, HC; Jones, JB; Phillipps, S				Drinkwater, MJ; Gregg, MD; Hilker, M; Bekki, K; Couch, WJ; Ferguson, HC; Jones, JB; Phillipps, S			A class of compact dwarf galaxies from disruptive processes in galaxy clusters	NATURE			English	Article							MASSIVE STAR-CLUSTERS; FORNAX CLUSTER; GLOBULAR-CLUSTERS; VIRGO CLUSTER; ELLIPTIC GALAXIES; STELLAR-SYSTEMS; SPACE-TELESCOPE; OMEGA-CENTAURI; DYNAMICS; LIGHT	Dwarf galaxies have attracted increased attention in recent years, because of their susceptibility to galaxy transformation processes within rich galaxy clusters(1-3). Direct evidence for these processes, however, has been difficult to obtain, with a small number of diffuse light trails(4) and intra-cluster stars(5,6) being the only signs of galaxy disruption. Furthermore, our current knowledge of dwarf galaxy populations may be very incomplete, because traditional galaxy surveys are insensitive to extremely diffuse or compact galaxies(7). Aware of these concerns, we recently undertook an all-object survey of the Fornax galaxy cluster(8). This revealed a new population of compact members(9,10), overlooked in previous conventional surveys. Here we demonstrate that these 'ultra-compact' dwarf galaxies are structurally and dynamically distinct from both globular star clusters and known types of dwarf galaxy, and thus represent a new class of dwarf galaxy. Our data are consistent with the interpretation that these are the remnant nuclei of disrupted dwarf galaxies, making them an easily observed tracer of galaxy disruption.	Univ Queensland, Dept Phys, Brisbane, Qld 4072, Australia; Univ Calif Davis, Dept Phys, Davis, CA 95616 USA; Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA; Univ Bonn, Sternwarte, D-53121 Bonn, Germany; Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England; Univ Bristol, Dept Phys, Astrophys Grp, Bristol BS8 1TL, Avon, England	University of Queensland; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Bonn; University of New South Wales Sydney; Space Telescope Science Institute; University of Nottingham; University of Bristol	Drinkwater, MJ (corresponding author), Univ Queensland, Dept Phys, Brisbane, Qld 4072, Australia.		Bekki, Kenji/H-8821-2014; Drinkwater, Michael/A-2201-2008	Drinkwater, Michael/0000-0003-4867-0022; Jones, Bryn/0000-0002-4679-5625; Bekki, Kenji/0000-0001-6163-4726; Hilker, Michael/0000-0002-2363-5522; Phillipps, Steven/0000-0001-5991-3486				BASSINO LP, 1994, ASTROPHYS J, V431, P634, DOI 10.1086/174514; Bekki K, 2002, ASTROPHYS J, V577, P651, DOI 10.1086/342221; Bekki K, 2001, ASTROPHYS J, V552, pL105, DOI 10.1086/320339; DISNEY MJ, 1976, NATURE, V263, P573, DOI 10.1038/263573a0; Djorgovski SG, 1997, ASTROPHYS J, V474, pL19, DOI 10.1086/310423; DRINKWATER M, 1991, ASTRON J, V101, P94, DOI 10.1086/115670; Drinkwater MJ, 2000, PUBL ASTRON SOC AUST, V17, P227, DOI 10.1071/AS00034; Drinkwater MJ, 2001, ASTROPHYS J, V548, pL139, DOI 10.1086/319113; Drinkwater MJ, 2000, ASTRON ASTROPHYS, V355, P900; Durrell PR, 2002, ASTROPHYS J, V570, P119, DOI 10.1086/339735; FABER SM, 1976, ASTROPHYS J, V204, P668, DOI 10.1086/154215; FERGUSON HC, 1989, ASTRON J, V98, P367, DOI 10.1086/115152; Ford H, 2002, ASTR SOC P, V273, P41; Gnedin OY, 2002, ASTROPHYS J, V568, pL23, DOI 10.1086/340319; Gregg MD, 1998, NATURE, V396, P549, DOI 10.1038/25078; HERNQUIST L, 1987, ASTROPHYS J SUPPL S, V64, P715, DOI 10.1086/191215; Hilker M, 1999, ASTRON ASTROPHYS SUP, V138, P55, DOI 10.1051/aas:1999495; Hilker M, 2003, ASTRON ASTROPHYS, V397, pL9, DOI 10.1051/0004-6361:20021766; Larsen SS, 1999, ASTRON ASTROPHYS SUP, V139, P393, DOI 10.1051/aas:1999509; Lotz JM, 2001, ASTROPHYS J, V552, P572, DOI 10.1086/320545; Merritt D, 1997, ASTRON J, V114, P1074, DOI 10.1086/118538; Meylan G, 2001, ASTRON J, V122, P830, DOI 10.1086/321166; Mieske S, 2002, ASTRON ASTROPHYS, V383, P823, DOI 10.1051/0004-6361:20011833; Miller BW, 1998, ASTROPHYS J, V508, pL133, DOI 10.1086/311739; Moore B, 1996, NATURE, V379, P613, DOI 10.1038/379613a0; Phillipps S, 2001, ASTROPHYS J, V560, P201, DOI 10.1086/322517	28	215	217	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					519	521		10.1038/nature01666	http://dx.doi.org/10.1038/nature01666			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774116	Green Submitted, Green Published			2022-12-28	WOS:000183162900037
J	Gomez-Cabrera, MC; Pallardo, FV; Sastre, J; Vina, J; Garcia-del-Moral, L				Gomez-Cabrera, MC; Pallardo, FV; Sastre, J; Vina, J; Garcia-del-Moral, L			Allopurinol and markers of muscle damage among participants in the Tour de France	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							EXERCISE		Fac Med Valencia, Dept Fisiol, Valencia, Spain; Inst Med Deporte, Dept Med, US Postal Cycling Team, Valencia, Spain		Gomez-Cabrera, MC (corresponding author), Fac Med Valencia, Dept Fisiol, Valencia, Spain.		Gomez-Cabrera, Maria Carmen/H-6911-2018; Pallardo, Federico V./T-1156-2017; Gomez-Cabrera, Mari Carmen/O-3109-2019; Vina, Jose/AAB-3069-2021	Gomez-Cabrera, Maria Carmen/0000-0003-4000-1684; Pallardo, Federico V./0000-0003-3715-1980; Gomez-Cabrera, Mari Carmen/0000-0003-4000-1684; Vina, Jose/0000-0001-9709-0089				de la Asuncion JG, 1998, J CLIN INVEST, V102, P4, DOI 10.1172/JCI1418; SASTRE J, 1992, AM J PHYSIOL, V263, pR992, DOI 10.1152/ajpregu.1992.263.5.R992; Sorichter S, 2001, J SPORT SCI, V19, P687, DOI 10.1080/02640410152475810; Vina J, 2000, IUBMB LIFE, V50, P271, DOI 10.1080/15216540051080994	4	95	96	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2503	2504		10.1001/jama.289.19.2503-b	http://dx.doi.org/10.1001/jama.289.19.2503-b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680KL	12759321				2022-12-28	WOS:000182976500018
J	Rathore, SS; Foody, JM; Wang, YF; Smith, GL; Herrin, J; Masoudi, FA; Wolfe, P; Havranek, EP; Ordin, DL; Krumholz, HM				Rathore, SS; Foody, JM; Wang, YF; Smith, GL; Herrin, J; Masoudi, FA; Wolfe, P; Havranek, EP; Ordin, DL; Krumholz, HM			Race, quality of care, and outcomes of elderly patients hospitalized with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PATIENTS GREATER-THAN-OR-EQUAL-TO-65 YEARS; ENZYME-INHIBITOR THERAPY; RACIAL-DIFFERENCES; UNITED-STATES; HEALTH-CARE; MEDICARE; READMISSION; MORTALITY; SURVIVAL	Context Black patients hospitalized with heart failure reportedly receive poorer quality of care and have worse outcomes than white patients. Because previous studies have been based on selected patient populations treated more than a decade ago, it is unclear if racial differences in quality of care and outcomes currently exist in the United States. Objective To evaluate differences in quality of care and patient outcomes between black and white Medicare beneficiaries hospitalized with heart failure. Design Retrospective analysis of medical record data systematically collected for the National Heart Failure Project. Setting and Patients Nationwide US sample of 29732 fee-for-service Medicare beneficiaries hospitalized with heart failure in 1998 and 1999. Main Outcome Measures Prescription of angiotensin-converting enzyme (ACE) inhibitors, measurement of left ventricular ejection fraction (LVEF), readmission within 1 year of discharge, and mortality within 30 days and 1 year of admission. Results Black patients and white patients had similar crude rates of LVEF assessment (67.8% black vs 66.6% white; P=.29). Among patients classified as ideal for ACE inhibitor use, black patients had higher crude rates of ACE inhibitor use than white patients (81.0% vs 73.8% white; P<.001) but had similar rates of ACE inhibitor or angiotensin receptor blocker (ARB) use (85.7% black vs 82.5% white; P=.08). After multivariable adjustment, black patients had comparable rates of LVEF assessment (risk ratio [RR], 0.99; 95% confidence interval [CI], 0.95-1.03). Black patients remained more likely to be prescribed ACE inhibitors (RR, 1.22; 95% CI, 1.14-1.28) than were white patients in an adjusted analysis, but there were no significant racial differences in the prescription of ACE inhibitors or ARBs (black vs white, RR, 1.03; 95% CI, 0.97-1.07). Black patients had higher rates of readmission within 1 year of discharge (68.2% vs 63.0%; P<.001) but had lower crude 30-day (6.3% vs 10.7%; P<.001) and 1-year (31.5% vs 40.1%; P<.001) mortality rates than white patients. After multivariable adjustment, black patients had a slightly higher rate of readmission than white patients (RR, 1.09; 95% CI, 1.06-1.13) but remained at lower risk of 30-day mortality (RR, 0.78; 95% CI, 0.68-0.91) and 1-year mortality (RR, 0.93; 95% CI, 0.88-0.98). Conclusions Black Medicare patients hospitalized with heart failure received comparable quality of care and had slightly higher rates of readmission but had lower mortality rates up to 1 year after hospitalization than did white patients.	Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA; Flying Buttress Associates, Charlottesville, VA USA; Denver Hlth Med Ctr, Dept Med, Div Cardiol, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Geriatr Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA; Colorado Fdn Med Care, Aurora, CO USA; Ctr Medicare & Medicaid Serv, Boston, MA USA	Yale University; Yale University; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Centers for Medicare & Medicaid Services	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, 333 Cedar St,Room I-456 SHM,POB 208025, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020; Masoudi, Frederick/Q-7467-2019	Smith, Grace/0000-0002-3171-2911	NIA NIH HHS [K08-AG01011] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG001011] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Afzal A, 1999, CLIN CARDIOL, V22, P791, DOI 10.1002/clc.4960221207; *AG HEALTHC RES QU, PROGR BRIEF EXC CTR; ALEXANDER M, 1995, JAMA-J AM MED ASSOC, V274, P1037, DOI 10.1001/jama.274.13.1037; Alexander M, 1999, AM HEART J, V137, P919, DOI 10.1016/S0002-8703(99)70417-5; *AM HEART ASS, 2001, 2002 HEART STROK STA; *AM HOSP ASS, 2000, CIRCULATION, V101, pE122; Ayanian JZ, 1999, MED CARE, V37, P1260, DOI 10.1097/00005650-199912000-00009; BOURASSA MG, 1993, J AM COLL CARDIOL, V22, pA14, DOI 10.1016/0735-1097(93)90456-B; Chin MH, 1997, AM J CARDIOL, V79, P1640, DOI 10.1016/S0002-9149(97)00214-2; Croft JB, 1999, ARCH INTERN MED, V159, P505, DOI 10.1001/archinte.159.5.505; Croft JB, 1997, J AM GERIATR SOC, V45, P270, DOI 10.1111/j.1532-5415.1997.tb00939.x; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; Dries DL, 2002, J AM COLL CARDIOL, V40, P311, DOI 10.1016/S0735-1097(02)01943-5; Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; Evangelista LS, 2002, J CARD FAIL, V8, P381, DOI 10.1054/jcaf.2002.129234; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GILLUM RF, 1993, AM HEART J, V126, P1042, DOI 10.1016/0002-8703(93)90738-U; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Gordon HS, 1996, JAMA-J AM MED ASSOC, V276, P1639, DOI 10.1001/jama.276.20.1639; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; *I MED, 2002, UN TREATM CONFR RAC; Ibrahim SA, 2003, J GERONTOL A-BIOL, V58, P56; Iglehart JK, 2001, NEW ENGL J MED, V345, P1920, DOI 10.1056/NEJM200112273452617; Jha AK, 2001, JAMA-J AM MED ASSOC, V285, P297, DOI 10.1001/jama.285.3.297; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; Kenward K, 1996, AM J PUBLIC HEALTH, V86, P1481, DOI 10.2105/AJPH.86.10.1481; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Luthi JC, 2002, INT J QUAL HEALTH C, V14, P15, DOI 10.1093/intqhc/14.1.15; Masoudi F A, 2000, Congest Heart Fail, V6, P337, DOI 10.1111/j.1527-5299.2000.80175.x; McCullough PA, 2002, J AM COLL CARDIOL, V39, P60, DOI 10.1016/S0735-1097(01)01700-4; OCONNELL JB, 1994, J HEART LUNG TRANSPL, V13, pS107; Philbin EF, 1998, AM J CARDIOL, V82, P76, DOI 10.1016/S0002-9149(98)00233-1; Philbin EF, 2001, AM J CARDIOL, V87, P1367, DOI 10.1016/S0002-9149(01)01554-5; *PRACT MAN INF COR, 1998, INT CLASS DIS 9 REV; Rathore SS, 2003, J AM COLL CARDIOL, V41, p518A; Stafford RS, 1997, ARCH INTERN MED, V157, P2460, DOI 10.1001/archinte.157.21.2460; Sueta CA, 2000, AM J CARDIOL, V86, P1151, DOI 10.1016/S0002-9149(00)01180-2; Sueta CA, 2003, AM J CARDIOL, V91, P363, DOI 10.1016/S0002-9149(02)03173-9; Vaccarino V, 1999, AM HEART J, V138, P835, DOI 10.1016/S0002-8703(99)70007-4; Vaccarino V, 2002, AM HEART J, V143, P1058, DOI 10.1067/mhj.2002.122123; Ventura HO, 2001, J AM COLL CARDIOL, V37, p209A; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; Wolinsky FD, 1997, MED CARE, V35, P1031, DOI 10.1097/00005650-199710000-00005; Yancy CW, 2001, NEW ENGL J MED, V344, P1358, DOI 10.1056/NEJM200105033441803; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	49	184	185	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2003	289	19					2517	2524		10.1001/jama.289.19.2517	http://dx.doi.org/10.1001/jama.289.19.2517			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680KL	12759323	Bronze			2022-12-28	WOS:000182976500020
J	Barbour, V				Barbour, V			UK Blobank: a project in search of a protocol?	LANCET			English	Article								Before it has even begun recruiting participants, the UK Biobank project has raised extraordinary passions among scientists. Some scientists are broadly supportive of the project, and feel that it is a scientifically valid, potentially valuable resource, although they still have reservations over the details of the current protocol. Others see it as, an ill-conceived, politically motivated project, in which consultations have only been done to give an appearance of legitimacy and in which the scientific case has not been made for its design. There has been resentment over how the protocol has evolved, and the secrecy and legal constraints that surrounded the process for groups bidding to be involved has had the appearance of attempting to stifle debate. For this article even supporters of the project have been unwilling to be quoted on the record. The only point that everyone seems to agree on is that sufficient debate about the project has not taken place.	Lancet, London NW1 7BY, England		Barbour, V (corresponding author), Lancet, 32 Jamestown Rd, London NW1 7BY, England.			Barbour, Virginia/0000-0002-2358-2440					0	64	65	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 17	2003	361	9370					1734	1738		10.1016/S0140-6736(03)13377-6	http://dx.doi.org/10.1016/S0140-6736(03)13377-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767753				2022-12-28	WOS:000182919700027
J	Jarvis, MJ; Wardle, J; Waller, J; Owen, L				Jarvis, MJ; Wardle, J; Waller, J; Owen, L			Prevalence of hardcore smoking in England, and associated attitudes and beliefs: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKERS	Objective To quantify the prevalence and characteristics of hardcore smokers in England. Design Cross sectional survey. Setting Interview in respondents' household. Participants 7766 adult cigarette smokers. Main outcome measures Hardcore smoking defined by four criteria (less than a day without cigarettes in the past five years; no attempt to quit in the past year; no desire to quit; no intention to quit), all of which had to be satisfied. Results Some 16% of all smokers were categorised as hardcore. Hardcore smoking was associated with nicotine dependence, socioeconomic deprivation, and age, rising front 5% in young adults aged 16-24 to 30% in those aged greater than or equal to 65 years. Hardcore smokers displayed distinctive attitudes towards and beliefs about smoking. In particular they were likely to deny that smoking affected their health or would do so in the future. prevalence of hardcore smoking was almost four times higher than in California. Conclusion Hardcore smoking presents a serious challenge to public health efforts to reduce the prevalence of smoking, but the proportion of hardcore smokers does not necessarily increase as overall prevalence in a population declines. More hardcore smokers could be persuaded to quit, but this will require interventions that are targeted to the particular needs and perceptions of both socially disadvantaged mid older smokers.	UCL, Canc Res UK Hlth Behav Unit, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; Hlth Dev Agcy, Smoking, London SW1 2HW, England	University of London; University College London	Jarvis, MJ (corresponding author), UCL, Canc Res UK Hlth Behav Unit, Dept Epidemiol & Publ Hlth, Torrington Pl, London WC1E 6BT, England.	martin.jarvis@ucl.ac.uk	Jarvis, Martin J/B-1034-2008; Waller, Jo/C-1705-2008	Jarvis, Martin J/0000-0001-9238-8038; Waller, Jo/0000-0003-4025-9132				Bolen J C, 2000, MMWR CDC Surveill Summ, V49, P1; Elder JP, 1996, PUBLIC HEALTH REP, V111, P353; Emery S, 2000, AM J PUBLIC HEALTH, V90, P387, DOI 10.2105/AJPH.90.3.387; HUGHES JR, IN PRESS SMOKING TOB, V15; Jarvis MJ, 1997, PROG RESPIR RES, V28, P151; JARVIS MJ, 1999, SOCIAL DETERMINANTS, P240; KVIZ FJ, 1994, PREV MED, V23, P211, DOI 10.1006/pmed.1994.1029; *NAT CANC I, IN PRESS SMOK TOB CO, V15; ORLEANS CT, 1994, CANCER-AM CANCER SOC, V74, P2055, DOI 10.1002/1097-0142(19941001)74:7+<2055::AID-CNCR2820741712>3.0.CO;2-Q; Siegel M, 2000, AM J PUBLIC HEALTH, V90, P372, DOI 10.2105/AJPH.90.3.372; Taylor DH, 2002, AM J PUBLIC HEALTH, V92, P990, DOI 10.2105/AJPH.92.6.990; Thomas M, 1998, LIVING BRITAIN RESUL; TURTLE J, 1998, 1153266 BMRB INT; Warner KE, 2003, NICOTINE TOB RES, V5, P37, DOI 10.1080/1462220021000060428	14	105	106	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	2003	326	7398					1061	1063		10.1136/bmj.326.7398.1061	http://dx.doi.org/10.1136/bmj.326.7398.1061			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681ZD	12750206	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000183064700014
J	Lyketsos, CG				Lyketsos, CG			Should pregnant women avoid eating fish? Lessons from the Seychelles	LANCET			English	Editorial Material							METHYLMERCURY; EXPOSURE; MERCURY; BRAIN		Johns Hopkins Univ Hosp, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Lyketsos, CG (corresponding author), Johns Hopkins Univ Hosp, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21287 USA.							CHOI BH, 1978, J NEUROPATH EXP NEUR, V37, P719, DOI 10.1097/00005072-197811000-00001; Crump KS, 1998, RISK ANAL, V18, P701, DOI 10.1023/B:RIAN.0000005917.52151.e6; El-Demerdash FM, 2001, J ENVIRON SCI HEAL B, V36, P489, DOI 10.1081/PFC-100104191; Grandjean P, 2003, AMBUL PEDIATR, V3, P18, DOI 10.1367/1539-4409(2003)003<0018:NRCBSA>2.0.CO;2; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; IPCS, 1990, ENV HLTH CRIT 101 ME; Kazantzis G, 2002, Med Lav, V93, P139; MOSCHEN, 2001, DENT RES, V80, P1753; Stein J, 2002, J DEV BEHAV PEDIATR, V23, pS13, DOI 10.1097/00004703-200202001-00004	9	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 17	2003	361	9370					1667	1668		10.1016/S0140-6736(03)13379-X	http://dx.doi.org/10.1016/S0140-6736(03)13379-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767728				2022-12-28	WOS:000182919700003
J	Ward, MD				Ward, MD			Molecular fuel tanks	SCIENCE			English	Editorial Material							INELASTIC NEUTRON-SCATTERING; CARBON NANOTUBES; HYDROGEN; STORAGE; DESIGN; FRAMEWORKS; SORPTION		Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ward, MD (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.							Cheng H, 2001, J AM CHEM SOC, V123, P5845, DOI 10.1021/ja0155231; Dagani R, 2002, CHEM ENG NEWS, V80, P25, DOI 10.1021/cen-v080n002.p025; Eckert J, 1996, J PHYS CHEM-US, V100, P10646, DOI 10.1021/jp952982d; Eddaoudi M, 2000, J AM CHEM SOC, V122, P1391, DOI 10.1021/ja9933386; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; Forster PM, 2003, J AM CHEM SOC, V125, P1309, DOI 10.1021/ja028341v; Hollingsworth MD, 2002, SCIENCE, V295, P2410; Holman KT, 2001, SCIENCE, V294, P1907, DOI 10.1126/science.1064432; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; Mojet BL, 2001, J AM CHEM SOC, V123, P8147, DOI 10.1021/ja016078c; NICOL JM, 1988, J PHYS CHEM-US, V92, P7117, DOI 10.1021/j100336a017; Pradhan BK, 2002, J MATER RES, V17, P2209, DOI 10.1557/JMR.2002.0326; Rosi NL, 2003, SCIENCE, V300, P1127, DOI 10.1126/science.1083440; Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634	14	68	72	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1104	1105		10.1126/science.1084940	http://dx.doi.org/10.1126/science.1084940			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750508				2022-12-28	WOS:000182886500031
J	Fleming, CM; Shepard, JAO; Mark, EJ; Scully, RE; Wright, CD				Fleming, CM; Shepard, JAO; Mark, EJ; Scully, RE; Wright, CD			Case 15-2003: A 47-year-old man with waxing and waning pulmonary nodules five years after treatment for testicular seminoma - Bronchiolitis obliterans with organizing pneumonia due to gastroesophageal reflux and occult aspiration	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIGH-RESOLUTION CT; LANGERHANS-CELL HISTIOCYTOSIS; HALO SIGN; LUNG; GRANULOMATOSIS; SARCOIDOSIS; FEATURES; RECIPIENTS; METASTASES; DISEASE		Massachusetts Gen Hosp, Div Pulm Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Thorac Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Fleming, CM (corresponding author), Massachusetts Gen Hosp, Div Pulm Med, Boston, MA 02114 USA.							ABERNATHY EC, 1991, HUM PATHOL, V22, P1102, DOI 10.1016/0046-8177(91)90262-N; Akira M, 2002, RADIOL CLIN N AM, V40, P43, DOI 10.1016/S0033-8389(03)00108-8; Akira M, 1998, AM J ROENTGENOL, V170, P291, DOI 10.2214/ajr.170.2.9456931; BEISTER RJ, 1987, J UROLOGY, V137, P749; BLACHER EJ, 1985, UROLOGY, V26, P288, DOI 10.1016/0090-4295(85)90128-1; Blanke CD, 1997, SOUTHERN MED J, V90, P653, DOI 10.1097/00007611-199706000-00016; BOUCHARDY LM, 1993, J COMPUT ASSIST TOMO, V17, P352, DOI 10.1097/00004728-199305000-00002; Choi YH, 2000, CHEST, V117, P117, DOI 10.1378/chest.117.1.117; COLEBUNDERS R, 1983, AM J ROENTGENOL, V140, P831, DOI 10.2214/ajr.140.4.831-a; CROME L, 1962, J CLIN PATHOL, V15, P21, DOI 10.1136/jcp.15.1.21; Dearnaley DP, 2001, BMJ-BRIT MED J, V322, P1583, DOI 10.1136/bmj.322.7302.1583; ELLIOTT CG, 1989, CHEST, V96, P672, DOI 10.1378/chest.96.3.672; Epler GR, 2001, ARCH INTERN MED, V161, P158, DOI 10.1001/archinte.161.2.158; Hunninghake GW, 1999, SARCOIDOSIS VASC DIF, V16, P149; Kim Y, 1999, J COMPUT ASSIST TOMO, V23, P622, DOI 10.1097/00004728-199907000-00025; KUHLMAN JE, 1991, J COMPUT ASSIST TOMO, V15, P948, DOI 10.1097/00004728-199111000-00008; Langford CA, 1999, THORAX, V54, P629, DOI 10.1136/thx.54.7.629; Lee JS, 2000, AM J ROENTGENOL, V175, P1335, DOI 10.2214/ajr.175.5.1751335; Lohr RH, 1997, ARCH INTERN MED, V157, P1323, DOI 10.1001/archinte.157.12.1323; Lynch DA, 2001, RADIOL CLIN N AM, V39, P1153, DOI 10.1016/S0033-8389(05)70336-5; Matsuse T, 1996, CHEST, V110, P1289, DOI 10.1378/chest.110.5.1289; MAYS EE, 1976, CHEST, V69, P512, DOI 10.1378/chest.69.4.512; MORAN TJ, 1955, ARCH PATHOL, V60, P122; OLLIFF JFC, 1990, CLIN RADIOL, V41, P395, DOI 10.1016/S0009-9260(05)80599-9; PRIMACK SL, 1994, RADIOLOGY, V190, P513, DOI 10.1148/radiology.190.2.8284408; Rayson D, 1998, CANCER, V83, P337, DOI 10.1002/(SICI)1097-0142(19980715)83:2<337::AID-CNCR18>3.0.CO;2-U; REID KR, 1990, LANCET, V336, P206, DOI 10.1016/0140-6736(90)91734-R; SADOUN D, 1988, PRESSE MED, V17, P2383; STROHMEYER T, 1992, UROLOGY, V39, P515, DOI 10.1016/0090-4295(92)90005-H; Tazi A, 2000, THORAX, V55, P405, DOI 10.1136/thorax.55.5.405; Travis LB, 1997, JNCI-J NATL CANCER I, V89, P1429, DOI 10.1093/jnci/89.19.1429; Vassallo R, 2000, NEW ENGL J MED, V342, P1969, DOI 10.1056/NEJM200006293422607; VIDYARTHI SC, 1967, ARCH PATHOL, V83, P215; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; Watanabe K, 1998, CHEST, V114, P1599, DOI 10.1378/chest.114.6.1599	35	14	16	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					2019	2027		10.1056/NEJMcpc030010	http://dx.doi.org/10.1056/NEJMcpc030010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12748318				2022-12-28	WOS:000182823400011
J	Flamm, SL				Flamm, SL			Chronic hepatitis C virus infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLUS RIBAVIRIN; RISK-FACTORS; THERAPY; INTERFERON-ALPHA-2B; TRANSMISSION; COMBINATION; MULTICENTER; PROGRESSION; ADHERENCE; CIRRHOSIS		Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Flamm, SL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, 675 N St Clair,Galter Pavil,Suite 15-250, Chicago, IL 60611 USA.	s-flamm@northwestern.edu						Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117; Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Colin C, 2001, J VIRAL HEPATITIS, V8, P87, DOI 10.1046/j.1365-2893.2001.00280.x; Davis GL, 2002, HEPATOLOGY, V36, pS145, DOI 10.1053/jhep.2002.36798; Feldman JG, 2000, SEX TRANSM DIS, V27, P338, DOI 10.1097/00007435-200007000-00007; Flamm SL, 1998, AM J GASTROENTEROL, V93, P597, DOI 10.1111/j.1572-0241.1998.171_b.x; Flamm SL, 2002, HEPATOLOGY, V36, p311A; Freeman AJ, 2001, HEPATOLOGY, V34, P809, DOI 10.1053/jhep.2001.27831; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Hadziyannis SJ, 2002, J HEPATOL, V36, P3, DOI 10.1016/S0168-8278(02)80001-0; Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; Hourigan LF, 1999, HEPATOLOGY, V29, P1215, DOI 10.1002/hep.510290401; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; MCCORMICK SE, 1995, AM J GASTROENTEROL, V90, P1250; McHutchison JG, 2002, HEPATOLOGY, V36, pS245, DOI 10.1053/jhep.2002.36795; McHutchison JG, 2002, GASTROENTEROLOGY, V123, P1061, DOI 10.1053/gast.2002.35950; McHutchison JG, 2001, HEPATOLOGY, V34, p244A; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; OSMOND DH, 1993, J INFECT DIS, V167, P66, DOI 10.1093/infdis/167.1.66; Ostapowicz G, 1998, HEPATOLOGY, V27, P1730, DOI 10.1002/hep.510270637; Terrault NA, 2002, HEPATOLOGY, V36, pS99, DOI 10.1053/jhep.2002.36797; THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Wasserman R, 2000, HEPATOLOGY, V32, p368A; WILLIAMS I, 1999, AM J MED S, V107, P2, DOI DOI 10.1016/S0002-9343(99)00373-3; Yeung LTF, 2001, HEPATOLOGY, V34, P223, DOI 10.1053/jhep.2001.25885; Zeuzem S, 1996, HEPATOLOGY, V24, P1003	33	88	105	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2413	2417		10.1001/jama.289.18.2413	http://dx.doi.org/10.1001/jama.289.18.2413			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677WF	12746366				2022-12-28	WOS:000182831200032
J	Finney, LA; O'Halloran, TV				Finney, LA; O'Halloran, TV			Transition metal speciation in the cell: Insights from the chemistry of metal ion receptors	SCIENCE			English	Review							P-TYPE ATPASE; COPPER-TRANSPORTING ATPASE; CYTOCHROME-C MATURATION; UREASE ACTIVE-SITE; ESCHERICHIA-COLI; TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; CRYSTAL-STRUCTURE; MENKES-DISEASE	The essential transition metal ions are avidly accumulated by cells, yet they have two faces: They are put to use as required cofactors, but they also can catalyze cytotoxic reactions. Several families of proteins are emerging that control the activity of intracellular metal ions and help con. ne them to vital roles. These include integral transmembrane transporters, metalloregulatory sensors, and diffusible cytoplasmic metallochaperone proteins that protect and guide metal ions to targets. It is becoming clear that many of these proteins use atypical coordination chemistry to accomplish their unique goals. The different coordination numbers, types of coordinating residues, and solvent accessibilities of these sites are providing insight into the inorganic chemistry of the cytoplasm.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.		O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NIGMS NIH HHS [R01 GM038784] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483; Arnesano F, 2003, P NATL ACAD SCI USA, V100, P3814, DOI 10.1073/pnas.0636904100; Arnesano F, 2002, BIOCHEMISTRY-US, V41, P13587, DOI 10.1021/bi026362w; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Banci L, 2003, BIOCHEMISTRY-US, V42, P1939, DOI 10.1021/bi027096p; Banci L, 2002, J MOL BIOL, V323, P883, DOI 10.1016/S0022-2836(02)01007-0; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Bertini I, 2003, P NATL ACAD SCI USA, V100, P3601, DOI 10.1073/pnas.0736657100; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Cave JS, 2002, J BIOL CHEM, V277, P38441, DOI 10.1074/jbc.M207677200; CAVET JS, IN PRESS FEMS MICROB; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Chivers PT, 2002, CHEM BIOL, V9, P1141, DOI 10.1016/S1074-5521(02)00241-7; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Ciurli S, 2002, J BIOL INORG CHEM, V7, P623, DOI 10.1007/s00775-002-0341-7; Cobine PA, 2002, J INORG BIOCHEM, V88, P192, DOI 10.1016/S0162-0134(01)00378-6; Cobine PA, 2002, BIOCHEMISTRY-US, V41, P5822, DOI 10.1021/bi025515c; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; El Meskini R, 2003, J BIOL CHEM, V278, P12278, DOI 10.1074/jbc.M211413200; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Helmann JD, 2002, CHEM BIOL, V9, P1055, DOI 10.1016/S1074-5521(02)00251-X; Hitomi Y, 2001, J AM CHEM SOC, V123, P8614, DOI 10.1021/ja016146v; Hou ZJ, 2001, J BIOL CHEM, V276, P40858, DOI 10.1074/jbc.M107455200; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2002, BIOCHEMISTRY-US, V41, P10046, DOI 10.1021/bi0259960; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lee SM, 2002, BIOCHEM BIOPH RES CO, V295, P616, DOI 10.1016/S0006-291X(02)00726-X; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; McMahon RJ, 1998, J NUTR, V128, P667, DOI 10.1093/jn/128.4.667; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Outten FW, 2001, J BIOL CHEM, V276, P30670, DOI 10.1074/jbc.M104122200; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; Peariso K, 2003, J AM CHEM SOC, V125, P342, DOI 10.1021/ja028935y; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, STRUCTURE, V10, P1292, DOI 10.1016/S0969-2126(02)00863-8; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Remaut H, 2001, J BIOL CHEM, V276, P49365, DOI 10.1074/jbc.M108304200; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Roberts SA, 2002, P NATL ACAD SCI USA, V99, P2766, DOI 10.1073/pnas.052710499; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Schulz H, 2000, J BACTERIOL, V182, P6831, DOI 10.1128/JB.182.23.6831-6833.2000; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Song HK, 2001, J BIOL CHEM, V276, P49359, DOI 10.1074/jbc.M108619200; Stoyanov JV, 2001, MOL MICROBIOL, V39, P502, DOI 10.1046/j.1365-2958.2001.02264.x; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; Wernimont AK, 2003, J BIOL INORG CHEM, V8, P185, DOI 10.1007/s00775-002-0404-9; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; WINGE DR, IN PRESS; Xiao ZG, 2002, CHEM COMMUN, P588, DOI 10.1039/b111180a	76	887	912	6	242	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					931	936		10.1126/science.1085049	http://dx.doi.org/10.1126/science.1085049			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738850				2022-12-28	WOS:000182719800042
J	Cordenonsi, M; Dupont, S; Maretto, S; Insinga, A; Imbriano, C; Piccolo, S				Cordenonsi, M; Dupont, S; Maretto, S; Insinga, A; Imbriano, C; Piccolo, S			Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads	CELL			English	Article							GROWTH-FACTOR-BETA; P63; EXPRESSION; BINDING; PROTEIN; P73; DIFFERENTIATION; MECHANISM; INDUCER; FORMS	The p53 tumor suppressor belongs to a family of proteins that sense multiple cellular inputs to regulate Cell proliferation, apoptosis, and differentiation. Whether and how these functions of p53 intersect with the activity of extracellular growth factors is not understood. Here, we report that key cellular responses to TGF-beta signals rely on p53 family members. During Xenopus embryonic development, p53 promotes the activation of multiple TGF-beta target genes. Moreover, mesoderm differentiation is inhibited in p53-depleted embryos. In mammalian cells, the full transcriptional activation of the CDK inhibitor p21(WAF1) by TGF-beta requires p53. p53-deficient cells display an impaired cytostatic response to TGF-beta signals. Smad and p53 protein complexes converge on separate cis binding elements on a target promoter and synergistically activate TGF-beta induced transcription. p53 can physically interact in vivo with Smad2 in a TGF-beta-dependent fashion. The results unveil a previously unrecognized link between two primary tumor suppressor pathways in vertebrates.	Univ Padua, Dept Histol Microbiol & Med Biotechnol, Sect Histol & Embryol, I-35121 Padua, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Modena & Reggio Emilia, Dept Biol, I-41100 Modena, Italy	University of Padua; IRCCS European Institute of Oncology (IEO); Universita di Modena e Reggio Emilia	Piccolo, S (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Sect Histol & Embryol, Viale Colombo 3, I-35121 Padua, Italy.	piccolo@civ.bio.unipd.it	Cordenonsi, Michelangelo/K-7692-2016; Imbriano, Carol/C-9376-2015; Imbriano, Carol/ABD-8204-2021; Dupont, Sirio/AAP-8133-2021; Insinga, Alessandra/AAR-9551-2020	Cordenonsi, Michelangelo/0000-0002-8253-5724; Imbriano, Carol/0000-0003-2864-4820; Imbriano, Carol/0000-0003-2864-4820; Insinga, Alessandra/0000-0002-6060-8339; Dupont, Sirio/0000-0002-6869-1966; PICCOLO, STEFANO/0000-0002-2037-0004	Telethon [E.0815] Funding Source: Medline	Telethon(Fondazione Telethon)		Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COX LS, 1994, ONCOGENE, V9, P2951; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fortunel NO, 2000, BLOOD, V96, P2022; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liu B, 2003, BLOOD, V101, P124, DOI 10.1182/blood-2002-02-0398; Lu PF, 2001, MECH DEVELOP, V102, P275, DOI 10.1016/S0925-4773(01)00315-X; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sun BI, 1999, DEVELOPMENT, V126, P1467; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127	32	317	328	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					301	314		10.1016/S0092-8674(03)00308-8	http://dx.doi.org/10.1016/S0092-8674(03)00308-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732139	Bronze, Green Published			2022-12-28	WOS:000182640800006
J	Meyer, AS; Gillespie, JR; Walther, D; Millet, IS; Doniach, S; Frydman, J				Meyer, AS; Gillespie, JR; Walther, D; Millet, IS; Doniach, S; Frydman, J			Closing the folding chamber of the eukaryotic chaperonin requires the transition state of ATP hydrolysis	CELL			English	Article							GROUP-II CHAPERONIN; CYTOPLASMIC CHAPERONIN; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; IN-VIVO; PROTEIN; BINDING; THERMOSOME; GROEL; RECONSTRUCTION	Chaperonins use ATPase cycling to promote conformational changes leading to protein folding. The prokaryotic chaperonin GroEL requires a cofactor, GroES, which serves as a "lid" enclosing substrates in the central cavity and confers an asymmetry on GroEL required for cooperative transitions driving the reaction. The eukaryotic chaperonin TRiC/CCT does not have such a cofactor but appears to have a "built-in" lid. Whether this seemingly symmetric chaperonin also operates through an asymmetric cycle is unclear. We show that unlike GroEL, TRiC does not close its lid upon nucleotide binding, but instead responds to the trigonal-bipyramidal transition state of ATP hydrolysis. Further, nucleotide analogs inducing this transition state confer an asymmetric conformation on TRiC. Similar to GroEL, lid closure in TRiC confines the substrates in the cavity and is essential for folding. Understanding the distinct mechanisms governing eukaryotic and bacterial chaperonin function may reveal how TRiC has evolved to fold specific eukaryotic proteins.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Incyte Genom Inc, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University; Incyte	Frydman, J (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	jfrydman@stanford.edu	Gillespie, Joel/GXW-0158-2022	Walther, Dirk/0000-0002-5755-9265; , judith/0000-0003-2302-6943; Meyer, Anne S./0000-0002-4164-0122; Gillespie, Joel/0000-0002-5075-1609	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056433, R37GM056433] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56433] Funding Source: Medline; NINR NIH HHS [NRSA 10965] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Bada M, 2000, J MOL BIOL, V300, P563, DOI 10.1006/jmbi.2000.3854; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Doniach S, 2001, CHEM REV, V101, P1763, DOI 10.1021/cr990071k; Ferreyra RG, 2000, METH MOL B, V140, P153; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Guinier A., 1955, SMALL ANGLE SCATTERI; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Gutsche I, 2001, J STRUCT BIOL, V135, P139, DOI 10.1006/jsbi.2001.4373; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; Horst M, 1996, PROTEIN SCI, V5, P759; Horwich AL, 1998, NAT STRUCT BIOL, V5, P333, DOI 10.1038/nsb0598-333; Kafri G, 2001, PROTEIN SCI, V10, P445, DOI 10.1110/ps.44401; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; Leroux MR, 2000, CURR BIOL, V10, pR260, DOI 10.1016/S0960-9822(00)00432-2; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; Nitsch M, 1998, NAT STRUCT BIOL, V5, P855, DOI 10.1038/2296; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PENNINGROTH SM, 1980, J BIOL CHEM, V255, P9545; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Szpikowska BK, 1998, PROTEIN SCI, V7, P1524, DOI 10.1002/pro.5560070705; Walther D, 2000, J APPL CRYSTALLOGR, V33, P350, DOI 10.1107/S0021889899015976; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1	39	142	146	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	2003	113	3					369	381		10.1016/S0092-8674(03)00307-6	http://dx.doi.org/10.1016/S0092-8674(03)00307-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	674MP	12732144	Bronze			2022-12-28	WOS:000182640800011
J	Rogers, G; Dragert, H				Rogers, G; Dragert, H			Episodic tremor and slip on the Cascadia subduction zone: The chatter of silent slip	SCIENCE			English	Article								We found that repeated slow slip events observed on the deeper interface of the northern Cascadia subduction zone, which were at first thought to be silent, have unique nonearthquake seismic signatures. Tremorlike seismic signals were found to correlate temporally and spatially with slip events identified from crustal motion data spanning the past 6 years. During the period between slips, tremor activity is minor or nonexistent. We call this associated tremor and slip phenomenon episodic tremor and slip (ETS) and propose that ETS activity can be used as a real-time indicator of stress loading of the Cascadia megathrust earthquake zone.	Geol Survey Canada, Pacific Geosci Ctr, Sidney, BC V8L 4B2, Canada	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Rogers, G (corresponding author), Geol Survey Canada, Pacific Geosci Ctr, 9860 W Saanich Rd, Sidney, BC V8L 4B2, Canada.							ATWATER BF, 1996, EARTHQ SPECTRA, V11, P1; DRAGERT H, 1994, J GEOPHYS RES-SOL EA, V99, P653, DOI 10.1029/93JB02516; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; Katsumata A, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL015981; LINDE AT, 1989, GEOPHYS RES LETT, V16, P1305, DOI 10.1029/GL016i011p01305; Miller MM, 2002, SCIENCE, V295, P2423, DOI 10.1126/science.1071193; Obara K, 2002, SCIENCE, V296, P1679, DOI 10.1126/science.1070378; PEACOCK SM, 1990, SCIENCE, V248, P329, DOI 10.1126/science.248.4953.329; Satake K, 1996, NATURE, V379, P246, DOI 10.1038/379246a0; THATCHER W, 1982, NATURE, V299, P12, DOI 10.1038/299012a0	10	855	881	3	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1942	1943		10.1126/science.1084783	http://dx.doi.org/10.1126/science.1084783			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12738870				2022-12-28	WOS:000183619400045
J	Peile, E				Peile, E			A 42 year old man with acute chest pain: case outcome - Commentary: More to be learnt from the discussion than the diagnosis	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Oxford, Dept Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford	Peile, E (corresponding author), Univ Oxford, Dept Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England.							MARINKER M, 1992, GEN PRACTITIONER ED, P75; 2003, BMJ	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1136	1136		10.1136/bmj.326.7399.1136	http://dx.doi.org/10.1136/bmj.326.7399.1136			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763993	Green Published			2022-12-28	WOS:000183245000030
J	Crackower, MA; Kolas, NK; Noguchi, J; Sarao, R; Kikuchi, K; Kaneko, H; Kobayashi, E; Kawai, Y; Kozieradzki, I; Landers, R; Mo, R; Hui, CC; Nieves, E; Cohen, PE; Osborne, LR; Wada, T; Kunieda, T; Moens, PB; Penninger, JM				Crackower, MA; Kolas, NK; Noguchi, J; Sarao, R; Kikuchi, K; Kaneko, H; Kobayashi, E; Kawai, Y; Kozieradzki, I; Landers, R; Mo, R; Hui, CC; Nieves, E; Cohen, PE; Osborne, LR; Wada, T; Kunieda, T; Moens, PB; Penninger, JM			Essential role of Fkbp6 in male fertility and homologous chromosome pairing in meiosis	SCIENCE			English	Article							SYNAPTONEMAL COMPLEX; MEIOTIC PROPHASE; GENE; RAT; SYNAPSIS; SPERMATOCYTES; RECOMBINATION; MOUSE; AS/AS	Meiosis is a critical stage of gametogenesis in which alignment and synapsis of chromosomal pairs occur, allowing for the recombination of maternal and paternal genomes. Here we show that FK506 binding protein (Fkbp6) localizes to meiotic chromosome cores and regions of homologous chromosome synapsis. Targeted inactivation of Fkbp6 in mice results in aspermic males and the absence of normal pachytene spermatocytes. Moreover, we identified the deletion of Fkbp6 exon 8 as the causative mutation in spontaneously male sterile as/as mutant rats. Loss of Fkbp6 results in abnormal pairing and misalignments between homologous chromosomes, nonhomologous partner switches, and autosynapsis of X chromosome cores in meiotic spermatocytes. Fertility and meiosis are normal in Fkbp6 mutant females. Thus, Fkbp6 is a component of the synaptonemal complex essential for sex-specific fertility and for the fidelity of homologous chromosome pairing in meiosis.	Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria; Albert Einstein Coll Med, AECOM, Dept Biochem, Lab Macromol Anal & Proteom, Bronx, NY 10461 USA; Natl Inst Agrobiol Sci, Germ Cell Conservat Lab, Tsukuba, Ibaraki 3058602, Japan; Natl Lifestock Breeding Ctr, Fukushima 961851, Japan; Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7000082, Japan; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; York Univ, Dept Biol, N York, ON M3J 1P3, Canada	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Yeshiva University; Albert Einstein College of Medicine; National Institute of Agrobiological Sciences - Japan; Okayama University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; York University - Canada	Penninger, JM (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, IMBA, Dr Bohrgasse 7, A-1030 Vienna, Austria.	josef.penninger@oeaw.ac.at	Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777	Canadian Institutes of Health Research [38103] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		ATAGI Y, 1993, J VET MED SCI, V55, P301, DOI 10.1292/jvms.55.301; Bayes M, 2001, MOL REPROD DEV, V60, P414, DOI 10.1002/mrd.1104; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; Dix DJ, 1997, DEVELOPMENT, V124, P4595; DRESSER ME, 1980, CHROMOSOMA, V76, P1, DOI 10.1007/BF00292222; FAWCETT DW, 1956, J BIOPHYS BIOCHEM CY, V2, P403, DOI 10.1083/jcb.2.4.403; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; IKADAI H, 1992, J VET MED SCI, V54, P745, DOI 10.1292/jvms.54.745; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; Matzuk MM, 2002, NAT CELL BIOL, V4, pS41; Meng X, 1998, GENOMICS, V52, P130, DOI 10.1006/geno.1998.5412; Moens PB, 2002, J CELL SCI, V115, P1611; MOSES MJ, 1956, J BIOPHYS BIOCHEM CY, V2, P215, DOI 10.1083/jcb.2.2.215; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Noguchi J, 1999, MAMM GENOME, V10, P189, DOI 10.1007/s003359900967; Odorisio T, 1998, NAT GENET, V18, P257, DOI 10.1038/ng0398-257; Osborne LR, 1999, MOL GENET METAB, V67, P1, DOI 10.1006/mgme.1999.2844; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; Yuan L, 2002, SCIENCE, V296, P1115, DOI 10.1126/science.1070594; Yuan L, 2000, MOL CELL, V5, P73, DOI 10.1016/S1097-2765(00)80404-9; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	23	152	169	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1291	1295		10.1126/science.1083022	http://dx.doi.org/10.1126/science.1083022			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764197	Green Accepted			2022-12-28	WOS:000183042400049
J	Kim, JM; Wu, H; Green, G; Winkler, CA; Kopp, JB; Miner, JH; Unanue, ER; Shaw, AS				Kim, JM; Wu, H; Green, G; Winkler, CA; Kopp, JB; Miner, JH; Unanue, ER; Shaw, AS			CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility	SCIENCE			English	Article							NEPHROTIC SYNDROME; DOWN-REGULATION; COMPLEX; MEMBRANE	Loss of CD2-associated protein (CD2AP), a component of the filtration complex in the kidney, causes death in mice at 6 weeks of age. Mice with CD2AP haploin-sufficiency developed glomerular changes at 9 months of age and had increased susceptibility to glomerular injury by nephrotoxic antibodies or immune complexes. Electron microscopic analysis of podocytes revealed defects in the formation of multivesicular bodies, suggesting an impairment of the intracellular degradation pathway. Two human patients with focal segmental glomerulosclerosis had a mutation predicted to ablate expression of one CD2AP allele, implicating CD2AP as a determinant of human susceptibility to glomerular disease.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Renal, St Louis, MO 63110 USA; NCI, Mol Epidemiol Sect, Lab Genom Divers, NIH, Frederick, MD 21702 USA; NIDDKD, Kidney Dis Sect, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shaw, AS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	shaw@pathology.wustl.edu	Kopp, Jeffrey B/O-2681-2015	Kopp, Jeffrey B/0000-0001-9052-186X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043308, ZIADK043308] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERS CE, 1993, AM J KIDNEY DIS, V22, P448, DOI 10.1016/S0272-6386(12)70151-8; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; KANWAR YS, 1981, RENAL PHYSIOL BIOCH, V4, P121; Kaplan J, 2001, CURR OPIN NEPHROL HY, V10, P183, DOI 10.1097/00041552-200103000-00005; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; KELLEY VE, 1972, LAB INVEST, V27, P149; KERJASCHKI D, 1989, J IMMUNOL, V143, P546; Kerjaschki D, 1997, J CLIN INVEST, V100, P2303, DOI 10.1172/JCI119768; KIM J, UNPUB; KORBET SM, 1985, MEDICINE, V64, P228, DOI 10.1097/00005792-198507000-00004; Kriz W, 2002, MICROSC RES TECHNIQ, V57, P189, DOI 10.1002/jemt.10072; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; RENNKE HG, 1975, J CELL BIOL, V67, P638, DOI 10.1083/jcb.67.3.638; ROSENMANN E, 1977, NEPHRON, V18, P301, DOI 10.1159/000180846; SEILER MW, 1975, SCIENCE, V189, P390, DOI 10.1126/science.1145209; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tucker JK, 2002, AM J MED SCI, V323, P90, DOI 10.1097/00000441-200202000-00006; XIAO W, 2001, HUM MUTAT, V17, P349; Yo Y, 2003, NEPHRON EXP NEPHROL, V93, P92, DOI 10.1159/000069551	23	364	410	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1298	1300		10.1126/science.1081068	http://dx.doi.org/10.1126/science.1081068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764198				2022-12-28	WOS:000183042400051
J	Nomura, K; Ohta, H; Ueda, K; Kamiya, T; Hirano, M; Hosono, H				Nomura, K; Ohta, H; Ueda, K; Kamiya, T; Hirano, M; Hosono, H			Thin-film transistor fabricated in single-crystalline transparent oxide semiconductor	SCIENCE			English	Article							HETEROEPITAXIAL GROWTH; HOMOLOGOUS COMPOUNDS; MOBILITY	We report the fabrication of transparent field-effect transistors using a single-crystalline thin-film transparent oxide semiconductor, InGaO3(ZnO)(5), as an electron channel and amorphous hafnium oxide as a gate insulator. The device exhibits an on-to-off current ratio of similar to10(6) and a field-effect mobility of similar to80 square centimeters per volt per second at room temperature, with operation insensitive to visible light irradiation. The result provides a step toward the realization of transparent electronics for next-generation optoelectronics.	Japan Sci & Technol, ERATO, Hosono Transparent ElectroAct Mat, Kawasaki, Kanagawa 2130012, Japan; Tokyo Inst Technol, Mat & Struct Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology	Nomura, K (corresponding author), Japan Sci & Technol, ERATO, Hosono Transparent ElectroAct Mat, 3-2-1 Sakado, Kawasaki, Kanagawa 2130012, Japan.	nomura@lucid.msl.titech.ac.jp	Hosono, HIdeo/J-3489-2013; Ohta, Hiromichi/H-4468-2012; Ohta, Hiromichi/ABB-7878-2021; 太田, 裕道/AAK-4915-2020; Hosono, Hideo/T-1845-2019; Kamiya, Toshio/E-8615-2014	Hosono, HIdeo/0000-0001-9260-6728; Ohta, Hiromichi/0000-0001-7013-0343; Ohta, Hiromichi/0000-0001-7013-0343; Kamiya, Toshio/0000-0002-8358-240X; Ueda, Kazushige/0000-0002-4527-799X				Arulkumaran S, 2002, APPL PHYS LETT, V81, P1131, DOI 10.1063/1.1498874; Harada S, 2002, MATER SCI FORUM, V389-3, P1069, DOI 10.4028/www.scientific.net/MSF.389-393.1069; Hiramatsu H, 2002, APPL PHYS LETT, V81, P598, DOI 10.1063/1.1494853; Hoffman RL, 2003, APPL PHYS LETT, V82, P733, DOI 10.1063/1.1542677; Kawazoe H, 1997, NATURE, V389, P939, DOI 10.1038/40087; KIMIZUKA N, 1995, J SOLID STATE CHEM, V116, P170, DOI 10.1006/jssc.1995.1198; Kudo A, 1999, APPL PHYS LETT, V75, P2851, DOI 10.1063/1.125171; Li CF, 1998, J SOLID STATE CHEM, V139, P347, DOI 10.1006/jssc.1998.7856; Lin YS, 2002, APPL PHYS LETT, V81, P2041, DOI 10.1063/1.1506207; Nomura K, 2002, THIN SOLID FILMS, V411, P147, DOI 10.1016/S0040-6090(02)00204-3; Ohta H, 1999, MATER RES SOC SYMP P, V570, P309, DOI 10.1557/PROC-570-309; Ohta H, 2000, APPL PHYS LETT, V77, P475, DOI 10.1063/1.127015; Ohta H, 2003, ADV FUNCT MATER, V13, P139, DOI 10.1002/adfm.200390020; Orita M, 2001, PHILOS MAG B, V81, P501, DOI 10.1080/13642810110045923; Prins MWJ, 1996, APPL PHYS LETT, V68, P3650, DOI 10.1063/1.115759; Prins MWJ, 1997, APPL PHYS LETT, V70, P458, DOI 10.1063/1.118180; Thomas G, 1997, NATURE, V389, P907, DOI 10.1038/39999; YANAGI H, 2001, SOLID STATE COMMUN, V121, P615	18	1545	2434	24	735	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2003	300	5623					1269	1272		10.1126/science.1083212	http://dx.doi.org/10.1126/science.1083212			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764192				2022-12-28	WOS:000183042400042
J	Campagna, JA; Miller, KW; Forman, SA				Campagna, JA; Miller, KW; Forman, SA			Drug therapy: Mechanisms of actions of inhaled anesthetics	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACID TYPE-A; NICOTINIC ACETYLCHOLINE-RECEPTORS; INHIBITORY SYNAPTIC-TRANSMISSION; MEDULLARY EXPIRATORY NEURONS; CENTRAL-NERVOUS-SYSTEM; IN-VITRO NETWORKS; PROTEIN-KINASE-C; GENERAL-ANESTHETICS; NITROUS-OXIDE; VOLATILE ANESTHETICS		Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Forman, SA (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, CLN-3,10 Fruit St, Boston, MA 02114 USA.	saforman@partners.org	Forman, Stuart/Q-6590-2019	Forman, Stuart/0000-0001-6340-2478				ABRAHAM MH, 1991, J PHARM SCI-US, V80, P719, DOI 10.1002/jps.2600800802; Alkire MT, 2000, CONSCIOUS COGN, V9, P370, DOI 10.1006/ccog.1999.0423; ANGEL A, 1993, BRIT J ANAESTH, V71, P148, DOI 10.1093/bja/71.1.148; [Anonymous], 1897, SLWN 1127; Antkowiak B, 2002, BRIT J ANAESTH, V89, P102, DOI 10.1093/bja/aef154; Antognini JF, 2000, ANESTHESIOLOGY, V92, P559, DOI 10.1097/00000542-200002000-00040; ANTOGNINI JF, 1993, ANESTHESIOLOGY, V79, P1244, DOI 10.1097/00000542-199312000-00015; Antognini JF, 2002, BRIT J ANAESTH, V89, P156, DOI 10.1093/bja/aef156; BLEAKMAN D, 1995, NEUROPHARMACOLOGY, V34, P541, DOI 10.1016/0028-3908(95)00022-X; BOSNJAK ZJ, 1992, ANESTHESIOLOGY, V76, P123, DOI 10.1097/00000542-199201000-00018; Brown K, 1998, ANESTHESIOLOGY, V89, P86, DOI 10.1097/00000542-199807000-00015; Camara AKS, 2001, ANESTHESIOLOGY, V95, P515, DOI 10.1097/00000542-200108000-00038; CAMPBELL DB, 1994, P NATL ACAD SCI USA, V91, P2135, DOI 10.1073/pnas.91.6.2135; Cantor RS, 2001, BIOPHYS J, V80, P2284, DOI 10.1016/S0006-3495(01)76200-5; Carlson BX, 1997, ANESTHESIA BIOL FDN, P259; CARROLL NV, 1994, J CLIN ANESTH, V6, P364, DOI 10.1016/S0952-8180(05)80004-2; Caton D, 2003, CONTEMPORARY CLIN NE, P3; Cheng G, 2000, ANESTHESIOLOGY, V93, P1075, DOI 10.1097/00000542-200010000-00032; COLLINS JG, 1995, TRENDS NEUROSCI, V18, P549, DOI 10.1016/0166-2236(95)98377-B; Cope DK, 1997, ANESTHESIOLOGY, V86, P699, DOI 10.1097/00000542-199703000-00023; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; Daniels S, 1998, TOXICOL LETT, V101, P71, DOI 10.1016/S0378-4274(98)00167-2; DILGER JP, 1994, ANESTHESIOLOGY, V81, P431, DOI 10.1097/00000542-199408000-00022; DODSON BA, 1987, MOL PHARMACOL, V32, P119; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; DWYER R, 1992, ANESTH ANALG, V75, P107; DWYER R, 1992, ANESTHESIOLOGY, V77, P888, DOI 10.1097/00000542-199211000-00009; Eckenhoff R G, 2001, Mol Interv, V1, P258; Eger EI, 1997, ANESTH ANALG, V84, P915, DOI 10.1097/00000539-199704000-00039; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; Flood P, 1997, ANESTHESIOLOGY, V86, P859, DOI 10.1097/00000542-199704000-00016; Flood P, 1998, TOXICOL LETT, V101, P149, DOI 10.1016/S0378-4274(98)00179-9; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; Franks NP, 1998, TOXICOL LETT, V101, P1, DOI 10.1016/S0378-4274(98)00158-1; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FRANKS NP, 1978, NATURE, V274, P339, DOI 10.1038/274339a0; FRAZER MJ, 1992, ANESTHESIOLOGY, V77, P316, DOI 10.1097/00000542-199208000-00015; Gamo S, 1998, TOXICOL LETT, V101, P329, DOI 10.1016/S0378-4274(98)00203-3; Ghoneim MM, 1997, ANESTHESIOLOGY, V87, P387, DOI 10.1097/00000542-199708000-00027; GOODMAN SJ, 1967, EXP NEUROL, V19, P11, DOI 10.1016/0014-4886(67)90003-9; Gyulai FE, 2001, ANESTHESIOLOGY, V95, P585, DOI 10.1097/00000542-200109000-00008; Harris RA, 1997, ALCOHOL CLIN EXP RES, V21, P444; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; Hartman PS, 2001, MECH AGEING DEV, V122, P1187, DOI 10.1016/S0047-6374(01)00259-7; Heinke W, 2002, BRIT J ANAESTH, V89, P112, DOI 10.1093/bja/aef155; Heinke W, 2001, ANESTHESIOLOGY, V94, P973, DOI 10.1097/00000542-200106000-00010; HEMMINGS HC, 1994, ANESTHESIOLOGY, V81, P147, DOI 10.1097/00000542-199407000-00021; HOBSON JA, 1974, J NEUROPHYSIOL, V37, P497, DOI 10.1152/jn.1974.37.3.497; Homanics GE, 1997, MOL PHARMACOL, V51, P588, DOI 10.1124/mol.51.4.588; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; Huneke R, 2001, ANESTHESIOLOGY, V95, P999; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; Jenkins A, 1996, BRIT J PHARMACOL, V117, P1507, DOI 10.1111/j.1476-5381.1996.tb15314.x; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; John ER, 2002, CONSCIOUS COGN, V11, P138, DOI 10.1006/ccog.2001.0543; John ER, 2001, CONSCIOUS COGN, V10, P165, DOI 10.1006/ccog.2001.0507; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339, DOI 10.1152/jn.1993.70.4.1339; Joo DT, 2001, ANESTHESIOLOGY, V94, P478, DOI 10.1097/00000542-200103000-00020; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Kandel L, 1996, ANESTH ANALG, V82, P321, DOI 10.1097/00000539-199602000-00019; Kayser B, 1998, TOXICOL LETT, V101, P339, DOI 10.1016/S0378-4274(98)00204-5; Keifer JC, 1996, ANESTHESIOLOGY, V84, P945, DOI 10.1097/00000542-199604000-00023; Kendig JJ, 2002, BRIT J ANAESTH, V89, P91, DOI 10.1093/bja/aef158; KENDIG JJ, 1991, ANN NY ACAD SCI, V625, P37, DOI 10.1111/j.1749-6632.1991.tb33828.x; KOBLIN DD, 1980, ANESTHESIOLOGY, V52, P401, DOI 10.1097/00000542-198005000-00005; KOBLIN DD, 1994, ANESTH ANALG, V79, P1043; KOBLIN DD, 1981, BRIT J ANAESTH, V53, P5, DOI 10.1093/bja/53.1.5; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Kohro S, 2001, ANESTHESIOLOGY, V95, P1435, DOI 10.1097/00000542-200112000-00024; Korpi ER, 2002, NEUROSCIENCE, V109, P733, DOI 10.1016/S0306-4522(01)00527-9; LEAKE C D, 1971, Anesthesiology (Hagerstown), V35, P112, DOI 10.1097/00000542-197108000-00002; LIN LH, 1993, FASEB J, V7, P479, DOI 10.1096/fasebj.7.5.7681790; Lingamaneni R, 2002, ANESTHESIOLOGY, V96, P782; Lingamaneni R, 2001, ANESTHESIOLOGY, V95, P1460, DOI 10.1097/00000542-200112000-00027; LYDIC R, 1997, ANESTHESIA BIOL FDN, P433; LYNCH C, 1994, BBA-BIOMEMBRANES, V1194, P109, DOI 10.1016/0005-2736(94)90208-9; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MACIVER MB, 1991, ANESTHESIOLOGY, V74, P83; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; McLeod HL, 2001, ANNU REV PHARMACOL, V41, P101, DOI 10.1146/annurev.pharmtox.41.1.101; Mennerick S, 1998, J NEUROSCI, V18, P9716; Meyer HZur, 1899, ARCH EXP PATHOL PHAR, V42, P109, DOI [10.1007/BF01834479, DOI 10.1007/BF01834479]; MIDDLETON AJ, 1975, P ROY SOC LOND B BIO, V193, P159; MIHIC SJ, 1994, MOL PHARMACOL, V46, P851; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; Mohler H, 2002, J PHARMACOL EXP THER, V300, P2, DOI 10.1124/jpet.300.1.2; Narahashi T, 1998, TOXICOL LETT, V101, P185, DOI 10.1016/S0378-4274(98)00184-2; Nash HA, 2002, BRIT J ANAESTH, V89, P143, DOI 10.1093/bja/aef159; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; North C, 1997, BIOPHYS J, V72, P1754, DOI 10.1016/S0006-3495(97)78821-0; Novalija E, 1998, ACTA ANAESTH SCAND, V42, P353, DOI 10.1111/j.1399-6576.1998.tb04929.x; Olsen RW, 1998, TOXICOL LETT, V101, P193, DOI 10.1016/S0378-4274(98)00185-4; Overton E., 1901, STUDIEN NARKOSE ZUGL; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 2001, ANESTHESIOLOGY, V95, P1013, DOI 10.1097/00000542-200110000-00034; PEROUANSKY M, 1995, ANESTHESIOLOGY, V83, P109, DOI 10.1097/00000542-199507000-00014; POCOCK G, 1991, BRIT J ANAESTH, V66, P116, DOI 10.1093/bja/66.1.116; Pohorille A, 1996, CHEM PHYS, V204, P337, DOI 10.1016/0301-0104(95)00292-8; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; Quinlan JJ, 1998, ANESTHESIOLOGY, V88, P775, DOI 10.1097/00000542-199803000-00030; RAINES DE, 1993, ANESTHESIOLOGY, V78, P918, DOI 10.1097/00000542-199305000-00017; Raines DE, 2002, ANESTH ANALG, V95, P573, DOI 10.1097/00000539-200209000-00015; Raines DE, 2001, ANESTHESIOLOGY, V95, P470, DOI 10.1097/00000542-200108000-00032; RAINES DE, 2002, ANESTH ANALG, V95, P869; Rehberg B, 1996, ANESTHESIOLOGY, V84, P1223, DOI 10.1097/00000542-199605000-00025; ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008; Sewell JC, 1998, TOXICOL LETT, V101, P359, DOI 10.1016/S0378-4274(98)00207-0; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; Sonner JM, 2000, ANESTH ANALG, V91, P720, DOI 10.1213/00000539-200009000-00042; Stadnicka A, 2000, ANESTH ANALG, V90, P824, DOI 10.1213/00000539-200004000-00010; STOELTING RK, 1970, ANESTHESIOLOGY, V33, P5, DOI 10.1097/00000542-197007000-00004; Stucke AG, 2001, ANESTHESIOLOGY, V95, P485, DOI 10.1097/00000542-200108000-00034; Stuth EAE, 2000, ANESTHESIOLOGY, V93, P1474, DOI 10.1097/00000542-200012000-00020; Tang P, 1997, BIOPHYS J, V72, P1676, DOI 10.1016/S0006-3495(97)78813-1; Twersky RS, 1998, CAN J ANAESTH, V45, pR76, DOI 10.1007/BF03019209; Urban BW, 2002, BRIT J ANAESTH, V89, P3, DOI 10.1093/bja/aef164; Vahle-Hinz C, 2002, BRIT J ANAESTH, V89, P123, DOI 10.1093/bja/aef166; van Swinderen B, 1999, P NATL ACAD SCI USA, V96, P2479, DOI 10.1073/pnas.96.5.2479; Veselis RA, 2001, ANESTHESIOLOGY, V95, P896, DOI 10.1097/00000542-200110000-00018; Violet JM, 1997, ANESTHESIOLOGY, V86, P866, DOI 10.1097/00000542-199704000-00017; Wakasugi M, 1999, ANESTH ANALG, V88, P676, DOI 10.1097/00000539-199903000-00039; Washburn MS, 1997, J NEUROSCI, V17, P9393; Weinstein JN, 2000, NEW ENGL J MED, V343, P1408, DOI 10.1056/NEJM200011093431910; Wiklund RA, 1997, NEW ENGL J MED, V337, P1132, DOI 10.1056/NEJM199710163371606; Wong SME, 2001, ANESTHESIOLOGY, V95, P154; WOOD SC, 1995, MOL PHARMACOL, V47, P121; Yamakura T, 2000, ANESTHESIOLOGY, V93, P1095, DOI 10.1097/00000542-200010000-00034; Yost CS, 1999, ANESTHESIOLOGY, V90, P1186, DOI 10.1097/00000542-199904000-00035; ZIMMERMAN SA, 1994, J PHARMACOL EXP THER, V270, P987	136	559	594	2	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2110	2124		10.1056/NEJMra021261	http://dx.doi.org/10.1056/NEJMra021261			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761368				2022-12-28	WOS:000183008300009
J	Iglehart, JK				Iglehart, JK			The dilemma of Medicaid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE; PARTICIPATION; ACCESS											Berman S, 2002, PEDIATRICS, V110, P239, DOI 10.1542/peds.110.2.239; Brown LD, 2003, HEALTH AFFAIR, V22, P31, DOI 10.1377/hlthaff.22.1.31; *C BUDG OFF, CBOS CURR BUDG PROJ; CALMES J, 2003, WALL STREET J   0225, pA5; Coburn AF, 1999, INQUIRY-J HEALTH CAR, V36, P265; Croghan TW, 2001, HEALTH AFFAIR, V20, P129, DOI 10.1377/hlthaff.20.2.129; CUNNINGHAM PJ, 2002, MOUNTING PRESSURES P; DALE SB, 2003, STATE MEDICAID PRESC; *DIV HLTH POL RES, 2001, PED PART MED SCHIP S; EGAN T, 2003, NY TIMES        0421, pA1; Ehrenhalt A., 2003, GOVERNING        APR, P6; FISHMAN E, 2002, RUNNING PLACE MEDICA; FOSSETT JW, 2002, IS MEDICAID RETRENCH; Frank RG, 2003, HEALTH AFFAIR, V22, P101, DOI 10.1377/hlthaff.22.1.101; FREUDENHEIM M, 2003, NY TIMES        0313, pC1; *GEN ACC OFF, 2002, GAOHEHS00149; *GEN ACC OFF, 2002, GAO02817; *GEN ACC OFF, 2001, GAO01883; *GEN ACC OFF, 2001, GAO01563T; *GEN ACC OFF, 2000, GAOTHEHS00193; *GEN ACC OFF, 1994, GAOHEHS94133; Gold M, 2003, HEALTH AFFAIR, V22, P230, DOI 10.1377/hlthaff.22.1.230; GOLDSTEIN A, 2003, WASH POST       0908, pA1; GREENBERGER RS, 2003, WALL ST J       0905, pB2; HEFFLER S, 2003, TRENDS HLTH SPENDING; HOLAHAN J, 2002, HLTH POLICY LOW INCO; HOLAHAN JJM, 2003, STATE FISCAL CRISIS; HOVEY HA, 1999, CAN STATES AFFORD DE; Hurley RE, 2002, HEALTH CARE FINANC R, V24, P11; Hurley RE, 2003, HEALTH AFFAIR, V22, P77, DOI 10.1377/hlthaff.22.1.77; JANOFSKY M, 2003, NY TIMES        0426, pA20; *KAIS COMM MED UN, 2002, MED RES BOOK; *KAIS COMM MED UN, 2002, MED FACTS MED PRESCR; LANDERS P, 2003, WALL STREET J   0220, pD3; Levit K, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.1.154; Mann C, 2003, HEALTH AFFAIR, V22, P62, DOI 10.1377/hlthaff.22.1.62; Mann C, 2002, NEW MEDICAID CHIP WA; Martin A, 2002, HEALTH AFFAIR, V21, P112, DOI 10.1377/hlthaff.21.4.112; MATHERLEE K, 2002, FEDERAL STATE STRUGG; MCNICHOL L, STATE FISCAL CRISIS; *NAT C STAT LEG, 2003, STAT BUDG UPD FEBR 2; National Governors Association, 2003, GOV REACH BIP AGR NG; OFFNER P, 1999, DEVOLUTION REVOLUTIO; PERLOFF JD, 1995, HEALTH SERV RES, V30, P7; REGENSTEIN M, 2000, MEDICAID MANAGED CAR; Rosenbaum S, 2002, NEW ENGL J MED, V346, P635, DOI 10.1056/NEJM200202213460825; Rowland D, 2003, HEALTH AFFAIR, V22, P138, DOI 10.1377/hlthaff.22.1.138; RUSSAKOFF D, 2003, WASHINGTON POST 0224, pA5; RYAN JM, 2002, SCHIP TURNS 5 TAKING; SCHOENMAN JA, 2003, RESULTS MEDICARE PAY; SERAFINI MW, 2003, NATL J          0405, P1072; Skaggs DL, 2001, PEDIATRICS, V107, P1405, DOI 10.1542/peds.107.6.1405; SMITH V, 2003, MEDICAID SPENDING GR; TONER R, 2003, NY TIMES        0428; Vladeck BC, 2003, HEALTH AFFAIR, V22, P90, DOI 10.1377/hlthaff.22.1.90; VONBEHREN G, 2002, FISCAL SURVEY STATES; Weil A, 2003, HEALTH AFFAIR, V22, P13, DOI 10.1377/hlthaff.22.1.13	57	24	24	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2140	2148		10.1056/NEJMhpr035376	http://dx.doi.org/10.1056/NEJMhpr035376			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761373				2022-12-28	WOS:000183008300015
J	Humbert, VH; Tuna, IC; Harrison, MR; Curtis, DB; Webster, SA				Humbert, VH; Tuna, IC; Harrison, MR; Curtis, DB; Webster, SA			Clinical picture - Aortic tumour in primary anti-phospholipid syndrome	LANCET			English	Editorial Material									Evansville Heart Ctr, Evansville, IN 47710 USA		Humbert, VH (corresponding author), Evansville Heart Ctr, 520 Mary St, Evansville, IN 47710 USA.		Harrison, Michael/GYD-8608-2022						0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 17	2003	361	9370					1676	1676		10.1016/S0140-6736(03)13369-7	http://dx.doi.org/10.1016/S0140-6736(03)13369-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767732				2022-12-28	WOS:000182919700007
J	van Guldener, C; Stehouwer, CDA				van Guldener, C; Stehouwer, CDA			Hyperhomocysteinaemia and vascular disease - a role for DNA hypomethylation?	LANCET			English	Editorial Material							S-ADENOSYLHOMOCYSTEINE; RENAL-FAILURE; METHYLATION; HOMOCYSTEINE; METABOLISM		Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands; Amphia Hosp, Dept Internal Med, Breda, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Amphia Hospital	van Guldener, C (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Amsterdam, Netherlands.	c.vanguldener@vumc.nl	Stehouwer, Coen/AAB-3435-2021		Telethon [GGP02308] Funding Source: Medline	Telethon(Fondazione Telethon)		Baigent C, 2000, LANCET, V356, P147, DOI 10.1016/S0140-6736(00)02456-9; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Hiltunen M, 2002, VASC MED, V7, P5, DOI 10.1191/1358863x02vm418oa; Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171; Loehrer FMT, 1998, NEPHROL DIAL TRANSPL, V13, P656, DOI 10.1093/ndt/13.3.656; Mallamaci F, 2002, KIDNEY INT, V61, P609, DOI 10.1046/j.1523-1755.2002.00144.x; PERNA AF, 1993, J CLIN INVEST, V91, P2497; PERNA AF, 1995, KIDNEY INT, V47, P247, DOI 10.1038/ki.1995.31; van Guldener C, 1999, KIDNEY INT, V56, P1064, DOI 10.1046/j.1523-1755.1999.00624.x; van Guldener C, 2001, KIDNEY INT, V59, pS234, DOI 10.1046/j.1523-1755.2001.59780234.x; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380	12	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1668	1669		10.1016/S0140-6736(03)13380-6	http://dx.doi.org/10.1016/S0140-6736(03)13380-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767729				2022-12-28	WOS:000182919700004
J	Sanford, E; Roth, MS; Johns, GC; Wares, JP; Somero, GN				Sanford, E; Roth, MS; Johns, GC; Wares, JP; Somero, GN			Local selection and latitudinal variation in a marine predator-prey interaction	SCIENCE			English	Article							GEOGRAPHIC-VARIATION; INTERACTION STRENGTH; GRADIENT; BIOGEOGRAPHY; EVOLUTION	Although pairs of species often interact over broad geographic ranges, few studies have explored how interactions vary across these large spatial scales. Surveys along 1500 kilometers of the Pacific coast of North America documented marked variation in the frequency of predation by the snail Nucella canaliculata on the intertidal mussel Mytilus californianus. Laboratory rearing experiments suggest that regional differences in drilling behavior have a genetic basis, and mitochondrial sequence variation confirms that gene flow is low among these snail populations. Marine communities separated by hundreds of kilometers may have intrinsically different dynamics, with interactions shaped by restricted gene flow and spatially varying selection.	Stanford Univ, Hopkins Marine Stn, Pacific Grove, CA 93950 USA; Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA; Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA	Stanford University; Brown University; University of California System; University of California Davis	Sanford, E (corresponding author), Stanford Univ, Hopkins Marine Stn, Pacific Grove, CA 93950 USA.	eric_sanford@brown.edu	Somero, George/AAC-3321-2019	Somero, George/0000-0003-1431-6455; Wares, John/0000-0003-1827-0669; Roth, Melissa/0000-0001-7389-5982				Barber PH, 2000, NATURE, V406, P692, DOI 10.1038/35021135; BRAY NA, 1993, J GEOPHYS RES-OCEANS, V98, P18119, DOI 10.1029/93JC01142; Brown J.H., 1995, MACROECOLOGY; Connolly SR, 1998, AM NAT, V151, P311, DOI 10.1086/286121; Connolly SR, 2001, ECOLOGY, V82, P1799, DOI 10.1890/0012-9658(2001)082[1799:ALGIRO]2.0.CO;2; Dawson MN, 2001, J BIOGEOGR, V28, P723, DOI 10.1046/j.1365-2699.2001.00572.x; DETHIER MN, 1988, MAR ECOL PROG SER, V50, P97, DOI 10.3354/meps050097; DUNGAN ML, 1982, SCIENCE, V216, P989, DOI 10.1126/science.216.4549.989; Endler J.A., 1977, Monographs in Population Biology, pi; Endler J. A., 1999, GEOGRAPHIC VARIATION; Grosberg R, 2001, MARINE COMMUNITY ECOLOGY, P61; Hellberg ME, 2001, SCIENCE, V292, P1707, DOI 10.1126/science.1060102; LEIGHTON BJ, 1991, DIS AQUAT ORGAN, V10, P71, DOI 10.3354/dao010071; Marko PB, 1998, EVOLUTION, V52, P757, DOI 10.1111/j.1558-5646.1998.tb03700.x; MENGE BA, 1994, ECOL MONOGR, V64, P249, DOI 10.2307/2937163; Navarrete SA, 1996, ECOL MONOGR, V66, P409, DOI 10.2307/2963488; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; PAINE RT, 1974, OECOLOGIA, V15, P93, DOI 10.1007/BF00345739; Power ME, 1996, BIOSCIENCE, V46, P609, DOI 10.2307/1312990; SANFORD E, UNPUB; Sotka EE, 2002, ECOLOGY, V83, P2721, DOI 10.2307/3072010; SOTKA EE, UNPUB; Stachowicz JJ, 2000, AM NAT, V156, P59, DOI 10.1086/303366; Suchanek T.H., 1986, ECOLOGY ROCKY COASTS, P71; Taylor MS, 2003, SCIENCE, V299, P107, DOI 10.1126/science.1079365; Thompson JN, 1998, TRENDS ECOL EVOL, V13, P329, DOI 10.1016/S0169-5347(98)01378-0	26	116	116	1	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2003	300	5622					1135	+		10.1126/science.1083437	http://dx.doi.org/10.1126/science.1083437			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750518				2022-12-28	WOS:000182886500042
J	Firestein, GS				Firestein, GS			Evolving concepts of rheumatoid arthritis	NATURE			English	Review							COLLAGEN-INDUCED ARTHRITIS; TUMOR-SUPPRESSOR GENE; ANTITUMOR NECROSIS FACTOR; KAPPA-B REGULATION; N-TERMINAL KINASE; T-CELLS; JOINT DESTRUCTION; INFLAMMATORY ARTHRITIS; SYNOVIAL TISSUE; OSTEOPROTEGERIN LIGAND	Rheumatoid arthritis is the most common inflammatory arthritis and is a major cause of disability. It existed in early Native American populations several thousand years ago but might not have appeared in Europe until the 17th century. Early theories on the pathogenesis of rheumatoid arthritis focused on autoantibodies and immune complexes. T-cell-mediated antigen-specific responses T-cell-independent cytokine networks, and aggressive tumour-like behavior of rheumatoid synovium have also been implicated. More recently, the contrition of autoantibodies has returned to the forefront. Based on the pathogenic mechanisms, specific therapeutic interventions can be designed to suppress synovial inflammation and joint destruction in rheumatoid arthritis.	Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Firestein, GS (corresponding author), Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gfirestein@ucsd.edu						Aceves-Avila FJ, 1998, J RHEUMATOL, V25, P776; Aupperle KR, 2001, J IMMUNOL, V166, P2705, DOI 10.4049/jimmunol.166.4.2705; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Banda NK, 2002, ARTHRITIS RHEUM-US, V46, P3065, DOI 10.1002/art.10591; BRENNAN FM, 2001, LANCET, V358, P244; Burger D, 1998, ARTHRITIS RHEUM, V41, P1748, DOI 10.1002/1529-0131(199810)41:10<1748::AID-ART7>3.3.CO;2-V; Chabaud M, 1998, J IMMUNOL, V161, P409; Clausen BE, 1998, MOL MED, V4, P240, DOI 10.1007/BF03401921; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; Firestein GS, 2002, ARTHRITIS RHEUM, V46, P298, DOI 10.1002/art.502; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; Firestein GS, 1997, P NATL ACAD SCI USA, V94, P10895, DOI 10.1073/pnas.94.20.10895; Fox DA, 1997, ARTHRITIS RHEUM, V40, P598, DOI 10.1002/art.1780400403; FRANKLIN EC, 1957, J EXP MED, V105, P425, DOI 10.1084/jem.105.5.425; Gebe JA, 2001, J IMMUNOL, V167, P3250, DOI 10.4049/jimmunol.167.6.3250; Gracie JA, 1999, J CLIN INVEST, V104, P1393, DOI 10.1172/JCI7317; Han ZN, 1998, AUTOIMMUNITY, V28, P197, DOI 10.3109/08916939808995367; Han ZN, 2002, ARTHRITIS RHEUM, V46, P818, DOI 10.1002/art.10104; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Imamura F, 1998, ARTHRITIS RHEUM, V41, P1979; Inazuka M, 2000, RHEUMATOLOGY, V39, P262, DOI 10.1093/rheumatology/39.3.262; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Kim HJ, 2000, ARTHRITIS RES, V2, P126, DOI 10.1186/ar77; KINNE RW, 1995, SCAND J RHEUMATOL, P121; KIRSCHMANN DA, 1995, J IMMUNOL, V155, P5655; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Lee SH, 2003, J IMMUNOL, V170, P2214, DOI 10.4049/jimmunol.170.4.2214; Li LN, 2000, CELL RES, V10, P39; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655; Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739; Matsumoto I, 2003, ARTHRITIS RHEUM-US, V48, P944, DOI 10.1002/art.10898; Matsuno H, 2002, J RHEUMATOL, V29, P1609; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; NEPOM GT, 1989, ARTHRITIS RHEUM, V32, P15, DOI 10.1002/anr.1780320104; Neumann E, 2002, ARTHRITIS RHEUM, V46, P934, DOI 10.1002/art.10183; ODA A, 1994, CLIN RHEUMATOL, V13, P261; Pap T, 2001, ARTHRITIS RHEUM, V44, P676, DOI 10.1002/1529-0131(200103)44:3<676::AID-ANR117>3.0.CO;2-6; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Reme T, 1998, CLIN EXP IMMUNOL, V111, P353; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; ROTHSCHILD BM, 1988, SCIENCE, V241, P1498, DOI 10.1126/science.3047874; ROUDIER J, 1989, P NATL ACAD SCI USA, V86, P5104, DOI 10.1073/pnas.86.13.5104; ROWLEY M, 1986, ARTHRITIS RHEUM, V29, P174, DOI 10.1002/art.1780290204; RUDDY S, 1975, ANN NY ACAD SCI, V256, P96, DOI 10.1111/j.1749-6632.1975.tb36039.x; Schett G, 2000, ARTHRITIS RHEUM, V43, P2501, DOI 10.1002/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K; Sen M, 2001, ARTHRITIS RHEUM, V44, P772, DOI 10.1002/1529-0131(200104)44:4<772::AID-ANR133>3.0.CO;2-L; Shiozawa S, 1997, J CLIN INVEST, V99, P1210, DOI 10.1172/JCI119277; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI200113568; Smeets TJM, 1999, J RHEUMATOL, V26, P2089; Smeets TJM, 1998, CLIN IMMUNOL IMMUNOP, V88, P84, DOI 10.1006/clin.1998.4525; STASTNY P, 1976, J CLIN INVEST, V57, P1148, DOI 10.1172/JCI108382; Steiner G, 2002, ARTHRITIS RES THER, V4; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Tak PP, 2001, ARTHRITIS RHEUM, V44, P1897, DOI 10.1002/1529-0131(200108)44:8<1897::AID-ART328>3.0.CO;2-4; Terato K, 1995, AUTOIMMUNITY, V22, P137, DOI 10.3109/08916939508995311; Union A, 2002, ARTHRITIS RHEUM, V46, P1185, DOI 10.1002/art.10229; van der Heijden IM, 2000, ARTHRITIS RHEUM-US, V43, P593, DOI 10.1002/1529-0131(200003)43:3<593::AID-ANR16>3.0.CO;2-1; Verheijden GFM, 1997, ARTHRITIS RHEUM, V40, P1115, DOI 10.1002/art.1780400616; VITA SD, 2002, ARTHRITIS RHEUM, V46, P2029; WalserKuntz DR, 1995, HUM IMMUNOL, V44, P203, DOI 10.1016/0198-8859(95)00109-3; Walsh DA, 1998, AM J PATHOL, V152, P691; Wang H, 2001, NAT IMMUNOL, V2, P632, DOI 10.1038/89782; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Zanelli E, 2000, RHEUMATOLOGY, V39, P1060, DOI 10.1093/rheumatology/39.10.1060; Ziolkowska M, 2002, ARTHRITIS RHEUM-US, V46, P1744, DOI 10.1002/art.10388; Zvaifler N J, 1973, Adv Immunol, V16, P265, DOI 10.1016/S0065-2776(08)60299-0	77	2594	2826	19	431	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					356	361		10.1038/nature01661	http://dx.doi.org/10.1038/nature01661			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748655				2022-12-28	WOS:000182853100057
J	Karsenty, G				Karsenty, G			The complexities of skeletal biology	NATURE			English	Review							VERTEBRATE LIMB DEVELOPMENT; BONE-FORMATION; MICE; OSTEOPETROSIS; OSTEOCLAST; CHICK	For a long time, the skeleton was seen as an amorphous tissue of little biological interest. But such a view ignored the large number of genetic and degenerative diseases affecting this organ. Over the past 15 years, molecular and genetic studies have modified our understanding of skeletal biology. By so doing this progress has affected our understanding of diseases and suggested in many instances new therapeutic opportunities.	Baylor Coll Med, Bone Dis Program Texas, Houston, TX 77030 USA	Baylor College of Medicine	Karsenty, G (corresponding author), Baylor Coll Med, Bone Dis Program Texas, 1 baylor Plaza, Houston, TX 77030 USA.	karsenty@bcm.tmc.edu						Bex M, 2002, J BONE MINER RES, V17, P1081, DOI 10.1359/jbmr.2002.17.6.1081; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Dudley AT, 2002, NATURE, V418, P539, DOI 10.1038/nature00945; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Niswander L, 2003, NAT REV GENET, V4, P133, DOI 10.1038/nrg1001; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tickle C, 2001, CURR OPIN GENET DEV, V11, P476, DOI 10.1016/S0959-437X(00)00220-3; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064	20	304	321	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					316	318		10.1038/nature01654	http://dx.doi.org/10.1038/nature01654			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748648				2022-12-28	WOS:000182853100050
J	Dunn, N				Dunn, N			10-minute consultation - Adverse drug event	BRITISH MEDICAL JOURNAL			English	Article									Univ Southampton, Sch Med, Southampton SO16 5ST, Hants, England	University of Southampton	Dunn, N (corresponding author), Univ Southampton, Sch Med, Southampton SO16 5ST, Hants, England.								0	1	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1018	1018		10.1136/bmj.326.7397.1018	http://dx.doi.org/10.1136/bmj.326.7397.1018			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KG	12742925	Bronze, Green Published			2022-12-28	WOS:000182920500019
J	Grech, ED				Grech, ED			ABC of interventional cardiology - Pathophysiology and investigation of coronary artery disease	BRITISH MEDICAL JOURNAL			English	Review							TASK-FORCE; ANGIOGRAPHY		Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB, Canada; Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Grech, ED (corresponding author), Hlth Sci Ctr, Winnipeg, MB, Canada.							MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; Marwick TH, 2001, J AM COLL CARDIOL, V37, P754, DOI 10.1016/S0735-1097(00)01191-8; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; Scanlon PJ, 1999, J AM COLL CARDIOL, V33, P1756, DOI 10.1016/S0735-1097(99)00126-6	4	36	38	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1027	1030		10.1136/bmj.326.7397.1027	http://dx.doi.org/10.1136/bmj.326.7397.1027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KG	12742929	Green Published			2022-12-28	WOS:000182920500024
J	Tsuda, A; Takeda, S; Saito, H; Nishioka, J; Nojiri, Y; Kudo, I; Kiyosawa, H; Shiomoto, A; Imai, K; Ono, T; Shimamoto, A; Tsumune, D; Yoshimura, T; Aono, T; Hinuma, A; Kinugasa, M; Suzuki, K; Sohrin, Y; Noiri, Y; Tani, H; Deguchi, Y; Tsurushima, N; Ogawa, H; Fukami, K; Kuma, K; Saino, T				Tsuda, A; Takeda, S; Saito, H; Nishioka, J; Nojiri, Y; Kudo, I; Kiyosawa, H; Shiomoto, A; Imai, K; Ono, T; Shimamoto, A; Tsumune, D; Yoshimura, T; Aono, T; Hinuma, A; Kinugasa, M; Suzuki, K; Sohrin, Y; Noiri, Y; Tani, H; Deguchi, Y; Tsurushima, N; Ogawa, H; Fukami, K; Kuma, K; Saino, T			A mesoscale iron enrichment in the western Subarctic Pacific induces a large centric diatom bloom	SCIENCE			English	Article							PHYTOPLANKTON BLOOM; SOUTHERN-OCEAN; FERTILIZATION; PRODUCTIVITY	We have performed an in situ test of the iron limitation hypothesis in the subarctic North Pacific Ocean. A single enrichment of dissolved iron caused a large increase in phytoplankton standing stock and decreases in macronutrients and dissolved carbon dioxide. The dominant phytoplankton species shifted after the iron addition from pennate diatoms to a centric diatom, Chaetoceros debilis, that showed a very high growth rate, 2.6 doublings per day. We conclude that the bioavailability of iron regulates the magnitude of the phytoplankton biomass and the key phytoplankton species that determine the biogeochemical sensitivity to iron supply of high-nitrate, low-chlorophyll waters.	Hokkaido Natl Res Inst, Kushira, Hokkaido 0850802, Japan; Univ Tokyo, Dept Aquat Biosci, Bunkyo Ku, Tokyo 1138657, Japan; Tohoku Natl Fisheries Res Inst, Shiogama, Miyagi 9850001, Japan; Cent Res Inst Elect Power Ind, Chiba 2701194, Japan; Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan; Hokkaido Univ, Grad Sch Fisheries Sci, Hakodate, Hokkaido 0418611, Japan; Marine Biol Res Inst Japan, Shinagawa Ku, Tokyo 1420042, Japan; Natl Res Inst Far Seas Fisheries, Shizuoka 4248633, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan; Kansai Environm Engn Ctr, Osaka 5410052, Japan; Natl Inst Radiol Sci, Hitachinaka, Ibaraki 3111202, Japan; Nagoya Univ, Hydrospher Atmospher Res Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058569, Japan; Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan; Kochi Univ, Nanko Ku, Kochi 7838502, Japan	University of Tokyo; Japan Fisheries Research & Education Agency (FRA); Central Research Institute of Electric Power Industry - Japan; National Institute for Environmental Studies - Japan; Hokkaido University; Japan Fisheries Research & Education Agency (FRA); Japan Science & Technology Agency (JST); National Institutes for Quantum Science & Technology; Nagoya University; Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; Kochi University	Tsuda, A (corresponding author), Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan.		SAITO, HIROAKI/J-6948-2017; Nojiri, Yukihiro/D-1999-2010; Suzuki, Koji/GVS-9807-2022; Kuma, Kenshi/B-2799-2012; 毅, 芳村/M-1778-2017; Nishioka, Jun/F-5314-2011; Tsurushima, Nobuo/L-6336-2018; Suzuki, Koji/A-4349-2013; Suzuki, Koji/AAD-2630-2022; Sohrin, Yoshiki/A-8133-2011	SAITO, HIROAKI/0000-0002-5502-9076; Nojiri, Yukihiro/0000-0001-9885-9195; Suzuki, Koji/0000-0001-5354-1044; Kuma, Kenshi/0000-0001-8851-5997; 毅, 芳村/0000-0001-5700-2590; Nishioka, Jun/0000-0003-1723-9344; Tsurushima, Nobuo/0000-0002-4741-7482; Suzuki, Koji/0000-0001-5354-1044; Sohrin, Yoshiki/0000-0001-6744-6048; Takeda, Shigenobu/0000-0002-4997-1583				Bishop JKB, 2002, SCIENCE, V298, P817, DOI 10.1126/science.1074961; Boyd PW, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014210; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; Boyd PW, 2001, DEEP-SEA RES PT II, V48, P2529, DOI 10.1016/S0967-0645(01)00007-8; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P352, DOI 10.1029/98PA00920; Cavender-Bares KK, 1999, LIMNOL OCEANOGR, V44, P237, DOI 10.4319/lo.1999.44.2.0237; CHISHOLM SW, 1991, LIMNOL OCEANOGR, V36, pU1507; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; Dalton R, 2002, NATURE, V420, P722, DOI 10.1038/420722a; DUCE RA, 1991, LIMNOL OCEANOGR, V36, P1715, DOI 10.4319/lo.1991.36.8.1715; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Fung IY, 2000, GLOBAL BIOGEOCHEM CY, V14, P281, DOI 10.1029/1999GB900059; Harrison PJ, 1999, PROG OCEANOGR, V43, P205, DOI 10.1016/S0079-6611(99)00015-4; KUDO I, UNPUB; KUMAR N, 1995, NATURE, V378, P675, DOI 10.1038/378675a0; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; McQuoid MR, 1996, J PHYCOL, V32, P889, DOI 10.1111/j.0022-3646.1996.00889.x; NISHIOKA J, IN PRESS GEOPHYS RES; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; SAINO T, 1990, J OCEANOGR, V54, P583; Suzuki Y, 1995, J PHYCOL, V31, P880, DOI 10.1111/j.0022-3646.1995.00880.x	22	391	415	4	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					958	961		10.1126/science.1082000	http://dx.doi.org/10.1126/science.1082000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738858				2022-12-28	WOS:000182719800050
J	Reynolds, RM; Browning, GGP; Nawroz, I; Campbell, IW				Reynolds, RM; Browning, GGP; Nawroz, I; Campbell, IW			Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1	LANCET			English	Editorial Material									Victoria Hosp, Fife Acute Hosp NHS Trust, Dept Med, Kirkcaldy KY2 5AH, Fife, Scotland; Victoria Hosp, Fife Acute Hosp NHS Trust, Dept Surg, Kirkcaldy KY2 5AH, Fife, Scotland; Victoria Hosp, Fife Acute Hosp NHS Trust, Dept Pathol, Kirkcaldy KY2 5AH, Fife, Scotland		Campbell, IW (corresponding author), Victoria Hosp, Fife Acute Hosp NHS Trust, Dept Med, Kirkcaldy KY2 5AH, Fife, Scotland.		Reynolds, Rebecca M/C-3044-2008	Reynolds, Rebecca M/0000-0001-6226-8270				Editorial, 1968, JAMA-J AM MED ASSOC, V205, P94; Hirsch NP, 2001, BRIT J ANAESTH, V86, P555, DOI 10.1093/bja/86.4.555; Koch C A, 2001, Endocr Regul, V35, P43; Korf B R, 2001, Curr Neurol Neurosci Rep, V1, P162, DOI 10.1007/s11910-001-0012-z	4	117	127	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1552	1554		10.1016/S0140-6736(03)13166-2	http://dx.doi.org/10.1016/S0140-6736(03)13166-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737880				2022-12-28	WOS:000182658900027
J	Evenson, RE; Gollin, D				Evenson, RE; Gollin, D			Assessing the impact of the Green Revolution, 1960 to 2000	SCIENCE			English	Review								We summarize the findings of a recently completed study of the productivity impacts of international crop genetic improvement research in developing countries. Over the period 1960 to 2000, international agricultural research centers, in collaboration with national research programs, contributed to the development of "modern varieties" for many crops. These varieties have contributed to large increases in crop production. Productivity gains, however, have been uneven across crops and regions. Consumers generally benefited from declines in food prices. Farmers benefited only where cost reductions exceeded price reductions.	Yale Univ, Dept Econ, New Haven, CT 06520 USA; Williams Coll, Dept Econ, Williamstown, MA 01267 USA	Yale University; Williams College	Evenson, RE (corresponding author), Yale Univ, Dept Econ, New Haven, CT 06520 USA.							[Anonymous], 2003, CROP VARIETY IMPROVE; Dalrymple DG, 1986, Development and spread of high -yielding wheat varieties in developing countries, V7th; DALTON TJ, 2003, CROP VARIETY IMPROVE, pCH6; EVENSON RE, 2003, CROP VARIET IMPROVEM, pCH23; EVENSON RE, 2003, CROP VFARIETY IMPROV, pCH21; Griffin K., 1979, POLITICAL EC AGRARIA; Hewitt de Alcantara Cynthia, 1976, MODERNIZING MEXICAN; JOHNSON NL, 2003, CROP VARIETY IMPROVE, pCH16; JOHNSON NL, 2003, CROP VARIETY IMPROVE, pCH12; MANYONG VM, 2003, CROP VARIETY IMPROVE, pCH8; MCKINSEY JW, 2003, CROP VARIETY IMPROVE, pCH19; Shiva V, 1993, MONOCULTURES MIND PE	12	1065	1111	21	590	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					758	762		10.1126/science.1078710	http://dx.doi.org/10.1126/science.1078710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730592				2022-12-28	WOS:000182579800038
J	Morse, DL				Morse, DL			West Nile virus - not a passing phenomenon	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									New York State Dept Hlth, Albany, NY 12237 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Morse, DL (corresponding author), New York State Dept Hlth, Albany, NY 12237 USA.								0	20	20	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2173	2174		10.1056/NEJMp030060	http://dx.doi.org/10.1056/NEJMp030060			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773644				2022-12-28	WOS:000183134700002
J	Schiermeier, Q				Schiermeier, Q			Deep-sea sub aims to get to the bottom of a muddy issue	NATURE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					469	469		10.1038/423469b	http://dx.doi.org/10.1038/423469b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774082	Bronze			2022-12-28	WOS:000183162900008
J	Wassertheil-Smoller, S; Hendrix, SL; Limacher, M; Heiss, G; Kooperberg, C; Baird, A; Kotchen, T; Curb, JD; Black, H; Rossouw, JE; Aragaki, A; Safford, M; Stein, E; Laowattana, S; Mysiw, WJ				Wassertheil-Smoller, S; Hendrix, SL; Limacher, M; Heiss, G; Kooperberg, C; Baird, A; Kotchen, T; Curb, JD; Black, H; Rossouw, JE; Aragaki, A; Safford, M; Stein, E; Laowattana, S; Mysiw, WJ		WHI Investigators	Effect of estrogen plus progestin on stroke in postmenopausal women - The Women's Health Initiative: A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; C-REACTIVE PROTEIN; ISCHEMIC-STROKE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; CIGARETTE-SMOKING; CLASSIFICATION; PLASMA; INFLAMMATION; CHOLESTEROL	Context The Women's Health Initiative (WHI) trial of estrogen plus progestin was stopped early because of adverse effects, including an increased risk of stroke in the estrogen plus progestin group. Objective To assess the effect of estrogen plus progestin on ischemic and hemorrhagic stroke and in subgroups, and to determine whether the effect of estrogen plus progestin was modified by baseline levels of blood biomarkers. Design Multicenter double-blind, placebo-controlled, randomized clinical trial involving 16608 women aged 50 through 79 years with an average follow-up of 5.6 years. Baseline levels of blood-based markers of inflammation, thrombosis, and lipid levels were measured in the first 140 centrally confirmed stroke cases and 513 controls. Interventions Participants received 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n=8506) or placebo (n=8102). Main Outcome Measures Overall strokes and stroke subtype and severity were centrally adjudicated by stroke neurologists. Results One hundred fifty-one patients (1.8%) in the estrogen plus progestin and 107 (1.3%) in the placebo groups had strokes. Overall 79.8% of strokes were ischemic. For combined ischemic and hemorrhagic strokes, the intention-to-treat hazard ratio (HR) for estrogen plus progestin vs placebo was 1.31 (95% confidence interval [CI], 1.02-1.68); with adjustment for adherence, the HR was 1.50 (95% CI, 1.08-2.08). The HR for ischemic stroke was 1.44 (95% CI, 1.09-1.90) and for hemorrhagic stroke, 0.82 (95% CI, 0.43-1.56). Point estimates of the HRs indicate that excess risk of all stroke was apparent in all age groups, in all categories of baseline stroke risk, and in women with and without hypertension, prior history of cardiovascular disease, use of hormones, statins, or aspirin. Other risk factors for stroke, including smoking, blood pressure, diabetes, lower use of vitamin C supplements, blood-based biomarkers of inflammation, higher white blood cell count, and higher hematocrit levels did not modify the effect of estrogen plus progestin on stroke risk. Conclusions Estrogen plus progestin increases the risk of ischemic stroke in generally healthy postmenopausal women. Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined.	Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA; Wayne State Univ, WHI Clin Ctr, Detroit, MI USA; Univ Florida, WHI Clin Ctr, Gainesville, FL USA; Univ N Carolina, Sch Med & Publ Hlth, Durham, NC USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; NINDS, Stroke Neurosci Unit, Bethesda, MD 20892 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Womens Hlth Hawaii, Honolulu, HI USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; NHLBI, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Med Res Labs, Highland Hts, KY USA; Georgetown Washington Univ, Washington, DC USA; Ohio State Univ, Columbus, OH 43210 USA	Yeshiva University; Albert Einstein College of Medicine; Wayne State University; State University System of Florida; University of Florida; University of North Carolina; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Medical College of Wisconsin; Rush University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University	Wassertheil-Smoller, S (corresponding author), Albert Einstein Coll Med, Dept Epidemiol & Social Med, 1300 Morris Pk Ave,Room 1312 Belfer, Bronx, NY 10461 USA.	smoller@aecom.yu.edu	Mysiw, Walter/E-3724-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002995] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Barnett HJM, 2000, JAMA-J AM MED ASSOC, V283, P1429, DOI 10.1001/jama.283.11.1429; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; Bousser MG, 1999, CIRCULATION, V99, P463, DOI 10.1161/01.CIR.99.4.463; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; DAC NV, 1989, J LIPID RES, V30, P1437; DAGOSTINO RB, 1994, STROKE, V25, P40, DOI 10.1161/01.STR.25.1.40; DECATERINA R, 1994, ARTERIOSCLER THROMB, V14, P1829, DOI 10.1161/01.ATV.14.11.1829; Devaraj S, 2000, CIRCULATION, V102, P191, DOI 10.1161/01.CIR.102.2.191; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gillum LA, 2000, JAMA-J AM MED ASSOC, V284, P72, DOI 10.1001/jama.284.1.72; Goldstein LB, 2001, STROKE, V32, P1091, DOI 10.1161/01.STR.32.5.1091; Gorelick PB, 1999, JAMA-J AM MED ASSOC, V281, P1112, DOI 10.1001/jama.281.12.1112; Hak AE, 1999, ARTERIOSCL THROM VAS, V19, P1986, DOI 10.1161/01.ATV.19.8.1986; Hart CL, 1999, STROKE, V30, P1999, DOI 10.1161/01.STR.30.10.1999; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lemaitre RN, 2002, ARCH INTERN MED, V162, P1954, DOI 10.1001/archinte.162.17.1954; LINDLEY RI, 1993, STROKE, V24, P1801, DOI 10.1161/01.STR.24.12.1801; Lip GYH, 1996, CIRCULATION, V94, P425, DOI 10.1161/01.CIR.94.3.425; MADDEN KP, 1995, NEUROLOGY, V45, P1975, DOI 10.1212/WNL.45.11.1975; Makris TK, 2000, AM J HYPERTENS, V13, P783, DOI 10.1016/S0895-7061(00)00262-4; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; Mustonen P, 1998, ARTERIOSCL THROM VAS, V18, P244, DOI 10.1161/01.ATV.18.2.244; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rohde LEP, 1999, AM J CARDIOL, V84, P1018, DOI 10.1016/S0002-9149(99)00491-9; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; RUSSELL WG, 1994, LAB MEASUREMENT LIPI, P207; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; STEINER PM, 1981, J CLIN CHEM CLIN BIO, V19, P850; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WARNICK GR, 1978, J LIPID RES, V19, P65; Whisnant JP, 1997, STROKE, V28, P1840, DOI 10.1161/01.STR.28.9.1840; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025	50	850	877	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2003	289	20					2673	2684		10.1001/jama.289.20.2673	http://dx.doi.org/10.1001/jama.289.20.2673			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682DG	12771114	Bronze			2022-12-28	WOS:000183075600026
J	Lang, I				Lang, I			A 42 year old man with acute chest pain: case outcome - Commentary: Cardiovascular management	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							AORTIC DISSECTION		Univ Vienna, A-1090 Vienna, Austria	University of Vienna	Lang, I (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	irene.lang@univie.ac.at	Winter, Max P/E-8456-2011	Lang, Irene/0000-0003-0485-2692				BARBANT SD, 1992, AM HEART J, V124, P541, DOI 10.1016/0002-8703(92)90632-6; DEMOS TC, 1989, SEMIN ROENTGENOL, V24, P22, DOI 10.1016/0037-198X(89)90051-5; ROBERTS CS, 1990, ANN THORAC SURG, V50, P762, DOI 10.1016/0003-4975(90)90681-U; Shennan T, 1934, MED RES CLIN SPECIAL, V193; SVENSSON LG, 1990, CIRCULATION, V82, P24; SVENSSON LG, 1992, CURR PROB SURG, V29, P915	6	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2003	326	7399					1135	1136		10.1136/bmj.326.7399.1135	http://dx.doi.org/10.1136/bmj.326.7399.1135			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763992	Green Published			2022-12-28	WOS:000183245000029
J	Paul, M; Soares-Weiser, K; Leibovici, L				Paul, M; Soares-Weiser, K; Leibovici, L			beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis	BRITISH MEDICAL JOURNAL			English	Review							PSEUDOMONAS-AERUGINOSA; CANCER-PATIENTS; CLINICAL-TRIALS; CEFTAZIDIME; GENTAMICIN; CARBENICILLIN; INFECTIONS; TOBRAMYCIN; BACTEREMIA; RESISTANCE	Objective To compare the effectiveness of beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy in the treatment of patients with fever and neutropenia. Data sources Medline, Embase, Lilacs, the Cochrane Library, and conference proceedings to 2002. References of included studies and contact with authors. No restrictions on language, year of publication, or publication status. Study selection All randomised trials of beta lactam monotherapy compared with beta lactamaminoglycoside combination therapy as empirical treatment for patients with fever and neutropenia. Data selection Two reviewers independently applied selection criteria, performed quality assessment, and extracted data. An intention to treat approach was used. Relative risks were pooled with the random effect model. Main outcome measure All cause fatality. Results Forty seven trials with 7807 patients met inclusion criteria. Nine trials compared the same beta lactam. There was no significant difference in all cause fatality (relative risk 0.85, 95% confidence interval 0.72 to 1.02). For success of treatment there was a significant advantage with monotherapy (0.92, 0.85 to 0.99), though there was considerable heterogeneity among trials. There was no significant difference between monotherapy and combination treatment in trials that compared the same beta lactam, whereas there was major advantage with monotherapy in trials that compared different beta lactams (0.87, 0.80 to 0.93). Rates of superinfection were similar. Adverse events, including those associated with severe morbidity, were significantly more common in the combination treatment group. Detected flaws in methods, did not affect results. Conclusions For patients with fever and neutropenia there is no clinical advantage in treatment with beta lactam-aminoglycoside combination therapy. Broad spectrum beta lactams as monotherapy should be regarded as the standard of care for such patients.	Rabin Med Ctr, Infect Dis Unit, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Med E, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center; Rabin Medical Center	Paul, M (corresponding author), Rabin Med Ctr, Infect Dis Unit, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.							[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD003038; BODEY GP, 1972, CANCER-AM CANCER SOC, V29, P1697, DOI 10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO;2-K; CALANDRA T, 1987, NEW ENGL J MED, V317, P1692; Clarke M, 2001, COCHRANE REV HDB 4 1; denHollander JG, 1997, ANTIMICROB AGENTS CH, V41, P95, DOI 10.1128/AAC.41.1.95; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ELPHICK HE, 2003, COCHRANE DATABASE SY, DOI UNSP CD002007; Elting LS, 1997, CLIN INFECT DIS, V25, P247, DOI 10.1086/514550; GIAMARELLOU H, 1986, AM J MED, V80, P126, DOI 10.1016/0002-9343(86)90490-0; GIAMARELLOU H, 1984, ANTIMICROB AGENTS CH, V25, P534, DOI 10.1128/AAC.25.4.534; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; KLASTERSKY J, 1977, AM J MED SCI, V273, P157, DOI 10.1097/00000441-197703000-00005; KLASTERSKY J, 1986, ANTIMICROB AGENTS CH, V29, P263, DOI 10.1128/AAC.29.2.263; KLASTERSKY J, 1982, REV INFECT DIS, V4, P294; KRAMER BS, 1986, ANTIMICROB AGENTS CH, V30, P64, DOI 10.1128/AAC.30.1.64; Leibovici L, 1997, ANTIMICROB AGENTS CH, V41, P1127, DOI 10.1128/AAC.41.5.1127; Mouton JW, 1999, INFECTION, V27, pS24, DOI 10.1007/BF02561666; Paesmans M, 2000, INT J ANTIMICROB AG, V16, P107, DOI 10.1016/S0924-8579(00)00213-2; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Wu YL, 1999, J ANTIMICROB CHEMOTH, V44, P389, DOI 10.1093/jac/44.3.389	22	169	179	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1111	1115		10.1136/bmj.326.7399.1111	http://dx.doi.org/10.1136/bmj.326.7399.1111			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763980	Green Published, Bronze			2022-12-28	WOS:000183245000016
J	Burke, JM; Rieseberg, LH				Burke, JM; Rieseberg, LH			Fitness effects of transgenic disease resistance in sunflowers	SCIENCE			English	Article							GENE FLOW; INTROGRESSION		Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Vanderbilt University; Indiana University System; Indiana University Bloomington	Burke, JM (corresponding author), Vanderbilt Univ, Dept Biol Sci, 221 Kirkland Hall, Nashville, TN 37235 USA.		Burke, John M/A-3502-2013; Rieseberg, Loren H/B-3591-2013	Burke, John M/0000-0002-1412-5539; Rieseberg, Loren H/0000-0002-2712-2417				Burke JM, 2002, AM J BOT, V89, P1550, DOI 10.3732/ajb.89.9.1550; Ellstrand NC, 1999, ANNU REV ECOL SYST, V30, P539, DOI 10.1146/annurev.ecolsys.30.1.539; Linder CR, 1998, THEOR APPL GENET, V96, P339, DOI 10.1007/s001220050746; NOYES RD, 1981, PHYSIOL PLANT PATHOL, V18, P123; Rieseberg LH, 2001, TAXON, V50, P47, DOI 10.2307/1224511	5	107	122	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1250	1250		10.1126/science.1084960	http://dx.doi.org/10.1126/science.1084960			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764188	Green Submitted			2022-12-28	WOS:000183042400037
J	Pennisi, E				Pennisi, E			Neuroscience - Monarchs check clock to chart migration route	SCIENCE			English	News Item																			0	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1216	1217						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12764162				2022-12-28	WOS:000183042400005
J	Hart, RG; Halperin, JL; Pearce, LA; Anderson, DC; Kronmal, RA; McBride, R; Nasco, E; Sherman, DG; Talbert, RL; Marler, JR				Hart, RG; Halperin, JL; Pearce, LA; Anderson, DC; Kronmal, RA; McBride, R; Nasco, E; Sherman, DG; Talbert, RL; Marler, JR		Stroke Prevention Atrial Fibrillat	Lessons from the Stroke Prevention in Atrial Fibrillation trials	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RISK-FACTORS; ISCHEMIC-STROKE; AORTIC PLAQUE; ASPIRIN; THROMBOEMBOLISM; PREVALENCE; WARFARIN; ANTICOAGULATION; PREDICTORS; SCHEMES	Atrial fibrillation predisposes to left atrial thrombus formation and carries a sixfold increased risk for stroke. Antithrombotic therapies are the mainstay for stroke prevention. The National Institute of Neurological Disorders and Stroke-sponsored Stroke Prevention in Atrial Fibrillation (SPAF) studies assessed the value of warfarin, aspirin, and their combination for preventing stroke in six multicenter trials involving 3950 participants. This review presents the major results and implications, which offer unique perspectives on antithrombotic therapies for stroke prevention in atrial fibrillation. Warfarin and aspirin reduce stroke. Anticoagulation substantially benefits high-risk patients with atrial fibrillation, while many younger patients with atrial fibrillation have a low stroke rate when given aspirin. Pathogenetic and transesophageal echocardiographic correlations shed light on mechanisms by which antithrombotic agents prevent stroke. Warfarin inhibits formation of atrial appendage thrombi and markedly reduces cardioembolic strokes, while aspirin primarily prevents smaller, noncardioembolic strokes. The SPAF III stroke risk stratification scheme has been validated for identifying patients with high versus moderate versus low risk for stroke. Women with atrial fibrillation benefit from anticoagulation significantly more than men do. Many elderly patients with recurrent paroxysmal atrial fibrillation have high rates of stroke. Antithrombotic prophylaxis should be individualized on the basis of the estimated risk for stroke during aspirin therapy and the risk for bleeding during anticoagulation. Overall, nearly one third of patients with atrial fibrillation are low risk and should be treated with aspirin, and about one third are high risk and should receive warfarin if it can be given safely. For patients at moderate risk for stroke, patient preferences and access to reliable anticoagulation monitoring are particularly relevant.	Univ Texas, Hlth Sci Ctr, Dept Med Neurol, San Antonio, TX 78229 USA; Mt Sinai Sch Med, Zena & Michael A Weiner Cardiovasc Inst, New York, NY USA; Univ Minnesota, Sch Med, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA; Univ Washington, Seattle, WA 98195 USA; Axio Res Corp, Seattle, WA USA; Univ Texas, Sch Pharm, Austin, TX 78712 USA; NINDS, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health San Antonio; Icahn School of Medicine at Mount Sinai; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Austin; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Hart, RG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med Neurol, 7703 Floyd Curl Dr,MC 7883, San Antonio, TX 78229 USA.	hartr@uthscsa.edu	Halperin, Jonathan/AAJ-4721-2020	Halperin, Jonathan/0000-0002-8318-5471; Anderson, David/0000-0001-9874-5649; Pearce, Lesly/0000-0002-0838-1739	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024224] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 24-224] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; Anderson DC, 2002, STROKE, V33, P1963, DOI 10.1161/01.STR.0000023445.20454.A8; ANDERSON DC, 1992, CEREBROVASC DIS, V2, P332; [Anonymous], 1997, ARCH INTERN MED, V157, P1237; Asinger RW, 1999, J AM SOC ECHOCARDIOG, V12, P1088, DOI 10.1016/S0894-7317(99)70106-9; Blackshear JL, 1996, LANCET, V348, P633; Blackshear JL, 1999, AM J CARDIOL, V83, P453, DOI 10.1016/S0002-9149(98)00886-8; Blackshear JL, 1999, STROKE, V30, P834, DOI 10.1161/01.STR.30.4.834; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; Conway DSG, 2002, CIRCULATION, V106, P1962, DOI 10.1161/01.CIR.0000033220.97592.9A; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; Feinberg WM, 1999, J GEN INTERN MED, V14, P56, DOI 10.1046/j.1525-1497.1999.00281.x; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; GAGE BF, 2003, IN PRESS J GEN INTER; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Go AS, 2000, CIRCULATION, V102, P11, DOI 10.1161/01.CIR.102.1.11; Goldman ME, 1999, J AM SOC ECHOCARDIOG, V12, P1080, DOI 10.1016/S0894-7317(99)70105-7; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hart RG, 2000, CEREBROVASC DIS, V10, P39, DOI 10.1159/000016023; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; KANTER MC, 1994, ARCH INTERN MED, V154, P1372, DOI 10.1001/archinte.154.12.1372; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCBRIDE R, 1990, STROKE, V21, P538; Miller VT, 1996, NEUROLOGY, V46, P238, DOI 10.1212/WNL.46.1.238; MILLER VT, 1993, NEUROLOGY, V43, P32, DOI 10.1212/WNL.43.1_Part_1.32; Pearce LA, 2000, AM J MED, V109, P45, DOI 10.1016/S0002-9343(00)00440-X; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, NEW ENGL J MED, V323, P482; PETERSEN P, 2000, J NEUROLOGICAL SC S1, V187, pS124; SINGER DE, 1992, AM HEART J, V124, P1567, DOI 10.1016/0002-8703(92)90074-6; Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1; Stroke Prevention in Atrial Fibrillation Investigators, 1997, J STROKE CEREBROVASC, V5, P341; Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography, 1996, J AM SOC ECHOCARDIOG, V9, P556; The-Stroke-Prevention-in-Atrial-Fibrillation-Investigators, 1993, J STROKE CEREBROVASC, V3, P181; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; VANWALRAVEN C, 2003, IN PRESS ARCH INTERN; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Zabalgoitia M, 1998, ANN INTERN MED, V128, P639, DOI 10.7326/0003-4819-128-8-199804150-00005; Zabalgoitia M, 1998, J AM COLL CARDIOL, V31, P1622, DOI 10.1016/S0735-1097(98)00146-6	47	175	181	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					831	838		10.7326/0003-4819-138-10-200305200-00011	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755555				2022-12-28	WOS:000182920700007
J	Kwon, HJ; Cote, TR; Cuffe, MS; Kramer, JM; Braun, MM				Kwon, HJ; Cote, TR; Cuffe, MS; Kramer, JM; Braun, MM			Case reports of heart failure after therapy with a tumor necrosis factor antagonist	ANNALS OF INTERNAL MEDICINE			English	Article							DILATED CARDIOMYOPATHY; TRANSGENIC MICE; FACTOR-ALPHA; ETANERCEPT; ENBREL	Background: Etanercept and infliximab are U.S. Food and Drug Administration-approved tumor necrosis factor (TNF) antagonists. Objective: To describe adverse event reports of heart failure after TNF antagonist therapy. Design: Case series. Setting: The U.S. Food and Drug Administration's MedWatch program. Patients: 47 patients who developed new or worsening heart failure during TNF antagonist therapy. Measurements: Clinical and laboratory reports. Results: After TNF antagonist therapy, 38 patients developed new-onset heart failure and 9 patients experienced heart failure exacerbation. Of the 38 patients with new-onset heart failure, 19 (50%) had no identifiable risk factors. Ten patients younger than 50 years of age developed new-onset heart failure after receiving TNF antagonists. After TNF antagonist therapy was discontinued and heart failure therapy was started in these 10 patients, 3 had complete resolution of heart failure, 6 improved, and 1 died. Conclusion: in a fraction of patients, TNF antagonists might induce new-onset heart failure or exacerbate existing disease.	US FDA, Div Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA; Duke Clin Res Inst, Durham, NC USA	US Food & Drug Administration (FDA); Duke University	Kwon, HJ (corresponding author), US FDA, Div Epidemiol, Ctr Biol Evaluat & Res, 1401 Rockville Pike,Suite 200S,HFM-224, Rockville, MD 20852 USA.	kwon@cber.fda.gov						Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044; Brewer T, 1999, JAMA-J AM MED ASSOC, V281, P824, DOI 10.1001/jama.281.9.824; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; CUSH JJ, FDA ADVISORY COMMITT; Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224; *EUR SOC CARD HEAR, RENEWAL TRIAL NO IMP; Feldman AM, 2000, J AM COLL CARDIOL, V35, P537, DOI 10.1016/S0735-1097(99)00600-2; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Louis A, 2001, EUR J HEART FAIL, V3, P381, DOI 10.1016/S1388-9842(01)00149-0; Manzi S, 2000, ANN RHEUM DIS, V59, P321, DOI 10.1136/ard.59.5.321; *NAT HEART LUNG BL, CONG HEART FAIL US N; Sliwa K, 1998, LANCET, V351, P1091, DOI 10.1016/S0140-6736(97)09338-0; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7	15	320	334	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					807	811		10.7326/0003-4819-138-10-200305200-00008	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KH	12755552				2022-12-28	WOS:000182920700004
J	Lynn, J; Goldstein, NE				Lynn, J; Goldstein, NE			Advance care planning for fatal chronic illness: Avoiding commonplace errors and unwarranted suffering	ANNALS OF INTERNAL MEDICINE			English	Article							OF-LIFE CARE; QUALITY-IMPROVEMENT; DIRECTIVES; END; MANAGEMENT; DISEASE; DYSPNEA; FORM	Patients with eventually fatal illnesses often receive routine treatments in response to health problems rather than treatments arising from planning that incorporates the patient's situation and preferences. This paper considers the case of an elderly man with advanced lung disease who had mechanical ventilation and aggressive intensive care, in part because his nursing home clinicians did not complete an advance care plan and his do-not-resuscitate order did not accompany him to the hospital. The errors that led to his hospitalization and his unwanted treatment there demonstrate how the ordinary lack of advance care planning is deleterious for patients who are nearing the end of life. We discuss serious, recurring, and generally unnoticed errors in planning for care near the end of life and possible steps toward improvement. Repairing these shortcomings will require quality improvement and system redesign efforts, methods familiar from patient safety initiatives. Reliable improvement will also require making it unacceptable for clinicians to fail to plan ahead for care during fatal chronic illness.	Washington Home Ctr Palliat Care Studies & RAND H, Washington, DC USA; Yale Univ, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA	Yale University	Lynn, J (corresponding author), Washington Home & Community Hospice, Ctr Palliat Care Studies, 4200 Wisconsin Ave NW,4th Floor, Washington, DC 20016 USA.	jlynn@thewashingtonhome.org			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011558] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM BETT CAR DYING, MAK PROM VIS BETT SY; Bates DW, 2002, ANN INTERN MED, V137, P110, DOI 10.7326/0003-4819-137-2-200207160-00009; Chassin MR, 2002, ANN INTERN MED, V136, P826, DOI 10.7326/0003-4819-136-11-200206040-00012; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146, DOI 10.1111/j.1532-5415.2000.tb03124.x; Cretin S, 2000, JAMA-J AM MED ASSOC, V284, P1786, DOI 10.1001/jama.284.14.1786; CRETIN S, 2000, JAMA-J AM MED ASSOC, V284, P1787; DANIS M, 1994, HASTINGS CENT REP, V24, pS21, DOI 10.2307/3563478; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Field MJ, 1997, APPROACHING DEATH IM; Foley KM, 2001, IMPROVING PALLIATIVE; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; GRADY D, 2000, NY TIMES        0529, P1; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Luce JM, 2000, AM J RESP CRIT CARE, V162, P2029, DOI 10.1164/ajrccm.162.6.1-00; Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331; Lynn J, 2002, ANN INTERN MED, V137, P117, DOI 10.7326/0003-4819-137-2-200207160-00010; Lynn J, 1997, New Horiz, V5, P56; Lynn J, 2001, J GEN INTERN MED, V16, P315, DOI 10.1046/j.1525-1497.2001.90901.x; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Lynn J, 2001, WESTERN J MED, V175, P299, DOI 10.1136/ewjm.175.5.299; LYNN J, 2000, IMPROVING CARE END L; LYNN J, 2001, ABCD EXCHANGE    MAY; Markowitz AJ, 2002, JAMA-J AM MED ASSOC, V287, P2261, DOI 10.1001/jama.287.17.2261; MATHERLEE K, 2002, 779 NAT HLTH POL FOR; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Meisel A, 2000, JAMA-J AM MED ASSOC, V284, P2495, DOI 10.1001/jama.284.19.2495; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; Myers S S, 2001, J Palliat Med, V4, P325, DOI 10.1089/109662101753123931; *NAT TASKF END OF, 1999, M CHALL 12 REC IMPR; Pan C X, 2001, J Palliat Med, V4, P315, DOI 10.1089/109662101753123922; STEGMAN M, 1999, HOSPICE PALLIATIVE M, P77; Teno JM, 1996, J CLIN ETHIC, V7, P205; TENO JM, 1994, J CLIN ETHIC, V5, P23; Teno JM, 1998, J AM GERIATR SOC, V46, P1170, DOI 10.1111/j.1532-5415.1998.tb06662.x; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Wenger NS, 2001, ANN INTERN MED, V135, P677, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00006	38	91	92	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2003	138	10					812	818		10.7326/0003-4819-138-10-200305200-00009	http://dx.doi.org/10.7326/0003-4819-138-10-200305200-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	679KH	12755553				2022-12-28	WOS:000182920700005
J	Fouchier, RAM; Kuiken, T; Schutten, M; van Amerongen, G; van Doornum, J; van den Hoogen, BG; Peiris, M; Lim, W; Stohr, K; Osterhaus, ADME				Fouchier, RAM; Kuiken, T; Schutten, M; van Amerongen, G; van Doornum, J; van den Hoogen, BG; Peiris, M; Lim, W; Stohr, K; Osterhaus, ADME			Aetiology - Koch's postulates fulfilled for SARS virus	NATURE			English	Article									Erasmus Med Ctr, Dept Virol, NL-3015 GE Rotterdam, Netherlands; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; 9F Publ Hlth Lab Ctr, Govt Virus Unit, Kowloon, Hong Kong, Peoples R China	Erasmus University Rotterdam; Erasmus MC; University of Hong Kong	Fouchier, RAM (corresponding author), Erasmus Med Ctr, Dept Virol, NL-3015 GE Rotterdam, Netherlands.		Fouchier, Ron A/A-1911-2014; van den Hoogen, Bernadette/J-5461-2013; Peiris, Joseph Sriyal Malik/C-4380-2009	Fouchier, Ron A/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995				[Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P81; DROSTEN C, IN PRESS N ENGL J ME; KSIAZEK TG, IN PRESS N ENGL J ME; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; POUTANEN SM, IN PRESS N ENGL J ME; Rivers TM, 1937, J BACTERIOL, V33, P1; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098	7	546	610	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					240	240		10.1038/423240a	http://dx.doi.org/10.1038/423240a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12748632	Green Published, Bronze			2022-12-28	WOS:000182853100032
J	Pollock, BH; Jenson, HB; Leach, CT; McClain, KL; Hutchison, RE; Garzarella, L; Joshi, VV; Parmley, RT; Murphy, SB				Pollock, BH; Jenson, HB; Leach, CT; McClain, KL; Hutchison, RE; Garzarella, L; Joshi, VV; Parmley, RT; Murphy, SB			Risk factors for pediatric human immunodeficiency virus-related malignancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPSTEIN-BARR-VIRUS; NON-HODGKIN-LYMPHOMA; CHILDREN; INFECTION; AIDS; CANCER; DNA; TYPE-1; AMPLIFICATION; HEMOPHILIA	Context Although cancers occur with increased frequency in children with human immunodeficiency virus (HIV) infection, the specific clinical, immunological, and viral risk factors for malignancy have not been identified. Objective To identify risk factors for malignancy among HIV-infected children. Design, Setting, and Patients A multicenter case-control study of children with HIV at 26 institutions participating in the Pediatric Oncology Group. Forty-three case patients with a new malignancy and 74 control patients without a malignancy were matched based on the duration of their infection. Patients were enrolled between January 1992 and July 1998. Main Outcome Measures Clinical and laboratory factors assessed as putative risk factors included demographic characteristics, HIV characteristics, prior antiretroviral treatment, and CD4 cell count. Coviral infections with Epstein-Barr virus (EBV), cytomegalovirus, and human herpesvirus 6 were assessed by semiquantitative polymerase chain reaction assays and serological testing. Results Case malignancy diagnoses included 28 non-Hodgkin lymphoma, 4 B-cell acute lymphoblastic leukemia, 1 Hodgkin disease, 9 leiomyosarcoma, 1 hepatoblastoma, and 1 schwannoma. Epstein Barr virus viral load of more than 50 viral genome copies per 10(5) peripheral blood mononuclear cells was strongly associated with cancer risk but only for children with CD4 cell counts of at least 200/muL (odds ratio [OR], 11.33; 95% confidence interval [CI], 2.09-65.66, P<.001). High EBV viral load was not associated with cancer for children with CD4 cell counts of less than 200/mu L (OR, 1.12; 95% CI, 0.13-9.62; P=.99). Zidovudine antiretroviral therapy did not confer a significant protective effect for either the high (OR, 0.81; 95% CI, 0.22-3.09; P=.77) or the low CD4 cell count groups (OR, 0.27; 95% CI, 0.04-1.46; P=.16). The route of HIV infection was not associated with increased cancer risk. Conclusions Route of infection, demographic characteristics, and zidovudine use were not associated with the,development of malignancy in HIV-infected children. High viral burden with EBV was associated with the development of malignancy in HIV-infected children although the effect was modified by CD4 cell count. The pathogenesis of HIV-related pediatric malignancies remains unclear and other contributing risk factors can be elucidated only through further study.	Univ Texas, Hlth Sci Ctr, Ctr Biostat & Epidemiol, Childrens Canc Res Inst, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA; Eastern Virginia Med Sch, Norfolk, VA 23501 USA; Childrens Hosp Kings Daughters, Norfolk, VA USA; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; SUNY Upstate Med Univ, Syracuse, NY USA; Univ Florida, Dept Hlth Policy & Epidemiol, Gainesville, FL USA; Hartford Hosp, Dept Pathol, Hartford, CT 06115 USA; Greenville Hosp Syst, Childrens Hosp, Dept Pediat, Greenville, SC USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Eastern Virginia Medical School; Baylor College of Medicine; Texas Children's Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University System of Florida; University of Florida; Hartford Hospital; Greenville Health System	Pollock, BH (corresponding author), Univ Texas, Hlth Sci Ctr, Ctr Biostat & Epidemiol, Childrens Canc Res Inst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	bpollock@uthscsa.edu		Jenson, Hal/0000-0002-6549-860X; McClain, Kenneth/0000-0003-0725-6263	NCI NIH HHS [CA55507, CA56296, CA07431, CA29139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA007431, R01CA056296, R01CA055507, U10CA029139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, CANCER, V49, P2112; Biggar RJ, 2000, JAMA-J AM MED ASSOC, V284, P205, DOI 10.1001/jama.284.2.205; Caselli D, 2000, J CLIN ONCOL, V18, P3854, DOI 10.1200/JCO.2000.18.22.3854; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DEMMLER GJ, 1988, J INFECT DIS, V158, P1177, DOI 10.1093/infdis/158.6.1177; GOPAL MR, 1990, LANCET, V335, P1598, DOI 10.1016/0140-6736(90)91433-B; Granovsky MO, 1998, J CLIN ONCOL, V16, P1729, DOI 10.1200/JCO.1998.16.5.1729; Jenson H, 1999, J INFECT DIS, V179, P1395, DOI 10.1086/314764; Jenson HB, 1997, LEUKEMIA LYMPHOMA, V27, P303, DOI 10.3109/10428199709059684; JENSON HB, 2002, MANUAL CLIN LAB IMMU, P615; Kawakami Kiyoshi, 1994, Acta Paediatrica Japonica (Overseas Edition), V36, P91; LEACH CT, 1994, J INFECT DIS, V169, P1281, DOI 10.1093/infdis/169.6.1281; Leach CT, 2002, PEDIATR INFECT DIS J, V21, P125, DOI 10.1097/00006454-200202000-00008; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; McClain KL, 2000, J ACQ IMMUN DEF SYND, V23, P152; Mueller BU, 1999, AIDS PATIENT CARE ST, V13, P527, DOI 10.1089/apc.1999.13.527; Olivero OA, 1997, J NATL CANCER I, V89, P1602, DOI 10.1093/jnci/89.21.1602; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RABKIN CS, 1992, JAMA-J AM MED ASSOC, V267, P1090, DOI 10.1001/jama.267.8.1090; RAGNI MV, 1993, BLOOD, V81, P1889; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; van Baarle D, 2002, J INFECT DIS, V186, P405, DOI 10.1086/341460	22	38	43	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2393	2399		10.1001/jama.289.18.2393	http://dx.doi.org/10.1001/jama.289.18.2393			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677WF	12746363				2022-12-28	WOS:000182831200029
J	Wolf-Maier, K; Cooper, RS; Banegas, JR; Giampaoli, S; Hense, HW; Joffres, M; Kastarinen, M; Poulter, N; Primatesta, P; Rodriguez-Artalejo, F; Stegmayr, B; Thamm, M; Tuomilehto, J; Vanuzzo, D; Vescio, F				Wolf-Maier, K; Cooper, RS; Banegas, JR; Giampaoli, S; Hense, HW; Joffres, M; Kastarinen, M; Poulter, N; Primatesta, P; Rodriguez-Artalejo, F; Stegmayr, B; Thamm, M; Tuomilehto, J; Vanuzzo, D; Vescio, F			Hypertension, prevalence and blood pressure levels in 6 European countries, Canada, and the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; MONICA PROJECT; CARDIOVASCULAR-DISEASE; REGIONAL-VARIATIONS; CASE-FATALITY; HEALTH SURVEY; RISK-FACTORS; TRENDS; MORTALITY; STROKE	Context Geographic variations in cardiovascular disease (CVD) and associated risk factors have been recognized worldwide. However, little attention has been directed to potential differences in hypertension between Europe and North America. Objective To determine whether higher blood pressure (BP) levels and hypertension are more prevalent in Europe than in the United States and Canada. Design, Setting, and Participants Sample surveys that were national in scope and conducted in the 1990s were identified in Germany, Finland, Sweden,, England, Spain, Italy, Canada, and the United States. Collaborating investigators provided tabular data in a consistent format by age and sex for persons at least 35 years of age. Population registries were the main basis for sampling. Survey sizes ranged from 1800 to 23 100, with response rates of 61% to 87.5%. The data were analyzed to provide age-specific and age-adjusted estimates of BP and hypertension prevalence by country and region (eg, European vs North American). Main Outcome Measures Blood pressure levels and prevalence of hypertension in Europe, the United States, and Canada. Results Average BP was 136/83 mm Hg in the European countries and 127/77 mm Hg in Canada and the United States among men and women combined who were 35 to 74 years of age. This difference already existed among younger persons (35-39 years) in whom treatment was uncommon (ie, 124/78 mm Hg and 115/75 mm Hg, respectively), and the slope with age was,steeper in the European countries. For all age groups, BP measurements were lowest in the United States,and highest in Germany. The age- and sex-adjusted prevalence of hypertension was 28% in the North American countries and 44% in the European countries at the 140/90 mm Hg threshold. The findings for men and women by region were similar. Hypertension prevalence was strongly correlated with stroke mortality (r=0.78) and more modestly with total CVD (r=0.44). Conclusions Despite extensive research on geographic patterns of CVD, the 60% higher prevalence of hypertension in Europe compared with the United States and Canada has not been generally appreciated. The implication of this finding for national prevention strategies should be vigorously explored.	Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA; Univ Autonoma Madrid, Fac Med, Dept Med Prevent & Salud Publ, Madrid, Spain; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Univ Munster, Inst Epidemiol & Social Med, Munster, Germany; Dalhousie Univ, Fac Med, Dept Epidemiol & Community Hlth, Halifax, NS, Canada; Kuopio Univ Hosp, Dept Internal Med, SF-70210 Kuopio, Finland; Univ London Imperial Coll Sci Technol & Med, Cardiovasc Studies Unit, London, England; UCL, Sch Med, Dept Epidemiol & Publ Hlth, London W1N 8AA, England; Univ Umea Hosp, Dept Med, S-90185 Umea, Sweden; Robert Koch Inst, D-1000 Berlin, Germany; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Helsinki, Finland; Agenzia Reg Friuli Venezia Giulia, Udine, Italy	Loyola University Chicago; Autonomous University of Madrid; Istituto Superiore di Sanita (ISS); University of Munster; Dalhousie University; Kuopio University Hospital; University of Eastern Finland; Imperial College London; University of London; University College London; UCL Medical School; Umea University; Robert Koch Institute; University of Helsinki; Finland National Institute for Health & Welfare	Cooper, RS (corresponding author), Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, 2160 S 1st Ave, Maywood, IL 60153 USA.	rcooper@lumc.edu	Vescio, Fenicia/N-5776-2017	Vescio, Fenicia/0000-0002-3285-919X				Ataman SL, 1996, J CLIN EPIDEMIOL, V49, P869, DOI 10.1016/0895-4356(96)00111-4; Banegas JR, 1998, HYPERTENSION, V32, P998, DOI 10.1161/01.HYP.32.6.998; Banegas JR, 2002, J HYPERTENS, V20, P2157, DOI 10.1097/00004872-200211000-00014; Bazzano LA, 2002, STROKE, V33, P1183, DOI 10.1161/01.STR.0000014607.90464.88; Beer-Borst S, 2000, J EPIDEMIOL COMMUN H, V54, P424, DOI 10.1136/jech.54.6.424; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper R, 2000, CIRCULATION, V102, P3137; ELLIOTT P, 1988, BRIT MED J, V297, P319; Gasse C, 2001, J HUM HYPERTENS, V15, P27, DOI 10.1038/sj.jhh.1001120; Giampaoli S, 2001, Ital Heart J Suppl, V2, P294; Hajjar I, 2003, J NUTR, V133, P211, DOI 10.1093/jn/133.1.211; Joffres MR, 1997, AM J HYPERTENS, V10, P1097; Joffres MR, 2001, AM J HYPERTENS, V14, P1099, DOI 10.1016/S0895-7061(01)02211-7; Kastarinen MJ, 1998, J HYPERTENS, V16, P1379, DOI 10.1097/00004872-199816090-00019; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KING H, 1991, B WORLD HEALTH ORGAN, V69, P643; Kotchen TA, 1997, CIRCULATION, V96, P1071, DOI 10.1161/01.CIR.96.4.1071; O'Brien, 1997, Blood Press Monit, V2, P31; O'Brien E, 2001, BMJ-BRIT MED J, V322, P531, DOI 10.1136/bmj.322.7285.531; Primatesta P, 2001, HYPERTENSION, V38, P827, DOI 10.1161/hyp.38.4.827; *PROD GED DMAK, 1999, WORLD DRINK TRENDS; Rehm J, 2000, EUR J EPIDEMIOL, V16, P669, DOI 10.1023/A:1007693009604; Rywik SL, 1998, ANN EPIDEMIOL, V8, P3, DOI 10.1016/S1047-2797(97)00177-4; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Sempos CT, 2000, ANN EPIDEMIOL, V10, P441, DOI 10.1016/S1047-2797(00)00068-5; Stegmayr B, 1996, CEREBROVASC DIS, V6, P80, DOI 10.1159/000108002; STEWART AW, 1994, INT J EPIDEMIOL, V23, P505; Strasser T, 1998, AM J HYPERTENS, V11, P756, DOI 10.1016/S0895-7061(98)00070-3; THAMM M, 1999, GESUNDHEITSWESEN, V61; THOM TJ, 1994, CIRCULATION, V90, P574, DOI 10.1161/01.CIR.90.1.574; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; TYROLER HA, 1979, NAT I HLTH PUBLICATI; *UN STAT DIV INT C, 2002, CAP REAL VAL FIN EXP; *WHO MONICA PROJ, 1988, WORLD HLTH STAT Q, V41, P115; *WHO REG OFF EUR, 2002, COUNTR INF; Wolf HK, 1997, J HUM HYPERTENS, V11, P733, DOI 10.1038/sj.jhh.1000531	40	1257	1328	1	68	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2003	289	18					2363	2369		10.1001/jama.289.18.2363	http://dx.doi.org/10.1001/jama.289.18.2363			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677WF	12746359	Bronze			2022-12-28	WOS:000182831200025
J	McClain, CS; Rosenfeld, B; Breitbart, W				McClain, CS; Rosenfeld, B; Breitbart, W			Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients	LANCET			English	Article							HOPELESSNESS; DEPRESSION; SUICIDE; DESIRE; DEATH; DISTRESS; RELIGION; SCALE	Background The importance of spirituality in coping with a terminal illness is becoming increasingly recognised. We aimed to assess the relation between spiritual well-being, depression, and end-of-life despair in terminally-ill cancer patients. Methods 160 patients in a palliative care hospital with a life expectancy of less than 3 months were interviewed with a series of standardised instruments, including the functional assessment of chronic illness therapy-spiritual well-being scale, the Hamilton depression rating scale, the Beck hopelessness scale, and the schedule of attitudes toward hastened death. Suicidal ideation was based on responses to the Hamilton depression rating scale. Findings Significant correlations were seen between spiritual well-being and desire for hastened death (r=-0.51), hopelessness (r=-0.68), and suicidal ideation (r=-0.41). Results of multiple regression analyses showed that spiritual well-being was the strongest predictor of each outcome variable and provided a unique significant contribution beyond that of depression and relevant covariates. Additionally, depression was highly correlated with desire for hastened death in participants low in spiritual well-being (r=-0.40, p<0.0001) but not in those high in spiritual well-being (r=0.20, p=0.06). Interpretation Spiritual well-being offers some protection against end-of-life despair in those for whom death is imminent. Our findings have important implications for palliative care practice. Controlled research assessing the effect of spirituality-based interventions is needed to establish what methods can help engender a sense of peace and meaning.	Fordham Univ, Dept Psychol, Bronx, NY 10458 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Fordham University; Memorial Sloan Kettering Cancer Center	Rosenfeld, B (corresponding author), Fordham Univ, Dept Psychol, 441 E Fordham Rd, Bronx, NY 10458 USA.	rosenfeld@fordham.edu	Pais-Ribeiro, Jose/K-1260-2013	Pais-Ribeiro, Jose/0000-0003-2882-8056	NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR005183] Funding Source: NIH RePORTER; NINR NIH HHS [NR-05183] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Akechi T, 2001, PSYCHOSOMATICS, V42, P141, DOI 10.1176/appi.psy.42.2.141; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Brady MJ, 1999, PSYCHO-ONCOLOGY, V8, P417, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<417::AID-PON398>3.0.CO;2-4; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COWARD DD, 1988, ONCOL NURS FORUM, V25, P75; Durkheim E., 1951, SUICIDE STUDY SOCIOL, DOI 10.2307/2088294; Fehring R J, 1997, Oncol Nurs Forum, V24, P663; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gil S, 2001, J PSYCHOSOC ONCOL, V19, P21, DOI 10.1300/J077v19n01_02; Greenstein M, 2000, AM J PSYCHOTHER, V54, P486, DOI 10.1176/appi.psychotherapy.2000.54.4.486; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; Kearney M, 2000, HANDBOOK OF PSYCHIATRY IN PALLIATIVE MEDICINE, P357; KENNELLY L, 2001, DISS ABSTR INT, V61, P5236; Kleespies PM, 2000, J CLIN PSYCHOL, V56, P1153, DOI 10.1002/1097-4679(200009)56:9<1153::AID-JCLP4>3.0.CO;2-Y; McCullough M E, 1999, Twin Res, V2, P126, DOI 10.1375/136905299320565997; Mickley J R, 1992, Image J Nurs Sch, V24, P267; Muldoon M, 1995, J RELIG HEALTH, V34, P329, DOI 10.1007/BF02248742; Nelson CJ, 2002, PSYCHOSOMATICS, V43, P213, DOI 10.1176/appi.psy.43.3.213; Pessin H, 2002, AM BEHAV SCI, V46, P357, DOI 10.1177/000276402237769; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Rabkin JG, 2000, PSYCHOSOM MED, V62, P271, DOI 10.1097/00006842-200003000-00020; Siegrist M, 1996, J SOC PSYCHOL, V136, P559, DOI 10.1080/00224545.1996.9714040; STACK S, 1991, SOC PSYCH PSYCH EPID, V26, P168; Taylor EJ., 1998, PSYCHOSOCIAL NURSING, P71	27	462	471	2	87	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	2003	361	9369					1603	1607		10.1016/S0140-6736(03)13310-7	http://dx.doi.org/10.1016/S0140-6736(03)13310-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	676HY	12747880				2022-12-28	WOS:000182746300010
J	Ramanan, SV				Ramanan, SV			The aggressive treatment of hypertension	LANCET			English	Editorial Material									Univ Connecticut, Sch Med, St Francis Hosp & Med Ctr, Hartford, CT 06105 USA	Saint Francis Hospital & Medical Center; University of Connecticut	Ramanan, SV (corresponding author), Univ Connecticut, Sch Med, St Francis Hosp & Med Ctr, 1000 Asylum Ave,Suite 1012, Hartford, CT 06105 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 3	2003	361	9368					1510	1510		10.1016/S0140-6736(03)13176-5	http://dx.doi.org/10.1016/S0140-6736(03)13176-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674WB	12737860				2022-12-28	WOS:000182658900009
J	Wickens, M; Goldstrohm, A				Wickens, M; Goldstrohm, A			A place to die, a place to sleep	SCIENCE			English	Editorial Material							DEAD BOX HELICASE; MESSENGER-RNA; LOCALIZATION; TRANSLATION; TRANSPORT		Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wickens, M (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	wickens@biochem.wisc.edu						Anderson P, 2002, J CELL SCI, V115, P3227; Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; Chartrand P, 2001, ANNU REV CELL DEV BI, V17, P297, DOI 10.1146/annurev.cellbio.17.1.297; Coller JM, 2001, RNA, V7, P1717, DOI 10.1017/S135583820101994X; Houston DW, 2000, CURR TOP DEV BIOL, V50, P155, DOI 10.1016/S0070-2153(00)50008-8; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Minshall N, 2001, RNA, V7, P1728, DOI 10.1017/S135583820101158X; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Oleynikov Y, 2003, CURR BIOL, V13, P199, DOI 10.1016/S0960-9822(03)00044-7; Schisa JA, 2001, DEVELOPMENT, V128, P1287; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	16	34	35	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					753	755		10.1126/science.1084512	http://dx.doi.org/10.1126/science.1084512			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730589				2022-12-28	WOS:000182579800035
J	Dhar, M; Bellevue, R; Carmel, R				Dhar, M; Bellevue, R; Carmel, R			Pernicious anemia with neuropsychiatric dysfunction in a patient with sickle cell anemia treated with folate supplementation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA HOMOCYSTEINE; DISEASE; DEFICIENCY; CHILDREN; ACID		New York Methodist Hosp, Dept Med, Brooklyn, NY 11215 USA; New York Methodist Hosp, Comprehens Sickle Cell Thalassemia Program, Brooklyn, NY USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA	NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; Cornell University	Carmel, R (corresponding author), New York Methodist Hosp, Dept Med, 506 6th St, Brooklyn, NY 11215 USA.							ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; Balasa VV, 2002, J PEDIAT HEMATOL ONC, V24, P374, DOI 10.1097/00043426-200206000-00010; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; Carmel R, 1996, ARCH INTERN MED, V156, P1097, DOI 10.1001/archinte.156.10.1097; Carmel R, 2003, BLOOD, V101, P3302, DOI 10.1182/blood-2002-09-2746; Carmel R, 1999, SEMIN HEMATOL, V36, P88; CARMEL R, 1978, NEW ENGL J MED, V298, P647, DOI 10.1056/NEJM197803232981203; CHEN MC, 1992, SOUTHERN MED J, V85, P215, DOI 10.1097/00007611-199202000-00028; CONLEY CL, 1951, NEW ENGL J MED, V245, P529, DOI 10.1056/NEJM195110042451404; Dhar M, 2001, BLOOD, V98, p490A; DICKINSON CJ, 1995, QJM-INT J MED, V88, P357; HALL BE, 1947, J LAB CLIN MED, V32, P622; HEINLE RW, 1947, JAMA-J AM MED ASSOC, V133, P739, DOI 10.1001/jama.1947.02880110005002; LINDENBAUM J, 1977, FOLIC ACID BIOCH PHY, P256; Lowenthal EA, 2000, J AM COLL NUTR, V19, P608, DOI 10.1080/07315724.2000.10718958; RABB LM, 1983, BRIT J HAEMATOL, V54, P589, DOI 10.1111/j.1365-2141.1983.tb02138.x; ROSS JF, 1948, BLOOD, V3, P68, DOI 10.1182/blood.V3.1.68.68; SCHWARTZ SO, 1950, J LAB CLIN MED, V35, P894; SERJEANT GR, 2001, SICKLE CELL DIS, P96; SINOW RM, 1987, ARCH INTERN MED, V147, P1828, DOI 10.1001/archinte.147.10.1828; UELAND PM, 1989, J LAB CLIN MED, V114, P473; van der Dijs FPL, 1998, AM J HEMATOL, V59, P192, DOI 10.1002/(SICI)1096-8652(199811)59:3<192::AID-AJH3>3.0.CO;2-8; VILTER CF, 1947, J LAB CLIN MED, V32, P262	23	39	40	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2204	2207		10.1056/NEJMoa022639	http://dx.doi.org/10.1056/NEJMoa022639			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12773647	Bronze			2022-12-28	WOS:000183134700006
J	Manes, G; Menchise, A; de Nucci, C; Balzano, A				Manes, G; Menchise, A; de Nucci, C; Balzano, A			Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment	BRITISH MEDICAL JOURNAL			English	Article							GASTROESOPHAGEAL REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; DUODENAL-ULCER; MANAGEMENT STRATEGIES; NONULCER DYSPEPSIA; PROMPT ENDOSCOPY; SYMPTOMS; ERADICATION; BENEFIT; ESOPHAGITIS	Objective To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia. Design Randomised controlled trial. Setting Hospital gastroenterology unit. Participants 219 patients under 45 years old presenting with dyspepsia Without alarm symptoms. Intervention Patients received treatment with omeprazole 20 mg (group A) or with a urea breath test followed by an eradication treatment in case of H pylori infection or omeprazole alone in non-infected patients (group B). Lack of improvement or recurrence of symptoms prompted endoscopy. Main outcome measures Improvement in symptoms assessed by a dyspepsia severity score every two months; use of medical resources (endoscopic workload and medical consultation); clinical outcome. Results 96/109 (88%) patients in group A and 61/110 (55%) in group B (P < 0.0001) had endoscopy: in 19 patients in group A and 32 in group B (20/67 infected and 12/43 non-infected) because of no improvement; in 77 further patients in group A and 29 in group B (7 infected and 22 non-infected) because of recurrence of symptoms during follow up. Endoscopy showed peptic ulcers only in group A; oesophagitis occurred significantly more often in group B than in group A. About 80% of examinations were normal in both groups, but nine duodenal scars occurred in group A. Conclusions Eradication treatment allows resolution of symptoms in a large number of patients with dyspepsia and reduces the endoscopic workload. After a trial of omeprazole, symptoms recur in nearly every patient. Such treatment is also likely to mask an appreciable number of peptic ulcers and cases of oesophagitis.	Cardarelli Hosp, Dept Gastroenterol, I-80129 Naples, Italy	Antonio Cardarelli Hospital	Manes, G (corresponding author), Cardarelli Hosp, Dept Gastroenterol, Via Solimena 101, I-80129 Naples, Italy.							BOYCE HW, 1987, GASTROENTEROLOGIC EN; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; Carlsson R, 1998, SCAND J GASTROENTERO, V33, P1023; Fass R, 1999, ARCH INTERN MED, V159, P2161, DOI 10.1001/archinte.159.18.2161; FENDRICK AM, 1995, ANN INTERN MED, V123, P260, DOI 10.7326/0003-4819-123-4-199508150-00003; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; Heaney A, 1999, GUT, V45, P186, DOI 10.1136/gut.45.2.186; Jaakkimainen RL, 1999, BMJ-BRIT MED J, V319, P1040, DOI 10.1136/bmj.319.7216.1040; JOHNSON NJ, 1989, ALIMENT PHARM THERAP, V3, P259; Jones RH, 1997, ALIMENT PHARM THERAP, V11, P541, DOI 10.1046/j.1365-2036.1997.00179.x; Labenz J, 1997, GASTROENTEROLOGY, V112, P1442, DOI 10.1016/S0016-5085(97)70024-6; Ladabaum U, 2002, ALIMENT PHARM THERAP, V16, P1491, DOI 10.1046/j.1365-2036.2002.01306.x; Lassen AT, 2000, LANCET, V356, P455, DOI 10.1016/S0140-6736(00)02553-8; Malfertheiner P, 1997, GUT, V41, P8; Manes G, 1999, SCAND J GASTROENTERO, V34, P658, DOI 10.1080/003655299750025840; Manes G, 2001, DIGEST LIVER DIS, V33, P665, DOI 10.1016/S1590-8658(01)80042-6; MARSHALL BJ, 1988, LANCET, V2, P1437; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601; McColl K. E. L., 2002, BMJ, V324, P999, DOI 10.1136/bmj.324.7344.999; Moayyedi P, 2001, GASTROENTEROLOGY, V121, P1120, DOI 10.1053/gast.2001.29332; NYREN O, 1986, NEW ENGL J MED, V314, P339, DOI 10.1056/NEJM198602063140603; Ofman JJ, 1997, ANN INTERN MED, V126, P280, DOI 10.7326/0003-4819-126-4-199702150-00004; OLMAN JJ, 1997, ANN INTERN MED, V126, P280; Silverstein MD, 1996, GASTROENTEROLOGY, V110, P72, DOI 10.1053/gast.1996.v110.pm8536890; Sonnenberg A, 1996, AM J GASTROENTEROL, V91, P1773; Vicari JJ, 1998, GASTROENTEROLOGY, V115, P50, DOI 10.1016/S0016-5085(98)70364-6; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266	27	46	48	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2003	326	7399					1118	1121		10.1136/bmj.326.7399.1118	http://dx.doi.org/10.1136/bmj.326.7399.1118			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	685DF	12763982	Green Published, Bronze			2022-12-28	WOS:000183245000018
J	Heuser, J				Heuser, J			"My little spontaneous blips"	SCIENCE			English	Editorial Material									Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL)	Heuser, J (corresponding author), Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA.							FATT P, 1952, J PHYSIOL-LONDON, V117, P109; KATZ B, 1994, CREATIVITY RES J, V7, P225, DOI 10.1080/10400419409534531; KATZ B, 1986, J PHYSIOL-LONDON, V370, P1; KATZ B, 1989, FERNSTROM FDN, V13; KATZ B, 1994, COMMUNICATION   0118	5	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1248	1248		10.1126/science.1086214	http://dx.doi.org/10.1126/science.1086214			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	681NN	12764186				2022-12-28	WOS:000183042400035
J	Olveczky, BP; Baccus, SA; Meister, M				Olveczky, BP; Baccus, SA; Meister, M			Segregation of object and background motion in the retina	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; POLYAXONAL AMACRINE CELLS; MACAQUE MONKEY RETINA; GANGLION-CELLS; SPATIAL SUMMATION; CONTRAST SENSITIVITY; RABBIT RETINA; RESPONSES; PHYSIOLOGY; SIGNALS	An important task in vision is to detect objects moving within a stationary scene. During normal viewing this is complicated by the presence of eye movements that continually scan the image across the retina, even during fixation. To detect moving objects, the brain must distinguish local motion within the scene from the global retinal image drift due to fixational eye movements. We have found that this process begins in the retina: a subset of retinal ganglion cells responds to motion in the receptive field centre, but only if the wider surround moves with a different trajectory. This selectivity for differential motion is independent of direction, and can be explained by a model of retinal circuitry that invokes pooling over nonlinear interneurons. The suppression by global image motion is probably mediated by polyaxonal, wide-field amacrine cells with transient responses. We show how a population of ganglion cells selective for differential motion can rapidly flag moving objects, and even segregate multiple moving objects.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; MIT, Div Hlth Sci & Technol, Cambridge, MA 02138 USA; Harvard Univ, Program Neurosci, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University	Meister, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.			Meister, Markus/0000-0003-2136-6506; Olveczky, Bence/0000-0003-2499-2705				[Anonymous], EYE MOVEMENTS THEIR; BENDER DB, 1986, BRAIN RES, V381, P372, DOI 10.1016/0006-8993(86)90092-2; BLAKEMORE C, 1986, J PHYSIOL-LONDON, V380, P453, DOI 10.1113/jphysiol.1986.sp016297; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; Chichilnisky EJ, 2001, NETWORK-COMP NEURAL, V12, P199, DOI 10.1088/0954-898X/12/2/306; Cook PB, 1998, J NEUROSCI, V18, P2301; Coppola D, 1996, P NATL ACAD SCI USA, V93, P8001, DOI 10.1073/pnas.93.15.8001; DACEY DM, 1989, J COMP NEUROL, V284, P275, DOI 10.1002/cne.902840210; Demb JB, 2001, J NEUROSCI, V21, P7447, DOI 10.1523/JNEUROSCI.21-19-07447.2001; DeVries SH, 1999, J NEUROPHYSIOL, V81, P908, DOI 10.1152/jn.1999.81.2.908; ENROTHCUGELL C, 1980, J PHYSIOL-LONDON, V302, P49; FAMIGLIETTI EV, 1992, J COMP NEUROL, V316, P406, DOI 10.1002/cne.903160403; FROST BJ, 1983, SCIENCE, V220, P744, DOI 10.1126/science.6836313; Gibson JJ, 1950, PERCEPTION VISUAL WO; GRAHAM CH, 1965, VISION VISUAL PERCEP, P575; Greschner M, 2002, NAT NEUROSCI, V5, P341, DOI 10.1038/nn821; GROSSMAN GE, 1989, J NEUROPHYSIOL, V62, P264, DOI 10.1152/jn.1989.62.1.264; HAMMOND P, 1982, EXP BRAIN RES, V47, P457; HOCHSTEIN S, 1976, J PHYSIOL-LONDON, V262, P265, DOI 10.1113/jphysiol.1976.sp011595; KAPLAN E, 1986, P NATL ACAD SCI USA, V83, P2755, DOI 10.1073/pnas.83.8.2755; MANTEUFFEL G, 1977, NATURWISSENSCHAFTEN, V64, P533, DOI 10.1007/BF00483559; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; Ouchi H, 1977, JAPANESE OPTICAL GEO; Passaglia CL, 2001, J NEUROSCI, V21, P5794, DOI 10.1523/JNEUROSCI.21-15-05794.2001; Regan David, 2000, HUMAN PERCEPTION OBJ; Ross J, 2001, TRENDS NEUROSCI, V24, P113, DOI 10.1016/S0166-2236(00)01685-4; SHAPLEY R, 1981, NATURE, V292, P543, DOI 10.1038/292543a0; SHAPLEY RM, 1979, J PHYSIOL-LONDON, V290, P141, DOI 10.1113/jphysiol.1979.sp012765; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; SKAVENSKI AA, 1979, VISION RES, V19, P675, DOI 10.1016/0042-6989(79)90243-8; Stafford DK, 1997, VISUAL NEUROSCI, V14, P507, DOI 10.1017/S0952523800012165; STEINMAN RM, 1980, VISION RES, V20, P415, DOI 10.1016/0042-6989(80)90032-2; STERLING P, 1969, J NEUROPHYSIOL, V32, P1, DOI 10.1152/jn.1969.32.1.1; VANDERSTEEN J, 1984, EXP BRAIN RES, V56, P263, DOI 10.1007/BF00236282; Vernon Magdalen D., 1962, PSYCHOL PERCEPTION; VICTOR JD, 1979, J GEN PHYSIOL, V74, P671, DOI 10.1085/jgp.74.6.671; Volgyi B, 2001, J COMP NEUROL, V440, P109, DOI 10.1002/cne.1373; Warland DK, 1997, J NEUROPHYSIOL, V78, P2336, DOI 10.1152/jn.1997.78.5.2336; WERBLIN F, 1988, VISUAL NEUROSCI, V1, P317, DOI 10.1017/S0952523800001978; WERBLIN FS, 1972, SCIENCE, V175, P1008, DOI 10.1126/science.175.4025.1008; Wu SM, 2000, J NEUROSCI, V20, P4462, DOI 10.1523/JNEUROSCI.20-12-04462.2000; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7	43	275	278	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					401	408		10.1038/nature01652	http://dx.doi.org/10.1038/nature01652			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12754524				2022-12-28	WOS:000183012000033
J	Samaha, FF; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, T; Williams, M; Gracely, EJ; Stern, L				Samaha, FF; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, T; Williams, M; Gracely, EJ; Stern, L			A low-carbohydrate as compared with a low-fat diet in severe obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; HYPERTRIGLYCERIDEMIA; CHOLESTEROL	Background: The effects of a carbohydrate-restricted diet on weight loss and risk factors for atherosclerosis have been incompletely assessed. METHODS: We randomly assigned 132 severely obese subjects (including 77 blacks and 23 women) with a mean body-mass index of 43 and a high prevalence of diabetes (39 percent) or the metabolic syndrome (43 percent) to a carbohydrate-restricted (low-carbohydrate) diet or a calorie- and fat-restricted (low-fat) diet. RESULTS: Seventy-nine subjects completed the six-month study. An analysis including all subjects, with the last observation carried forward for those who dropped out, showed that subjects on the low-carbohydrate diet lost more weight than those on the low-fat diet (mean [+/-SD], -5.8+/-8.6 kg vs. -1.9+/-4.2 kg; P=0.002) and had greater decreases in triglyceride levels (mean, -20+/-43 percent vs. -4+/-31 percent; P=0.001), irrespective of the use or nonuse of hypoglycemic or lipid-lowering medications. Insulin sensitivity, measured only in subjects without diabetes, also improved more among subjects on the low-carbohydrate diet (6+/-9 percent vs. -3+/-8 percent, P=0.01). The amount of weight lost (P<0.001) and assignment to the low-carbohydrate diet (P=0.01) were independent predictors of improvement in triglyceride levels and insulin sensitivity. CONCLUSIONS: Severely obese subjects with a high prevalence of diabetes or the metabolic syndrome lost more weight during six months on a carbohydrate-restricted diet than on a calorie- and fat-restricted diet, with a relative improvement in insulin sensitivity and triglyceride levels, even after adjustment for the amount of weight lost. This finding should be interpreted with caution, given the small magnitude of overall and between-group differences in weight loss in these markedly obese subjects and the short duration of the study. Future studies evaluating long-term cardiovascular outcomes are needed before a carbohydrate-restricted diet can be endorsed.	Vet Affairs Med Ctr, Philadelphia, PA USA; Univ Penn, Med Ctr, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Div Endocrinol, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Family Community & Prevent Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; Drexel University	Samaha, FF (corresponding author), Cardiol 8th Fl,MC 111C,Univ & Woodland Ave, Philadelphia, PA 19104 USA.	rick.samaha@med.va.gov	Gracely, Ed/B-7188-2014	Gracely, Ed/0000-0002-8344-3223				Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; EADES MR, 2000, PROTEIN POWER LIFEPL, P434; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Ginsberg HN, 1997, ANN INTERN MED, V126, P912, DOI 10.7326/0003-4819-126-11-199706010-00012; Howard BV, 1998, METABOLISM, V47, P1174, DOI 10.1016/S0026-0495(98)90319-5; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; KARVETTI RL, 1985, J AM DIET ASSOC, V85, P1437; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Kennedy ET, 2001, J AM DIET ASSOC, V101, P411, DOI 10.1016/S0002-8223(01)00108-0; NATOW AB, 1991, DIABETES CARBOHYDRAT; *NIH, 1998, OBES RES S2, V6, pS51, DOI DOI 10.1001/JAMA.2012.39; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 2002, CIRCULATION, V105, P1424, DOI 10.1161/01.CIR.0000012918.84068.43; St-Pierre J, 2002, AM J CARDIOL, V90, P15, DOI 10.1016/S0002-9149(02)02378-0; Stuhlinger MC, 2002, JAMA-J AM MED ASSOC, V287, P1420, DOI 10.1001/jama.287.11.1420; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Westman EC, 1999, J CLIN OUTCOMES MANA, V6, P36	21	846	871	4	131	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2003	348	21					2074	2081		10.1056/NEJMoa022637	http://dx.doi.org/10.1056/NEJMoa022637			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680YU	12761364				2022-12-28	WOS:000183008300004
J	Guttuso, T; Roscoe, J; Griggs, J				Guttuso, T; Roscoe, J; Griggs, J			Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer	LANCET			English	Article								In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin. On this basis, we did an open-label study in which oral gabapentin 300 mg thrice daily was given for every other chemotherapy treatment in nine patients with breast cancer. Six of the nine reported at least a three-point improvement in peak delayed nausea (on an eight-point nausea scale), and three patients had complete resolution of nausea when taking gabapentin. This preliminary evidence shows that gabapentin might have a role in treatment of chemotherapy-induced nausea.	Univ Rochester, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Guttuso, T (corresponding author), Univ Rochester, Dept Neurol, Box 673, Rochester, NY 14642 USA.	thomas_guttuso@urmc.rochester.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007338] Funding Source: NIH RePORTER; NINDS NIH HHS [5 T32 NS07338-12] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Guttuso T, 2003, OBSTET GYNECOL, V101, P337, DOI 10.1016/S0029-7844(02)02712-6; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; Navari RM, 1999, NEW ENGL J MED, V340, P190, DOI 10.1056/NEJM199901213400304; Pater JL, 1997, ANN ONCOL, V8, P181, DOI 10.1023/A:1008247830641; Roila F, 2000, NEW ENGL J MED, V342, P1554	5	61	61	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2003	361	9370					1703	1705		10.1016/S0140-6736(03)13365-X	http://dx.doi.org/10.1016/S0140-6736(03)13365-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KB	12767738				2022-12-28	WOS:000182919700013
J	Gambardella, P; Rusponi, S; Veronese, M; Dhesi, SS; Grazioli, C; Dallmeyer, A; Cabria I; Zeller, R; Dederichs, PH; Kern, K; Carbone, C; Brune, H				Gambardella, P; Rusponi, S; Veronese, M; Dhesi, SS; Grazioli, C; Dallmeyer, A; Cabria, I; Zeller, R; Dederichs, PH; Kern, K; Carbone, C; Brune, H			Giant magnetic anisotropy of single cobalt atoms and nanoparticles	SCIENCE			English	Article							RAY CIRCULAR-DICHROISM; ORBITAL MAGNETIZATION; MAGNETOCRYSTALLINE ANISOTROPY; MICROSCOPIC ORIGIN; CLUSTERS; AGGREGATION; MOMENT; METALS; IRON; SPIN	The isotropic magnetic moment of a free atom is shown to develop giant magnetic anisotropy energy due to symmetry reduction at an atomically ordered surface. Single cobalt atoms deposited onto platinum ( 111) are found to have a magnetic anisotropy energy of 9 millielectron volts per atom arising from the combination of unquenched orbital moments (1.1 Bohr magnetons) and strong spin-orbit coupling induced by the platinum substrate. By assembling cobalt nanoparticles containing up to 40 atoms, the magnetic anisotropy energy is further shown to be dependent on single-atom coordination changes. These results confirm theoretical predictions and are of fundamental value to understanding how magnetic anisotropy develops infinite-sized magnetic particles.	Ecole Polytech Fed Lausanne, Inst Phys Nanostruct, CH-1015 Lausanne, Switzerland; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; CNR, Ist Struttura Mat, I-34012 Trieste, Italy; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Forschungszentrum Julich, Inst Festkorperforsch, D-52425 Julich, Germany	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Max Planck Society; Consiglio Nazionale delle Ricerche (CNR); Istituto di Struttura della Materia (ISM-CNR); European Synchrotron Radiation Facility (ESRF); Helmholtz Association; Research Center Julich	Gambardella, P (corresponding author), Ecole Polytech Fed Lausanne, Inst Phys Nanostruct, CH-1015 Lausanne, Switzerland.	pietro.gambardella@epfl.ch	Carbone, Carlo/B-2626-2010; Cabria, Iván/D-7278-2016; Gambardella, Pietro/B-1880-2009; Grazioli, Cesare/I-8156-2018; Zeller, Rudolf/K-7094-2013; Brune, Harald/E-7284-2017	Cabria, Iván/0000-0003-2460-7643; Gambardella, Pietro/0000-0003-0031-9217; Grazioli, Cesare/0000-0002-6255-2041; Zeller, Rudolf/0000-0002-9462-2649; Brune, Harald/0000-0003-4459-3111; Veronese, Marco/0000-0002-0650-4731; Rusponi, Stefano/0000-0002-8494-5532; Carbone, Carlo/0000-0002-8675-7850				BILLAS IML, 1994, SCIENCE, V265, P1682, DOI 10.1126/science.265.5179.1682; BROOKS MSS, 1985, PHYSICA B & C, V130, P6, DOI 10.1016/0378-4363(85)90170-6; Brune H, 1998, SURF SCI REP, V31, P121, DOI 10.1016/S0167-5729(99)80001-6; BRUNO P, 1989, PHYS REV B, V39, P865, DOI 10.1103/PhysRevB.39.865; CARRA P, 1993, PHYS REV LETT, V70, P694, DOI 10.1103/PhysRevLett.70.694; CHEN CT, 1995, PHYS REV LETT, V75, P152, DOI 10.1103/PhysRevLett.75.152; CHIKAZUMI S, 1997, PHYSICS FERROMAGNETI; Durr HA, 1999, PHYS REV B, V59, pR701, DOI 10.1103/PhysRevB.59.R701; Gambardella P, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.047202; Gambardella P, 2002, NATURE, V416, P301, DOI 10.1038/416301a; Hewson A C, 1993, KONDO PROBLEM HEAVY; Koide T, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.257201; MYDOSH JA, 1980, FERROMAGNETIC MAT; Nakajima N, 1998, PHYS REV LETT, V81, P5229, DOI 10.1103/PhysRevLett.81.5229; Nonas B, 2001, PHYS REV LETT, V86, P2146, DOI 10.1103/PhysRevLett.86.2146; PASTOR GM, 1995, PHYS REV LETT, V75, P326, DOI 10.1103/PhysRevLett.75.326; RODER H, 1993, NATURE, V366, P141, DOI 10.1038/366141a0; SOLOVYEV IV, 1995, PHYS REV B, V52, P13419, DOI 10.1103/PhysRevB.52.13419; Stohr J, 1999, J MAGN MAGN MATER, V200, P470, DOI 10.1016/S0304-8853(99)00407-2; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; THOLE BT, 1992, PHYS REV LETT, V68, P1943, DOI 10.1103/PhysRevLett.68.1943; VANDERLAARN G, 1997, J PHYS CONDENS MATT, V30, P3239; WELLER D, 1995, PHYS REV LETT, V75, P3752, DOI 10.1103/PhysRevLett.75.3752; Weller D, 1999, IEEE T MAGN, V35, P4423, DOI 10.1109/20.809134; WU RQ, 1994, PHYS REV LETT, V73, P1994, DOI 10.1103/PhysRevLett.73.1994	25	876	879	9	385	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1130	1133		10.1126/science.1082857	http://dx.doi.org/10.1126/science.1082857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12750516	Green Submitted			2022-12-28	WOS:000182886500040
J	Goldacre, MJ; Lambert, T; Evans, J; Turner, G				Goldacre, MJ; Lambert, T; Evans, J; Turner, G			Preregistration house officers' views on whether their experience at medical school prepared them well for their jobs: national questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							UNITED-KINGDOM; DOCTORS		Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Unit Healthcare Epidemiol, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Unit Healthcare Epidemiol, Oxford OX3 7LF, England.			Lambert, Trevor/0000-0001-9688-3036				*GEN MED COUNC, 2002, IMPL NEW DOCT ED COM; Goldacre MJ, 1999, MED EDUC, V33, P882, DOI 10.1046/j.1365-2923.1999.00560.x; Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; *NHS EX, 2002, UNF BUS PROP REF SEN	4	99	100	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 10	2003	326	7397					1011	1012		10.1136/bmj.326.7397.1011	http://dx.doi.org/10.1136/bmj.326.7397.1011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	679KG	12742922	Green Published, Bronze			2022-12-28	WOS:000182920500016
J	Kamata, K; Yonehara, K; Sumida, Y; Yamaguchi, K; Hikichi, S; Mizuno, N				Kamata, K; Yonehara, K; Sumida, Y; Yamaguchi, K; Hikichi, S; Mizuno, N			Efficient epoxidation of olefins with >= 99% selectivity and use of hydrogen peroxide	SCIENCE			English	Article							TITANIUM SILICALITE; CATALYTIC-SYSTEM; OXIDATION; POLYOXOMETALATE; COMPLEXES; PRECURSOR; CHEMISTRY; TI	Epoxides are an important class of industrial chemicals that have been used as chemical intermediates. Catalytic epoxidation of olefins affords an interesting production technology. We found a widely usable green route to the production of epoxides: A silicotungstate compound, [gamma-SiW10O34(H2O)(2)](4-), is synthesized by protonation of a divacant, lacunary, Keggin-type polyoxometalate of [gamma-SiW10O36](8-) and exhibits high catalytic performance for the epoxidation of various olefins, including propylene, with a hydrogen peroxide (H2O2) oxidant at 305 kelvin. The effectiveness of this catalyst is evidenced by greater than or equal to99% selectivity to epoxide, greater than or equal to99% efficiency of H2O2 utilization, high stereospecificity, and easy recovery of the catalyst from the homogeneous reaction mixture.	Univ Tokyo, Sch Engn, Dept Appl Chem, Bunkyo Ku, Tokyo 1138656, Japan; Nippon Shokubai, Strateg Technol Res, Osaka 5648512, Japan	University of Tokyo; Nippon Shokubai Co Ltd	Mizuno, N (corresponding author), Univ Tokyo, Sch Engn, Dept Appl Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	tmizuno@mail.ecc.u-tokyo.ac.jp	Kamata, Keigo/E-6997-2014; Yamaguchi, Kazuya/R-7990-2016	Kamata, Keigo/0000-0002-0624-8483; Yamaguchi, Kazuya/0000-0002-7661-4936				BAILEY AJ, 1995, J CHEM SOC DALTON, P1833, DOI 10.1039/dt9950001833; BATTIONI P, 1988, J AM CHEM SOC, V110, P8462, DOI 10.1021/ja00233a023; BAUMSTARK AL, 1988, J ORG CHEM, V53, P3437, DOI 10.1021/jo00250a007; BLASCO T, 1993, J AM CHEM SOC, V115, P11806, DOI 10.1021/ja00078a020; CANNY J, 1986, INORG CHEM, V25, P2114, DOI 10.1021/ic00233a003; CLERICI MG, 1991, J CATAL, V129, P159, DOI 10.1016/0021-9517(91)90019-Z; CLERICI MG, 1993, J CATAL, V140, P71, DOI 10.1006/jcat.1993.1069; DeVos DE, 1996, ANGEW CHEM INT EDIT, V35, P2211, DOI 10.1002/anie.199622111; Hill C. L., 1988, ADV OXYGENATED PROCE, V1, P1; HILL CL, 1995, COORDIN CHEM REV, V143, P407, DOI 10.1016/0010-8545(95)01141-B; Hudlucky M., 1990, ACS MONOGRAPH SERIES; ISHII Y, 1988, J ORG CHEM, V53, P3587, DOI 10.1021/jo00250a032; JORGENSEN KA, 1989, CHEM REV, V89, P431; MASHMEYER T, 1995, NATURE, V378, P159; Mizuno N, 1998, J AM CHEM SOC, V120, P9267, DOI 10.1021/ja980006c; Neumann R, 1998, PROG INORG CHEM, V47, P317; NEUMANN R, 1995, J AM CHEM SOC, V117, P5066, DOI 10.1021/ja00123a008; Notari B, 1996, ADV CATAL, V41, P253, DOI 10.1016/S0360-0564(08)60042-5; Okuhara T, 1996, ADV CATAL, V41, P113, DOI 10.1016/S0360-0564(08)60041-3; Romao CC, 1997, CHEM REV, V97, P3197, DOI 10.1021/cr9703212; Sato K, 1997, B CHEM SOC JPN, V70, P905, DOI 10.1246/bcsj.70.905; Sheldon R A., 1981, METAL CATALYZED OXID; TANEV PT, 1994, NATURE, V368, P321, DOI 10.1038/368321a0; Teazea A., 2007, INORG SYNTH, V27, P85; VENTURELLO C, 1983, J ORG CHEM, V48, P3831, DOI 10.1021/jo00169a052; Wu P, 2002, CHEM COMMUN, P1026, DOI 10.1039/b201170k; Zuwei X, 2001, Science, V292, P1139, DOI 10.1126/science.292.5519.1139	27	520	545	7	315	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2003	300	5621					964	966		10.1126/science.1083176	http://dx.doi.org/10.1126/science.1083176			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	675WD	12738860				2022-12-28	WOS:000182719800052
J	Schmitz, B; Haggstrom, T; Tassinari, M				Schmitz, B; Haggstrom, T; Tassinari, M			Sediment-dispersed extraterrestrial chromite traces a major asteroid disruption event	SCIENCE			English	Article							METEORITES; IMPACT; ARENIG; SWEDEN; FAMILY	Abundant extraterrestrial chromite grains from decomposed meteorites occur in middle Ordovician (480 million years ago) marine limestone over an area of similar to250,000 square kilometers in southern Sweden. The chromite anomaly gives support for an increase of two orders of magnitude in the influx of meteorites to Earth during the mid-Ordovician, as previously indicated by fossil meteorites. Extraterrestrial chromite grains in mid-Ordovician limestone can be used to constrain in detail the temporal variations influx of extraterrestrial matter after one of the largest asteroid disruption events in the asteroid belt in late solar-system history.	Rice Univ, Dept Earth Sci, Houston, TX 77251 USA; Ctr Earth Sci, SE-40530 Gothenburg, Sweden	Rice University	Schmitz, B (corresponding author), Rice Univ, Dept Earth Sci, POB 1892, Houston, TX 77251 USA.							Bland P. A., 2001, ACCRETION EXTRATERRE, P267; BOGARD DD, 1995, METEORITICS, V30, P244, DOI 10.1111/j.1945-5100.1995.tb01124.x; BUNCH TE, 1967, GEOCHIM COSMOCHIM AC, V31, P1569; Dronov A., 2001, WOGOGOB 2001, P8; Gersonde R, 1997, NATURE, V390, P357, DOI 10.1038/37044; Grieve R. A, 2001, ACCRETION EXTRATERRE, P379, DOI DOI 10.1007/978-1-4419-8694-8_19; HESSLAND I, 1949, B GEOLOGICAL I U UPP, V33, P1; HEYMANN D, 1967, ICARUS, V6, P189, DOI 10.1016/0019-1035(67)90017-6; JIANHUA Z, 1998, THESIS STOCKHOLM U; KEIL K, 1994, PLANET SPACE SCI, V42, P1109, DOI 10.1016/0032-0633(94)90011-6; KEIL K, 1962, J GEOPHYS RES, V67, P4055, DOI 10.1029/JZ067i010p04055; Kunz J, 1997, METEORIT PLANET SCI, V32, P647, DOI 10.1111/j.1945-5100.1997.tb01550.x; Lindstrom M, 1979, GEOL PALAEONTOL, V13, P9; LINDSTROM M, 1971, GEOL RUNDSCH, V60, P419, DOI DOI 10.1007/BF02000464; LOFGREN A, 1995, GEOL MAG, V132, P693, DOI 10.1017/S0016756800018926; Lofgren A, 2000, GEOL MAG, V137, P53, DOI 10.1017/S0016756800003484; Nesvorny D, 2002, ICARUS, V157, P155, DOI 10.1006/icar.2002.6830; NYSTROM JO, 1988, NATURE, V336, P572, DOI 10.1038/336572a0; Rubin AE, 1997, METEORIT PLANET SCI, V32, P231, DOI 10.1111/j.1945-5100.1997.tb01262.x; Schmitz B, 2001, EARTH PLANET SC LETT, V194, P1, DOI 10.1016/S0012-821X(01)00559-3; Stouge S., 2001, WOGOGOB 2001, P42; Villumsen J., 2001, WOGOGOB 2001; Zappala V, 1998, ICARUS, V134, P176, DOI 10.1006/icar.1998.5946	23	112	113	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2003	300	5621					961	964		10.1126/science.1082182	http://dx.doi.org/10.1126/science.1082182			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675WD	12738859				2022-12-28	WOS:000182719800051
J	Anderson, RM; Bitterman, KJ; Wood, JG; Medvedik, O; Sinclair, DA				Anderson, RM; Bitterman, KJ; Wood, JG; Medvedik, O; Sinclair, DA			Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae	NATURE			English	Article							NAD(+) SALVAGE PATHWAY; SILENCING PROTEIN SIR2; DEACETYLASE ACTIVITY; YEAST; SPAN; EXPRESSION; LONGEVITY; GENE; METHYLTRANSFERASE; IDENTIFICATION	Calorie restriction extends lifespan in a broad range of organisms, from yeasts to mammals. Numerous hypotheses have been proposed to explain this phenomenon, including decreased oxidative damage and altered energy metabolism. In Saccharomyces cerevisiae, lifespan extension by calorie restriction requires the NAD(+)-dependent histone deacetylase, Sir2 (ref. 1). We have recently shown that Sir2 and its closest human homologue SIRT1, a p53 deacetylase, are strongly inhibited by the vitamin B3 precursor nicotinamide2. Here we show that increased expression of PNC1 (pyrazinamidase/nicotinamidase 1), which encodes an enzyme that deaminates nicotinamide, is both necessary and sufficient for lifespan extension by calorie restriction and low-intensity stress. We also identify PNC1 as a longevity gene that is responsive to all stimuli that extend lifespan. We provide evidence that nicotinamide depletion is sufficient to activate Sir2 and that this is the mechanism by which PNC1 regulates longevity. We conclude that yeast lifespan extension by calorie restriction is the consequence of an active cellular response to a low-intensity stress and speculate that nicotinamide might regulate critical cellular processes in higher organisms.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.			Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [R01 AG019719, R37 AG028730, P01 AG027916, R01 AG028730, R01 AG019972] Funding Source: Medline; NIGMS NIH HHS [R01 GM068072] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019972, R01AG019719, R01AG028730, R37AG028730, P01AG027916] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKSOY S, 1994, J BIOL CHEM, V269, P14835; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; Grant RS, 1998, J NEUROCHEM, V70, P1759; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; Kassem HS, 2002, INT J CANCER, V101, P454, DOI 10.1002/ijc.10631; Lal A, 1999, CANCER RES, V59, P5403; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Perichon R, 1998, CELL MOL LIFE SCI, V54, P641, DOI 10.1007/s000180050192; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Sandmeier JJ, 2002, GENETICS, V160, P877; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Swiecilo A, 2000, ACTA BIOCHIM POL, V47, P355; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; UNKEFER CJ, 1984, J BIOL CHEM, V259, P2311; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375	30	573	601	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2003	423	6936					181	185		10.1038/nature01578	http://dx.doi.org/10.1038/nature01578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12736687	Green Accepted			2022-12-28	WOS:000182699600049
J	Glynn, SA; Busch, MP; Schreiber, GB; Murphy, EL; Wright, DJ; Tu, Y; Kleinman, SH				Glynn, SA; Busch, MP; Schreiber, GB; Murphy, EL; Wright, DJ; Tu, Y; Kleinman, SH		NHLBI REDS Study Grp	Effect of a national disaster on blood supply and safety - The September 11 experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DONORS; RECRUITMENT; RISK	Context An understanding of characteristics of blood donors donating in times of crisis may help. predict blood supply safety and donor return patterns. Objectives. To characterize the volume of donations and prevalence of infectious disease markers in blood donated by US donors responding to the September 11, 2001, terrorist attacks, and. to evaluate return rates in those who donated for the first time. Design Cross-sectional survey data from the National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study for 4 weeks before:and 4 weeks starting with September 11, 2001, and the corresponding 8-week period in 2000. Setting and Participants A total of 327065 volunteer blood donors making 373628 allogeneic donations at 5 large regional US blood centers. Main Outcome.-Measures Changes in number of donations overall and by first-time and repeat status, prevalence of infectious disease markers, estimated risks of transfusion-transmitted viral infections, and first-time donor return rates. Results About 20000 allogeneic donations were collected Weekly in the 4 weeks preceding September 11, whereas approximate to49000 (2.5-fold increase) and approximate to26000 to 28000 (1.3-fold to 1.4-fold increases) donations were made per week in the first and in the second through fourth weeks starting with September 11; respectively. All demographic groups donated more than usual after the attacks, and after adjusting for seasonal and annual variation there was a 5.2-fold (95% confidence interval, 5.0-5.4) increase in the number of first-time donations vs a 1.5-fold (1.4-1.5) increase in the number of repeat donations made in the first week starting on September 11 vs the 4 weeks before. The weekly proportion of repeat donors returning after not donating for 10 or more years increased from 2% before September 11 to 6% in the first week starting with September 11. Donations confirmed positive for human immunodeficiency virus (HIV); hepatitis C virus (HCV), and hepatitis B surface antigen nearly tripled between 1 week before September 11 (0.1%) and 1 week after the attacks'(0.3%), largely explained by the increase in first-time and lapsed repeat donors: Estimated viral residual risks increased slightly after the attacks (HIV, 1/1.5 million vs 1/1.8 million donations; HCV, 1/1.3 million vs 1/1.6 million; hepatitis B virus, 1/140 000 vs 1/170000). First-time donor 12-month return rates for 2000 and 2001 were similar, approximate to28% (P=.37) for donors in the first week starting with September 11 (or September 12, 2000) and 30% (P=.69) for the second to,fourth weeks. Conclusions The September 11 events resulted in an influx of first-time donors without substantial increase in absolute risk of transfusion-transmissible viral infections. First-time donor return rates were equally relatively low before and after the attacks, suggesting that those donating in times of crisis have return behaviors similar to those of other first-time donors. Their relatively low return rates reinforce the need for education about. the importance of donating regularly.	Westat Corp, Rockville, MD 20850 USA; Blood Ctr Pacific, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Westat; University of California System; University of California San Francisco	Glynn, SA (corresponding author), Westat Corp, WB 280,1441 W Montgomery Ave, Rockville, MD 20850 USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097077, N01HB097082, N01HB097078, N01HB097080, N01HB047114, N01HB097079, N01HB097081] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-97082, N01-HB-97081, N01-HB-97080, N01-HB-97079, N01-HB-97078, N01-HB-97077, N01-HB-47114] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*ADV COMM BLOOD SA, 2002, 16 M ADV COMM BLOOD; *AM ASS BLOOD BANK, 2002, REP REC; *AM ASS BLOOD BANK, 2001, REC DEP HLTH HUM SER; *AM ASS BLOOD BANK, 2001, AABB WKLY REP, V7, P1; Becker C, 2001, MOD HLTH, P18; BUSCH M, 2002, 27 C INT SOC BLOOD T; BUSCH MP, 1991, TRANSFUSION, V31, P719, DOI 10.1046/j.1537-2995.1991.31892023497.x; Dodd RY, 2002, TRANSFUSION, V42, P975, DOI 10.1046/j.1537-2995.2002.00174.x; Dodd RY, 2002, TRANSFUSION, V42, P1240, DOI 10.1046/j.1537-2995.2002.00231.x; DOHERTY B, 2001, AM BLOOD CTR NE 0919; DRAKE AW, 1978, PUBLIC ATTITUDES DEC, P1; EDWARDS PW, 1985, PERS INDIV DIFFER, V6, P743, DOI 10.1016/0191-8869(85)90085-6; FIENBERG SE, 1980, ANAL CROSS CLASSIFIE, P16; GIMBLE JG, 1994, TRANSFUSION, V34, P586, DOI 10.1046/j.1537-2995.1994.34794330012.x; Glynn SA, 2002, TRANSFUSION, V42, P966, DOI 10.1046/j.1537-2995.2002.00200.x; Glynn SA, 2002, TRANSFUSION, V42, P216, DOI 10.1046/j.1537-2995.2002.00008.x; Glynn SA, 2001, TRANSFUSION, V41, P736, DOI 10.1046/j.1537-2995.2001.41060736.x; HONAWAR V, 2001, WASHINGTON TIME 0921, pB4; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; MECKLER L, 2002, STANDARD TIMES  0910, pA7; OSWALT RM, 1977, TRANSFUSION, V17, P123, DOI 10.1046/j.1537-2995.1977.17277151916.x; PILIAVIN JA, 1990, TRANSFUSION, V30, P444, DOI 10.1046/j.1537-2995.1990.30590296381.x; *SAS I INC, 1989, SAS STAT US GUID VER, P405; Schmidt PJ, 2002, NEW ENGL J MED, V346, P617, DOI 10.1056/NEJM200202213460813; Schmidt PJ, 1985, SUPPORTIVE THERAPY H, P371; US Food and Drug Administration (FDA), 2002, REV PREV MEAS RED PO; Villarosa L, 2001, NY TIMES        1220, pB6; Williams AE, 1997, JAMA-J AM MED ASSOC, V277, P967, DOI 10.1001/jama.277.12.967; Wu Y, 2000, TRANSFUSION, V40, p16S; Wu Y, 2001, TRANSFUSION, V41, P360, DOI 10.1046/j.1537-2995.2001.41030360.x; [No title captured]	31	81	87	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2003	289	17					2246	2253		10.1001/jama.289.17.2246	http://dx.doi.org/10.1001/jama.289.17.2246			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675ET	12734136				2022-12-28	WOS:000182680700027
J	Porteus, MH; Baltimore, D				Porteus, MH; Baltimore, D			Chimeric nucleases stimulate gene targeting in human cells	SCIENCE			English	Article							HOMOLOGOUS RECOMBINATION; RESTRICTION ENZYMES; CLEAVAGE		CALTECH, Dept Biol, Pasadena, CA 91125 USA	California Institute of Technology	Porteus, MH (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Pediat & Biochem, Dallas, TX 75390 USA.	matthew.porteus@UTSouthwestern.edu; baltimo@caltech.edu	Wilson, Matthew H/K-3193-2013		NIGMS NIH HHS [R01-GM39458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bibikova M, 2001, MOL CELL BIOL, V21, P289, DOI 10.1128/MCB.21.1.289-297.2001; Bibikova M, 2002, GENETICS, V161, P1169; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chandrasegaran S, 1999, BIOL CHEM, V380, P841, DOI 10.1515/BC.1999.103; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; SEDIVY JM, 1989, P NATL ACAD SCI USA, V86, P227, DOI 10.1073/pnas.86.1.227; SHI YG, 1995, SCIENCE, V268, P282, DOI 10.1126/science.7536342; Smith J, 2000, NUCLEIC ACIDS RES, V28, P3361, DOI 10.1093/nar/28.17.3361; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183	10	544	695	3	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					763	763		10.1126/science.1078395	http://dx.doi.org/10.1126/science.1078395			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730593	Green Accepted			2022-12-28	WOS:000182579800039
J	Schlessinger, J				Schlessinger, J			Autoinhibition control	SCIENCE			English	Editorial Material							RECEPTOR; REVEALS; KINASE		Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Schlessinger, J (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	joseph.schlessinger@yale.edu						Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2	10	88	89	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					750	752		10.1126/science.1082024	http://dx.doi.org/10.1126/science.1082024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12730587				2022-12-28	WOS:000182579800033
J	Seibert, C; Barbouche, E; Fagan, J; Myint, E; Wetterneck, T; Wittemyer, M				Seibert, C; Barbouche, E; Fagan, J; Myint, E; Wetterneck, T; Wittemyer, M			Prescribing oral contraceptives for women older than 35 years of age	ANNALS OF INTERNAL MEDICINE			English	Review							HORMONE REPLACEMENT THERAPY; VENOUS THROMBOEMBOLIC DISEASE; METABOLIC RISK MARKERS; BONE-MINERAL DENSITY; G ETHINYL ESTRADIOL; BREAST-CANCER RISK; FACTOR-V-LEIDEN; YOUNG-WOMEN; UNITED-STATES; MYOCARDIAL-INFARCTION	This paper addresses the use of combined oral contraceptives in women older than 35 years of age, including the potential risks and benefits, pretreatment assessment, common side effects and their management, appropriate follow-up, and diagnosis of menopause. The case-based discussion also focuses on issues that pertain to women who smoke, have hypertension, or have dyslipidemia.	Univ Wisconsin, Sch Med, UW Hlth Clin E, Dept Med, Madison, WI 53706 USA; Virginia Mason Med Ctr, Lynnwood, WA USA	University of Wisconsin System; University of Wisconsin Madison; University Wisconsin Health; Virginia Mason Medical Center	Seibert, C (corresponding author), Univ Wisconsin, Sch Med, UW Hlth Clin E, Dept Med, 5249 E Terrace Dr, Madison, WI 53706 USA.	cseibert@facstaff.wisc.edu						ABMA J, 1997, VITAL HLTH STAT, V23; Adesanya OO, 1996, J REPROD MED, V41, P431; AKERLUND M, 1993, BRIT J OBSTET GYNAEC, V100, P832, DOI 10.1111/j.1471-0528.1993.tb14309.x; *AM COLL OBST GYN, 1996, GUID WOM HLTH CAR; [Anonymous], 1983, JAMA, V249, P1596; [Anonymous], 1986, NEW ENGL J MED, V315, P405; Barrett D H, 1994, Arch Fam Med, V3, P438, DOI 10.1001/archfami.3.5.438; Berg AO, 2001, AM J PREV MED, V20, P73, DOI 10.1016/S0749-3797(01)00266-5; Bloemenkamp KWM, 1999, ARCH INTERN MED, V159, P65, DOI 10.1001/archinte.159.1.65; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Bousser MG, 2000, CEPHALALGIA, V20, P147, DOI 10.1046/j.1468-2982.2000.00050.x; Brinton LA, 1998, MENOPAUSE, V5, P145; Brinton LA, 1997, CONTRACEPTION, V55, P197, DOI 10.1016/S0010-7824(97)00012-7; Burkman RT, 1998, CONTRACEPTION, V58, p35S, DOI 10.1016/S0010-7824(98)00081-X; BURKMAN RT, 2000, INT J FERTIL S2, V45, P134; Burt VK, 1998, HARVARD REV PSYCHIAT, V6, P121, DOI 10.3109/10673229809000320; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Cardoso F, 1997, INT J GYNECOL OBSTET, V59, P237, DOI 10.1016/S0020-7292(97)00239-7; CASPER RF, 1991, FERTIL STERIL, V55, P292; Castracane VD, 1995, CONTRACEPTION, V52, P371; CAUFIELD KA, 1998, WOMENS HLTH PRIMARY, P161; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; ChasanTaber L, 1996, CIRCULATION, V94, P483, DOI 10.1161/01.CIR.94.3.483; Coney P, 2001, CONTRACEPTION, V63, P297, DOI 10.1016/S0010-7824(01)00208-6; CONNELL EB, 1993, J REPROD MED, V38, P1036; Connelly PW, 1999, CAN J CARDIOL, V15, P419; COOPER C, 1993, BONE, V14, P41, DOI 10.1016/8756-3282(93)90254-8; Corson SL, 1996, INT J FERTIL MENOP S, V41, P77; Crook D, 1997, CONTRACEPTION, V55, P219, DOI 10.1016/S0010-7824(97)00010-3; Crosignani PG, 2000, HUM REPROD, V15, P1865; CULLBERG G, 1985, ACTA OBSTET GYN SCAN, V64, P195, DOI 10.3109/00016348509155112; DEWIS P, 1985, CLIN ENDOCRINOL, V22, P29, DOI 10.1111/j.1365-2265.1985.tb01061.x; DICKEY RP, 1994, MANAGING CONTRACEPTI, P60; DIEHL AK, 1991, GASTROENTEROL CLIN N, V20, P1; Dong W, 1997, J HYPERTENS, V15, P1063, DOI 10.1097/00004872-199715100-00003; Douketis JD, 1997, ARCH INTERN MED, V157, P1522, DOI 10.1001/archinte.157.14.1522; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; Eck LH, 1997, AM J CLIN NUTR, V65, P419, DOI 10.1093/ajcn/65.2.419; EDGREN RA, 1989, CONTRACEPTION, V40, P285, DOI 10.1016/0010-7824(89)90093-0; FARLEY TMM, 1995, LANCET, V346, P1582; Farley TMM, 1998, CONTRACEPTION, V57, P211, DOI 10.1016/S0010-7824(98)00019-5; Farmer RDT, 2000, BRIT J CLIN PHARMACO, V49, P580, DOI 10.1046/j.1365-2125.2000.00198.x; Farmer RDT, 1998, AM J OBSTET GYNECOL, V179, pS78, DOI 10.1053/ob.1998.v179.a92634; Franceschi S, 1998, CONTRACEPTION, V58, P335, DOI 10.1016/S0010-7824(98)00128-0; Fruzzetti F, 1999, AM J OBSTET GYNECOL, V180, pS369, DOI 10.1016/S0002-9378(99)70698-8; Gabrick DM, 2000, JAMA-J AM MED ASSOC, V284, P1791, DOI 10.1001/jama.284.14.1791; GAMBACCIANI M, 1994, MATURITAS, V19, P125, DOI 10.1016/0378-5122(94)90062-0; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; Gillum LA, 2000, JAMA-J AM MED ASSOC, V284, P72, DOI 10.1001/jama.284.1.72; GODSLAND IF, 1995, CONTRACEPTION, V52, P143, DOI 10.1016/0010-7824(95)00153-2; Godsland IF, 1996, CONTRACEPTION, V53, P9, DOI 10.1016/0010-7824(95)00260-X; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; Hankinson SE, 1997, CANCER CAUSE CONTROL, V8, P65, DOI 10.1023/A:1018435205695; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; Hannaford PC, 1996, CONTRACEPTION, V54, P125, DOI 10.1016/S0010-7824(96)00167-9; HATCHER RA, 1999, MANAGING CONTRACEPTI, P97; Hatcher RA, 1998, CONTRACEPTIVE TECHNO, P405; Heinemann LAJ, 1998, CONTRACEPTION, V57, P29, DOI 10.1016/S0010-7824(97)00204-7; Helmerhorst FM, 1998, HUM REPROD, V13, P2981, DOI 10.1093/humrep/13.11.2981; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Kaunitz AM, 2001, AM J OBSTET GYNECOL, V185, pS32, DOI 10.1067/mob.2001.116525; KAUNITZ AM, 2001, DIALOGUES CONTRACEPT, V6, P4; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; Klein NA, 1998, CLIN OBSTET GYNECOL, V41, P912, DOI 10.1097/00003081-199812000-00017; KNOPP RH, 1993, AM J OBSTET GYNECOL, V168, P1994, DOI 10.1016/S0002-9378(12)90941-2; KRETTEK JE, 1993, OBSTET GYNECOL, V81, P728; Kuohung W, 2000, CONTRACEPTION, V61, P77, DOI 10.1016/S0010-7824(00)00086-X; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Lewis MA, 1998, AM J OBSTET GYNECOL, V179, pS68, DOI 10.1053/ob.1998.v179.a93122; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; LIDEGAARD O, 1995, BRIT J OBSTET GYNAEC, V102, P153, DOI 10.1111/j.1471-0528.1995.tb09070.x; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; Lidegaard O, 1998, AM J OBSTET GYNECOL, V179, pS62, DOI 10.1053/ob.1998.v179.a91674; Lidegaard O, 1999, AM J OBSTET GYNECOL, V180, pS357, DOI 10.1016/S0002-9378(99)70696-4; Lidegaard O, 1998, CONTRACEPTION, V57, P303, DOI 10.1016/S0010-7824(98)00032-8; Lidegaard O, 1997, ACTA OBSTET GYN SCAN, V76, P252; Lobo RA, 1996, FERTIL STERIL, V65, P1100, DOI 10.1016/S0015-0282(16)58321-6; Lobo RA, 1998, CLIN OBSTET GYNECOL, V41, P895, DOI 10.1097/00003081-199812000-00015; Lucky AW, 1997, J AM ACAD DERMATOL, V37, P746, DOI 10.1016/S0190-9622(97)70112-9; Magnusson CM, 1999, INT J CANCER, V80, P231, DOI 10.1002/(SICI)1097-0215(19990118)80:2<231::AID-IJC11>3.3.CO;2-I; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; Marchbanks PA, 2002, NEW ENGL J MED, V346, P2025, DOI 10.1056/NEJMoa013202; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; MEADE TW, 1977, LANCET, V2, P948; *MED EC, 2000, RED BOOK 2000 DRUG T, P313; Michaelsson K, 1999, LANCET, V353, P1481, DOI 10.1016/S0140-6736(98)09044-8; Newcomb PA, 1996, CANCER CAUSE CONTROL, V7, P525, DOI 10.1007/BF00051885; Oddens BJ, 1999, CONTRACEPTION, V59, P277, DOI 10.1016/S0010-7824(99)00034-7; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; Poulter NR, 1996, LANCET, V348, P505; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; RAMCHARAN S, 1981, NIH PUBLICATION, V3; Redmond GP, 1997, OBSTET GYNECOL, V89, P615, DOI 10.1016/S0029-7844(97)00059-8; REUBINOFF BE, 1995, FERTIL STERIL, V63, P516, DOI 10.1016/S0015-0282(16)57419-6; Rosenberg L, 1996, AM J EPIDEMIOL, V143, P25; Rosenberg M, 1998, CONTRACEPTION, V58, P345, DOI 10.1016/S0010-7824(98)00127-9; Rosenberg MJ, 1996, CONTRACEPTION, V53, P85, DOI 10.1016/0010-7824(95)00270-7; Rosenberg MJ, 1998, AM J OBSTET GYNECOL, V179, P577, DOI 10.1016/S0002-9378(98)70047-X; Rosenberg MJ, 1996, AM J OBSTET GYNECOL, V174, P628, DOI 10.1016/S0002-9378(96)70440-4; Rosing J, 1999, AM J OBSTET GYNECOL, V180, pS375, DOI 10.1016/S0002-9378(99)70699-X; Rossing MA, 1996, AM J EPIDEMIOL, V144, P161, DOI 10.1093/oxfordjournals.aje.a008903; SALEH WA, 1993, AM J OBSTET GYNECOL, V168, P1740, DOI 10.1016/0002-9378(93)90685-C; Schiff I, 1999, AM J OBSTET GYNECOL, V180, pS383, DOI 10.1016/S0002-9378(99)70700-3; Schlesselman JJ, 1997, HUM REPROD, V12, P1851, DOI 10.1093/humrep/12.9.1851; SCHLESSELMAN JJ, 1995, OBSTET GYNECOL, V85, P793, DOI 10.1016/0029-7844(95)00022-J; Schmidt PJ, 2000, AM J OBSTET GYNECOL, V183, P414, DOI 10.1067/mob.2000.106004; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277; Schwartz SM, 1997, ANN INTERN MED, V127, P596, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00003; Schwingl PJ, 1999, AM J OBSTET GYNECOL, V180, P241, DOI 10.1016/S0002-9378(99)70182-1; SCRAGG RKR, 1984, BRIT MED J, V288, P1795, DOI 10.1136/bmj.288.6433.1795; Seifer DB, 1998, FERTIL STERIL, V69, P387; SHARGIL AA, 1985, INT J FERTIL, V30, P15; Sherif K, 1999, AM J OBSTET GYNECOL, V180, pS343, DOI 10.1016/S0002-9378(99)70694-0; Shulman LP, 2000, OBSTET GYN CLIN N AM, V27, P695, DOI 10.1016/S0889-8545(05)70168-6; Shulman LP, 1999, INT J FERTIL WOMEN M, V44, P78; Sidney S, 1996, OBSTET GYNECOL, V88, P939, DOI 10.1016/S0029-7844(96)00351-1; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; SPEROFF L, 1994, CLIN GYNECOLOGIC END, P722; Spitzer WO, 1998, AM J OBSTET GYNECOL, V179, pS43, DOI 10.1053/ob.1998.v179.a93059; Spitzer WO, 1996, BRIT MED J, V312, P83; Stahl SM, 1998, PSYCHOPHARMACOL BULL, V34, P319; STERGACHIS A, 1992, AM J OBSTET GYNECOL, V167, P1165, DOI 10.1016/S0002-9378(12)90406-8; Stern RS, 2000, J AM ACAD DERMATOL, V43, P1042, DOI 10.1067/mjd.2000.110901; Stewart FH, 2001, JAMA-J AM MED ASSOC, V285, P2232, DOI 10.1001/jama.285.17.2232; STROM BL, 1986, CLIN PHARMACOL THER, V39, P335, DOI 10.1038/clpt.1986.49; Sulak P, 1999, CONTRACEPTION, V59, P161, DOI 10.1016/S0010-7824(99)00026-8; Tanis BC, 2001, NEW ENGL J MED, V345, P1787, DOI 10.1056/NEJMoa003216; Thorneycroft IH, 1999, AM J OBSTET GYNECOL, V180, pS280, DOI 10.1016/S0002-9378(99)70719-2; Thorneycroft IH, 1999, AM J OBSTET GYNECOL, V180, pS288, DOI 10.1016/S0002-9378(99)70720-9; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Tomasson H, 1996, ACTA OBSTET GYN SCAN, V75, P157, DOI 10.3109/00016349609033309; Tryggvadottir L, 1997, BRIT J CANCER, V75, P139, DOI 10.1038/bjc.1997.23; Tyden T, 1999, ADV CONTRACEPT, V15, P133, DOI 10.1023/A:1006749709993; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; Ursin G, 1999, AM J EPIDEMIOL, V150, P561; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P73; Van Winter JT, 1998, AM FAM PHYSICIAN, V58, P1373; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; Vessey M, 1998, CONTRACEPTION, V57, P231, DOI 10.1016/S0010-7824(98)00026-2; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VOLPE A, 1993, CONTRACEPTION, V47, P229, DOI 10.1016/0010-7824(93)90040-E; Warren MP, 1998, CLIN OBSTET GYNECOL, V41, P976, DOI 10.1097/00003081-199812000-00024; Weiss G, 1999, AM J OBSTET GYNECOL, V180, pS295, DOI 10.1016/S0002-9378(99)70721-0; Westhoff CL, 1998, AM J OBSTET GYNECOL, V179, pS38, DOI 10.1053/ob.1998.v179.a91673; *WHO, 2000, IMPR ACC QUAL CAR FA, P1; *WHO US AG INT DEV, 1994, REC UPD SEL PRACT CO, V1; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; 1999, FERTIL STERIL S3, V71, pS1; 1998, HUM REPROD, V13, P2325; 2000, AM COLL OBSTERTRICIA, V18, P1071; 1996, CONTRACEPTION, V54, pS1	157	24	26	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 7	2003	138	1					54	64		10.7326/0003-4819-138-1-200301070-00013	http://dx.doi.org/10.7326/0003-4819-138-1-200301070-00013			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645TV	12513046				2022-12-28	WOS:000180996200008
J	Chobanian, AV; Bakris, GL; Black, HR; Cushman, WC; Green, LA; Izzo, JL; Jones, DW; Materson, BJ; Oparil, S; Wright, JT; Roccella, EJ				Chobanian, AV; Bakris, GL; Black, HR; Cushman, WC; Green, LA; Izzo, JL; Jones, DW; Materson, BJ; Oparil, S; Wright, JT; Roccella, EJ		Natl High Blood Pressure Educ Prog	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure	HYPERTENSION			English	Review							NUTRITION EXAMINATION SURVEY; POSITIVE AIRWAY PRESSURE; LEFT-VENTRICULAR MASS; ISOLATED SYSTOLIC HYPERTENSION; PRACTICE GUIDELINES COMMITTEE; CONVERTING-ENZYME-INHIBITION; OBSTRUCTIVE SLEEP-APNEA; RANDOMIZED DOUBLE-BLIND; ASSOCIATION TASK-FORCE; CORONARY-HEART-DISEASE	The National High Blood Pressure Education Program presents the complete Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Like its predecessors, the purpose is to provide an evidence- based approach to the prevention and management of hypertension. The key messages of this report are these: in those older than age 50, systolic blood pressure ( BP) of greater than 140 mm Hg is a more important cardiovascular disease ( CVD) risk factor than diastolic BP; beginning at 115/ 75 mm Hg, CVD risk doubles for each increment of 20/ 10 mm Hg; those who are normotensive at 55 years of age will have a 90% lifetime risk of developing hypertension; prehypertensive individuals ( systolic BP 120 - 139 mm Hg or diastolic BP 80 - 89 mm Hg) require health- promoting lifestyle modifications to prevent the progressive rise in blood pressure and CVD; for uncomplicated hypertension, thiazide diuretic should be used in drug treatment for most, either alone or combined with drugs from other classes; this report delineates specific high- risk conditions that are compelling indications for the use of other antihypertensive drug classes ( angiotensin- converting enzyme inhibitors, angiotensin- receptor blockers, beta- blockers, calcium channel blockers); two or more antihypertensive medications will be required to achieve goal BP ( < 140/ 90 mm Hg, or < 130/ 80 mm Hg) for patients with diabetes and chronic kidney disease; for patients whose BP is more than 20 mm Hg above the systolic BP goal or more than 10 mm Hg above the diastolic BP goal, initiation of therapy using two agents, one of which usually will be a thiazide diuretic, should be considered; regardless of therapy or care, hypertension will be controlled only if patients are motivated to stay on their treatment plan. Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount.	NHLBI, Natl High Blood Pressure Educ Program, NIH, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Rush Univ, Med Ctr, Chicago, IL 60612 USA; Vet Affairs Med Ctr, Memphis, TN USA; Univ Michigan, Ann Arbor, MI 48109 USA; SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Univ Miami, Miami, FL 33152 USA; Univ Alabama Birmingham, Birmingham, AL USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Rush University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Mississippi; University of Mississippi Medical Center; University of Miami; University of Alabama System; University of Alabama Birmingham; Case Western Reserve University	Roccella, EJ (corresponding author), NHLBI, Natl High Blood Pressure Educ Program, NIH, Bldg 31,Room 4A10,31 Ctr Dr MSC 2480, Bethesda, MD 20892 USA.	roccelle@nhlbi.nih.gov	Lakić, Dragana/F-8688-2011	Hershey, Linda/0000-0001-5090-6634				Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; ALPER A, 2002, CARDIOVASCULAR THERA, P817; *AM AC OPHTH, 1999, BAS CLIN SCI COURS, P68; *AM DIAB ASS, 2002, DIABETES CARE S1, V25, pS85, DOI DOI 10.2337/DIACARE.25.2007.S85; *AM HEART ASS, 2002, HEART DIS STROK STAT; Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213; American Diabetes Association, 2003, DIABETES CARE, V26, pS80, DOI DOI 10.2337/DIACARE.26.2007.S80; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 2001, OBSTET GYNECOL, V98, P177; [Anonymous], 2002, SCI MED ASP HUM REPR, P1; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Appel LJ, 2001, ARCH INTERN MED, V161, P685, DOI 10.1001/archinte.161.5.685; APPEL RG, 1995, KIDNEY INT, V48, P171, DOI 10.1038/ki.1995.281; Assmann G, 1998, EUR HEART J, V19, pA2; AWAD IA, 1986, STROKE, V17, P1090, DOI 10.1161/01.STR.17.6.1090; Awada A, 1996, ACTA NEUROL SCAND, V94, P415, DOI 10.1111/j.1600-0404.1996.tb00054.x; Bacon CG, 2003, ANN INTERN MED, V139, P161, DOI 10.7326/0003-4819-139-3-200308050-00005; Bader JD, 2002, ORAL SURG ORAL MED O, V93, P647, DOI 10.1067/moe.2002.123866; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Balas EA, 2000, ARCH INTERN MED, V160, P301, DOI 10.1001/archinte.160.3.301; BALL SG, 1993, LANCET, V342, P821; BALOH RW, 1995, ARCH NEUROL-CHICAGO, V52, P975, DOI 10.1001/archneur.1995.00540340067014; Bandura A., 1977, SOCIAL LEARNING THEO, V1; Barrier PA, 2003, MAYO CLIN PROC, V78, P211, DOI 10.4065/78.2.211; Bastard JP, 2000, DIABETES-METAB RES, V16, P192, DOI 10.1002/1520-7560(200005/06)16:3<192::AID-DMRR114>3.3.CO;2-7; Becker HF, 2003, CIRCULATION, V107, P68, DOI 10.1161/01.CIR.0000042706.47107.7A; Beddhu S, 2002, KIDNEY INT, V62, P1776, DOI 10.1046/j.1523-1755.2002.00629.x; Beeks E, 2001, AM J HYPERTENS, V14, P1185, DOI 10.1016/S0895-7061(01)02216-6; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Betancourt J R, 1999, Curr Hypertens Rep, V1, P482, DOI 10.1007/BF03215777; Biglieri E G, 1997, Curr Ther Endocrinol Metab, V6, P170; Black Henry R., 1996, American Journal of Medicine, V101, p47S, DOI 10.1016/S0002-9343(96)00267-7; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; Black HR, 2001, HYPERTENSION, V37, P12, DOI 10.1161/01.HYP.37.1.12; Boden-Albala B, 2000, Curr Atheroscler Rep, V2, P160, DOI 10.1007/s11883-000-0111-3; BONELLI FS, 1995, MAYO CLIN PROC, V70, P1041, DOI 10.4065/70.11.1041; Boulware LE, 2001, AM J PREV MED, V21, P221, DOI 10.1016/S0749-3797(01)00356-7; Bradley TD, 2003, CIRCULATION, V107, P1671, DOI 10.1161/01.CIR.0000061757.12581.15; Bray MS, 2000, AM J HYPERTENS, V13, P699, DOI 10.1016/S0895-7061(00)00242-9; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; Buchbinder A, 2002, AM J OBSTET GYNECOL, V186, P66, DOI 10.1067/mob.2002.120080; Burt VL, 1996, HYPERTENSION, V27, P1192; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; Calhoun D.A., 2003, HYPERTENSION PRIMER, P253; CALHOUN DA, 2000, HYPERTENSION COMPANI, P715; Canzanello VJ, 2001, ARCH INTERN MED, V161, P729, DOI 10.1001/archinte.161.5.729; Canzanello VJ, 2003, HYPERTENSION PRIMER, P519; *CDCP, 1995, 5 DAY SURV BEH RISK; Chalmers J, 1996, J HYPERTENS, V14, P929; ChasanTaber L, 1996, CIRCULATION, V94, P483, DOI 10.1161/01.CIR.94.3.483; CHIMOWITZ MI, 1992, ARCH NEUROL-CHICAGO, V49, P747, DOI 10.1001/archneur.1992.00530310095018; Chin KZ, 1999, CIRCULATION, V100, P706, DOI 10.1161/01.CIR.100.7.706; Chobanian AV, 2000, HYPERTENSION, V35, P858, DOI 10.1161/01.HYP.35.4.858; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CHRYSANT GS, 2001, CARDIOVASCULAR THERA, P768; Clement DL, 2003, NEW ENGL J MED, V348, P2407, DOI 10.1056/NEJMoa022273; CLEVELAND L, 1996, DATA TABLES RESULTS; COFFMAN JD, 1979, NEW ENGL J MED, V300, P713; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COLLINS AJ, 2001, AM J KIDNEY DIS, V38, pS7; COLLINS R, 1990, LANCET, V336, P370, DOI 10.1016/0140-6736(90)91908-S; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cooper R, 1997, AM J HYPERTENS, V10, P804, DOI 10.1016/S0895-7061(97)00211-2; Cooper-DeHoff RM, 2003, AM J HYPERTENS, V16, p27A, DOI 10.1016/S0895-7061(03)00142-0; Coresh J, 2001, ARCH INTERN MED, V161, P1207, DOI 10.1001/archinte.161.9.1207; Crespo CJ, 1996, PUBLIC HEALTH REP, V111, P7; Cushman WC, 2000, ARCH INTERN MED, V160, P825, DOI 10.1001/archinte.160.6.825; Cushman William C, 2002, J Clin Hypertens (Greenwich), V4, P393; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; Dart RA, 2003, CHEST, V123, P244, DOI 10.1378/chest.123.1.244; Davis TME, 1999, ARCH INTERN MED, V159, P1097, DOI 10.1001/archinte.159.10.1097; Del Bigio MR, 1999, STROKE, V30, P2440, DOI 10.1161/01.STR.30.11.2440; Delbecq AL, 1975, J HUMAN SCI; Della Chiesa A, 2003, J HUM HYPERTENS, V17, P515, DOI 10.1038/sj.jhh.1001580; DEVEREUX R, 2003, HYPERTENSION PRIMER, P460; Di Bari M, 2001, AM J EPIDEMIOL, V153, P72, DOI 10.1093/aje/153.1.72; Douglas JG, 2003, ARCH INTERN MED, V163, P525, DOI 10.1001/archinte.163.5.525; DOZONO K, 1991, STROKE, V22, P993, DOI 10.1161/01.STR.22.8.993; Dufouil C, 2001, NEUROLOGY, V56, P921, DOI 10.1212/WNL.56.7.921; Dyken ME, 1996, STROKE, V27, P401, DOI 10.1161/01.STR.27.3.401; Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0; Egan BM, 2003, CURR HYPERTENS REP, V5, P247, DOI 10.1007/s11906-003-0028-7; Elliott WJ, 1996, CLIN PHARMACOL THER, V60, P582, DOI 10.1016/S0009-9236(96)90155-1; Emmons KM, 2001, AM J PREV MED, V20, P68, DOI 10.1016/S0749-3797(00)00254-3; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; ESTES ML, 1991, ARCH NEUROL-CHICAGO, V48, P631, DOI 10.1001/archneur.1991.00530180087022; Faccenda JF, 2001, AM J RESP CRIT CARE, V163, P344, DOI 10.1164/ajrccm.163.2.2005037; Facchini FS, 2000, FREE RADICAL BIO MED, V29, P1302, DOI 10.1016/S0891-5849(00)00438-X; Fagan TC, 1999, ARCH INTERN MED, V159, P1033, DOI 10.1001/archinte.159.10.1033; Falkner B, 1996, PEDIATRICS, V98, P649; Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581; Flack John M., 1996, American Journal of Medicine, V101, p53S, DOI 10.1016/S0002-9343(96)00268-9; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fogari R, 2001, AM J HYPERTENS, V14, P27, DOI 10.1016/S0895-7061(00)01214-0; FORD CE, 1988, JAMA-J AM MED ASSOC, V259, P2113; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Fox KM, 2003, LANCET, V362, P782; FRANKLIN KA, 1995, LANCET, V345, P1085, DOI 10.1016/S0140-6736(95)90820-X; Franklin SS, 2001, HYPERTENSION, V37, P869, DOI 10.1161/01.HYP.37.3.869; Franklin SS, 2001, CIRCULATION, V103, P1245; Franklin SS, 1997, CIRCULATION, V96, P308; Franse LV, 2000, HYPERTENSION, V35, P1025, DOI 10.1161/01.HYP.35.5.1025; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FURUTA A, 1991, STROKE, V22, P442, DOI 10.1161/01.STR.22.4.442; Garg JP, 2002, VASC MED, V7, P35, DOI 10.1191/1358863x02vm412ra; Gerin W, 2002, BLOOD PRESS MONIT, V7, P313, DOI 10.1097/00126097-200212000-00004; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; Gerstein HC, 2000, LANCET, V355, P253; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; Gidding Samuel S., 2002, Ethnicity and Disease, V12, P171; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; GILLMAN MW, 1993, AM HEART J, V125, P1148, DOI 10.1016/0002-8703(93)90128-V; Glynn RJ, 1999, JAMA-J AM MED ASSOC, V281, P438, DOI 10.1001/jama.281.5.438; Goldstein LB, 2001, CIRCULATION, V103, P163; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; Gregg EW, 2003, JAMA-J AM MED ASSOC, V289, P2379, DOI 10.1001/jama.289.18.2379; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Grimm RH, 1997, HYPERTENSION, V29, P8, DOI 10.1161/01.HYP.29.1.8; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Grundy SM, 1999, CIRCULATION, V100, P1134, DOI 10.1161/01.CIR.100.10.1134; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Harden PN, 1997, LANCET, V349, P1133, DOI 10.1016/S0140-6736(96)10093-3; HAYNES WG, 1996, CARDIOVASCULAR THERA, P503; He JA, 2000, HYPERTENSION, V35, P544, DOI 10.1161/01.HYP.35.2.544; He JA, 1999, JAMA-J AM MED ASSOC, V282, P2027, DOI 10.1001/jama.282.21.2027; HERZLINGER RE, 1997, MARKET DRIVEN HLTH C, P65; HIATT WR, 1990, CIRCULATION, V81, P602, DOI 10.1161/01.CIR.81.2.602; Hill MN, 1996, CIRCULATION, V93, P4, DOI 10.1161/01.CIR.93.1.4; Hillege HL, 2002, CIRCULATION, V106, P1777, DOI 10.1161/01.CIR.0000031732.78052.81; Hsia J, 2003, AM HEART J, V146, P439, DOI 10.1016/S0002-8703(03)00227-8; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Hyman David J., 2000, J Clin Hypertens (Greenwich), V2, P324; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; Izzo JL, 2000, HYPERTENSION, V35, P1021, DOI 10.1161/01.HYP.35.5.1021; Jafar TH, 2003, ANN INTERN MED, V139, P244, DOI 10.7326/0003-4819-139-4-200308190-00006; Jafar TH, 2001, ANN INTERN MED, V135, P73, DOI 10.7326/0003-4819-135-2-200107170-00007; Jamerson Kenneth, 1996, American Journal of Medicine, V101, p22S, DOI 10.1016/S0002-9343(96)00265-3; JAMES WPT, 1987, LANCET, V1, P426; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; Jensen JS, 2000, HYPERTENSION, V35, P898, DOI 10.1161/01.HYP.35.4.898; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; Joint National Committee on Prevention Detection evaluation and treatment of high blood pressure, 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005; Jones DW, 2003, JAMA-J AM MED ASSOC, V289, P1027, DOI 10.1001/jama.289.8.1027; JONSSON PV, 1990, ARCH INTERN MED, V150, P1518, DOI 10.1001/archinte.150.7.1518; Kanagala R, 2003, CIRCULATION, V107, P2589, DOI 10.1161/01.CIR.0000068337.25994.21; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kario K, 2003, CIRCULATION, V107, P1401, DOI 10.1161/01.CIR.0000056521.67546.AA; Kato M, 2000, CIRCULATION, V102, P2607; Kato M, 2000, HYPERTENSION, V35, P1173, DOI 10.1161/01.HYP.35.5.1173; Kelley GA, 2000, HYPERTENSION, V35, P838, DOI 10.1161/01.HYP.35.3.838; KIRBY RS, 1995, UROLOGY, V46, P182, DOI 10.1016/S0090-4295(99)80191-5; Kivipelto M, 2001, NEUROLOGY, V56, P1683, DOI 10.1212/WNL.56.12.1683; Kloner RA, 2001, AM J HYPERTENS, V14, P70, DOI 10.1016/S0895-7061(00)01177-8; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KOCHWESER J, 1973, NEW ENGL J MED, V289, P481, DOI 10.1056/NEJM197308302890913; Koga H, 2002, J NEUROL NEUROSUR PS, V72, P737, DOI 10.1136/jnnp.72.6.737; Kohner EM, 1998, ARCH OPHTHALMOL-CHIC, V116, P297, DOI 10.1001/archopht.116.3.297; KOREN MJ, 1993, AM J HYPERTENS, V6, P815, DOI 10.1093/ajh/6.10.815; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; Laaksonen DE, 2002, DIABETES CARE, V25, P1612, DOI 10.2337/diacare.25.9.1612; Laaksonen DE, 2002, AM J EPIDEMIOL, V156, P1070, DOI 10.1093/aje/kwf145; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Lakshman MR, 1999, ARCH INTERN MED, V159, P551, DOI 10.1001/archinte.159.6.551; LAST JM, 1995, DICT EPIDEMIOLOGY; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; LAWRENCE J, 2002, JOINT STAT CLIN REV, P1; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; Lee IM, 2001, JAMA-J AM MED ASSOC, V285, P1447, DOI 10.1001/jama.285.11.1447; Leung RST, 2001, AM J RESP CRIT CARE, V164, P2147, DOI 10.1164/ajrccm.164.12.2107045; LEUNG SY, 1993, STROKE, V24, P779, DOI 10.1161/01.STR.24.6.779; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; LEVINSON PD, 1993, CHEST, V103, P1336, DOI 10.1378/chest.103.5.1336; LEVY D, 1990, NEW ENGL J MED, V0322; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lewis CE, 1996, ARCH INTERN MED, V156, P377, DOI 10.1001/archinte.156.4.377; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LICATA G, 1995, J HYPERTENS, V13, P611, DOI 10.1097/00004872-199506000-00006; LIEBSON PR, 1995, CIRCULATION, V91, P698, DOI 10.1161/01.CIR.91.3.698; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Lloyd-Jones DM, 2000, HYPERTENSION, V36, P594, DOI 10.1161/01.HYP.36.4.594; Longstreth WT, 1996, STROKE, V27, P1274, DOI 10.1161/01.STR.27.8.1274; MAKI DD, 1995, ARCH INTERN MED, V155, P1073, DOI 10.1001/archinte.155.10.1073; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Manger WM, 2002, PHEOCHROMOCYTOMA, V4, P62; Manjunath G, 2003, J AM COLL CARDIOL, V41, P47, DOI 10.1016/S0735-1097(02)02663-3; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; MARSHALL VG, 1988, RADIOLOGY, V167, P517, DOI 10.1148/radiology.167.2.3357964; Masaki KH, 1998, CIRCULATION, V98, P2290, DOI 10.1161/01.CIR.98.21.2290; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MATERSON BJ, 1990, HYPERTENSION, V15, P348, DOI 10.1161/01.HYP.15.4.348; Maue SK, 2002, FAM MED, V34, P508; McMurray J, 2003, EUR J HEART FAIL, V5, P261, DOI 10.1016/S1388-9842(03)00052-7; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MILLMAN RP, 1995, CHEST, V107, P362, DOI 10.1378/chest.107.2.362; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; MORGAN BJ, 2003, HYPERTENSION PRIMER, P156; Moser M, 1998, JAMA-J AM MED ASSOC, V279, P1813, DOI 10.1001/jama.279.22.1813; Mukai S, 2002, CLIN GERIATR MED, V18, P253, DOI 10.1016/S0749-0690(02)00008-3; NALLY J, 2003, HYPERTENSION PRIMER, P500; *NAT HEART LUNG BL, CARD DIS ENH DISS UT; *NAT HEART LUNG BL, SAL COR; National Heart Lung and Blood Institute, YOUR GUID LOW HIGH B; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581, DOI [10.1056/NEJM199512143332401, DOI 10.1056/NEJM199512143332401]; National Research Council, 2001, NUTR REQ DAIR CATTL, P19; Neal B, 2000, LANCET, V356, P1955; Nelson RG, 1996, NEW ENGL J MED, V335, P1636, DOI 10.1056/NEJM199611283352203; Newman AB, 2001, AM J EPIDEMIOL, V154, P50, DOI 10.1093/aje/154.1.50; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; *NIH, 1998, OBES RES S2, V6, pS51, DOI DOI 10.1001/JAMA.2012.39; *NIH, MOB AFR AM COMM ADDR; *NIH, MAD HATT JOIN OUR CA; *NIH, HEALTHB RAD NETW; *NIH, HEARTS N PARKS; Ogden LG, 2000, HYPERTENSION, V35, P539, DOI 10.1161/01.HYP.35.2.539; Okin PM, 2002, AM J HYPERTENS, V15, P663, DOI 10.1016/S0895-7061(02)02945-X; OLIN JW, 2003, HYPERTENSION PRIMER, P467; Ooi WL, 2000, AM J MED, V108, P106, DOI 10.1016/S0002-9343(99)00425-8; OSTER JR, 1986, J CLIN HYPERTENS, V4, P307; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; PAPADEMETRIOU V, 1988, ARCH INTERN MED, V148, P1272, DOI 10.1001/archinte.148.6.1272; Park YW, 2003, ARCH INTERN MED, V163, P427, DOI 10.1001/archinte.163.4.427; Parsons DS, 2002, AM J KIDNEY DIS, V40, P916, DOI 10.1053/ajkd.2002.36321; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; Peled N, 1999, J AM COLL CARDIOL, V34, P1744, DOI 10.1016/S0735-1097(99)00407-6; Pepine CJ, 2003, JAMA-J AM MED ASSOC, V290, P2805, DOI 10.1001/jama.290.21.2805; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460; Perry G, 1997, NEW ENGL J MED, V336, P525; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Phillips BG, 2000, AM J PHYSIOL-HEART C, V279, pH234, DOI 10.1152/ajpheart.2000.279.1.H234; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Pickering T, 1996, AM J HYPERTENS, V9, P1, DOI 10.1016/0895-7061(95)00341-X; Pickering T G, 1999, Blood Press Monit, V4, P333, DOI 10.1097/00126097-199905000-00006; Pignone MP, 2003, AM J PREV MED, V24, P75, DOI 10.1016/S0749-3797(02)00580-9; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; POHL MA, 1999, ATLAS DIS KIDNEY; Porush JG, 1996, ARCH INTERN MED, V156, P1938; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 2002, ARCH INTERN MED, V162, P2325, DOI 10.1001/archinte.162.20.2325; Psaty BM, 2002, JAMA-J AM MED ASSOC, V287, P1680, DOI 10.1001/jama.287.13.1680; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Punjabi NM, 2002, AM J RESP CRIT CARE, V165, P677, DOI 10.1164/ajrccm.165.5.2104087; RADACK K, 1991, ARCH INTERN MED, V151, P1769, DOI 10.1001/archinte.151.9.1769; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; REED DM, 1988, STROKE, V19, P820, DOI 10.1161/01.STR.19.7.820; Remuzzi G, 2002, NEW ENGL J MED, V346, P1145, DOI 10.1056/NEJMcp011773; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; ROBERTS DH, 1987, LANCET, V2, P650; ROCCELLA EJ, 2003, HYPERTENSION PRIMER, P126; ROSENDORFF C, 2003, HYPERTENSION PRIMER, P456; Rosenthal T, 2000, J HUM HYPERTENS, V14, P691, DOI 10.1038/sj.jhh.1001095; Rowley Kevin, 2003, Curr Diab Rep, V3, P80, DOI 10.1007/s11892-003-0058-1; Ruggenenti P, 1997, LANCET, V349, P1857; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Sacktor N, 1999, J GERIATR PSYCH NEUR, V12, P1, DOI 10.1177/089198879901200102; SAUNDERS E, 1990, ARCH INTERN MED, V150, P1707, DOI 10.1001/archinte.150.8.1707; Schmidt R, 1999, NEUROLOGY, V53, P132, DOI 10.1212/WNL.53.1.132; SCHMIDT R, 1995, ARCH NEUROL-CHICAGO, V52, P905, DOI 10.1001/archneur.1995.00540330087019; Schmieder RE, 1998, NEPHROL DIAL TRANSPL, V13, P564, DOI 10.1093/ndt/13.3.564; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x; Senni M, 2001, J AM COLL CARDIOL, V38, P1277, DOI 10.1016/S0735-1097(01)01567-4; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; Shamsuzzaman ASM, 2002, CIRCULATION, V105, P2462, DOI 10.1161/01.CIR.0000018948.95175.03; SHAUGHNESSY AF, 1994, J FAM PRACTICE, V39, P489; Sheps S G, 1999, Curr Hypertens Rep, V1, P342, DOI 10.1007/s11906-999-0044-3; Shih SC, 2003, AM J PREV MED, V24, P293, DOI 10.1016/S0749-3797(03)00025-4; Sibai BM, 1996, NEW ENGL J MED, V335, P257, DOI 10.1056/NEJM199607253350407; Sica DA, 2002, DRUGS, V62, P443, DOI 10.2165/00003495-200262030-00003; Simons-Morton DG, 2000, PREV MED, V31, P513, DOI 10.1006/pmed.2000.0733; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Slawson DC, 1997, BRIT MED J, V314, P947, DOI 10.1136/bmj.314.7085.947; SOLOMON SA, 1991, BRIT MED J, V303, P1100, DOI 10.1136/bmj.303.6810.1100; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; SOMERS VK, 2003, HYPERTENSION PRIMER, P512; Somes GW, 1999, ARCH INTERN MED, V159, P2004, DOI 10.1001/archinte.159.17.2004; SOS TA, 1991, CIRCULATION, V83, P162; Sowers James R., 2000, J Clin Hypertens (Greenwich), V2, P132; Sowers JR, 2000, NEW ENGL J MED, V342, P969, DOI 10.1056/NEJM200003303421310; Sowers JR, 2003, J AM COLL CARDIOL, V41, p320A; Sowers JR, 2002, HYPERTENSION, V40, P781, DOI 10.1161/01.HYP.0000042097.39655.B7; SPENCE JD, 1978, CLIN SCI MOL MED, V55, pS399, DOI 10.1042/cs055399s; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; STAESSEN J, 1989, J HUM HYPERTENS, V3, P427; Staessen JA, 1998, ARCH INTERN MED, V158, P1681, DOI 10.1001/archinte.158.15.1681; Staessen JA, 2000, LANCET, V355, P865, DOI 10.1016/S0140-6736(99)07330-4; Staessen JA, 1999, JAMA-J AM MED ASSOC, V282, P539, DOI 10.1001/jama.282.6.539; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Staessen JA, 1997, J HUM HYPERTENS, V11, P507, DOI 10.1038/sj.jhh.1000476; Staessen JA, 2001, LANCET, V358, P1026, DOI 10.1016/S0140-6736(01)06226-2; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; STAMLER R, 1991, HYPERTENSION, V17, pI16, DOI 10.1161/01.HYP.17.1_Suppl.I16; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stevens J, 2002, AM J EPIDEMIOL, V156, P832, DOI 10.1093/aje/kwf114; Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845; Swan GE, 1998, NEUROLOGY, V51, P986, DOI 10.1212/WNL.51.4.986; TALER SJ, 2003, HYPERTENSION PRIMER, P491; Tepper David, 1999, Congest Heart Fail, V5, P184; Textor SC, 1998, KIDNEY INT, V53, P799, DOI 10.1038/ki.1998.37; Textor SC, 1997, SEMIN NEPHROL, V17, P67; Textor SC, 2003, HYPERTENSION PRIMER, P163; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; TSUJI H, 1994, CIRCULATION, V90, P878, DOI 10.1161/01.CIR.90.2.878; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Tzourio C, 2003, ARCH INTERN MED, V163, P1069; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; *US BUR CENS, 2001, 2002 STAT ABSTR US, P43; *US DEP HHS, HLTH PEOPL 2010; *US DEP HHS, HEART TRUTH NAT AW C; *US DEP HHS, FACTS DASH EAT PLAN; *US DEP HHS, 2000, HLTH PEOPL 2010, P19; *US DEP HHS, NAT HIGH BLOOD PRESS; *US DEP HHS, NHLBI HLTH PEOPL 201; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417; Vasan RS, 2001, LANCET, V358, P1682, DOI 10.1016/S0140-6736(01)06710-1; Verdecchia P, 2000, HYPERTENSION, V35, P844, DOI 10.1161/01.HYP.35.3.844; Vgontzas AN, 2000, J CLIN ENDOCR METAB, V85, P1151, DOI 10.1210/jc.85.3.1151; Vidt D, 1999, HYPERTENSION PRIMER, V2nd, P437; Vidt D G, 2001, J Clin Hypertens (Greenwich), V3, P158, DOI 10.1111/j.1524-6175.2001.00449.x; VIDT DG, 2003, HYPERTENSION PRIMER, P452; Vollmer WM, 2001, ANN INTERN MED, V135, P1019, DOI 10.7326/0003-4819-135-12-200112180-00005; von Dadelszen P, 2000, LANCET, V355, P87, DOI 10.1016/S0140-6736(98)08049-0; Wang JJ, 2003, HYPERTENSION, V42, P534, DOI 10.1161/01.HYP.0000090122.38230.41; Wassertheil-Smoller S, 2000, HYPERTENSION, V36, P780, DOI 10.1161/01.HYP.36.5.780; WEINBERGER MH, 1985, J CARDIOVASC PHARM, V7, pS52, DOI 10.1097/00005344-198507001-00011; Weir MR, 2000, ARCH INTERN MED, V160, P481, DOI 10.1001/archinte.160.4.481; Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002-9149(02)02661-9; Whelton A, 2001, Am J Ther, V8, P85, DOI 10.1097/00045391-200103000-00003; Whelton A., 1999, AM J MED, V106, p13S, DOI [10.1016/s0002-9343(99)00113-8, DOI 10.1016/S0002-9343(99)00113-8]; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; White WB, 2002, HYPERTENSION, V39, P929, DOI 10.1161/01.HYP.0000014323.99765.16; WHO, 2002, RED RISKS PROM HLTH; Wilson PWF, 1999, ARCH INTERN MED, V159, P1104, DOI 10.1001/archinte.159.10.1104; Wilson PWF, 2002, DIABETES, V51, pA242; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; Wolk R, 2003, CIRCULATION, V108, P9, DOI 10.1161/01.CIR.0000072346.56728.E4; Wolz M, 2000, AM J HYPERTENS, V13, P103, DOI 10.1016/S0895-7061(99)00241-1; Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0; World Hypertension League, MEAS YOUR BLOOD PRES; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Wright JT, 2002, ARCH INTERN MED, V162, P1636, DOI 10.1001/archinte.162.14.1636; Xin X, 2001, HYPERTENSION, V38, P1112, DOI 10.1161/hy1101.093424; YAMAGUCHI S, 1996, J STROKE CEREBROVASC, V6, P106; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zampaglione B, 1996, HYPERTENSION, V27, P144, DOI 10.1161/01.HYP.27.1.144; 2002, ASS NEWS, P5; GFR 1 73 M2 MDRD SUN; 2003, MORBIDITY MORTALITY, V52, P833; WORK M BLOOD PRESS M	386	20433	21896	85	1341	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0194-911X	1524-4563		HYPERTENSION	Hypertension	DEC	2003	42	6					1206	1252		10.1161/01.HYP.0000107251.49515.c2	http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2			47	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	752TR	12748199	Bronze			2022-12-28	WOS:000187183700022
